S.NO,DB_ID,DIS_CLASS,GENE,PUBMED.ID,LACKASSO,TITLE,YEAR,CONCLUSION,REF_SENTENCE,ASSOCIATION_CLASS,REF_GENE,GENE_NEW,WEIGHT
1,bc_id1,CANCER,MYCL1,1345822,Y,Association between restriction fragment length polymorphism of the L-myc gene and lung metastasis in human breast cancer.,1992,,No differences in the patterns of L-myc RFLP were found between breast cancer patients and healthy individuals.,N,L-myc,MYCL,1
2,bc_id2,CANCER,HRAS,2086347,Y,Analysis of the association of inherited predisposition to breast cancer with c-Ha-ras-1 oncogene alleles trans Analiz assotsiatsii nasledstvennoi predraspolozhennosti k raku molochnoi zhelezy s allel'nymi variantami c-Ha-ras-1 onkogena.,1990,,No absolute relationship between the genetic predisposition to breast cancer and the Ha-ras genotype was assumed,N,Ha-ras,HRAS,1
3,bc_id3,CANCER,ERBB2,3664511,Y,Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.,,,Amplification of c-erbB-2 was found in 15 of 86 primary breast cancers and in 3 of 12 secondary breast cancers.,Y,c-erbB-2,ERBB2,0.285714286
4,bc_id4,CANCER,TP53,7524772,B,Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.,1994,,"Breast tumors are thought to originate, grow, and metastasize in an environment which includes steroid hormone receptors... Association analysis between all five biochemical parameters revealed strong negative associations between p53 and receptors and strong positive associations between CEA and receptors",Y,p53,TP53,0.367816092
5,bc_id5,CANCER,RB1,7615356,Y,Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer without effect on survival.,1995,,"The retinoblastoma (RB) tumour suppressor gene has been associated not only with retinoblastoma but also with several other tumours like osteosarcoma, small cell lung carcinoma and prostate and breast cancer",Y,RB,RB1,0.5
6,bc_id6,CANCER,CYP1A1,7641189,Y,A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women.,1995,,"It is possible that the CYP1A1 MspI RFLP is linked with other polymorphisms in the African-American population, either in the CYP1A1 gene, which is involved in estrogen metabolism, or other genes related to risk of breast cancer.",A,CYP1A1,CYP1A1,0.456521739
7,bc_id7,CANCER,TP53,7882357,Y,Racial disparity in the association of p53 gene alterations with breast cancer survival.,1995,,The findings suggest that the types of p53 gene alterations may contribute to the racial difference in breast cancer survival,A,p53,TP53,0.482758621
8,bc_id8,CANCER,TP53,7910151,B,Association among p53 gene mutation nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer.,1994,,"Regardless of differences in their protein-expression pattern, a majority of the p53 gene mutations were suggested to function in a recessive mode and to be involved in the development of histologically aggressive breast cancer.",Y,p53,TP53,0.367816092
9,bc_id9,CANCER,ERBB2,7927865,B,Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type.,1994,,"In addition, we have shown that c-erbB2 amplification, found in 30 (17%) specimens, was associated with a high risk of multiple metastases developing simultaneously...  the c-erbB2 amplification detected in 24 (36%) specimens was not found to be associated with a higher risk of death, suggesting that the c-erbB2 gene plays a different role in the progression of these 2 types of breast cancer.",Y,c-erbB2,ERBB2,0.285714286
10,bc_id10,CANCER,CYP1A1,8000303,B,Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer.,1994,,CYP1A1 is a gene of the cytochrome P-450 family that has been proposed to be a biomarker of cancer risk... The distribution of this polymorphism was the same in breast cancer cases as in two sets of healthy controls.,A,CYP1A1,CYP1A1,0.456521739
11,bc_id11,CANCER,BCL2,8286195,B,bcl-2 in normal human breast and carcinoma association with oestrogen receptor-positive epidermal growth factor receptor-negative tumours and in situ cancer.,1994,,"Thus, loss of bcl-2 expression in breast cancer is associated with a range of molecular markers of poor prognosis and may define part of an ER-negative, EGFR-positive phenotype.",A,bcl-2,bcl-2,1
12,bc_id12,CANCER,PDS,9155067,N,No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer.,1997,,ANF,ANF,ANF,ANF,0
13,bc_id13,CANCER,TP53,9421363,B,Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer.,1997,,We examined the association between mutation of the p53 gene and survival in a large cohort of breast cancer patients... Mutations were found in 19% of tumours.,A,p53,TP53,0.482758621
14,bc_id14,CANCER,GSTP1,9539246,Y,Association between glutathione S-transferase M1 P1 and T1 genetic polymorphisms and development of breast cancer.,1998,Our findings suggest that genetic variability in members of the GST gene family may be associated with an increased susceptibility to breast cancer.,"For GSTP1, the data were suggestive of a trend of increasing risk with higher numbers of codon 105 valine alleles (compared with isoleucine alleles); a 1.97-fold increased risk of breast cancer (95% CI = 0.77-5.02) was associated with valine/valine homozygosity",Y,GSTP1,GSTP1,0.428571429
15,bc_id15,CANCER,GSTM1,9539246,Y,Association between glutathione S-transferase M1 P1 and T1 genetic polymorphisms and development of breast cancer.,1998,Our findings suggest that genetic variability in members of the GST gene family may be associated with an increased susceptibility to breast cancer.,"The GSTM1 homozygous null genotype was associated with an increased risk of developing breast cancer (OR = 2.10; 95% CI = 1.22-3.64), principally due to an association with postmenopausal breast cancer (OR = 2.50; 95% CI = 1.34-4.65).",Y,GSTM1,GSTM1,0.452830189
16,bc_id16,CANCER,VDR,9613456,Y,Vitamin D receptor gene polymorphism is associated with metastatic breast cancer.,1998,,we believe that the VDR gene polymorphism may represent an important determinant in the evaluation of women affected by breast cancer and might help design targeted therapy.,A,VDR,VDR,0.538461538
17,bc_id17,CANCER,IGFBP7,9627112,Y,Down-regulation of T1A12/mac25 a novel insulin-like growth factor binding protein related gene is associated with disease progression in breast carcinomas.,1998,,"Our data indicate that T1A12/mac25 expression is abrogated during breast cancer progression concomitant with loss of heterozygosity on chromosome 4q. T1A12/mac25 may therefore have a tumor suppressor-like function and its expression could indicate a disease with a more favorable status, having a better prognosis.",Y,T1A12/mac25,IGFBP7,1
18,bc_id18,CANCER,CYP17A1,9667690,N,No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer.,1998,We conclude that  these alleles do not significantly alter breast cancer risk in the English population.,"A recent study showed an association between a single base substitution, T-->C, in the promotor region of the CYP17 gene... We found no evidence of an increased risk of breast cancer [odds ratio (OR) 1.10, confidence interval (CI) 0.89-1.37] or advanced breast cancer (OR 0.88, CI 0.38-2.01) in C allele carriers, nor any association between age at menarche and genotype",N,CYP17,CYP17A1,0.266666667
19,bc_id19,CANCER,GSTM1,9679567,B,Allelic deletion at glutathione S-transferase M1 locus and its association with breast cancer susceptibility.,1998,,"The predominance of the null genotype was significant in the oldest group of patients (> or = 55) (P = 0.006), suggesting that GSTM1 null genotype may play an important role in breast cancer susceptibility in the elderly.",A,GSTM1,GSTM1,0.339622642
20,bc_id20,CANCER,CYP17A1,9796641,Y,Association between CYP17 polymorphisms and the development of breast cancer.,1998,,Additional studies of larger size are needed to achieve a consensus regarding the relevance of CYP17 genotypes to the risk of developing breast cancer.,A,CYP17,CYP17A1,0.466666667
21,bc_id21,CANCER,CYP1B1,9823305,Y,Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer.,1998,,These data suggest that the CYP1B1 polymorphisms in exon 3 are not associated with increased breast cancer risk but that the m1 polymorphism may be functionally important for steroid receptor expression in breast cancer of Caucasian patients.,A,CYP1B1,CYP1B1,0.384615385
22,bc_id22,CANCER,BRCA1,9839523,Y,Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.,1998,"Among women with a moderate family history of breast cancer, i.e., predicted noncarriers of BRCA1 and/or BRCA2 mutations, family history remains a factor in predicting breast cancer risk. In families with breast and ovarian cancers, the aggregation of these two cancers appears to be explained by BRCA1/BRCA2 mutation-carrier probability.","Among women with a moderate family history of breast cancer, i.e., predicted noncarriers of BRCA1 and/or BRCA2 mutations, family history remains a factor in predicting breast cancer risk",Y,BRCA1,BRCA1,0.326180258
23,bc_id23,CANCER,AR,10205268,B,Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.,1999,,We found that women were at significantly increased risk of breast cancer if they carried at least one AR allele with >/=28 CAG repeats.,Y,AR,AR,0.291666667
24,bc_id24,CANCER,VDR,10344739,Y,Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group.,1999,We conclude that  polymorphism in the VDR gene may influence tumor progression and tamoxifen treatment response in early-onset breast carcinomas.,We conclude that  polymorphism in the VDR gene may influence tumor progression and tamoxifen treatment response in early-onset breast carcinomas.,A,VDR,VDR,0.538461538
25,bc_id25,CANCER,CYP17A1,10404084,Y,Association between CYP17 gene polymorphism and risk of breast cancer in young women.,1999,,Our findings suggest that CYP17 gene polymorphism influences breast carcinogenesis in young women.,Y,CYP17,CYP17A1,0.266666667
26,bc_id26,CANCER,CYP17A1,10487625,Y,A polymorphism in the CYP17 gene is associated with male breast cancer.,1999,,This case-control study from the South East of Scotland shows that a polymorphism of the CYP17 gene is associated with an increased risk of male breast cancer.,Y,CYP17,CYP17A1,0.266666667
27,bc_id27,CANCER,VDR,10545416,N,No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer.,1999,,None of the AR or VDR polymorphisms investigated has a major effect on risk of breast cancer in the British population.,Y,VDR,VDR,0.269230769
28,bc_id28,CANCER,VDR,10597185,Y,Association of A vitamin D receptor polymorphism with sporadic breast cancer development.,1999,,Our results suggest that specific alleles of the VDR gene located near the 3' region may identify an increased risk for breast cancer and justify further investigation of the role of VDR in breast cancer.,A,VDR,VDR,0.538461538
29,bc_id29,CANCER,TP53,10618725,B,Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers.,1999,,X,X,X,X,0
30,bc_id30,CANCER,CYP1B1,10739169,Y,Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer.,2000,,"In this study, we investigated the association between CYP1B1 genetic polymorphism and breast or lung cancer incidence...  Thus, inter-individual differences in activation of procarcinogens or metabolism of oestrogen originating from genetic polymorphisms of the human CYP1B1 gene may contribute to the susceptibility of human cancers.",A,CYP1B1,CYP1B1,0.384615385
31,bc_id31,CANCER,PDS,10811106,Y,Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50.,2000,,X,X,X,X,0
32,bc_id32,CANCER,AR,10817350,Y,Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer.,2000,,"Although AR is expressed in breast cancer and the impact of androgen and AR on breast cancer has been recognized, the role of the CAG repeats in breast cancer remains unknown.",Y,AR,AR,0.291666667
33,bc_id33,CANCER,PAI1,10961693,N,Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.,2000,,The 4G/5G polymorphism may not be linked with elevated level of PAI-1 observed in breast cancer and therefore may not be associated with appearance and/or progression of breast cancer.,A,PAI-1,SERPINE1,1
34,bc_id34,CANCER,MTA1,10967548,B,Tumor metastasis-associated human MTA1 gene: its deduced protein sequence localization and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides.,2000,,Experimental inhibition of MTA1 protein expression using antisense phosphorothioate oligonucleotides resulted in growth inhibition of human MDA-MB-231 breast cancer cells with relatively high expression of the MTA1 gene.,Y,MTA1,MTA1,1
35,bc_id35,CANCER,NAT2,11008907,B,"N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women.",2000,,These results are consistent with a role for O-acetylation in the activation of heterocyclic amine carcinogens and support the hypothesis that the NAT2 acetylation polymorphism is a breast cancer risk factor among postmenopausal women with high levels of heterocyclic amine exposure.,Y,NAT2,NAT2,0.37037037
36,bc_id38,CANCER,TP53,11024482,Y,Immunohistochemical expression of p53 in breast carcinoma is associated with the intron 1 BglII polymorphism of the p53 gene.,2000,,In this study we have evaluated the intron 1 BglII polymorphism of the p53 gene with a PCR-based approach in 117 cases of breast cancer and 102 healthy women and its association with the immunohistochemical expression of p53 in the tumors. The results showed that the presence of the polymorphism (allele 2) is highly associated with the tumor expression of p53 (p<0.0001) and that there is a trend for increased frequency of allele 2 in cases than in controls (p=0.2376).,Y,p53,TP53,0.367816092
37,bc_id39,CANCER,HLA-DRB1,11027344,Y,Genetic susceptibility to breast cancer: HLADQB*03032 and HLA DRB1*11 may represent protective alleles.,2000,HLA DQB*03032 and HLA DRB1*11 alleles may have a protective role in human breast cancer.,HLA DRB1*11 alleles were also significantly overrepresented (P < 0.0001) in controls (16. 3%) as compared with patients with early-onset breast cancer (3.5%).,Y,HLA DRB1*11,HLA-DRB1,1
38,bc_id40,CANCER,HLA-DQB1,11027344,Y,Genetic susceptibility to breast cancer: HLADQB*03032 and HLA DRB1*11 may represent protective alleles.,2000,HLA DQB*03032 and HLA DRB1*11 alleles may have a protective role in human breast cancer.,HLA DQB*03032 was identified in 7% of controls but in no patients with early-onset breast cancer (P = 0.0001).,Y,HLA DQB*03032,HLA-DQB1,0.5
39,bc_id41,CANCER,HLA-DPB1,11027344,B,Genetic susceptibility to breast cancer: HLADQB*03032 and HLA DRB1*11 may represent protective alleles.,2000,HLA DQB*03032 and HLA DRB1*11 alleles may have a protective role in human breast cancer.,X,X,X,X,0
40,bc_id42,CANCER,HLA-DRB1,11027344,B,Genetic susceptibility to breast cancer: HLADQB*03032 and HLA DRB1*11 may represent protective alleles.,2000,HLA DQB*03032 and HLA DRB1*11 alleles may have a protective role in human breast cancer.,MC,MC,MC,MC,0
41,bc_id43,CANCER,CYP17A1,11036113,B,CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.,2000,The CC genotype may modify the effect of other familial risk factors for early-onset breast cancer.,X,X,X,X,0
42,bc_id46,CANCER,BRCA2,11044354,B,Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.,2000,,Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer,Y,BRCA2,BRCA2,0.324175824
43,bc_id47,CANCER,BRCA1,11044354,B,Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.,2000,,Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer,Y,BRCA1,BRCA1,0.326180258
44,bc_id48,CANCER,ADH1C,11045794,B,A prospective study of the effect of alcohol consumption and ADH3 genotype on plasma steroid hormone levels and breast cancer risk.,2000,the ADH3 polymorphism modestly influences the response of some plasma hormones to alcohol consumption but is not independently associated with breast cancer risk and does not modify the association between alcohol and breast cancer risk.,No association was observed between ADH3 genotype and overall breast cancer risk (relative risk = 0.9 for slow oxidizers compared with fast; 95% confidence interval = 0.6-1.3).,N,ADH3,ADH1C,0.5
45,bc_id49,CANCER,NCOA3,11056690,N,Polymorphic repeat in AIB1 does not alter breast cancer risk.,2000,AIB1 repeat genotype does not influence postmenopausal breast cancer risk among Caucasian women in the general population.,"We observed no association between AIB1 genotype and breast cancer incidence, or specific tumor characteristics.",N,AIB1,NCOA3,0.571428571
46,bc_id50,CANCER,GSTP1,11059750,B,Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism.,2000,,"We evaluated survival according to GSTP1 genotype among women (n = 240) treated for breast cancer. Women with the low-activity Val/Val genotype had better survival. Compared with Ile/Ile, hazard ratios for overall survival were 0.8 (95% confidence interval, 0.5-1.3) for Ile/Val and 0.3 (95% confidence interval, 0.1-1.0) for Val/Val (P for trend = 0.04).",Y,GSTP1,GSTP1,0.428571429
47,bc_id51,CANCER,ERCC1,11062157,B,Identification of single nucleotide polymorphisms in human DNA repair genes.,2000,"Using this approach, possible associations of sequence variation, and hence of variation in DNA repair, with disease risk can be assessed.",NR,NR,NR,NR,0
48,bc_id52,CANCER,CDK7,11062157,B,Identification of single nucleotide polymorphisms in human DNA repair genes.,2000,"Using this approach, possible associations of sequence variation, and hence of variation in DNA repair, with disease risk can be assessed.",NR,NR,NR,NR,0
49,bc_id53,CANCER,MGMT,11062157,B,Identification of single nucleotide polymorphisms in human DNA repair genes.,2000,"Using this approach, possible associations of sequence variation, and hence of variation in DNA repair, with disease risk can be assessed.",NR,NR,NR,NR,0
50,bc_id54,CANCER,XRCC4,11062157,B,Identification of single nucleotide polymorphisms in human DNA repair genes.,2000,"Using this approach, possible associations of sequence variation, and hence of variation in DNA repair, with disease risk can be assessed.",NR,NR,NR,NR,0
51,bc_id55,CANCER,CCNH,11062157,B,Identification of single nucleotide polymorphisms in human DNA repair genes.,2000,"Using this approach, possible associations of sequence variation, and hence of variation in DNA repair, with disease risk can be assessed.",NR,NR,NR,NR,0
52,bc_id56,CANCER,CYP11A1,11062177,B,Interindividual variation in CYP1A1 expression in breast tissue and the role of genetic polymorphism.,2000,We conclude that  high CYP1A1 expression could be a risk factor for breast cancer and that the known CYP1A1 polymorphisms are not good predictors of CYP1A1 expression.,We conclude that high CYP1A1 expression could be a risk factor for breast cancer and that the known CYP1A1 polymorphisms are not good predictors of CYP1A1 expression.,A,CYP1A1,CYP1A1,0.456521739
53,bc_id57,CANCER,BRCA2,11062481,Y,A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability.,2000,The N372H variant of BRCA2 appears also to affect fetal survival in a sex-dependent manner,Here we show that a common human polymorphism (N372H) in exon 10 of BRCA2 confers an increased risk of breast cancer:,Y,BRCA2,BRCA2,0.324175824
54,bc_id58,CANCER,BRCA2,11073541,B,An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.,2000,"These findings have a direct impact on the counselling and risk management of female BRCA mutation carriers. Age, education, and a previous diagnosis of cancer are important determinants in a woman's decision making after receiving positive genetic test results.",The discovery of the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 has improved our ability to counsel women at increased risk of developing breast and ovarian cancer.,Y,BRCA2,BRCA2,0.324175824
55,bc_id59,CANCER,BRCA1,11073541,B,An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.,2000,"These findings have a direct impact on the counselling and risk management of female BRCA mutation carriers. Age, education, and a previous diagnosis of cancer are important determinants in a woman's decision making after receiving positive genetic test results.",The discovery of the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 has improved our ability to counsel women at increased risk of developing breast and ovarian cancer.,Y,BRCA1,BRCA1,0.326180258
56,bc_id60,CANCER,CYP17A1,11094312,B,Genetic polymorphism in CYP17 and breast cancer risk in japanese women,2000,These results suggest that CYP17 polymorphism(1931T/C) would be useful in the selection of Japanese women at a high risk for developing breast cancer at the age of >/=55 years.,These results suggest that CYP17 polymorphism(1931T/C) would be useful in the selection of Japanese women at a high risk for developing breast cancer at the age of >/=55 years.,Y,CYP17,CYP17A1,0.266666667
57,bc_id61,CANCER,TYMS,11102983,B,Novel thymidylate synthase enhancer region alleles in African populations,2000,"The novel alleles identified in this study decrease in frequency with Western migration, while the common alleles are relatively stable",NR,NR,NR,NR,0
58,bc_id62,CANCER,HER2,11115354,Y,The association of HER-2/neu amplification with breast cancer recurrence.,2000,"The HER-2/neu oncogene is an independent prognostic indicator of a subset of breast cancers that are at high risk of early recurrence, regardless of tumor grade, estrogen/progesterone receptor status, and lymph node status. Patients amplifying the HER-2/neu oncogene have a shorter disease-free survival than patients without the oncogene.","The HER-2/neu oncogene is an independent prognostic indicator of a subset of breast cancers that are at high risk of early recurrence, regardless of tumor grade, estrogen/progesterone receptor status, and lymph node status.",Y,HER-2,ERBB2,0.285714286
59,bc_id63,CANCER,BRCA2,11130383,B,Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.,2000,,Women with a mutation in BRCA1 or BRCA2 have a high risk of developing breast cancer and of contralateral cancer after the initial diagnosis of breast cancer,Y,BRCA2,BRCA2,0.324175824
60,bc_id64,CANCER,BRCA1,11130383,B,Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.,2000,,Women with a mutation in BRCA1 or BRCA2 have a high risk of developing breast cancer and of contralateral cancer after the initial diagnosis of breast cancer,Y,BRCA1,BRCA1,0.326180258
61,bc_id65,CANCER,CYP17A1,11142420,B,Steroid metabolism gene CYP17 polymorphism and the development of breast cancer.,2000,"Because these findings (a tendency of inverse association was found for premenopausal women carrying the A2 allele containing genotypes and a protective effect of later age at menarche (> or =13 years) was mainly limited to women with A1/A1 genotype and a remarkably lower risk for premenopausal women with at least one child (odds ratio, 0.22; 95% CI, 0.07-0.62) to be mainly attributable to the A1/A1 genotype) are based on relatively small numbers in stratified analysis, they should, however, be interpreted with caution before being confirmed in future studies.","CYP17 genotypes may thus modify individual breast cancer proneness in certain subpopulations, although they appear not to have any major modifying role in the risk of this malignancy overall.",A,CYP17,CYP17A1,0.466666667
62,bc_id66,CANCER,BRCA2,11149425,B,Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.,2001,,These results demonstrate that family profiles are important determinants of risk for carrying a BRCA1 or BRCA2 mutation and that cumulative frequency of BRCA1 and BRCA2 mutations in Japanese breast cancer families (31.9%) is within the range observed in Caucasian breast cancer families,Y,BRCA2,BRCA2,0.324175824
63,bc_id67,CANCER,BRCA1,11149425,B,Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.,2001,,These results demonstrate that family profiles are important determinants of risk for carrying a BRCA1 or BRCA2 mutation and that cumulative frequency of BRCA1 and BRCA2 mutations in Japanese breast cancer families (31.9%) is within the range observed in Caucasian breast cancer families,Y,BRCA1,BRCA1,0.326180258
64,bc_id68,CANCER,SULT1A1,11156380,Y,"Phenol sulfotransferases: hormonal regulation,polymorphism, and age of onset of breast cancer.",2000,"no effect of SULT1A1 genotype on the risk of breast cancer, but it did influence age of onset among early-affected patients, and individuals with the *1 allele were more likely to have other tumors","On the basis of the induction of SULT1A by 4-OH-tamoxifen and the known inherited variability in SULT1A enzymatic activity, we hypothesized that polymorphism in sulfotransferase genes might influence the risk of breast cancer.",A,SULT1A,SULT1A,1
65,bc_id69,CANCER,GSTP1,11169956,B,Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier.,2001,,"Our results show that in addition to well-known risk factors, in particular, a family history of cancer, GSTP1 allelopolymorphism is a significant modifier of breast cancer risk.",Y,GSTP1,GSTP1,0.428571429
66,bc_id70,CANCER,GSTM1,11169956,B,Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier.,2001,,"GSTM1 genotypes did not emerge as risk factor. Our results show that in addition to well-known risk factors, in particular, a family history of cancer, GSTP1 allelopolymorphism is a significant modifier of breast cancer risk.",N,GSTM1,GSTM1,0.20754717
67,bc_id71,CANCER,BRCA2,11180449,B,Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.,2001,,"This is one of the few geographically ascertained, population-based studies that indicate an overall frequency of BRCA1 and BRCA2 mutations at about 2--3% in all breast cancer cases.",Y,BRCA2,BRCA2,0.324175824
68,bc_id72,CANCER,BRCA1,11180449,B,Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.,2001,,"This is one of the few geographically ascertained, population-based studies that indicate an overall frequency of BRCA1 and BRCA2 mutations at about 2--3% in all breast cancer cases.",Y,BRCA1,BRCA1,0.326180258
69,bc_id73,CANCER,CYP19A1,11181459,B,Polymorphic variation in CYP19 and the risk of breast cancer.,2001,,We have assessed the frequency of allelic variants of the CYP19 intron 4 [TTTA]n repeat in 327 breast cancer cases and 253 controls from southern England... The CYP19 intron 4 [TTTA]n repeat is unlikely to have a functional effect on aromatase activity and it is more likely that the [TTTA](8) and [TTTA](10) variants are in linkage disequilibrium with other functional CYP19 variants.,A,CYP19,CYP19A1,0.484848485
70,bc_id74,CANCER,BRCA2,11181654,B,Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.,2001,It is possible to identify young women at high risk for breast cancer.,"It is possible to identify young women at high risk for breast cancer... Overall, screening parameters were comparable to population screening data, with less favorable results in the youngest age group (< 40) and BRCA1/2 carriers.",Y,BRCA1/2,BRCA2,0.324175824
71,bc_id75,CANCER,BRCA1,11181654,B,Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.,2001,It is possible to identify young women at high risk for breast cancer.,"It is possible to identify young women at high risk for breast cancer... Overall, screening parameters were comparable to population screening data, with less favorable results in the youngest age group (< 40) and BRCA1/2 carriers.",Y,BRCA1/2,BRCA1,0.326180258
72,bc_id76,CANCER,BRCA1,11183185,B,Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history.,2000,,ANF,ANF,ANF,ANF,0
73,bc_id77,CANCER,BRCA2,11192759,Y,A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families,2000,Molecular genetic testing of BRCA1 and BRCA2 genes in high-risk women with breast/ovarian cancer is effective in determining genetic predisposition to cancer. Spectrum of mutations found in both genes is variable and further investigation is needed for estimation of more frequent or founder mutations. The genetic counselling and preventive clinical follow-up of gene carriers has to be part of the genetic program.,Molecular genetic testing of BRCA1 and BRCA2 genes in high-risk women with breast/ovarian cancer is effective in determining genetic predisposition to cancer.,Y,BRCA2,BRCA2,0.324175824
74,bc_id78,CANCER,BRCA1,11192759,Y,A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families,2000,Molecular genetic testing of BRCA1 and BRCA2 genes in high-risk women with breast/ovarian cancer is effective in determining genetic predisposition to cancer. Spectrum of mutations found in both genes is variable and further investigation is needed for estimation of more frequent or founder mutations. The genetic counselling and preventive clinical follow-up of gene carriers has to be part of the genetic program.,Molecular genetic testing of BRCA1 and BRCA2 genes in high-risk women with breast/ovarian cancer is effective in determining genetic predisposition to cancer.,Y,BRCA1,BRCA1,0.326180258
75,bc_id79,CANCER,AHR,11207035,B,Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro,2001,We investigated the Lys554 allele in 386 individuals of various ethnic origins and found the,NR,NR,NR,NR,0
76,bc_id80,CANCER,CYP17A1,11212283,B,Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two importantcandidates,2001,,"We conducted a nested case-control study to evaluate whether polymorphisms in two genes involved in estrogen metabolism, CYP17 and HSD17B1, were useful in developing a breast cancer risk model that could help discriminate women who are at higher risk of breast cancer. If polymorphisms in these genes affect the level of circulating estrogens, they may directly influence breast cancer risk",A,CYP17,CYP17A1,0.466666667
77,bc_id81,CANCER,HSD17B1,11212283,B,Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two importantcandidates,2001,,"We conducted a nested case-control study to evaluate whether polymorphisms in two genes involved in estrogen metabolism, CYP17 and HSD17B1, were useful in developing a breast cancer risk model that could help discriminate women who are at higher risk of breast cancer. If polymorphisms in these genes affect the level of circulating estrogens, they may directly influence breast cancer risk",A,HSD17B1,HSD17B1,0.454545455
78,bc_id82,CANCER,SULT1A1,11219777,Y,"Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk",2001,"The results from this study suggest that homozygosity for the SULT1A1 His213 allele may be a risk factor for breast cancer, and its effect may be modified by the exposure level of endogenous estrogens and heterocyclic amines.","The results from this study suggest that homozygosity for the SULT1A1 His213 allele may be a risk factor for breast cancer, and its effect may be modified by the exposure level of endogenous estrogens and heterocyclic amines.",Y,SULT1A1,SULT1A1,0.322580645
79,bc_id83,CANCER,BRCA2,11248061,B,A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.,2001,"These results show RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages.","These results show RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages.",Y,BRCA2,BRCA2,0.324175824
80,bc_id84,CANCER,BRCA1,11248061,B,A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.,2001,"These results show RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages.",A preliminary report suggested that a single nucleotide polymorphism in the 5' untranslated region of RAD51 (135C/G) increases breast cancer risk in BRCA1 and BRCA2 carriers.,A,BRCA1,BRCA1,0.60944206
81,bc_id85,CANCER,RAD51,11248061,Y,A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.,2001,"These results show RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages.","These results show RAD51-135C is a clinically significant modifier of BRCA2 penetrance, specifically in raising breast cancer risk at younger ages.",Y,RAD51-135C,RAD51,0.230769231
82,bc_id86,CANCER,BRCA1,11248423,B,Germline BRCA1 mutations in Iranian women with breast cancer.,2001,,"To understand the significance of the contribution of the BRCA1 gene in the breast cancer among Iranian, further investigations are needed.",A,BRCA1,BRCA1,0.60944206
83,bc_id87,CANCER,GSTT1,11291049,B,Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizingenzymes and gene-environment interactions,2001,"These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.","Since individuals with modified ability to metabolize these carcinogens could have a different risk for breast cancer, we investigated the role of cytochromes P-450 (CYP1A1, CYP2D6), glutathione-S-transferases (GSTM1, GSTT1, GSTP1) and N-acetyltransferases (NAT1, NAT2) gene variants in breast carcinogenesis... These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.",A,GSTT1,GSTT1,0.289473684
84,bc_id88,CANCER,GSTM1,11291049,B,Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizingenzymes and gene-environment interactions,2001,"These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.","Since individuals with modified ability to metabolize these carcinogens could have a different risk for breast cancer, we investigated the role of cytochromes P-450 (CYP1A1, CYP2D6), glutathione-S-transferases (GSTM1, GSTT1, GSTP1) and N-acetyltransferases (NAT1, NAT2) gene variants in breast carcinogenesis... These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.",A,GSTM1,GSTM1,0.339622642
85,bc_id89,CANCER,CYP1A1,11291049,Y,Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizingenzymes and gene-environment interactions,2001,"These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.","These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.",Y,CYP1A1*4,CYP1A1,0.304347826
86,bc_id90,CANCER,NAT2,11291049,Y,Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizingenzymes and gene-environment interactions,2001,"These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.","These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.",Y,NAT2,NAT2,0.37037037
87,bc_id91,CANCER,NAT1,11291049,Y,Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizingenzymes and gene-environment interactions,2001,"These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.","These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.",Y,NAT1,NAT1,0.2
88,bc_id92,CANCER,CYP2D6,11291049,B,Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizingenzymes and gene-environment interactions,2001,"These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.","Since individuals with modified ability to metabolize these carcinogens could have a different risk for breast cancer, we investigated the role of cytochromes P-450 (CYP1A1, CYP2D6), glutathione-S-transferases (GSTM1, GSTT1, GSTP1) and N-acetyltransferases (NAT1, NAT2) gene variants in breast carcinogenesis... These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.",A,CYP2D6,CYP2D6,0.590909091
89,bc_id93,CANCER,GSTP1,11291049,B,Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizingenzymes and gene-environment interactions,2001,"These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.","Since individuals with modified ability to metabolize these carcinogens could have a different risk for breast cancer, we investigated the role of cytochromes P-450 (CYP1A1, CYP2D6), glutathione-S-transferases (GSTM1, GSTT1, GSTP1) and N-acetyltransferases (NAT1, NAT2) gene variants in breast carcinogenesis... These data suggest that CYP1A1*4, NAT1 and NAT2 variants are involved in the susceptibility to breast carcinoma by modifying the impact of exogenous and/or endogenous exposures.",A,GSTP1,GSTP1,0.485714286
90,bc_id94,CANCER,XRCC1,11303590,B,Polymorphisms in the DNA repair gene XRCC1 and breast cancer.,2001,,High-dose radiation to the chest was more strongly associated with breast cancer among white women with XRCC1 codon 399 Arg/Arg genotype.,Y,XRCC1,XRCC1,0.239130435
91,bc_id95,CANCER,GSTT1,11303592,Y,"Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer.",2001,"Our findings support the view that GST genotypes contribute to the individual breast cancer risk, especially in certain combinations.","Although only a moderate risk of breast cancer was seen for premenopausal women concurrently carrying the GSTM3*B allele containing genotypes and the GSTP1 Ile/ Ile genotype (OR, 2.07; 95% CI, 1.02-4.18), the risk rose steeply if they simultaneously lacked the GSTT1 gene (OR, 9.93, 95% CI, 1.10-90.0). A borderline significant increase in the risk of breast cancer was also seen for premenopausal women with the combination of GSTM1 null, GSTP1 Ile/Ile, and GSTT1 null genotypes (OR, 3.96; 95% CI, 0.99-15.8).",Y,GSTT1,GSTT1,0.578947368
92,bc_id96,CANCER,GSTP1,11303592,Y,"Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer.",2001,"Our findings support the view that GST genotypes contribute to the individual breast cancer risk, especially in certain combinations.","Although only a moderate risk of breast cancer was seen for premenopausal women concurrently carrying the GSTM3*B allele containing genotypes and the GSTP1 Ile/ Ile genotype (OR, 2.07; 95% CI, 1.02-4.18), the risk rose steeply if they simultaneously lacked the GSTT1 gene (OR, 9.93, 95% CI, 1.10-90.0). A borderline significant increase in the risk of breast cancer was also seen for premenopausal women with the combination of GSTM1 null, GSTP1 Ile/Ile, and GSTT1 null genotypes (OR, 3.96; 95% CI, 0.99-15.8).",Y,GSTP1 Ile/ Ile,GSTP1,0.428571429
93,bc_id97,CANCER,GSTM3,11303592,Y,"Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer.",2001,"Our findings support the view that GST genotypes contribute to the individual breast cancer risk, especially in certain combinations.","Although only a moderate risk of breast cancer was seen for premenopausal women concurrently carrying the GSTM3*B allele containing genotypes and the GSTP1 Ile/ Ile genotype (OR, 2.07; 95% CI, 1.02-4.18), the risk rose steeply if they simultaneously lacked the GSTT1 gene (OR, 9.93, 95% CI, 1.10-90.0). A borderline significant increase in the risk of breast cancer was also seen for premenopausal women with the combination of GSTM1 null, GSTP1 Ile/Ile, and GSTT1 null genotypes (OR, 3.96; 95% CI, 0.99-15.8).",Y,GSTM3*B,GSTM3,0.333333333
94,bc_id98,CANCER,GSTM1,11303592,B,"Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer.",2001,"Our findings support the view that GST genotypes contribute to the individual breast cancer risk, especially in certain combinations.","Although only a moderate risk of breast cancer was seen for premenopausal women concurrently carrying the GSTM3*B allele containing genotypes and the GSTP1 Ile/ Ile genotype (OR, 2.07; 95% CI, 1.02-4.18), the risk rose steeply if they simultaneously lacked the GSTT1 gene (OR, 9.93, 95% CI, 1.10-90.0). A borderline significant increase in the risk of breast cancer was also seen for premenopausal women with the combination of GSTM1 null, GSTP1 Ile/Ile, and GSTT1 null genotypes (OR, 3.96; 95% CI, 0.99-15.8).",Y,GSTM1 null,GSTM1,0.452830189
95,bc_id99,CANCER,RASSF1A,11306494,B,Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A) a putative tumor suppressor gene from the 3p21.3 locus occurs in a large percentage of human breast cancers.,2001,,The data suggest that hypermethylation of the CpG island promoter of RASSF1A may play an important role in breast cancer pathogenesis.,A,RASSF1A,RASSF1A,1
96,bc_id100,CANCER,CDH1,11322170,B,Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas.,2001,These data support the hypothesis that LCIS is not a precursor of invasive breast carcinoma but a marker of increased risk of developing invasive disease.,"However, mutational analysis of E-cadherin in multiple foci of carcinoma in situ surrounding an invasive lesion provided evidence to support ductal carcinoma in situ as a precursor of invasive ductal carcinoma... These data support the hypothesis that LCIS is not a precursor of invasive breast carcinoma but a marker of increased risk of developing invasive disease.",A,E-cadherin,CDH1,0.428571429
97,bc_id101,CANCER,SOD2,11323405,Y,Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk.,2001,This finding supports the proposal that MnSOD genotypes may modify individual breast cancer risk.,MnSOD genotypes containing the variant A allele were found to be associated with a 1.5-fold (95% CI 1.1-2.0) increased risk of breast cancer compared with those with the homozygous wild-type genotype (MnSOD VV). This finding supports the proposal that MnSOD genotypes may modify individual breast cancer risk.,Y,MnSOD,SOD2,0.25
98,bc_id103,CANCER,HLA-DRB1,11349219,B,HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer.,2001,were compared with those of 36 female control subjects.,"The current study investigate the alfele frequency of HLA-DRB 1 in 36 primary operable female breast cancer patients from southern Iran by polymerase chain reaction using sequence specific primers (PCR-SSP). Results were compared with those of 36 female control subjects... Our results indicated that the frequency of HLA-DRB 1*12 allele is significantly higher in the patient group (p<0.03) compared to the control group. In addition, HLA-DRB1*11 appeared to be as the most frequent allele in the control group (29.2%) and had approximately the same distribution among the patient group (22.5%).",Y,HLA-DRB 1*12,HLA-DRB1,1
99,bc_id104,CANCER,AR,11368874,N,Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer.,2001,,"Even though a substantially larger sample size would be required to reach conclusive evidence, our findings suggest that the AR-CAG polymorphism does not act as a modifier of tumor onset or tumor phenotype in breast/ovarian cancer families.",N,AR,AR,0.25
100,bc_id105,CANCER,PHB,11377649,B,Single nucleotide polymorphism in prohibitin 39 untranslated region and breast-cancer susceptibility.,2001,These data suggest that prohibitin genotyping has value in assessing risk of breast cancer in women aged 50 years or younger with at least one first-degree relative with the disease.,These data suggest that prohibitin genotyping has value in assessing risk of breast cancer in women aged 50 years or younger with at least one first-degree relative with the disease.,Y,prohibitin,PHB,0.4
101,bc_id106,CANCER,TGFB1,11401606,Y,Association between the T29-->C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study ofOsteoporotic Fractures.,2001,"Our findings suggest that TGF-beta1 genotype is associated with risk of breast cancer in white women aged 65 years or older. Because the T allele is the common variant and confers an increased risk, it may be associated with a large proportion of breast cancer cases.",Our findings suggest that TGF-beta1 genotype is associated with risk of breast cancer in white women aged 65 years or older.,Y,TGF-beta1,LTBP1,1
102,bc_id107,CANCER,COMT,11401913,B,Polymorphic catechol-O-methyltransferase gene and breast cancer risk.,2001,,"Our study, therefore, suggests that the COMT genotype may define a portion of the individual breast cancer susceptibility that is associated with reproductive events and hormone exposure even if it does not seem to be a major overall risk factor for this malignancy.",A,COMT,COMT,0.425531915
103,bc_id108,CANCER,UGT1A1,11401924,N,Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels.,2001,The results presented do not support a strong association between the UGT1A1 promoter polymorphism and the risk of breast cancer.,The results presented do not support a strong association between the UGT1A1 promoter polymorphism and the risk of breast cancer.,N,UGT1A1,UGT1A1,0.2
104,bc_id109,CANCER,GSTT1,11408954,Y,"Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer.",2001,"Genotyping analysis did not show any correlation to breast cancer risk. However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.","However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.",Y,GSTT1,GSTT1,0.578947368
105,bc_id110,CANCER,GSTP1,11408954,Y,"Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer.",2001,"Genotyping analysis did not show any correlation to breast cancer risk. However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.","However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.",Y,GSTP1,GSTP1,0.428571429
106,bc_id111,CANCER,GSTM1,11408954,Y,"Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer.",2001,"Genotyping analysis did not show any correlation to breast cancer risk. However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.","However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.",Y,GSTM1,GSTM1,0.452830189
107,bc_id112,CANCER,CYP1A1,11408954,Y,"Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer.",2001,"Genotyping analysis did not show any correlation to breast cancer risk. However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.","However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.",Y,CYP1A1,CYP1A1,0.304347826
108,bc_id113,CANCER,AHR,11408954,Y,"Genetic polymorphisms and transcriptional pattern analysis of CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes in breast cancer.",2001,"Genotyping analysis did not show any correlation to breast cancer risk. However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.","However, RT-PCR analysis provided evidence that CYP1A1, AhR, GSTM1, GSTP1 and GSTT1 genes are frequently deregulated in breast cancer and could be used as molecular biomarkers for better clinical management of such patients, with respect to chemotherapy.",Y,AhR,AHR,0.2
109,bc_id115,CANCER,BRCA1,11410514,B,Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.,2001,,"In patients < 45 years of age, 25% (6 of 24) of ER-negative and TD3 breast cancers were found to harbor mutations in BRCA1. Only 5.6% (2 of 36) of BRCA1-associated breast cancers did not have this morphological profile, compared with 94.4% (34 of 36) patients without BRCA1 mutations, giving an odds ratio of 5.67 (95% confidence interval, 1.04-32; P = 0.05). Finally, only one patient with BRCA1 mutations had a significant family history.",Y,BRCA1,BRCA1,0.326180258
110,bc_id114,CANCER,BRCA2,11410514,B,Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.,2001,,X,X,X,X,0
111,bc_id116,CANCER,BRCA2,11433401,B,"Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland.",2001,,"The overall 5-year RSR of the patients in the BRCA1 families, BRCA2 families, non-BRCA1/2 families and among sporadic cases was 67%, 77%, 86% and 78%, respectively. However, we found no significant differences in the RR adjusted for age, stage and year of diagnosis between the different familial patient groups or the general breast cancer population.",A,BRCA2,BRCA2,0.576923077
112,bc_id117,CANCER,BRCA1,11433401,B,"Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland.",2001,,"The overall 5-year RSR of the patients in the BRCA1 families, BRCA2 families, non-BRCA1/2 families and among sporadic cases was 67%, 77%, 86% and 78%, respectively. However, we found no significant differences in the RR adjusted for age, stage and year of diagnosis between the different familial patient groups or the general breast cancer population.",A,BRCA1,BRCA1,0.60944206
113,bc_id118,CANCER,COMT,11434504,B,Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer.,2001,,"These results are consistent with studies showing that COMT genotype of lower enzyme activity might be related to increase in risk of breast cancer, and extend this finding to Korean women.",A,COMT,COMT,0.425531915
114,bc_id119,CANCER,ADRB2,11434877,Y,Possible association of beta2- and beta3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer.,2001,A potential association may exist between risk of breast cancer and polymorphisms in the ADRB2 and ADRB3 genes; further studies in larger samples and/or in different ethnic groups are warranted to investigate this potential association.,A potential association may exist between risk of breast cancer and polymorphisms in the ADRB2 and ADRB3 genes; further studies in larger samples and/or in different ethnic groups are warranted to investigate this potential association.,A,ADRB2,ADRB2,1
115,bc_id120,CANCER,AR,11437399,B,CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.,2001,", in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak.","A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the androgen receptor (AR) gene are at increased risk of breast cancer (BC)... We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak.",A,AR,AR,0.458333333
116,bc_id121,CANCER,BRCA2,11437399,B,CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.,2001,", in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak.",We found no association of the CAG and GGC repeats with BC risk in either BRCA1/2 carriers or in the general population,N,BRCA1/2,BRCA2,0.098901099
117,bc_id122,CANCER,BRCA1,11437399,B,CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.,2001,", in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak.",We found no association of the CAG and GGC repeats with BC risk in either BRCA1/2 carriers or in the general population,N,BRCA1/2,BRCA1,0.064377682
118,bc_id123,CANCER,BRCA2,11448436,B,Genetic counseling impacts decision for prophylactic surgery for patients perceived to be at high risk for breast cancer.,2001,Breast cancer risk estimation and genetic evaluation can be complex.,X,X,X,X,0
119,bc_id124,CANCER,BRCA1,11448436,B,Genetic counseling impacts decision for prophylactic surgery for patients perceived to be at high risk for breast cancer.,2001,Breast cancer risk estimation and genetic evaluation can be complex.,X,X,X,X,0
120,bc_id125,CANCER,VDR,11461072,Y,Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population.,2001,,"The VDR polymorphism Bsm I, an intronic 3' gene variant, was significantly associated with increased breast cancer risk: odds ratio bb vs BB genotype = 2.32 (95% CI, 1.23-4.39). The Bsm I polymorphism was in linkage disequilibrium with a candidate translational control site, the variable length poly (A) sequence in the 3' untranslated region. Thus, the 'L' poly (A) variant was also associated with a similar breast cancer risk. A 5' VDR gene variant, Fok I, was not associated with breast cancer risk.",A,VDR,VDR,0.538461538
121,bc_id126,CANCER,RAD53,11461078,B,Mutation analysis of the CHK2 gene in families with hereditary breast cancer,2001,"The high Ile(157)--> Thr(157)mutation frequency (6.5%) observed in healthy controls and the lack of other mutations suggest that CHK2 does not contribute significantly to the hereditary breast cancer or LFL-associated breast cancer risk, at least not in the Finnish population.","Only one missense-type mutation, Ile(157)-->Thr(157), was detected. The high Ile(157)--> Thr(157)mutation frequency (6.5%) observed in healthy controls and the lack of other mutations suggest that CHK2 does not contribute significantly to the hereditary breast cancer or LFL-associated breast cancer risk, at least not in the Finnish population.",A,CHK2,RAD53/CHEK2,1
122,bc_id127,CANCER,BRCA2,11481082,B,[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations],2001,X,X,X,X,X,0
123,bc_id128,CANCER,BRCA1,11481082,B,[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations],2001,There were no differences in age at diagnosis and stage between BRCA1 and BRCA2 breast cancer. The mammographic pattern in BRCA2 was more heterogeneous. BRCA1 mutations were associated with more aggressive histopathologic findings and a higher risk of a second BC and OC.,BRCA1 mutations were associated with more aggressive histopathologic findings and a higher risk of a second BC and OC.,Y,BRCA1,BRCA1,0.326180258
124,bc_id129,CANCER,VDR,11484168,B,[Relationship of vitamin D receptor polymorphism with breast cancer],2001,There is association between vitamin D receptor polymorphism and breast cancer.,There is association between vitamin D receptor polymorphism and breast cancer.,Y,vitamin D receptor,VDR,0.269230769
125,bc_id130,CANCER,BRCA2,11504767,B,Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.,2001,,"Almost half (48%) of women in southern Sweden with early-onset breast cancer have some family history of breast or ovarian cancer, and 9.0% of early-onset breast cancer cases are associated with a germline mutation in BRCA1 or BRCA2. Mutation carriers were more prevalent among young women, women with at least one first- or second-degree relative with breast or ovarian cancer, and women with bilateral breast cancer.",Y,BRCA2,BRCA2,0.324175824
126,bc_id131,CANCER,BRCA1,11504767,B,Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.,2001,,"Almost half (48%) of women in southern Sweden with early-onset breast cancer have some family history of breast or ovarian cancer, and 9.0% of early-onset breast cancer cases are associated with a germline mutation in BRCA1 or BRCA2. Mutation carriers were more prevalent among young women, women with at least one first- or second-degree relative with breast or ovarian cancer, and women with bilateral breast cancer.",Y,BRCA1,BRCA1,0.326180258
127,bc_id132,CANCER,BRCA2,11505617,B,[Bilateral breast carcinoma and local recurrence:prevalence of BRCA-1 and BRCA-2 gene mutations in an unselected patient sample],2001,"We failed to confirm an increased prevalence of BRCA 1/BRCA 2 mutations in our hospital-based series of patients with bilateral breast cancer. However, local relapse, especially when occurring after radiotherapy, may be predictive for an underlying pathogenic BRCA 1 and BRCA 2 gene mutation in patients with bilateral breast cancer.","However, local relapse, especially when occurring after radiotherapy, may be predictive for an underlying pathogenic BRCA 1 and BRCA 2 gene mutation in patients with bilateral breast cancer.",A,BRCA 2,BRCA2,0.576923077
128,bc_id133,CANCER,BRCA1,11505617,B,[Bilateral breast carcinoma and local recurrence:prevalence of BRCA-1 and BRCA-2 gene mutations in an unselected patient sample],2001,"We failed to confirm an increased prevalence of BRCA 1/BRCA 2 mutations in our hospital-based series of patients with bilateral breast cancer. However, local relapse, especially when occurring after radiotherapy, may be predictive for an underlying pathogenic BRCA 1 and BRCA 2 gene mutation in patients with bilateral breast cancer.","We failed to confirm an increased prevalence of BRCA 1/BRCA 2 mutations in our hospital-based series of patients with bilateral breast cancer. However, local relapse, especially when occurring after radiotherapy, may be predictive for an underlying pathogenic BRCA 1 and BRCA 2 gene mutation in patients with bilateral breast cancer.",A,BRCA 1,BRCA1,0.60944206
129,bc_id134,CANCER,BRCA2,11535547,B,A Single Nucleotide Polymorphism in the 5' Untranslated Region of RAD51 and Risk of Cancer among BRCA1/2 Mutation Carriers,2001,We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers. The biochemical basis of this risk modifier is currently unknown.,We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers.,A,BRCA2,BRCA2,0.576923077
130,bc_id136,CANCER,RAD51,11535547,Y,A Single Nucleotide Polymorphism in the 5' Untranslated Region of RAD51 and Risk of Cancer among BRCA1/2 Mutation Carriers,2001,We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers. The biochemical basis of this risk modifier is currently unknown.,We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers.,A,RAD51,RAD51,0.615384615
131,bc_id135,CANCER,BRCA1,11535547,B,A Single Nucleotide Polymorphism in the 5' Untranslated Region of RAD51 and Risk of Cancer among BRCA1/2 Mutation Carriers,2001,We have identified a RAD51 5' untranslated region SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer among BRCA2 mutation carriers. The biochemical basis of this risk modifier is currently unknown.,X,X,X,X,0
132,bc_id137,CANCER,BRCA2,11556836,B,Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.,2001,bilaterality of breast cancer on its own is not strongly associated with BRCA1 and BRCA2 mutations when adjusted for age and family history.,The high frequency of bilateral disease in multi-case breast cancer families may be due to a familial aggregation of additional susceptibility factors modifying the penetrance of BRCA1 and BRCA2 mutations.,A,BRCA2,BRCA2,0.576923077
133,bc_id138,CANCER,BRCA1,11556836,B,Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.,2001,bilaterality of breast cancer on its own is not strongly associated with BRCA1 and BRCA2 mutations when adjusted for age and family history.,The high frequency of bilateral disease in multi-case breast cancer families may be due to a familial aggregation of additional susceptibility factors modifying the penetrance of BRCA1 and BRCA2 mutations.,A,BRCA1,BRCA1,0.60944206
134,bc_id139,CANCER,COMT,11556837,B,Catechol-O-Methyltransferase (COMT) gene polymorphism and breast cancer risk in young women.,2001,,"We hypothesized that the low-activity allele, COMT(Met), may be implicated in early onset breast cancer.",A,COMT,COMT,0.425531915
135,bc_id140,CANCER,BRCA2,11562929,B,An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility.,2001,,X,X,X,X,0
136,bc_id141,CANCER,BRCA1,11562929,B,An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility.,2001,,X,X,X,X,0
137,bc_id142,CANCER,COMT,11577006,B,"COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk.",2001,,These findings are consistent with a role for certain folate pathway micronutrients in mediating the association between COMT genotype and breast cancer risk.,Y,COMT,COMT,0.276595745
138,bc_id143,CANCER,ERBB2,11578807,B,Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States.,2001,"The current study suggests the HER2(V655) allele is not a breast cancer risk factor for Caucasians, African-Americans, or Latinas.","The current study suggests the HER2(V655) allele is not a breast cancer risk factor for Caucasians, African-Americans, or Latinas.",N,HER2(V655),ERBB2,0.261904762
139,bc_id144,CANCER,BRCA2,11584901,B,Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer.,2002,Increased knowledge following genetic counselling was not accompanied by an increase in anxiety or depression.,"The recent discovery of susceptibility genes relating to breast cancer, BRCA1 and BRCA2, now allows women with breast cancer and a family history of breast/ovarian cancer to undergo genetic testing to identify a causative germ-line mutation.",Y,BRCA2,BRCA2,0.324175824
140,bc_id145,CANCER,BRCA1,11584901,B,Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer.,2002,Increased knowledge following genetic counselling was not accompanied by an increase in anxiety or depression.,"The recent discovery of susceptibility genes relating to breast cancer, BRCA1 and BRCA2, now allows women with breast cancer and a family history of breast/ovarian cancer to undergo genetic testing to identify a causative germ-line mutation.",Y,BRCA1,BRCA1,0.326180258
141,bc_id146,CANCER,GSTT1,11585745,B,Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer.,2001,,"In this retrospective study, we evaluated the role of GSTM1- and GSTT1-null genotypes on disease-free and overall survival among 251 women who received treatment for incident, primary breast cancer. Women were identified through Tumor Registry records and normal archived tissue retrieved for genotyping. Adjusting for age, race, and stage at diagnosis, women with null genotypes for GSTM1 and GSTT1 had reduced hazard of death [adjusted hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.36-0.97; and HR, 0.51; CI, 0.29-0.90, respectively] in relation to those with alleles present.",Y,GSTT1,GSTT1,0.578947368
142,bc_id147,CANCER,GSTM1,11585745,B,Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer.,2001,,"In this retrospective study, we evaluated the role of GSTM1- and GSTT1-null genotypes on disease-free and overall survival among 251 women who received treatment for incident, primary breast cancer. Women were identified through Tumor Registry records and normal archived tissue retrieved for genotyping. Adjusting for age, race, and stage at diagnosis, women with null genotypes for GSTM1 and GSTT1 had reduced hazard of death [adjusted hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.36-0.97; and HR, 0.51; CI, 0.29-0.90, respectively] in relation to those with alleles present.",Y,GSTM1,GSTM1,0.452830189
143,bc_id148,CANCER,TP53,11597326,B,The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia.,2001,,"It was recently reported that an intronic variant of p53--G13964C--occurred in three out of 42 (7.1%) 'hereditary' breast cancer patients, but not in any of 171 'sporadic' breast cancer control individuals (P = 0.0003)... The present study would have had 80% power to detect an odds ratio of 4.4, and we therefore conclude that the G13946C polymorphism is not a 'high-risk' mutation for familial breast cancer.",N,p53--G13964C,TP53,0.149425287
144,bc_id149,CANCER,ATM,11606401,Y,Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients.,2001,"We conclude that  a large variety of distinct ATM mutations and variants exist among breast cancer patients, some of which can contribute to the etiology and progression of the malignancy. Screening for frequent A-T mutations such as the 1066-6-->G splice site substitution can be effective to prospectively identify A-T heterozygotes in an unselected cancer patient population.","We conclude that a large variety of distinct ATM mutations and variants exist among breast cancer patients, some of which can contribute to the etiology and progression of the malignancy.",Y,ATM,ATM,0.333333333
145,bc_id150,CANCER,BRCA2,11668223,B,Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives,2001,"Among the 214 carriers with no past exposure to oral contraceptives, the presence of one or more PROGINS alleles was associated with an OR of 2.4 for ovarian cancer, compared to women without ovarian cancer and with no PROGINS allele (P = 0.004; 95% CI 1.4-4.3). The association was present after adjustment for ethnic group and for year of birth.","The study included 195 BRCA1 and BRCA2 carriers with a prior diagnosis of ovarian cancer, 392 carriers with a diagnosis of breast cancer and 249 carriers with neither cancer. Fifty-eight women had both forms of cancer. Five hundred and ninety-five women had a BRCA1 mutation and 183 women had a BRCA2 mutation. Overall, there was no association between disease status and the presence of the PROGINS allele.",N,BRCA2,BRCA2,0.098901099
146,bc_id151,CANCER,BRCA1,11668223,B,Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives,2001,"Among the 214 carriers with no past exposure to oral contraceptives, the presence of one or more PROGINS alleles was associated with an OR of 2.4 for ovarian cancer, compared to women without ovarian cancer and with no PROGINS allele (P = 0.004; 95% CI 1.4-4.3). The association was present after adjustment for ethnic group and for year of birth.","The study included 195 BRCA1 and BRCA2 carriers with a prior diagnosis of ovarian cancer, 392 carriers with a diagnosis of breast cancer and 249 carriers with neither cancer. Fifty-eight women had both forms of cancer. Five hundred and ninety-five women had a BRCA1 mutation and 183 women had a BRCA2 mutation. Overall, there was no association between disease status and the presence of the PROGINS allele.",N,BRCA1,BRCA1,0.064377682
147,bc_id152,CANCER,PGR,11668223,Y,Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives,2001,"Among the 214 carriers with no past exposure to oral contraceptives, the presence of one or more PROGINS alleles was associated with an OR of 2.4 for ovarian cancer, compared to women without ovarian cancer and with no PROGINS allele (P = 0.004; 95% CI 1.4-4.3). The association was present after adjustment for ethnic group and for year of birth.",X,X,X,X,0
148,bc_id153,CANCER,CYP1A1,11698341,B,Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk.,2001,,"We have carried out a population based case-control study of the Thr461Asn and Ile462Val polymorphisms in CYP1A1 to clarify their importance in determining breast cancer susceptibility... We combined our data for the Ile462Val polymorphism with those from four other published studies, but even with >5000 subjects, none of the genotype-associated risks achieved statistical significance, and there was no consistent pattern to the risks associated with increasing Val allele dosage [Ile/Val OR = 0.9 (0.7-1.1), Val/Val OR = 2.3 (0.4-12), and Val carrier OR = 1.0 (0.9-1.1)].",N,CYP1A1,CYP1A1,0.239130435
149,bc_id154,CANCER,GSTT1,11700265,B,"GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene.",2001,"the GSTP1 and GSTT1 genes could play a role in carcinogenesis in the breast, possibly through increased frequency of mutations in tumor suppressor genes such as p53.","The GSTM1 and GSTT1 polymorphisms did not show an association with breast cancer... We conclude that the GSTP1 and GSTT1 genes could play a role in carcinogenesis in the breast, possibly through increased frequency of mutations in tumor suppressor genes such as p53.",A,GSTT1,GSTT1,0.289473684
150,bc_id155,CANCER,GSTP1,11700265,B,"GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene.",2001,"the GSTP1 and GSTT1 genes could play a role in carcinogenesis in the breast, possibly through increased frequency of mutations in tumor suppressor genes such as p53.","A suggestive trend of increasing risk of breast cancer with increasing number of G alleles of the GSTP1 was observed (P for trend, 0.11)... We conclude that the GSTP1 and GSTT1 genes could play a role in carcinogenesis in the breast, possibly through increased frequency of mutations in tumor suppressor genes such as p53.",A,GSTP1,GSTP1,0.485714286
151,bc_id156,CANCER,GSTM1,11700265,B,"GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene.",2001,"the GSTP1 and GSTT1 genes could play a role in carcinogenesis in the breast, possibly through increased frequency of mutations in tumor suppressor genes such as p53.",The GSTM1 and GSTT1 polymorphisms did not show an association with breast cancer.,N,GSTM1,GSTM1,0.20754717
152,bc_id157,CANCER,EBAG9,11705872,Y,Overrepresentation of the EBAG9 gene at 8q23 associated with early-stage breast cancers.,2001,,These data suggest that EBAG9 and CMYC gene are independent targets of gain and that overrepresentation of EBAG9 may play a specific role in early stages of breast carcinogenesis.,A,EBAG9,EBAG9,1
153,bc_id158,CANCER,COMT,11706521,B,Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan.,2001,The present study suggested that any association of the COMT polymorphism with breast cancer risk is limited in Japanese.,The present study suggested that any association of the COMT polymorphism with breast cancer risk is limited in Japanese.,Y,COMT,COMT,0.276595745
154,bc_id159,CANCER,BRCA2,11710890,B,Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.,2001,,"ifen reduced breast cancer incidence among healthy BRCA2 carriers by 62%, similar to the reduction in incidence of ER-positive breast cancer among all women in the Breast Cancer Prevention Trial.",Y,BRCA2,BRCA2,0.324175824
155,bc_id160,CANCER,BRCA1,11710890,B,Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.,2001,,Whether tamoxifen use at a younger age would reduce breast cancer incidence among healthy women with BRCA1 mutations remains unknown.,A,BRCA1,BRCA1,0.60944206
156,bc_id161,CANCER,BRCA1,11720473,B,Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.,2001,that can be drawn.,We conclude that the features of BRCA1 associated tumours detected in a hospital-based series of breast cancer patients not selected for family history of age at diagnosis are similar to tumours in cases selected for family history or age at diagnosis.,Y,BRCA1,BRCA1,0.326180258
157,bc_id162,CANCER,ERBB2,11731415,B,Germ-line HER-2 variant and breast cancer risk by stage of disease.,2001,"Risk of localized breast cancer was significantly elevated among women with the HER-2 variant, but not among women with regional or metastatic disease. Women with at least one copy of the Valine variant were approximately one-half as likely to have high-stage as low-stage breast cancer (P =.02), and this effect was present across racial/ethnic groups.","Risk of localized breast cancer was significantly elevated among women with the HER-2 variant, but not among women with regional or metastatic disease. Women with at least one copy of the Valine variant were approximately one-half as likely to have high-stage as low-stage breast cancer (P =.02), and this effect was present across racial/ethnic groups.",Y,HER-2,ERBB2,0.285714286
158,bc_id163,CANCER,GSTT1,11731429,B,Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case-control study.,2001,,"To test this hypothesis, we evaluated benzo(a)pyrene diol-epoxide (BPDE)-induced mutagen sensitivity and polymorphisms of GSTM1 and GSTT1 in a pilot case-control study of breast cancer. Short-term cell cultures were established from blood samples of 100 female breast cancer patients and 105 healthy controls... The level of chromatid breaks greater than the median value of controls was associated with a >3-fold increased risk of breast cancer [adjusted odds ratio (ORadj) = 3.11; 95% CI = 1.72-5.64].",Y,GSTT1,GSTT1,0.578947368
159,bc_id164,CANCER,GSTM1,11731429,B,Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case-control study.,2001,,"To test this hypothesis, we evaluated benzo(a)pyrene diol-epoxide (BPDE)-induced mutagen sensitivity and polymorphisms of GSTM1 and GSTT1 in a pilot case-control study of breast cancer. Short-term cell cultures were established from blood samples of 100 female breast cancer patients and 105 healthy controls... The level of chromatid breaks greater than the median value of controls was associated with a >3-fold increased risk of breast cancer [adjusted odds ratio (ORadj) = 3.11; 95% CI = 1.72-5.64].",Y,GSTM1,GSTM1,0.452830189
160,bc_id165,CANCER,GSTZ1,11737895,N,Investigation of glutathione S-transferase zeta and the development of sporadic breast cancer,2001,Statistical analysis indicates that there is no association of the GSTZ1 variant and hence the gene does not appear to play a significant role in the development of sporadic breast cancer.,Statistical analysis indicates that there is no association of the GSTZ1 variant and hence the gene does not appear to play a significant role in the development of sporadic breast cancer.,N,GSTZ1,GSTZ1,1
161,bc_id166,CANCER,SRD5A2,11751447,N,The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.,2001,"Given that this study had sufficient power to detect altered risks in the order of 1.4- to 1.7-fold, our results suggest that the SRD5A2 (TA)(9) allele is unlikely to be associated with moderate alterations in breast or ovarian cancer risk.","Given that this study had sufficient power to detect altered risks in the order of 1.4- to 1.7-fold, our results suggest that the SRD5A2 (TA)(9) allele is unlikely to be associated with moderate alterations in breast or ovarian cancer risk.",N,SRD5A2,SRD5A2,0.333333333
162,bc_id168,CANCER,BRCA2,11754111,B,BRCA2 gene mutations in Greek patients with familial breast cancer.,2002,,Although patients with BRCA2 germline mutations did not have a distinct histological phenotype they had an improved overall survival (100% vs 65%). Our findings suggest that there is a cluster of novel mutations in exons 10 and 11 in Greek patients with familial breast cancer.,Y,BRCA2,BRCA2,0.324175824
163,bc_id169,CANCER,IGF1,11768601,B,Polymorphic CA repeats in the IGF-I gene and breast cancer.,NA,,"If our observations can be confirmed in larger studies, the findings will provide further evidence to support the role of IGF-I in breast cancer and the link between genetic polymorphism and cancer susceptibility.",Y,IGF-I,IGF1,0.35
164,bc_id170,CANCER,GSTT1,11773866,B,Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk.,NA,,X,X,X,X,0
165,bc_id171,CANCER,GSTP1,11773866,B,Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk.,NA,,X,X,X,X,0
166,bc_id172,CANCER,COMT,11773866,B,Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk.,NA,,These results suggest that the use of HRT could substantially increase the risk of breast cancer among women with specific combinations of the at-risk genotypes of COMT and GST genes.,Y,COMT,COMT,0.276595745
167,bc_id173,CANCER,BRCA1,11807889,B,All in the family: evaluation of the process andcontent of sisters' communication about BRCA1 and BRCA2 genetic test results.,2002,"The results of this study suggest that probands are likely to quickly communicate their BRCA1/2 test results to relatives and that although needs for social support may motivate family communication, emotionally distant relationships may be a barrier to communication with relatives.",X,X,X,X,0
168,bc_id174,CANCER,BRCA2,11807889,B,All in the family: evaluation of the process andcontent of sisters' communication about BRCA1 and BRCA2 genetic test results.,2002,"The results of this study suggest that probands are likely to quickly communicate their BRCA1/2 test results to relatives and that although needs for social support may motivate family communication, emotionally distant relationships may be a barrier to communication with relatives.",X,X,X,X,0
169,bc_id175,CANCER,GSTM1,11810042,B,Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development.,2002,"while these loci are not associated with breast cancer occurrence, the GSTM1 locus is likely associated with tumor progression.","We conclude that while these loci are not associated with breast cancer occurrence, the GSTM1 locus is likely associated with tumor progression. NQO1 results suggest that different quinones (possibly estrogenic quinone metabolites) might affect the histological development of breast tumors.",A,GSTM1,GSTM1,0.339622642
170,bc_id176,CANCER,NQO1,11810042,B,Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development.,2002,"while these loci are not associated with breast cancer occurrence, the GSTM1 locus is likely associated with tumor progression.","We conclude that while these loci are not associated with breast cancer occurrence, the GSTM1 locus is likely associated with tumor progression. NQO1 results suggest that different quinones (possibly estrogenic quinone metabolites) might affect the histological development of breast tumors.",Y,NQO1,NQO1,0.5
171,bc_id177,CANCER,CDKN1A,11815410,B,Waf-1 (p21) and p53 polymorphisms in breast cancer.,2002,we did not see an interaction between Waf-1(ser31) and p53(1--2-1). Consistent with the finding that p53(1--2-1) is a risk factor for Caucasian women was the observation of a strong interaction between race and p53 (P < 0.01).,"Whereas multivariate analysis suggested associations between breast cancer and inheritance of Waf-1(ser31) in African-Americans (OR, 2.32; 95% CI = 0.66-5.60; n = 37 cases and 65 controls) and Latinas (OR, 2.22; 95% CI = 0.71-6.89; n = 30 cases and 75 controls), and inheritance of p53(1-2-1) in Caucasians (OR, 3.15; 95% CI = 1.14-8.89; n = 93 cases and 187 controls), we did not see an interaction between Waf-1(ser31) and p53(1-2-1).",N,Waf-1(ser31),CDKN1A,0.25
172,bc_id178,CANCER,TP53,11815410,B,Waf-1 (p21) and p53 polymorphisms in breast cancer.,2002,we did not see an interaction between Waf-1(ser31) and p53(1--2-1). Consistent with the finding that p53(1--2-1) is a risk factor for Caucasian women was the observation of a strong interaction between race and p53 (P < 0.01).,"Previous studies indicated that certain p53 polymorphisms confer an increased risk of breast cancer [odds ratios (ORs) and 95% confidence intervals (CIs) = 2.9, 1.4-6.3 Carcinogenesis (Lond.), 17: 1313, 1996; 2.5, 1.3-4.8 Cancer Epidemiol...  Whereas multivariate analysis suggested associations between breast cancer and inheritance of Waf-1(ser31) in African-Americans (OR, 2.32; 95% CI = 0.66-5.60; n = 37 cases and 65 controls) and Latinas (OR, 2.22; 95% CI = 0.71-6.89; n = 30 cases and 75 controls), and inheritance of p53(1-2-1) in Caucasians (OR, 3.15; 95% CI = 1.14-8.89; n = 93 cases and 187 controls), we did not see an interaction between Waf-1(ser31) and p53(1-2-1). Consistent with the finding that p53(1-2-1) is a risk factor for Caucasian women was the observation of a strong interaction between race and p53 (P < 0.01).",Y,p53,TP53,0.367816092
173,bc_id179,CANCER,BRCA2,11822793,B,Measuring Women's preferences for breast cancer treatments and BRCA1/BRCA2 testing.,2002,,X,X,X,X,0
174,bc_id180,CANCER,BRCA1,11822793,B,Measuring Women's preferences for breast cancer treatments and BRCA1/BRCA2 testing.,2002,,X,X,X,X,0
175,bc_id181,CANCER,BRCA1,11826460,B,[Information to families with hereditary breast and ovarian cancer],2001,"The legislation constituted no barrier to offering health services to the target group. Information on our services had reached all close relatives who could benefit from them. This may be representative for curable inherited disorders. We examined inherited cancer limited to females; similar studies on inherited cancers in males and on other curable inherited disorders should be performed. Outside the framework of the present study, we are aware of rare examples of distant cousins who have not been properly informed through their families. One legally acceptable way of identifying mutation carrier families is to test all patients with breast or ovarian cancer for causative mutations. Health services should be monitored to make future decisions based on empirical evidence.","We identified all first-degree relatives of all 75 BRCA1 mutation carriers diagnosed within a given period of time and asked them whether or not they had been informed by their relatives... After two years, 60/63 (95%) adult sisters and daughters had made contact with us; the remaining three (5%) had been informed... One legally acceptable way of identifying mutation carrier families is to test all patients with breast or ovarian cancer for causative mutations.",Y,BRCA1,BRCA1,0.326180258
176,bc_id182,CANCER,FGFR4,11830541,Y,Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.,2002,Our results support the conclusion that the FGFR4 Arg(388) allele represents a determinant that is innocuous in healthy individuals but predisposes cancer patients for significantly accelerated disease progression.,"Consistent with this finding, MDA-MB-231 mammary tumor cells expressing FGFR4 Arg(388) exhibited increased motility relative to cells expressing the FGFR4 Gly(388) isotype. Our results support the conclusion that the FGFR4 Arg(388) allele represents a determinant that is innocuous in healthy individuals but predisposes cancer patients for significantly accelerated disease progression.",Y,FGFR4,FGFR4,0.6
177,bc_id183,CANCER,BRCA1,11836613,Y,Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Cypriot family.,2002,,"Since these BRCA2 variants appear to be polymorphisms in the Cypriot population, we suggest that the two BRCA1 mutations, Q356R and S1512I, may be related to the breast cancer phenotype.",A,BRCA1,BRCA1,0.60944206
178,bc_id184,CANCER,LTA,11841482,B,Polymorphisms of tumour necrosis factors A and B in breast cancer.,2002,,X,X,X,X,0
179,bc_id185,CANCER,TNF,11841482,B,Polymorphisms of tumour necrosis factors A and B in breast cancer.,2002,,X,X,X,X,0
180,bc_id186,CANCER,BRCA2,11844822,B,BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.,2002,BRCA1 mutations were three times more prevalent than BRCA2 mutations.,Evidence for reduced breast cancer penetrance associated with the BRCA2 mutation 6174delT was noted,Y,BRCA2,BRCA2,0.324175824
181,bc_id187,CANCER,BRCA1,11844822,B,BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.,2002,BRCA1 mutations were three times more prevalent than BRCA2 mutations.,"BRCA1 mutations were three times more prevalent than BRCA2 mutations. Breast cancer diagnosis before 50 years of age, ovarian cancer, breast and ovarian cancer in a single individual, and male breast cancer were all significantly more common in families with BRCA1 and BRCA2 mutations, but none of these factors distinguished between BRCA1 and BRCA2 mutations.",A,BRCA1,BRCA1,0.60944206
182,bc_id188,CANCER,ATM,11849780,Y,ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects.,2002,"Possession of an ATM mutation, particularly when 2 are present, may be predictive of an increase in subcutaneous late tissue effects after RT for breast cancer and may subsequently prove to be a relative contraindication to standard management. These patients may be better served with reduced doses of radiation. Equivalent local control remains to be tested, but this germline alteration may radiosensitize normal tissues, as well as the tumor itself. DHPLC is effective in the identification of these patients. A larger study is required to confirm these findings.","Possession of an ATM mutation, particularly when 2 are present, may be predictive of an increase in subcutaneous late tissue effects after RT for breast cancer and may subsequently prove to be a relative contraindication to standard management.",A,ATM,ATM,0.422222222
183,bc_id189,CANCER,BRCA2,11857015,B,"A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.",2002,"The findings suggest that several common, low penetrance genes with multiplicative effects on risk may account for the residual non-BRCA1/2 familial aggregation of breast cancer. The modifying effect may explain the previously reported differences between population based estimates for BRCA1/2 penetrance and estimates based on high-risk families.","The findings suggest that several common, low penetrance genes with multiplicative effects on risk may account for the residual non-BRCA1/2 familial aggregation of breast cancer.",A,BRCA1/2,BRCA2,0.576923077
184,bc_id190,CANCER,BRCA1,11857015,B,"A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.",2002,"The findings suggest that several common, low penetrance genes with multiplicative effects on risk may account for the residual non-BRCA1/2 familial aggregation of breast cancer. The modifying effect may explain the previously reported differences between population based estimates for BRCA1/2 penetrance and estimates based on high-risk families.","The findings suggest that several common, low penetrance genes with multiplicative effects on risk may account for the residual non-BRCA1/2 familial aggregation of breast cancer.",A,BRCA1,BRCA1,0.60944206
185,bc_id191,CANCER,CDH1,11857408,N,"CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk.",2002,"These results do not support CDH1 as a prominent low-penetrance cancer susceptibility gene, but indicate that CDH1 mutations contribute to the progression of both lobular and ductal tumors.","In a case-control study, we also tested whether a variant adenine allele in the promoter polymorphism -161C-->A with a putative influence on the transcriptional activity of CDH1 in vitro confers any detectable risk of breast cancer. No significant difference in the allelic frequency between patients with breast cancer (326/1,152, 28.3%) and controls (190/696, 27.3%, p > 0.05; relative risk 1.05, 95% confidence interval 0.85-1.30) was found.",N,CDH1,CDH1,0.428571429
186,bc_id192,CANCER,AR,11861380,B,The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses Health Study.,2002,", we observed no overall relation of AR genotype with breast cancer risk among mostly postmenopausal Caucasian women.","In summary, we observed no overall relation of AR genotype with breast cancer risk among mostly postmenopausal Caucasian women.",N,AR,AR,0.25
187,bc_id193,CANCER,ESR1,11867202,B,Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk.,2002,,"The estrogen receptor-alpha (ERalpha) has been known to play a role in the development and progression of breast cancer...  Although this allele had no direct effect in individual breast cancer risk, it was positively associated with tumor PR (P for trend=0.04) and ER expression (P for trend=0.06) and negatively associated with p53 expression (P for trend=0.02).",A,estrogen receptor-alpha,ESR1,0.586956522
188,bc_id194,CANCER,TGFBR1,11867510,B,Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer.,2002,"Our study provides additional evidence for an association of the TbetaR-I (6A) allele with cancer predisposition, but we find no evidence of a mutational hot-spot in exon 5 of TbetaR-I in either ovarian or breast cancers.",ANF,ANF,ANF,ANF,0
189,bc_id195,CANCER,NAT2,11872636,B,"Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer.",2002,,"These findings suggest that polymorphisms of CYP1A1, GSTM1, and NAT2 significantly affect either the frequency or the level of DNA adducts in normal breast tissues of women having breast cancer, especially in smokers. Further large-scale studies are required to determine the exact role of these polymorphisms and types of DNA damage in breast cancer susceptibility.",Y,NAT2,NAT2,0.37037037
190,bc_id196,CANCER,GSTM1,11872636,B,"Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer.",2002,,"These findings suggest that polymorphisms of CYP1A1, GSTM1, and NAT2 significantly affect either the frequency or the level of DNA adducts in normal breast tissues of women having breast cancer, especially in smokers. Further large-scale studies are required to determine the exact role of these polymorphisms and types of DNA damage in breast cancer susceptibility.",Y,GSTM1,GSTM1,0.452830189
191,bc_id197,CANCER,CYP1A1,11872636,B,"Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer.",2002,,"These findings suggest that polymorphisms of CYP1A1, GSTM1, and NAT2 significantly affect either the frequency or the level of DNA adducts in normal breast tissues of women having breast cancer, especially in smokers. Further large-scale studies are required to determine the exact role of these polymorphisms and types of DNA damage in breast cancer susceptibility.",Y,CYP1A1,CYP1A1,0.304347826
192,bc_id198,CANCER,CDKN1A,11872638,B,Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer.,2002,,"A single nucleotide polymorphism in intron 2 of p21 was associated with slightly increased breast cancer risk (RR = 1.4, P = 0.011) and with well/moderately differentiated tumour histology (P = 0.029). The 16 bp insertion polymorphism in intron 3 of TP53 was associated with poor histological grade (OR = 2.3, P = 0.013) independently of other pathological features.",A,p21,CDKN1A,0.5
193,bc_id199,CANCER,BRCA2,11879560,B,BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.,2002,These data suggest that other genes that confer an increased risk for both female and male breast cancer have yet to be found.,"No BRCA1 mutation carriers were identified and five cases were found to carry a mutation in BRCA2.... However, BRCA2 accounted for only 15% of the excess familial risk of breast cancer in female first-degree relatives...",Y,BRCA2,BRCA2,0.324175824
194,bc_id200,CANCER,BRCA1,11879560,B,BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.,2002,These data suggest that other genes that confer an increased risk for both female and male breast cancer have yet to be found.,"No BRCA1 mutation carriers were identified and five cases were found to carry a mutation in BRCA2.... However, BRCA2 accounted for only 15% of the excess familial risk of breast cancer in female first-degree relatives...",N,BRCA1,BRCA1,0.064377682
195,bc_id201,CANCER,CYP17A1,11880540,N,The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.,2002,Our results suggest that CYP17 MspA1 polymorphism may be at best a weak modifier of breast cancer risk but is not a significant independent risk factor.,Our results suggest that CYP17 MspA1 polymorphism may be at best a weak modifier of breast cancer risk but is not a significant independent risk factor.,N,CYP17 MspA1,CYP17A1,0.266666667
196,bc_id202,CANCER,BRCA2,11920621,B,BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines.,2002,,"Our data suggest that penetrance of BRCA mutations is not reduced in the Philippines. Germline mutations in the BRCA2 gene contribute more than mutations BRCA1 to breast cancer in the Philippines, due in large part to the presence of 2 common founder mutations.",Y,BRCA2,BRCA2,0.324175824
197,bc_id203,CANCER,BRCA1,11920621,B,BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines.,2002,,"Our data suggest that penetrance of BRCA mutations is not reduced in the Philippines. Germline mutations in the BRCA2 gene contribute more than mutations BRCA1 to breast cancer in the Philippines, due in large part to the presence of 2 common founder mutations.",A,BRCA1,BRCA1,0.60944206
198,bc_id204,CANCER,KLK10,11920956,B,Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate breast testicular and ovarian cancers.,2002,"We found no evidence for somatic mutations of the KLK10 gene in cancers of the prostate, breast, ovary, and testis. The single nucleotide variation at codon 50 appears to be associated with prostate cancer risk.","We found no evidence for somatic mutations of the KLK10 gene in cancers of the prostate, breast, ovary, and testis. ",N,KLK10,KLK10,1
199,bc_id205,CANCER,KLK10,11920956,N,"Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers.",2002,"We found no evidence for somatic mutations of the KLK10 gene in cancers of the prostate, breast, ovary, and testis. The single nucleotide variation at codon 50 appears to be associated with prostate cancer risk.",MC,MC,MC,MC,0
200,bc_id212,CANCER,CYP1A1,11934439,B,Association of DNA-protein crosslinks and breast cancer.,2002,", our findings were inconsistent with those of previous studies that showed polymorphism genes (CYP1A1, NAT2, GSTM1 and GSTT1) were associated with cancer risk.","In conclusion, our findings were inconsistent with those of previous studies that showed polymorphism genes (CYP1A1, NAT2, GSTM1 and GSTT1) were associated with cancer risk. However, this study indicated that genotypic variants of these polymorphisms did not elevate the risk for breast cancer, individually or interactively.",A,CYP1A1,CYP1A1,0.456521739
201,bc_id213,CANCER,CDH1,11948460,N,"Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer",2002,"We found several germline mutations of unknown clinical significance in the CDH1 gene that probably do not explain the association of prostate, gastric and/or breast cancers in the HPC-families. Two missense mutations and a mutation in intron 5 were identified that do not influence the risk of hereditary or sporadic prostate cancer in general and are considered to be pedigree specific. In a family with hereditary gastric cancer of the diffuse type, we identified the first truncating germline mutation in a Scandinavian family.","We found several germline mutations of unknown clinical significance in the CDH1 gene that probably do not explain the association of prostate, gastric and/or breast cancers in the HPC-families.",N,CDH1,CDH1,0.428571429
202,bc_id214,CANCER,BRCA2,11950848,B,Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.,2002,,This review focuses on genes other than the high penetrance genes BRCA1 and BRCA2 that are involved in breast cancer susceptibility...  An association with breast cancer at a 5% significance level was found for 13 polymorphisms in 10 genes described in more than one breast cancer study.,A,BRCA2,BRCA2,0.576923077
203,bc_id215,CANCER,BRCA1,11950848,B,Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.,2002,,This review focuses on genes other than the high penetrance genes BRCA1 and BRCA2 that are involved in breast cancer susceptibility...  An association with breast cancer at a 5% significance level was found for 13 polymorphisms in 10 genes described in more than one breast cancer study.,A,BRCA1,BRCA1,0.60944206
204,bc_id216,CANCER,BRCA2,11964925,B,Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history.,2002,It is not yet clear whether the recognized breast cancer risk factors operate in the same way in women who carry a mutation in the BRCA1 or BRCA2 genes.,It is not yet clear whether the recognized breast cancer risk factors operate in the same way in women who carry a mutation in the BRCA1 or BRCA2 genes.,A,BRCA2,BRCA2,0.576923077
205,bc_id217,CANCER,BRCA1,11964925,B,Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history.,2002,It is not yet clear whether the recognized breast cancer risk factors operate in the same way in women who carry a mutation in the BRCA1 or BRCA2 genes.,It is not yet clear whether the recognized breast cancer risk factors operate in the same way in women who carry a mutation in the BRCA1 or BRCA2 genes.,A,BRCA1,BRCA1,0.60944206
206,bc_id218,CANCER,CHEK2,11967536,B,Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations,2002,"This suggests that the biological mechanisms underlying the elevated risk of breast cancer in CHEK2 mutation carriers are already subverted in carriers of BRCA1 or BRCA2 mutations, which is consistent with participation of the encoded proteins in the same pathway.","By contrast, the variant confers no increased cancer risk in carriers of BRCA1 or BRCA2 mutations. This suggests that the biological mechanisms underlying the elevated risk of breast cancer in CHEK2 mutation carriers are already subverted in carriers of BRCA1 or BRCA2 mutations, which is consistent with participation of the encoded proteins in the same pathway.",A,CHEK2,CHEK2,0.383333333
207,bc_id219,CANCER,BRCA2,11977534,B,[Genetic test and prophylactic treatment in breast cancer families],2002,"These results indicate that genetic testing and prophylactic surgery would be acceptable among a considerable number of Japanese women, and seem to support the establishment an infrastructure for genetic testing in Japan.","Lifetime risk of breast cancer in BRCA1 or BRCA2 mutation carriers was estimated at nearly 80%, and that of ovarian cancer in BRCA1 mutation carriers was about 40%",Y,BRCA2,BRCA2,0.324175824
208,bc_id220,CANCER,BRCA1,11977534,B,[Genetic test and prophylactic treatment in breast cancer families],2002,"These results indicate that genetic testing and prophylactic surgery would be acceptable among a considerable number of Japanese women, and seem to support the establishment an infrastructure for genetic testing in Japan.","Lifetime risk of breast cancer in BRCA1 or BRCA2 mutation carriers was estimated at nearly 80%, and that of ovarian cancer in BRCA1 mutation carriers was about 40%",Y,BRCA1,BRCA1,0.326180258
209,bc_id221,CANCER,BRCA2,11981002,B,"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.",2002,BRCA1 has a distinctive morphology and immunohistochemical phenotype.,"Breast cancers in patients with BRCA1 germline mutations are more often negative for estrogen receptor, progesterone receptor, and HER-2, and are more likely to be positive for p53 protein compared with controls. In contrast, BRCA2 tumors do not show a significant difference in the expression of any of these proteins compared with controls.",A,BRCA2,BRCA2,0.576923077
210,bc_id222,CANCER,BRCA1,11981002,B,"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.",2002,BRCA1 has a distinctive morphology and immunohistochemical phenotype.,"Breast cancers in patients with BRCA1 germline mutations are more often negative for estrogen receptor, progesterone receptor, and HER-2, and are more likely to be positive for p53 protein compared with controls. In contrast, BRCA2 tumors do not show a significant difference in the expression of any of these proteins compared with controls.",A,BRCA1,BRCA1,0.60944206
211,bc_id223,CANCER,PTEN,11986403,B,A 39-bp deletion polymorphism in PTEN in African American individuals: implications for moleculardiagnostic testing.,2002,"Due to its location immediately upstream of the splicing site of exon 8, this polymorphism could be mistaken for a deleterious mutation in the PTEN.","Germline mutations in the PTEN/MMAC1/TEP1 tumor suppressor gene cause Cowden syndrome (CS), a hereditary hamartoma-tumor syndrome with an increased risk of breast, thyroid, and endometrial cancers, and seemingly unrelated developmental disorders, such as Bannayan-Riley-Ruvalcaba (BRR) syndrome, Proteus, and Proteus-like syndromes.",Y,PTEN,PTEN,0.166666667
212,bc_id224,CANCER,IL6,11988246,B,Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.,2002,,NR,NR,NR,NR,0
213,bc_id225,CANCER,ATM,11996792,Y,Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls,2002,The data are compatible with certain missense mutations in ATM predisposing to breast cancer.,"Studies of families of patients with ataxia telangiectasia (A-T) show an increased risk of breast cancer in heterozygous A-T carriers. However, expected increased levels of mutations in the ATM gene among unselected breast cancer patients have not been found to date...  The background of missense changes in controls is high. There is a trend towards elevation of all structural changes in cases, but the results are not statistically significant. Cohort-specific structural changes are significantly more prevalent in the breast cancer patients. The data are compatible with certain missense mutations in ATM predisposing to breast cancer.",A,ATM,ATM,0.422222222
214,bc_id226,CANCER,PGR,12010857,B,The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.,2002,,"We investigated whether the exon 4 PR polymorphism was associated with breast cancer in Australian women, using a population-based study of 1452 cases and 793 controls, half of whom were <40 years of age, and the other half were 40-59 years of age... We therefore conclude that this polymorphism is not associated with a markedly reduced or increased risk of breast cancer in Australian women <60 years of age.",N,PR,PGR,0.357142857
215,bc_id227,CANCER,CYP1B1,12010864,Y,Association of CYP1B1 polymorphisms and breast cancer risk,2002,The results presented do not support a strong association between m1 and m2 and the risk of breast cancer.,"We sought to determine whether two common functional polymorphisms in Cytochrome P450 1B1, V432L (m1), and A453S (m2) are related to breast cancer risk... The results presented do not support a strong association between m1 and m2 and the risk of breast cancer.",A,Cytochrome P450 1B1,CYP1B1,0.384615385
216,bc_id228,CANCER,RAD52,12023982,B,Variants in DNA double-strand break repair genes and breast cancer susceptibility.,2002,"These data provide some evidence that variants in XRCC2 and LIG4 alter breast cancer risk, together with stronger evidence that variants of XRCC3 are associated with risk. If these results can be confirmed, understanding the functional basis should improve our understanding of the role of DNA repair in breast carcinogenesis.","We performed genetic association studies in a population-based breast cancer case-control study analysing polymorphisms in genes involved in homologous recombination (NBS1, RAD52, RAD51, XRCC2 and XRCC3) and non-homologous end-joining (KU70/80 and LIG4). These DNA double-strand break repair genes are candidates for breast cancer susceptibility. Genotype results were available for up to 2205 cases and 1826 controls.",A,RAD52,RAD52,0.666666667
217,bc_id229,CANCER,RAD51,12023982,B,Variants in DNA double-strand break repair genes and breast cancer susceptibility.,2002,"These data provide some evidence that variants in XRCC2 and LIG4 alter breast cancer risk, together with stronger evidence that variants of XRCC3 are associated with risk. If these results can be confirmed, understanding the functional basis should improve our understanding of the role of DNA repair in breast carcinogenesis.","We performed genetic association studies in a population-based breast cancer case-control study analysing polymorphisms in genes involved in homologous recombination (NBS1, RAD52, RAD51, XRCC2 and XRCC3) and non-homologous end-joining (KU70/80 and LIG4). These DNA double-strand break repair genes are candidates for breast cancer susceptibility. Genotype results were available for up to 2205 cases and 1826 controls.",A,RAD51,RAD51,0.615384615
218,bc_id230,CANCER,NBN,12023982,B,Variants in DNA double-strand break repair genes and breast cancer susceptibility.,2002,"These data provide some evidence that variants in XRCC2 and LIG4 alter breast cancer risk, together with stronger evidence that variants of XRCC3 are associated with risk. If these results can be confirmed, understanding the functional basis should improve our understanding of the role of DNA repair in breast carcinogenesis.","We performed genetic association studies in a population-based breast cancer case-control study analysing polymorphisms in genes involved in homologous recombination (NBS1, RAD52, RAD51, XRCC2 and XRCC3) and non-homologous end-joining (KU70/80 and LIG4). These DNA double-strand break repair genes are candidates for breast cancer susceptibility. Genotype results were available for up to 2205 cases and 1826 controls.",A,NBS1,NBN,0.571428571
219,bc_id231,CANCER,XRCC2,12023982,Y,Variants in DNA double-strand break repair genes and breast cancer susceptibility.,2002,"These data provide some evidence that variants in XRCC2 and LIG4 alter breast cancer risk, together with stronger evidence that variants of XRCC3 are associated with risk. If these results can be confirmed, understanding the functional basis should improve our understanding of the role of DNA repair in breast carcinogenesis.","These data provide some evidence that variants in XRCC2 and LIG4 alter breast cancer risk, together with stronger evidence that variants of XRCC3 are associated with risk.",Y,XRCC2,XRCC2,0.272727273
220,bc_id232,CANCER,XRCC3,12023982,Y,Variants in DNA double-strand break repair genes and breast cancer susceptibility.,2002,"These data provide some evidence that variants in XRCC2 and LIG4 alter breast cancer risk, together with stronger evidence that variants of XRCC3 are associated with risk. If these results can be confirmed, understanding the functional basis should improve our understanding of the role of DNA repair in breast carcinogenesis.","These data provide some evidence that variants in XRCC2 and LIG4 alter breast cancer risk, together with stronger evidence that variants of XRCC3 are associated with risk.",Y,XRCC3,XRCC3,0.269230769
221,bc_id233,CANCER,XRCC2,12023985,B,A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer.,2002,These results support the hypothesis that subtle variation in DNA repair capacity may influence cancer susceptibility in the population.,"Carriage of the rare allele of XRCC2 R188H was associated with breast cancer overall [odds ratio 1.3; 95% confidence interval (CI)=(1.0, 1.8)] and when younger-onset cases with a positive family history were compared with older controls with no family history [odds ratio 1.9; 95% CI=(1.0, 3.8)].",Y,XRCC2,XRCC2,0.272727273
222,bc_id234,CANCER,GSTP1,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,GSTP1,GSTP1,0.085714286
223,bc_id235,CANCER,CYP1A1,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,CYP1A1,CYP1A1,0.239130435
224,bc_id237,CANCER,CDH1,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,CDH1,CDH1,0.428571429
225,bc_id238,CANCER,BRCA2,12036913,N,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1. Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.",N,BRCA1/2,BRCA2,0.098901099
226,bc_id239,CANCER,BRCA1,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,BRCA1,BRCA1,0.064377682
227,bc_id240,CANCER,AR,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,AR,AR,0.25
228,bc_id241,CANCER,TGFB1,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1. Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.",N,TGF-beta,TGFB1,0.296296296
229,bc_id242,CANCER,RAD52,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,RAD52,RAD52,0.333333333
230,bc_id243,CANCER,RAD51C,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1. Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.",N,RAD51,RAD51C,1
231,bc_id244,CANCER,NQO1,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,NQO1,NQO1,0.25
232,bc_id245,CANCER,NBN,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,NBS1,NBN,0.238095238
233,bc_id246,CANCER,LIG4,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",Y,LIG4,LIG4,0.25
234,bc_id247,CANCER,TP53,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","CYP17 (P = 0.05) and TP53 (P = 0.06) polymorphisms showed marginally significant associations in unstratified analyses... However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.",Y,TP53,TP53,0.367816092
235,bc_id248,CANCER,VDR,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,VDR,VDR,0.192307692
236,bc_id249,CANCER,XRCC3,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,XRCC3,XRCC3,0.269230769
237,bc_id250,CANCER,ATM,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,ATM,ATM,0.244444444
238,bc_id251,CANCER,COMT,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.","We assessed the effect of germ-line variation on survival among women with breast cancer participating in a British population-based study...  The largest effect was observed for the silent polymorphism D501D (t>c) in LIG4, a gene involved in DNA double-strand break repair... No effect on survival was seen for polymorphisms in ATM, BRCA1/2, CHK2, KU70, NBS1, RAD51, RAD52, XRCC3, AR, COMT, NQO1, VDR, ADH3, CYP1A1, GSTP1, TGF-beta, or CDH1.",N,COMT,COMT,0.29787234
239,bc_id236,CANCER,CYP17A1,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.",NR,NR,NR,NR,0
240,bc_id252,CANCER,CYP19A1,12036913,B,Effect of germ-line genetic variation on breast cancer survival in a population-based study.,2002,"Even if confirmed, the prognostic markers identified in this study are unlikely to replace current markers of prognosis such as estrogen receptor status. However, our results demonstrate the potential of the analysis of germ-line variation to provide insight into the biological determinants of response to treatment and prognosis in breast cancer.",NR,NR,NR,NR,0
241,bc_id253,CANCER,PGR,12038703,N,Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women.,2002,"No statistically significant difference was found between breast cancer patients and healthy control group, indicating that PROGINS is not associated with either an increased or a decreased risk for breast cancer. Furthermore, no associations between the PROGINS status and the protein levels of ER and PR, clinical data like tumor type, differentiation grade, tumor size, and the nodal status as well as the age of the patients were found. There was also no significant difference in the frequency of LOH affecting the PR gene in the PROGINS carriers and non carriers, demonstrating that LOH at PR gene is not associated with the PROGINS status.",X,X,X,X,0
242,bc_id254,CANCER,BRCA2,12039933,B,"BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.",2002,BRCAPRO is an accurate counseling tool for determining the probability of carrying mutations of BRCA1 and BRCA2.,"In the populations studied, breast cancer susceptibility genes other than BRCA1 and BRCA2 either do not exist, are rare, or are associated with low disease penetrance",Y,BRCA2,BRCA2,0.324175824
243,bc_id255,CANCER,BRCA1,12039933,B,"BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.",2002,BRCAPRO is an accurate counseling tool for determining the probability of carrying mutations of BRCA1 and BRCA2.,"In the populations studied, breast cancer susceptibility genes other than BRCA1 and BRCA2 either do not exist, are rare, or are associated with low disease penetrance",Y,BRCA1,BRCA1,0.326180258
244,bc_id256,CANCER,XRCC1,12042672,B,XRCC1 genetic polymorphism and breast cancer risk.,2002,,ANF,ANF,ANF,ANF,0
245,bc_id257,CANCER,SOD2,12063011,N,Variation in the manganese superoxide dismutase gene (SOD2) is not a major cause of radiotherapy complications in breast cancer patients.,2002,Sequence variation in SOD2 is not the major cause of radiotherapy complications in women with breast cancer.,Sequence variation in SOD2 is not the major cause of radiotherapy complications in women with breast cancer.,N,SOD2,SOD2,0.375
246,bc_id258,CANCER,BRCA2,12070551,B,BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia.,2002,BRCA1 and BRCA2 mutations are likely to contribute to the pathogenesis of familial breast cancer in female patients from the Kingdom of Saudi Arabia.,We conclude that BRCA1 and BRCA2 mutations are likely to contribute to the pathogenesis of familial breast cancer in female patients from the Kingdom of Saudi Arabia.,A,BRCA2,BRCA2,0.576923077
247,bc_id259,CANCER,BRCA1,12070551,B,BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia.,2002,BRCA1 and BRCA2 mutations are likely to contribute to the pathogenesis of familial breast cancer in female patients from the Kingdom of Saudi Arabia.,We conclude that BRCA1 and BRCA2 mutations are likely to contribute to the pathogenesis of familial breast cancer in female patients from the Kingdom of Saudi Arabia.,A,BRCA1,BRCA1,0.60944206
248,bc_id260,CANCER,NAT2,12088198,B,Differences in N-acetylation genotypes between Caucasians and Black South Africans: implicationsfor cancer prevention.,2002,The significant differences in N-acetylation genotypes can be among the factors determining a distinctive cancer morbidity and mortality pattern observed in Black South Africans. Both further genetic characterization of different populations and development of preventive strategies adopted for ethnicities with different genetic backgrounds are needed to deal adequately with the emerging health care problems in developing multiethnic societies.,NR,NR,NR,NR,0
249,bc_id261,CANCER,NAT1,12088198,B,Differences in N-acetylation genotypes between Caucasians and Black South Africans: implicationsfor cancer prevention.,2002,The significant differences in N-acetylation genotypes can be among the factors determining a distinctive cancer morbidity and mortality pattern observed in Black South Africans. Both further genetic characterization of different populations and development of preventive strategies adopted for ethnicities with different genetic backgrounds are needed to deal adequately with the emerging health care problems in developing multiethnic societies.,NR,NR,NR,NR,0
250,bc_id262,CANCER,BRCA1,12088199,B,Oral contraceptives and risk of familial breast cancer.,2003,the effects of OC use on breast cancer risk in familial breast cancer may be similar to the effects in the general population.,"We conclude that the effects of OC use on breast cancer risk in familial breast cancer may be similar to the effects in the general population. For BRCA1 mutation carriers, the point estimate is a doubling of risk, but CI is wide and no conclusion may be drawn from this study alone.",A,BRCA1,BRCA1,0.60944206
251,bc_id263,CANCER,ESR1,12100115,B,Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association withlymph node metastasis.,2002,Our data suggest that there is a relationship between the ER325 polymorphism and susceptibility to breast cancer (OR = 2.3; 1.10 < OR < 5.1) and that it can also be related with the metastasization process.,X,X,X,X,0
252,bc_id264,CANCER,BRCA2,12100744,B,Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.,2003,Identification of these novel mutations suggests that any given population should develop a mutation database for its programme of breast cancer screening.,"The pattern of mutations seen in the BRCA genes seems not to differ from other populations studied. Early-onset breast cancer (less than 45 years) and a limited family history is sufficient to justify mutation screening with a detection rate of over 25% in this group, whereas sporadic early-onset breast cancer (detection rate less than 5%) is unlikely to be cost-effective.",A,BRCA,BRCA2,0.576923077
253,bc_id265,CANCER,BRCA1,12100744,B,Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.,2003,Identification of these novel mutations suggests that any given population should develop a mutation database for its programme of breast cancer screening.,"The pattern of mutations seen in the BRCA genes seems not to differ from other populations studied. Early-onset breast cancer (less than 45 years) and a limited family history is sufficient to justify mutation screening with a detection rate of over 25% in this group, whereas sporadic early-onset breast cancer (detection rate less than 5%) is unlikely to be cost-effective.",A,BRCA,BRCA1,0.60944206
254,bc_id266,CANCER,SRD5A2,12100746,Y,"A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.",2002,"This study is the first to our knowledge focusing on Japanese women, suggesting that SRD5A2 polymorphisms might have an association with breast cancer risk. Further large-sample studies will be required to confirm the association and to assess any interactions with environmental factors.","This study is the first to our knowledge focusing on Japanese women, suggesting that SRD5A2 polymorphisms might have an association with breast cancer risk. Further large-sample studies will be required to confirm the association and to assess any interactions with environmental factors.",A,SRD5A2,SRD5A2,0.666666667
255,bc_id267,CANCER,BRCA2,12101561,B,[Investigation of mutations of BRCA1 and BRCA2 genes in 52 breast cancer patients],2002,"The frequency of carriers of mutations among familial cancer cases was 16%, among cases of disease till 40 years--9%. 538insC BRCA1 was the most common genetic mutation among hereditary cases of breast cancer.","The proportion of BRCA1/2 genes varies widely among populations. We investigated 52 cases of breast cancer: 24 cases of familial breast cancer, 22--early-onset (till 40 years) and 6--bilateral cancer. The frequency of carriers of mutations among familial cancer cases was 16%, among cases of disease till 40 years--9%. 538insC BRCA1 was the most common genetic mutation among hereditary cases of breast cancer.",A,BRCA1/2,BRCA2,0.576923077
256,bc_id268,CANCER,BRCA1,12101561,Y,[Investigation of mutations of BRCA1 and BRCA2 genes in 52 breast cancer patients],2002,"The frequency of carriers of mutations among familial cancer cases was 16%, among cases of disease till 40 years--9%. 538insC BRCA1 was the most common genetic mutation among hereditary cases of breast cancer.","The frequency of carriers of mutations among familial cancer cases was 16%, among cases of disease till 40 years--9%. 538insC BRCA1 was the most common genetic mutation among hereditary cases of breast cancer.",Y,BRCA1,BRCA1,0.326180258
257,bc_id269,CANCER,IGF1,12115549,N,A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer.,2002,"Although a modest association cannot be excluded, our data do not support an important relation between this IGF-1 gene polymorphism and breast cancer risk.","Although a modest association cannot be excluded, our data do not support an important relation between this IGF-1 gene polymorphism and breast cancer risk.",N,IGF-1,IGF1,0.4
258,bc_id270,CANCER,BRCA2,12125210,B,Analysis of 5382insC (BRCA1) and 6174delT (BRCA2) mutations in 382 healthy Chilean women with a family history of breast cancer.,2002,,"BRCA1 and BRCA2 are the two main hereditary breast cancer susceptibility genes, and mutations in these genes are related to inherited breast cancer. In specific populations only some mutations have been found to be associated with susceptibility... The results obtained showed that 5382insC and 6174delT mutations were not found in either of the groups studied. The ethnic origin of the contemporary Chilean population and the data reported in the literature suggest that these mutations may be absent or have a very low frequency in this population.. This genetic study is part of a breast cancer screening program that also includes annual mammography and clinical breast examination over a five-year period.",A,BRCA2,BRCA2,0.576923077
259,bc_id271,CANCER,BRCA1,12125210,B,Analysis of 5382insC (BRCA1) and 6174delT (BRCA2) mutations in 382 healthy Chilean women with a family history of breast cancer.,2002,,"BRCA1 and BRCA2 are the two main hereditary breast cancer susceptibility genes, and mutations in these genes are related to inherited breast cancer. In specific populations only some mutations have been found to be associated with susceptibility... The results obtained showed that 5382insC and 6174delT mutations were not found in either of the groups studied. The ethnic origin of the contemporary Chilean population and the data reported in the literature suggest that these mutations may be absent or have a very low frequency in this population.. This genetic study is part of a breast cancer screening program that also includes annual mammography and clinical breast examination over a five-year period.",A,BRCA1,BRCA1,0.60944206
260,bc_id272,CANCER,CYP3A4,12142725,N,The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.,2002,"Our data suggest that the CYP3A4*1B polymorphism is not associated with risk of breast or ovarian cancer. In support of this negative finding, in-vitro functional studies indicate that NFSE genotype is not a critical factor in the transcriptional activity of the CYP3A4 5'-flanking region, and is thus unlikely to modulate CYP3A4-mediated metabolism of steroids.","Our data suggest that the CYP3A4*1B polymorphism is not associated with risk of breast or ovarian cancer. In support of this negative finding, in-vitro functional studies indicate that NFSE genotype is not a critical factor in the transcriptional activity of the CYP3A4 5'-flanking region, and is thus unlikely to modulate CYP3A4-mediated metabolism of steroids.",N,CYP3A4*1B,CYP3A4,0.363636364
261,bc_id274,CANCER,VDR,12150447,Y,Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients.,2002,These results suggest that polymorphic variation in or near the 3' end of the VDR gene may influence breast cancer risk in Taiwanese women and justifies further investigation of the role of VDR for sporadic breast cancer in low-incidence areas. These findings also should help when designing targeted therapy.,These results suggest that polymorphic variation in or near the 3' end of the VDR gene may influence breast cancer risk in Taiwanese women and justifies further investigation of the role of VDR for sporadic breast cancer in low-incidence areas. These findings also should help when designing targeted therapy.,A,VDR,VDR,0.538461538
262,bc_id275,CANCER,GSTT1,12150456,B,GSTM1 and GSTT1 polymorphisms and postmenopausal breast cancer risk.,2002,,X,X,X,X,0
263,bc_id276,CANCER,GSTM1,12150456,B,GSTM1 and GSTT1 polymorphisms and postmenopausal breast cancer risk.,2002,,X,X,X,X,0
264,bc_id277,CANCER,CBS,12154064,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.,2002,The existence of these associations may provide another example of the interplay between genetic and epigenetic factors in the cancer cell.,X,X,X,X,0
265,bc_id278,CANCER,MS,12154064,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.,2002,The existence of these associations may provide another example of the interplay between genetic and epigenetic factors in the cancer cell.,X,X,X,X,0
266,bc_id279,CANCER,MTHFR,12154064,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors.,2002,The existence of these associations may provide another example of the interplay between genetic and epigenetic factors in the cancer cell.,X,X,X,X,0
267,bc_id280,CANCER,NAT2,12163321,Y,Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk.,2002,Our results suggest that the NAT2 status has a differential effect on the association of active and passive smoking with breast cancer and demonstrate the need to consider possible different mechanisms associated with exposure to main- and sidestream tobacco smoke.,Our results suggest that the NAT2 status has a differential effect on the association of active and passive smoking with breast cancer and demonstrate the need to consider possible different mechanisms associated with exposure to main- and sidestream tobacco smoke.,Y,NAT2,NAT2,0.37037037
268,bc_id282,CANCER,ERBB2,12166652,B,Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer.,2002,The findings in this study correspond with the lower incidence and lower risk of breast cancer in African women compared with Caucasian and African-American women.,Alterations of the HER-2 gene have been implicated in the carcinogenesis and prognosis of breast cancer and other solid tumors...  The data suggest that this SNP has variable frequency in different ethnic groups. The findings in this study correspond with the lower incidence and lower risk of breast cancer in African women compared with Caucasian and African-American women.,Y,HER-2,ERBB2,0.285714286
269,bc_id281,CANCER,HER2,12166652,Y,Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer.,2002,,MC,MC,MC,MC,0
270,bc_id283,CANCER,KLK3,12168876,Y,Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer.,2002,Our results suggest that the presence of the A-AA allele at the PSA promoter region is associated with less aggressive forms of breast cancer and could be looked on as a favorable prognostic factor.,X,X,X,X,0
271,bc_id284,CANCER,TP53,12170762,B,Mutations in the p53 tumor suppressor gene and early onset breast cancer.,2002,,"Patients with mutations in exon 8 of the p53 gene were 6-times more likely to be diagnosed with early onset breast cancer (OR = 6.48, 95% CI = 1.37-30.6). These findings suggest that p53 gene mutation may hasten the onset of female breast cancer.",Y,p53,TP53,0.367816092
272,bc_id285,CANCER,GSTT1,12175533,B,"CYP1A1, GSTM1, and GSTT1 polymorphisms and breast cancer risk in Brazilian women.",2002,,"The frequency of CYP1A1 (CYP1A1*2A), GSTM1, and GSTT1 polymorphisms, as well as the main risk factors associated with breast cancer were studied in Brazilian women, with malignant breast cancer (n=128), or age-matched controls (n=256). Only a family history of breast cancer presented a significant risk (OR=3.00, CI=1.27-7.06)... Statistical analysis indicated that this polymorphism may decrease the risk of breast cancer among these individuals, particularly after adjusting for the risk presented by selected risk factors (OR=0.30, 95% CI=0.12-0.76).",A,GSTT1,GSTT1,0.289473684
273,bc_id286,CANCER,GSTM1,12175533,B,"CYP1A1, GSTM1, and GSTT1 polymorphisms and breast cancer risk in Brazilian women.",2002,,"The frequency of CYP1A1 (CYP1A1*2A), GSTM1, and GSTT1 polymorphisms, as well as the main risk factors associated with breast cancer were studied in Brazilian women, with malignant breast cancer (n=128), or age-matched controls (n=256). Only a family history of breast cancer presented a significant risk (OR=3.00, CI=1.27-7.06)... Statistical analysis indicated that this polymorphism may decrease the risk of breast cancer among these individuals, particularly after adjusting for the risk presented by selected risk factors (OR=0.30, 95% CI=0.12-0.76).",A,GSTM1,GSTM1,0.339622642
274,bc_id287,CANCER,CYP1A1,12175533,B,"CYP1A1, GSTM1, and GSTT1 polymorphisms and breast cancer risk in Brazilian women.",2002,,"The frequency of CYP1A1 (CYP1A1*2A), GSTM1, and GSTT1 polymorphisms, as well as the main risk factors associated with breast cancer were studied in Brazilian women, with malignant breast cancer (n=128), or age-matched controls (n=256). Only a family history of breast cancer presented a significant risk (OR=3.00, CI=1.27-7.06)... Statistical analysis indicated that this polymorphism may decrease the risk of breast cancer among these individuals, particularly after adjusting for the risk presented by selected risk factors (OR=0.30, 95% CI=0.12-0.76).",A,CYP1A1,CYP1A1,0.456521739
275,bc_id288,CANCER,CYP1B1,12183407,B,Genetic and environmental determinants on tissue response to in vitro carcinogen exposure and risk of breast cancer.,2002,These observations suggest that genetic susceptibility to carcinogen exposure may play an important role in breast carcinogenesis.,"Stratified analysis and regression analysis demonstrated that race, pack-years of smoking, family history of breast cancer, and CYP1B1 genotype were significant predictors of the level of benzo(a)pyrene-induced adducts in the breast tissues. These observations suggest that genetic susceptibility to carcinogen exposure may play an important role in breast carcinogenesis.",A,CYP1B1,CYP1B1,0.384615385
276,bc_id289,CANCER,ALDH2,12189549,B,"Interaction between alcohol dehydrogenase II gene, alcohol consumption, and risk for breast cancer.",2002,,"Breast cancer risk associated with alcohol consumption may vary according to the alcohol dehydrogenase II polymorphism, probably due to differences in alcohol metabolism.",A,alcohol dehydrogenase II,ALDH2,1
277,bc_id290,CANCER,CYP17A1,12202634,B,Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.,2002,,ANF,ANF,ANF,ANF,0
278,bc_id291,CANCER,CYP19A1,12204674,B,"Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals.",2002,,"A polymorphism in CYP19 in intron 4 (TTTA)n has been reported to be associated with breast cancer (BC) risk, although conflicting evidence has also been published.",A,CYP19,CYP19A1,0.484848485
279,bc_id292,CANCER,BRCA2,12220452,B,Anticipation in hereditary breast cancer.,2002,,"BRCA1 mutations predispose to breast cancer at an early age in both mothers and daughters, whereas mutations in BRCA2 were associated with significantly younger age at diagnosis in the second generation. This observation could be related to gene-environmental interactions causing anticipation in BRCA2 mutation carriers.",Y,BRCA2,BRCA2,0.324175824
280,bc_id293,CANCER,BRCA1,12220452,B,Anticipation in hereditary breast cancer.,2002,,"BRCA1 mutations predispose to breast cancer at an early age in both mothers and daughters, whereas mutations in BRCA2 were associated with significantly younger age at diagnosis in the second generation. This observation could be related to gene-environmental interactions causing anticipation in BRCA2 mutation carriers.",Y,BRCA1,BRCA1,0.326180258
281,bc_id294,CANCER,ERCC2,12243508,B,Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer.,2002,,XPD polymorphisms at codons 312 and 751 were associated with higher levels of PAH-DNA in tumor tissue from breast cancer cases... The trend of increasing PAH-DNA adduct levels with either the Asn/Asn or Gln/Gln genotype was greater in tumor tissue than the trend in BBD control tissue.,Y,XPD,ERCC2,0.125
282,bc_id295,CANCER,GSTT1,12296511,B,"Cigarette smoking, glutathione-s-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States).",2002,,"None of the GSTM 1 genotypes, either alone or in combination with cigarette smoking, was associated with breast cancer risk. There was, however, a significantly increased risk of breast cancer among postmenopausal women with a GSTTI null genotype (OR= 1.9, 95% CI 1.2-2.9).",Y,GSTTI,GSTT1,0.578947368
283,bc_id296,CANCER,GSTM1,12296511,B,"Cigarette smoking, glutathione-s-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States).",2002,,"None of the GSTM 1 genotypes, either alone or in combination with cigarette smoking, was associated with breast cancer risk. There was, however, a significantly increased risk of breast cancer among postmenopausal women with a GSTTI null genotype (OR= 1.9, 95% CI 1.2-2.9).",N,GSTM 1,GSTM1,0.20754717
284,bc_id297,CANCER,PHB,12354477,N,Prohibitin 3' untranslated region polymorphism and breast cancer risk in Australian women.,2002,"Hence, our results do not lend support to the hypothesis that this polymorphism contributes to risk of breast cancer.","A C to T transition within the 3' untranslated region of the prohibitin gene alters mRNA function, and an association between the T allele and an increased risk of breast cancer has been reported in North American women, specifically in those aged under 50 years with a first-degree family history of breast cancer. We did a population-based case-control study to assess whether this association existed in Australian women... Hence, our results do not lend support to the hypothesis that this polymorphism contributes to risk of breast cancer.",N,prohibitin,PHB,0.4
285,bc_id298,CANCER,BRCA1,12362311,N,[Analysis of mutation sites of BRCA1 gene in Chinese patients with breast cancer],2002,"The above results suggest this SNP may not be associated with the breast cancer in Chinese population, and indicates that the gene sequence of what we have studied doesn't account much for occurrence of the breast cancer in the population of China.",X,X,X,X,0
286,bc_id299,CANCER,CYP17A1,12368392,B,The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women,2002,"Our results suggest that CYP17 genotype may be important in modifying the effect on breast cancer risk of exogenous estrogens, particularly for premenopausal women.","Our results suggest that CYP17 genotype may be important in modifying the effect on breast cancer risk of exogenous estrogens, particularly for premenopausal women.",A,CYP17,CYP17A1,0.466666667
287,bc_id300,CANCER,SULT1A2,12373301,B,Sulfotransferase 1A2*2 is a risk factor for early-onset breast cancer,2002,"In comparison with the frequency of healthy controls (96.0% and 4.0% for SULT1A2*1 and SULT1A2*2, respectively), the allelic frequencies of SULT1A2 polymorphisms in these patients were not statistically significant (p=0.398). However, the SULT1A2*2 allele seems to influence the age of onset among early-onset breast cancer patients (p=0.021, OR=2.74, 95%CI=1.13-6.65).","In comparison with the frequency of healthy controls (96.0% and 4.0% for SULT1A2*1 and SULT1A2*2, respectively), the allelic frequencies of SULT1A2 polymorphisms in these patients were not statistically significant (p=0.398). However, the SULT1A2*2 allele seems to influence the age of onset among early-onset breast cancer patients (p=0.021, OR=2.74, 95%CI=1.13-6.65).",A,SULT1A2,SULT1A2,1
288,bc_id301,CANCER,BRCA2,12376208,B,Psychological impact of genetic testing in women from high-risk breast cancer families.,2002,,"psychological adjustment in 90 women (30 carriers and 60 non-carriers) who had undergone genetic testing for mutations in BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes was compared with that of 53 women who were not offered genetic testing... These data show that non-carriers derive psychological benefits from genetic testing. Women testing positive may anticipate a sustained increase in breast cancer distress following disclosure, although no other adverse psychological outcomes were observed in this group.",Y,BRCA2,BRCA1,0.326180258
289,bc_id302,CANCER,BRCA1,12376208,B,Psychological impact of genetic testing in women from high-risk breast cancer families.,2002,,"psychological adjustment in 90 women (30 carriers and 60 non-carriers) who had undergone genetic testing for mutations in BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes was compared with that of 53 women who were not offered genetic testing... These data show that non-carriers derive psychological benefits from genetic testing. Women testing positive may anticipate a sustained increase in breast cancer distress following disclosure, although no other adverse psychological outcomes were observed in this group.",Y,BRCA1,BRCA2,0.324175824
290,bc_id303,CANCER,BRCA2,12376518,B,Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.,2002,,"We conducted a prospective, observational study to determine breast cancer screening practices among self-referred high-risk women who pursued genetic testing for BRCA1 and BRCA2 mutations... The effects of perceived likelihood of having a BRCA1/2 gene alteration and the interaction between test result and perceived likelihood were not significant.",A,BRCA2,BRCA1,0.60944206
291,bc_id304,CANCER,BRCA1,12376518,B,Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.,2002,,"We conducted a prospective, observational study to determine breast cancer screening practices among self-referred high-risk women who pursued genetic testing for BRCA1 and BRCA2 mutations... The effects of perceived likelihood of having a BRCA1/2 gene alteration and the interaction between test result and perceived likelihood were not significant.",A,BRCA1,BRCA1,0.60944206
292,bc_id305,CANCER,IGF1,12389335,B,Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.,2002,,"The IGF-I polymorphism may serve as a marker for breast cancer risk in the general Jewish population, in particular non-Ashkenazi Jews, but extension and confirmation of these preliminary data are needed.",A,IGF-I,IGF1,0.25
293,bc_id306,CANCER,BRCA1,12389335,B,Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women.,2002,,"Among women with breast cancer, with or without BRCA germline mutations, 196 and 198 basepair alleles were present in 4.7% (25/536 alleles), compared with 9% (26/288) controls (P = 0.02). This difference was more pronounced and significant in the non-Ashkenazi population. Conversely, the smaller size allele (176 bp) was present in the breast cancer group only (3/536, 0.6%).",A,BRCA,BRCA1,0.60944206
294,bc_id307,CANCER,BRCA1,12402341,B,Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer.,2002,,"Since these newly discovered nucleotide changes were only detected in patients, our results suggest that BRCA1 may also play a role in the development of sporadic breast cancer in Chinese populations.",A,BRCA1,BRCA1,0.60944206
295,bc_id308,CANCER,BRCA2,12404104,B,Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers:association with breast/ovarian cancer phenotype.,2002,There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.,There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.,A,BRCA1/2,BRCA2,0.576923077
296,bc_id309,CANCER,BRCA1,12404104,B,Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers:association with breast/ovarian cancer phenotype.,2002,There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.,There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.,A,BRCA1/2,BRCA1,0.60944206
297,bc_id310,CANCER,AR,12404104,N,Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.,2002,There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.,There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers. A small effect of a short AR CAG allele size on breast cancer at early age (<42 years) cannot be excluded.,Y,AR,AR,0.291666667
298,bc_id312,CANCER,NFKBIA,12406554,N,"Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer.",2002,"Results do not support an involvement of the tested NFKB1 and NFKBIA polymorphisms in susceptibility to sporadic breast cancer, in the tested Caucasian population.","Results do not support an involvement of the tested NFKB1 and NFKBIA polymorphisms in susceptibility to sporadic breast cancer, in the tested Caucasian population.",N,NFKBIA,NFKBIA,1
299,bc_id313,CANCER,NFKB1,12406554,N,"Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer.",2002,"Results do not support an involvement of the tested NFKB1 and NFKBIA polymorphisms in susceptibility to sporadic breast cancer, in the tested Caucasian population.","Results do not support an involvement of the tested NFKB1 and NFKBIA polymorphisms in susceptibility to sporadic breast cancer, in the tested Caucasian population.",N,NFKB1,NFKB1,1
300,bc_id314,CANCER,CYP1B1,12415427,Y,Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population.,2002,We conclude that  the CYP1B1* 3 allele appears to be a factor for susceptibility to breast cancer in Turkish women especially those with a BMI greater than 24 kg/m(2).,"In the case of COMT, there was no significant difference in susceptibility for breast cancer development between patients with low activity COMT-L (V158 M) allele and high activity COMT-H allele, and susceptibility was not affected by menopausal status, BMI or CYP1B1 genotype. We conclude that the CYP1B1* 3 allele appears to be a factor for susceptibility to breast cancer in Turkish women especially those with a BMI greater than 24 kg/m(2).",Y,CYP1B1* 3,CYP1B1,0.358974359
301,bc_id315,CANCER,COMT,12415427,B,Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population.,2002,We conclude that  the CYP1B1* 3 allele appears to be a factor for susceptibility to breast cancer in Turkish women especially those with a BMI greater than 24 kg/m(2).,"In the case of COMT, there was no significant difference in susceptibility for breast cancer development between patients with low activity COMT-L (V158 M) allele and high activity COMT-H allele, and susceptibility was not affected by menopausal status, BMI or CYP1B1 genotype. We conclude that the CYP1B1* 3 allele appears to be a factor for susceptibility to breast cancer in Turkish women especially those with a BMI greater than 24 kg/m(2).",N,COMT,COMT,0.29787234
302,bc_id316,CANCER,SULT1A1,12419790,B,Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.,2002,"Sulfation of 4-OH TAM provides a previously unanticipated benefit, possibly due to alterations in the bioavailability of the active metabolite or to undefined estrogen receptor-mediated events. These data alternatively suggest that variability in the metabolism of tamoxifen may affect its efficacy.","We examined the relationship between the SULT1A1*2 allele and survival in a cohort of 337 women with breast cancer who received tamoxifen (n = 160) or who did not (n = 177). SULT1A1 genotype was determined by restriction fragment polymorphism analysis... Among tamoxifen-treated patients, those who were homozygous for the SULT1A1*2 low-activity allele had approximately three times the risk of death (HR = 2.9, 95% confidence interval [CI] = 1.1 to 7.6) as those who were homozygous for the common allele or those who were heterozygous (SULT1A1*1/*2). Among patients who did not receive tamoxifen, there was no association between survival and SULT1A1 genotype (HR = 0.7, 95% CI = 0.3 to 1.5).",A,SULT1A1,SULT1A1,0.387096774
303,bc_id317,CANCER,SULT1A1,12419790,Y,Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.,2002,"Sulfation of 4-OH TAM provides a previously unanticipated benefit, possibly due to alterations in the bioavailability of the active metabolite or to undefined estrogen receptor-mediated events. These data alternatively suggest that variability in the metabolism of tamoxifen may affect its efficacy.",MC,MC,MC,MC,0
304,bc_id318,CANCER,MTHFR,12430180,B,Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR).,2002,,The roles of MTHFR and folate in breast cancer aetiology are likely to be complex.,A,MTHFR,MTHFR,0.403846154
305,bc_id319,CANCER,NAT2,12430181,B,GSTT1 null genotype increases risk of premenopausal breast cancer.,2002,,"We conducted a case-control study to investigate the role of NAT2, GSTM1 and GSTT1 in premenopausal breast cancer. Women with the GSTT1 null genotype were found to have a significant 3.15-fold increased risk of breast cancer (95% CI = 1.7-5.8), while GSTM1 and NAT2 genotypes were not associated with breast cancer risk. Our results suggest that the GSTT1 null genotype may play a role in early onset breast cancer.",N,NAT2,NAT2,0.37037037
306,bc_id320,CANCER,GSTT1,12430181,B,GSTT1 null genotype increases risk of premenopausal breast cancer.,2002,,"We conducted a case-control study to investigate the role of NAT2, GSTM1 and GSTT1 in premenopausal breast cancer. Women with the GSTT1 null genotype were found to have a significant 3.15-fold increased risk of breast cancer (95% CI = 1.7-5.8), while GSTM1 and NAT2 genotypes were not associated with breast cancer risk. Our results suggest that the GSTT1 null genotype may play a role in early onset breast cancer.",Y,GSTT1,GSTT1,0.578947368
307,bc_id321,CANCER,GSTM1,12430181,B,GSTT1 null genotype increases risk of premenopausal breast cancer.,2002,,"We conducted a case-control study to investigate the role of NAT2, GSTM1 and GSTT1 in premenopausal breast cancer. Women with the GSTT1 null genotype were found to have a significant 3.15-fold increased risk of breast cancer (95% CI = 1.7-5.8), while GSTM1 and NAT2 genotypes were not associated with breast cancer risk. Our results suggest that the GSTT1 null genotype may play a role in early onset breast cancer.",N,GSTM1,GSTM1,0.20754717
308,bc_id322,CANCER,BRCA2,12433008,B,A brief assessment of concerns associated with genetic testing for cancer: the MultidimensionalImpact of Cancer Risk Assessment (MICRA) questionnaire,2002,Factor analysis supported the formation of 3,NR,NR,NR,NR,0
309,bc_id323,CANCER,BRCA1,12433008,Y,A brief assessment of concerns associated with genetic testing for cancer: the MultidimensionalImpact of Cancer Risk Assessment (MICRA) questionnaire,2002,Factor analysis supported the formation of 3,NR,NR,NR,NR,0
310,bc_id324,CANCER,VDR,12433736,B,Vitamin D receptor polymorphism and breast cancer risk.,2002,,ANF,ANF,ANF,ANF,0
311,bc_id325,CANCER,PPARG,12439219,N,Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass.,2002,,"We did not find evidence to support a role for this polymorphism in breast cancer susceptibility... Furthermore, similar to others, we did not find evidence to suggest that Pro12Ala PPARgamma polymorphism is directly associated with body mass or weight gain.",N,PPARgamma,PPARG,0.4
312,bc_id326,CANCER,SRD5A2,12446983,B,Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.,2002,These results suggest that ethnicity-specific differences in genotype frequencies exist for SRD5A2 and CYP3A4. Africans and African-Americans have the highest frequency of those alleles that have previously been associated with increased prostate cancer risk. Future studies should address whether allele frequency differences in part explain differences in prostate cancer incidence in these populations.,NR,NR,NR,NR,0
313,bc_id327,CANCER,CYP3A4,12446983,B,Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.,2002,These results suggest that ethnicity-specific differences in genotype frequencies exist for SRD5A2 and CYP3A4. Africans and African-Americans have the highest frequency of those alleles that have previously been associated with increased prostate cancer risk. Future studies should address whether allele frequency differences in part explain differences in prostate cancer incidence in these populations.,NR,NR,NR,NR,0
314,bc_id328,CANCER,CHEK2,12454775,Y,CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours.,2002,"This study provides further evidence that sequence variation in CHEK2 is associated with an increased risk of breast cancer, and implies that tumorigenesis in association with CHEK2 mutations does not involve loss of the wild type allele.","This study provides further evidence that sequence variation in CHEK2 is associated with an increased risk of breast cancer, and implies that tumorigenesis in association with CHEK2 mutations does not involve loss of the wild type allele.",Y,CHEK2,CHEK2,0.383333333
315,bc_id329,CANCER,BRCA2,12464649,B,Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,2002,,"Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who used them for 5 or more years may have an increased risk of early-onset breast cancer. Oral contraceptives do not appear to be associated with risk of breast cancer in BRCA2 carriers, but data for BRCA2 carriers are limited.",N,BRCA2,BRCA2,0.098901099
316,bc_id330,CANCER,BRCA1,12464649,B,Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,2002,,"Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who used them for 5 or more years may have an increased risk of early-onset breast cancer. Oral contraceptives do not appear to be associated with risk of breast cancer in BRCA2 carriers, but data for BRCA2 carriers are limited.",A,BRCA1,BRCA1,0.60944206
317,bc_id331,CANCER,TP53,12471629,B,Evidence against involvement of p53 polymorphism in breast cancer predisposition.,2003,,ANF,ANF,ANF,ANF,0
318,bc_id332,CANCER,MTHFR,12473175,B,Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer.,2003,The low activity C677T (valine) genotype of MTHFR may increase the risk of early onset breast cancer.,The low activity C677T (valine) genotype of MTHFR may increase the risk of early onset breast cancer.,A,MTHFR,MTHFR,0.403846154
319,bc_id333,CANCER,ATM,12473176,N,No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer.,2002,The 2119C and 3161G amino acid substitution variants are not associated with moderate or high risks of breast cancer in Australian women.,There is evidence that certain mutations in the double-strand break repair pathway ataxia-telangiectasia mutated gene act in a dominant-negative manner to increase the risk of breast cancer... The 2119C and 3161G amino acid substitution variants are not associated with moderate or high risks of breast cancer in Australian women.,Y,ataxia-telangiectasia mutated,ATM,0.333333333
320,bc_id335,CANCER,ATM,12473594,N,Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers.,2002,Heterozygous protein-truncating or missense mutations of ATM were not associated with increased radiation-associated risk of BC after HD. The observation of multiple germ-line mutations and a homozygote suggests that rare ATM variants may constitute cancer-susceptibility alleles in a subset of cases.,X,X,X,X,0
321,bc_id336,CANCER,MMP3,12473595,B,A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility.,2002,"Although this should be considered only as a pilot study, our results suggest that the presence of 5A polymorphism at the MMP-3 promoter region may represent an unfavorable prognostic feature in breast cancer patients associated with more invasive disease.","Although this should be considered only as a pilot study, our results suggest that the presence of 5A polymorphism at the MMP-3 promoter region may represent an unfavorable prognostic feature in breast cancer patients associated with more invasive disease.",A,MMP-3,MMP3,0.666666667
322,bc_id337,CANCER,MMP1,12473595,B,A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility.,2002,"Although this should be considered only as a pilot study, our results suggest that the presence of 5A polymorphism at the MMP-3 promoter region may represent an unfavorable prognostic feature in breast cancer patients associated with more invasive disease.","The 1G/2G gene promoter polymorphism for MMP-1 was additionally tested... Although this should be considered only as a pilot study, our results suggest that the presence of 5A polymorphism at the MMP-3 promoter region may represent an unfavorable prognostic feature in breast cancer patients associated with more invasive disease.",A,MMP-1,MMP1,0.833333333
323,bc_id338,CANCER,BRCA2,12484126,B,A European case-only study on familial breast cancer,2002,"The small size of the sudy does not permit any firm conclusions so far, but suggests that high parity and frequent x-ray exposure in childhood are associated with and increased risk of breast cancer in mutation carriers. Oral contraceptives do not seem to increase the risk and tobacco smoking does not seem to protect.",ANF,ANF,ANF,ANF,0
324,bc_id339,CANCER,BRCA1,12484126,B,A European case-only study on familial breast cancer,2002,"The small size of the sudy does not permit any firm conclusions so far, but suggests that high parity and frequent x-ray exposure in childhood are associated with and increased risk of breast cancer in mutation carriers. Oral contraceptives do not seem to increase the risk and tobacco smoking does not seem to protect.",ANF,ANF,ANF,ANF,0
325,bc_id340,CANCER,BRCA2,12491487,B,Breast cancer genetics in African Americans.,2003,,"Although only a few African-American families have been tested for BRCA1 and BRCA2 mutations, the probability of finding a mutation is invariably dependent on the age of onset and the number of breast and/or ovarian cancer cases in the family.",A,BRCA2,BRCA2,0.576923077
326,bc_id341,CANCER,BRCA1,12491487,B,Breast cancer genetics in African Americans.,2003,,"Although only a few African-American families have been tested for BRCA1 and BRCA2 mutations, the probability of finding a mutation is invariably dependent on the age of onset and the number of breast and/or ovarian cancer cases in the family.",A,BRCA1,BRCA1,0.60944206
327,bc_id342,CANCER,BRCA2,12491828,B,[Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer],2002,The frequency of the 185delAG mutation in BRCA1 was 0.26% (1/382) in Chilean healthy women with a family history of breast cancer.,BRCA1 and BRCA2 are two major hereditary breast cancer susceptibility genes.,Y,BRCA2,BRCA2,0.324175824
328,bc_id343,CANCER,BRCA1,12491828,B,[Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer],2002,The frequency of the 185delAG mutation in BRCA1 was 0.26% (1/382) in Chilean healthy women with a family history of breast cancer.,The frequency of the 185delAG mutation in BRCA1 was 0.26% (1/382) in Chilean healthy women with a family history of breast cancer.,A,BRCA1,BRCA1,0.60944206
329,bc_id344,CANCER,ERCC5,12494477,B,Single nucleotide polymorphisms in the XPG gene:determination of role in DNA repair and breast cancer risk.,2003,The XPG gene exhibited marginally significant increased frequency of the variant allele in cases compared to controlsCombined heterozygote and variant homozygote genotype frequency was also higher in cases than controls,"Genotyping of 220 breast cancer cases and 308 controls for the same single nucleotide polymorphism in exon 15 of the XPG gene exhibited marginally significant increased frequency of the variant allele (chi(2) 3.84, p = 0.05; OR 1.33, 95% CI 1.0-1.8) in cases (C-allele 0.29) compared to controls (C-allele 0.24).",Y,XPG,ERCC5,0.166666667
330,bc_id345,CANCER,NBN,12505263,B,Frequency of 657del(5) mutation of the NBS1 gene in the Czech population by polymerase chain reaction with sequence specific primers.,2002,"Here, we present polymerase chain reaction with sequence specific primers as a method for the detection of Slavic NBS1 mutation and confirm the high carrier frequency in the Czech population",NR,NR,NR,NR,0
331,bc_id346,CANCER,PTCH,12516098,Y,The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk,2003,Our novel observation of a differential effect of OC use on breast cancer risk by PTCH1 1315Leu-carrier status suggests the interesting possibility of the Sonic hedgehog/Patched (SHH/PTCH1) signaling pathway being involved in hormone-induced development of breast carcinoma.,Our novel observation of a differential effect of OC use on breast cancer risk by PTCH1 1315Leu-carrier status suggests the interesting possibility of the Sonic hedgehog/Patched (SHH/PTCH1) signaling pathway being involved in hormone-induced development of breast carcinoma.,Y,PTCH1,PTCH1,1
332,bc_id348,CANCER,GSTA1,12516103,Y,Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment,2003,"These results, although based on a small study population, describe an apparent difference in survival after treatment for breast cancer according to GSTA1 genotype. Further studies should consider the possible association between the novel GSTA1*B variant and outcomes of cancer therapy.","These results, although based on a small study population, describe an apparent difference in survival after treatment for breast cancer according to GSTA1 genotype.",Y,GSTA1,GSTA1,0.6
333,bc_id349,CANCER,TGFB1,12525765,B,Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women.,2003,"The present study showed risk reduction for Japanese premenopausal women with the CC genotype, but not for postmenopausal Japanese women.","A cohort study for Caucasians aged 65 years or older demonstrated a marked breast cancer risk reduction for those with the CC genotype of transforming growth factor B1 (TGF B1) T29C polymorphism... The present study showed risk reduction for Japanese premenopausal women with the CC genotype, but not for postmenopausal Japanese women.",Y,TGF B1,TGFB1,0.185185185
334,bc_id350,CANCER,CHEK2,12529183,N,Frequency of CHEK2*1100delC in New York breast cancer cases and controls.,2003,"The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for CHEK2*1100delC in North American kindreds.","The 1100delC CHEK2 allele has been associated with a 1.4-4.7 fold increased risk for breast cancer in women carrying this mutation... The relatively low breast cancer penetrance of this allele, along with the low population frequency, will limit the clinical applicability of germline testing for CHEK2*1100delC in North American kindreds.",N,CHEK2*1100delC,CHEK2,0.233333333
335,bc_id351,CANCER,BRCA2,12543786,B,BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.,2003,,This suggests that phenotypic characteristics may contribute to the identification of hereditary BRCA2-related male breast cancers and that these tumors might share a unique molecular pathway of cancer progression.,A,BRCA2,BRCA2,0.576923077
336,bc_id352,CANCER,BRCA1,12543786,B,BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.,2003,,"In conclusion, constitutional BRCA1/BRCA2 mutations accounted for 16% of the male breast cancer cases in this area of Central Italy.",A,BRCA1/BRCA2,BRCA1,0.60944206
337,bc_id353,CANCER,GSTT1,12556960,B,"Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk.",2003,", alcohol consumption may increase breast cancer risk among those who carry susceptible GST genotypes.",X,X,X,X,0
338,bc_id354,CANCER,GSTM1,12556960,B,"Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk.",2003,", alcohol consumption may increase breast cancer risk among those who carry susceptible GST genotypes.",X,X,X,X,0
339,bc_id355,CANCER,ALDH2,12563175,B,Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development.,2003,,"The CYP2E1 RsaI polymorphism was determined by a real time PCR method, and the ALDH2 Glu487 Lys polymorphism was determined by a PCR method with confronting two-pair primers (PCR-CTPP)... This study therefore suggests that the CYP2E1 c2 allele may influence the individual susceptibility to breast cancer in alcohol-consuming women.",A,ALDH2,ALDH2,1
340,bc_id356,CANCER,CYP2E1,12563175,B,Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development.,2003,,This study therefore suggests that the CYP2E1 c2 allele may influence the individual susceptibility to breast cancer in alcohol-consuming women.,A,CYP2E1,CYP2E1,1
341,bc_id357,CANCER,XRCC3,12565173,B,Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer.,2003,,"Although larger studies are needed to validate the study results, our data suggest that amino acid substitution variants of XRCC1 and XRCC3 genes may contribute to breast cancer susceptibility.",A,XRCC3,XRCC3,0.461538462
342,bc_id358,CANCER,XRCC1,12565173,B,Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer.,2003,,"Although larger studies are needed to validate the study results, our data suggest that amino acid substitution variants of XRCC1 and XRCC3 genes may contribute to breast cancer susceptibility.",A,XRCC1,XRCC1,0.543478261
343,bc_id359,CANCER,ACE,12566298,B,Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore.,2003,,"Our findings support experimental data implicating ACE and angiotensin II in breast cancer, and suggest that the renin-angiotensin system may serve as a therapeutic target for breast cancer treatment and prevention.",A,ACE,ACE,0.571428571
344,bc_id360,CANCER,BRCA2,12567413,B,Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.,2003,,"However, even after adjusting for breast cancer risk, there was a substantial racial disparity in use of BRCA1/2 testing.",A,BRCA1/2,BRCA2,0.576923077
345,bc_id361,CANCER,BRCA1,12567413,B,Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.,2003,,"As suggested by the association with family history, use of counseling was associated with having a higher predicted risk of breast cancer and a higher predicted risk of carrying a BRCA1 mutation",Y,BRCA1,BRCA1,0.326180258
346,bc_id362,CANCER,AR,12582022,Y,Androgen Receptor (CAG)(n) and (GGC)(n) Polymorphisms and Breast Cancer Risk in a Population-Based Case-Control Study of Young Women,2003,"In addition, these data suggest that AR repeat length may be partly responsible for the increased risk for early-onset breast cancer in women who use OCs, although these findings need replication in other populations.","In addition, these data suggest that AR repeat length may be partly responsible for the increased risk for early-onset breast cancer in women who use OCs, although these findings need replication in other populations.",A,AR,AR,0.458333333
347,bc_id363,CANCER,OGG1,12582029,B,No association between OGG1 Ser326Cys polymorphism and breast cancer risk.,2003,,ANF,ANF,ANF,ANF,0
348,bc_id364,CANCER,CYP17,12584742,Y,,2003,,"In addition, the significant increased risk of breast cancer associated with nulliparity or late age at first live birth (age 31 years or older) was largely limited to women with the high-risk CYP17 A1A2/A2A2 or HSD17B1 AA genotypes (RR=2.41, 95% CI=1.56-3.72; RR=4.39, 95% CI=1.71-11.30, respectively).",Y,CYP17 A1A2/A2A2,CYP17A1,0.266666667
349,bc_id365,CANCER,HSD17B1,12584742,Y,HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore,2003,We observed an elevated joint effect of the CYP17 and HSD17B1 genes on risk,"In addition, the significant increased risk of breast cancer associated with nulliparity or late age at first live birth (age 31 years or older) was largely limited to women with the high-risk CYP17 A1A2/A2A2 or HSD17B1 AA genotypes (RR=2.41, 95% CI=1.56-3.72; RR=4.39, 95% CI=1.71-11.30, respectively).",Y,HSD17B1,HSD17B1,0.181818182
350,bc_id368,CANCER,BRCA1,12602912,B,"Mutational screening of breast cancer susceptibility gene 1 from early onset, bi-lateral, and familial breast cancer patients in Taiwan.",2003,,These results suggest that the mutation of BRCA1 contributes little to the occurrence of breast cancer in the Taiwanese population.,A,BRCA1,BRCA1,0.60944206
351,bc_id369,CANCER,AR,12602915,B,Androgen receptor gene alterations in Finnish male breast cancer.,2003,,Our data indicate that the AR gene does not substantially contribute to MBC predisposition.,A,AR,AR,0.458333333
352,bc_id370,CANCER,MTHFR,12602921,B,Breast cancer risk and methylenetetrahydrofolate reductase polymorphism.,2003,"These data suggest that polymorphic MTHFR increases risk of premenopausal, but not postmenopausal, breast cancer.","These data suggest that polymorphic MTHFR increases risk of premenopausal, but not postmenopausal, breast cancer.",A,MTHFR,MTHFR,0.403846154
353,bc_id371,CANCER,IGF1,12610514,B,"IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort.",2003,,"It is unlikely that any involvement of IGF1 in breast cancer aetiology is mediated by the IGF1 dinucleotide repeat polymorphism, which was not significantly associated with circulating IGF1 levels nor breast cancer risk in this study. Research into relevant determinants of IGF1 levels in the blood must continue.",A,IGF1,IGF1,0.25
354,bc_id372,CANCER,GSTT1,12611461,B,"Reproductive factors, glutathione S-transferase M1 and T1 genetic polymorphism and breast cancer risk.",2003,,The interaction between the combined genotypes of GSTM1 and GSTT1 and status of parity factor was also significant in all women and in premenopausal women (P < 0.01). Our findings suggest that genetic polymorphisms GSTM1/T1 could modify estrogen-related breast cancer risk.,A,GSTT1,GSTT1,0.289473684
355,bc_id373,CANCER,GSTM1,12611461,B,"Reproductive factors, glutathione S-transferase M1 and T1 genetic polymorphism and breast cancer risk.",2003,,The interaction between the combined genotypes of GSTM1 and GSTT1 and status of parity factor was also significant in all women and in premenopausal women (P < 0.01). Our findings suggest that genetic polymorphisms GSTM1/T1 could modify estrogen-related breast cancer risk.,A,GSTM1,GSTM1,0.339622642
356,bc_id374,CANCER,CYP1B1,12618873,N,"Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women.",2003,"The results suggest that the CYP19 Arg(264)Cys polymorphism modifies breast cancer risk (OR=1.5, 95% CI=1.1-2.2), especially in association with alcohol consumption (P for interaction=0.04), whereas the CYP1B1 Leu(432)Val polymorphism appears to play no role here.","The results suggest that the CYP19 Arg(264)Cys polymorphism modifies breast cancer risk (OR=1.5, 95% CI=1.1-2.2), especially in association with alcohol consumption (P for interaction=0.04), whereas the CYP1B1 Leu(432)Val polymorphism appears to play no role here.",N,CYP1B1,CYP1B1,0.256410256
357,bc_id375,CANCER,CYP19A1,12618873,Y,"Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women.",2003,"The results suggest that the CYP19 Arg(264)Cys polymorphism modifies breast cancer risk (OR=1.5, 95% CI=1.1-2.2), especially in association with alcohol consumption (P for interaction=0.04), whereas the CYP1B1 Leu(432)Val polymorphism appears to play no role here.","The results suggest that the CYP19 Arg(264)Cys polymorphism modifies breast cancer risk (OR=1.5, 95% CI=1.1-2.2), especially in association with alcohol consumption (P for interaction=0.04), whereas the CYP1B1 Leu(432)Val polymorphism appears to play no role here.",Y,CYP19,CYP19A1,0.333333333
358,bc_id376,CANCER,CYP17A1,12631398,B,"CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors.",2003,These results suggest that the effects of factors that may alter breast cancer risk through a hormonal mechanism may be less important among premenopausal women with putative higher lifetime exposures to circulating estrogens related to the CYP17 A2 allele.,These results suggest that the effects of factors that may alter breast cancer risk through a hormonal mechanism may be less important among premenopausal women with putative higher lifetime exposures to circulating estrogens related to the CYP17 A2 allele.,A,CYP17,CYP17A1,0.466666667
359,bc_id377,CANCER,BRCA2,12644538,B,"Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.",2003,"Mutations in genes other than BRCA1 and BRCA2 may be associated with a high risk of breast cancer, especially in young women.","Mutations in genes other than BRCA1 and BRCA2 may be associated with a high risk of breast cancer, especially in young women.",A,BRCA2,BRCA2,0.576923077
360,bc_id378,CANCER,BRCA1,12644538,B,"Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.",2003,"Mutations in genes other than BRCA1 and BRCA2 may be associated with a high risk of breast cancer, especially in young women.","Mutations in genes other than BRCA1 and BRCA2 may be associated with a high risk of breast cancer, especially in young women.",A,BRCA1,BRCA1,0.60944206
361,bc_id379,CANCER,CYP17A1,12644832,N,CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status.,2003,"Our findings do not indicate a role for the CYP17 T-C polymorphism in female breast cancer, but a role in male carriers of a BRCA2 mutation could not be excluded because of the small sample size.","No association was observed with breast cancer risk among females irrespective of menopausal status, stage of the disease or BRCA2 status. Our findings do not indicate a role for the CYP17 T-C polymorphism in female breast cancer, but a role in male carriers of a BRCA2 mutation could not be excluded because of the small sample size.",N,CYP17,CYP17A1,0.266666667
362,bc_id380,CANCER,CYP17A1,12652520,Y,"Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer.",2003,"This analytical approach is well-suited to the data that arise from population-based case-control-family studies, in which cases, controls and relatives are studied, and genotype is measured for some but not all subjects.","Breast cancer data for first- and second-degree relatives of case probands were used. The three methods gave consistent estimates. The best-fitting model involved a recessive inheritance, with homozygotes being at an increased risk of 47% (95% CI, 28-68%)... The three methods gave consistent estimates. The best-fitting model involved a recessive inheritance, with homozygotes being at an increased risk of 47% (95% CI, 28-68%). The cumulative risk of the disease up to age 70 years was estimated to be 10% or 22% for a CYP17 homozygote whose mother was unaffected or affected, respectively. This analytical approach is well-suited to the data that arise from population-based case-control-family studies, in which cases, controls and relatives are studied, and genotype is measured for some but not all subjects.",A,CYP17,CYP17A1,0.466666667
363,bc_id381,CANCER,BRCA2,12655567,B,Mutational analysis of BRCA2 in Spanish breast cancer patients from Castilla-Leon: identification of four novel truncating mutations.,2003,,Mutations in BRCA1 and BRCA2 account for approximately 5% of the overall familial risk of breast cancer.,A,BRCA2,BRCA2,0.576923077
364,bc_id383,CANCER,RAD51,12673366,N,Analysis of the G/C polymorphism in the 5'-untranslated region of the RAD51 gene in breast cancer.,2003,Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and/or progression of breast cancer and so it may not be useful as an independent marker in this disease.,Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and/or progression of breast cancer and so it may not be useful as an independent marker in this disease.,A,RAD51,RAD51,0.615384615
365,bc_id384,CANCER,LHCGR,12679452,Y,Luteinizing hormone signaling and breast cancer:polymorphisms and age of onset.,2003,Our findings suggest that the LHR18insLQ gene polymorphism determines an earlier age of disease onset and is prognostic for poor outcome of breast cancer.,"In contrast, no associations between the LH genotype and any of the clinical parameters were observed. Our findings suggest that the LHR18insLQ gene polymorphism determines an earlier age of disease onset and is prognostic for poor outcome of breast cancer.",Y,LHR,LHCGR,0.333333333
366,bc_id385,CANCER,TP53,12684392,B,Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.,2003,,"Combined TP53 gene mutation status and high VEGF levels of ER-positive primary breast tumors independently predict a poor course of the disease of patients with advanced breast cancer treated with tamoxifen. These patients, having unfavorable tumor characteristics, might benefit more from other types of (individualized) treatment protocols.",A,TP53,TP53,0.482758621
367,bc_id386,CANCER,BRCA2,12684407,B,Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.,2003,,"The association of BRCA2 polymorphisms at codon 372 [Asn (N)/His (H)]and codon 784 [Met (M)/Val (V)] with breast cancer risk was evaluated in Japanese women. In addition, the prognostic significance of these polymorphisms was studied in breast cancer patients... These results suggest that the M/V784 polymorphism, but not the N/H372 polymorphism, would be useful in the selection of women at high risk for developing breast cancer and would also serve as a clinically useful prognostic factor in breast cancer patients.",A,BRCA2,BRCA2,0.576923077
368,bc_id387,CANCER,TP53,12684648,B,P53 codon 72 polymorphism in breast cancer.,2003,,A significantly higher prevalence of homozygosity for the p53 Arg allele was observed in the patients as compared to the controls. Statistical analysis suggested a strong association between the Arg/Arg genotype and breast cancer.,Y,p53,TP53,0.367816092
369,bc_id388,CANCER,ABCB1,12684679,B,Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer.,2003,MDR-1 polymorphism C3435T in exon 26 may co-determine resistance to chemotherapy and provide useful information to individualize therapy.,We analysed the allelic frequencies at the polymorphic site C3435T in a group of patients with locally advanced breast cancer treated by preoperative chemotherapy to evaluate its predictive value... Statistical analysis revealed a significant correlation (p=0.029) between clinical complete response to preoperative chemotherapy and the T/T genotype. MDR-1 polymorphism C3435T in exon 26 may co-determine resistance to chemotherapy and provide useful information to individualize therapy.,A,MDR-1,ABCB1,0.6875
370,bc_id389,CANCER,TP53,12708345,B,[Risk factors for cervico-uterine cancer associated to HPV: p53 codon 72 polymorphism in womenattending hospital care],2003,"The detection of a high percentage of arginine homocygotes suggests that this genotype, considered as a risk factor for cancer associated to oncogenic HPV, has a high prevalence in the north of Mexico. The determination of this kind of polymorphisms is important as preventive action with regard to identification of risk factors for CaCu associated to HPV infection.",NR,NR,NR,NR,0
371,bc_id390,CANCER,NAT2,12708724,B,Association of NAT2 and smoking in relation to breast cancer incidence in a population-based case-control study (United States).,2003,"Results of the study are compatible with the majority of previous studies that indicate little or no association of NAT2, smoking, or their interaction with the occurrence of breast cancer.","Results of the study are compatible with the majority of previous studies that indicate little or no association of NAT2, smoking, or their interaction with the occurrence of breast cancer.",A,NAT2,NAT2,0.259259259
372,bc_id391,CANCER,ESR1,12712467,B,A multigene test for the risk of sporadic breast carcinoma.,2003,These results demonstrate a potentially powerful method of evaluating the additive effect of multiple breast carcinoma risk genes to form a potentially clinically useful assessment of women's risk for sporadic breast carcinoma.,"The authors hypothesized that six genes relevant to the timing of the onset of menarche and related risk factors might be candidate genes for breast carcinoma. These were the leptin gene (LEP), the leptin receptor gene (LEPR), the catechol-0-methyltransferase gene (COMT), the dopamine D(2) receptor gene (DRD2), the estrogen 1 receptor gene (ESR1), and the androgen receptor gene (AR).",A,ESR1,ESR1,0.586956522
373,bc_id392,CANCER,DRD2,12712467,B,A multigene test for the risk of sporadic breast carcinoma.,2003,These results demonstrate a potentially powerful method of evaluating the additive effect of multiple breast carcinoma risk genes to form a potentially clinically useful assessment of women's risk for sporadic breast carcinoma.,"The authors hypothesized that six genes relevant to the timing of the onset of menarche and related risk factors might be candidate genes for breast carcinoma. These were the leptin gene (LEP), the leptin receptor gene (LEPR), the catechol-0-methyltransferase gene (COMT), the dopamine D(2) receptor gene (DRD2), the estrogen 1 receptor gene (ESR1), and the androgen receptor gene (AR).",A,DRD2,DRD2,0.5
374,bc_id393,CANCER,AR,12712467,B,A multigene test for the risk of sporadic breast carcinoma.,2003,These results demonstrate a potentially powerful method of evaluating the additive effect of multiple breast carcinoma risk genes to form a potentially clinically useful assessment of women's risk for sporadic breast carcinoma.,"The authors hypothesized that six genes relevant to the timing of the onset of menarche and related risk factors might be candidate genes for breast carcinoma. These were the leptin gene (LEP), the leptin receptor gene (LEPR), the catechol-0-methyltransferase gene (COMT), the dopamine D(2) receptor gene (DRD2), the estrogen 1 receptor gene (ESR1), and the androgen receptor gene (AR).",A,AR,AR,0.458333333
375,bc_id394,CANCER,LEP,12712467,B,A multigene test for the risk of sporadic breast carcinoma.,2003,These results demonstrate a potentially powerful method of evaluating the additive effect of multiple breast carcinoma risk genes to form a potentially clinically useful assessment of women's risk for sporadic breast carcinoma.,"The authors hypothesized that six genes relevant to the timing of the onset of menarche and related risk factors might be candidate genes for breast carcinoma. These were the leptin gene (LEP), the leptin receptor gene (LEPR), the catechol-0-methyltransferase gene (COMT), the dopamine D(2) receptor gene (DRD2), the estrogen 1 receptor gene (ESR1), and the androgen receptor gene (AR).",A,LEP,LEP,0.333333333
376,bc_id395,CANCER,COMT,12712467,B,A multigene test for the risk of sporadic breast carcinoma.,2003,These results demonstrate a potentially powerful method of evaluating the additive effect of multiple breast carcinoma risk genes to form a potentially clinically useful assessment of women's risk for sporadic breast carcinoma.,"The authors hypothesized that six genes relevant to the timing of the onset of menarche and related risk factors might be candidate genes for breast carcinoma. These were the leptin gene (LEP), the leptin receptor gene (LEPR), the catechol-0-methyltransferase gene (COMT), the dopamine D(2) receptor gene (DRD2), the estrogen 1 receptor gene (ESR1), and the androgen receptor gene (AR).",A,COMT,COMT,0.425531915
377,bc_id396,CANCER,LEPR,12712467,B,A multigene test for the risk of sporadic breast carcinoma.,2003,These results demonstrate a potentially powerful method of evaluating the additive effect of multiple breast carcinoma risk genes to form a potentially clinically useful assessment of women's risk for sporadic breast carcinoma.,"The authors hypothesized that six genes relevant to the timing of the onset of menarche and related risk factors might be candidate genes for breast carcinoma. These were the leptin gene (LEP), the leptin receptor gene (LEPR), the catechol-0-methyltransferase gene (COMT), the dopamine D(2) receptor gene (DRD2), the estrogen 1 receptor gene (ESR1), and the androgen receptor gene (AR).",A,LEPR,LEPR,0.285714286
378,bc_id397,CANCER,SULT1A1,12725421,Y,"Sulfotransferase 1A1 (SULT1A1) polymorphism, PAH-DNA adduct levels in breast tissue and breast cancer risk in a case-control study",2003,Our findings are consistent with a prior report that the Arg/His polymorphism in SULT1A1 is associated with breast cancer risk.,Our findings are consistent with a prior report that the Arg/His polymorphism in SULT1A1 is associated with breast cancer risk.,Y,SULT1A1,SULT1A1,0.322580645
379,bc_id398,CANCER,COMT,12727796,B,Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk.,2003,,"Based on our findings, COMT activity alone does not seem to play a major role in breast carcinogenesis, but may be of importance in certain histotypes or in conjunction with other exposures.",A,COMT,COMT,0.425531915
380,bc_id399,CANCER,BRCA1,12750242,Y,Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.,2003,This finding suggests that RAD51 is a genetic modifier of breast cancer risk in BRCA1 carriers in the Polish population. It will be of interest to confirm this in other populations as well.,This finding suggests that RAD51 is a genetic modifier of breast cancer risk in BRCA1 carriers in the Polish population. It will be of interest to confirm this in other populations as well.,Y,BRCA1,BRCA1,0.326180258
381,bc_id400,CANCER,RAD51,12750242,Y,Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland.,2003,This finding suggests that RAD51 is a genetic modifier of breast cancer risk in BRCA1 carriers in the Polish population. It will be of interest to confirm this in other populations as well.,This finding suggests that RAD51 is a genetic modifier of breast cancer risk in BRCA1 carriers in the Polish population. It will be of interest to confirm this in other populations as well.,Y,RAD51,RAD51,0.230769231
382,bc_id402,CANCER,PRKDC,12750264,B,Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.,2003,"Based on comprehensive NHEJ gene profiles, this study provides new insights to suggest the role of the NHEJ pathway in breast cancer development and supports the possibility that breast cancer is initiated by estrogen exposure, which causes DNA DSBs.","Because single nucleotide polymorphisms (SNPs) are the most subtle genetic variation in the genome, to examine these hypotheses, we have genotyped 30 SNPs in all five NHEJ genes (Ku70, Ku80, DNA-PKcs, Ligase IV, and XRCC4) in 254 primary breast cancer patients and 379 healthy controls...  Based on comprehensive NHEJ gene profiles, this study provides new insights to suggest the role of the NHEJ pathway in breast cancer development and supports the possibility that breast cancer is initiated by estrogen exposure, which causes DNA DSBs.",A,DNA-PKcs,PRKDC,1
383,bc_id403,CANCER,LIG4,12750264,B,Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.,2003,"Based on comprehensive NHEJ gene profiles, this study provides new insights to suggest the role of the NHEJ pathway in breast cancer development and supports the possibility that breast cancer is initiated by estrogen exposure, which causes DNA DSBs.","Because single nucleotide polymorphisms (SNPs) are the most subtle genetic variation in the genome, to examine these hypotheses, we have genotyped 30 SNPs in all five NHEJ genes (Ku70, Ku80, DNA-PKcs, Ligase IV, and XRCC4) in 254 primary breast cancer patients and 379 healthy controls...  Based on comprehensive NHEJ gene profiles, this study provides new insights to suggest the role of the NHEJ pathway in breast cancer development and supports the possibility that breast cancer is initiated by estrogen exposure, which causes DNA DSBs.",A,Ligase IV,LIG4,0.25
384,bc_id404,CANCER,XRCC4,12750264,B,Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.,2003,"Based on comprehensive NHEJ gene profiles, this study provides new insights to suggest the role of the NHEJ pathway in breast cancer development and supports the possibility that breast cancer is initiated by estrogen exposure, which causes DNA DSBs.",Support for these hypotheses came from the observations that (a) two SNPs in Ku70 and XRCC4 were associated with breast cancer risk (P < 0.05);,Y,XRCC4,XRCC4,0.4
385,bc_id401,CANCER,XRCC6,12750264,B,Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.,2003,"Based on comprehensive NHEJ gene profiles, this study provides new insights to suggest the role of the NHEJ pathway in breast cancer development and supports the possibility that breast cancer is initiated by estrogen exposure, which causes DNA DSBs.",X,X,X,X,0
386,bc_id405,CANCER,XRCC5,12750264,B,Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility.,2003,"Based on comprehensive NHEJ gene profiles, this study provides new insights to suggest the role of the NHEJ pathway in breast cancer development and supports the possibility that breast cancer is initiated by estrogen exposure, which causes DNA DSBs.",X,X,X,X,0
387,bc_id406,CANCER,TGFB,12750287,Y,A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer.,2003,,These data indicate that the allele encoding Pro10 is associated with increased rates of TGFbeta1 secretion and with increased incidence of invasive breast cancer for the population samples described. It is estimated that 3% of all breast cancer cases may be attributable to Pro10 homozygosity.,A,TGFbeta1,TGIF1,1
388,bc_id407,CANCER,CYP3A5,12756511,B,CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.,2003,"These results seem to suggest that genetic polymorphisms in CYP3A5 in Asians, in particular Malays and Indians but also Chinese although to a lesser extent, may be an important genetic contributor to interindividual as well as interethnic differences in clearance of CYP3A substrates.",NR,NR,NR,NR,0
389,bc_id409,CANCER,BRCA2,12774040,B,Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.,2003,,Our findings show that mutations in BRCA1 and BRCA2 may contribute similarly to early-onset breast cancer in Germany.,A,BRCA2,BRCA2,0.576923077
390,bc_id410,CANCER,BRCA1,12774040,B,Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.,2003,,Our findings show that mutations in BRCA1 and BRCA2 may contribute similarly to early-onset breast cancer in Germany.,A,BRCA1,BRCA1,0.60944206
391,bc_id411,CANCER,OGG1,12779082,B,hOGG1 Ser326Cys polymorphism and breast cancer risk among Asian women.,2003,,Our novel findings therefore suggest that hOGG1 Ser326Cys polymorphism is unlikely to play a modifying role in individual susceptibility to breast cancer among Asian women.,A,hOGG1,OGG1,0.444444444
392,bc_id412,CANCER,LRP1,12793904,Y,C766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancer.,2003,The T allele of the C766T polymorphism in the LRP1 gene is associated with an increased risk of breast cancer development in women of Caucasian origin.,The T allele of the C766T polymorphism in the LRP1 gene is associated with an increased risk of breast cancer development in women of Caucasian origin.,Y,LRP1,LRP1,1
393,bc_id413,CANCER,GSTT1,12814450,B,"Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.",2003,"We found that Egyptians resemble other Caucasians with regard to allelic frequencies of the tested variants of NAT2, GST and MDR-1. By contrast, this Egyptian population more closely resemble Africans with respect to the TPMT*3C allele, and shows a distinctly different frequency with regard to the SULT1A1*2 variant. The predominance of the slow acetylator genotype in the present study (60.50%) could not confirm a previously reported higher frequency of the slow acetylator phenotype in Egyptians (92.00%), indicating the possibility of the presence of other mutations not detectable as T341C, G590A and G857A. The purpose of our future studies is to investigate for new polymorphisms, which could be relatively unique to the Egyptian population.",NR,NR,NR,NR,0
394,bc_id414,CANCER,GSTM1,12814450,B,"Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.",2003,"We found that Egyptians resemble other Caucasians with regard to allelic frequencies of the tested variants of NAT2, GST and MDR-1. By contrast, this Egyptian population more closely resemble Africans with respect to the TPMT*3C allele, and shows a distinctly different frequency with regard to the SULT1A1*2 variant. The predominance of the slow acetylator genotype in the present study (60.50%) could not confirm a previously reported higher frequency of the slow acetylator phenotype in Egyptians (92.00%), indicating the possibility of the presence of other mutations not detectable as T341C, G590A and G857A. The purpose of our future studies is to investigate for new polymorphisms, which could be relatively unique to the Egyptian population.",NR,NR,NR,NR,0
395,bc_id415,CANCER,SULT1A1,12814450,B,"Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.",2003,"We found that Egyptians resemble other Caucasians with regard to allelic frequencies of the tested variants of NAT2, GST and MDR-1. By contrast, this Egyptian population more closely resemble Africans with respect to the TPMT*3C allele, and shows a distinctly different frequency with regard to the SULT1A1*2 variant. The predominance of the slow acetylator genotype in the present study (60.50%) could not confirm a previously reported higher frequency of the slow acetylator phenotype in Egyptians (92.00%), indicating the possibility of the presence of other mutations not detectable as T341C, G590A and G857A. The purpose of our future studies is to investigate for new polymorphisms, which could be relatively unique to the Egyptian population.",NR,NR,NR,NR,0
396,bc_id416,CANCER,TPMT,12814450,B,"Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.",2003,"We found that Egyptians resemble other Caucasians with regard to allelic frequencies of the tested variants of NAT2, GST and MDR-1. By contrast, this Egyptian population more closely resemble Africans with respect to the TPMT*3C allele, and shows a distinctly different frequency with regard to the SULT1A1*2 variant. The predominance of the slow acetylator genotype in the present study (60.50%) could not confirm a previously reported higher frequency of the slow acetylator phenotype in Egyptians (92.00%), indicating the possibility of the presence of other mutations not detectable as T341C, G590A and G857A. The purpose of our future studies is to investigate for new polymorphisms, which could be relatively unique to the Egyptian population.",NR,NR,NR,NR,0
397,bc_id417,CANCER,NAT2,12814450,B,"Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.",2003,"We found that Egyptians resemble other Caucasians with regard to allelic frequencies of the tested variants of NAT2, GST and MDR-1. By contrast, this Egyptian population more closely resemble Africans with respect to the TPMT*3C allele, and shows a distinctly different frequency with regard to the SULT1A1*2 variant. The predominance of the slow acetylator genotype in the present study (60.50%) could not confirm a previously reported higher frequency of the slow acetylator phenotype in Egyptians (92.00%), indicating the possibility of the presence of other mutations not detectable as T341C, G590A and G857A. The purpose of our future studies is to investigate for new polymorphisms, which could be relatively unique to the Egyptian population.",NR,NR,NR,NR,0
398,bc_id418,CANCER,BRCA1,12815604,B,The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives.,2003,,"The prevalence of BRCA1 mutations in Chinese patients in Shanghai with early onset breast cancer is similar to that observed in western women, but the incidence of mutations in breast cancer patients in Shanghai with affected relatives isn't as high as that in western women.",A,BRCA1,BRCA1,0.60944206
399,bc_id419,CANCER,CYP3A5,12822676,Y,CYP3A5*1 is an inhibitory factor for lung cancer in Taiwanese.,2003,We suggest that CYP3A5*1 may play an important role in individual predisposition to lung cancer in Taiwan.,"The allelic frequencies of CYP3A5*1 were 25% in hepatoma patients, 33% in cervical cancer patients, 31% in breast cancer patients, 22% in oral cancer patients, 23% in thyroid cancer patients, 20% in lung cancer patients, and 27% in healthy subjects.",Y,CYP3A5*1,CYP3A5,0.2
400,bc_id420,CANCER,NAT2,12835615,B,NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women.,2003,", our results provide support for the view that women who smoke and who have a genetically determined reduced inactivation of carcinogens (GSTM1 null genotype or slow NAT2 genotype (especially very slow NAT2 genotype)) are at increased risk of breast cancer.","In conclusion, our results provide support for the view that women who smoke and who have a genetically determined reduced inactivation of carcinogens (GSTM1 null genotype or slow NAT2 genotype (especially very slow NAT2 genotype)) are at increased risk of breast cancer.",Y,NAT2,NAT2,0.37037037
401,bc_id421,CANCER,NAT1,12835615,B,NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women.,2003,", our results provide support for the view that women who smoke and who have a genetically determined reduced inactivation of carcinogens (GSTM1 null genotype or slow NAT2 genotype (especially very slow NAT2 genotype)) are at increased risk of breast cancer.","Neither NAT1 slow genotype, or GSTT1 null genotype, alone or in combination with smoking, affected breast cancer risk.",N,NAT1,NAT2,0.37037037
402,bc_id422,CANCER,GSTT1,12835615,B,NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women.,2003,", our results provide support for the view that women who smoke and who have a genetically determined reduced inactivation of carcinogens (GSTM1 null genotype or slow NAT2 genotype (especially very slow NAT2 genotype)) are at increased risk of breast cancer.","Neither NAT1 slow genotype, or GSTT1 null genotype, alone or in combination with smoking, affected breast cancer risk.",N,GSTT1,GSTT1,0.131578947
403,bc_id423,CANCER,GSTM1,12835615,B,NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women.,2003,", our results provide support for the view that women who smoke and who have a genetically determined reduced inactivation of carcinogens (GSTM1 null genotype or slow NAT2 genotype (especially very slow NAT2 genotype)) are at increased risk of breast cancer.","In conclusion, our results provide support for the view that women who smoke and who have a genetically determined reduced inactivation of carcinogens (GSTM1 null genotype or slow NAT2 genotype (especially very slow NAT2 genotype)) are at increased risk of breast cancer.",Y,GSTM1,GSTM1,0.452830189
404,bc_id424,CANCER,BRCA1,12838555,B,"Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination.",2003,,"In this cohort of women, these results indicate that information about increased breast cancer risk is associated with increase in life insurance purchasing, raising the possibility of adverse selection. Although fear of insurance discrimination is associated with the decision not to undergo BRCA1/2 testing, there was no evidence of actual insurance discrimination from BRCA1/2 testing.",A,BRCA1,BRCA1,0.60944206
405,bc_id425,CANCER,CYP1B1,12844487,N,Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk.,2003,"We explored the effect of CYP1B1 genotype on breast cancer risk in subgroups defined by body mass index, family history, smoking and Catechol-O-methyl transferase genotype, but found no convincing evidence for interaction. In summary, our results strongly indicate that the studied CYP1B1 gene polymorphisms do not influence breast cancer risk overall but may modify the risk after long-term menopausal hormone use.","We explored the effect of CYP1B1 genotype on breast cancer risk in subgroups defined by body mass index, family history, smoking and Catechol-O-methyl transferase genotype, but found no convincing evidence for interaction. In summary, our results strongly indicate that the studied CYP1B1 gene polymorphisms do not influence breast cancer risk overall but may modify the risk after long-term menopausal hormone use.",N,CYP1B1,CYP1B1,0.256410256
406,bc_id428,CANCER,VEGFA,12845639,Y,A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk.,2003,"We conclude that  carriers of a VEGF 936T-allele are at decreased risk for breast cancer, this, however, requiring further confirmation in a larger study.","We conclude that  carriers of a VEGF 936T-allele are at decreased risk for breast cancer, this, however, requiring further confirmation in a larger study.",Y,VEGF 936T-allele,VEGFA,0.25
407,bc_id430,CANCER,BRCA2,12845657,B,Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.,2003,,Mutations in the BRCA1 and BRCA2 genes explain at least 10% of breast cancer cases diagnosed before age 40 years. The contribution of these genes to early-onset breast cancer is likely to be even higher given that certain UV cases might be disease-associated.,A,BRCA2,BRCA2,0.576923077
408,bc_id431,CANCER,BRCA1,12845657,B,Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.,2003,,Mutations in the BRCA1 and BRCA2 genes explain at least 10% of breast cancer cases diagnosed before age 40 years. The contribution of these genes to early-onset breast cancer is likely to be even higher given that certain UV cases might be disease-associated.,A,BRCA1,BRCA1,0.60944206
409,bc_id432,CANCER,NBN,12845677,B,Germline 657del5 mutation in the NBS1 gene in breast cancer patients.,2003,It appears that the 657del5 mutation in exon 6 of the NBS1 gene is responsible for the occurrence of a small but significant proportion of familial breast cancer patients.,It appears that the 657del5 mutation in exon 6 of the NBS1 gene is responsible for the occurrence of a small but significant proportion of familial breast cancer patients.,Y,NBS1,NBN,0.19047619
410,bc_id434,CANCER,ERBB2,12846420,B,HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.,2003,"The HER2 codon 655 polymorphism may be one of many low-penetrant genes that make a minor contribution to breast cancer, particularly in subgroups of women. Additional large studies, as well as data pooling, will be needed to estimate the contribution of such genes to breast cancer risk.","The HER2 codon 655 polymorphism may be one of many low-penetrant genes that make a minor contribution to breast cancer, particularly in subgroups of women. Additional large studies, as well as data pooling, will be needed to estimate the contribution of such genes to breast cancer risk.",A,HER2,ERBB2,0.452380952
411,bc_id435,CANCER,ESR2,12846425,B,Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association.,2003,No difference in the allele distribution of the six studied polymorphisms was found between the breast cancer and control groups.,In this first association study about breast cancer risk and polymorphisms in the ERbeta gene we have screened 219 Finnish sporadic breast cancer cases and 248 ethnically matched male controls. No difference in the allele distribution of the six studied polymorphisms was found between the breast cancer and control groups.,A,ERbeta,ESR2,0.533333333
412,bc_id436,CANCER,GSTT1,12860276,B,"N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1~~~ GSTT1) polymorphisms in breast cancer.",2003,,"These results suggest that genetic polymorphisms of NAT1 and NAT2 have no independent effect on breast cancer risk, but they modulate breast cancer risk in the presence of GSTM1 and GSTT1 null genotypes.",Y,GSTT1,GSTT1,0.578947368
413,bc_id437,CANCER,GSTM1,12860276,B,"N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1~~~ GSTT1) polymorphisms in breast cancer.",2003,,"These results suggest that genetic polymorphisms of NAT1 and NAT2 have no independent effect on breast cancer risk, but they modulate breast cancer risk in the presence of GSTM1 and GSTT1 null genotypes.",Y,GSTM1,GSTM1,0.452830189
414,bc_id438,CANCER,NAT2,12860276,B,"N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1~~~ GSTT1) polymorphisms in breast cancer.",2003,,"These results suggest that genetic polymorphisms of NAT1 and NAT2 have no independent effect on breast cancer risk, but they modulate breast cancer risk in the presence of GSTM1 and GSTT1 null genotypes.",N,NAT2,NAT2,0.37037037
415,bc_id439,CANCER,NAT1,12860276,B,"N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1~~~ GSTT1) polymorphisms in breast cancer.",2003,,"These results suggest that genetic polymorphisms of NAT1 and NAT2 have no independent effect on breast cancer risk, but they modulate breast cancer risk in the presence of GSTM1 and GSTT1 null genotypes.",N,NAT1,NAT1,0.6
416,bc_id440,CANCER,BACH1,12872252,B,Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.,2003,Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to breast cancer in the general population.,"Based on sequencing of ZBRK1 and BRIP1 in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families, it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer.",A,BRIP1,BACH1,0.5
417,bc_id441,CANCER,ESR1,12889606,B,Estrogen receptor alpha gene polymorphisms and breast cancer risk.,2003,,Our results therefore suggest that the ER alpha XbaI polymorphism modifies individual susceptibility to breast cancer in Korean women.,Y,ER alpha,ESR1,0.282608696
418,bc_id442,CANCER,TUBB,12893435,N,Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer.,2003,Our results suggest that mutation of the class I beta-tubulin gene is unlikely to play an important role in the mechanism of resistance to paclitaxel in breast cancer.,Our results suggest that mutation of the class I beta-tubulin gene is unlikely to play an important role in the mechanism of resistance to paclitaxel in breast cancer.,Y,I beta-tubulin,TUBB,1
419,bc_id443,CANCER,VDR,12899513,B,Approaches to evaluating the association of vitamin D receptor gene polymorphisms with breast cancer risk.,2003,,Further investigations into how these different genotypes may affect the functional mechanisms of the VDR will provide a better strategy for identifying women at risk of breast cancer and for developing improved treatments.,A,VDR,VDR,0.538461538
420,bc_id444,CANCER,GP1BA,12908817,B,Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation.,2003,"Although confirmatory studies are needed, our results suggest that polymorphic genetic variation of integrins expressed in platelets and epithelial breast cells could modify the risk and the biological aggressiveness of breast carcinomas.","No association was found between VNTR (GP Ibalpha) polymorphism and breast cancer risk or presentation. Genotype and allele frequencies of C807T and G1648A polymorphisms of integrin alpha2 were not statistically different in breast cancer patients and controls, although we found an association between the 1648G/G genotype and higher disease stages (III and IV) (p = 0.02).",N,VNTR (GP Ibalpha,GP1BA,1
421,bc_id445,CANCER,ITGA3,12908817,B,Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation.,2003,,X,X,X,X,0
422,bc_id446,CANCER,ITGA2,12908817,B,Genetic polymorphisms of platelet adhesive molecules: association with breast cancer risk and clinical presentation.,2003,,"No association was found between VNTR (GP Ibalpha) polymorphism and breast cancer risk or presentation. Genotype and allele frequencies of C807T and G1648A polymorphisms of integrin alpha2 were not statistically different in breast cancer patients and controls, although we found an association between the 1648G/G genotype and higher disease stages (III and IV) (p = 0.02).",N,integrin alpha2,ITGA2,0.666666667
423,bc_id447,CANCER,MICA,12915440,B,The HLA class III subregion is responsible for an increased breast cancer risk.,2003,,"The results were confirmed with association analyses. Individuals homozygous for haplotype 110-184 (D6S2672-MICA) were observed in 9.0% of moderate-risk patients and 1.5% of controls [odds ratio (OR)=7.14], while heterozygotes were at a lower risk (OR=1.41), suggesting a recessive effect. No association was observed between the two SNPs in TNFalpha (-308) and TNFbeta (intron 1) and breast cancer risk.",Y,MICA,MICA,1
424,bc_id448,CANCER,LTA,12915440,B,The HLA class III subregion is responsible for an increased breast cancer risk.,2003,,No association was observed between the two SNPs in TNFalpha (-308) and TNFbeta (intron 1) and breast cancer risk.,N,TNFB,LTA,0.25
425,bc_id449,CANCER,TNF,12915440,B,The HLA class III subregion is responsible for an increased breast cancer risk.,2003,,No association was observed between the two SNPs in TNFalpha (-308) and TNFbeta (intron 1) and breast cancer risk.,N,TNFalpha,TNFA,1
426,bc_id450,CANCER,ATM,12917204,B,The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort.,2003,"The distribution of ATM missense mutations and polymorphisms varied widely across the four ethnic groups studied. Although a single missense variant (L546V) appeared to act as a modest predictor of risk, the remaining variants were no more common in breast cancer cases as compared with controls.","The distribution of ATM missense mutations and polymorphisms varied widely across the four ethnic groups studied. Although a single missense variant (L546V) appeared to act as a modest predictor of risk, the remaining variants were no more common in breast cancer cases as compared with controls.",A,ATM,ATM,0.422222222
427,bc_id452,CANCER,CHEK2,12917215,N,Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk.,2003,"We conclude that  the CHEK2 polymorphisms IVS + 1a and a1013g do not confer an increased risk of breast cancer. It is also unlikely that other, as yet unidentified, common polymorphisms that affect risk are present in the gene in the British population.","We conclude that  the CHEK2 polymorphisms IVS + 1a and a1013g do not confer an increased risk of breast cancer. It is also unlikely that other, as yet unidentified, common polymorphisms that affect risk are present in the gene in the British population.",N,CHEK2,CHEK2,0.233333333
428,bc_id454,CANCER,IGFBP3,12925957,N,"Polymorphic variation at the -202 locus in IGFBP3:Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk",2003,"Our data do not demonstrate a significant influence of this locus on breast cancer risk, but we cannot exclude a minor influence or an influence confined to subgroups.","We confirmed a relation between the -202 IGFBP3 polymorphism and IGFBP-3 serum levels and observed a positive correlation between circulating retinol levels and circulating IGFBP-3 levels, providing further evidence that retinoids may influence IGF physiology. Our data do not demonstrate a significant influence of this locus on breast cancer risk, but we cannot exclude a minor influence or an influence confined to subgroups.",A,IGFBP3,IGFBP3,0.428571429
429,bc_id456,CANCER,BRCA2,12927042,B,"BRCA2 mutation carriers, reproductive factors and breast cancer risk.",2003,The association between breast cancer and the number of pregnancies and between breast cancer and the duration of breast feeding was not the same for carriers and noncarriers of a detrimental BRCA2 mutation.,"The association between breast cancer and the number of pregnancies and between breast cancer and the duration of breast feeding was not the same for carriers and noncarriers of a detrimental BRCA2 mutation. In the context of other epidemiological and laboratory studies, this may indicate that the product of the BRCA2 gene has a function relating to the differentiation of epithelial tissue in the breast",A,BRCA2,BRCA2,0.576923077
430,bc_id457,CANCER,BRCA1,12928470,Y,"Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer~~~ or both.",2003,"In these families with breast and/or ovarian cancer, mutations in BRCA1 but not BRCA2 were associated with a sex ratio skewed against male births.","In these families with breast and/or ovarian cancer, mutations in BRCA1 but not BRCA2 were associated with a sex ratio skewed against male births.",Y,BRCA1,BRCA1,0.326180258
431,bc_id458,CANCER,ATM,12935922,B,ATM missense mutations are frequent inpatients with breast cancer,2003,It is estimated that the attributable risk of mutations in the ATM gene is 13% in this cohort of women with breast cancer.,It is estimated that the attributable risk of mutations in the ATM gene is 13% in this cohort of women with breast cancer.,A,ATM,ATM,0.422222222
432,bc_id459,CANCER,CYP19A1,12944421,B,A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.,2003,Our findings suggest the hypothesis that women with the long-range CYP19 haplotype 2b-3c may be carriers of a predisposing breast cancer susceptibility allele.,Our findings suggest the hypothesis that women with the long-range CYP19 haplotype 2b-3c may be carriers of a predisposing breast cancer susceptibility allele.,A,CYP19,CYP19A1,0.484848485
433,bc_id460,CANCER,SOD2,12963120,N,MnSOD polymorphism and breast cancer in a population-based case-control study.,2003,Results do not support any overall association of the Ala-9Val MnSOD polymorphism to the development of breast cancer.,X,X,X,X,0
434,bc_id462,CANCER,PGR,14500352,Y,A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk.,2003,Our findings suggest that the increased production of hPR-B by the +331 G/A polymorphism may predispose women to breast cancer development through increased hPR-B-dependent stimulation of mammary cell growth.,Our findings suggest that the increased production of hPR-B by the +331 G/A polymorphism may predispose women to breast cancer development through increased hPR-B-dependent stimulation of mammary cell growth.,A,hPR-B,PGR,0.5
435,bc_id464,CANCER,COMT,14504192,Y,Val158Met Polymorphism in catechol-O-methyltransferase gene associated with risk factors for breast cancer.,2003,,These findings indicate that COMT genotype is associated with several risk factors for breast cancer and suggest that the low-activity COMT*2 allele is associated with a reduced risk of breast cancer among premenopausal women.,Y,COMT,COMT,0.276595745
436,bc_id465,CANCER,AR,14504193,B,Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines.,2003,,These findings support the theory that short trinucleotide repeat genotypes of the AR gene protect against breast cancer.,Y,AR,AR,0.291666667
437,bc_id466,CANCER,ESR1,14504194,B,Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study.,2003,,Results of this study indicate that genetic polymorphisms in the ER-alpha gene may play a role in the etiology of breast cancer.,A,ER-alpha,ESR1,0.586956522
438,bc_id467,CANCER,CHEK2,14507240,B,"BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.",2003,"This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.","This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.",A,CHEK2,CHEK2,0.383333333
439,bc_id468,CANCER,BRCA2,14507240,B,"BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.",2003,"This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.","This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.",A,BRCA2,BRCA2,0.576923077
440,bc_id469,CANCER,BRCA1,14507240,B,"BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India.",2003,"This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.","This is the first study from South India, on BRCA1, BRCA2 & CHEK2 (1100 del C) mutations in patients with a family history of breast and/or ovarian cancer and early onset breast/ovarian cancer, using the sensitive DHPLC approach.",A,BRCA1,BRCA1,0.60944206
441,bc_id470,CANCER,F5,14512389,B,Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.,2003,"Tamoxifen and prior surgery, fracture, or immobilization were associated with a significantly increased risk of developing a VTE.",X,X,X,X,0
442,bc_id471,CANCER,F2,14512389,B,Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.,2003,"Tamoxifen and prior surgery, fracture, or immobilization were associated with a significantly increased risk of developing a VTE.",X,X,X,X,0
443,bc_id472,CANCER,BRCA2,14517958,B,Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.,2003,,"We carried out a mutational analysis of the BRCA1 and BRCA2 genes in 124 Spanish women diagnosed with breast cancer before the age 41 and who were not selected for a family history of this disease.... We categorized patients into familial or non-familial groups on the basis of her family history of breast/ovarian cancer; this analysis indicated that among Spanish women with early-onset breast cancer, an even moderate family history is a good predictor of being a BRCA mutation carrier.",Y,BRCA2,BRCA2,0.324175824
444,bc_id473,CANCER,BRCA1,14517958,B,Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations.,2003,X,"We carried out a mutational analysis of the BRCA1 and BRCA2 genes in 124 Spanish women diagnosed with breast cancer before the age 41 and who were not selected for a family history of this disease.... We categorized patients into familial or non-familial groups on the basis of her family history of breast/ovarian cancer; this analysis indicated that among Spanish women with early-onset breast cancer, an even moderate family history is a good predictor of being a BRCA mutation carrier.",Y,BRCA1,BRCA1,0.326180258
445,bc_id475,CANCER,BRCA1,14519755,B,Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.,2003,,"Thus, germline BRCA1 mutations appear to be associated with a distinctive breast cancer phenotype.",Y,BRCA1,BRCA1,0.326180258
446,bc_id474,CANCER,BRCA2,14519755,B,Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.,2003,,X,X,X,X,0
447,bc_id476,CANCER,CYP1B1,14520706,Y,"Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk",2003,Our study showed that gene polymorphisms of CYP1B1 and SULT1A1 induce an individual susceptibility to breast cancer among current smokers.,Our study showed that gene polymorphisms of CYP1B1 and SULT1A1 induce an individual susceptibility to breast cancer among current smokers.,Y,CYP1B1,CYP1B1,0.358974359
448,bc_id478,CANCER,SULT1A1,14520706,Y,"Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk",2003,Our study showed that gene polymorphisms of CYP1B1 and SULT1A1 induce an individual susceptibility to breast cancer among current smokers.,Our study showed that gene polymorphisms of CYP1B1 and SULT1A1 induce an individual susceptibility to breast cancer among current smokers.,Y,SULT1A1,SULT1A1,0.322580645
449,bc_id480,CANCER,COMT,14520706,B,"Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1~~~ catechol-o-methyltransferase and tobacco exposure in breast cancer risk.",2003,Our study showed that gene polymorphisms of CYP1B1 and SULT1A1 induce an individual susceptibility to breast cancer among current smokers.,The Met COMT allele with a lower methylation activity than Val COMT did not modify the risk among smokers... Our study showed that gene polymorphisms of CYP1B1 and SULT1A1 induce an individual susceptibility to breast cancer among current smokers.,N,COMT,COMT,0.29787234
450,bc_id482,CANCER,ESR1,14522892,Y,Association of breast cancer risk with a GT dinucleotide repeat polymorphism upstream of the estrogen receptor-alpha gene.,2003,,Results of this study indicate that the GT dinucleotide repeat polymorphism in ER-alpha gene promoter region may be a new biomarker for genetic susceptibility to breast cancer.,A,ER-alpha,ESR1,0.586956522
451,bc_id483,CANCER,BARD1,14550946,B,Mutational analysis of BARD1 in familial breast cancer patients in Japan,2003,"These results suggest that BARD1 mutations are responsible for, if any, a very small number of familial breast cancers. Genetic polymorphism of BARD1 (Val/Met 507) could be useful in the selection of postmenopausal women at a high risk for developing breast cancer.","These results suggest that BARD1 mutations are responsible for, if any, a very small number of familial breast cancers. Genetic polymorphism of BARD1 (Val/Met 507) could be useful in the selection of postmenopausal women at a high risk for developing breast cancer.",Y,BARD1,BARD1,0.363636364
452,bc_id484,CANCER,BARD1,14550946,N,Mutational analysis of BARD1 in familial breast cancer patients in Japan.,2003,"These results suggest that BARD1 mutations are responsible for, if any, a very small number of familial breast cancers. Genetic polymorphism of BARD1 (Val/Met 507) could be useful in the selection of postmenopausal women at a high risk for developing breast cancer.",MC,MC,MC,MC,0
453,bc_id485,OTHER,BRCA2,14551306,Y,Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.,2003,"Our findings support the emerging consensus that genetic predisposition testing for BRCA1/2 does not pose major mental health risks, but our findings also show that the impact of prophylactic surgery on aspects such as body image and sexuality should not be underestimated, and that some women are at risk for high distress, and as a result, need more attentive care.",X,X,X,X,0
454,bc_id486,OTHER,BRCA1,14551306,B,Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.,2003,"Our findings support the emerging consensus that genetic predisposition testing for BRCA1/2 does not pose major mental health risks, but our findings also show that the impact of prophylactic surgery on aspects such as body image and sexuality should not be underestimated, and that some women are at risk for high distress, and as a result, need more attentive care.",X,X,X,X,0
455,bc_id487,CANCER,BRCA2,14555518,B,BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.,2003,The BRCA2 mutations and AR expression in tumor tissue are independent adverse factors for MBC prognosis.,The BRCA2 mutations and AR expression in tumor tissue are independent adverse factors for MBC prognosis.,Y,BRCA2,BRCA2,0.324175824
456,bc_id488,CANCER,BRCA2,14559878,Y,"Shared genetic susceptibility to breast cancer, brain tumors~~~ and Fanconi anemia.",2003,,"The co-occurrence of brain tumors, Fanconi anemia, and breast cancer observed in one of these kindreds constitutes a new syndromic association. Individuals who carry a germline BRCA2 mutation and who plan to have children with a partner of Ashkenazi Jewish descent should consider undergoing genetic counseling.",Y,BRCA2,BRCA2,0.324175824
457,bc_id489,CANCER,GSTM1,14562023,B,Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma.,2003,,This association was even higher in patients carrying both null-GSTT1 and -GSTM1 genotypes. The gene deletion of GSTs may predict not only the early onset of breast carcinoma but also the clinical response to chemotherapy and the recurrence-free survival for patients with lymph node-negative breast carcinoma.,A,GSTM1,GSTM1,0.339622642
458,bc_id490,CANCER,ATM,14562025,B,ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer.,2003,"Given the likelihood that young women with bilateral breast cancer have a genetic predisposition, the observed mutation distribution is contrary to that expected if these two mutations were to play an important role in breast carcinogenesis among individuals at high risk.","Recent reports suggest that two ATM gene mutations, 7271T>G and IVS10-6T>G, are associated with a high risk of breast cancer among multiple-case families... Given the likelihood that young women with bilateral breast cancer have a genetic predisposition, the observed mutation distribution is contrary to that expected if these two mutations were to play an important role in breast carcinogenesis among individuals at high risk.",A,ATM,ATM,0.422222222
459,bc_id492,CANCER,ERBB2,14569185,B,The HER2 I655V polymorphism and breast cancer risk in Ashkenazim.,2003,"These analyses suggest that the HER2 valine allele might be associated with increased risk of breast cancer, especially in young women and in women with a family history of the disease.","These analyses suggest that the HER2 valine allele might be associated with increased risk of breast cancer, especially in young women and in women with a family history of the disease.",A,HER2,ERBB2,0.452380952
460,bc_id493,CANCER,MTHFR,14572159,N,The common 677C&gt;T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk.,2003,,"Therefore, we conclude that the MTHFR 677C>T polymorphism is not associated with individual susceptibility to breast cancer.",N,MTHFR 677C,MTHFR,0.326923077
461,bc_id494,CANCER,CYP17A1,14575568,N,"[Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women]",2003,"The allele encoding for low activity COMT, but not CYP17, may be a genetic risk factor for breast cancer among Chinese women.","The allele encoding for low activity COMT, but not CYP17, may be a genetic risk factor for breast cancer among Chinese women.",A,CYP17,CYP17A1,0.466666667
462,bc_id495,CANCER,COMT,14575568,Y,"[Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women]",2003,"The allele encoding for low activity COMT, but not CYP17, may be a genetic risk factor for breast cancer among Chinese women.","The allele encoding for low activity COMT, but not CYP17, may be a genetic risk factor for breast cancer among Chinese women.",Y,COMT,COMT,0.276595745
463,bc_id496,CANCER,ERBB2,14578152,B,The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years.,2003,"Although the biological role of the I655V polymorphism is not known, large independent studies of early onset breast cancer are warranted to attempt to replicate this finding.","The HER2 gene controls cellular function and has prognostic significance in breast cancer. The I655V polymorphism was associated with increased risk of breast cancer in Chinese women under the age of 45 years and in women with a first-degree family history of the disease... Although the biological role of the I655V polymorphism is not known, large independent studies of early onset breast cancer are warranted to attempt to replicate this finding.",A,HER2,ERBB2,0.452380952
464,bc_id497,CANCER,LIG4,14578164,B,Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study.,2003,No significant interactions were seen between any of these polymorphisms and duration or dose of cigarette smoking. The gene-environment interaction data suggest that the subtle effects of some of these variants on breast cancer risk may be magnified in the presence of certain exposures.,"We prospectively assessed the associations of candidate polymorphisms G31479A (R188H) in XRCC2, A4541G (5'-UTR), A17893G (IVS5-14) and C18067T (T241 M) in XRCC3, and C299T (5'-UTR) and T1977C (D501D) in Ligase IV with breast cancer risk in a nested case-control study within the Nurses' Health Study (incident cases, n=1004; controls, n=1385). We observed no overall associations of these six genotypes with breast cancer risk.",N,Ligase IV,LIG4,0.5
465,bc_id499,CANCER,XRCC2,14578164,N,Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study.,2004,No significant interactions were seen between any of these polymorphisms and duration or dose of cigarette smoking. The gene-environment interaction data suggest that the subtle effects of some of these variants on breast cancer risk may be magnified in the presence of certain exposures.,"We prospectively assessed the associations of candidate polymorphisms G31479A (R188H) in XRCC2, A4541G (5'-UTR), A17893G (IVS5-14) and C18067T (T241 M) in XRCC3, and C299T (5'-UTR) and T1977C (D501D) in Ligase IV with breast cancer risk in a nested case-control study within the Nurses' Health Study (incident cases, n=1004; controls, n=1385). We observed no overall associations of these six genotypes with breast cancer risk.",N,XRCC2,XRCC2,0.454545455
466,bc_id501,CANCER,XRCC3,14578164,N,Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study.,2004,No significant interactions were seen between any of these polymorphisms and duration or dose of cigarette smoking. The gene-environment interaction data suggest that the subtle effects of some of these variants on breast cancer risk may be magnified in the presence of certain exposures.,"We prospectively assessed the associations of candidate polymorphisms G31479A (R188H) in XRCC2, A4541G (5'-UTR), A17893G (IVS5-14) and C18067T (T241 M) in XRCC3, and C299T (5'-UTR) and T1977C (D501D) in Ligase IV with breast cancer risk in a nested case-control study within the Nurses' Health Study (incident cases, n=1004; controls, n=1385). We observed no overall associations of these six genotypes with breast cancer risk.",N,XRCC3,XRCC3,0.269230769
467,bc_id498,CANCER,LIG4,14578164,N,Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study.,2004,No significant interactions were seen between any of these polymorphisms and duration or dose of cigarette smoking. The gene-environment interaction data suggest that the subtle effects of some of these variants on breast cancer risk may be magnified in the presence of certain exposures.,MC,MC,MC,MC,0
468,bc_id500,CANCER,XRCC2,14578164,B,Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study.,2003,No significant interactions were seen between any of these polymorphisms and duration or dose of cigarette smoking. The gene-environment interaction data suggest that the subtle effects of some of these variants on breast cancer risk may be magnified in the presence of certain exposures.,MC,MC,MC,MC,0
469,bc_id502,CANCER,XRCC3,14578164,B,Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study.,2003,No significant interactions were seen between any of these polymorphisms and duration or dose of cigarette smoking. The gene-environment interaction data suggest that the subtle effects of some of these variants on breast cancer risk may be magnified in the presence of certain exposures.,MC,MC,MC,MC,0
470,bc_id503,CANCER,BRCA2,14580253,B,Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.,2003,,"The incidences of prostate cancer, cervix cancer and nonmelanoma skin cancer are elevated for FDRs of early-onset breast cancer cases without a BRCA mutation, indicating a possible association between these cancers and early-onset breast cancer.",Y,BRCA,BRCA2,0.324175824
471,bc_id504,CANCER,BRCA1,14580253,B,Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.,2003,,"The incidences of prostate cancer, cervix cancer and nonmelanoma skin cancer are elevated for FDRs of early-onset breast cancer cases without a BRCA mutation, indicating a possible association between these cancers and early-onset breast cancer.",Y,BRCA,BRCA1,0.326180258
472,bc_id505,CANCER,TP53,14581358,B,Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients.,2003,,Our findings suggest that the genotyping for p53 codon 72 locus in both the tumor tissue and in the lymph node of breast cancer patients could contribute to identify a subset of arginine/proline heterozygous patients who have a reduced survival that is associated with the specific retention of the arginine allele in the tumor tissue.,A,p53,TP53,0.482758621
473,bc_id506,CANCER,ACE,14583500,B,Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort.,2003,,"Overall, these results suggest that the A-240T and I/D ACE polymorphisms are not likely to be strong predictors of breast cancer risk.",N,ACE,ACE,0.142857143
474,bc_id507,CANCER,CYP1A1,14602139,B,Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk.,2003,"The combination of CYP19 (TTTA)(7(-3bp)) and CYP1A1 (6235)C/T polymorphisms is associated with an ER-positive, but not ER-negative, breast cancer risk, and, thus, would be useful in the selection of candidates for chemoprevention with tamoxifen.","The combination of CYP19 (TTTA)(7(-3bp)) and CYP1A1 (6235)C/T polymorphisms is associated with an ER-positive, but not ER-negative, breast cancer risk, and, thus, would be useful in the selection of candidates for chemoprevention with tamoxifen.",Y,CYP1A1,CYP1A1,0.304347826
475,bc_id508,CANCER,CYP19A1,14602139,Y,Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk.,2003,"The combination of CYP19 (TTTA)(7(-3bp)) and CYP1A1 (6235)C/T polymorphisms is associated with an ER-positive, but not ER-negative, breast cancer risk, and, thus, would be useful in the selection of candidates for chemoprevention with tamoxifen.","The combination of CYP19 (TTTA)(7(-3bp)) and CYP1A1 (6235)C/T polymorphisms is associated with an ER-positive, but not ER-negative, breast cancer risk, and, thus, would be useful in the selection of candidates for chemoprevention with tamoxifen.",Y,CYP19,CYP19A1,0.333333333
476,bc_id509,CANCER,TIMP2,14604886,Y,Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes,2004,These findings suggest that the presence of the variant allele in the promoter of MMP2 or TIMP2 may be a protective factor for the development of breast cancer.,These findings suggest that the presence of the variant allele in the promoter of MMP2 or TIMP2 may be a protective factor for the development of breast cancer.,A,TIMP2,TIMP2,1
477,bc_id511,CANCER,MMP2,14604886,Y,Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes,2004,These findings suggest that the presence of the variant allele in the promoter of MMP2 or TIMP2 may be a protective factor for the development of breast cancer.,These findings suggest that the presence of the variant allele in the promoter of MMP2 or TIMP2 may be a protective factor for the development of breast cancer.,A,MMP2,MMP2,0.5
478,bc_id513,CANCER,TGFB1,14607332,N,The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk.,2003,We conclude that  the TGFB1 L10P polymorphism is not associated with breast cancer risk.,We conclude that  the TGFB1 L10P polymorphism is not associated with breast cancer risk.,N,TGFB1 L10P,TGFB1,0.296296296
479,bc_id514,CANCER,COMT,14612555,B,"Tea intake, COMT genotype, and breast cancer in Asian-American women.",2003,,"In conclusion, tea catechins appeared to reduce breast cancer risk in this study of Asian-American women. Reduction in risk was strongest among persons who had the low activity COMT alleles, suggesting these individuals were less efficient in eliminating tea catechins and may derive the most benefit from these compounds.",Y,COMT,COMT,0.276595745
480,bc_id515,CANCER,CHEK2,14618615,B,The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.,2003,,"Recently, the CHEK 2 gene, involved in DNA damage and replication checkpoints, has been pointed out as a good candidate; moreover, a specific variant in this gene,1100delC, has been found to increase breast cancer susceptibility among familial breast cancer cases not attributable to mutations in BRCA1 or BRCA2 genes.",Y,CHEK 2,CHEK2,0.383333333
481,bc_id516,CANCER,NOS3,14623178,Y,Vascular invasion in human breast cancer is correlated to T-->786C polymorphism of NOS3 gene.,2003,Our results suggest that T allele reduction at the NOS3 promoter region may reduce vascular invasion in breast cancer and consequently reduce metastatic spread and be a favorable prognostic factor. These results need further validation in larger studies.,Our results suggest that T allele reduction at the NOS3 promoter region may reduce vascular invasion in breast cancer and consequently reduce metastatic spread and be a favorable prognostic factor. These results need further validation in larger studies.,A,NOS3,NOS3,0.461538462
482,bc_id517,CANCER,ESR2,14633679,Y,Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women.,2003,Our results are consistent with the hypothesis of a joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk.,Our results are consistent with the hypothesis of a joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk.,Y,estrogen receptor,ESR2,0.333333333
483,bc_id518,CANCER,IL6,14633738,B,Interleukin-6 -174G--&gt;C polymorphism is associated with improved outcome in high-risk breast cancer.,2003,,We hypothesized that polymorphisms in IL-6 (-174 G>C) or TNF-alpha (G-238 or G-308) might be associated with prognosis in a subset of patients with high-risk breast cancer.,A,IL-6,IL6,0.285714286
484,bc_id519,CANCER,TNF,14633738,B,Interleukin-6 -174G--&gt;C polymorphism is associated with improved outcome in high-risk breast cancer.,2003,,We hypothesized that polymorphisms in IL-6 (-174 G>C) or TNF-alpha (G-238 or G-308) might be associated with prognosis in a subset of patients with high-risk breast cancer.,A,TNF-alpha,TNF,0.4
485,bc_id520,CANCER,TP53,14634508,B,Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer.,2004,"This study implies an association of breast cancer risk with the p53 polymorphism Arg72Pro, but not with p73 G4A.","This study implies an association of breast cancer risk with the p53 polymorphism Arg72Pro, but not with p73 G4A.",Y,p53,TP53,0.367816092
486,bc_id521,CANCER,SULT1A1,14642079,Y,[The association of sulfotransferase1A1 His allele and breast cancer in Han ethnic Chinese women],2003,"SULT1A1 His allele is positively associated with the risk of breast cancer, and an interaction exist between this allele and related exposure factors.","SULT1A1 His allele is positively associated with the risk of breast cancer, and an interaction exist between this allele and related exposure factors.",Y,SULT1A1,SULT1A1,0.322580645
487,bc_id522,CANCER,BRCA1,14648706,B,Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.,2004,,"These results indicate significant association of the risk for BC in carriers of BRCA1 mutations with the polyglutamine chain of the AIB1 gene. Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers.",Y,BRCA1,BRCA1,0.326180258
488,bc_id523,CANCER,CHEK2,14648717,N,CHEK2 1100delC is not a risk factor for male breast cancer population.,2004,"Our results indicate that CHEK2 1100delC variant does not substantially increase the risk of male breast cancer at the population level. We cannot exclude the fact that a small fraction of hereditary, family-positive male breast cancers could be attributable to CHEK2 mutations.","Our results indicate that CHEK2 1100delC variant does not substantially increase the risk of male breast cancer at the population level. We cannot exclude the fact that a small fraction of hereditary, family-positive male breast cancers could be attributable to CHEK2 mutations.",N,CHEK2 1100delC,CHEK2,0.233333333
489,bc_id524,CANCER,XRCC1,14652276,B,"Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy.",2003,,Distinct combinations of XRCC1 polymorphisms appear to be associated with either an increased BC risk or the possibility of developing an adverse radiotherapy response seen in some BC patients.,A,XRCC1,XRCC1,0.543478261
490,bc_id525,CANCER,SRD5A2,14652280,B,The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.,2003,"In conclusion, our findings do not provide evidence for an important role of the V89L polymorphism in the etiology of breast cancer. However, in breast cancer patients, the LL genotype may be associated with unfavorable prognosis.","The SRD5A2 gene contains a polymorphism leading to a valine to leucine change in codon 89 (V89L)... In conclusion, our findings do not provide evidence for an important role of the V89L polymorphism in the etiology of breast cancer. However, in breast cancer patients, the LL genotype may be associated with unfavorable prognosis.",N,SRD5A2,SRD5A2,0.333333333
491,bc_id526,CANCER,ERCC4,14652281,Y,DNA-repair genetic polymorphisms and breast cancer risk.,2003,"We provide evidence that variants of XRCC1, XRCC3, and ERCC4/XPF genes, particularly in combination, contribute to breast cancer susceptibility.","We provide evidence that variants of XRCC1, XRCC3, and ERCC4/XPF genes, particularly in combination, contribute to breast cancer susceptibility.",Y,ERCC4/XPF,ERCC4,0.25
492,bc_id527,CANCER,XRCC1,14652281,Y,DNA-repair genetic polymorphisms and breast cancer risk.,2003,"We provide evidence that variants of XRCC1, XRCC3, and ERCC4/XPF genes, particularly in combination, contribute to breast cancer susceptibility.","We provide evidence that variants of XRCC1, XRCC3, and ERCC4/XPF genes, particularly in combination, contribute to breast cancer susceptibility.",Y,XRCC1,XRCC1,0.239130435
493,bc_id528,CANCER,XRCC3,14652281,Y,DNA-repair genetic polymorphisms and breast cancer risk.,2003,"We provide evidence that variants of XRCC1, XRCC3, and ERCC4/XPF genes, particularly in combination, contribute to breast cancer susceptibility.","We provide evidence that variants of XRCC1, XRCC3, and ERCC4/XPF genes, particularly in combination, contribute to breast cancer susceptibility.",Y,XRCC3,XRCC3,0.269230769
494,bc_id529,CANCER,TP53,14654539,B,TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.,2003,,"This study revealed a significant association between lack of response to 5-fluorouracil and mitomycin and mutations affecting the L2/L3 domains of the p53 protein. Together with our previous finding that such mutations predict resistance to weekly doxorubicin, our data suggest that mutations affecting this particular domain of the p53 protein may cause resistance to several different cytotoxic compounds applied in breast cancer treatment.",Y,p53,TP53,0.367816092
495,bc_id530,CANCER,BRCA2,14662532,B,Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis.,2003,,"These results indicate significant association of the risk for BC in carriers of BRCA1 mutations with the polyglutamine chain of the AIB1 gene. Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers.",N,BRCA2,BRCA2,0.098901099
496,bc_id531,CANCER,BRCA1,14662532,B,Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis.,2003,,"These results indicate significant association of the risk for BC in carriers of BRCA1 mutations with the polyglutamine chain of the AIB1 gene. Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers.",Y,BRCA1,BRCA1,0.326180258
497,bc_id532,CANCER,CCND1,14666635,N,Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers.,2003,"Although the CCND1 G870A polymorphism has been reported as a genetic risk factor for some tumour types, it does not appear to be linked to the risk of breast and colorectal cancers.","Although the CCND1 G870A polymorphism has been reported as a genetic risk factor for some tumour types, it does not appear to be linked to the risk of breast and colorectal cancers.",N,CCND1 G870A,CCND1,0.3125
498,bc_id534,CANCER,CHEK2,14678969,B,The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.,2003,,"Thus, selecting for breast cancer cases with a strong familial background not accounted for by BRCA1 or BRCA2 strongly enriches for carriers of CHEK2*1100delC. Our results support a model in which CHEK2*1100delC interacts with an as yet unknown gene (or genes) to increase breast cancer risk.",Y,CHEK2,CHEK2,0.383333333
499,bc_id536,CANCER,BRCA2,14678969,B,The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.,2003,,"Thus, selecting for breast cancer cases with a strong familial background not accounted for by BRCA1 or BRCA2 strongly enriches for carriers of CHEK2*1100delC. Our results support a model in which CHEK2*1100delC interacts with an as yet unknown gene (or genes) to increase breast cancer risk.",A,BRCA2,BRCA2,0.576923077
500,bc_id537,CANCER,BRCA1,14678969,B,The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.,2003,,"Thus, selecting for breast cancer cases with a strong familial background not accounted for by BRCA1 or BRCA2 strongly enriches for carriers of CHEK2*1100delC. Our results support a model in which CHEK2*1100delC interacts with an as yet unknown gene (or genes) to increase breast cancer risk.",A,BRCA1,BRCA1,0.60944206
501,bc_id535,CANCER,TP53,14678969,B,The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.,2003,,NR,NR,NR,NR,0
502,bc_id538,CANCER,XRCC1,14679022,B,A prospective study of XRCC1 haplotypes and their interaction with plasma carotenoids on breast cancer risk.,2003,The findings of the effect modification of the Arg(194)Trp on the relations of plasma alpha- and beta-carotene levels with breast cancer risk suggest a potential protective effect of carotenoids in breast carcinogenesis by preventing oxidative DNA damage.,Our results suggest an inverse association between XRCC1 (194)Trp allele and breast cancer risk.,Y,XRCC1,XRCC1,0.239130435
503,bc_id539,CANCER,BRCA1,14680492,B,Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?,2004,,In this issue of Breast Cancer Research Robson and colleagues provide further evidence for poorer survival in BRCA1 carriers and show that it could be attributed to failure to treat small node-negative grade 3 breast cancers with chemotherapy.,A,BRCA1,BRCA1,0.60944206
504,bc_id540,CANCER,BRCA2,14680495,N,A combined analysis of outcome following breast cancer: differences in survival based onBRCA1/BRCA2 mutation status and administration of adjuvant treatment.,2004,"BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. The risk for metachronous ipsilateral disease does not appear to be increased for either BRCA1 or BRCA2 mutation carriers, at least up to 10 years of follow up.",X,X,X,X,0
505,bc_id541,CANCER,BRCA1,14680495,Y,A combined analysis of outcome following breast cancer: differences in survival based onBRCA1/BRCA2 mutation status and administration of adjuvant treatment.,2004,"BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. The risk for metachronous ipsilateral disease does not appear to be increased for either BRCA1 or BRCA2 mutation carriers, at least up to 10 years of follow up.","BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. The risk for metachronous ipsilateral disease does not appear to be increased for either BRCA1 or BRCA2 mutation carriers, at least up to 10 years of follow up.",Y,BRCA1,BRCA1,0.326180258
506,bc_id543,CANCER,XRCC1,14693738,N,A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer.,2003,The overall results of the study suggest that Arg399Gln polymorphism of the XRCC1 gene alone may not play a substantial role in the risk of breast cancer among Chinese women.,The overall results of the study suggest that Arg399Gln polymorphism of the XRCC1 gene alone may not play a substantial role in the risk of breast cancer among Chinese women.,A,XRCC1,XRCC1,0.543478261
507,bc_id544,CANCER,HRAS,14693748,N,The HRAS1 Variable Number of Tandem Repeats and Risk of Breast Cancer,2003,These results suggest that there is no overall association between rare alleles of the HRAS1 VNTR and breast cancer.,These results suggest that there is no overall association between rare alleles of the HRAS1 VNTR and breast cancer.,N,HRAS1,HRAS,1
508,bc_id545,CANCER,TP53,14697642,B,Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations.,2004,,"About 19% of the breast cancers examined carried a TP53 mutation in exons 4-9. Of these, 88% (15/17) were missense point mutations and these were distributed randomly along the tested gene fragments without apparent clustering, as has been shown in certain other ethnic or regional studies.",A,TP53,TP53,0.482758621
509,bc_id546,CANCER,TP53,14701769,B,The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.,2004,"Evaluation of tumors for p53 mutations may be beneficial to identify women at higher risk of disease recurrence and death when the tumor has neu/erbB-2 amplification, but in the absence of neu/erbB-2 amplification, the presence of p53 mutation may not provide additional independent prognostic information.",p53 mutations occurred in 24.5% of the axillary node-negative breast carcinomas. Mutations were more frequent in carcinomas with neu/erbB-2 amplification: 38.9% compared with only 20.9% in those without neu/erbB-2 amplification.,A,p53,TP53,0.482758621
510,bc_id547,CANCER,CCND1,14703063,N,The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer,2003,We conclude that  the CCND1 870G > A polymorphism is not associated with breast cancer.,We conclude that  the CCND1 870G > A polymorphism is not associated with breast cancer.,N,CCND1 870G,CCND1,0.3125
511,bc_id548,CANCER,CYP19A1,14714492,B,[In Process Citation],2003,"Risk of BC was especially high in the presence of both factors (7.3% vs. 0%, P < 0.01). Allele (TTTA)8 and genotype A2/A2 were assumed to be risk factors of BC.",Microsatellite (TTTA)n and 3-bp deletion of CYP19 and single-nucleotide polymorphism T27C of CYP17 were analyzed in 123 BC patients and 119 healthy women...  Allele (TTTA)8 and genotype A2/A2 were assumed to be risk factors of BC.,Y,CYP19,CYP19A1,0.333333333
512,bc_id549,CANCER,CYP17A1,14714492,B,[In Process Citation],2003,"Risk of BC was especially high in the presence of both factors (7.3% vs. 0%, P < 0.01). Allele (TTTA)8 and genotype A2/A2 were assumed to be risk factors of BC.","Genotype A2/A2 of CYP17 was also associated with BC (32.5% vs. 20.2%, P = 0.04).",Y,CYP17,CYP17A1,0.266666667
513,bc_id550,CANCER,EGFR,14729599,B,Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene.,2004,,"The length of the egfr CA SSR may increase the risk for familial breast cancers, and its effect could be modulated by dietary factors.",A,egfr,EGFR,0.571428571
514,bc_id552,CANCER,CYP1A1,14734460,B,Associations between Breast Cancer Susceptibility Gene Polymorphisms and Clinicopathological Features,2004,These results indicate that polymorphisms of some selected breast cancer susceptibility genes are associated with the clinicopathological phenotypes of breast cancer.,Cases with Ile/Val at CYP1A1 codon 462 were 2.6-fold and those with Val/Val were 5.1-fold more likely to have first-degree relatives with breast cancer than those with Ile/Ile (P = 0.002).,A,CYP1A1,CYP1A1,0.456521739
515,bc_id551,CANCER,CYP1B1,14734460,B,Associations between Breast Cancer Susceptibility Gene Polymorphisms and Clinicopathological Features,2004,These results indicate that polymorphisms of some selected breast cancer susceptibility genes are associated with the clinicopathological phenotypes of breast cancer.,X,X,X,X,0
516,bc_id553,CANCER,IL6,14735187,B,The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype.,2004,We conclude that  the -174 C allele of IL-6 is associated with a more aggressive breast cancer phenotype.,We conclude that  the -174 C allele of IL-6 is associated with a more aggressive breast cancer phenotype.,Y,IL-6,IL6,0.285714286
517,bc_id554,CANCER,GPX1,14744747,B,Genetic variants of GPX1 and SOD2 and breast cancer risk at the Ontario site of the Breast Cancer Family Registry.,2004,There is a significant trend of increasing risk with increasing number of alleles with four GCG repeats (P = 0.03). This variant has not previously been reported to be associated with breast cancer.,"We were unable to replicate the previously observed association with SOD2 Val-9Ala and also found no association between breast cancer and GPX1 Pro198Leu. However, the allele of GPX1 containing four GCG repeats was significantly associated with breast cancer risk in premenopausal women (odds ratio, 1.55; 95% confidence interval, 1.04-2.30 for carriers versus noncarriers).",A,GPX1,GPX1,0.4
518,bc_id555,CANCER,SOD2,14744747,B,Genetic variants of GPX1 and SOD2 and breast cancer risk at the Ontario site of the Breast Cancer Family Registry.,2004,There is a significant trend of increasing risk with increasing number of alleles with four GCG repeats (P = 0.03). This variant has not previously been reported to be associated with breast cancer.,We were unable to replicate the previously observed association with SOD2 Val-9Ala and also found no association between breast cancer and GPX1 Pro198Leu. ,N,SOD2,SOD2,0.375
519,bc_id558,CANCER,VDR,14749534,B,Vitamin D receptor gene polymorphisms in breast cancer.,2003,,The prevalence of the VDR Taq I and Bsm I alleles and the genotype frequencies in patients with breast cancer was similar to that in the normal population. Our data indicate that no significant differences exist between the patients and control subjects.,N,VDR,VDR,0.192307692
520,bc_id559,CANCER,BRCA2,14761918,B,Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.,2004,,Breast cancer patients with BRCA1/2 mutations have a similar outcome as non-mutation carriers.,N,BRCA1/2,BRCA2,0.098901099
521,bc_id560,CANCER,BRCA1,14761918,B,Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.,2004,,Breast cancer patients with BRCA1/2 mutations have a similar outcome as non-mutation carriers.,N,BRCA1,BRCA1,0.064377682
522,bc_id561,CANCER,BRCA1,14871808,B,The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.,2004,,X,X,X,X,0
523,bc_id562,CANCER,TGFB1,14871809,B,Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study.,2004,,Our study suggests that genetic polymorphisms in the TGF-beta1 gene may play a role in breast cancer progression.,A,TGF-beta1,TGFB1,0.518518519
524,bc_id563,CANCER,CALCR,14965723,B,Genetic variants of calcitonin receptor and breast cancer in Japanese,1999,These results indicate that allelic variation of the CTR gene is not a significant risk factor for the development of breast carcinoma in Japanese women. Further studies are needed to clarify the role of CT and CTR in human breast tissue.,These results indicate that allelic variation of the CTR gene is not a significant risk factor for the development of breast carcinoma in Japanese women.,N,CTR,CALCR,1
525,bc_id564,CANCER,HP,14967153,B,Haptoglobin polymorphism in breast cancer patients form Jordan,2004,"Results of this study demonstrate that the pattern of Hp phenotype distribution in breast cancer patients is family history-dependent. Hp1 and Hp2 allele frequencies were over-represented in patients with familial and nonfamilial breast cancer, respectively. The pattern is probably attributed to genetic and oxidative stress mechanisms.","Results of this study demonstrate that the pattern of Hp phenotype distribution in breast cancer patients is family history-dependent. Hp1 and Hp2 allele frequencies were over-represented in patients with familial and nonfamilial breast cancer, respectively. The pattern is probably attributed to genetic and oxidative stress mechanisms.",A,HP,HP,1
526,bc_id565,CANCER,MTHFR,14973091,B,"MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study.",2004,of this study suggest that the MTHFR C677T polymorphisms may modify the association between dietary folate intake and breast cancer risk.,of this study suggest that the MTHFR C677T polymorphisms may modify the association between dietary folate intake and breast cancer risk.,A,MTHFR C677T,MTHFR,0.403846154
527,bc_id566,CANCER,GSTT1,14973092,B,"Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis.",2004,,This large case-control study provides strong support for earlier studies showing no overall association of the GSTM1 and GSTT1 deletion polymorphisms with breast cancer risk. The GSTP1 variant may be relevant to breast cancer risk in Asian populations.,N,GSTT1,GSTT1,0.131578947
528,bc_id567,CANCER,GSTM1,14973092,B,"Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis.",2004,,This large case-control study provides strong support for earlier studies showing no overall association of the GSTM1 and GSTT1 deletion polymorphisms with breast cancer risk. The GSTP1 variant may be relevant to breast cancer risk in Asian populations.,N,GSTM1,GSTM1,0.20754717
529,bc_id568,CANCER,HFE,14973098,B,Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer.,2004,,Individuals with the major hemochromatosis (HFE) allele C282Y and iron overload develop hepatocellular and some extrahepatic malignancies at increased rates... A high prevalence of C282Y alleles in women with breast cancer with and without poor risk features suggests that altered iron metabolism in C282Y carriers may promote the development of breast cancer and/or more aggressive forms of the disease.,A,HFE,HFE,0.333333333
530,bc_id569,CANCER,GSTM1,14973116,B,Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk.,2004,,"Compared with women with the -/- genotype, the relative risk of breast cancer for the +/+ genotype was 2.83 (95% confidence interval, 1.45-5.59; P = 0.002), suggesting a protective effect of the GSTM1 deletion.",A,GSTM1,GSTM1,0.339622642
531,bc_id570,CANCER,CLCA2,14973555,B,CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer.,2004,,"These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.",Y,CLCA2,CLCA2,1
532,bc_id571,CANCER,BRCA1,14981104,B,Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.,2004,Bilateral prophylactic mastectomy reduces the risk of breast cancer in women with BRCA1/2 mutations by approximately 90%.,Bilateral prophylactic mastectomy reduces the risk of breast cancer in women with BRCA1/2 mutations by approximately 90%.,Y,BRCA1,BRCA1,0.326180258
533,bc_id572,CANCER,ESR1,14981916,B,Full sequencing analysis of estrogen receptor-alpha gene polymorphism and its association with breast cancer risk.,2004,,"Polymorphisms in ER-alpha gene can affect the breast cancer susceptibility and may be related to other protein expression, such as p53 and bcl-2.",A,ER-alpha,ESR1,0.586956522
534,bc_id573,CANCER,ERBB2,14991893,B,Comparative multi-methodological measurement of ERBB2 status in breast cancer.,2004,,"The 94 breast cancers tested were enriched in cases scoring 2+ using the IHC scoring system currently in use and for which the actual ERBB2 status remains ill defined... It is shown that the combination of the two tissue-based methods gives the best results. The use of either PCR-based method did not improve the results significantly. A new combined IHC score based on the association of two selected anti-ERBB2 antibodies (HercepTest trade mark and TAB250) and a dual scale for improved assessment of ERBB2 protein expression, particularly in 2+ cases, are proposed.",A,ERBB2,ERBB2,0.452380952
535,bc_id574,CANCER,TP53,14997055,B,Spectrum of p53 tumor suppressor gene mutations and breast cancer survival.,2004,"These findings indicate that not just p53 mutation per se but the full spectrum (i.e., different types, locations, and numbers) of p53 mutation needs to be examined when it is used as a prognostic marker of survival in breast cancer patients.","These findings indicate that not just p53 mutation per se but the full spectrum (i.e., different types, locations, and numbers) of p53 mutation needs to be examined when it is used as a prognostic marker of survival in breast cancer patients.",A,p53,TP53,0.482758621
536,bc_id575,CANCER,CHEK2,14997059,Y,Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.,2004,These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.,These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.,A,CHEK2,CHEK2,0.383333333
537,bc_id576,CANCER,MTHFR,15004488,B,Polymorphisms in the MTHFR gene are associated with breast cancer.,2004,,"In conclusion, our data suggest that the MTHFR 677T, 1298C alleles, T677T, C1298C genotypes, and C677C/C1298C and T677T/A1298A compound genotypes are genetic risk factors for premenopausal women with sporadic breast cancer.",Y,"MTHFR 677T,",MTHFR,0.269230769
538,bc_id577,CANCER,TGFB1,15006917,B,T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study.,2004,,"Given the strong biological rationale and the scarce and divergent epidemiologic data to date, additional investigations of the relationship between breast cancer and genetic variants in the TGF-beta signaling pathway appear warranted.",A,TGF-beta,TGFB1,0.518518519
539,bc_id578,CANCER,TGFB1,15009180,B,"Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5'-untranslated-region and exon-1 polymorphisms.",2004,,X,X,X,X,0
540,bc_id579,CANCER,DMTF1,15010895,B,Single nucleotide polymorphisms in breast cancer.,2004,"We conclude that  within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.",X,X,X,X,0
541,bc_id580,CANCER,NBN,15010895,B,Single nucleotide polymorphisms in breast cancer.,2004,"We conclude that  within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.","The frequencies for single nucleotide polymorphisms (SNPs) were measured in the following genes: NBS1, XPC, XPD, XRCC1, XRCC3, MTHFR, and cyclin D1. Odds ratios (ORs) were calculated to the wild-type genotype.We conclude that within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.",N,NBS1,NBN,0.238095238
542,bc_id581,CANCER,XPC,15010895,B,Single nucleotide polymorphisms in breast cancer.,2004,"We conclude that  within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.","The frequencies for single nucleotide polymorphisms (SNPs) were measured in the following genes: NBS1, XPC, XPD, XRCC1, XRCC3, MTHFR, and cyclin D1. Odds ratios (ORs) were calculated to the wild-type genotype.We conclude that within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.",N,XPC,XPC,0.285714286
543,bc_id582,CANCER,XRCC1,15010895,B,Single nucleotide polymorphisms in breast cancer.,2004,"We conclude that  within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.","The frequencies for single nucleotide polymorphisms (SNPs) were measured in the following genes: NBS1, XPC, XPD, XRCC1, XRCC3, MTHFR, and cyclin D1. Odds ratios (ORs) were calculated to the wild-type genotype.We conclude that within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.",N,XRCC1,XRCC1,0.217391304
544,bc_id583,CANCER,XRCC3,15010895,B,Single nucleotide polymorphisms in breast cancer.,2004,"We conclude that  within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.","The frequencies for single nucleotide polymorphisms (SNPs) were measured in the following genes: NBS1, XPC, XPD, XRCC1, XRCC3, MTHFR, and cyclin D1. Odds ratios (ORs) were calculated to the wild-type genotype.We conclude that within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.",N,XRCC3,XRCC3,0.269230769
545,bc_id584,CANCER,MTHFR,15010895,B,Single nucleotide polymorphisms in breast cancer.,2004,"We conclude that  within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.","The frequencies for single nucleotide polymorphisms (SNPs) were measured in the following genes: NBS1, XPC, XPD, XRCC1, XRCC3, MTHFR, and cyclin D1. Odds ratios (ORs) were calculated to the wild-type genotype.We conclude that within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.",N,MTHFR,MTHFR,0.326923077
546,bc_id585,CANCER,XRCC2,15010895,B,Single nucleotide polymorphisms in breast cancer.,2004,"We conclude that  within statistical power of the present study, none of the tested polymorphisms associated with BC, with the probable exception of XPD.",X,X,X,X,0
547,bc_id586,CANCER,MMP21,15015597,N,The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer.,2004,The MMP-21 gene 572C/T polymorphism has no significant effect on the development and progression of breast cancer.,The MMP-21 gene 572C/T polymorphism has no significant effect on the development and progression of breast cancer.,N,MMP-21,MMP21,1
548,bc_id588,CANCER,GNB3,15019160,B,The 825C>T polymorphism of the G-protein beta-3 subunit gene (GNB3) and breast cancer.,2004,"We conclude that  the GNB3 825C>T polymorphism does not appear to be associated with breast cancer risk, but may influence development of metastasis in low-grade tumors.","We conclude that  the GNB3 825C>T polymorphism does not appear to be associated with breast cancer risk, but may influence development of metastasis in low-grade tumors.",N,GNB3 825C,GNB3,0.666666667
549,bc_id589,CANCER,F5,15033664,B,Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.,2004,,Factor V Leiden carriers with locally advanced or metastatic breast cancer have an increased risk of developing catheter-related DVT during chemotherapy.,Y,Factor V,F5,1
550,bc_id590,CANCER,F2,15033664,B,Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter.,2004,,X,X,X,X,0
551,bc_id592,CANCER,BRCA1,15041722,B,"Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.",2004,,"BRCA1 mutation carriers were more likely to have ER-negative breast cancers than were women in other groups, after adjustment for age, grade, and histological subtype (P < 0.001).",A,BRCA1,BRCA1,0.60944206
552,bc_id591,CANCER,BRCA2,15041722,B,"Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.",2004,,X,X,X,X,0
553,bc_id593,CANCER,ATM,15042666,B,"A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls",2004,"Patients with breast carcinoma, particularly those with bilateral disease, were more likely to have a variant in the ATM gene that resulted in a Ser49Cys substitution in the gene product. Additional studies are needed to evaluate the potential functional consequences of the Ser49Cys substitution and confirm the relevance of this variant in the development of breast carcinoma.","Patients with breast carcinoma, particularly those with bilateral disease, were more likely to have a variant in the ATM gene that resulted in a Ser49Cys substitution in the gene product. Additional studies are needed to evaluate the potential functional consequences of the Ser49Cys substitution and confirm the relevance of this variant in the development of breast carcinoma.",A,ATM,ATM,0.422222222
554,bc_id594,CANCER,ABCB1,15044620,B,CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells.,2004,,X,X,X,X,0
555,bc_id595,CANCER,UQCRFS1,15047214,Y,Ubiquinol cytochrome c reductase (UQCRFS1) gene amplification in primary breast cancer core biopsy samples.,2004,These results suggest that the UQCRFS1 gene appears to be involved in development of more aggressive phenotype of breast cancer.,These results suggest that the UQCRFS1 gene appears to be involved in development of more aggressive phenotype of breast cancer.,Y,UQCRFS1,UQCRFS1,1
556,bc_id597,CANCER,BRCA1,15059511,Y,[Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people],2004,Two pathogenic SNPs have been found in BRCA1 and may be related to early-onset breast cancer. One of them may be a novel mutation characterized of familial breast cancer in China.,Two pathogenic SNPs have been found in BRCA1 and may be related to early-onset breast cancer. One of them may be a novel mutation characterized of familial breast cancer in China.,Y,BRCA1,BRCA1,0.326180258
557,bc_id596,CANCER,BRCA2,15059511,B,[Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people],2004,Two pathogenic SNPs have been found in BRCA1 and may be related to early-onset breast cancer. One of them may be a novel mutation characterized of familial breast cancer in China.,X,X,X,X,0
558,bc_id598,CANCER,XRCC1,15066914,B,Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk.,2004,"Although none of the statistical tests for interaction was significant, these data give some support for the hypothesis that genetic variations in DNA repair genes may modify the relation between plasma folate level and breast cancer risk.","We prospectively investigated the a priori hypothesized interaction between plasma folate levels and five nonsynonymous polymorphisms in the XRCC1, XRCC2, and XRCC3 genes on breast cancer risk in a nested case-control study within the Nurses' Health Study (712 case-control pairs)... Although none of the statistical tests for interaction was significant, these data give some support for the hypothesis that genetic variations in DNA repair genes may modify the relation between plasma folate level and breast cancer risk.",A,XRCC1,XRCC1,0.543478261
559,bc_id599,CANCER,XRCC2,15066914,B,Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk.,2004,"Although none of the statistical tests for interaction was significant, these data give some support for the hypothesis that genetic variations in DNA repair genes may modify the relation between plasma folate level and breast cancer risk.","We prospectively investigated the a priori hypothesized interaction between plasma folate levels and five nonsynonymous polymorphisms in the XRCC1, XRCC2, and XRCC3 genes on breast cancer risk in a nested case-control study within the Nurses' Health Study (712 case-control pairs)... Although none of the statistical tests for interaction was significant, these data give some support for the hypothesis that genetic variations in DNA repair genes may modify the relation between plasma folate level and breast cancer risk.",A,XRCC2,XRCC2,0.272727273
560,bc_id600,CANCER,XRCC3,15066914,B,Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk.,2004,"Although none of the statistical tests for interaction was significant, these data give some support for the hypothesis that genetic variations in DNA repair genes may modify the relation between plasma folate level and breast cancer risk.","We prospectively investigated the a priori hypothesized interaction between plasma folate levels and five nonsynonymous polymorphisms in the XRCC1, XRCC2, and XRCC3 genes on breast cancer risk in a nested case-control study within the Nurses' Health Study (712 case-control pairs)... Although none of the statistical tests for interaction was significant, these data give some support for the hypothesis that genetic variations in DNA repair genes may modify the relation between plasma folate level and breast cancer risk.",A,XRCC3,XRCC3,0.461538462
561,bc_id601,NORMALVARIATION,IGFBP3,15066922,B,A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density.,2004,"This is the first study to report a strong relationship between a polymorphic gene locus (IGFBP3) and mammographic breast density. However, we could not confirm an association between serum IGF-I levels and breast density among premenopausal women, as demonstrated in previous studies.","Mammographic breast density is a significant risk factor for breast cancer... This is the first study to report a strong relationship between a polymorphic gene locus (IGFBP3) and mammographic breast density. However, we could not confirm an association between serum IGF-I levels and breast density among premenopausal women, as demonstrated in previous studies.",A,IGFBP3,IGFBP3,0.428571429
562,bc_id602,CANCER,XRCC3,15066923,B,Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry.,2004,,"A marginal positive association for XRCC3-241 M/M compared with T/T genotype was found (OR = 1.44, 95% CI = 0.94-2.19), but the heterozygous T/M was not associated with an increase in risk (OR = 0.96, 95% CI = 0.71-1.32)...  Our results suggest that these polymorphisms may influence breast cancer risk by modifying the effect of risk factors such as FH.",A,XRCC3,XRCC3,0.461538462
563,bc_id603,CANCER,XRCC1,15066923,B,Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry.,2004,,No evidence for a main effect of the XRCC1-R399Q genotype on breast cancer risk was observed.,N,XRCC1,XRCC1,0.217391304
564,bc_id604,CANCER,BRCA2,15067026,B,Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.,2004,,"Most importantly, these results demonstrate that BRCA1/2 test results significantly affect patients' surgical decision-making. The availability of genetic counseling and testing could serve as a valuable aid to patient decision-making for newly diagnosed breast cancer patients at high-risk for carrying a mutation",A,BRCA1/2,BRCA2,0.576923077
565,bc_id605,CANCER,BRCA1,15067026,B,Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.,2004,,"Most importantly, these results demonstrate that BRCA1/2 test results significantly affect patients' surgical decision-making. The availability of genetic counseling and testing could serve as a valuable aid to patient decision-making for newly diagnosed breast cancer patients at high-risk for carrying a mutation",A,BRCA1/2,BRCA1,0.60944206
566,bc_id606,CANCER,CYP1B1,15072827,N,CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study,2004,Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.,Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.,N,CYP1B1,CYP1B1,0.256410256
567,bc_id607,CANCER,CYP19A1,15072827,N,CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study,2004,Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.,Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.,N,CYP19,CYP19A1,0.181818182
568,bc_id608,CANCER,CYP1B1,15075793,Y,Interaction between genetic polymorphism of cytochrome P450-1B1 and environmental pollutants in breast cancer risk,2004,Our results suggested that the Val CYP1B1 allele increases the susceptibility to breast cancer in women exposed to waste incinerator or agricultural pollutants.,Our results suggested that the Val CYP1B1 allele increases the susceptibility to breast cancer in women exposed to waste incinerator or agricultural pollutants.,Y,CYP1B1,CYP1B1,0.358974359
569,bc_id609,CANCER,BRCA2,15082902,B,Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients.,2004,,These findings suggest that BRCA gene mutation analysis should be performed on Korean patients with high-risk factors for breast cancer.,Y,BRCA,BRCA2,0.324175824
570,bc_id610,CANCER,BRCA1,15082902,B,Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients.,2004,,These findings suggest that BRCA gene mutation analysis should be performed on Korean patients with high-risk factors for breast cancer.,Y,BRCA,BRCA1,0.326180258
571,bc_id611,CANCER,VDR,15083068,B,Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk.,2004,", our results suggest that the VDR ApaI genotype may be an important modifier of individual breast cancer risk among Finnish women, especially if they have a positive family history of breast cancer.","In conclusion, our results suggest that the VDR ApaI genotype may be an important modifier of individual breast cancer risk among Finnish women, especially if they have a positive family history of breast cancer.",A,VDR,VDR,0.538461538
572,bc_id612,CANCER,ESR1,15084241,B,Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study.,2004,,"Our data suggest that ER-alpha polymorphisms are correlated with various aspects of breast cancer in Taiwan. ER-alpha genotype, as determined during presurgical evaluation, might represent a surrogate marker for predicting breast cancer lymph node metastasis.",A,ER-alpha,ESR1,0.586956522
573,bc_id613,CANCER,CTCF,15084242,N,A screen for germline mutations in the gene encoding CCCTC-binding factor (CTCF) in familial non-BRCA1/BRCA2 breast cancer,2004,The present study suggests that germline mutations in CTCF are not important as a risk factor for breast cancer.,The present study suggests that germline mutations in CTCF are not important as a risk factor for breast cancer.,N,CTCF,CTCF,1
574,bc_id614,CANCER,BRCA2,15084244,B,Study design: Evaluating gene-environmentinteractions in the etiology of breast cancer - the WECARE study,2004,"Our study design improves the potential for detecting gene-environment interactions for diseases when both gene mutations and the environmental exposures of interest are rare in the general population. This is particularly applicable to the study of bilateral breast cancer because both radiation dose and genetic susceptibility have important etiologic roles, possibly by interactive mechanisms. By using counter-matching, we optimized the informativeness of the collected dosimetry data by increasing the variability of radiation dose within the case-control sets and enhanced our ability to detect radiation-genotype interactions.","Three genes (ATM, BRCA1, and BRCA2) encode products that are essential for the normal cellular response to DSBs, but predispose to breast cancer when mutated.",Y,BRCA2,BRCA2,0.324175824
575,bc_id615,CANCER,BRCA1,15084244,B,Study design: Evaluating gene-environmentinteractions in the etiology of breast cancer - the WECARE study,2004,"Our study design improves the potential for detecting gene-environment interactions for diseases when both gene mutations and the environmental exposures of interest are rare in the general population. This is particularly applicable to the study of bilateral breast cancer because both radiation dose and genetic susceptibility have important etiologic roles, possibly by interactive mechanisms. By using counter-matching, we optimized the informativeness of the collected dosimetry data by increasing the variability of radiation dose within the case-control sets and enhanced our ability to detect radiation-genotype interactions.","Three genes (ATM, BRCA1, and BRCA2) encode products that are essential for the normal cellular response to DSBs, but predispose to breast cancer when mutated.",Y,BRCA1,BRCA1,0.326180258
576,bc_id616,CANCER,ATM,15084244,B,Study design: Evaluating gene-environmentinteractions in the etiology of breast cancer - the WECARE study,2004,"Our study design improves the potential for detecting gene-environment interactions for diseases when both gene mutations and the environmental exposures of interest are rare in the general population. This is particularly applicable to the study of bilateral breast cancer because both radiation dose and genetic susceptibility have important etiologic roles, possibly by interactive mechanisms. By using counter-matching, we optimized the informativeness of the collected dosimetry data by increasing the variability of radiation dose within the case-control sets and enhanced our ability to detect radiation-genotype interactions.","Three genes (ATM, BRCA1, and BRCA2) encode products that are essential for the normal cellular response to DSBs, but predispose to breast cancer when mutated.",Y,ATM,ATM,0.333333333
577,bc_id617,CANCER,ERCC2,15090466,B,Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients.,2004,,"The XPD variant genotypes in general predicted the DRC better in the controls than in the cases, suggesting genetic variants of other DNA repair genes may be involved in these breast cancer patients. These findings suggest that women with reduced DRC may be at an increased risk of developing breast cancer. Large studies are warranted to confirm these preliminary findings.",A,XPD,ERCC2,0.6875
578,bc_id618,CANCER,NAT2,15090724,B,"GSTM1 null genotype, red meat consumption and breast cancer risk (The Netherlands).",2004,GSTM1 null genotype increases breast cancer risk.,"GSTM1 null genotype increases breast cancer risk. Red meat consumption slightly increases breast cancer risk, but the relation is not statistically significant and GSTM1, NAT1, NAT2 and GSTT1 polymorphisms do not modify this relation.",N,NAT2,NAT2,0.37037037
579,bc_id619,CANCER,NAT1,15090724,B,"GSTM1 null genotype, red meat consumption and breast cancer risk (The Netherlands).",2004,GSTM1 null genotype increases breast cancer risk.,"GSTM1 null genotype increases breast cancer risk. Red meat consumption slightly increases breast cancer risk, but the relation is not statistically significant and GSTM1, NAT1, NAT2 and GSTT1 polymorphisms do not modify this relation.",N,NAT1,NAT1,0.6
580,bc_id620,CANCER,GSTT1,15090724,B,"GSTM1 null genotype, red meat consumption and breast cancer risk (The Netherlands).",2004,GSTM1 null genotype increases breast cancer risk.,"GSTM1 null genotype increases breast cancer risk. Red meat consumption slightly increases breast cancer risk, but the relation is not statistically significant and GSTM1, NAT1, NAT2 and GSTT1 polymorphisms do not modify this relation.",N,GSTT1,GSTT1,0.131578947
581,bc_id621,CANCER,GSTM1,15090724,B,"GSTM1 null genotype, red meat consumption and breast cancer risk (The Netherlands).",2004,GSTM1 null genotype increases breast cancer risk.,"GSTM1 null genotype increases breast cancer risk. Red meat consumption slightly increases breast cancer risk, but the relation is not statistically significant and GSTM1, NAT1, NAT2 and GSTT1 polymorphisms do not modify this relation.",Y,GSTM1,GSTM1,0.452830189
582,bc_id622,CANCER,SULT1A1,15093672,Y,Sulfotransferase 1A1 (SULT1A1) polymorphism and breast cancer risk in Chinese women.,2004,Our findings suggest that the SULT1A1 His allele was positively associated with the risk of breast cancer in Chinese women. And there was interaction between SULT1A1 polymorphism and related exposure factors.,Our findings suggest that the SULT1A1 His allele was positively associated with the risk of breast cancer in Chinese women. And there was interaction between SULT1A1 polymorphism and related exposure factors.,Y,SULT1A1,SULT1A1,0.322580645
583,bc_id624,CANCER,CHEK2,15095295,B,Limited relevance of the CHEK2 gene in hereditary breast cancer.,2004,"The low prevalence and penetrance of the exon 10 deletion mutations together with no, or an uncertain elevation in risk for other CHEK2 mutations suggests a limited relevance for CHEK2 mutations in familial breast cancer. Further evaluation of the unique variants observed in breast cancer is required to determine if they may play a role in a polygenic model of familial breast cancer. Nevertheless, it seems premature to include CHEK2 screening in genetic testing.","The low prevalence and penetrance of the exon 10 deletion mutations together with no, or an uncertain elevation in risk for other CHEK2 mutations suggests a limited relevance for CHEK2 mutations in familial breast cancer.",A,CHEK2,CHEK2,0.383333333
584,bc_id625,CANCER,BRCA2,15095307,B,Smoking and the risk of breast cancer among carriers of BRCA mutations.,2004,", contrary to our previous report, smoking does not appear to be a risk factor for breast cancer among carriers of BRCA mutations.","In conclusion, contrary to our previous report, smoking does not appear to be a risk factor for breast cancer among carriers of BRCA mutations.",N,BRCA,BRCA2,0.098901099
585,bc_id626,CANCER,BRCA1,15095307,B,Smoking and the risk of breast cancer among carriers of BRCA mutations.,2004,", contrary to our previous report, smoking does not appear to be a risk factor for breast cancer among carriers of BRCA mutations.","In conclusion, contrary to our previous report, smoking does not appear to be a risk factor for breast cancer among carriers of BRCA mutations.",N,BRCA,BRCA1,0.064377682
586,bc_id627,CANCER,EGFR,15095477,B,Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study.,2004,,"On the other hand, the data demonstrate clearly for the first time an interaction between the length of a polymorphism in intron 1 of egfr as an inherited genetic factor and the frequency of egfr amplification, as an acquired genetic factor, both factors contributing to EGFR overexpression in breast cancer. This new knowledge about mechanisms of regulation of EGFR expression might serve as an additional basis for evaluating anti-EGFR-based therapies.",Y,EGFR,EGFR,0.285714286
587,bc_id628,CANCER,CYP1B1,15102677,B,Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms,2004,"We have shown that multiple SNP sites from different genes over distant parts of the genome are better at identifying breast cancer patients than any one SNP alone. As high-throughput technology for SNPs improves and as more SNPs are identified, it is likely that much higher predictive accuracy will be achieved and a useful clinical tool developed.",The three SNP sites most useful in this model were (a) the +4536T/C site of the aldosterone synthase gene CYP11B2 at amino acid residue 386 Val/Ala (T/C) (rs4541); (b) the +4328C/G site of the aryl hydrocarbon hydroxylase CYP1B1 at amino acid residue 293 Leu/Val (C/G) (rs5292); and (c) the +4449C/T site of the transcription factor BCL6 at amino acid 387 Asp/Asp (rs1056932). No single SNP site on its own could achieve more than 60% in predictive accuracy. We have shown that multiple SNP sites from different genes over distant parts of the genome are better at identifying breast cancer patients than any one SNP alone.,A,CYP1B1,CYP1B1,0.384615385
588,bc_id629,CANCER,CYP11B2,15102677,B,Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms,2004,"We have shown that multiple SNP sites from different genes over distant parts of the genome are better at identifying breast cancer patients than any one SNP alone. As high-throughput technology for SNPs improves and as more SNPs are identified, it is likely that much higher predictive accuracy will be achieved and a useful clinical tool developed.",The three SNP sites most useful in this model were (a) the +4536T/C site of the aldosterone synthase gene CYP11B2 at amino acid residue 386 Val/Ala (T/C) (rs4541); (b) the +4328C/G site of the aryl hydrocarbon hydroxylase CYP1B1 at amino acid residue 293 Leu/Val (C/G) (rs5292); and (c) the +4449C/T site of the transcription factor BCL6 at amino acid 387 Asp/Asp (rs1056932). No single SNP site on its own could achieve more than 60% in predictive accuracy. We have shown that multiple SNP sites from different genes over distant parts of the genome are better at identifying breast cancer patients than any one SNP alone.,A,CYP11B2,CYP11B2,1
589,bc_id630,CANCER,BRCA1,15104281,B,Loss of heterozygosity in normal breast epithelial t and benign breast lesions in BRCA1/2 carriers with breast cancer.,2004,,We evaluated the early genomic changes that occur in the mammary glands of patients with increased predisposition to breast cancer due to germline mutations in the BRCA1/2 genes... Our results suggest that there is a field effect of early genetic events preceding morphologic changes in the mammary glands of BRCA mutation carriers.,Y,BRCA1,BRCA1,0.326180258
590,bc_id631,CANCER,MTHFR,15110890,B,Reduced breast cancer risk with increasing serum folate in a case-control study of the C677T genotype of the methylenetetrahydrofolate reductase gene.,2004,,Breast cancer risk may be associated with folate status or the C677T genotype of the methylenetetrahydrofolate reductase (MTHFR) gene.,Y,MTHFR,MTHFR,0.269230769
591,bc_id632,CANCER,UGT1A1,15111762,N,Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer.,2004,No significant associations were observed with *28 allele and breast cancer risk by estrogen receptor/progesterone receptor status.,These results suggested that the *28 allele in the UGT1A1 gene may be associated with an increased risk for breast cancer among Chinese women under age 40. No significant associations were observed with *28 allele and breast cancer risk by estrogen receptor/progesterone receptor status.,A,UGT1A1,UGT1A1,0.7
592,bc_id633,CANCER,BRIP1,15113441,B,"Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.",2004,"Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.","No associations with breast cancer were observed for: APEX Q51H; XRCC1 R280H; IGFPB3 -202A>C; TGFss1 L10P, P25R, and T263I; BRCA2 N289H and T1915M; BRIP1 -64A>C; and ZNF350 (or ZBRK1) 1845C>T, L66P, R501S, and S472P...  Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks.",A,BRIP1,BRIP1,0.5
593,bc_id634,CANCER,BRCA1,15113441,B,"Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.",2004,"Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.","No associations with breast cancer were observed for: APEX Q51H; XRCC1 R280H; IGFPB3 -202A>C; TGFss1 L10P, P25R, and T263I; BRCA2 N289H and T1915M; BRIP1 -64A>C; and ZNF350 (or ZBRK1) 1845C>T, L66P, R501S, and S472P...  Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks.",A,BRCA1,BRCA1,0.60944206
594,bc_id635,CANCER,APEX1,15113441,B,"Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.",2004,"Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.","No associations with breast cancer were observed for: APEX Q51H; XRCC1 R280H; IGFPB3 -202A>C; TGFss1 L10P, P25R, and T263I; BRCA2 N289H and T1915M; BRIP1 -64A>C; and ZNF350 (or ZBRK1) 1845C>T, L66P, R501S, and S472P...  Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks.",N,APEX,APEX1,0.5
595,bc_id636,CANCER,POLD1,15113441,B,"Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.",2004,"Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.","Thus, 19 single nucleotide polymorphisms (SNPs) in eight genes involved in base excision repair (XRCC1, APEX, POLD1), BRCA1 protein interaction (BRIP1, ZNF350, BRCA2), and growth regulation (TGFss1, IGFBP3) were evaluated...  Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles.",A,POLD1,POLD1,1
596,bc_id637,CANCER,XRCC1,15113441,B,"Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.",2004,"Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.","No associations with breast cancer were observed for: APEX Q51H; XRCC1 R280H; IGFPB3 -202A>C; TGFss1 L10P, P25R, and T263I; BRCA2 N289H and T1915M; BRIP1 -64A>C; and ZNF350 (or ZBRK1) 1845C>T, L66P, R501S, and S472P...  Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks.",A,XRCC1,XRCC1,0.543478261
597,bc_id638,CANCER,ZNF350,15113441,B,"Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes.",2004,"Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks. Due to the many comparisons, cautious interpretation and replication of these relationships are warranted.","No associations with breast cancer were observed for: APEX Q51H; XRCC1 R280H; IGFPB3 -202A>C; TGFss1 L10P, P25R, and T263I; BRCA2 N289H and T1915M; BRIP1 -64A>C; and ZNF350 (or ZBRK1) 1845C>T, L66P, R501S, and S472P...  Some variants in genes within the base-excision repair pathway (XRCC1) and BRCA1 interacting proteins (BRIP1) may play a role as low penetrance breast cancer risk alleles. Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks.",N,ZNF350,ZNF350,0.333333333
598,bc_id639,CANCER,GSTT1,15113959,B,"Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype.",2004,,X,X,X,X,0
599,bc_id640,CANCER,GSTM1,15113959,B,"Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype.",2004,,X,X,X,X,0
600,bc_id641,CANCER,BRCA2,15117986,B,Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.,2004,The prevalence of BRCA1 and BRCA2 mutations in Korean women with breast cancer at a young age was high.,"The prevalence of BRCA1 and BRCA2 mutations in Korean women with breast cancer at a young age was high. However, the penetrance, as evidenced by the low frequency of breast and ovarian cancers in family members, appears to be low. These data suggest that there may be different genetic and etiologic factors affecting transmission and penetrance of the BRCA genes in Korean patients with breast cancer diagnosed at a young age.",A,BRCA2,BRCA2,0.576923077
601,bc_id642,CANCER,BRCA1,15117986,B,Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.,2004,The prevalence of BRCA1 and BRCA2 mutations in Korean women with breast cancer at a young age was high.,"The prevalence of BRCA1 and BRCA2 mutations in Korean women with breast cancer at a young age was high. However, the penetrance, as evidenced by the low frequency of breast and ovarian cancers in family members, appears to be low. These data suggest that there may be different genetic and etiologic factors affecting transmission and penetrance of the BRCA genes in Korean patients with breast cancer diagnosed at a young age.",A,BRCA1,BRCA1,0.60944206
602,bc_id643,CANCER,PRLR,15119991,B,Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma?,2004,Polymorphism of prolactin receptors might play a role in mammary carcinogenesis as a consequence of intracellular changes of PRLR signalling.,Polymorphism of prolactin receptors might play a role in mammary carcinogenesis as a consequence of intracellular changes of PRLR signalling.,A,PRLR,PRLR,0.333333333
603,bc_id644,CANCER,CHEK2,15122511,Y,"CHEK2*1100delC and susceptibility to breast cancer:a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.",2004,The results are consistent with the hypothesis that CHEK2*1100delC multiplies the risks associated with susceptibility alleles in other genes to increase the risk of breast cancer.,The results are consistent with the hypothesis that CHEK2*1100delC multiplies the risks associated with susceptibility alleles in other genes to increase the risk of breast cancer.,Y,CHEK2*1100delC,CHEK2,0.383333333
604,bc_id645,CANCER,CDKN2A,15122588,N,Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer.,2004,"The results revealed a paucity of mutations in CDKN2A/ARF, suggesting that in the Polish population this gene does not contribute significantly to either FMM or MM within the context of CFA.","We examined 16 FMM cases (group 1), 44 MM probands with a cancer family aggregation (CFA) that included at least one breast cancer (group 2) and 22 breast cancer probands with CFA and MM (group 3). The results revealed a paucity of mutations in CDKN2A/ARF, suggesting that in the Polish population this gene does not contribute significantly to either FMM or MM within the context of CFA.",N,CDKN2A,CDKN2A,0.25
605,bc_id646,CANCER,ERBB2,15126109,N,Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.,2004,"In conclusion, our results support the view that both the ER codon 594 and HER2 codon 655 polymorphisms are not associated with increased risk of breast cancer.","In conclusion, our results support the view that both the ER codon 594 and HER2 codon 655 polymorphisms are not associated with increased risk of breast cancer.",N,HER2,ERBB2,0.261904762
606,bc_id647,CANCER,BRCA2,15131403,B,An audit of screening for familial breast cancer before 50 years in the South Thames Region - have we got it right?,2004,"This audit suggests that screening below the age 50 years may be unnecessary in families with a low chance of having a BRCA1 or -2 mutation, but it is important to screen high-risk women at least annually and possibly under 35 years.","In the 192 women in the screened cohort, 9 breast cancers were diagnosed (4.7%), all in high-risk women... This audit suggests that screening below the age 50 years may be unnecessary in families with a low chance of having a BRCA1 or -2 mutation, but it is important to screen high-risk women at least annually and possibly under 35 years.",A,BRCA1 or -2,BRCA2,0.576923077
607,bc_id648,CANCER,BRCA1,15131403,B,An audit of screening for familial breast cancer before 50 years in the South Thames Region - have we got it right?,2004,"This audit suggests that screening below the age 50 years may be unnecessary in families with a low chance of having a BRCA1 or -2 mutation, but it is important to screen high-risk women at least annually and possibly under 35 years.","In the 192 women in the screened cohort, 9 breast cancers were diagnosed (4.7%), all in high-risk women... This audit suggests that screening below the age 50 years may be unnecessary in families with a low chance of having a BRCA1 or -2 mutation, but it is important to screen high-risk women at least annually and possibly under 35 years.",A,BRCA1,BRCA1,0.60944206
608,bc_id649,CANCER,GNB3,15138483,B,Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations.,2004,"Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.","Six SNPs, Q356R and P871L in BRCA1, N372H in BRCA2, C112R (E4) and R158C (E2) in ApoE and C825T in GNB3, did not show any sign of association. The P187S polymorphism in NQO1 was associated with breast cancer in both populations from Tyrol and Prague with a higher risk for carriers of the 187S allele...  Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.",N,GNB3,GNB3,0.666666667
609,bc_id650,CANCER,BRCA2,15138483,B,Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations.,2004,"Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.","Six SNPs, Q356R and P871L in BRCA1, N372H in BRCA2, C112R (E4) and R158C (E2) in ApoE and C825T in GNB3, did not show any sign of association. The P187S polymorphism in NQO1 was associated with breast cancer in both populations from Tyrol and Prague with a higher risk for carriers of the 187S allele...  Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.",N,BRCA2,BRCA2,0.098901099
610,bc_id651,CANCER,BRCA1,15138483,B,Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations.,2004,"Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.","Six SNPs, Q356R and P871L in BRCA1, N372H in BRCA2, C112R (E4) and R158C (E2) in ApoE and C825T in GNB3, did not show any sign of association. The P187S polymorphism in NQO1 was associated with breast cancer in both populations from Tyrol and Prague with a higher risk for carriers of the 187S allele...  Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.",N,BRCA1,BRCA1,0.064377682
611,bc_id652,CANCER,APOE,15138483,B,Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations.,2004,"Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.","Six SNPs, Q356R and P871L in BRCA1, N372H in BRCA2, C112R (E4) and R158C (E2) in ApoE and C825T in GNB3, did not show any sign of association. The P187S polymorphism in NQO1 was associated with breast cancer in both populations from Tyrol and Prague with a higher risk for carriers of the 187S allele...  Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.",N,APOE,APOE,0.666666667
612,bc_id653,CANCER,NQO1,15138483,Y,Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations.,2004,"Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.","Six SNPs, Q356R and P871L in BRCA1, N372H in BRCA2, C112R (E4) and R158C (E2) in ApoE and C825T in GNB3, did not show any sign of association. The P187S polymorphism in NQO1 was associated with breast cancer in both populations from Tyrol and Prague with a higher risk for carriers of the 187S allele...  Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.",Y,NQO1,NQO1,0.5
613,bc_id654,CANCER,TP53,15138483,Y,Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations.,2004,"Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.","Six SNPs, Q356R and P871L in BRCA1, N372H in BRCA2, C112R (E4) and R158C (E2) in ApoE and C825T in GNB3, did not show any sign of association. The P187S polymorphism in NQO1 was associated with breast cancer in both populations from Tyrol and Prague with a higher risk for carriers of the 187S allele...  Combining the two 'candidate' SNPs (P187S and R72P) revealed an increased risk for breast cancer of double heterozygotes (P187S/R72P) of the NQO1 and TP53 genes (OR=1.88; 95% CI 1.13-3.15; P=0.011), suggesting a possible interaction of these two loci.",Y,TP53,TP53,0.367816092
614,bc_id655,CANCER,BRCA2,15138485,Y,"A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.",2004,"These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found.","In noncarrier BC cases, carrying RAD51-135c was not associated with BC risk (0.97; 95% CI 0.47-2.00). These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found.",Y,BRCA2,BRCA2,0.324175824
615,bc_id656,CANCER,BRCA1,15138485,N,"A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.",2004,"These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found.",X,X,X,X,0
616,bc_id657,CANCER,RAD51,15138485,Y,"A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers.",2004,"These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found.","In noncarrier BC cases, carrying RAD51-135c was not associated with BC risk (0.97; 95% CI 0.47-2.00).",N,RAD51-135c,RAD51,0.153846154
617,bc_id658,CANCER,GSTM1,15141140,B,Breast tissue organochlorine levels and metabolic genotypes in relation to breast cancer risk Canada.,2004,,"In general, women who carried inactive alleles of the GSTM1 had higher levels of breast organochlorines, and were at modestly increased risk of breast cancer (odds ratio = 2.2; 95% CI = 1.1-4.4).",Y,GSTM1,GSTM1,0.452830189
618,bc_id659,CANCER,BRCA2,15144764,B,Accommodating risk: responses to BRCA1/2 genetictesting of women who have had cancer.,2004,The data suggest that affected women understand their genetic risks of cancer within the context of their previous disease experiences. It is observed that women's responses to their genetic risk are influenced by the degree to which they have accommodated their risk status in their biography following their diagnosis and treatment of cancer.,X,X,X,X,0
619,bc_id660,CANCER,BRCA1,15144764,B,Accommodating risk: responses to BRCA1/2 genetictesting of women who have had cancer.,2004,The data suggest that affected women understand their genetic risks of cancer within the context of their previous disease experiences. It is observed that women's responses to their genetic risk are influenced by the degree to which they have accommodated their risk status in their biography following their diagnosis and treatment of cancer.,X,X,X,X,0
620,bc_id661,CANCER,MMP1,15149160,Y,An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer.,2004,Our results suggest that allele 2G may be associated with lymphnode metastasis in patients with breast cancer and therefore it can be considered as a prognostic marker in this disease.,An elevated level of MMP-1 in cancer cells may facilitate their invasion and contribute to metastasis... Our results suggest that allele 2G may be associated with lymphnode metastasis in patients with breast cancer and therefore it can be considered as a prognostic marker in this disease.,A,MMP-1,MMP1,0.833333333
621,bc_id662,CANCER,MTHFR,15150439,B,"Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women.",2004,,Our findings suggest that MTHFR polymorphism did not influence individual susceptibility to breast cancer.,N,MTHFR,MTHFR,0.326923077
622,bc_id663,CANCER,CYP11A1,15159300,Y,Population-Based Case-Control Study of CYP11A Gene Polymorphism and Breast Cancer Risk,2004,The results from this study indicate that the TAAAA repeat polymorphism near the promoter region of the CYP11A gene may be an important susceptibility factor for breast cancer risk.,The results from this study indicate that the TAAAA repeat polymorphism near the promoter region of the CYP11A gene may be an important susceptibility factor for breast cancer risk.,Y,CYP11A,CYP11A1,0.25
623,bc_id664,CANCER,MMP3,15161710,N,The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer.,2004,The MMP3 5A/6A promoter polymorphism does not appear to influence breast cancer susceptibility but may be linked to a higher risk for metastasizing among breast cancer patients.,The MMP3 5A/6A promoter polymorphism does not appear to influence breast cancer susceptibility but may be linked to a higher risk for metastasizing among breast cancer patients.,N,MMP3 5A/6A,MMP3,0.333333333
624,bc_id665,CANCER,NAT2,15162844,N,N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population.,2004,,"To our knowledge, this is the first genetic study on the association of NAT2 genotypes with breast cancer in the TUrkish population, and this finding showed that NAT2 polymorphism does not play an important role in breast cancer risk of Turkish women by altering the capacity in deactivation of environmental carcinogens, even though small sample size and wide confidence interval.",N,NAT2,NAT2,0.37037037
625,bc_id666,CANCER,ERBB2,15167216,B,HER2 polymorphism and breast cancer risk in Portugal,2004,Our results indicate an association between the presence of the Val allele in the HER2 polymorphism and the risk of breast cancer. Further studies are needed to evaluate the role of this polymorphism in the behaviour of breast cancer.,Our results indicate an association between the presence of the Val allele in the HER2 polymorphism and the risk of breast cancer. Further studies are needed to evaluate the role of this polymorphism in the behaviour of breast cancer.,Y,HER2,ERBB2,0.285714286
626,bc_id667,CANCER,RAD51L3,15170666,B,The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations.,2004,"Finally, the structural prediction of the putative functional consequence of this change indicates that it can diminish protein stability and structure. This suggests a role for E233G as a low-penetrance susceptibility gene in the specific subgroup of high-risk familial breast cancer cases that are not related to BRCA1/2.","The novel variant E233G in RAD51D is more highly represented in high-risk, site-specific, familial breast cancer cases that are not associated with the BRCA1/2 genes, with a frequency of 5.74% (n = 174) compared to a control population (n = 567) and another subset of breast cancer patients (n = 765) with a prevalence of around 2% only (comparison to controls, OR = 2.6, 95% CI 1.12-6.03; p < 0.021).",Y,RAD51D,RAD51D,1
627,bc_id668,CANCER,RAD51C,15170666,B,The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations.,2004,"Finally, the structural prediction of the putative functional consequence of this change indicates that it can diminish protein stability and structure. This suggests a role for E233G as a low-penetrance susceptibility gene in the specific subgroup of high-risk familial breast cancer cases that are not related to BRCA1/2.",X,X,X,X,0
628,bc_id669,CANCER,CYP19A1,15177662,N,A tetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides.,2004,Lack of strong association suggests that the polymorphic TTTA short tandem repeat of CYP19 gene may have not a functional effect on the enzyme's activity and thus its role in the development of breast cancer remains unclear.,Lack of strong association suggests that the polymorphic TTTA short tandem repeat of CYP19 gene may have not a functional effect on the enzyme's activity and thus its role in the development of breast cancer remains unclear.,A,CYP19,CYP19A1,0.484848485
629,bc_id670,CANCER,TP53,15183535,B,Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.,2004,,"It is suggested that p53Arg72Pro polymorphism is associated with ER positive breast cancer risk, especially, in postmenopausal women. The higher frequency of p53 somatic mutation in p5372Arg/Arg homozygotes than p5372Pro/Pro homozygotes is consistent with the thesis that the function of p5372Pro/Pro is impaired so that a further alteration of p53 gene is less required in p5372Pro/Pro homozygotes than p5372Arg/Arg homozygotes.",Y,p53,TP53,0.367816092
630,bc_id671,CANCER,SOD2,15184255,Y,"Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer.",2004,"These data suggest that the Ala allele of MnSOD may modify breast cancer risk among current smokers, but is not an independent risk factor for breast cancer.","These data suggest that the Ala allele of MnSOD may modify breast cancer risk among current smokers, but is not an independent risk factor for breast cancer.",A,MnSOD,SOD2,0.375
631,bc_id672,CANCER,NBN,15185344,B,Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland.,2004,"Most of the 657del5 mutation carriers were found among patients with melanoma (4/105), non-Hodgkin lymphoma (2/42) and breast cancer (4/224) and of the 234 patients with colorectal carcinoma 3 carried the 657del5 mutation and 3 others the R215W molecular variant... These results suggest strongly that NBS1 heterozygosity may be associated with elevated risk of some cancers. Larger studies are needed to evaluate the impact of the high frequency of germline NBS1 mutations on the cancer burden in the Slav populations.",X,X,X,X,0
632,bc_id673,CANCER,SOD2,15217492,Y,Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites.,2004,The MnSOD genotype may contribute to an increased risk of breast cancer in the presence of specific environmental exposures. These results provide further evidence for the importance of reactive oxygen species and of oxidative DNA damage in the etiology of breast cancer.,The MnSOD genotype may contribute to an increased risk of breast cancer in the presence of specific environmental exposures. These results provide further evidence for the importance of reactive oxygen species and of oxidative DNA damage in the etiology of breast cancer.,A,MnSOD,SOD2,0.375
633,bc_id674,CANCER,DNMT3B,15217506,B,The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: acase-control study.,2004,"Our findings contrast with those of a previous study, which showed that individuals carrying at least one T allele have a significantly increased risk of developing lung cancer. This discrepancy might be an artefact resulting from a chance variation, or it might point to differing influences of promoter hypermethylation in these cancer types.","DNMT1, DNM3A and DNMT3B. The C-->T transition polymorphism (C46359T) in the promoter of the DNMT3B gene, which significantly increases transcriptional activity, has been postulated to increase the propensity for promoter-hypermethylation-mediated silencing of tumour suppressor genes... The C allele was found to be more common in case subjects than in control subjects (cases, 0.59; controls, 0.54) corresponding to a nominally significant increase in breast cancer risk to heterozygotes and CC homozygotes (odds ratio 1.51, 95% confidence interval 1.01-2.25) in the dominant inheritance model.",A,DNMT3B,DNMT3B,0.25
634,bc_id675,CANCER,TNF,15217507,B,Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity.,2004,,"We demonstrated no association between the -308G>A polymorphism and the -238G>A polymorphism in the promoter region of TNF and susceptibility to breast cancer, in a large North European population. However, the -308 G>A polymorphism was found to be associated with the presence of vascular invasion in breast tumours.",Y,TNF,TNF,0.333333333
635,bc_id676,CANCER,BRCA2,15217508,B,Frequency of the ATM IVS10-6T--&gt;G variant in Australian multiple-case breast cancer families.,2004,,X,X,X,X,0
636,bc_id677,CANCER,BRCA1,15217508,B,Frequency of the ATM IVS10-6T--&gt;G variant in Australian multiple-case breast cancer families.,2004,,X,X,X,X,0
637,bc_id678,CANCER,ATM,15217510,N,Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study.,2004,There was no evidence that common haplotypes of ATM are associated with breast cancer risk. Extensive single nucleotide polymorphism detection using the entire genomic sequence of ATM will be necessary to rule out less common variation in ATM and sporadic breast cancer risk.,There was no evidence that common haplotypes of ATM are associated with breast cancer risk. Extensive single nucleotide polymorphism detection using the entire genomic sequence of ATM will be necessary to rule out less common variation in ATM and sporadic breast cancer risk.,N,ATM,ATM,0.244444444
638,bc_id679,CANCER,ESR1,15217512,B,Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study.,2004,We found suggestions of an association between common haplotypes in ESR1 and the risk for ductal breast cancer that is stronger in heavy women.,We found suggestions of an association between common haplotypes in ESR1 and the risk for ductal breast cancer that is stronger in heavy women.,A,ESR1,ESR1,0.586956522
639,bc_id680,CANCER,CYP1A1,15217514,B,"Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African-American and white women.",2004,,"Cigarette smoking increases breast cancer risk in women with CYP1A1 M1 variant genotypes and in African-American women with CYP1A1 M3 variant genotypes, but the modifying effects of the CYP1A1 genotype are quite weak.",Y,CYP1A1,CYP1A1,0.304347826
640,bc_id681,CANCER,CTLA4,15218356,Y,Cytotoxic T lymphocyte antigen-4 gene in breast cancer.,2004,"The observed decrease in the frequency of GG genotype in the breast cancer patients is contrary to the frequently reported increase of GG genotype in autoimmune diseases. In addition, the data implies that polymorphism of ctla-4 exon 1 contributes in tumor progression.","The ctla-4 49A/G polymorphism was studied in 197 women with primary breast cancer and 151 age/sex matched normal individuals... The observed decrease in the frequency of GG genotype in the breast cancer patients is contrary to the frequently reported increase of GG genotype in autoimmune diseases. In addition, the data implies that polymorphism of ctla-4 exon 1 contributes in tumor progression.",Y,ctla-4,CTLA4,0.666666667
641,bc_id682,CANCER,NAT2,15225898,B,"N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer.",2004,,The results for smoking were consistent with an inactivation role for NAT2 in breast cancer.,Y,NAT2,NAT2,0.37037037
642,bc_id683,CANCER,CHEK2,15239132,B,CHEK2 variant I157T may be associated with increased breast cancer risk.,2004,"These functional properties of the I157T protein suggest that this variant may have negative effect on the pool of normal CHEK2 protein in heterozygous carrier cells by formation of heterodimers with wild-type CHEK2. The I157T variant may be associated with breast cancer risk, but the risk is lower than for 1100delC.","These functional properties of the I157T protein suggest that this variant may have negative effect on the pool of normal CHEK2 protein in heterozygous carrier cells by formation of heterodimers with wild-type CHEK2. The I157T variant may be associated with breast cancer risk, but the risk is lower than for 1100delC.",A,CHEK2,CHEK2,0.383333333
643,bc_id684,CANCER,GH1,15241820,N,Genetic polymorphisms in the human growth hormone-1 gene (GH1) and the risk of breast carcinoma.,2004,The results of the current study suggest that genetic polymorphisms in the proximal promoter region and in the fourth intron of the GH1 gene are unrelated to breast carcinoma risk in Chinese women.,The results of the current study suggest that genetic polymorphisms in the proximal promoter region and in the fourth intron of the GH1 gene are unrelated to breast carcinoma risk in Chinese women.,N,GH1,GH1,0.75
644,bc_id685,CANCER,CYP1A1,15241822,Y,Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.,2004,"The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.","When two-way interactions involving investigated SNPs were ascertained, no significant interactions among polymorphisms were noted.... The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.",Y,CYP1A1-1,CYP1A1,0.304347826
645,bc_id687,CANCER,CYP17A1,15241822,Y,Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.,2004,"The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.","When two-way interactions involving investigated SNPs were ascertained, no significant interactions among polymorphisms were noted.... The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.",Y,CYP17,CYP17A1,0.266666667
646,bc_id686,CANCER,CYP19A1,15241822,B,Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.,2004,"The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.",X,X,X,X,0
647,bc_id688,CANCER,SRD5A2,15241822,B,Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.,2004,"The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.",X,X,X,X,0
648,bc_id689,CANCER,VDR,15241822,B,Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.,2004,"The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.",X,X,X,X,0
649,bc_id690,CANCER,COMT,15241822,B,Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.,2004,"The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.",X,X,X,X,0
650,bc_id691,CANCER,HSD17B1,15241822,B,Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.,2004,"The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women.",X,X,X,X,0
651,bc_id692,CANCER,BRCA1,15256476,Y,Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.,2004,"Because BRCA1 is a well-documented breast cancer susceptibility gene, this association between NHEJ and BRCA1 not only suggests a role of BRCA1 in NHEJ but also provides essential support for the tumorigenic contribution of NHEJ in breast cancer development..","Because BRCA1 is a well-documented breast cancer susceptibility gene, this association between NHEJ and BRCA1 not only suggests a role of BRCA1 in NHEJ but also provides essential support for the tumorigenic contribution of NHEJ in breast cancer development..",Y,BRCA1,BRCA1,0.326180258
652,bc_id693,CANCER,LIG4,15256476,Y,Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.,2004,"Because BRCA1 is a well-documented breast cancer susceptibility gene, this association between NHEJ and BRCA1 not only suggests a role of BRCA1 in NHEJ but also provides essential support for the tumorigenic contribution of NHEJ in breast cancer development..",X,X,X,X,0
653,bc_id694,CANCER,GSTT1,15256483,B,"Marine n-3 fatty acid intake, glutathione S-transferase polymorphisms and breast cancer risk in post-menopausal Chinese women in Singapore.",2004,breast cancer risk was unrelated to GSTM1 and GSTP1 genotypes.,"Therefore, we hypothesized that individuals possessing the low activity genotypes of GSTM1, GSTT1 and/or GSTP1 (i.e. the GSTM1 null, GSTT1 null and GSTP1 AB/BB genotypes, respectively) may exhibit a stronger marine n-3 fatty acid-breast cancer association than their high activity counterparts.",Y,GSTT1,GSTT1,0.578947368
654,bc_id695,CANCER,GSTP1,15256483,B,"Marine n-3 fatty acid intake, glutathione S-transferase polymorphisms and breast cancer risk in post-menopausal Chinese women in Singapore.",2004,breast cancer risk was unrelated to GSTM1 and GSTP1 genotypes.,"Therefore, we hypothesized that individuals possessing the low activity genotypes of GSTM1, GSTT1 and/or GSTP1 (i.e. the GSTM1 null, GSTT1 null and GSTP1 AB/BB genotypes, respectively) may exhibit a stronger marine n-3 fatty acid-breast cancer association than their high activity counterparts.",Y,GSTP1,GSTP1,0.428571429
655,bc_id696,CANCER,GSTM1,15256483,B,"Marine n-3 fatty acid intake, glutathione S-transferase polymorphisms and breast cancer risk in post-menopausal Chinese women in Singapore.",2004,breast cancer risk was unrelated to GSTM1 and GSTP1 genotypes.,"Therefore, we hypothesized that individuals possessing the low activity genotypes of GSTM1, GSTT1 and/or GSTP1 (i.e. the GSTM1 null, GSTT1 null and GSTP1 AB/BB genotypes, respectively) may exhibit a stronger marine n-3 fatty acid-breast cancer association than their high activity counterparts.",Y,GSTM1,GSTM1,0.452830189
656,bc_id697,CANCER,TNF,15265021,B,Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.,2004,These results suggest that the role of cytokine promoter SNPs in both susceptibility to and prognosis in breast cancer requires further investigation in a larger study.,"A total of 144 female breast cancer patients and 263 cancer-free population controls were genotyped for the interleukin (IL)-1beta-511 (T/C), IL-6 -174 (G/C), tumour necrosis factor (TNF)-alpha-308 (A/G), IL-10 -1082 (A/G), IL-8 -251 (A/T) and vascular endothelial growth factor (VEGF) -1154 (A/G) SNPs, using amplification refractory mutation system polymerase chain reaction (ARMS-PCR) and TaqMan (Applied Biosystems, Foster City, CA, USA) 5' nuclease assays for allelic discrimination. No significant associations were seen.",N,(TNF)-alpha-308,TNF,0.266666667
657,bc_id698,CANCER,IL8,15265021,B,Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.,2004,These results suggest that the role of cytokine promoter SNPs in both susceptibility to and prognosis in breast cancer requires further investigation in a larger study.,"A total of 144 female breast cancer patients and 263 cancer-free population controls were genotyped for the interleukin (IL)-1beta-511 (T/C), IL-6 -174 (G/C), tumour necrosis factor (TNF)-alpha-308 (A/G), IL-10 -1082 (A/G), IL-8 -251 (A/T) and vascular endothelial growth factor (VEGF) -1154 (A/G) SNPs, using amplification refractory mutation system polymerase chain reaction (ARMS-PCR) and TaqMan (Applied Biosystems, Foster City, CA, USA) 5' nuclease assays for allelic discrimination. No significant associations were seen.",N,IL-8 -251,IL8,0.4
658,bc_id699,CANCER,IL1B,15265021,B,Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.,2004,These results suggest that the role of cytokine promoter SNPs in both susceptibility to and prognosis in breast cancer requires further investigation in a larger study.,"A total of 144 female breast cancer patients and 263 cancer-free population controls were genotyped for the interleukin (IL)-1beta-511 (T/C), IL-6 -174 (G/C), tumour necrosis factor (TNF)-alpha-308 (A/G), IL-10 -1082 (A/G), IL-8 -251 (A/T) and vascular endothelial growth factor (VEGF) -1154 (A/G) SNPs, using amplification refractory mutation system polymerase chain reaction (ARMS-PCR) and TaqMan (Applied Biosystems, Foster City, CA, USA) 5' nuclease assays for allelic discrimination. No significant associations were seen.",N,(IL)-1beta-511,IL1B,0.4
659,bc_id700,CANCER,IL10,15265021,B,Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.,2004,These results suggest that the role of cytokine promoter SNPs in both susceptibility to and prognosis in breast cancer requires further investigation in a larger study.,"A total of 144 female breast cancer patients and 263 cancer-free population controls were genotyped for the interleukin (IL)-1beta-511 (T/C), IL-6 -174 (G/C), tumour necrosis factor (TNF)-alpha-308 (A/G), IL-10 -1082 (A/G), IL-8 -251 (A/T) and vascular endothelial growth factor (VEGF) -1154 (A/G) SNPs, using amplification refractory mutation system polymerase chain reaction (ARMS-PCR) and TaqMan (Applied Biosystems, Foster City, CA, USA) 5' nuclease assays for allelic discrimination. No significant associations were seen.",N,IL-10 -1082,IL10,0.25
660,bc_id701,CANCER,IL6,15265021,B,Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.,2004,These results suggest that the role of cytokine promoter SNPs in both susceptibility to and prognosis in breast cancer requires further investigation in a larger study.,"A total of 144 female breast cancer patients and 263 cancer-free population controls were genotyped for the interleukin (IL)-1beta-511 (T/C), IL-6 -174 (G/C), tumour necrosis factor (TNF)-alpha-308 (A/G), IL-10 -1082 (A/G), IL-8 -251 (A/T) and vascular endothelial growth factor (VEGF) -1154 (A/G) SNPs, using amplification refractory mutation system polymerase chain reaction (ARMS-PCR) and TaqMan (Applied Biosystems, Foster City, CA, USA) 5' nuclease assays for allelic discrimination. No significant associations were seen.",N,IL-6 -174,IL6,0.428571429
661,bc_id702,CANCER,VEGFA,15265021,B,Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.,2004,These results suggest that the role of cytokine promoter SNPs in both susceptibility to and prognosis in breast cancer requires further investigation in a larger study.,"A total of 144 female breast cancer patients and 263 cancer-free population controls were genotyped for the interleukin (IL)-1beta-511 (T/C), IL-6 -174 (G/C), tumour necrosis factor (TNF)-alpha-308 (A/G), IL-10 -1082 (A/G), IL-8 -251 (A/T) and vascular endothelial growth factor (VEGF) -1154 (A/G) SNPs, using amplification refractory mutation system polymerase chain reaction (ARMS-PCR) and TaqMan (Applied Biosystems, Foster City, CA, USA) 5' nuclease assays for allelic discrimination. No significant associations were seen.",N,vascular endothelial growth factor (VEGF) -1154,VEGFA,0.333333333
662,bc_id703,CANCER,BRCA2,15265971,B,Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,2004,,X,X,X,X,0
663,bc_id704,CANCER,BRCA1,15265971,B,Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,2004,,"Women with BRCA1 mutations who breast-fed for more than 1 year were less likely to have breast cancer than those who never breast-fed (OR = 0.55, 95% CI = 0.38 to 0.80; P =.001), although no such association was seen for BRCA2 (OR = 0.95, 95% CI = 0.56 to 1.59; P =.83).",Y,BRCA1,BRCA1,0.326180258
664,bc_id705,CANCER,AURKA,15271853,B,STK15 polymorphism and breast cancer risk in a population-based study.,2004,These results suggest that STK15 may represent a low penetrance type breast cancer susceptibility gene.,These results suggest that STK15 may represent a low penetrance type breast cancer susceptibility gene.,A,STK15,AURKA,0.5
665,bc_id706,CANCER,STK6,15271856,B,Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma.,2004,No significant association was observed between the polymorphism and metastasis and disease stage of the cancer. These findings suggest that the Phe31Ile polymorphism in Aurora A may be a genetic modifier for developing breast carcinoma.,X,X,X,X,0
666,bc_id707,CANCER,BRCA2,15280188,B,Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population.,2005,Southern Italian women seem highly interested in genetic testing for breast cancer risk.,X,X,X,X,0
667,bc_id708,CANCER,BRCA1,15280188,B,Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population.,2005,Southern Italian women seem highly interested in genetic testing for breast cancer risk.,X,X,X,X,0
668,bc_id709,CANCER,BRCA2,15280342,B,"Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.",2004,An interactive computer program was more effective than standard genetic counseling for increasing knowledge of breast cancer and genetic testing among women at low risk of carrying a BRCA1 or BRCA2 mutation.,An interactive computer program was more effective than standard genetic counseling for increasing knowledge of breast cancer and genetic testing among women at low risk of carrying a BRCA1 or BRCA2 mutation.,A,BRCA2,BRCA2,0.576923077
669,bc_id710,CANCER,BRCA1,15280342,B,"Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.",2004,An interactive computer program was more effective than standard genetic counseling for increasing knowledge of breast cancer and genetic testing among women at low risk of carrying a BRCA1 or BRCA2 mutation.,An interactive computer program was more effective than standard genetic counseling for increasing knowledge of breast cancer and genetic testing among women at low risk of carrying a BRCA1 or BRCA2 mutation.,A,BRCA1,BRCA1,0.60944206
670,bc_id711,CANCER,GSTM1,15280903,B,Breast cancer: role of polymorphisms inbiotransformation enzymes,2004,"In conclusion, the results suggest that genetic polymorphisms in biotransformation enzymes may play a significant role in the development of breast cancer.","Combinations of either GSTM1null or GSTP1*2 with low activity of EPHX1 presented significant risk of breast cancer (OR = 1.88, CI = 1.00-3.52, P = 0.049 and OR = 2.40, CI = 1.15-5.00, P = 0.019, respectively) as well. In conclusion, the results suggest that genetic polymorphisms in biotransformation enzymes may play a significant role in the development of breast cancer.",A,GSTM1,GSTM1,0.339622642
671,bc_id712,CANCER,EPHX1,15280903,B,Breast cancer: role of polymorphisms inbiotransformation enzymes,2004,"In conclusion, the results suggest that genetic polymorphisms in biotransformation enzymes may play a significant role in the development of breast cancer.","Combinations of either GSTM1null or GSTP1*2 with low activity of EPHX1 presented significant risk of breast cancer (OR = 1.88, CI = 1.00-3.52, P = 0.049 and OR = 2.40, CI = 1.15-5.00, P = 0.019, respectively) as well. In conclusion, the results suggest that genetic polymorphisms in biotransformation enzymes may play a significant role in the development of breast cancer.",A,EPHX1,EPHX1,1
672,bc_id713,CANCER,NQO1,15280903,B,Breast cancer: role of polymorphisms inbiotransformation enzymes,2004,"In conclusion, the results suggest that genetic polymorphisms in biotransformation enzymes may play a significant role in the development of breast cancer.",The distribution of genotypes in exon 6 of NQO1 was significantly different between the control group and breast cancer cases.,Y,NQO1,NQO1,0.5
673,bc_id714,CANCER,CYP1B1,15285606,Y,[Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer],2004,"Risk of endometrial, but not breast, cancer was significantly higher in carriers of CYP1B1 genotype Val432/Val. This was explained by stronger estrogen dependence and, consequently, higher estrogen reactivity of the endometrium as compared with the mammary gland.","Risk of endometrial, but not breast, cancer was significantly higher in carriers of CYP1B1 genotype Val432/Val. This was explained by stronger estrogen dependence and, consequently, higher estrogen reactivity of the endometrium as compared with the mammary gland.",Y,CYP1B1,CYP1B1,0.358974359
674,bc_id715,CANCER,COMT,15285606,B,[Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer],2004,"Risk of endometrial, but not breast, cancer was significantly higher in carriers of CYP1B1 genotype Val432/Val. This was explained by stronger estrogen dependence and, consequently, higher estrogen reactivity of the endometrium as compared with the mammary gland.",The COMT polymorphism showed no significant association with breast or endometrial cancer.,N,COMT,COMT,0.29787234
675,bc_id716,CANCER,IGFBP3,15298948,Y,Genetic Polymorphisms in the IGFBP3 Gene:Association with Breast Cancer Risk and Blood IGFBP-3 Protein Levels among Chinese Women,2004,These results indicated that IGFBP3 polymorphisms may be associated with the level of blood IGFBP-3 protein and an increased risk of breast cancer.,These results indicated that IGFBP3 polymorphisms may be associated with the level of blood IGFBP-3 protein and an increased risk of breast cancer.,A,IGFBP3,IGFBP3,0.428571429
676,bc_id717,CANCER,NQO1,15298951,B,Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms.,2004,,Breast cancer was not significantly associated with NQO1 genotype.,N,NQO1,NQO1,0.25
677,bc_id718,CANCER,CYP19A1,15298966,B,The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese.,2004,,"There was no association between CYP19 gene polymorphism and breast cancer risk in the study group as a whole, but homozygous and heterozygous carriers of the variant Arg allele showed a significantly increased risk of breast cancer among premenopausal women with a late age at first full-term pregnancy (OR 7.31, 95% CI 1.88-28.5) or a high body mass index (OR 2.77, 95% CI 1.12-6.87).",N,CYP19,CYP19A1,0.181818182
678,bc_id719,CANCER,GSTT1,15302996,B,Glutathione S-transferase genotype GSTM1 as a predictor of elevated angiogenic phenotype in patients with early onset breast cancer.,2005,,"This was even more evident for women with a breast cancer onset before the age of 35 (106.9 +/- 11.9 vs. 61.8 +/- 9.8; P =0.011).Multivariate logistic regression analysis of GSTM1 and GSTT1 genotypes, histologic grade, axillary node status and age at diagnosis demonstrate the independent association between GSTM1 genotypes and angiogenesis and the association of GSTM1 -wild type genotype with high MVD index (adjusted OR = 5.98, 95% CI 1.28-28.10, P = 0.023).",Y,GSTT1,GSTT1,0.578947368
679,bc_id720,CANCER,GSTM1,15302996,B,Glutathione S-transferase genotype GSTM1 as a predictor of elevated angiogenic phenotype in patients with early onset breast cancer.,2005,,"This was even more evident for women with a breast cancer onset before the age of 35 (106.9 +/- 11.9 vs. 61.8 +/- 9.8; P =0.011).Multivariate logistic regression analysis of GSTM1 and GSTT1 genotypes, histologic grade, axillary node status and age at diagnosis demonstrate the independent association between GSTM1 genotypes and angiogenesis and the association of GSTM1 -wild type genotype with high MVD index (adjusted OR = 5.98, 95% CI 1.28-28.10, P = 0.023).",Y,GSTM1,GSTM1,0.452830189
680,bc_id721,CANCER,TGFBR2,15305380,B,Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers.,2004,"Thus, none of the studied polymorphisms from the TGF-beta1 and its receptor genes was found to influence significantly susceptibility to breast cancer. The possible contribution of 6A/6A homozygosity in the TGF-betaRI gene to breast cancer needs to be confirmed in an independent study.",X,X,X,X,0
681,bc_id722,CANCER,TGFBR1,15305380,B,Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers.,2004,"Thus, none of the studied polymorphisms from the TGF-beta1 and its receptor genes was found to influence significantly susceptibility to breast cancer. The possible contribution of 6A/6A homozygosity in the TGF-betaRI gene to breast cancer needs to be confirmed in an independent study.",The possible contribution of 6A/6A homozygosity in the TGF-betaRI gene to breast cancer needs to be confirmed in an independent study.,N,TGF-beta1,TGFBR1,0.666666667
682,bc_id723,CANCER,TGFB1,15305380,B,Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers.,2004,"Thus, none of the studied polymorphisms from the TGF-beta1 and its receptor genes was found to influence significantly susceptibility to breast cancer. The possible contribution of 6A/6A homozygosity in the TGF-betaRI gene to breast cancer needs to be confirmed in an independent study.","However, no statistically significant difference between the breast cancer and healthy control groups was found for any of the 8 polymorphisms nor did the haplotype or genotype combination analysis reach statistical significance. Thus, none of the studied polymorphisms from the TGF-beta1 and its receptor genes was found to influence significantly susceptibility to breast cancer.",N,TGF-beta1,TGFB1,0.296296296
683,bc_id724,CANCER,SHC1,15308584,N,The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect inbreast cancer.,2004,"A genotype combination analysis of the nonsynonymous polymorphisms in the IRS1, IRS2 and SHC1 genes did not show any effect on breast cancer risk.","A genotype combination analysis of the nonsynonymous polymorphisms in the IRS1, IRS2 and SHC1 genes did not show any effect on breast cancer risk.",N,SHC1,SHC1,0.5
684,bc_id725,CANCER,IRS2,15308584,N,The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect inbreast cancer.,2004,"A genotype combination analysis of the nonsynonymous polymorphisms in the IRS1, IRS2 and SHC1 genes did not show any effect on breast cancer risk.","A genotype combination analysis of the nonsynonymous polymorphisms in the IRS1, IRS2 and SHC1 genes did not show any effect on breast cancer risk.",N,IRS2,IRS2,0.333333333
685,bc_id726,CANCER,IRS1,15308584,N,The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect inbreast cancer.,2004,"A genotype combination analysis of the nonsynonymous polymorphisms in the IRS1, IRS2 and SHC1 genes did not show any effect on breast cancer risk.","A genotype combination analysis of the nonsynonymous polymorphisms in the IRS1, IRS2 and SHC1 genes did not show any effect on breast cancer risk.",N,IRS1,IRS1,0.666666667
686,bc_id727,CANCER,MTHFR,15312365,Y,[Association between genetic polymorphisms in methylenetetrahydrofolate reductase and risk of breast cancer],2004,These findings suggest that 677CT polymorphism in MTHFR may be a genetic susceptibility factor for breast cancer among Chinese women.,These findings suggest that 677CT polymorphism in MTHFR may be a genetic susceptibility factor for breast cancer among Chinese women.,A,MTHFR,MTHFR,0.403846154
687,bc_id728,CANCER,BRCA2,15317758,B,Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort.,2004,,"In this exploratory analysis, we found little indication that common variation in BRCA2 dramatically impacts sporadic breast cancer risk. However, a significant elevation in risk was observed among approximately 6% of women who carried a specific haplotype pattern and may harbor a susceptibility allele at the BRCA2 locus.",A,BRCA2,BRCA2,0.576923077
688,bc_id729,CANCER,SULT1A1,15318931,B,"UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.",2004,"The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.","The variant allele of UGT1A1 was associated with reduced risk of an ER- tumor (P for trend = 0.03), and variants of UGT2B15 and SULT1A1 were associated with non-statistically significant risk reductions... The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.",A,SULT,SULT1A1,0.387096774
689,bc_id730,CANCER,UGT2B15,15318931,B,"UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.",2004,"The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.","The variant allele of UGT1A1 was associated with reduced risk of an ER- tumor (P for trend = 0.03), and variants of UGT2B15 and SULT1A1 were associated with non-statistically significant risk reductions... The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.",A,UGT,UGT2B15,0.333333333
690,bc_id731,CANCER,UGT2B4,15318931,B,"UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.",2004,"The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.",X,X,X,X,0
691,bc_id732,CANCER,UGT2B7,15318931,B,"UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.",2004,"The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.",X,X,X,X,0
692,bc_id733,CANCER,UGT1A1,15318931,B,"UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients.",2004,"The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.","The variant allele of UGT1A1 was associated with reduced risk of an ER- tumor (P for trend = 0.03), and variants of UGT2B15 and SULT1A1 were associated with non-statistically significant risk reductions... The risk of ER- breast cancer tumors may vary by UGT or SULT genotype. Further, plasma estradiol and testosterone concentrations in breast cancer patients may differ depending on some UGT and SULT genotypes.",A,UGT,UGT1A1,0.7
693,bc_id734,CANCER,BRCA2,15319244,B,BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients.,2004,,Patients with bilateral BC having BRCA mutations are significantly younger than non-carriers. They also have a significantly higher family history of BC and an increased risk of developing ovarian cancer.,Y,BRCA,BRCA2,0.324175824
694,bc_id735,CANCER,BRCA1,15319244,B,BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients.,2004,,Patients with bilateral BC having BRCA mutations are significantly younger than non-carriers. They also have a significantly higher family history of BC and an increased risk of developing ovarian cancer.,Y,BRCA,BRCA1,0.326180258
695,bc_id736,CANCER,UGT2B4,15319348,B,Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population.,2004,"Our findings provide fundamental and useful information for genotyping UGT2B4 and UGT2B7 in the Japanese, and probably other populations.",NR,NR,NR,NR,0
696,bc_id737,CANCER,UGT2B7,15319348,B,Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population.,2004,"Our findings provide fundamental and useful information for genotyping UGT2B4 and UGT2B7 in the Japanese, and probably other populations.",NR,NR,NR,NR,0
697,bc_id738,CANCER,VDR,15328186,B,Vitamin D receptor gene polymorphisms and breast cancer risk.,2004,VDR polymorphisms are associated with breast cancer risk and may be associated with disease progression.,VDR polymorphisms are associated with breast cancer risk and may be associated with disease progression.,A,VDR,VDR,0.538461538
698,bc_id739,CANCER,RNASEL,15330212,N,Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer.,2004,Although an increasing number of studies report an association between the RNASEL G1385A variant and prostate cancer risk; this variant does not appear to be implicated in the development of breast cancer.,Although an increasing number of studies report an association between the RNASEL G1385A variant and prostate cancer risk; this variant does not appear to be implicated in the development of breast cancer.,N,RNASEL G1385A,RNASEL,0.5
699,bc_id740,CANCER,ACACA,15333468,Y,Acetyl-CoA carboxylase {alpha} gene and breast cancer susceptibility,2004,"This study provides a first insight into the involvement of the ACCalpha gene in breast cancer predisposition and calls for further, large-scale studies that will be needed to understand the role of ACCalpha in tumour susceptibility and development.","This study provides the first insight into the involvement of the ACCalpha gene in breast cancer predisposition and calls for further, large-scale studies that will be needed to understand the role of ACCalpha in tumour susceptibility and development.",A,ACCalpha,ACACA,0.5
700,bc_id741,CANCER,GSTT1,15342448,B,"Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis.",2004,,X,X,X,X,0
701,bc_id742,CANCER,GSTP1,15342448,B,"Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis.",2004,,X,X,X,X,0
702,bc_id743,CANCER,GSTM1,15342448,B,"Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis.",2004,,X,X,X,X,0
703,bc_id744,CANCER,GSTM1,15344211,B,Glutathione S-transferase M1 status and breast cancer risk: a meta-analysis.,2004,,Further studies focusing on the structure of haplotype blocks of GSTM1 are required in order to find a specific haplotype with a predisposing breast cancer susceptibility allele.,Y,GSTM1,GSTM1,0.452830189
704,bc_id745,CANCER,BRCA2,15345109,B,BRCA1 mutations in a population-based study of breast cancer in Stockholm County.,2005,,X,X,X,X,0
705,bc_id746,CANCER,BRCA1,15345109,B,BRCA1 mutations in a population-based study of breast cancer in Stockholm County.,2005,,Mutations in BRCA1 in unselected breast cancer cases in our region are rare and likely to be found only in high-risk families,A,BRCA1,BRCA1,0.60944206
706,bc_id747,CANCER,DNASE1,15363449,B,A novel 56-bp variable tandem repeat polymorphism in the human deoxyribonuclease I gene and its population data.,2004,"Although there was a general uniformity for the polymorphism in the Japanese population, significant differences in genotype distribution were found between the Japanese and German populations. Furthermore, linkage disequilibrium between the HumDN1 and DNase I protein polymorphisms was revealed.",NR,NR,NR,NR,0
707,bc_id748,CANCER,BRCA2,15365993,B,BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.,2004,,"Considering that the majority of breast cancer cases are sporadic, the present study will be helpful in the evaluation of the need for the genetic screening of germline BRCA mutations in sporadic breast cancer patients. Further study using a larger sample size is required to determine the merits of genetic diagnosis and counseling in breast cancer patients.",A,BRCA,BRCA2,0.576923077
708,bc_id749,CANCER,BRCA1,15365993,B,BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.,2004,,"Considering that the majority of breast cancer cases are sporadic, the present study will be helpful in the evaluation of the need for the genetic screening of germline BRCA mutations in sporadic breast cancer patients. Further study using a larger sample size is required to determine the merits of genetic diagnosis and counseling in breast cancer patients.",A,BRCA,BRCA1,0.60944206
709,bc_id750,CANCER,ERBB2,15374636,B,Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women.,2004,"This association was not found to be significant in the present study. The association between HER-2 genotypes frequency and clinicopathological data was also insignificant, suggesting that the HER-2 polymorphism at codon 655 is unlikely to be a susceptibility locus in Iranian patients with breast cancer.","The association between HER-2 genotypes frequency and clinicopathological data was also insignificant, suggesting that the HER-2 polymorphism at codon 655 is unlikely to be a susceptibility locus in Iranian patients with breast cancer.",A,HER-2,ERBB2,0.452380952
710,bc_id751,CANCER,ADH1C,15375565,B,Risk factors in alcohol associated breast cancer: alcohol dehydrogenase polymorphism and estrogens.,2004,,The data demonstrate that moderate alcohol consumers with the ADH1C*1 allele have an increased risk to develop breast cancer and even small amounts of alcohol increase serum estradiol levels significantly in premenopausal women especially in the midphase of the menstrual cycle.,Y,ADH1C*1,ADH1C,0.333333333
711,bc_id752,CANCER,SULT1A1,15377847,B,Genetic variants of the sulfotransferase 1A1 and breast cancer risk.,2004,"We conclude that  the SULT1A1 R213H polymorphism is not a general risk factor for breast cancer, but may be involved in lymph node metastazing in breast cancer patients.","We conclude that  the SULT1A1 R213H polymorphism is not a general risk factor for breast cancer, but may be involved in lymph node metastazing in breast cancer patients.",A,SULT1A1 R213H,SULT1A1,0.387096774
712,bc_id753,CANCER,IGF1,15386404,B,Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women.,2005,,"The meta-analysis results indicated that IGF-I genotypes containing the (CA)19 were consistently associated with increased risk of breast cancer across studies (overall OR = 1.22, 95% CI: 1.06-1.41, p for heterogeneity test = 0.524).",Y,IGF-I,IGF1,0.35
713,bc_id754,CANCER,CYP1B1,15386537,B,Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility.,2005,,"When MnSOD Ala was combined with either cytochrome P450 1B1 CYP1B1*1 and catechol O-methyltransferase COMT-L (V158M) genotypes, the risk for developing breast cancer was significantly increased in patients with a body mass index (BMI) greater than 24 kg m(-2) (OR: 1.42 (95%CI=1.04-1.93)).",Y,CYP1B1*1,CYP1B1,0.358974359
714,bc_id755,CANCER,SOD2,15386537,B,Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility.,2005,,X,X,X,X,0
715,bc_id756,CANCER,COMT,15386537,B,Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility.,2005,,"When MnSOD Ala was combined with either cytochrome P450 1B1 CYP1B1*1 and catechol O-methyltransferase COMT-L (V158M) genotypes, the risk for developing breast cancer was significantly increased in patients with a body mass index (BMI) greater than 24 kg m(-2) (OR: 1.42 (95%CI=1.04-1.93)).",Y,COMT-L,COMT,0.276595745
716,bc_id757,CANCER,COMT,15388245,B,Catechol-O-methyltransferase Val 108/158 Met polymorphism in premenopausal breast cancer patients.,2004,,"In conclusion, the COMT-L allele and COMT-LL genotype are genetic risk factors for sporadic breast cancer in premenopausal Turkish women.",Y,COMT-L,COMT,0.276595745
717,bc_id758,CANCER,ATM,15450731,N,Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy,2004,Our results do not support the hypothesis that breast cancer patients carrying a sequence variant in the ATM gene differentially benefit from postoperative radiotherapy. These findings have to be verified using larger number of cases to clarify the clinical consequences of sequence variants in the ATM gene.,Our results do not support the hypothesis that breast cancer patients carrying a sequence variant in the ATM gene differentially benefit from postoperative radiotherapy.,N,ATM,ATM,0.244444444
718,bc_id759,CANCER,SLC45A2,15455243,B,MATP polymorphisms in Germans and Japanese: theL374F mutation as a population marker for Caucasoids.,2004,This extreme difference in allele frequency suggests that the L374F mutation is valuable as a population and ancestry informative marker for Caucasoids.,NR,NR,NR,NR,0
719,bc_id760,CANCER,GSTT1,15455371,B,Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.,2004,"Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.","We studied the 3 genes involved in CE detoxification by conjugation reactions involving methylation (catechol-O-methyltransferase, COMT), sulfation (sulfotransferase 1A1, SULT1A1), or glucuronidation (UDP-glucuronosyltransferase 1A1, UGT1A1), one (manganese superoxide dismutase, MnSOD) involved in protection against reactive oxidative species-mediated oxidation during the conversion of CE-semiquinone (CE-SQ) to CE-quinone (CE-Q), and 2 of the glutathione S-transferase superfamily, GSTM1 and GSTT1, involved in CE-Q metabolism... Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.",A,GSTT1,GSTT1,0.289473684
720,bc_id761,CANCER,SULT1A1,15455371,B,Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.,2004,"Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.","We studied the 3 genes involved in CE detoxification by conjugation reactions involving methylation (catechol-O-methyltransferase, COMT), sulfation (sulfotransferase 1A1, SULT1A1), or glucuronidation (UDP-glucuronosyltransferase 1A1, UGT1A1), one (manganese superoxide dismutase, MnSOD) involved in protection against reactive oxidative species-mediated oxidation during the conversion of CE-semiquinone (CE-SQ) to CE-quinone (CE-Q), and 2 of the glutathione S-transferase superfamily, GSTM1 and GSTT1, involved in CE-Q metabolism... Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.",A,SULT1A1,SULT1A1,0.387096774
721,bc_id762,CANCER,SOD2,15455371,B,Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.,2004,"Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.",X,X,X,X,0
722,bc_id763,CANCER,UGT1A1,15455371,B,Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.,2004,"Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.","We studied the 3 genes involved in CE detoxification by conjugation reactions involving methylation (catechol-O-methyltransferase, COMT), sulfation (sulfotransferase 1A1, SULT1A1), or glucuronidation (UDP-glucuronosyltransferase 1A1, UGT1A1), one (manganese superoxide dismutase, MnSOD) involved in protection against reactive oxidative species-mediated oxidation during the conversion of CE-semiquinone (CE-SQ) to CE-quinone (CE-Q), and 2 of the glutathione S-transferase superfamily, GSTM1 and GSTT1, involved in CE-Q metabolism... Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.",A,UGT1A1,UGT1A1,0.7
723,bc_id764,CANCER,GSTM1,15455371,B,Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.,2004,"Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.","We studied the 3 genes involved in CE detoxification by conjugation reactions involving methylation (catechol-O-methyltransferase, COMT), sulfation (sulfotransferase 1A1, SULT1A1), or glucuronidation (UDP-glucuronosyltransferase 1A1, UGT1A1), one (manganese superoxide dismutase, MnSOD) involved in protection against reactive oxidative species-mediated oxidation during the conversion of CE-semiquinone (CE-SQ) to CE-quinone (CE-Q), and 2 of the glutathione S-transferase superfamily, GSTM1 and GSTT1, involved in CE-Q metabolism... Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.",A,GSTM1,GSTM1,0.339622642
724,bc_id765,CANCER,COMT,15455371,B,Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.,2004,"Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.","We studied the 3 genes involved in CE detoxification by conjugation reactions involving methylation (catechol-O-methyltransferase, COMT), sulfation (sulfotransferase 1A1, SULT1A1), or glucuronidation (UDP-glucuronosyltransferase 1A1, UGT1A1), one (manganese superoxide dismutase, MnSOD) involved in protection against reactive oxidative species-mediated oxidation during the conversion of CE-semiquinone (CE-SQ) to CE-quinone (CE-Q), and 2 of the glutathione S-transferase superfamily, GSTM1 and GSTT1, involved in CE-Q metabolism... Based on comprehensive CE metabolizing gene profiles, our study provides support to the hypotheses that breast cancer can be initiated by estrogen exposure and that increased estrogen exposure confers a higher risk of breast cancer by causing DSB to DNA.",A,COMT,COMT,0.425531915
725,bc_id766,CANCER,CHEK2,15466005,B,Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.,2004,,"We conclude that carrying the CHEK2*1100delC mutation is an adverse prognostic indicator for breast cancer. If independently confirmed by others, intensive surveillance, and possibly preventive measures, should be considered for newly diagnosed breast cancer cases carrying the CHEK2*1100delC variant.",Y,CHEK2*1100delC,CHEK2,0.383333333
726,bc_id767,CANCER,CHEK2,15472904,N,Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.,2004,"No significant correlation was seen between CHEK2 status and hormone receptor status, histology, lymph node status, or overall survival.","The c.1100delC mutation is associated with familial breast cancer, and tumors from mutation carriers show reduced or absent CHEK2 protein expression.",N,CHEK2,CHEK2,0.233333333
727,bc_id768,CANCER,GSTP1,15479622,B,Genetic polymorphism of glutathione S-transferase P1 and breast cancer risk.,2004,,Our findings suggest that the GSTP1 polymorphism influences individual susceptibility to breast cancer in the Korean women and this effect may be modified by alcohol consumption.,Y,GSTP1,GSTP1,0.428571429
728,bc_id769,CANCER,CHEK2,15488637,B,Analysis of familial male breast cancer for germline mutations in CHEK2.,2004,One individual was found to harbour the 1100delC variant. No other mutations were identified. Variants other than 1100delC are rare in male breast cancer.,To extend our knowledge on the role of CHEK2 in susceptibility to male breast cancer we have screened a series of 26 breast cancer cases with male representation for germline sequence variation in the CHEK2 gene. One individual was found to harbour the 1100delC variant. No other mutations were identified. Variants other than 1100delC are rare in male breast cancer.,A,CHEK2,CHEK2,0.383333333
729,bc_id770,CANCER,PIG3,15491642,Y,Absence of association with cancer risk and low frequency of alterations at a p53 responsive PIG3 gene polymorphism in breast and lung carcinomas.,2004,"Taken together, these data do not support the notion that this PIG3 polymorphism is associated with an increased risk for cancer susceptibility. Larger studies including other types of cancer should also be performed.","Therefore, in the present analysis we examined this polymorphism in two common human cancers, lung and breast and compared it with corresponding control cases... Taken together, these data do not support the notion that this PIG3 polymorphism is associated with an increased risk for cancer susceptibility.",N,PIG3,TP53I3,1
730,bc_id771,CANCER,MPO,15492293,Y,"Myeloperoxidase genotype, fruit and vegetable consumption, and breast cancer risk.",2004,"Results from this first study of MPO genotypes and breast cancer risk indicate that MPO variants, related to reduced generation of ROS, are associated with decreased breast cancer risk, and emphasize the importance of fruit and vegetable consumption in reduction of breast cancer risk.","Results from this first study of MPO genotypes and breast cancer risk indicate that MPO variants, related to reduced generation of ROS, are associated with decreased breast cancer risk, and emphasize the importance of fruit and vegetable consumption in reduction of breast cancer risk.",Y,MPO,MPO,0.428571429
731,bc_id772,CANCER,CYP3A4,15496535,B,CYP3A4 Polymorphisms--Potential Risk Factors for Breast and Prostate Cancer: A HuGE Review,2004,"HuGE Review-These observations support the notion that development of robust, conventional molecular epidemiologic case-control studies to address these questions, including gene-gene and gene-environment interactions, will be timely.","The CYP3A4 gene is expressed in the liver, gut, colon, prostate, and breast. Individual variation in CYP3A4 may play a role in breast and prostate carcinogenesis through modulation of sex hormone metabolite levels... However, an Australian breast cancer case-control study found no association with CYP3A4*1B. Two Scottish prospective studies showed CYP3A4*1B to be a risk factor for prostate cancer among men with benign prostatic hyperplasia. Three other studies were undertaken in the United States: two were case-only studies and the other was a case-sibling control study.",A,CYP3A4*1B,CYP3A4,0.363636364
732,bc_id774,CANCER,AGTR1,15498791,B,Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore.,2005,,Our findings suggest that pharmacological inhibition of the angiotensin II effect by blockade of ACE and/or AGTR1 could be potential targets for the prevention and treatment of breast cancer.,Y,AGTR1,AGTR1,0.5
733,bc_id776,CANCER,ACE,15498791,B,Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore.,2005,,Our findings suggest that pharmacological inhibition of the angiotensin II effect by blockade of ACE and/or AGTR1 could be potential targets for the prevention and treatment of breast cancer.,Y,ACE,ACE,0.285714286
734,bc_id773,CANCER,AGTR2,15498791,B,Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore.,2005,,X,X,X,X,0
735,bc_id775,CANCER,AGT,15498791,B,Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore.,2005,,X,X,X,X,0
736,bc_id777,CANCER,AHR,15499202,B,Genetic Variations of the AHR Gene Encoding Aryl Hydrocarbon Receptor in a Japanese Population,2004,The allele frequencies were 0.010 for 1459A>G (Asn487Asp) and 0.002 for the other 3 variations. Also detected in this analysis was the known nonsynonymous single nucleotide polymorphism 1661G>A (Arg554Lys) at a 0.444 frequency.,NR,NR,NR,NR,0
737,bc_id778,CANCER,MPO,15507753,B,Genomic variations in myeloperoxidase gene in the Japanese population.,2004,"The frequency of mutation in the exon 9 coding region was estimated to be one heterozygote in 129, thus the homozygote of such mutations would be revealed one in 16,000 in the Japanese population.",NR,NR,NR,NR,0
738,bc_id779,CANCER,MTHFR,15510613,N,Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype.,2004,The common MTHFR C677T and TS enhancer region polymorphisms were not risk factors for breast cancer in this patient cohort nor were they associated with phenotypic features or with prognosis.,The common MTHFR C677T and TS enhancer region polymorphisms were not risk factors for breast cancer in this patient cohort nor were they associated with phenotypic features or with prognosis.,N,MTHFR C677T,MTHFR,0.326923077
739,bc_id780,CANCER,TYMS,15510613,B,Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype.,2004,The common MTHFR C677T and TS enhancer region polymorphisms were not risk factors for breast cancer in this patient cohort nor were they associated with phenotypic features or with prognosis.,The common MTHFR C677T and TS enhancer region polymorphisms were not risk factors for breast cancer in this patient cohort nor were they associated with phenotypic features or with prognosis.,N,TS,TYMS,0.3
740,bc_id781,CANCER,BRCA2,15519522,Y,A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?,2004,"The possible modifying effect on MBC risk in subjects carrying BRCA1/2 germ-line mutations of an occupation characterised by exposure to chemicals such as polycyclic aromatic hydrocarbons (PAH) that are capable of inducing DNA damage, may provide clues to the role of environmental exposures in modifying BC risk in mutation carriers in both genders.","The possible modifying effect on MBC risk in subjects carrying BRCA1/2 germ-line mutations of an occupation characterised by exposure to chemicals such as polycyclic aromatic hydrocarbons (PAH) that are capable of inducing DNA damage, may provide clues to the role of environmental exposures in modifying BC risk in mutation carriers in both genders.",A,BRCA1/2,BRCA2,0.576923077
741,bc_id782,CANCER,BRCA1,15519522,Y,A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?,2004,"The possible modifying effect on MBC risk in subjects carrying BRCA1/2 germ-line mutations of an occupation characterised by exposure to chemicals such as polycyclic aromatic hydrocarbons (PAH) that are capable of inducing DNA damage, may provide clues to the role of environmental exposures in modifying BC risk in mutation carriers in both genders.","The possible modifying effect on MBC risk in subjects carrying BRCA1/2 germ-line mutations of an occupation characterised by exposure to chemicals such as polycyclic aromatic hydrocarbons (PAH) that are capable of inducing DNA damage, may provide clues to the role of environmental exposures in modifying BC risk in mutation carriers in both genders.",A,BRCA1,BRCA1,0.60944206
742,bc_id783,CANCER,CHEK2,15535844,N,"Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.",2004,"The CHEK2 variants are rare in the western Washington population and, based on accumulated evidence across studies, are unlikely to be major breast cancer susceptibility genes. Thus, screening for the 1100delC variant may have limited usefulness in breast cancer prevention programs in the USA.","The CHEK2 variants are rare in the western Washington population and, based on accumulated evidence across studies, are unlikely to be major breast cancer susceptibility genes. Thus, screening for the 1100delC variant may have limited usefulness in breast cancer prevention programs in the USA.",A,CHEK2,CHEK2,0.383333333
743,bc_id784,CANCER,PGR,15535845,B,The progesterone receptor Val660--&gt;Leu polymorphism and breast cancer risk.,2005,,"Progesterone exerts its effect on target cells by interacting with its receptor; thus, genetic variations, which might cause alterations in the biological function in the progesterone receptor (PGR), can potentially contribute to an individual's susceptibility to breast cancer...  Overall, our study does not support an association between the Val660-->Leu PROGINS polymorphism and breast cancer risk.",N,PGR,PGR,0.357142857
744,bc_id785,CANCER,SOD2,15535847,Y,"Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai BreastCancer Study.",2004,The present study provides some evidence that genetic polymorphism in the MnSOD gene may be associated with increased risk of breast cancer among Chinese women with high levels of oxidative stress or low intake of antioxidants. Studies with a larger sample size are needed to confirm the findings.,X,X,X,X,0
745,bc_id786,CANCER,GSTT1,15538046,B,"Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk.",2004,,"Moreover, the breast cancer risk increased in parallel with the number of COMT , GSTM1 , and GSTT1 at-risk genotypes (p for trend = 0.003). This association was particularly clear in pre-menopausal women among whom combination of all three high-risk genotypes posed a 4.1-fold breast cancer risk (95% CI = 1.4-12.7) compared with pre-menopausal women without at-risk genotypes (p for trend = 0.001).",Y,GSTT1,GSTT1,0.578947368
746,bc_id787,CANCER,GSTM1,15538046,B,"Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk.",2004,,"Moreover, the breast cancer risk increased in parallel with the number of COMT , GSTM1 , and GSTT1 at-risk genotypes (p for trend = 0.003). This association was particularly clear in pre-menopausal women among whom combination of all three high-risk genotypes posed a 4.1-fold breast cancer risk (95% CI = 1.4-12.7) compared with pre-menopausal women without at-risk genotypes (p for trend = 0.001).",Y,GSTM1,GSTM1,0.452830189
747,bc_id788,CANCER,COMT,15538046,B,"Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk.",2004,,"Moreover, the breast cancer risk increased in parallel with the number of COMT , GSTM1 , and GSTT1 at-risk genotypes (p for trend = 0.003). This association was particularly clear in pre-menopausal women among whom combination of all three high-risk genotypes posed a 4.1-fold breast cancer risk (95% CI = 1.4-12.7) compared with pre-menopausal women without at-risk genotypes (p for trend = 0.001).",Y,COMT,COMT,0.276595745
748,bc_id789,CANCER,BRCA2,15548363,B,BRCA2 mutations in 154 finnish male breast cancer patients.,2005,,The variation in BRCA2 mutation spectrum between Finnish MBC patients and FBC patients in Finland and breast cancer patients in Iceland suggests that modifying genetic and environmental factors may significantly influence the penetrance of MBC and FBC in individuals carrying germline BRCA2 mutations in some populations.,A,BRCA2,BRCA2,0.576923077
749,bc_id790,CANCER,ERBB2,15550452,Y,The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.,2005,"Computational analyses suggest that the Val654-Val655 allele provokes receptor dimerization and activation, thus stimulating kinase activity and cell transformation. We hypothesize that ERBB2 Val654 represents an oncogenic variant which might, in addition, influence clinical outcome and predict a worse prognosis.","Overexpression of the proto-oncogene ERBB2 (HER2/NEU) has been observed in 20-30% of breast cancers involving poor prognosis.  ... The ERBB2 variant Ile654Val, however, revealed an increased risk for carriers of the heterozygous Val654 allele (OR = 2.56, 95% CI = 1.08-6.08, P = 0.028).",Y,ERBB2,ERBB2,0.285714286
750,bc_id791,CANCER,TP53,15564800,B,"Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.",2004,,"Interestingly, three (3%) p53 mutations in its exon 5 were detected in sporadic breast cancer patients.",A,p53,TP53,0.482758621
751,bc_id792,CANCER,BRCA2,15564800,B,"Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.",2004,,None of the 100 sporadic breast cancer patients revealed any protein truncating or deleterious BRCA1 or BRCA2 gene mutation.,N,BRCA2,BRCA2,0.098901099
752,bc_id793,CANCER,BRCA1,15564800,B,"Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.",2004,,"Although three novel BRCA1 mutations including a founder Ashkenazi Jewish BRCA1 mutation were recorded in Indian women with familial breast cancer, the overall prevalence of BRCA gene mutations in Indian women with a family history of breast cancer appears to be low.",A,BRCA1,BRCA1,0.60944206
753,bc_id794,CANCER,TP53,15573180,B,Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma.,2004,X,X,X,X,X,0
754,bc_id795,CANCER,BRCA2,15576832,B,Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors.,2004,"Differential frequencies and interrelationships of genetic alterations and prognoses in these two age groups indicate that the molecular pathways for the development of tumors in both age groups may not be similar, though the ultimate effect is deregulation of cell cycle checkpoints and defects in the DNA repair pathway.",X,X,X,X,0
755,bc_id796,CANCER,BRCA1,15576832,B,Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors.,2004,"Differential frequencies and interrelationships of genetic alterations and prognoses in these two age groups indicate that the molecular pathways for the development of tumors in both age groups may not be similar, though the ultimate effect is deregulation of cell cycle checkpoints and defects in the DNA repair pathway.",X,X,X,X,0
756,bc_id797,CANCER,NBN,15578693,B,NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia.,2005,"Overall, our data suggest that the NBS1 657del5 allele may contribute only to a limited fraction of breast cancer cases in Russia.","Overall, our data suggest that the NBS1 657del5 allele may contribute only to a limited fraction of breast cancer cases in Russia.",A,NBS1 657del5,NBN,0.571428571
757,bc_id798,CANCER,CYP1A1,15583370,B,"Serum polychlorinated biphenyls, cytochrome P-450 1A1 polymorphisms, and risk of breast cancer in Connecticut women.",2004,", the CYP1A1 m2 genetic polymorphism was associated with increased risk of female breast cancer and may modify the relation between PCB exposure and breast cancer risk.","In summary, the CYP1A1 m2 genetic polymorphism was associated with increased risk of female breast cancer and may modify the relation between PCB exposure and breast cancer risk.",Y,CYP1A1,CYP1A1,0.304347826
758,bc_id799,CANCER,BRCA2,15589605,B,The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.,2005,"The high incidence of ovarian cancer suggests that oophorectomy should be recommended in female BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer, especially those with stage I disease.","The high incidence of ovarian cancer suggests that oophorectomy should be recommended in female BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer, especially those with stage I disease.",A,BRCA2,BRCA2,0.576923077
759,bc_id800,CANCER,BRCA1,15589605,B,The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.,2005,"The high incidence of ovarian cancer suggests that oophorectomy should be recommended in female BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer, especially those with stage I disease.","The high incidence of ovarian cancer suggests that oophorectomy should be recommended in female BRCA1 and BRCA2 mutation carriers with a diagnosis of breast cancer, especially those with stage I disease.",A,BRCA1,BRCA1,0.60944206
760,bc_id801,CANCER,PTGS2,15596291,Y,Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer.,2005,"In conclusion, our results suggest that polymorphisms in nucleotide -1186, which is in the NF-kappaB binding promoter region of the COX-2 gene, may be associated with an increased risk of bladder cancer. Further research is needed to investigate the functional implications of the polymorphisms of the COX-2 promoter gene in human cancer.",NR,NR,NR,NR,0
761,bc_id802,CANCER,CYP3A5,15596297,Y,"Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients.",2005,"Taken together, these data suggest that racial differences in CYP3A5 polymorphisms exist although the polymorphisms do not appear to be associated with levels of TAM metabolites and side effects.","The data indicate that 40.7% of the breast cancer patients had the CYP3A5*3 polymorphism, and 9.1% had the CYP3A5*6 polymorphism... Taken together, these data suggest that racial differences in CYP3A5 polymorphisms exist although the polymorphisms do not appear to be associated with levels of TAM metabolites and side effects.",N,CYP3A5,CYP3A5,0.4
762,bc_id803,CANCER,ERCC2,15598760,B,"Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk.",2004,,"Overall, this study suggests that those individuals with this polymorphism in the XPD gene may face an increased risk of breast cancer from PAH-DNA adducts and cigarette smoking.",A,XPD,ERCC2,0.6875
763,bc_id804,CANCER,ERCC2,15598761,B,ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population.,2004,,"To our knowledge, this is the first study assigning breast cancer risk to both the ERCC2 genotype encoding Asp(312)Asp and the haplotype encoding Asp(312)/Gln(751).",Y,ERCC2,ERCC2,0.125
764,bc_id805,CANCER,AURKA,15598762,B,Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer.,2004,"The findings from this study are consistent with the evidence from invitro and in vivo experiments, implicating an etiologic role of the STK15 gene in human breast cancer, and provide evidence for the modifying effects of genetic background on human cancer risk.","The findings from this study are consistent with the evidence from invitro and in vivo experiments, implicating an etiologic role of the STK15 gene in human breast cancer, and provide evidence for the modifying effects of genetic background on human cancer risk.",A,STK15,AURKA,0.5
765,bc_id806,CANCER,MTHFR,15598763,B,"MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study.",2004,,These findings suggest that the MTHFR 677TT genotype may confer a 40% decreased breast cancer risk in postmenopausal women using HRT.,A,MTHFR 677TT,MTHFR,0.403846154
766,bc_id807,CANCER,CASP8,15601643,Y,Association of a common variant of the CASP8 gene with reduced risk of breast cancer.,2004,"The reproducible, dose-dependent association of CASP8 D302H with breast cancer indicates the potential importance of inherited variation in the apoptosis pathway in breast cancer susceptibility.","The reproducible, dose-dependent association of CASP8 D302H with breast cancer indicates the potential importance of inherited variation in the apoptosis pathway in breast cancer susceptibility.",Y,CASP8 D302H,CASP8,0.642857143
767,bc_id808,CANCER,ESR2,15604249,B,Estrogen receptor genotypes and haplotypes associated with breast cancer risk.,2004,"We define several other haplotypes in Ashkenazi Jews in both ESR1 and ESR2 that may elevate susceptibility to breast cancer. In contrast, we found no association between any PGR variant or haplotype and breast cancer. Genetic epidemiology study replication and functional assays of the haplotypes should permit a better understanding of the role of steroid receptor genetic variants and breast cancer risk.",We define several other haplotypes in Ashkenazi Jews in both ESR1 and ESR2 that may elevate susceptibility to breast cancer.,A,ESR2,ESR2,0.533333333
768,bc_id809,CANCER,ESR1,15604249,N,Estrogen receptor genotypes and haplotypes associated with breast cancer risk.,2004,"We define several other haplotypes in Ashkenazi Jews in both ESR1 and ESR2 that may elevate susceptibility to breast cancer. In contrast, we found no association between any PGR variant or haplotype and breast cancer. Genetic epidemiology study replication and functional assays of the haplotypes should permit a better understanding of the role of steroid receptor genetic variants and breast cancer risk.",We define several other haplotypes in Ashkenazi Jews in both ESR1 and ESR2 that may elevate susceptibility to breast cancer. ,A,ESR1,ESR1,0.586956522
769,bc_id810,CANCER,CYP17A1,15604994,Y,CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer.,2004,"These results suggest that both CYP17 and SULT1A1 genotypes could be important determinants of breast cancer risk in Indian women and may help in early identification of high risk subjects. Such genotype analysis resulting in a high-risk profile holds considerable promise for individualizing screening, diagnosis and therapeutic intervention in breast cancer.",These results suggest that both CYP17 and SULT1A1 genotypes could be important determinants of breast cancer risk in Indian women and may help in early identification of high risk subjects.,Y,CYP17,CYP17A1,0.266666667
770,bc_id811,CANCER,SULT1A1,15604994,Y,CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer.,2004,"These results suggest that both CYP17 and SULT1A1 genotypes could be important determinants of breast cancer risk in Indian women and may help in early identification of high risk subjects. Such genotype analysis resulting in a high-risk profile holds considerable promise for individualizing screening, diagnosis and therapeutic intervention in breast cancer.",These results suggest that both CYP17 and SULT1A1 genotypes could be important determinants of breast cancer risk in Indian women and may help in early identification of high risk subjects.,Y,SULT1A1,SULT1A1,0.322580645
771,bc_id812,CANCER,MMP2,15609121,Y,Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype,2004,These findings suggest that breast cancer phenotype and outcome can be influenced by common functional polymorphisms in MMP genes.,"A single nucleotide polymorphism in the promoter region of MMP-2 (-1306 C-->T) abolishes Sp1 binding and is associated with lower transcriptional activity, while another in the promoter region of MMP-9 (-1562 C-->T) increases the transcription of this gene... These findings suggest that breast cancer phenotype and outcome can be influenced by common functional polymorphisms in MMP genes.",Y,MMP,MMP-2,1
772,bc_id813,CANCER,MMP9,15609121,Y,Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype,2004,These findings suggest that breast cancer phenotype and outcome can be influenced by common functional polymorphisms in MMP genes.,"A single nucleotide polymorphism in the promoter region of MMP-2 (-1306 C-->T) abolishes Sp1 binding and is associated with lower transcriptional activity, while another in the promoter region of 
 (-1562 C-->T) increases the transcription of this gene... These findings suggest that breast cancer phenotype and outcome can be influenced by common functional polymorphisms in MMP genes.",Y,MMP,MMP-9,1
773,bc_id814,CANCER,CYP17A1,15609124,Y,Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer,2004,"Our findings suggest that the CYP17 A2 allele is associated with hormone levels, and interacts with insulin levels and diet to affect breast density levels and potentially breast cancer risk.","Our findings suggest that the CYP17 A2 allele is associated with hormone levels, and interacts with insulin levels and diet to affect breast density levels and potentially breast cancer risk.",Y,CYP17,CYP17A1,0.266666667
774,bc_id815,CANCER,ITGB3,15609125,Y,Integrin beta3 Leu33Pro polymorphism and breast cancer risk: a population-based case-control studyin Germany,2004,Our data suggest that inheritance of the integrin beta(3) Leu33Pro polymorphism may increase the breast cancer risk by age 45 in the German population.,Our data suggest that inheritance of the integrin beta3 Leu33Pro polymorphism may increase the breast cancer risk by age 45 in the German population.,Y,integrin beta3 Leu33Pro,ITGB3,0.333333333
775,bc_id816,CANCER,BRCA1,15609132,B,Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients.,2004,,We found statistically significant lower levels of VEGF in patients with BRCA1 gene mutation as compared with breast cancer patients without this mutation.,A,BRCA1,BRCA1,0.60944206
776,bc_id817,CANCER,NAT2,15609332,B,NAT2 slow acetylator genotype as an important modifier of breast cancer risk.,2005,,Our results therefore suggest that NAT2 slow acetylator genotype may be an important modifier of environmentally induced breast cancer risk in Finnish women.,A,NAT2,NAT2,0.259259259
777,bc_id819,CANCER,CDKN1B,15627896,Y,The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients.,2004,"In conclusion, the determination of the CDKN1B genotype might be a powerful tool for the prognosis of patients with early breast cancer.","In conclusion, the determination of the CDKN1B genotype might be a powerful tool for the prognosis of patients with early breast cancer.",A,CDKN1B,CDKN1B,0.714285714
778,bc_id820,CANCER,PGR,15632380,Y,Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-basedanalysis.,2005,"Variation in PGR was associated with ovarian cancer risk, although the strongest result was not with the PROGINS allele. Instead, any causal allele(s) are likely in or downstream of block 4 and carried on haplotypes 4-D and 4-E. There was some evidence that the same variation was associated with a reduced risk of breast cancer, but the association was not statistically significant.","Variation in PGR was associated with ovarian cancer risk, although the strongest result was not with the PROGINS allele. Instead, any causal allele(s) are likely in or downstream of block 4 and carried on haplotypes 4-D and 4-E. There was some evidence that the same variation was associated with a reduced risk of breast cancer, but the association was not statistically significant.",A,PGR,PGR,0.5
779,bc_id821,CANCER,CYP1A1,15642161,B,"Polychlorinated biphenyls, cytochrome P450 1A1 (CYP1A1) polymorphisms, and breast cancer risk among African American women and white women in North Carolina: a population-based case-control study.",2006,,Our results confirm previous reports that CYP1A1 M2-containing genotypes modify the association between PCB exposure and risk of breast cancer.,Y,CYP1A1 M2,CYP1A1,0.304347826
780,bc_id822,CANCER,CHEK2,15649950,Y,Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population,2005,"We conclude that  CHEK2.S428F increases breast cancer risk approximately 2-fold among Ashkenazi Jewish women, whereas CHEK2.P85L is a neutral allele. In general, these results suggest that selecting probands with extended haplotypes that co-segregate with disease can improve the efficiency of resequencing efforts and that quantitative complementation tests in yeast can be used to evaluate variants in genes with highly conserved function.","We conclude that CHEK2.S428F increases breast cancer risk approximately 2-fold among Ashkenazi Jewish women, whereas CHEK2.P85L is a neutral allele.",A,CHEK2.S428F,CHEK2,0.383333333
781,bc_id823,CANCER,XRCC1,15665590,Y,Association of the XRCC1 gene polymorphisms with cancer risk in Turkish breast cancer patients.,2004,Our results do not support evidence for a role of the XRCC1 polymorphism in developing breast cancer.,Our results do not support evidence for a role of the XRCC1 polymorphism in developing breast cancer.,N,XRCC1,XRCC1,0.217391304
782,bc_id824,CANCER,XRCC1,15666192,B,Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer.,2005,", the present study suggested involvement of XRCC1 codon 194 and 399 polymorphisms in the genetic predisposition to breast cancer among South Indian women.",Our preliminary results based on the analysis of functionally relevant polymorphisms in XRCC1 low penetrance gene may provide a better model that would exhibit additive effects on individual susceptibility to breast cancer.,A,XRCC1,XRCC1,0.543478261
783,bc_id825,CANCER,NOD2,15666202,B,The 3020insC allele of NOD2 predisposes to early-onset breast cancer.,2005,,"Overall there was no association between breast cancer and NOD2 (OR = 1.1; p = 0.76), but significant associations were observed between the presence of the allele and early-onset breast cancer (OR = 1.9; p = 0.01) and between the allele and ductal breast cancer with an in situ component (OR = 2.2; p = 0.006).",N,NOD2,NOD2,1
784,bc_id826,CANCER,IGFBP3,15668470,Y,Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review.,2005,"Variation within the reference range of IGF-I and IGFBP-3 may confer only modest increases in breast cancer risk, and any single polymorphism may only account for a small proportion of that variation. Nevertheless, population attributable fractions for high circulating levels of IGF-I and IGFBP-3 and for common genetic variants could be substantial. Further large studies, or combined analysis of data from existing studies, are needed to quantify these effects more precisely.","Variation within the reference range of IGF-I and IGFBP-3 may confer only modest increases in breast cancer risk, and any single polymorphism may only account for a small proportion of that variation.",A,IGFBP-3,IGFBP3,0.428571429
785,bc_id827,CANCER,IGF1,15668470,Y,Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review.,2005,"Variation within the reference range of IGF-I and IGFBP-3 may confer only modest increases in breast cancer risk, and any single polymorphism may only account for a small proportion of that variation. Nevertheless, population attributable fractions for high circulating levels of IGF-I and IGFBP-3 and for common genetic variants could be substantial. Further large studies, or combined analysis of data from existing studies, are needed to quantify these effects more precisely.","Variation within the reference range of IGF-I and IGFBP-3 may confer only modest increases in breast cancer risk, and any single polymorphism may only account for a small proportion of that variation.",A,IGF-I,IGF1,0.25
786,bc_id828,CANCER,CCND1,15668481,Y,Association of cyclin D1 genotype with breast cancer risk and survival.,2005,This study suggests that CCND1 A870G polymorphism may modify the postmenopausal breast cancer risk associated with hormonal exposure and predict survival after breast cancer diagnosis.,This study suggests that CCND1 A870G polymorphism may modify the postmenopausal breast cancer risk associated with hormonal exposure and predict survival after breast cancer diagnosis.,A,CCND1 A870G,CCND1,0.5
787,bc_id829,CANCER,AURKA,15688402,Y,Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK.,2005,"Our study provides new findings supporting the mutator role of Aurora-A in breast cancer development, suggesting that breast cancer could be driven by genomic instability associated with variant Aurora-A, the tumorigenic contribution of which could be enhanced as a result of increased mitosis due to estrogen exposure.",X,X,X,X,0
788,bc_id830,CANCER,ERBB2,15693849,N,Her2 genotype and breast cancer progression in Korean women.,2005,"These results suggest that Her2 polymorphism at codon 655 is not associated with the development of breast cancer in Korean women. However, there is a possibility that the valine allele at codon 655 might be related to increased risk of breast cancer progression.","These results suggest that Her2 polymorphism at codon 655 is not associated with the development of breast cancer in Korean women. However, there is a possibility that the valine allele at codon 655 might be related to increased risk of breast cancer progression.",N,Her2,ERBB2,0.261904762
789,bc_id831,CANCER,CYP3A4,15698606,B,CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.,2005,"We developed a simple assay for the detection of the CYP3A4*18 allele and showed that in a Chinese population, CYP3A4*18 and CYP3A5*3 allelic frequencies are similar to that reported previously in Chinese resident in Taiwan. The frequency of the CYP3A5*3 allele in Chinese population is similar to the Japanese but lower than Caucasians. Meanwhile, our findings suggest that an approximate 62% of the Chinese population carrying CYP3A5*3/*3 genotype may appear not to express CYP3A5 protein.",NR,NR,NR,NR,0
790,bc_id832,CANCER,CYP3A5,15698606,B,CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.,2005,"We developed a simple assay for the detection of the CYP3A4*18 allele and showed that in a Chinese population, CYP3A4*18 and CYP3A5*3 allelic frequencies are similar to that reported previously in Chinese resident in Taiwan. The frequency of the CYP3A5*3 allele in Chinese population is similar to the Japanese but lower than Caucasians. Meanwhile, our findings suggest that an approximate 62% of the Chinese population carrying CYP3A5*3/*3 genotype may appear not to express CYP3A5 protein.",NR,NR,NR,NR,0
791,bc_id833,CANCER,CAT,15705913,B,"Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer.",2005,These data indicate that gene variants that impact oxidative stress modify prognosis after treatment for breast cancer.,"Both CAT TT and MnSOD CC genotypes were associated with nonsignificant reduced hazard of death. When we combined genotypes associated with higher levels of reactive oxygen species for MnSOD and MPO, women with MnSOD CC and MPO GG genotypes had a 3-fold decrease in hazard of death (hazard ratio, 0.33; 95% confidence interval, 0.13-0.80; P = 0.01). These data indicate that gene variants that impact oxidative stress modify prognosis after treatment for breast cancer.",A,CAT ,CAT,0.4
792,bc_id834,CANCER,SOD2,15705913,B,"Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer.",2005,These data indicate that gene variants that impact oxidative stress modify prognosis after treatment for breast cancer.,X,X,X,X,0
793,bc_id835,CANCER,MPO,15705913,B,"Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer.",2005,These data indicate that gene variants that impact oxidative stress modify prognosis after treatment for breast cancer.,"Both CAT TT and MnSOD CC genotypes were associated with nonsignificant reduced hazard of death. When we combined genotypes associated with higher levels of reactive oxygen species for MnSOD and MPO, women with MnSOD CC and MPO GG genotypes had a 3-fold decrease in hazard of death (hazard ratio, 0.33; 95% confidence interval, 0.13-0.80; P = 0.01). These data indicate that gene variants that impact oxidative stress modify prognosis after treatment for breast cancer.",A,MPO,MPO,0.571428571
794,bc_id836,CANCER,ESR1,15709176,B,Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival.,2005,,These data suggest that the ER-alpha gene polymorphisms and ER status may have an interactive effect on breast cancer survival.,A,ER-alpha,ESR1,0.586956522
795,bc_id837,CANCER,GSTT1,15725614,B,Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.,2005,,"The associations of CYP1A1, GSTM1 and GSTT1 genotypes with breast cancer risk were more pronounced among the pre-menopausal patients.",Y,GSTT1,GSTT1,0.578947368
796,bc_id838,CANCER,GSTM1,15725614,B,Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.,2005,,"The associations of CYP1A1, GSTM1 and GSTT1 genotypes with breast cancer risk were more pronounced among the pre-menopausal patients.",Y,GSTM1,GSTM1,0.452830189
797,bc_id839,CANCER,CYP1A1,15725614,B,Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.,2005,,"The associations of CYP1A1, GSTM1 and GSTT1 genotypes with breast cancer risk were more pronounced among the pre-menopausal patients.",Y,CYP1A1,CYP1A1,0.304347826
798,bc_id840,CANCER,BRCA2,15733268,B,Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.,2005,,Breast cancer due to mutations in BRCA1 and BRCA2 genes appears to be a heterogeneous syndrome in the Greek population.,A,BRCA2,BRCA2,0.576923077
799,bc_id841,CANCER,BRCA1,15733268,B,Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.,2005,,Breast cancer due to mutations in BRCA1 and BRCA2 genes appears to be a heterogeneous syndrome in the Greek population.,A,BRCA1,BRCA1,0.60944206
800,bc_id842,CANCER,RAD51,15734952,N,Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.,2005,"Although there was little statistical power to detect modest increases in risk for the homozygote variant genotypes, particularly for the rare RAD51 and XRCC2 variants, the data suggest that none of these variants play a major role in the etiology of breast or ovarian cancer.","Although there was little statistical power to detect modest increases in risk for the homozygote variant genotypes, particularly for the rare RAD51 and XRCC2 variants, the data suggest that none of these variants play a major role in the etiology of breast or ovarian cancer.",N,RAD51,RAD51,0.153846154
801,bc_id843,CANCER,XRCC2,15734952,N,Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.,2005,"Although there was little statistical power to detect modest increases in risk for the homozygote variant genotypes, particularly for the rare RAD51 and XRCC2 variants, the data suggest that none of these variants play a major role in the etiology of breast or ovarian cancer.","Although there was little statistical power to detect modest increases in risk for the homozygote variant genotypes, particularly for the rare RAD51 and XRCC2 variants, the data suggest that none of these variants play a major role in the etiology of breast or ovarian cancer.",N,XRCC2,XRCC2,0.454545455
802,bc_id844,CANCER,XRCC3,15734952,B,Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.,2005,"Although there was little statistical power to detect modest increases in risk for the homozygote variant genotypes, particularly for the rare RAD51 and XRCC2 variants, the data suggest that none of these variants play a major role in the etiology of breast or ovarian cancer.","Similarly, there were no increased risks associated with the XRCC2 GA/AA genotype (OR, 0.98; 95% CI, 0.76-1.26 for breast cancer and OR, 0.93; 95% CI, 0.69-1.25 for ovarian cancer) or the XRCC3 CT/TT genotype (OR, 0.92; 95% CI, 0.77-1.10 for breast cancer and OR, 0.87; 95% CI, 0.71-1.08 for ovarian cancer).",N,XRCC3 CT/TT,XRCC3,0.269230769
803,bc_id845,CANCER,COMT,15734954,N,Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: resultsfrom the shanghai breast cancer study and a meta-analysis.,2005,"To summarize the findings from this and previous studies. Included in this study were 1,135 incident breast cancer cases diagnosed from August 1996 through March 1998 among female residents of Shanghai and 1,235 randomly selected, age frequency-matched controls from the same general population. The common alleles of the CYP1B1 gene were Arg (79.97%) in codon 48, Ala (80.53%) in codon 119, and Leu (86.57%) in codon 432. The Val allele accounted for 72.46% of the total alleles identified in codon 108/158 of the COMT gene. No overall associations of breast cancer risk were found with any of the single nucleotide polymorphisms described above. This finding was supported by a meta-analysis of all previous published studies. No gene-gene interactions were observed between CYP1B1 and COMT genotypes. The associations of breast cancer risk with factors related to endogenous estrogen exposure, such as years of menstruation and body mass index, were not significantly modified by the CYP1B1 and COMT genotypes. We observed, however, that women who carried one copy of the variant allele in CYP1B1 codons 48 or 119 were less likely to have estrogen receptor-positive breast cancer than those who carried two copies of the corresponding wild-type alleles. The results from this study were consistent with those from most previous studies, indicating no major associations of breast cancer risk with CYP1B1 and COMT polymorphisms.","The associations of breast cancer risk with factors related to endogenous estrogen exposure, such as years of menstruation and body mass index, were not significantly modified by the CYP1B1 and COMT genotypes.",N,COMT,COMT,0.29787234
804,bc_id846,CANCER,CYP1B1,15734954,N,Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: resultsfrom the shanghai breast cancer study and a meta-analysis.,2005,"To summarize the findings from this and previous studies. Included in this study were 1,135 incident breast cancer cases diagnosed from August 1996 through March 1998 among female residents of Shanghai and 1,235 randomly selected, age frequency-matched controls from the same general population. The common alleles of the CYP1B1 gene were Arg (79.97%) in codon 48, Ala (80.53%) in codon 119, and Leu (86.57%) in codon 432. The Val allele accounted for 72.46% of the total alleles identified in codon 108/158 of the COMT gene. No overall associations of breast cancer risk were found with any of the single nucleotide polymorphisms described above. This finding was supported by a meta-analysis of all previous published studies. No gene-gene interactions were observed between CYP1B1 and COMT genotypes. The associations of breast cancer risk with factors related to endogenous estrogen exposure, such as years of menstruation and body mass index, were not significantly modified by the CYP1B1 and COMT genotypes. We observed, however, that women who carried one copy of the variant allele in CYP1B1 codons 48 or 119 were less likely to have estrogen receptor-positive breast cancer than those who carried two copies of the corresponding wild-type alleles. The results from this study were consistent with those from most previous studies, indicating no major associations of breast cancer risk with CYP1B1 and COMT polymorphisms.","The associations of breast cancer risk with factors related to endogenous estrogen exposure, such as years of menstruation and body mass index, were not significantly modified by the CYP1B1 and COMT genotypes.",N,CYP1B1,CYP1B1,0.256410256
805,bc_id847,CANCER,XRCC1,15734955,B,"Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk.",2005,,These results do not show that the two genetic polymorphisms of XRCC1 independently influence breast cancer risk.,N,XRCC1,XRCC1,0.217391304
806,bc_id848,CANCER,BRCA2,15734957,B,Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.,2005,,X,X,X,X,0
807,bc_id849,CANCER,BRCA1,15734957,B,Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.,2005,,"After adjustment for potential confounders, oral contraceptive use for at least 12 months was associated with decreased breast cancer risk for BRCA1 mutation carriers [odds ratio (OR), 0.22; 95% confidence interval (CI), 0.10-0.49; P < 0.001], but not for BRCA2 mutation carriers (OR, 1.02; 95% CI, 0.34-3.09) or noncarriers (OR, 0.93; 95% CI, 0.69-1.24).",Y,BRCA1,BRCA1,0.326180258
808,bc_id850,CANCER,MTHFR,15735051,B,"One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer.",2005,,"The MTHFR 677T variant allele was associated with increased risk of breast cancer (P, trend = 0.03) with a multivariate-adjusted OR of 1.37 (95% CI, 1.06-1.78) for the 677TT genotype.",Y,MTHFR 677T,MTHFR,0.269230769
809,bc_id851,CANCER,MTHFR,15736423,B,"The MTHFR C677T polymorphism, estrogen exposure and breast cancer risk: a nested case-control study in Taiwan.",2005,"The results of this study suggest that the MTHFR 677T variant genotype per se may have no overall association with breast cancer risk, but a sizable association could be observed in the presence of relevant environmental exposure.","The results of this study suggest that the MTHFR 677T variant genotype per se may have no overall association with breast cancer risk, but a sizable association could be observed in the presence of relevant environmental exposure.",A,MTHFR 677T,MTHFR,0.403846154
810,bc_id852,CANCER,BRCA1,15743496,B,Haplotype analysis of common variants in the BRCA1 gene and risk of sporadic breast cancer.,2006,,"We have described a haplotype in the BRCA1 gene that was associated with an approximately 20% increase in risk of sporadic breast cancer in the general population. However, the functional variant(s) responsible for the association are unclear.",A,BRCA1,BRCA1,0.60944206
811,bc_id853,CANCER,ERBB2,15743501,N,Common ERBB2 polymorphisms and risk of breast cancer in a white British population: acase-control study.,2005,"In our population, common ERBB2 polymorphisms are not involved in predisposition to breast cancer.","In our population, common ERBB2 polymorphisms are not involved in predisposition to breast cancer.",N,ERBB2,ERBB2,0.261904762
812,bc_id854,CANCER,SULT1A1,15743503,B,"SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case-control study.",2005,"We found no evidence that the SULT1A1 genotype in itself modifies breast cancer risk associated with smoking in women up to age 50 years. In combination with NAT2 fast acetylator status, however, the SULT1A1*1/*1 genotype might increase breast cancer risk in women exposed to tobacco smoke.",We found no evidence that the SULT1A1 genotype in itself modifies breast cancer risk associated with smoking in women up to age 50 years.,N,SULT1A1,SULT1A1,0.290322581
813,bc_id855,CANCER,NAT2,15743503,B,"SULT1A1 genotype, active and passive smoking, and breast cancer risk by age 50 years in a German case-control study.",2005,"We found no evidence that the SULT1A1 genotype in itself modifies breast cancer risk associated with smoking in women up to age 50 years. In combination with NAT2 fast acetylator status, however, the SULT1A1*1/*1 genotype might increase breast cancer risk in women exposed to tobacco smoke.",We recently reported a differential effect of N-acetyltransferase (NAT) 2 genotype on the association between active and passive smoking and breast cancer.,A,N-acetyltransferase (NAT) 2,NAT2,0.259259259
814,bc_id856,CANCER,ERBB2,15754131,B,HER2 codon 655 polymorphism and breast cancer:results from kin-cohort and case-control analyses.,2005,The results provide additional evidence that HER2 codon 655 genotype may predispose to early-onset breast cancer.,The results provide additional evidence that HER2 codon 655 genotype may predispose to early-onset breast cancer.,A,HER2,ERBB2,0.452380952
815,bc_id857,CANCER,IGF1,15756256,B,Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.,2005,,"Our results suggest that lack of the IGF1 19-repeat allele modifies IGF-1 levels, breast volume and possibly early-onset breast cancer risk after hormone exposure in young high-risk women.",A,IGF-1,IGF1,0.25
816,bc_id858,CANCER,TP53,15756275,B,The R72P P53 mutation is associated with familial breast cancer in Jewish women.,2005,,We conclude that arginine homozygosity at codon 72 of the p53 gene is associated with a significant increased breast cancer risk in Jewish high-risk population.,Y,p53,TP53,0.367816092
817,bc_id859,CANCER,IFNG,15756547,B,Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer.,2005,,PNF,PNF,PNF,PNF,0
818,bc_id860,CANCER,CYP17A1,15761247,B,Genetic polymorphism of CYP17 and breast cancer risk in Korean women.,2005,Our results suggest that genetic polymorphism in 5'-untranslated region of CYP17 might play a role in breast cancer development in Korean women among younger women aged less than 50 or leaner women with body mass index less than 22 kg/m(2).,Our results suggest that genetic polymorphism in 5'-untranslated region of CYP17 might play a role in breast cancer development in Korean women among younger women aged less than 50 or leaner women with body mass index less than 22 kg/m2.,A,CYP17,CYP17A1,0.466666667
819,bc_id861,CANCER,MLH1,15769334,Y,[Study on the relationship between genetic polymorphism Val384Asp in hMLH1 gene and the risk of four different carcinomas.],2004,Determination of Val384Asp in hMLH1 gene single nucleotide polymorphism seemed to be suitable for identifying individuals with increased risk of gastrointestinal cancer in the Chinese population.,X,X,X,X,0
820,bc_id862,CANCER,BRCA1,15777502,Y,[Analysis of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.],2004,"The incidence of BRCA1 mutations in Chinese patients with early onset breast cancer is similar to that reported from western countries, but the incidence of mutations in Chinese breast cancer patients with affected relatives is comparatively low.","The incidence of BRCA1 mutations in Chinese patients with early onset breast cancer is similar to that reported from western countries, but the incidence of mutations in Chinese breast cancer patients with affected relatives is comparatively low.",Y,BRCA1,BRCA1,0.326180258
821,bc_id863,CANCER,NCOA3,15788663,B,Association of NCOA3 polymorphisms with breast cancer risk.,2005,"Because of the impact of NCOA3 in antiestrogen therapy resistance, these polymorphisms might also influence therapy outcome in breast cancer.","Because of the impact of NCOA3 in antiestrogen therapy resistance, these polymorphisms might also influence therapy outcome in breast cancer.",A,NCOA3,NCOA3,0.142857143
822,bc_id864,CANCER,TP53,15802278,B,Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.,2005,TP53 mutations might induce resistance to certain modalities of breast cancer therapy.,TP53 mutations might induce resistance to certain modalities of breast cancer therapy. Sequence-determined TP53 mutation was of negative prognostic value in the total patient population and in the CMF treated patients.,A,TP53,TP53,0.482758621
823,bc_id865,CANCER,ACE,15802301,B,"Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore.",2005,,X,X,X,X,0
824,bc_id866,CANCER,IL10,15803357,B,Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk.,2005,,Therefore we conclude that the IL-10 -592C > A promoter polymorphism may be associated with a reduced breast cancer risk.,A,IL-10 -592C,IL10,0.625
825,bc_id867,CANCER,LTA,15803361,B,Genetic polymorphisms of TGF-beta1 &amp; TNF-beta and breast cancer risk.,2005,,The results of this study therefore suggest that polymorphisms of TGF-beta1 and TNF-beta genes may modify individual susceptibility to breast cancer in Korean women.,A,TNF-beta,LTA,0.75
826,bc_id868,CANCER,TGFB1,15803361,B,Genetic polymorphisms of TGF-beta1 &amp; TNF-beta and breast cancer risk.,2005,,The results of this study therefore suggest that polymorphisms of TGF-beta1 and TNF-beta genes may modify individual susceptibility to breast cancer in Korean women.,A,TGF-beta1,TGFB1,0.518518519
827,bc_id869,CANCER,CHEK2,15803363,B,The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic.,2005,,"In this study we performed the CHEK2 c.1100delC mutation analysis in 1046 breast cancer patients and 730 unaffected control individuals... Based on our results, genotyping of CHEK2 c.1100delC mutation in clinical settings in the Czech Republic could not be recommended.",N,CHEK2 c.1100delC,CHEK2,0.233333333
828,bc_id870,CANCER,CHEK2,15810020,Y,Association of two mutations in the CHEK2 gene with breast cancer.,2005,"Our data indicate that the I157T allele, and possibly the IVS2+1G > A allele, of the CHEK2 gene contribute to inherited breast cancer susceptibility.","Our data indicate that the I157T allele, and possibly the IVS2+1G > A allele, of the CHEK2 gene contribute to inherited breast cancer susceptibility.",Y,CHEK2,CHEK2,0.383333333
829,bc_id871,CANCER,CYP17A1,15824149,B,"Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women.",2005,"In conclusion, this paper shows that women with low BMI and the A2A2 genotype had higher endogenous sex steroid levels compared with women with the A1A1 genotype. However, these increased sex steroid levels are not translated into an increased breast cancer risk in these women.","Cytochrome P450c17alpha (Cyp17) functions at key branch points in human steroidogenesis... However, these increased sex steroid levels are not translated into an increased breast cancer risk in these women.",N,Cyp17,CYP17A1,0.266666667
830,bc_id872,CANCER,ATM,15824150,B,Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk.,2005,Our results thus suggest that genetic polymorphisms of ATM play an important role in the development of breast cancer in Korean women.,Our results thus suggest that genetic polymorphisms of ATM play an important role in the development of breast cancer in Korean women.,Y,ATM,ATM,0.333333333
831,bc_id873,CANCER,TGFBR1,15833881,B,Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.,2005,This is the first study assessing the TGF-beta signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.,This is the first study assessing the TGF-beta signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.,A,TGFBR1,TGFBR1,0.166666667
832,bc_id874,CANCER,TGFB1,15833881,B,Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.,2005,This is the first study assessing the TGF-beta signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.,This is the first study assessing the TGF-beta signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.,A,TGFB1,TGFB1,0.518518519
833,bc_id875,CANCER,ERBB2,15837541,Y,"The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece.",2005,"results showed that p53 codon 72 polymorphism is statistically significantly associated with breast cancer (OR for Arg/Arg to non-Arg/Arg was 6.66, P=0.0001 at 95% CI 2.63-16.9), but not Her 2 and MTHFR polymorphisms","The aim of this study was to explore a possible association between p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms and breast cancer in Northern Greece... A total of 42 women with breast cancer as well as healthy controls were investigated and results showed that p53 codon 72 polymorphism is statistically significantly associated with breast cancer (OR for Arg/Arg to non-Arg/Arg was 6.66, P = 0.0001 at 95% CI 2.63-16.9), but not Her 2 and MTHFR polymorphisms are associated with breast cancer (OR for Ile/Ile to non-Ile/Ile was 1.33, P = 0.54 at 95% CI 0.52-3.38 and OR for T/T versus non-T/T was 1.07, P = 0.89 at 95% CI 0.35-3.25).",N,Her 2,ERBB2,0.261904762
834,bc_id876,CANCER,TP53,15837541,Y,"The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece.",2005,"results showed that p53 codon 72 polymorphism is statistically significantly associated with breast cancer (OR for Arg/Arg to non-Arg/Arg was 6.66, P=0.0001 at 95% CI 2.63-16.9), but not Her 2 and MTHFR polymorphisms","The aim of this study was to explore a possible association between p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms and breast cancer in Northern Greece... A total of 42 women with breast cancer as well as healthy controls were investigated and results showed that p53 codon 72 polymorphism is statistically significantly associated with breast cancer (OR for Arg/Arg to non-Arg/Arg was 6.66, P = 0.0001 at 95% CI 2.63-16.9), but not Her 2 and MTHFR polymorphisms are associated with breast cancer (OR for Ile/Ile to non-Ile/Ile was 1.33, P = 0.54 at 95% CI 0.52-3.38 and OR for T/T versus non-T/T was 1.07, P = 0.89 at 95% CI 0.35-3.25).",Y,p53,TP53,0.367816092
835,bc_id877,CANCER,MTHFR,15837541,N,"The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece.",2005,"results showed that p53 codon 72 polymorphism is statistically significantly associated with breast cancer (OR for Arg/Arg to non-Arg/Arg was 6.66, P=0.0001 at 95% CI 2.63-16.9), but not Her 2 and MTHFR polymorphisms","The aim of this study was to explore a possible association between p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms and breast cancer in Northern Greece... A total of 42 women with breast cancer as well as healthy controls were investigated and results showed that p53 codon 72 polymorphism is statistically significantly associated with breast cancer (OR for Arg/Arg to non-Arg/Arg was 6.66, P = 0.0001 at 95% CI 2.63-16.9), but not Her 2 and MTHFR polymorphisms are associated with breast cancer (OR for Ile/Ile to non-Ile/Ile was 1.33, P = 0.54 at 95% CI 0.52-3.38 and OR for T/T versus non-T/T was 1.07, P = 0.89 at 95% CI 0.35-3.25).",N,MTHFR C677T,MTHFR,0.326923077
836,bc_id878,CANCER,ESR1,15842934,Y,[The XbaI and PvuII gene polymorphisms of the estrogen receptor alpha gene in Chinese women with breast cancer],2005,"The XbaI gene polymorphism of ERalpha gene was associated with breast cancer risk, more significantly in postmenopausal women. The XbaI X allele could decrease the risk of breast cancer. No apparent effect of the PvuII gene polymorphisms of ERalpha gene was identified.","The XbaI gene polymorphism of ER alpha gene was associated with breast cancer risk, more significantly in postmenopausal women.",Y,ER alpha,ESR1,0.282608696
837,bc_id879,CANCER,GSTT1,15845652,B,The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore.,2005,"The AA genotype did not affect breast cancer risk. The results of this study are compatible with the hypothesis that the oxidant-antioxidant balance in cells is an important determinant of the direction of the cyclin D1 effect, leading either to cell proliferation or cell death.",X,X,X,X,0
838,bc_id880,CANCER,GSTP1,15845652,B,The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore.,2005,"The AA genotype did not affect breast cancer risk. The results of this study are compatible with the hypothesis that the oxidant-antioxidant balance in cells is an important determinant of the direction of the cyclin D1 effect, leading either to cell proliferation or cell death.",X,X,X,X,0
839,bc_id881,CANCER,GSTM1,15845652,B,The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore.,2005,"The AA genotype did not affect breast cancer risk. The results of this study are compatible with the hypothesis that the oxidant-antioxidant balance in cells is an important determinant of the direction of the cyclin D1 effect, leading either to cell proliferation or cell death.",X,X,X,X,0
840,bc_id882,CANCER,CCND1,15845652,B,The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore.,2005,"The AA genotype did not affect breast cancer risk. The results of this study are compatible with the hypothesis that the oxidant-antioxidant balance in cells is an important determinant of the direction of the cyclin D1 effect, leading either to cell proliferation or cell death.","Genomic DNA collected from 258 incident cases of breast cancer and 670 female cohort controls was examined for CCND1, GSTM1, GSTT1 and GSTP1 genes using fluorogenic 5'-nuclease assay... The heterozygous CCND1 GA genotype significantly reduced the breast cancer risk in all subjects (OR=0.67, 95% CI 0.45-0.99) when compared with the GG genotype. The association was restricted to women with a high (above median value) intake level of n-6 fatty acids (OR=0.51, 95% CI 0.30-0.87), a low (below median value) intake level of the antagonistic marine n-3 fatty acids (OR=0.54, 95% CI 0.32-0.93) or a total lack of the antioxidative GSTM1 (OR=0.44, 95% CI 0.25-0.80) or GSTT1 genes (OR=0.46, 95% CI 0.24-0.87).",Y,CCND1,CCND1,0.1875
841,bc_id883,CANCER,ESR1,15856463,B,Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women.,2005,,ESR1 polymorphisms in combination with lifestyle factors may be associated with breast cancer risk in older Caucasian women.,A,ESR1,ESR1,0.586956522
842,bc_id884,CANCER,FANCA,15860134,B,A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer.,2005,The allele with the tandem duplication does not appear to modify breast cancer risk but may act as a low penetrance protective allele for ovarian cancer.,"The FANCA gene is one of the genes in which mutations lead to Fanconi anaemia, a rare autosomal recessive disorder characterised by congenital abnormalities, bone marrow failure, and predisposition to malignancy. FANCA is also a potential breast and ovarian cancer susceptibility gene... The allele with the tandem duplication does not appear to modify breast cancer risk but may act as a low penetrance protective allele for ovarian cancer.",A,FANCA,FANCA,0.5
843,bc_id885,CANCER,TNFRSF1B,15863392,Y,A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma.,2005,"Genetic variation in TNFRII may predict the late onset of breast carcinoma, relapse and death for patients with breast carcinoma.","Genetic variation in TNFRII may predict the late onset of breast carcinoma, relapse and death for patients with breast carcinoma.",A,TNFRII,TNFRSF1B,1
844,bc_id886,CANCER,MTHFR,15868433,Y,MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study.,2005,,This study suggests that the MTHFR C677T polymorphisms may affect long-term survival from advanced breast cancer.,A,MTHFR C677T,MTHFR,0.403846154
845,bc_id889,CANCER,CYP1A1,15870154,B,Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review.,2005,,"The functional significance of the polymorphisms is unclear. In 17 studies, no consistent association between breast cancer and CYP1A1 genotype was found.",N,CYP1A1,CYP1A1,0.239130435
846,bc_id887,CANCER,GSTT1,15870154,B,Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review.,2005,,X,X,X,X,0
847,bc_id888,CANCER,GSTM1,15870154,B,Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review.,2005,,X,X,X,X,0
848,bc_id890,CANCER,CDKN2A,15879498,B,A Common Variant of CDKN2A (p16) Predisposes to Breast Cancer,2005,CDKN2A appears to be a low penetrance breast cancer susceptibility gene in Poland. The association should be confirmed in other populations.,CDKN2A appears to be a low penetrance breast cancer susceptibility gene in Poland.,Y,CDKN2A,CDKN2A,0.125
849,bc_id891,CANCER,ATM,15880680,B,Two ATM variants and breast cancer risk.,2005,", we found no evidence that the ATM c.","In conclusion, we found no evidence that the ATM c.4258C>T variant increases breast cancer risk, and little evidence that c.1066-6T>G confers an elevated risk. Analysis of additional families will be necessary to define more precisely the risk, if any, associated with c.1066-6T>G.",N,ATM,ATM,0.244444444
850,bc_id892,CANCER,SOD2,15883815,Y,Polymorphism in the manganese superoxide dismutase (MnSOD) gene and risk of breast cancer in young women.,2005,The present study suggests that MnSOD may be implicated in breast carcinogenesis in young women.,X,X,X,X,0
851,bc_id893,CANCER,ERCC4,15886521,B,Obesity and genetic polymorphism of ERCC2 and ERCC4 as modifiers of risk of breast cancer.,2005,Our finding suggests that the combined effect of ERCC2 Asp(312)Asn and ERCC4 Ser(835)Ser genotypes might be associated with breast cancer risk in Korean women.,Our finding suggests that the combined effect of ERCC2 Asp(312)Asn and ERCC4 Ser(835)Ser genotypes might be associated with breast cancer risk in Korean women.,A,ERCC4,ERCC4,0.5
852,bc_id894,CANCER,ERCC2,15886521,B,Obesity and genetic polymorphism of ERCC2 and ERCC4 as modifiers of risk of breast cancer.,2005,Our finding suggests that the combined effect of ERCC2 Asp(312)Asn and ERCC4 Ser(835)Ser genotypes might be associated with breast cancer risk in Korean women.,Our finding suggests that the combined effect of ERCC2 Asp(312)Asn and ERCC4 Ser(835)Ser genotypes might be associated with breast cancer risk in Korean women.,A,ERCC2,ERCC2,0.6875
853,bc_id895,CANCER,ADH1B,15886702,N,"Alcohol dehydrogenase 1B (ADH1B) genotype, alcohol consumption and breast cancer risk by age 50 years in a German case-control study.",2005,"Alcohol dehydrogenase 1B (ADH1B) genotype was not an independent risk factor for breast cancer, athough the possibility was raised that it modifies risk associated with high levels of alcohol consumption (OR 1.1, 95% confidence interval (CI) 0.8-1.6 for ADH1B*1/*1 genotype vs 0.2, 95% CI 0.1-1.0 for ADH1B*2 carriers).","In a population-based study of 613 cases and 1082 controls, alcohol dehydrogenase 1B (ADH1B) genotype was not an independent risk factor for breast cancer, although the possibility was raised that it modifies risk associated with high levels of alcohol consumption (OR 1.1, 95% confidence interval (CI) 0.8-1.6 for ADH1B*1/*1 genotype vs 0.2, 95% CI 0.1-1.0 for ADH1B*2 carriers).",N,ADH1B,ADH1B,0.6
854,bc_id896,CANCER,BRCA2,15887246,B,Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.,2005,,"BRCA1/2 mutation screening should be considered for all women diagnosed before age 41, except for those with isolated BC in a large pedigree including multiple unaffected female relatives. The clinical assessment of HBC risk that we have developed should help in the decision to perform genetic testing.",A,BRCA1/2,BRCA2,0.576923077
855,bc_id897,CANCER,BRCA1,15887246,B,Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.,2005,,"BRCA1/2 mutation screening should be considered for all women diagnosed before age 41, except for those with isolated BC in a large pedigree including multiple unaffected female relatives. The clinical assessment of HBC risk that we have developed should help in the decision to perform genetic testing.",A,BRCA1/2,BRCA1,0.60944206
856,bc_id898,CANCER,TNF,15890243,N,Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer.,2005,"There were no differences in the TNF-alpha and TNF-beta alleles and genotypes frequencies between breast cancer patients (n=223) and control subjects (n=267). The correlations between TNFA or TNFB alleles or genotypes and clinicopathological indices were also insignificant. However, the frequency of IFN-gamma+874 T/T genotype was significantly higher in breast cancer patients compared to those of controls (P<0.002; OR=2.03, 95% CI=1.28-3.2) which indicates that Iranian women carrying the IFN-gamma+874 T/T genotype may be exposed to an increased risk of breast cancer development.","There were no differences in the TNF-alpha and TNF-beta alleles and genotypes frequencies between breast cancer patients (n=223) and control subjects (n=267). The correlations between TNFA or TNFB alleles or genotypes and clinicopathological indices were also insignificant. However, the frequency of IFN-gamma+874 T/T genotype was significantly higher in breast cancer patients compared to those of controls (P<0.002; OR=2.03, 95% CI=1.28-3.2) which indicates that Iranian women carrying the IFN-gamma+874 T/T genotype may be exposed to an increased risk of breast cancer development.",N,TNFA or TNFB,TNF,0.266666667
857,bc_id899,CANCER,IFNG,15890243,Y,Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer.,2005,"There were no differences in the TNF-alpha and TNF-beta alleles and genotypes frequencies between breast cancer patients (n=223) and control subjects (n=267). The correlations between TNFA or TNFB alleles or genotypes and clinicopathological indices were also insignificant. However, the frequency of IFN-gamma+874 T/T genotype was significantly higher in breast cancer patients compared to those of controls (P<0.002; OR=2.03, 95% CI=1.28-3.2) which indicates that Iranian women carrying the IFN-gamma+874 T/T genotype may be exposed to an increased risk of breast cancer development.","There were no differences in the TNF-alpha and TNF-beta alleles and genotypes frequencies between breast cancer patients (n=223) and control subjects (n=267). The correlations between TNFA or TNFB alleles or genotypes and clinicopathological indices were also insignificant. However, the frequency of IFN-gamma+874 T/T genotype was significantly higher in breast cancer patients compared to those of controls (P<0.002; OR=2.03, 95% CI=1.28-3.2) which indicates that Iranian women carrying the IFN-gamma+874 T/T genotype may be exposed to an increased risk of breast cancer development.",Y,IFN-gamma,IFNG,0.25
858,bc_id900,CANCER,LTA,15890243,B,Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer.,2005,"There were no differences in the TNF-alpha and TNF-beta alleles and genotypes frequencies between breast cancer patients (n=223) and control subjects (n=267). The correlations between TNFA or TNFB alleles or genotypes and clinicopathological indices were also insignificant. However, the frequency of IFN-gamma+874 T/T genotype was significantly higher in breast cancer patients compared to those of controls (P<0.002; OR=2.03, 95% CI=1.28-3.2) which indicates that Iranian women carrying the IFN-gamma+874 T/T genotype may be exposed to an increased risk of breast cancer development.","There were no differences in the TNF-alpha and TNF-beta alleles and genotypes frequencies between breast cancer patients (n=223) and control subjects (n=267). The correlations between TNFA or TNFB alleles or genotypes and clinicopathological indices were also insignificant. However, the frequency of IFN-gamma+874 T/T genotype was significantly higher in breast cancer patients compared to those of controls (P<0.002; OR=2.03, 95% CI=1.28-3.2) which indicates that Iranian women carrying the IFN-gamma+874 T/T genotype may be exposed to an increased risk of breast cancer development.",N,TNFB,TNFB,1
859,bc_id901,CANCER,SULT1E1,15894657,Y,Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.,2005,These findings suggest that genetic polymorphisms of SULT1E1 are associated with increased risk and a disease free survival of breast cancer in Korean women.,"We examined whether common single nucleotide polymorphisms (SNP) in SULT1A1 (c.779G>A, *14A>G, and *85C>T) and SULT1E1 (IVS1-447C>A, IVS4-1653T>C, and *959G>A) genes influenced the risk and survival of breast cancer... These findings suggest that genetic polymorphisms of SULT1E1 are associated with increased risk and a disease free survival of breast cancer in Korean women.",Y,SULT1E1,SULT1E1,0.5
860,bc_id902,CANCER,SULT1A1,15894657,B,Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.,2005,These findings suggest that genetic polymorphisms of SULT1E1 are associated with increased risk and a disease free survival of breast cancer in Korean women.,X,X,X,X,0
861,bc_id903,CANCER,SHBG,15894658,Y,Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene.,2005,This study suggests that the Asn allele in the SHBG gene may be related to a reduced risk of breast cancer among postmenopausal women by increasing their blood SHBG levels.,This study suggests that the Asn allele in the SHBG gene may be related to a reduced risk of breast cancer among postmenopausal women by increasing their blood SHBG levels.,A,SHBG,SHBG,0.666666667
862,bc_id904,CANCER,HFE,15894659,B,Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer.,2005,Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive.,"To understand the role of hemochromatosis and transferrin receptor system mutations in breast cancer, we analyzed 19 sequence variations at HFE, TFR1, TFR2, and FPN1 and compared genotype frequencies between cases and controls in a German population... Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive.",N,HFE,HFE,0.333333333
863,bc_id905,CANCER,TFRC,15894659,B,Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer.,2005,Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive.,"To understand the role of hemochromatosis and transferrin receptor system mutations in breast cancer, we analyzed 19 sequence variations at HFE, TFR1, TFR2, and FPN1 and compared genotype frequencies between cases and controls in a German population... Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive.",N,TFR1,TFRC,1
864,bc_id906,CANCER,TFR2,15894659,B,Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer.,2005,Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive.,"To understand the role of hemochromatosis and transferrin receptor system mutations in breast cancer, we analyzed 19 sequence variations at HFE, TFR1, TFR2, and FPN1 and compared genotype frequencies between cases and controls in a German population... Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive.",N,TFR2,TFR2,1
865,bc_id907,CANCER,SLC40A1,15894659,B,Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer.,2005,Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive.,"To understand the role of hemochromatosis and transferrin receptor system mutations in breast cancer, we analyzed 19 sequence variations at HFE, TFR1, TFR2, and FPN1 and compared genotype frequencies between cases and controls in a German population... Our data suggest that variants of the hemochromatosis-transferrin receptor system have no direct effect on the incidence of breast cancer in Germany. Possible effects on tumor progression and prognosis remain elusive.",N,FPN1,SLC40A1,1
866,bc_id908,CANCER,VEGFA,15897560,B,Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.,2005,"Although none of the polymorphisms studied in the VEGF gene was found to influence susceptibility to breast cancer significantly, some of the VEGF genotypes and haplotypes may influence tumor growth through an altered expression of VEGF and tumor angiogenesis.",X,X,X,X,0
867,bc_id909,CANCER,IFNG,15900487,Y,Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer.,2005,The study concludes that such genetic background for a proposed non-specific enhancer element with (CA)(n) repeat within intron 1 of the IFNG gene might put the individuals with this genotype at higher risk to promote the development of sporadic breast cancer due to a resultant compromised immune surveillance.,The study concludes that such genetic background for a proposed non-specific enhancer element with (CA)(n) repeat within intron 1 of the IFNG gene might put the individuals with this genotype at higher risk to promote the development of sporadic breast cancer due to a resultant compromised immune surveillance.,A,IFNG,IFNG,0.75
868,bc_id911,CANCER,BRCA2,15900600,B,Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.,2005,"These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.","These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.",N,BRCA2,BRCA2,0.098901099
869,bc_id912,CANCER,BRCA1,15900600,B,Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.,2005,"These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.","These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.",N,BRCA1,BRCA1,0.064377682
870,bc_id913,CANCER,NCOA3,15900600,B,Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.,2005,"These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.","These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.",N,AIB1,NCOA3,0.571428571
871,bc_id914,CANCER,MPO,15901995,Y,Genetic variants of myeloperoxidase and catechol-O-methyltransferase and breast cancer risk.,2005,"Our results demonstrate that the MPO A/A genotype was associated with a reduced risk of breast cancer (odds ratio (OR) 0.64; 95% confidence interval (CI) 0.11-3.76), whereas there was no overall association of COMT genotype with breast cancer. Of note, an elevated breast cancer risk associated with the increasing numbers of high-risk genotypes of MPO and COMT genes was observed in women with a longer duration between menarche and first full-term pregnancy.","Our results demonstrate that the MPO A/A genotype was associated with a reduced risk of breast cancer (odds ratio (OR) 0.64; 95% confidence interval (CI) 0.11-3.76), whereas there was no overall association of COMT genotype with breast cancer. Of note, an elevated breast cancer risk associated with the increasing numbers of high-risk genotypes of MPO and COMT genes was observed in women with a longer duration between menarche and first full-term pregnancy.",Y,MPO,MPO,0.428571429
872,bc_id915,CANCER,COMT,15901995,N,Genetic variants of myeloperoxidase and catechol-O-methyltransferase and breast cancer risk.,2005,"Our results demonstrate that the MPO A/A genotype was associated with a reduced risk of breast cancer (odds ratio (OR) 0.64; 95% confidence interval (CI) 0.11-3.76), whereas there was no overall association of COMT genotype with breast cancer. Of note, an elevated breast cancer risk associated with the increasing numbers of high-risk genotypes of MPO and COMT genes was observed in women with a longer duration between menarche and first full-term pregnancy.","Our results demonstrate that the MPO A/A genotype was associated with a reduced risk of breast cancer (odds ratio (OR) 0.64; 95% confidence interval (CI) 0.11-3.76), whereas there was no overall association of COMT genotype with breast cancer.",N,COMT,COMT,0.29787234
873,bc_id916,CANCER,SERPINE1,15907980,Y,Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.,2005,Tissue PAI-1 antigen levels and tumor severity seem to be associated with the PAI-1 4G/5G polymorphism. Further studies with a larger number of patients are needed to clarify the influence of this polymorphism in breast cancer.,Tissue PAI-1 antigen levels and tumor severity seem to be associated with the PAI-1 4G/5G polymorphism. Further studies with a larger number of patients are needed to clarify the influence of this polymorphism in breast cancer.,A,PAI-1,SERPINE1,1
874,bc_id917,CANCER,VDR,15911240,B,"Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population.",2005,,"This study indicates that low levels of circulating 25(OH)D, both alone and in combination with BsmI VDR genotype, may increase risk of breast cancer in a UK Caucasian population.",A,VDR,VDR,0.538461538
875,bc_id918,CANCER,MYC,15929079,Y,c-MYC Asn11Ser is associated with increased risk for familial breast cancer.,2005,"The breast cancer risk associated with this genotype increases above the age of 50 years (OR = 2.24, 95% CI 1.20-4.21, p = 0.012). The wild-type amino acid Asn of this polymorphism is located in the N-terminal MYC transactivation domain and is highly conserved not only among most diverse species but also in the N-MYC homologue. Due to the pivotal role of c-MYC in diverse tumours, this variant might affect the genetic susceptibility of other cancers as well.","The breast cancer risk associated with this genotype increases above the age of 50 years (OR = 2.24, 95% CI 1.20-4.21, p = 0.012). The wild-type amino acid Asn of this polymorphism is located in the N-terminal MYC transactivation domain and is highly conserved not only among most diverse species but also in the N-MYC homologue. Due to the pivotal role of c-MYC in diverse tumours, this variant might affect the genetic susceptibility of other cancers as well.",A,MYC,MYC,0.5
876,bc_id919,CANCER,BRCA2,15930334,B,Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.,2005,,X,X,X,X,0
877,bc_id920,CANCER,BRCA1,15930334,B,Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.,2005,,X,X,X,X,0
878,bc_id921,CANCER,IL10,15931634,B,The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer.,2005,Inheritance of specific alleles that modify IL-10 and IFN-gamma production may have unexpected effects on the efficacy of immune-based strategies after autologous BMT. Additional studies are necessary to further define the influence of IL-10 and IFN-gamma on the immune response after BMT.,This study evaluated the relationship between inheritance of polymorphisms within the IL-10 promoter and in the IFN-gamma gene and the overall survival of patients who received autologous BMT for metastatic breast cancer... Inheritance of specific alleles that modify IL-10 and IFN-gamma production may have unexpected effects on the efficacy of immune-based strategies after autologous BMT. Additional studies are necessary to further define the influence of IL-10 and IFN-gamma on the immune response after BMT.,A,IL-10,IL10,0.625
879,bc_id922,CANCER,IFNG,15931634,B,The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer.,2005,Inheritance of specific alleles that modify IL-10 and IFN-gamma production may have unexpected effects on the efficacy of immune-based strategies after autologous BMT. Additional studies are necessary to further define the influence of IL-10 and IFN-gamma on the immune response after BMT.,This study evaluated the relationship between inheritance of polymorphisms within the IL-10 promoter and in the IFN-gamma gene and the overall survival of patients who received autologous BMT for metastatic breast cancer... Inheritance of specific alleles that modify IL-10 and IFN-gamma production may have unexpected effects on the efficacy of immune-based strategies after autologous BMT. Additional studies are necessary to further define the influence of IL-10 and IFN-gamma on the immune response after BMT.,A,IFN-gamma,IFNG,0.75
880,bc_id923,CANCER,SOD2,15933380,B,Is the Val16Ala manganese superoxide dismutase polymorphism associated with the aging process?,2005,"We did not find an association between SOD2 polymorphisms and mortality. However, the AA genotype was associated with increased risk for prostate and breast cancer, immunosenescence profile, as well as DNA damage. These data suggest that SOD2 presents characteristics that support the free radical theory of aging.",We did not find an association between SOD2 polymorphisms and mortality.,N,SOD2,SOD2,0.375
881,bc_id924,CANCER,TGFB1,15941974,B,Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages.,2005,,"On the other hand, the same allele was associated with nonsignificantly increased risk of breast cancer with advanced stages III and IV (OR, 1.33; 95% CI, 0.81-2.18), which differed significantly from that observed for early-stage cancer (P = 0.04). This result suggests a possible dual effect of TGF-beta1 shown by in vitro experiments and provides an explanation for some of the inconsistent findings from previous epidemiologic studies that did not evaluate this association by cancer stage.",A,TGF-beta1,TGFB1,0.518518519
882,bc_id925,CANCER,RASSF1,15942659,Y,A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast.,2005,,Our data indicate that the mutant T-allele of RASSF1A at codon 133 is correlated with an increased number of breast tumors.,Y,RASSF1A,RASSF1,0.666666667
883,bc_id926,CANCER,SULT1A1,15952058,B,Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.,2005,,"When UGT2B15 and SULT1A1 'at-risk' alleles were combined, women with two variant alleles had significantly greater risk of recurrence and poorer survival than those with common alleles. These studies indicate that genetic variation in Phase II conjugating enzymes can influence the efficacy of tamoxifen therapy for breast cancer.",Y,SULT1A1,SULT1A1,0.322580645
884,bc_id927,CANCER,UGT2B15,15952058,B,Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.,2005,,"When UGT2B15 and SULT1A1 'at-risk' alleles were combined, women with two variant alleles had significantly greater risk of recurrence and poorer survival than those with common alleles. These studies indicate that genetic variation in Phase II conjugating enzymes can influence the efficacy of tamoxifen therapy for breast cancer.",Y,UGT2B15,UGT2B15,0.333333333
885,bc_id928,CANCER,CYP2D6,15952058,B,Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.,2005,,we found no significant association between CYP2D6 genotype and overall survival in either group of breast cancer patients.,N,CYP2D6,CYP2D6,0.136363636
886,bc_id929,CANCER,VEGFA,15958542,B,Association of genetic polymorphisms in the VEGF gene with breast cancer survival.,2005,,This study suggests that VEGF polymorphisms may be a significant genetic marker for breast cancer prognosis.,A,VEGF,VEGFA,0.416666667
887,bc_id930,CANCER,XRCC6,15958648,B,"Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.",2005,"Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.",X,X,X,X,0
888,bc_id931,CANCER,ERCC1,15958648,B,"Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.",2005,"Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.","Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.",A,ERCC1,ERCC1,1
889,bc_id932,CANCER,RAD52,15958648,B,"Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.",2005,"Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.","Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.",A,RAD52,RAD52,0.666666667
890,bc_id933,CANCER,RAD51,15958648,B,"Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.",2005,"Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.",X,X,X,X,0
891,bc_id934,CANCER,MLH1,15958648,B,"Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.",2005,"Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.","Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.",A,MLH1,MLH1,1
892,bc_id935,CANCER,LIG4,15958648,B,"Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.",2005,"Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.",X,X,X,X,0
893,bc_id936,CANCER,LIG1,15958648,B,"Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.",2005,"Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.",X,X,X,X,0
894,bc_id937,CANCER,XRCC2,15958648,B,"Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.",2005,"Our findings suggest that genetic polymorphisms of RAD52, ERCC1, and hMLH1 may be associated with breast cancer risk in Korean women.",X,X,X,X,0
895,bc_id938,CANCER,ERBB2,15970791,B,The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk.,2005,"We conclude that  this polymorphism is not associated with an increase in breast cancer risk, and may in fact be associated with a modest decrease in risk.","The erbB2 (HER2/neu) gene is found amplified in tumours. A single nucleotide polymorphism at codon 655 (Ile655Val) has been studied in a number of case-control studies with respect to breast cancer risk, with conflicting results...  We conclude that this polymorphism is not associated with an increase in breast cancer risk, and may in fact be associated with a modest decrease in risk.",A,erbB2,ERBB2,0.452380952
896,bc_id939,CANCER,ITGB3,15970922,B,No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype.,2005,,"To pursue a borderline increased risk of breast cancer for carriers of two integrin beta(3) (ITGB3) 33Pro alleles found in a recent prospective study, we conducted a case-control study of 1088 women with breast cancer and 4815 female controls... After stratification for conventional risk factors, odds ratio for breast cancer in heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers were not increased above 1.0 in any of the 14 strata examined. This was also true after stratification for tumour histological subtype and cancer stage at the time of diagnosis.",N,ITGB3,ITGB3,0.666666667
897,bc_id940,CANCER,TNFRSF10A,15975957,Y,Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk.,2005,,X,X,X,X,0
898,bc_id941,CANCER,CXCL12,15978329,B,Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma.,2005,"Results showed that the frequency of AA and AG genotypes was higher among patients, while the frequency of GG genotype was lower compared to the controls. Thus AA and AG genotypes of SDF-1 may be considered as factors increasing the susceptibility of Iranian women to breast cancer.","Results showed that the frequency of AA and AG genotypes was higher among patients, while the frequency of GG genotype was lower compared to the controls. Thus AA and AG genotypes of SDF-1 may be considered as factors increasing the susceptibility of Iranian women to breast cancer.",A,SDF-1,CXCL12,0.333333333
899,bc_id942,CANCER,BRCA2,15978801,B,Hereditary breast cancer growth rates and its impact on screening policy.,2005,", age at detection indicated the growth rates of hereditary and familial breast cancers.","Imaging is often performed yearly for the surveillance of BRCA1/2 mutation carriers and women at high familial breast cancer risk... In conclusion, age at detection indicated the growth rates of hereditary and familial breast cancers.",Y,BRCA1/2,BRCA2,0.324175824
900,bc_id943,CANCER,BRCA1,15978801,B,Hereditary breast cancer growth rates and its impact on screening policy.,2005,", age at detection indicated the growth rates of hereditary and familial breast cancers.","Imaging is often performed yearly for the surveillance of BRCA1/2 mutation carriers and women at high familial breast cancer risk... In conclusion, age at detection indicated the growth rates of hereditary and familial breast cancers.",Y,BRCA1/2,BRCA1,0.326180258
901,bc_id944,CANCER,CHEK2,15980987,B,Breast cancer predisposing alleles in Poland.,2005,,"In Poland founder alleles of the BRCA1, CHEK2 and NBS1 genes have been associated with an increased risk of breast cancer, but the relative contribution of each of these alleles to the overall breast cancer burden has not yet been determined.",Y,CHEK2,CHEK2,0.383333333
902,bc_id945,CANCER,BRCA1,15980987,B,Breast cancer predisposing alleles in Poland.,2005,,"In Poland founder alleles of the BRCA1, CHEK2 and NBS1 genes have been associated with an increased risk of breast cancer, but the relative contribution of each of these alleles to the overall breast cancer burden has not yet been determined.",Y,BRCA1,BRCA1,0.326180258
903,bc_id946,CANCER,NBN,15980987,B,Breast cancer predisposing alleles in Poland.,2005,,"In Poland founder alleles of the BRCA1, CHEK2 and NBS1 genes have been associated with an increased risk of breast cancer, but the relative contribution of each of these alleles to the overall breast cancer burden has not yet been determined.",Y,NBS1,NBN,0.19047619
904,bc_id947,CANCER,BRCA2,15983021,B,Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women.,2006,"Young African American women with breast cancer have a similar frequency of deleterious mutations as white women, but have a significantly higher frequency of variants of uncertain significance.","After IRB approved informed consent, 170 white women and 30 African American women with known breast cancer diagnosed at a young age (45 years or less) underwent complete sequencing of the BRCA1 and BRCA2 genes. Each cohort represented approximately 40% of women of the same ethnic background aged 45 years or younger in a breast cancer database.",Y,BRCA2,BRCA2,0.324175824
905,bc_id948,CANCER,BRCA1,15983021,B,Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women.,2006,"Young African American women with breast cancer have a similar frequency of deleterious mutations as white women, but have a significantly higher frequency of variants of uncertain significance.","After IRB approved informed consent, 170 white women and 30 African American women with known breast cancer diagnosed at a young age (45 years or less) underwent complete sequencing of the BRCA1 and BRCA2 genes. Each cohort represented approximately 40% of women of the same ethnic background aged 45 years or younger in a breast cancer database.",Y,BRCA1,BRCA1,0.326180258
906,bc_id949,CANCER,IGFBP3,15986122,B,Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer.,2005,,"Thus, the polymorphisms in the IGF-1 and IGFBP 3 genes associated with an increased risk of breast cancer in familial cases carrying the variant alleles.",Y,IGFBP 3,IGFBP3,0.357142857
907,bc_id950,CANCER,IGF1,15986122,B,Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer.,2005,,"Thus, the polymorphisms in the IGF-1 and IGFBP 3 genes associated with an increased risk of breast cancer in familial cases carrying the variant alleles.",Y,IGF-1,IGF1,0.35
908,bc_id951,CANCER,BRCA2,15986445,B,Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.,2005,,"A modest reduction in risk of breast cancer was observed among BRCA1 carriers with 4 or more births. Among BRCA2 carriers, increasing parity was associated with a significant increase in the risk of breast cancer before age 50 and this increase was greatest in the 2-year period following a pregnancy.",A,BRCA2,BRCA2,0.576923077
909,bc_id952,CANCER,BRCA1,15986445,B,Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.,2005,,"A modest reduction in risk of breast cancer was observed among BRCA1 carriers with 4 or more births. Among BRCA2 carriers, increasing parity was associated with a significant increase in the risk of breast cancer before age 50 and this increase was greatest in the 2-year period following a pregnancy.",A,BRCA1,BRCA1,0.60944206
910,bc_id953,CANCER,SULT1A1,15987423,B,Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.,2005,"The present study suggests that genotype of metabolic enzymes might be useful as a guide for adjuvant endocrine treatment of postmenopausal breast cancer patients. However, results are in contradiction to prior hypotheses and the present sample size is relatively small. Findings therefore need to be confirmed in a larger cohort.",The CYP2D6*4 and SULT1A1*2 genotypes result in decreased enzyme activity. We therefore investigated the genotypes of CYP2D6 and SULT1A1 in 226 breast cancer patients participating in a trial of adjuvant tamoxifen treatment in order to validate the benefit from the therapy.,Y,SULT1A1*2,SULT1A1,0.322580645
911,bc_id954,CANCER,CYP2D6,15987423,B,Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.,2005,"The present study suggests that genotype of metabolic enzymes might be useful as a guide for adjuvant endocrine treatment of postmenopausal breast cancer patients. However, results are in contradiction to prior hypotheses and the present sample size is relatively small. Findings therefore need to be confirmed in a larger cohort.",The CYP2D6*4 and SULT1A1*2 genotypes result in decreased enzyme activity. We therefore investigated the genotypes of CYP2D6 and SULT1A1 in 226 breast cancer patients participating in a trial of adjuvant tamoxifen treatment in order to validate the benefit from the therapy.,Y,CYP2D6*4,CYP2D6,0.272727273
912,bc_id955,CANCER,NCOA3,15987430,N,The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.,2005,"There was no evidence that risk of breast cancer depends on AIB1 CAG/CAA polymorphism status, even if affected women carry a mutation in BRCA1 or BRCA2.","There was no evidence that risk of breast cancer depends on AIB1 CAG/CAA polymorphism status, even if affected women carry a mutation in BRCA1 or BRCA2.",N,AIB1,NCOA3,0.571428571
913,bc_id956,CANCER,ERBB2,15987431,B,A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.,2005,"Although results from our population-based case-control study show an inverse association between the HER2 Ile655Val polymorphism and risk of invasive breast cancer, most other studies of this single-nucleotide polymorphism suggest an overall null association. Any further study of this polymorphism should involve sample populations with complete risk factor information and sufficient power to evaluate gene-environment interactions between the HER2 polymorphism and factors such as age and family history of breast cancer.","Although results from our population-based case-control study show an inverse association between the HER2 Ile655Val polymorphism and risk of invasive breast cancer, most other studies of this single-nucleotide polymorphism suggest an overall null association. Any further study of this polymorphism should involve sample populations with complete risk factor information and sufficient power to evaluate gene-environment interactions between the HER2 polymorphism and factors such as age and family history of breast cancer.",Y,HER2,ERBB2,0.285714286
914,bc_id957,CANCER,NAT2,15987434,B,A case-only analysis of the interaction between N-acetyltransferase 2 haplotypes and tobacco smoke in breast cancer etiology.,2005,"In this, the largest case-only study to evaluate the interaction between acetylation status and active or passive exposure to tobacco smoke, we found little evidence to support the idea of a departure from multiplicativity.","N-acetyltransferase 2 is a polymorphic enzyme in humans. Women who possess homozygous polymorphic alleles have a slower rate of metabolic activation of aryl aromatic amines, one of the constituents of tobacco smoke that has been identified as carcinogenic. We hypothesized that women with breast cancer who were slow acetylators would be at increased risk of breast cancer associated with active and passive exposure to tobacco smoke.",Y,N-acetyltransferase 2,NAT2,0.37037037
915,bc_id958,CANCER,CYP17A1,15987450,B,CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.,2005,"Our results do not indicate a major influence of CYP17 MspA1 polymorphism on the risk of premenopausal breast cancer, but suggest that it may have an impact on breast cancer risk among nulliparous women. The finding, however, needs to be confirmed in further studies.","Our results do not indicate a major influence of CYP17 MspA1 polymorphism on the risk of premenopausal breast cancer, but suggest that it may have an impact on breast cancer risk among nulliparous women. The finding, however, needs to be confirmed in further studies.",A,CYP17,CYP17A1,0.466666667
916,bc_id959,CANCER,ATR,15987455,B,Mutation analysis of the ATR gene in breast and ovarian cancer families.,2005,The present study does not support a major role for ATR mutations in hereditary susceptibility to breast and ovarian cancer.,The present study does not support a major role for ATR mutations in hereditary susceptibility to breast and ovarian cancer.,N,ATR,ATR,0.333333333
917,bc_id960,CANCER,CHEK2,15987456,B,TP53-binding protein variants and breast cancer risk: a case-control study.,2005,"The lack of association casts doubt on the putative effects of D353E, G412S, and K1136Q on breast cancer risk. Investigating a larger study cohort might elucidate the influence of the 6bp deletion 1347_1352delTATCCC. Studying the functional effect and the impact of this variant on the risk of other cancers may be revealing.","Genetic aberrations in TP53 and in ATM and CHEK2 predispose to cancer... The lack of association casts doubt on the putative effects of D353E, G412S, and K1136Q on breast cancer risk. Investigating a larger study cohort might elucidate the influence of the 6bp deletion 1347_1352delTATCCC. Studying the functional effect and the impact of this variant on the risk of other cancers may be revealing.",A,CHEK2,CHEK2,0.383333333
918,bc_id961,CANCER,TP53,15987456,B,TP53-binding protein variants and breast cancer risk: a case-control study.,2005,"The lack of association casts doubt on the putative effects of D353E, G412S, and K1136Q on breast cancer risk. Investigating a larger study cohort might elucidate the influence of the 6bp deletion 1347_1352delTATCCC. Studying the functional effect and the impact of this variant on the risk of other cancers may be revealing.","Genetic aberrations in TP53 and in ATM and CHEK2 predispose to cancer... The lack of association casts doubt on the putative effects of D353E, G412S, and K1136Q on breast cancer risk. Investigating a larger study cohort might elucidate the influence of the 6bp deletion 1347_1352delTATCCC. Studying the functional effect and the impact of this variant on the risk of other cancers may be revealing.",A,TP53,TP53,0.482758621
919,bc_id962,CANCER,ATM,15987456,B,TP53-binding protein variants and breast cancer risk: a case-control study.,2005,"The lack of association casts doubt on the putative effects of D353E, G412S, and K1136Q on breast cancer risk. Investigating a larger study cohort might elucidate the influence of the 6bp deletion 1347_1352delTATCCC. Studying the functional effect and the impact of this variant on the risk of other cancers may be revealing.","Genetic aberrations in TP53 and in ATM and CHEK2 predispose to cancer... The lack of association casts doubt on the putative effects of D353E, G412S, and K1136Q on breast cancer risk. Investigating a larger study cohort might elucidate the influence of the 6bp deletion 1347_1352delTATCCC. Studying the functional effect and the impact of this variant on the risk of other cancers may be revealing.",A,ATM,ATM,0.422222222
920,bc_id963,CANCER,MMP12,15987457,B,Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast CancerStudy.,2005,This result suggests that MMP12 A1082G polymorphism may be related to prognosis in breast cancer patients. Additional studies with larger sample sizes are warranted.,This result suggests that MMP12 A1082G polymorphism may be related to prognosis in breast cancer patients. Additional studies with larger sample sizes are warranted.,A,MMP12,MMP12,1
921,bc_id964,CANCER,CYP17A1,15987458,B,"CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian BreastCancer Family Study.",2005,"We observed no evidence of effect modification of reproductive risk factors by CYP17 genotype, although the experiment did not have sufficient statistical power to detect small main effects and modest effects in subgroups. Associations found only in subgroup analyses based on relatively small numbers require cautious interpretation without confirmation by other studies. This emphasizes the need for replication in multiple and large population-based studies to provide convincing evidence for gene-environment interactions.",We found no associations between the CYP17 genotype and breast cancer overall.,N,CYP17,CYP17A1,0.266666667
922,bc_id965,CANCER,GSTO2,15992993,B,Polymorphism of glutathione S-transferase Omega gene and risk of cancer.,2005,,"In this case control study, 28 cases of hepatocellular carcinoma, 30 cases of cholangiocarcinoma, 31 cases of colorectal cancer, 30 cases of breast cancer and 98 controls were compared for frequencies of GSTO1 and GSTO2 genotypes...  The study suggests that GSTO1*A140D polymorphism could play an important role as a risk factor for the development of hepatocellular carcinoma, cholangiocarcinoma and breast cancer.",A,GSTO2,GSTO2,1
923,bc_id966,CANCER,GSTO1,15992993,B,Polymorphism of glutathione S-transferase Omega gene and risk of cancer.,2005,,"In this case control study, 28 cases of hepatocellular carcinoma, 30 cases of cholangiocarcinoma, 31 cases of colorectal cancer, 30 cases of breast cancer and 98 controls were compared for frequencies of GSTO1 and GSTO2 genotypes...  The study suggests that GSTO1*A140D polymorphism could play an important role as a risk factor for the development of hepatocellular carcinoma, cholangiocarcinoma and breast cancer.",A,GSTO1,GSTO1,0.666666667
924,bc_id967,CANCER,BRCA2,15996267,B,Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.,2006,,"In the 86 BRCA-WT patients, the first event was a local relapse in 3 (3%), metachronous contralateral breast cancer in 7 (8%) and distant metastases in 16 (19%). In the 39 BRCA positive patients, the corresponding figures were 3 (8%), 8 (21%) and 3 (8%). There was no difference in event free survival, with a median of 180 months in both groups of patients. At 20 years, projected survival was 85% for BRCA positive patients and 55% for BRCA-WT, but this difference was not statistically significant.",A,BRCA,BRCA2,0.576923077
925,bc_id968,CANCER,BRCA1,15996267,B,Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases.,2006,,"In the 86 BRCA-WT patients, the first event was a local relapse in 3 (3%), metachronous contralateral breast cancer in 7 (8%) and distant metastases in 16 (19%). In the 39 BRCA positive patients, the corresponding figures were 3 (8%), 8 (21%) and 3 (8%). There was no difference in event free survival, with a median of 180 months in both groups of patients. At 20 years, projected survival was 85% for BRCA positive patients and 55% for BRCA-WT, but this difference was not statistically significant.",A,BRCA,BRCA1,0.60944206
926,bc_id969,CANCER,LTA,15999154,B,Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients.,2005,,Our findings indicate that TNFA and TNFB polymorphisms may be associated with the levels of steroid receptor expression in breast cancer patients.,A,TNFB,LTA,0.75
927,bc_id970,CANCER,TNF,15999154,B,Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients.,2005,,Our findings indicate that TNFA and TNFB polymorphisms may be associated with the levels of steroid receptor expression in breast cancer patients.,A,TNFA,TNF,0.4
928,bc_id971,CANCER,PTPRJ,16000320,B,Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer.,2005,,"Thus, carrying a specific PTPRJ haplotype confers a protective effect on the risk of breast cancer.",Y,PTPRJ,PTPRJ,1
929,bc_id972,CANCER,ERBB2,16000574,B,"A haplotype analysis of HER-2 gene polymorphisms:association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.",2005,"Our results suggest that the currently identified genetic polymorphisms of HER-2 are not associated with an increased risk of breast cancer in Korean women, whereas one haplotype does affect protein expression of the tumor and disease outcome.","Our results suggest that the currently identified genetic polymorphisms of HER-2 are not associated with an increased risk of breast cancer in Korean women, whereas one haplotype does affect protein expression of the tumor and disease outcome.",N,HER-2,ERBB2,0.261904762
930,bc_id973,CANCER,ERCC2,16002061,B,Single nucleotide polymorphisms for DNA repair genes in breast cancer patients.,2005,"The genotypes of A/C in XPC exon 15, T/C in XRCC3 exon 7 and A/A in XPD exon 10 studied were significantly different between BC group and control group in Chinese population.","The genotypes of A/C in XPC exon 15, T/C in XRCC3 exon 7 and A/A in XPD exon 10 studied were significantly different between BC group and control group in Chinese population.",A,XPD,ERCC2,0.6875
931,bc_id974,CANCER,NBN,16002061,B,Single nucleotide polymorphisms for DNA repair genes in breast cancer patients.,2005,"The genotypes of A/C in XPC exon 15, T/C in XRCC3 exon 7 and A/A in XPD exon 10 studied were significantly different between BC group and control group in Chinese population.","For the SNPs in NBS1 exon 5 (Glu185Gln, G/C) and XPD exon 23 (Lys751Gln, A/C), no remarkable difference for genotype distributions and allele frequencies was observed between BC group and control group in the study.",A,NBS1,NBN,0.571428571
932,bc_id975,CANCER,XPC,16002061,B,Single nucleotide polymorphisms for DNA repair genes in breast cancer patients.,2005,"The genotypes of A/C in XPC exon 15, T/C in XRCC3 exon 7 and A/A in XPD exon 10 studied were significantly different between BC group and control group in Chinese population.","The genotypes of A/C in XPC exon 15, T/C in XRCC3 exon 7 and A/A in XPD exon 10 studied were significantly different between BC group and control group in Chinese population.",A,XPC,XPC,0.571428571
933,bc_id976,CANCER,XRCC3,16002061,B,Single nucleotide polymorphisms for DNA repair genes in breast cancer patients.,2005,"The genotypes of A/C in XPC exon 15, T/C in XRCC3 exon 7 and A/A in XPD exon 10 studied were significantly different between BC group and control group in Chinese population.","The genotypes of A/C in XPC exon 15, T/C in XRCC3 exon 7 and A/A in XPD exon 10 studied were significantly different between BC group and control group in Chinese population.",A,XRCC3,XRCC3,0.461538462
934,bc_id977,CANCER,LEPR,16011872,B,"Relationships among serum leptin, leptin receptor gene polymorphisms, and breast cancer in Korea.",2006,,Our results indicate that it is difficult to explain breast cancer on the basis of serum leptin concentrations or polymorphisms in the LEPR gene.,N,LEPR,LEPR,0.428571429
935,bc_id978,CANCER,FGFR4,16012724,B,FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.,2005,,"Thus, the FGFR4 polymorphism may not be relevant in predicting nodal involvement of breast cancer or colon cancer patients.",A,FGFR4,FGFR4,0.2
936,bc_id979,CANCER,MGMT,16014702,B,"MGMT genotype modulates the associations between cigarette smoking, dietary antioxidants and breast cancer risk.",2005,,"These data suggest that polymorphisms in MGMT may modulate the inverse association previously observed between fruits and vegetables consumption, dietary antioxidants and breast cancer risk, and support the importance of fruits and vegetables on breast cancer risk reduction.",A,MGMT,MGMT,0.5
937,bc_id980,CANCER,BRCA1,16026807,B,"BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.",2005,Mutations in the BRCA1 gene are frequent also in our consecutive series of patients from southern Italy.,"Mutations in the BRCA1 gene are frequent also in our consecutive series of patients from southern Italy. An association between two detected single nucleotide polymorphisms (SNPs) and BRCA1 mutational risk was ascertained. Finally, we confirm the fact that peculiar clinical-pathological features seem to characterize patients with a family history of breast cancer and BRCA1 alterations.",Y,BRCA1,BRCA1,0.326180258
938,bc_id981,CANCER,ERCC2,16030124,N,Common polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not associated with breast cancer risk.,2005,,"We have examined the association between single nucleotide polymorphisms in the ERCC2 gene and the incidence of invasive breast cancer in three case-control series, with a maximum of 3,634 patients and of 3,340 controls. None of the three single nucleotide polymorphisms were significantly associated with the incidence of breast cancer.",N,ERCC2,ERCC2,0.1875
939,bc_id982,CANCER,BRCA2,16032702,B,Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers.,2006,,X,X,X,X,0
940,bc_id983,CANCER,BRCA1,16032702,B,Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers.,2006,,X,X,X,X,0
941,bc_id984,CANCER,TP53,16033823,B,Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.,2005,These results suggest no effect of either R72P allele on breast cancer risk but a significantly reduced survival for 72P homozygous breast cancer patients.,"The p53 R72P polymorphism has been suggested to play a role in many cancers, including breast cancer... These results suggest no effect of either R72P allele on breast cancer risk but a significantly reduced survival for 72P homozygous breast cancer patients.",Y,p53,TP53,0.367816092
942,bc_id985,CANCER,CHEK2,16043347,B,No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors.,2005,,"The CHEK2 1100delC mutation was analysed in the same series of patients and controls as in the HLA breast cancer study...The 1100delC mutation and the HLA risk haplotype confer increased breast cancer risks, but an interactive effect on breast cancer between both factors is unlikely.",Y,CHEK2,CHEK2,0.383333333
943,bc_id986,CANCER,BRCA2,16049805,B,Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,2005,,X,X,X,X,0
944,bc_id987,CANCER,BRCA1,16049805,B,Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,2005,,X,X,X,X,0
945,bc_id988,CANCER,GSTT1,16049806,B,Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands).,2005,,"Smoking did not influence breast cancer risk nor did genetic variations in NAT1, NAT2 or GSTM1 in combination with smoking. Compared to women who never smoked with GSTT1 present, women with GSTT1 null genotype and who formerly smoked showed an increased breast cancer risk (RR = 2.55 (95% CI 1.10-5.90)), but current smokers who smoked 20 cigarettes or more per day did not (RR = 1.06 (95% CI 0.51-2.18)). Increasing numbers of putative at risk genotypes increased breast cancer risk in a dose dependent manner (p for trend 0.01).",Y,GSTT1,GSTT1,0.578947368
946,bc_id989,CANCER,GSTM1,16049806,B,Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands).,2005,,"Smoking did not influence breast cancer risk nor did genetic variations in NAT1, NAT2 or GSTM1 in combination with smoking. Compared to women who never smoked with GSTT1 present, women with GSTT1 null genotype and who formerly smoked showed an increased breast cancer risk (RR = 2.55 (95% CI 1.10-5.90)), but current smokers who smoked 20 cigarettes or more per day did not (RR = 1.06 (95% CI 0.51-2.18)). Increasing numbers of putative at risk genotypes increased breast cancer risk in a dose dependent manner (p for trend 0.01).",N,GSTM1,GSTM1,0.20754717
947,bc_id990,CANCER,NAT2,16049806,B,Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands).,2005,,"Smoking did not influence breast cancer risk nor did genetic variations in NAT1, NAT2 or GSTM1 in combination with smoking. Compared to women who never smoked with GSTT1 present, women with GSTT1 null genotype and who formerly smoked showed an increased breast cancer risk (RR = 2.55 (95% CI 1.10-5.90)), but current smokers who smoked 20 cigarettes or more per day did not (RR = 1.06 (95% CI 0.51-2.18)). Increasing numbers of putative at risk genotypes increased breast cancer risk in a dose dependent manner (p for trend 0.01).",N,NAT2,NAT2,0.37037037
948,bc_id991,CANCER,NAT1,16049806,B,Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands).,2005,,"Smoking did not influence breast cancer risk nor did genetic variations in NAT1, NAT2 or GSTM1 in combination with smoking. Compared to women who never smoked with GSTT1 present, women with GSTT1 null genotype and who formerly smoked showed an increased breast cancer risk (RR = 2.55 (95% CI 1.10-5.90)), but current smokers who smoked 20 cigarettes or more per day did not (RR = 1.06 (95% CI 0.51-2.18)). Increasing numbers of putative at risk genotypes increased breast cancer risk in a dose dependent manner (p for trend 0.01).",N,NAT1,NAT1,0.6
949,bc_id992,CANCER,COMT,16077979,B,Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer.,2005,,These results suggest that COMT polymorphism may thus be implicated as a genetic trait affecting the susceptibility of an individual to breast cancer in a Japanese population and be an important genetic risk factor in the development of breast cancer in post-menopausal women.,A,COMT,COMT,0.425531915
950,bc_id993,CANCER,SULT1A1,16080486,B,Sulfotransferase1A1 and risk of postmenopausal breast cancer.,2005,,"The detoxification enzyme sulfotransferase1A1 (SULT1A1) is implicated in the inactivation of estrogens and the activation of promutagens and procarcinogens. SULT1A1 activity varies among individuals, and this difference in phenotype is, in part, controlled by genetic polymorphism (Arg-->His in codon 213). It is hypothesized that the His allele contributes to the risk of postmenopausal breast cancer.",A,SULT1A1,SULT1A1,0.387096774
951,bc_id995,CANCER,MTHFR,16097444,B,Homozygosity at the C677T of the MTHFR gene is associated with increased breast cancer risk in the Turkish population.,2005,,"In this case-controlled study, a possible effect of the common MTHFR C677T (ala-->val) polymorphism on breast cancer susceptibility in Turkish patients was investigated... Homozygosity for the low-activity C677T genotype (TT) may represent a genetic determinant increasing breast cancer risk.",A,MTHFR,MTHFR,0.403846154
952,bc_id996,CANCER,BRCA1,16103107,B,A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.,2005,,"Given the large size of our study population and detailed analysis of the locus, this result indicates either that common variants in BRCA1 do not substantially influence sporadic breast cancer risk, or that unmeasured heterogeneity in the breast cancer phenotype or unmeasured interactions with genetic or environmental exposures obscure our ability to detect any influence that may be present.",N,BRCA1,BRCA1,0.064377682
953,bc_id997,CANCER,CYP1B1,16103451,B,Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.,2003,,"The findings provide no evidence for a role of COMT Val58Met, CYP1A1*2A, CYP3A4*1B, CYP1B1 Leu432Val, SULT1A1 Arg213His, and AHR Arg554Lys in breast cancer etiology. They also provide support for an inverse association between CYP1A2*1F and breast cancer, which is consistent with the observation of lower circulating estrogen levels in premenopausal women with the CC genotype in a previous study.",N,CYP1B1,CYP1B1,0.256410256
954,bc_id998,CANCER,CYP1A2,16103451,B,Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.,2003,,"The findings provide no evidence for a role of COMT Val58Met, CYP1A1*2A, CYP3A4*1B, CYP1B1 Leu432Val, SULT1A1 Arg213His, and AHR Arg554Lys in breast cancer etiology. They also provide support for an inverse association between CYP1A2*1F and breast cancer, which is consistent with the observation of lower circulating estrogen levels in premenopausal women with the CC genotype in a previous study.",Y,CYP1A2*1F,CYP1A2,0.083333333
955,bc_id999,CANCER,CYP1A1,16103451,B,Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.,2003,,"The findings provide no evidence for a role of COMT Val58Met, CYP1A1*2A, CYP3A4*1B, CYP1B1 Leu432Val, SULT1A1 Arg213His, and AHR Arg554Lys in breast cancer etiology. They also provide support for an inverse association between CYP1A2*1F and breast cancer, which is consistent with the observation of lower circulating estrogen levels in premenopausal women with the CC genotype in a previous study.",N,CYP1A1*2A,CYP1A1,0.239130435
956,bc_id1000,CANCER,AHR,16103451,B,Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.,2003,,"The findings provide no evidence for a role of COMT Val58Met, CYP1A1*2A, CYP3A4*1B, CYP1B1 Leu432Val, SULT1A1 Arg213His, and AHR Arg554Lys in breast cancer etiology. They also provide support for an inverse association between CYP1A2*1F and breast cancer, which is consistent with the observation of lower circulating estrogen levels in premenopausal women with the CC genotype in a previous study.",N,AHR,AHR,0.4
957,bc_id1001,CANCER,SULT1A1,16103451,B,Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.,2003,,"The findings provide no evidence for a role of COMT Val58Met, CYP1A1*2A, CYP3A4*1B, CYP1B1 Leu432Val, SULT1A1 Arg213His, and AHR Arg554Lys in breast cancer etiology. They also provide support for an inverse association between CYP1A2*1F and breast cancer, which is consistent with the observation of lower circulating estrogen levels in premenopausal women with the CC genotype in a previous study.",N,SULT1A1,SULT1A1,0.290322581
958,bc_id1002,CANCER,COMT,16103451,B,Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.,2003,,"The findings provide no evidence for a role of COMT Val58Met, CYP1A1*2A, CYP3A4*1B, CYP1B1 Leu432Val, SULT1A1 Arg213His, and AHR Arg554Lys in breast cancer etiology. They also provide support for an inverse association between CYP1A2*1F and breast cancer, which is consistent with the observation of lower circulating estrogen levels in premenopausal women with the CC genotype in a previous study.",N,COMT,COMT,0.29787234
959,bc_id1003,CANCER,CYP3A4,16103451,B,Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.,2003,,"The findings provide no evidence for a role of COMT Val58Met, CYP1A1*2A, CYP3A4*1B, CYP1B1 Leu432Val, SULT1A1 Arg213His, and AHR Arg554Lys in breast cancer etiology. They also provide support for an inverse association between CYP1A2*1F and breast cancer, which is consistent with the observation of lower circulating estrogen levels in premenopausal women with the CC genotype in a previous study.",N,CYP3A4*1B,CYP3A4,0.363636364
960,bc_id1004,CANCER,CERD4,16109180,B,Genetic polymorphisms in DPF3 associated with risk of breast cancer and lymph node metastases.,2005,"Polymorphisms in the 5' region of DPF3 were associated with increased risk of breast cancer development, lymph node metastases, age of onset, and tumor size in women of European ancestry. This large-scale association study suggests that genetic variation in DPF3 contributes to breast cancer susceptibility and severity.","Polymorphisms in the 5' region of DPF3 were associated with increased risk of breast cancer development, lymph node metastases, age of onset, and tumor size in women of European ancestry.",Y,DPF3,CERD4,1
961,bc_id1005,CANCER,GSTT1,16110016,B,Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.,2005,"Combined genotypes at CYP3A4, CYP3A5, GSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.","Combined genotypes at CYP3A4, CYP3A5, GSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.",Y,GSTT1,GSTT1,0.578947368
962,bc_id1006,CANCER,GSTM1,16110016,B,Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.,2005,"Combined genotypes at CYP3A4, CYP3A5, GSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.","Combined genotypes at CYP3A4, CYP3A5, GSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.",Y,GSTM1,GSTM1,0.452830189
963,bc_id1007,CANCER,CYP3A5,16110016,B,Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.,2005,"Combined genotypes at CYP3A4, CYP3A5, GSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.","Combined genotypes at CYP3A4, CYP3A5, GSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.",Y,CYP3A5,CYP3A5,0.2
964,bc_id1008,CANCER,CYP3A4,16110016,B,Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.,2005,"Combined genotypes at CYP3A4, CYP3A5, GSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.","Combined genotypes at CYP3A4, CYP3A5, GSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.",Y,CYP3A4,CYP3A4,0.272727273
965,bc_id1009,CANCER,IL6,16115908,B,Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women.,2005,,"Although polymorphisms within the IL1 gene cluster do not seem to influence breast cancer risk or phenotype, presence of the -174C IL6 allele increases the risk of breast cancer in Caucasian women in a dose-dependent fashion.",Y,IL6,IL6,0.285714286
966,bc_id1010,CANCER,IL1RN,16115908,B,Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women.,2005,,X,X,X,X,0
967,bc_id1011,CANCER,IL1B,16115908,B,Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women.,2005,,X,X,X,X,0
968,bc_id1012,CANCER,IL1A,16115908,B,Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women.,2005,,"Although polymorphisms within the IL1 gene cluster do not seem to influence breast cancer risk or phenotype, presence of the -174C IL6 allele increases the risk of breast cancer in Caucasian women in a dose-dependent fashion.",N,IL1,IL1A,0.5
969,bc_id1013,CANCER,BRCA2,16118051,B,Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.,2005,,X,X,X,X,0
970,bc_id1014,CANCER,BRCA1,16118051,B,Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.,2005,,X,X,X,X,0
971,bc_id1015,CANCER,MTHFR,16134079,B,No association between methylenetetrahydrofolate reductase C677T polymorphism and breast cancer.,2007,,"Furthermore, association was observed among family history, metastatic risk and MTHFR genotypes in patients. Our data fail to support a relationship between MTHFR C677T and the risk for breast cancer.",N,MTHFR C677T,MTHFR,0.326923077
972,bc_id1016,CANCER,BRCA2,16140006,B,Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.,2005,,"BRCA1 and BRCA2 germline mutations are associated with a strong risk of breast cancer, which may preclude breast-conserving treatment in carriers.",Y,BRCA2,BRCA2,0.324175824
973,bc_id1017,CANCER,BRCA1,16140006,B,Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.,2005,,"BRCA1 and BRCA2 germline mutations are associated with a strong risk of breast cancer, which may preclude breast-conserving treatment in carriers.",Y,BRCA1,BRCA1,0.326180258
974,bc_id1018,CANCER,MT-ND3,16140977,B,Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women.,2005,,X,X,X,X,0
975,bc_id1019,CANCER,SULT1A1,16141802,B,Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women.,2005,,"Our results suggest that the SULT1A1 genotype is not an important risk factor for breast cancer in general, but may modify the risk among premenopausaul women with high parity.",N,SULT1A1,SULT1A1,0.290322581
976,bc_id1020,CANCER,CYP1A1,16142442,B,Estrogen metabolizing polymorphisms and breast cancer risk among older white women.,2005,,"The HR (95% CI) for breast cancer was 1.24 (0.87-1.75) for COMT(Val/Met) and 1.35 (0.93-1.97) for COMT(Met/Met). No interactions with lifestyle and reproductive factors were found. The HR associated with the CYP1A1*2C Val allele was 0.80 (0.46, 1.39) with little evidence for interactions with lifestyle or reproductive factors.",A,CYP1A1*2C,CYP1A1,0.456521739
977,bc_id1021,CANCER,COMT,16142442,B,Estrogen metabolizing polymorphisms and breast cancer risk among older white women.,2005,,"The HR (95% CI) for breast cancer was 1.24 (0.87-1.75) for COMT(Val/Met) and 1.35 (0.93-1.97) for COMT(Met/Met). No interactions with lifestyle and reproductive factors were found. The HR associated with the CYP1A1*2C Val allele was 0.80 (0.46, 1.39) with little evidence for interactions with lifestyle or reproductive factors.",A,COMT,COMT,0.425531915
978,bc_id1022,CANCER,SMYD3,16155568,B,A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.,2005,,"Here we report significant associations between homozygosity with respect to an allele with three tandem repeats of a CCGCC unit in the regulatory region of SMYD3 and increased risk of colorectal cancer (P = 9.1 x 10(-6), odds ratio = 2.58), hepatocellular carcinoma (P = 2.3 x 10(-8), odds ratio = 3.50) and breast cancer (P = 7.0 x 10(-10), odds ratio = 4.48)... These data suggest that the common variable number of tandem repeats polymorphism in SMYD3 is a susceptibility factor for some types of human cancer.",Y,SMYD3,SMYD3,1
979,bc_id1023,CANCER,BRCA1,16161633,Y,[Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer],2005,,These findings point to the association between the combinations of the BRCA1 and P53 allelic variants and the risk of breast cancer.,Y,BRCA1,BRCA1,0.326180258
980,bc_id1024,CANCER,TP53,16161633,B,[Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer],2005,,These findings point to the association between the combinations of the BRCA1 and P53 allelic variants and the risk of breast cancer.,Y,P53,TP53,0.367816092
981,bc_id1025,CANCER,PIK3CA,16168105,B,Somatic mutation and gain of copy number of PIK3CA in human breast cancer.,2005,Somatic mutation rather than a gain of gene copy number of PIK3CA is the frequent genetic alteration that contributes to human breast cancer progression. The frequent and clustered mutations within PIK3CA make it an attractive molecular marker for early detection and a promising therapeutic target in breast cancer.,Somatic mutation rather than a gain of gene copy number of PIK3CA is the frequent genetic alteration that contributes to human breast cancer progression. The frequent and clustered mutations within PIK3CA make it an attractive molecular marker for early detection and a promising therapeutic target in breast cancer.,Y,PIK3CA,PIK3CA,0.4
982,bc_id1026,CANCER,MBD2,16168120,B,Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status.,2005,Our results demonstrate a role for the MBD2 gene in breast carcinogenesis in premenopausal women. These findings suggest that genetic variations in methylation related genes may potentially serve as a biomarker in risk estimates for breast cancer.,Our results demonstrate a role for the MBD2 gene in breast carcinogenesis in premenopausal women. These findings suggest that genetic variations in methylation related genes may potentially serve as a biomarker in risk estimates for breast cancer.,Y,MBD2,MBD2,1
983,bc_id1027,CANCER,BRCA2,16168130,B,Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,2006,,"The results from this study suggest that weight loss in early adult life (age 18 to 30) protects against early-onset BRCA-associated breast cancers. Weight gain should also be avoided, particularly among BRCA1 mutation carriers who elect to have at least two pregnancies.",Y,BRCA,BRCA2,0.324175824
984,bc_id1028,CANCER,BRCA1,16168130,B,Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,2006,,"The results from this study suggest that weight loss in early adult life (age 18 to 30) protects against early-onset BRCA-associated breast cancers. Weight gain should also be avoided, particularly among BRCA1 mutation carriers who elect to have at least two pregnancies.",Y,BRCA1,BRCA1,0.326180258
985,bc_id1029,CANCER,ACE,16172223,B,Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk.,2005,,Our results suggest that the ACE I/D polymorphism plays an important role in breast cancer risk and disease-free survival in Caucasian postmenopausal women.,Y,ACE,ACE,0.285714286
986,bc_id1030,CANCER,SULT1A1,16175316,B,Modifying Effects of Sulfotransferase 1A1 Gene Polymorphism on the Association of Breast Cancer Risk with Body Mass Index or Endogenous Steroid Hormones.,2005,,These data suggest that the SULT1A1 Arg213His polymorphism may modify the effect of endogenous sex hormone exposures on postmenopausal breast cancer risk.,A,SULT1A1,SULT1A1,0.387096774
987,bc_id1031,CANCER,HLA-B,16188571,B,The HLA-B7 allele confers susceptibility to breast cancer in Spanish women.,2005,,These results support previous suggestions that HLA-B7 is associated with the development of breast cancer in our area.,Y,HLA-B7,HLA-B,0.5
988,bc_id1032,CANCER,COMT,16191465,B,"Polymorphic catechol-O-methyltransferase gene, duration of estrogen exposure, and breast cancer risk: a nested case-control study in Taiwan.",2005,,"This study based on limited sample sizes suggests that there may be no overall association of COMT genotype with breast cancer, but the COMT-L allele could pose enhanced risk of breast cancer in the presence of relevant environmental exposures, as most low penetrance gene are expected to act through gene-environment interactions.",A,COMT,COMT,0.425531915
989,bc_id1033,CANCER,CAT,16192345,B,"Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use.",2005,,X,X,X,X,0
990,bc_id1034,CANCER,GHRHR,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,"We genotyped 22 common single nucleotide polymorphisms in 10 genes involved in GH production and action (GHRH, GHRHR, SST, SSTR1-SSTR5, POU1F1, and GH1), and in parallel, we measured serum levels of IGF-I and IGFBP-3, its major binding protein, in samples of cases and controls... Our conclusion is that common genetic variation in the GH synthesis pathway, as measured by single nucleotide polymorphisms selected in the present study, is not a major determinant of IGF-I and IGFBP-3 circulating levels, and it does not play a major role in altering breast cancer risk.",N,GHRHR,GHRHR,1
991,bc_id1035,CANCER,GHRH,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,"We genotyped 22 common single nucleotide polymorphisms in 10 genes involved in GH production and action (GHRH, GHRHR, SST, SSTR1-SSTR5, POU1F1, and GH1), and in parallel, we measured serum levels of IGF-I and IGFBP-3, its major binding protein, in samples of cases and controls... Our conclusion is that common genetic variation in the GH synthesis pathway, as measured by single nucleotide polymorphisms selected in the present study, is not a major determinant of IGF-I and IGFBP-3 circulating levels, and it does not play a major role in altering breast cancer risk.",N,GHRH,GHRH,1
992,bc_id1036,CANCER,GH1,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,"We genotyped 22 common single nucleotide polymorphisms in 10 genes involved in GH production and action (GHRH, GHRHR, SST, SSTR1-SSTR5, POU1F1, and GH1), and in parallel, we measured serum levels of IGF-I and IGFBP-3, its major binding protein, in samples of cases and controls... Our conclusion is that common genetic variation in the GH synthesis pathway, as measured by single nucleotide polymorphisms selected in the present study, is not a major determinant of IGF-I and IGFBP-3 circulating levels, and it does not play a major role in altering breast cancer risk.",N,GH1,GH1,0.75
993,bc_id1037,CANCER,SSTR5,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,"We genotyped 22 common single nucleotide polymorphisms in 10 genes involved in GH production and action (GHRH, GHRHR, SST, SSTR1-SSTR5, POU1F1, and GH1), and in parallel, we measured serum levels of IGF-I and IGFBP-3, its major binding protein, in samples of cases and controls... Our conclusion is that common genetic variation in the GH synthesis pathway, as measured by single nucleotide polymorphisms selected in the present study, is not a major determinant of IGF-I and IGFBP-3 circulating levels, and it does not play a major role in altering breast cancer risk.",N,SSTR1-SSTR5,SSTR5,1
994,bc_id1038,CANCER,SSTR3,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,X,X,X,X,0
995,bc_id1039,CANCER,SSTR4,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,X,X,X,X,0
996,bc_id1040,CANCER,SSTR1,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,"We genotyped 22 common single nucleotide polymorphisms in 10 genes involved in GH production and action (GHRH, GHRHR, SST, SSTR1-SSTR5, POU1F1, and GH1), and in parallel, we measured serum levels of IGF-I and IGFBP-3, its major binding protein, in samples of cases and controls... Our conclusion is that common genetic variation in the GH synthesis pathway, as measured by single nucleotide polymorphisms selected in the present study, is not a major determinant of IGF-I and IGFBP-3 circulating levels, and it does not play a major role in altering breast cancer risk.",N,SSTR1-SSTR5,SSTR1,1
997,bc_id1041,CANCER,SSTR2,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,X,X,X,X,0
998,bc_id1042,CANCER,SST,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,"We genotyped 22 common single nucleotide polymorphisms in 10 genes involved in GH production and action (GHRH, GHRHR, SST, SSTR1-SSTR5, POU1F1, and GH1), and in parallel, we measured serum levels of IGF-I and IGFBP-3, its major binding protein, in samples of cases and controls... Our conclusion is that common genetic variation in the GH synthesis pathway, as measured by single nucleotide polymorphisms selected in the present study, is not a major determinant of IGF-I and IGFBP-3 circulating levels, and it does not play a major role in altering breast cancer risk.",N,SSTR1-SSTR5,SST,0.5
999,bc_id1043,CANCER,POU1F1,16214911,B,"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from theEuropean prospective investigation into cancer and nu",2005,,"We genotyped 22 common single nucleotide polymorphisms in 10 genes involved in GH production and action (GHRH, GHRHR, SST, SSTR1-SSTR5, POU1F1, and GH1), and in parallel, we measured serum levels of IGF-I and IGFBP-3, its major binding protein, in samples of cases and controls... Our conclusion is that common genetic variation in the GH synthesis pathway, as measured by single nucleotide polymorphisms selected in the present study, is not a major determinant of IGF-I and IGFBP-3 circulating levels, and it does not play a major role in altering breast cancer risk.",N,POU1F1,POU1F1,1
1000,bc_id1045,CANCER,NBN,16214912,B,"Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk.",2005,,"X-ray cross-complementing group 3 (XRCC3) codon 241 Thr/Met, Nijmegen breakage syndrome 1 (NBS1) codon 185 Glu/Gln, X-ray cross-complementing group 2 (XRCC2) codon 188 Arg/His, and breast cancer susceptibility gene 2 (BRCH2) codon 372 Asn/His. Allele and genotype frequencies were not significantly different in cases compared with controls for all four genetic polymorphisms, and odds ratios for breast cancer were close to the null.",N,NBS1,NBN,0.238095238
1001,bc_id1046,CANCER,XRCC2,16214912,B,"Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk.",2005,,"X-ray cross-complementing group 3 (XRCC3) codon 241 Thr/Met, Nijmegen breakage syndrome 1 (NBS1) codon 185 Glu/Gln, X-ray cross-complementing group 2 (XRCC2) codon 188 Arg/His, and breast cancer susceptibility gene 2 (BRCH2) codon 372 Asn/His. Allele and genotype frequencies were not significantly different in cases compared with controls for all four genetic polymorphisms, and odds ratios for breast cancer were close to the null.",N,XRCC2,XRCC2,0.454545455
1002,bc_id1047,CANCER,XRCC3,16214912,B,"Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk.",2005,,"X-ray cross-complementing group 3 (XRCC3) codon 241 Thr/Met, Nijmegen breakage syndrome 1 (NBS1) codon 185 Glu/Gln, X-ray cross-complementing group 2 (XRCC2) codon 188 Arg/His, and breast cancer susceptibility gene 2 (BRCH2) codon 372 Asn/His. Allele and genotype frequencies were not significantly different in cases compared with controls for all four genetic polymorphisms, and odds ratios for breast cancer were close to the null.",N,XRCC3,XRCC3,0.269230769
1003,bc_id1044,CANCER,BRCA2,16214912,B,"Polymorphisms in DNA repair genes, medical exposure to ionizing radiation, and breast cancer risk.",2005,,NR,NR,NR,NR,0
1004,bc_id1048,CANCER,VDR,16214913,B,Associations between polymorphisms in the vitamin D receptor and breast cancer risk.,2005,,Our results suggest that the VDR may be a mediator of breast cancer risk and could represent a target for cancer prevention efforts.,A,VDR,VDR,0.538461538
1005,bc_id1049,CANCER,ESR1,16215870,B,The estrogen receptor alpha gene and breast cancer risk (The Netherlands).,2005,,"The results of this study suggest that the PvuII polymorphism in the ER-alpha, or another mutation in linkage disequilibrium with PvuII, in combination with high E2 levels increases breast cancer risk in postmenopausal women.",Y,ER-alpha,ESR1,0.282608696
1006,bc_id1050,CANCER,SOD2,16215873,B,"MnSOD Val-9Ala Genotype, Pro- and Anti-oxidant Environmental Modifiers, and Breast Cancer Among Women on Long Island, New York.",2005,,This study provides little evidence that variation in Val-9Ala polymorphism of MnSOD alone or through substantial interaction with key exposures believed to be pro- or anti-oxidant properties influences breast cancer risk.,Y,MnSOD,SOD2,0.25
1007,bc_id1051,CANCER,CYP19A1,16232327,B,Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.,2005,This study supports the hypothesis that breast cancer can be initiated by estrogen exposure and that estrogen metabolizing genes are involved in this mechanism. This multigenic model is useful for identifying individuals who are at higher risks of breast cancer.,"When the CYP17 A2 allele, CYP19 (TTTA) 10 and SULT1A1 His allele were considered as the ""putative high-risk"" genotype, there was an increased risk of breast cancer with the number of high-risk genotypes in a dose-response effect (trend, P = 0.05).",Y,CYP19,CYP19A1,0.333333333
1008,bc_id1052,CANCER,CYP17A1,16232327,B,Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.,2005,This study supports the hypothesis that breast cancer can be initiated by estrogen exposure and that estrogen metabolizing genes are involved in this mechanism. This multigenic model is useful for identifying individuals who are at higher risks of breast cancer.,"When the CYP17 A2 allele, CYP19 (TTTA) 10 and SULT1A1 His allele were considered as the ""putative high-risk"" genotype, there was an increased risk of breast cancer with the number of high-risk genotypes in a dose-response effect (trend, P = 0.05).",Y,CYP17,CYP17A1,0.266666667
1009,bc_id1053,CANCER,SULT1A1,16232327,B,Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.,2005,This study supports the hypothesis that breast cancer can be initiated by estrogen exposure and that estrogen metabolizing genes are involved in this mechanism. This multigenic model is useful for identifying individuals who are at higher risks of breast cancer.,"When the CYP17 A2 allele, CYP19 (TTTA) 10 and SULT1A1 His allele were considered as the ""putative high-risk"" genotype, there was an increased risk of breast cancer with the number of high-risk genotypes in a dose-response effect (trend, P = 0.05).",Y,SULT1A1,SULT1A1,0.322580645
1010,bc_id1054,CANCER,AKAP13,16234258,Y,Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer.,2005,,"The newfound Lys526Gln polymorphism revealed a significant association with familial breast cancer (OR = 1.58, 95% CI = 1.07-2.35) and an even stronger association with high-risk familial breast cancer (OR = 1.85, 95% CI = 1.19-2.88)... Due to the pivotal role of AKAP13 in the Rho GTPases signalling network, this variant might affect the susceptibility to other cancers as well.",Y,AKAP13,AKAP13,1
1011,bc_id1055,CANCER,BRCA2,16234515,B,Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.,2005,Oophorectomy is an effective means of reducing the risk of breast cancer in carriers of BRCA1 mutations.,X,X,X,X,0
1012,bc_id1056,CANCER,BRCA1,16234515,B,Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.,2005,Oophorectomy is an effective means of reducing the risk of breast cancer in carriers of BRCA1 mutations.,X,X,X,X,0
1013,bc_id1057,CANCER,GSTM1,16238106,B,Genetic polymorphism of GSTM1 in women with breast cancer and interact with reproductive history and several clinical pathologies.,2006,,The results conclusively show that single gene GSTM1 polymorphisms do not confer a substantial risk of breast cancer to its carriers.,N,GSTM1,GSTM1,0.20754717
1014,bc_id1058,CANCER,MDM2,16239061,N,No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.,2005,,This study has found no evidence that the GG genotype of the MDM2 SNP309 polymorphism is associated with early onset or familial breast cancer or with ovarian cancer.,N,MDM2,MDM2,0.444444444
1015,bc_id1059,CANCER,CHEK2,16239104,B,German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.,2005,,"In patients with a high-risk profile however, CHEK2*1100delC was indicative for this risk and highest for early-onset breast cancer.",Y,CHEK2*1100delC,CHEK2,0.383333333
1016,bc_id1060,CANCER,GIPC1,16240642,B,[Analysis of polymorphic variants of gene GIPC1 CGG repeats in healthy individuals and in patients with breast cancer and non-small cell lung cancer],2005,,X,X,X,X,0
1017,bc_id1061,CANCER,TP53,16243804,B,p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.,2005,,Our study indicates that breast cancer patients with the Pro/Pro variant may be less sensitive to anthracycline-based treatment than those with the Pro/Arg or Arg/Arg variant and suggests that analysis of p53 codon 72 polymorphism may provide a simple predictive marker for selecting the right breast cancer patients to anthracycline-based neoadjuvant chemotherapy in clinical setting.,A,p53,TP53,0.482758621
1018,bc_id1062,CANCER,NCOA3,16244359,B,The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.,2005,,"Since AIB1 appears to modulate the effect of endogenous hormones via the estrogen receptor, and smoking affects circulating hormone levels, these results support evidence that steroid hormones play an important role in breast carcinogenesis in BRCA1 mutation carriers, and suggest mechanisms for developing novel cancer prevention strategies for BRCA1 mutation carriers.",Y,AIB1,NCOA3,0.285714286
1019,bc_id1063,CANCER,CASP10,16251207,B,Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant.,2005,,"As CASP10 and CASP8 functionally co-operate during apoptosis, we analysed the mutual effect of both CASP10 V410I and CASP8 D302H, resulting in a significant association between the number of the variant alleles I410 and H302 and a highly decreased familial BC risk (OR = 0.35, P(trend) = 0.007), pointing to the interaction between the CASP10 and CASP8 polymorphisms in breast carcinogenesis.",Y,CASP10,CASP10,0.666666667
1020,bc_id1064,CANCER,CASP8,16251207,B,Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant.,2005,,"As CASP10 and CASP8 functionally co-operate during apoptosis, we analysed the mutual effect of both CASP10 V410I and CASP8 D302H, resulting in a significant association between the number of the variant alleles I410 and H302 and a highly decreased familial BC risk (OR = 0.35, P(trend) = 0.007), pointing to the interaction between the CASP10 and CASP8 polymorphisms in breast carcinogenesis.",Y,CASP8,CASP8,0.642857143
1021,bc_id1065,CANCER,MSH2,16252083,B,Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression.,2005,,"Therefore, MMR may play a role in the breast carcinogenesis and the Gly322Asp polymorphism of the hMSH2 gene may be considered as a potential marker in breast cancer.",A,hMSH2,MSH2,1
1022,bc_id1066,CANCER,CYP1A1,16254684,B,Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Nigerian women.,2005,,"This study has shown that while the CYP1A1 M1 polymorphism conferred reduced risk of breast cancer, homozygosity for the CYP1A1 M3 (C/C) was associated with increased risk of breast cancer although these risks did not attain statistical significance.",A,CYP1A1,CYP1A1,0.456521739
1023,bc_id1067,CANCER,CHEK2,16257342,B,Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes:a familial study.,2005,,"In women with a family history of bilateral disease, CHEK2*1100delC confers a high lifetime risk and might be useful for predictive testing. Bilateral breast cancer cases and their families are likely to provide an efficient basis for identification of additional low-penetrance breast-cancer genes.",Y,CHEK2*1100delC,CHEK2,0.383333333
1024,bc_id1068,CANCER,BRCA2,16261408,B,Polymorphisms of the BRCA2 and RAD51 Genes in Breast Cancer.,2005,,"We performed a case-control study (150 cases and 150 controls) to test the association between three polymorphisms in BRCA2 and RAD51 genes and breast cancer risk. Genotypes were determined in DNA from blood cells by PCR-RFLP... Gene-gene interaction between the BRCA2-Met1915Thr Thr/Thr and BRCA2-Met784Val Met/Met homozygous variants increased the risk. Therefore, the Met1915Thr polymorphism in the BRCA2 gene may be considered as an independent marker of breast cancer.",Y,BRCA2-Met1915Thr,BRCA2,0.324175824
1025,bc_id1069,CANCER,RAD51,16261408,B,Polymorphisms of the BRCA2 and RAD51 Genes in Breast Cancer.,2005,,X,X,X,X,0
1026,bc_id1070,CANCER,ESR2,16261413,B,Estrogen Receptor Beta (ESR2) Polymorphisms in Familial and Sporadic Breast Cancer.,2005,,"We found no overall statistically significant association for any of the single polymorphisms studied. Haplotype analysis suggested one haplotype associated with increased risk in sporadic breast cancer patients (OR = 3.0, p = 0.03). Further analysis is needed to elucidate the role of estrogen receptor beta in breast cancer susceptibility.",A,estrogen receptor beta,ESR2,0.533333333
1027,bc_id1071,CANCER,MMP1,16267613,B,Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer.,2005,The results suggest that MMP-1 is responsible for the local invasion and MMP-9 is associated with the malignance and the growth of the tumor. We suggest that the 2G allele of the 1G/2G MMP-1 gene polymorphism may be associated with the lymph node metastasis in patients with breast cancer and therefore it can be considered as a progression marker in this disease.,The results suggest that MMP-1 is responsible for the local invasion and MMP-9 is associated with the malignance and the growth of the tumor. We suggest that the 2G allele of the 1G/2G MMP-1 gene polymorphism may be associated with the lymph node metastasis in patients with breast cancer and therefore it can be considered as a progression marker in this disease.,A,MMP-1,MMP1,0.833333333
1028,bc_id1072,CANCER,PPP2R1B,16276521,B,The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.,2005,,"Mutations of the PPP2R1B gene, which encodes the Abeta scaffolding subunit of serine/threonine protein phosphatase 2A (PP2A), have been identified in several types of cancer including lung and breast carcinoma.",Y,PPP2R1B,PPP2R1B,1
1029,bc_id1073,CANCER,SULT1A1,16280036,B,Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics:a case-series study.,2005,The data suggest that genetic variation in SULT1A1 and UGT1A1 may influence breast cancer characteristics and might be important for breast cancer prognosis.,The data suggest that genetic variation in SULT1A1 and UGT1A1 may influence breast cancer characteristics and might be important for breast cancer prognosis.,A,SULT1A1,SULT1A1,0.387096774
1030,bc_id1074,CANCER,UGT1A1,16280036,B,Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics:a case-series study.,2005,The data suggest that genetic variation in SULT1A1 and UGT1A1 may influence breast cancer characteristics and might be important for breast cancer prognosis.,The data suggest that genetic variation in SULT1A1 and UGT1A1 may influence breast cancer characteristics and might be important for breast cancer prognosis.,A,UGT1A1,UGT1A1,0.7
1031,bc_id1075,CANCER,CYP17A1,16280037,N,CYP17 gene polymorphism in relation to breast cancer risk: a case-control study.,2005,"It is unlikely that CYP17 c.1-34T>C has a role in breast cancer etiology, overall or in combination with established non-genetic breast cancer risk factors.","It is unlikely that CYP17 c.1-34T>C has a role in breast cancer etiology, overall or in combination with established non-genetic breast cancer risk factors.",N,CYP17,CYP17A1,0.266666667
1032,bc_id1076,CANCER,ERCC2,16280050,B,"XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study.",2006,"Our results do not indicate a major role for XRCC1 and XPD polymorphisms in breast cancer susceptibility, but suggest that they may modify the risk especially among smoking women.","Our results do not indicate a major role for XRCC1 and XPD polymorphisms in breast cancer susceptibility, but suggest that they may modify the risk especially among smoking women.",A,XPD,ERCC2,0.6875
1033,bc_id1077,CANCER,XRCC1,16280050,B,"XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study.",2006,"Our results do not indicate a major role for XRCC1 and XPD polymorphisms in breast cancer susceptibility, but suggest that they may modify the risk especially among smoking women.","Our results do not indicate a major role for XRCC1 and XPD polymorphisms in breast cancer susceptibility, but suggest that they may modify the risk especially among smoking women.",A,XRCC1,XRCC1,0.543478261
1034,bc_id1078,CANCER,BRCA2,16280055,B,A common missense variant in BRCA2 predisposes to early onset breast cancer.,2005,The BRCA2 C5972T allele is a common variant in Poland that increases the risk of DCIS with micro-invasion. The homozygous state is rare but increases the risk of breast cancer five-fold.,The BRCA2 C5972T allele is a common variant in Poland that increases the risk of DCIS with micro-invasion. The homozygous state is rare but increases the risk of breast cancer five-fold.,Y,BRCA2,BRCA2,0.324175824
1035,bc_id1079,CANCER,GPX1,16287877,B,"Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study.",2005,,Results from this prospective study suggest that the GPX1 Pro198Leu-associated lowered GPX activity is associated with higher breast cancer risk among Danish women.,Y,GPX1,GPX1,0.2
1036,bc_id1080,CANCER,MDM2,16288830,B,Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinesepopulation.,2005,,These findings suggest that these two MDM2 promoter variants may not play a major role in the etiology of breast cancer.,A,MDM2,MDM2,0.444444444
1037,bc_id1081,CANCER,IGF1,16306136,Y,"IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer",2006,,Our data indicate that common variants in the IGF1 and IGFBP3 genes are associated with differences in circulating levels of IGF1 and IGFBP3 and with breast cancer risk.,Y,IGF1,IGF1,0.35
1038,bc_id1082,CANCER,IGFBP3,16306136,Y,"IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer",2006,,Our data indicate that common variants in the IGF1 and IGFBP3 genes are associated with differences in circulating levels of IGF1 and IGFBP3 and with breast cancer risk.,Y,IGFBP3,IGFBP3,0.357142857
1039,bc_id1083,CANCER,TP53,16314399,B,Joint effects of single nucleotide polymorphisms in P53BP1 and P53 on breast cancer risk in a chinese population,2005,,"These findings indicate that the SNPs in P53BP1 and p53 jointly contribute to breast cancer risk, particularly ER (-) or PR (-) breast cancer, and the p53 Arg72Pro polymorphism may serve as a risk modifier. Further functional studies are needed to confirm our findings.",Y,p53,TP53,0.367816092
1040,bc_id1084,CANCER,TP53BP1,16314399,B,Joint effects of single nucleotide polymorphisms in P53BP1 and P53 on breast cancer risk in a chinese population,2005,,"These findings indicate that the SNPs in P53BP1 and p53 jointly contribute to breast cancer risk, particularly ER (-) or PR (-) breast cancer, and the p53 Arg72Pro polymorphism may serve as a risk modifier. Further functional studies are needed to confirm our findings.",Y,P53BP1,TP53BP1,1
1041,bc_id1085,CANCER,ITGB3,16317580,B,Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk,2005,"We conclude that  functional polymorphisms in integrin genes ITGA2 and ITGB3 influence the development and progression of breast cancer, respectively. The precise mechanism remains to be determined, but likely involves dysregulated signaling pathways.","We conclude that  functional polymorphisms in integrin genes ITGA2 and ITGB3 influence the development and progression of breast cancer, respectively. The precise mechanism remains to be determined, but likely involves dysregulated signaling pathways.",Y,ITGB3,ITGB3,0.333333333
1042,bc_id1086,CANCER,ITGA2,16317580,B,Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk,2005,"We conclude that  functional polymorphisms in integrin genes ITGA2 and ITGB3 influence the development and progression of breast cancer, respectively. The precise mechanism remains to be determined, but likely involves dysregulated signaling pathways.","We conclude that  functional polymorphisms in integrin genes ITGA2 and ITGB3 influence the development and progression of breast cancer, respectively. The precise mechanism remains to be determined, but likely involves dysregulated signaling pathways.",Y,ITGA2,ITGA2,0.333333333
1043,bc_id1087,CANCER,NME1,16317582,B,EcoRI polymorphism of the metastasis-suppressor gene NME1 in Mexican patients with breast cancer,2005,,"Human breast cancer cells with high metastatic potential show reduced expression of the metastasis-suppressor gene NME1... Thus, EcoR1 polymorphic site was not associated with breast cancer in this series, but could be analyzed in association with metastases and might be informative in the evaluation of loss of heterozygosity in women with breast cancer.",A,NME1,NME1,1
1044,bc_id1088,CANCER,ESR2,16317584,B,Microsatellite profile in hormonal receptor genes associated with breast cancer,2005,,"Our results sustain a polygenic model of breast cancer with gene-gene interactions; combined effects of three low-risk polymorphisms conferred significant genetic predisposition. Genotyping hormonal receptor genes ERa, ERb and AR could be a useful genetic marker for defining disease risk.",A,ERb,ESR2,0.533333333
1045,bc_id1089,CANCER,AR,16317584,B,Microsatellite profile in hormonal receptor genes associated with breast cancer,2005,,"Our results sustain a polygenic model of breast cancer with gene-gene interactions; combined effects of three low-risk polymorphisms conferred significant genetic predisposition. Genotyping hormonal receptor genes ERa, ERb and AR could be a useful genetic marker for defining disease risk.",A,AR,AR,0.458333333
1046,bc_id1090,CANCER,ESR1,16317584,B,Microsatellite profile in hormonal receptor genes associated with breast cancer,2005,,"Our results sustain a polygenic model of breast cancer with gene-gene interactions; combined effects of three low-risk polymorphisms conferred significant genetic predisposition. Genotyping hormonal receptor genes ERa, ERb and AR could be a useful genetic marker for defining disease risk.",A,ERa,ESR1,0.586956522
1047,bc_id1091,CANCER,PIK3CA,16317585,Y,PIK3CA mutations in breast cancer are associated with poor outcome,2005,,"PIK3CA mutation was an independent factor for worse survival in breast cancer patients with non-amplified erbB2 (RR = 2.6, 95%CI [1.2-5.5], p = 0.016).",Y,PIK3CA,PIK3CA,0.4
1048,bc_id1092,CANCER,SULT1A1,16317586,B,Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy,2005,,SULT1A1 genotype did not correlate with any prognostic or predictive markers associated with breast cancer.,N,SULT1A1,SULT1A1,0.290322581
1049,bc_id1093,CANCER,IL1RN,16319982,B,Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women.,2006,,"The IL-1RN *2-allele was associated with decreased breast cancer risk with marginal significance (OR = 0.7, 95% CI = 0.48-1.05).",Y,IL-1RN,IL1RN,0.25
1050,bc_id1094,CANCER,IL1B,16319982,B,Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women.,2006,,"The IL-1B CC or TC genotype was not associated with decreased risk of breast cancer (OR = 0.9, 95% CI = 0.65-1.16).",N, IL-1B,IL1B,0.4
1051,bc_id1095,CANCER,ERCC2,16319991,B,Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer.,2006,,X,X,X,X,0
1052,bc_id1096,CANCER,XRCC1,16319991,B,Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer.,2006,,These results indicate that these polymorphisms in XPD and XRCC1 genes are only weakly associated with breast cancer.,A,XRCC1,XRCC1,0.543478261
1053,bc_id1097,CANCER,GH1,16322331,Y,Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer,2005,,The growth hormone 1 (GH1)/insulin-like growth factor I (IGF-I) axis plays an important role in the development of breast cancer.,Y,GH1,GH1,0.25
1054,bc_id1098,CANCER,IGF1,16322331,B,Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer,2005,,The growth hormone 1 (GH1)/insulin-like growth factor I (IGF-I) axis plays an important role in the development of breast cancer.,Y,IGF-I,IGF1,0.35
1055,bc_id1099,CANCER,BRCA2,16324400,B,[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai.],2005,Four novel mutations in BRCA1 and one novel mutation in BRCA2 may be mutations characterized of early-onset breast cancer in Chinese population. Germline mutations in BRCA2 may contribute less than mutations in BRCA1 to early-onset breast cancer in Shanghai. These data contribute to information on spectrum of BRCA gene in Chinese population and also offer a recommended screening mode for clinical genetic testing programme in China.,Four novel mutations in BRCA1 and one novel mutation in BRCA2 may be mutations characterized of early-onset breast cancer in Chinese population.,A,BRCA2,BRCA2,0.576923077
1056,bc_id1100,CANCER,BRCA1,16324400,B,[Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai.],2005,Four novel mutations in BRCA1 and one novel mutation in BRCA2 may be mutations characterized of early-onset breast cancer in Chinese population. Germline mutations in BRCA2 may contribute less than mutations in BRCA1 to early-onset breast cancer in Shanghai. These data contribute to information on spectrum of BRCA gene in Chinese population and also offer a recommended screening mode for clinical genetic testing programme in China.,Four novel mutations in BRCA1 and one novel mutation in BRCA2 may be mutations characterized of early-onset breast cancer in Chinese population.,A,BRCA1,BRCA1,0.60944206
1057,bc_id1101,CANCER,CBS,16328059,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer,2006,,"we investigated whether common polymorphisms in 6 key genes involved in methyl group metabolism (thymidylate synthase, methylene tetrahydrofolate reductase, cystathione beta-synthase, DNA methyltransferase 3B, methylene tetrahydrofolate dehydrogenase, and methionine synthase) were associated with major pathological features of this disease or the frequency of CpG island hypermethylation. No associations were observed between any of the polymorphisms and patient age, tumour size, histological grade or patient outcome... Our results show that polymorphisms in two genes involved in methyl group metabolism are associated with hormone receptor content and DNA methylation frequency in breast cancer, however these observations are unlikely to be linked.",N,cystathione beta-synthase,CBS,1
1058,bc_id1102,CANCER,DNMT3B,16328059,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer,2006,,"we investigated whether common polymorphisms in 6 key genes involved in methyl group metabolism (thymidylate synthase, methylene tetrahydrofolate reductase, cystathione beta-synthase, DNA methyltransferase 3B, methylene tetrahydrofolate dehydrogenase, and methionine synthase) were associated with major pathological features of this disease or the frequency of CpG island hypermethylation. No associations were observed between any of the polymorphisms and patient age, tumour size, histological grade or patient outcome... Our results show that polymorphisms in two genes involved in methyl group metabolism are associated with hormone receptor content and DNA methylation frequency in breast cancer, however these observations are unlikely to be linked.",N,DNA methyltransferase 3B,DNMT3B,0.5
1059,bc_id1103,CANCER,MTHFD1,16328059,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer,2006,,"we investigated whether common polymorphisms in 6 key genes involved in methyl group metabolism (thymidylate synthase, methylene tetrahydrofolate reductase, cystathione beta-synthase, DNA methyltransferase 3B, methylene tetrahydrofolate dehydrogenase, and methionine synthase) were associated with major pathological features of this disease or the frequency of CpG island hypermethylation. No associations were observed between any of the polymorphisms and patient age, tumour size, histological grade or patient outcome... Our results show that polymorphisms in two genes involved in methyl group metabolism are associated with hormone receptor content and DNA methylation frequency in breast cancer, however these observations are unlikely to be linked.",N,methylene tetrahydrofolate dehydrogenase,MTHFD1,0.666666667
1060,bc_id1104,CANCER,MTHFR,16328059,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer,2006,,"we investigated whether common polymorphisms in 6 key genes involved in methyl group metabolism (thymidylate synthase, methylene tetrahydrofolate reductase, cystathione beta-synthase, DNA methyltransferase 3B, methylene tetrahydrofolate dehydrogenase, and methionine synthase) were associated with major pathological features of this disease or the frequency of CpG island hypermethylation. No associations were observed between any of the polymorphisms and patient age, tumour size, histological grade or patient outcome... Our results show that polymorphisms in two genes involved in methyl group metabolism are associated with hormone receptor content and DNA methylation frequency in breast cancer, however these observations are unlikely to be linked.",N,methylene tetrahydrofolate reductase,MTHFR,0.326923077
1061,bc_id1105,CANCER,MTR,16328059,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer,2006,,"we investigated whether common polymorphisms in 6 key genes involved in methyl group metabolism (thymidylate synthase, methylene tetrahydrofolate reductase, cystathione beta-synthase, DNA methyltransferase 3B, methylene tetrahydrofolate dehydrogenase, and methionine synthase) were associated with major pathological features of this disease or the frequency of CpG island hypermethylation. No associations were observed between any of the polymorphisms and patient age, tumour size, histological grade or patient outcome... Our results show that polymorphisms in two genes involved in methyl group metabolism are associated with hormone receptor content and DNA methylation frequency in breast cancer, however these observations are unlikely to be linked.",N,methionine synthase,MTR,0.333333333
1062,bc_id1106,CANCER,TYMS,16328059,B,Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer,2006,,"we investigated whether common polymorphisms in 6 key genes involved in methyl group metabolism (thymidylate synthase, methylene tetrahydrofolate reductase, cystathione beta-synthase, DNA methyltransferase 3B, methylene tetrahydrofolate dehydrogenase, and methionine synthase) were associated with major pathological features of this disease or the frequency of CpG island hypermethylation. No associations were observed between any of the polymorphisms and patient age, tumour size, histological grade or patient outcome... Our results show that polymorphisms in two genes involved in methyl group metabolism are associated with hormone receptor content and DNA methylation frequency in breast cancer, however these observations are unlikely to be linked.",N,thymidylate synthase,TYMS,0.3
1063,bc_id1107,CANCER,XRCC1,16328064,B,Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Glu and risk of breast cancer in Chinese women,2006,,These findings suggest that the ADPRT Val762Ala and XRCC1 Arg399Gln polymorphisms may not play a role in the etiology of breast cancer.,A,XRCC1,XRCC1,0.543478261
1064,bc_id1108,CANCER,PARP1,16328064,B,Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Glu and risk of breast cancer in Chinese women,2006,,These findings suggest that the ADPRT Val762Ala and XRCC1 Arg399Gln polymorphisms may not play a role in the etiology of breast cancer.,A,ADPRT,PARP1,0.666666667
1065,bc_id1109,CANCER,BRCA2,16331614,B,Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.,2006,,"Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is approximately 30%.",Y,BRCA2,BRCA2,0.324175824
1066,bc_id1110,CANCER,BRCA1,16331614,B,Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.,2006,,"Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is approximately 30%.",Y,BRCA1,BRCA1,0.326180258
1067,bc_id1111,CANCER,IGF1,16332723,B,"IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project.",2006,,X,X,X,X,0
1068,bc_id1112,CANCER,GH1,16332723,B,"IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project.",2006,,X,X,X,X,0
1069,bc_id1113,CANCER,BARD1,16333312,B,BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition,2005,,"These results suggest that the contribution of the BARD1 germline variants to breast cancer predisposition is very limited, and that neither Cys557Ser nor Val507Met have an effect on familial breast cancer susceptibility.",A,BARD1,BARD1,0.454545455
1070,bc_id1114,CANCER,ADH1C,16344274,B,"ADH3 genotype, alcohol intake, and breast cancer risk",2005,,"Using data from the Long Island Breast Cancer Study Project, we examined whether fast metabolizers of alcohol, as measured by the ADH3(1-1) genotype, have a higher risk of breast cancer from alcohol intake compared with those individuals who are slow metabolizers, but consume similar amounts of alcohol.",Y,ADH3(1-1),ADH1C,0.333333333
1071,bc_id1115,CANCER,ARL11,16353159,B,Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk,2005,,"The ARLTS1 Trp149Stop mutation has been shown to predispose to general familial cancer and high-risk familial breast cancer (BC), provoking the attenuation of apoptotic function.",Y,ARLTS1,ARL11,0.333333333
1072,bc_id1116,CANCER,PIK3CA,16353168,B,PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobularcarcinoma,2005,,"The findings indicate that in invasive breast carcinomas, PIK3CA alterations are mainly present in lobular and ductal tumours, whereas the other histological types, known to be associated with a favourable prognosis, show a very low incidence of PIK3CA mutations",Y,PIK3CA,PIK3CA,0.4
1073,bc_id1117,CANCER,IL1B,16358261,B,Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population.,2006,,These findings indicate that these 2 IL-1beta promoter variants may contribute to risk of developing breast cancer in the Chinese population.,A,IL-1beta,IL1B,0.4
1074,bc_id1118,CANCER,CYP2D6,16361630,Y,Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes,2005,"In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with our previous observation that CYP2D6 is responsible for the metabolic activation of tamoxifen to endoxifen.","We determined cytochrome P450 (CYP)2D6 (*4 and *6) and CYP3A5 (*3) genotype from paraffin-embedded tumor samples and buccal cells (living patients) in tamoxifen-treated women enrolled onto a North Central Cancer Treatment Group adjuvant breast cancer trial... The CYP3A5*3 variant was not associated with any of these clinical outcomes.... In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with our previous observation that CYP2D6 is responsible for the metabolic activation of tamoxifen to endoxifen.",A,CYP2D6 *4,CYP2D6,0.590909091
1075,bc_id1119,CANCER,CYP3A5,16361630,B,Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes,2005,"In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with our previous observation that CYP2D6 is responsible for the metabolic activation of tamoxifen to endoxifen.","We determined cytochrome P450 (CYP)2D6 (*4 and *6) and CYP3A5 (*3) genotype from paraffin-embedded tumor samples and buccal cells (living patients) in tamoxifen-treated women enrolled onto a North Central Cancer Treatment Group adjuvant breast cancer trial... The CYP3A5*3 variant was not associated with any of these clinical outcomes.... In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with our previous observation that CYP2D6 is responsible for the metabolic activation of tamoxifen to endoxifen.",N,CYP3A5*3,CYP3A5,0.4
1076,bc_id1120,CANCER,AR,16365023,B,Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women,2005,,"In summary, our results further support that shorter CAG repeats (stronger AR transactivation activity) may reduce the risk of breast cancer, at least among some groups of women. Our data, however, are unable to provide evidence that PSA is the pathway through which the protective effect of androgens operates.",A,AR,AR,0.458333333
1077,bc_id1121,CANCER,KLK3,16365023,B,Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women,2005,,"In summary, our results further support that shorter CAG repeats (stronger AR transactivation activity) may reduce the risk of breast cancer, at least among some groups of women. Our data, however, are unable to provide evidence that PSA is the pathway through which the protective effect of androgens operates.",A,PSA,KLK3,1
1078,bc_id1122,CANCER,AR,16365681,B,Androgen receptor CAG and GGC polymorphisms in Mediterraneans: repeat dynamics and populationrelationships,2005,,NR,NR,NR,NR,0
1079,bc_id1123,CANCER,GHR,16381017,B,Polymorphisms in the growth hormone receptor: Acase-control study in breast cancer,2005,,"However, a rare haplotype (dGGC), containing the GHRd3 allele, was associated with a decreased breast cancer risk (OR 0.30, 95% CI 0.11-0.80).",Y,GHRd3,GHR,1
1080,bc_id1124,CANCER,DNASE1,16382368,B,Analysis of genetic polymorphism of deoxyribonuclease I in ovambo and turk populations using a genotyping method,2005,,NR,NR,NR,NR,0
1081,bc_id1125,CANCER,RAD50,16385572,B,Evaluation of RAD50 in familial breast cancer predisposition,2005,,"These data indicate that RAD50 mutations are rare in familial breast cancer and either carry no, or a very small, increased risk of cancer. Altogether, these results suggest RAD50 can only be making a very minor contribution to familial breast cancer predisposition in UK and Finland.",N,RAD50,RAD50,0.5
1082,bc_id1126,CANCER,BRCA2,16389418,B,Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history.,2005,,The BRCA1 or BRCA2 mutation prevalence found among women with breast cancer and such family history was 13% (4/31).,Y,BRCA2,BRCA2,0.324175824
1083,bc_id1127,CANCER,BRCA1,16389418,B,Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history.,2005,,The BRCA1 or BRCA2 mutation prevalence found among women with breast cancer and such family history was 13% (4/31).,Y,BRCA1,BRCA1,0.326180258
1084,bc_id1128,CANCER,EGFR,16397024,B,"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas",2006,"This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.",X,X,X,X,0
1085,bc_id1129,CANCER,ERBB2,16397024,Y,"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas",2006,"This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.","We simultaneously analyzed the somatic mutations of EGFR, K-RAS, PIK3CA, and BRAF genes in the 16 samples with ERBB2 mutations, and found that all of the 3 colorectal carcinoma samples with ERBB2 mutations harbored K-RAS mutations.... This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.",A,ERBB2,ERBB2,0.452380952
1086,bc_id1130,CANCER,KRAS,16397024,Y,"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas",2006,"This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.","We simultaneously analyzed the somatic mutations of EGFR, K-RAS, PIK3CA, and BRAF genes in the 16 samples with ERBB2 mutations, and found that all of the 3 colorectal carcinoma samples with ERBB2 mutations harbored K-RAS mutations.... This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.",A,K-RAS,KRAS,1
1087,bc_id1131,CANCER,PIK3CA,16397024,B,"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas",2006,"This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.",X,X,X,X,0
1088,bc_id1132,CANCER,BRAF,16397024,B,"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas",2006,"This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.",X,X,X,X,0
1089,bc_id1133,CANCER,ERCC4,16399771,B,"Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in African Americans and whites",2006,,"Odds ratios (ORs) were calculated for breast cancer and smoking, and for breast cancer and nine non-synonymous coding polymorphisms in six NER genes (XPD codons 312 and 751, RAD23B codon 249, XPG codon 1104, XPC codon 939, XPF codons 415 and 662, and ERCC6 codons 1213 and 1230)... Therefore, polymorphisms in NER genes may modify the relationship between breast cancer and smoking.",A,XPF,ERCC4,0.5
1090,bc_id1134,CANCER,ERCC6,16399771,B,"Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in African Americans and whites",2006,,"Odds ratios (ORs) were calculated for breast cancer and smoking, and for breast cancer and nine non-synonymous coding polymorphisms in six NER genes (XPD codons 312 and 751, RAD23B codon 249, XPG codon 1104, XPC codon 939, XPF codons 415 and 662, and ERCC6 codons 1213 and 1230)... Therefore, polymorphisms in NER genes may modify the relationship between breast cancer and smoking.",A,ERCC6,ERCC6,1
1091,bc_id1135,CANCER,RAD23B,16399771,B,"Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in African Americans and whites",2006,,"Odds ratios (ORs) were calculated for breast cancer and smoking, and for breast cancer and nine non-synonymous coding polymorphisms in six NER genes (XPD codons 312 and 751, RAD23B codon 249, XPG codon 1104, XPC codon 939, XPF codons 415 and 662, and ERCC6 codons 1213 and 1230)... Therefore, polymorphisms in NER genes may modify the relationship between breast cancer and smoking.",A,RAD23B,RAD23B,1
1092,bc_id1136,CANCER,ERCC2,16399771,B,"Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in African Americans and whites",2006,,"Odds ratios (ORs) were calculated for breast cancer and smoking, and for breast cancer and nine non-synonymous coding polymorphisms in six NER genes (XPD codons 312 and 751, RAD23B codon 249, XPG codon 1104, XPC codon 939, XPF codons 415 and 662, and ERCC6 codons 1213 and 1230)... Therefore, polymorphisms in NER genes may modify the relationship between breast cancer and smoking.",A,XPD,ERCC2,0.6875
1093,bc_id1137,CANCER,ERCC5,16399771,B,"Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in African Americans and whites",2006,,"Odds ratios (ORs) were calculated for breast cancer and smoking, and for breast cancer and nine non-synonymous coding polymorphisms in six NER genes (XPD codons 312 and 751, RAD23B codon 249, XPG codon 1104, XPC codon 939, XPF codons 415 and 662, and ERCC6 codons 1213 and 1230)... Therefore, polymorphisms in NER genes may modify the relationship between breast cancer and smoking.",A,XPG,ERCC5,0.666666667
1094,bc_id1138,CANCER,XPC,16399771,B,"Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in African Americans and whites",2006,,"Odds ratios (ORs) were calculated for breast cancer and smoking, and for breast cancer and nine non-synonymous coding polymorphisms in six NER genes (XPD codons 312 and 751, RAD23B codon 249, XPG codon 1104, XPC codon 939, XPF codons 415 and 662, and ERCC6 codons 1213 and 1230)... Therefore, polymorphisms in NER genes may modify the relationship between breast cancer and smoking.",A,XPC,XPC,0.571428571
1095,bc_id1139,CANCER,IGFALS,16404426,B,"Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk",2006,,X,X,X,X,0
1096,bc_id1140,CANCER,IGFBP3,16404426,B,"Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk",2006,,"We genotyped 23 common single nucleotide polymorphisms in IGF1, IGFBP1, IGFBP3 and IGFALS, and measured serum levels of IGF-I and IGFBP-3 in samples of cases and controls. We found a weak but significant association of polymorphisms at the 5' end of the IGF1 gene with breast cancer risk, particularly among women younger than 55 years, and a strong association of polymorphisms located in the 5' end of IGFBP3 with circulating levels of IGFBP-3, which confirms previous findings.",Y,IGFBP3,IGFBP3,0.357142857
1097,bc_id1141,CANCER,IGF1,16404426,B,"Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk",2006,,"We genotyped 23 common single nucleotide polymorphisms in IGF1, IGFBP1, IGFBP3 and IGFALS, and measured serum levels of IGF-I and IGFBP-3 in samples of cases and controls. We found a weak but significant association of polymorphisms at the 5' end of the IGF1 gene with breast cancer risk, particularly among women younger than 55 years, and a strong association of polymorphisms located in the 5' end of IGFBP3 with circulating levels of IGFBP-3, which confirms previous findings.",N,IGF1,IGF1,0.4
1098,bc_id1142,CANCER,IGFBP1,16404426,B,"Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk",2006,,X,X,X,X,0
1099,bc_id1143,CANCER,CYP19A1,16406421,B,CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women.,2006,,CYP19 alleles containing different numbers of tetranucleotide TTTA repeats in intron 4 have been associated with increased breast cancer risk.,Y,CYP19,CYP19A1,0.333333333
1100,bc_id1144,CANCER,AURKA,16411056,B,Polymorphisms of the AURKA (STK15/Aurora Kinase) Gene and Breast Cancer Risk (United States),2006,OR 1.,These results confirm prior findings that AURKA represents a low penetrance breast cancer susceptibility gene.,Y,AURKA,AURKA,0.25
1101,bc_id1146,CANCER,BRCA2,16418514,B,"Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.",2006,"The results indicate that the penetrance of the Icelandic BRCA2 founder mutation increased nearly fourfold in 80 years, whereas the risk of death from breast cancer before age 70 years increased only approximately twofold.","The results indicate that the penetrance of the Icelandic BRCA2 founder mutation increased nearly fourfold in 80 years, whereas the risk of death from breast cancer before age 70 years increased only approximately twofold.",A,BRCA2,BRCA2,0.576923077
1102,bc_id1147,CANCER,GPX1,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,GPX1,GPX1,0.4
1103,bc_id1148,CANCER,GPX4,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,GPX4,GPX4,0.666666667
1104,bc_id1149,CANCER,GSR,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,GSR,GSR,1
1105,bc_id1150,CANCER,SOD1,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,SOD1,SOD1,1
1106,bc_id1151,CANCER,TXN,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,TXN,TXN,1
1107,bc_id1152,CANCER,TXN2,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,TXN2,TXN2,1
1108,bc_id1153,CANCER,TXNRD1,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,TXNRD1,TXNRD1,1
1109,bc_id1154,CANCER,TXNRD2,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,TXNRD2,TXNRD2,1
1110,bc_id1155,CANCER,CAT,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,CAT,CAT,0.4
1111,bc_id1156,CANCER,SOD2,16424062,B,Tagging Single-Nucleotide Polymorphisms in Antioxidant Defense Enzymes and Susceptibility to Breast Cancer,2006,,"We found no evidence for association of common variants in SOD1, SOD2, GPX1, GPX4, GSR, TXNRD1, and TXN2. There was borderline evidence for association of variants in CAT g27168a {P [2 degrees of freedom (df)] = 0.05}, TXN t2715c [P (2 df) = 0.007], and TXNRD2 A66S and TXNRD2 g23524a (P(trend) = 0.074 and 0.046, respectively). For TXNRD2 A66S [AS versus AA: odds ratio (OR), 1.05; 95% confidence intervals (95% CI), 0.96-1.15; SS versus AA: OR, 1.12; 95% CI, 0.98-1.29], there are bioinformatics data to suggest that it is functional but confirmation in independent data sets is required before they can be regarded as definitive breast cancer susceptibility alleles.",N,SOD2,SOD2,0.375
1112,bc_id1157,CANCER,TGFBR1,16428477,B,Int7G24A Variant of Transforming Growth Factor-{beta} Receptor Type I Is Associated with Invasive Breast Cancer,2006,These data suggest that the germline Int7G24A variant may represent a risk factor for invasive breast cancer and a marker for breast cancer progression.,The TGFBR1*6A allele was not significantly associated with breast cancer patients and only one somatic mutation was found in 71 breast cancers.,N,TGFBR1*6A,TGFBR1,0.666666667
1113,bc_id1158,CANCER,BACH1,16430786,N,BACH1 Ser919Pro variant and breast cancer risk,2006,Our results suggest that the BACH1 Ser919 is not a breast cancer predisposition allele in the Finnish study population.,Our results suggest that the BACH1 Ser919 is not a breast cancer predisposition allele in the Finnish study population.,N,BACH1,BACH1,0.5
1114,bc_id1159,CANCER,PRL,16434456,Y,Association of prolactin and its receptor gene regions with familial breast cancer,2006,Genetic variation in the PRL and PRLR genes was shown to influence BC risk.,Genetic variation in the PRL and PRLR genes was shown to influence BC risk.,Y,PRL,PRL,0.5
1115,bc_id1160,CANCER,PRLR,16434456,Y,Association of prolactin and its receptor gene regions with familial breast cancer,2006,Genetic variation in the PRL and PRLR genes was shown to influence BC risk.,Genetic variation in the PRL and PRLR genes was shown to influence BC risk.,Y,PRLR,PRLR,0.333333333
1116,bc_id1161,CANCER,NCOA3,16434590,N,The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers,2006,the AIB1 glutamine repeat does not substantially modify risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,the AIB1 glutamine repeat does not substantially modify risk of breast cancer in BRCA1 and BRCA2 mutation carriers.,N,AIB1,NCOA3,0.571428571
1117,bc_id1162,CANCER,MYLK2,16448786,B,Mutational analysis of the kinase domain of MYLK2 gene in common human cancers,2006,,"We analyzed exons 6 and 7 eccoding the kinase domain of MYLK2 for somatic mutations in 60 gastric, 104 colorectal, 79 non-small cell lung, and 54 breast cancers using a polymerase chain reaction (PCR)-based single-strand conformation polymorphism (SSCP)... These data suggest that the kinase domain of MYLK2 is rarely mutated in common human carcinomas and that it does not play a dominant role in cancer pathogenesis.",N,MYLK2,MYLK2,1
1118,bc_id1163,CANCER,BRCA2,16455195,B,BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.,2007,,"We analyzed the mutation spectrum of BRCA1 and BRCA2 genes in 354 Korean breast cancer patients. Overall, 40 patients carried 25 distinct BRCA1/2 mutations including 12 novel mutations.",A,BRCA2,BRCA2,0.576923077
1119,bc_id1164,CANCER,BRCA1,16455195,B,BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.,2007,,"We analyzed the mutation spectrum of BRCA1 and BRCA2 genes in 354 Korean breast cancer patients. Overall, 40 patients carried 25 distinct BRCA1/2 mutations including 12 novel mutations.",A,BRCA1,BRCA1,0.60944206
1120,bc_id1165,CANCER,BRCA1,16456781,Y,BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China.,2006,Two novel mutations in BRCA1 may be mutations characterized to familial breast cancer of Chinese Shanghai population.,Two novel mutations in BRCA1 may be mutations characterized to familial breast cancer of Chinese Shanghai population... The BRCA2 may contribute to mutation less than BRCA1 in familial breast cancer.,A,BRCA1,BRCA1,0.60944206
1121,bc_id1166,CANCER,BRCA2,16456781,Y,BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China.,2006,Two novel mutations in BRCA1 may be mutations characterized to familial breast cancer of Chinese Shanghai population.,Two novel mutations in BRCA1 may be mutations characterized to familial breast cancer of Chinese Shanghai population... The BRCA2 may contribute to mutation less than BRCA1 in familial breast cancer.,A,BRCA2,BRCA2,0.576923077
1122,bc_id1167,CANCER,XRCC1,16457697,B,A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk.,2006,"Our results support the hypothesis that genetic variation in XRCC1, particularly in Arg194Trp, may influence postmenopausal breast cancer risk.","Our results support the hypothesis that genetic variation in XRCC1, particularly in Arg194Trp, may influence postmenopausal breast cancer risk.",A,XRCC1,XRCC1,0.543478261
1123,bc_id1168,CANCER,IL1A,16464738,N,"Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.",2005,"The polymorphisms in the promoter region of the IL-6 gene may represent a marker for the increased risk of breast carcinoma. Genetic variations in IL-1alpha, IL-1beta and IL-6 may predict the clinical outcome of breast carcinoma.","The polymorphisms in the promoter region of the IL-6 gene may represent a marker for the increased risk of breast carcinoma. Genetic variations in IL-1alpha, IL-1beta and IL-6 may predict the clinical outcome of breast carcinoma.",A,IL-1alpha,IL1A,0.5
1124,bc_id1169,CANCER,IL6,16464738,Y,"Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.",2005,"The polymorphisms in the promoter region of the IL-6 gene may represent a marker for the increased risk of breast carcinoma. Genetic variations in IL-1alpha, IL-1beta and IL-6 may predict the clinical outcome of breast carcinoma.","The polymorphisms in the promoter region of the IL-6 gene may represent a marker for the increased risk of breast carcinoma. Genetic variations in IL-1alpha, IL-1beta and IL-6 may predict the clinical outcome of breast carcinoma.",A,IL-6,IL6,0.285714286
1125,bc_id1170,CANCER,IL1B,16464738,N,"Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.",2005,"The polymorphisms in the promoter region of the IL-6 gene may represent a marker for the increased risk of breast carcinoma. Genetic variations in IL-1alpha, IL-1beta and IL-6 may predict the clinical outcome of breast carcinoma.","The polymorphisms in the promoter region of the IL-6 gene may represent a marker for the increased risk of breast carcinoma. Genetic variations in IL-1alpha, IL-1beta and IL-6 may predict the clinical outcome of breast carcinoma.",A,IL-1beta,IL1B,0.4
1126,bc_id1171,CANCER,C1QA,16465510,B,The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement,2006,,"Breast cancer subjects with heterozygous or homozygous C1qA[276G] genotype had a higher rate of metastasis than subjects with the homozygous C1qA[276A] genotype [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.1-4.1].",Y,C1qA[276G],C1QA,0.5
1127,bc_id1172,CANCER,ERCC2,16475125,B,"DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil",2005,,"Polymorphisms have been identified in several DNA repair genes, such as XRCC1, XPD, XRCC3, and RAD51, but the influence of specific genetic variants on repair phenotype and cancer risk has not yet been clarified... The control group included 120 women with no breast cancer and no family history.",A,XPD,ERCC2,0.6875
1128,bc_id1173,CANCER,XRCC1,16475125,B,"DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil",2005,,"Polymorphisms have been identified in several DNA repair genes, such as XRCC1, XPD, XRCC3, and RAD51, but the influence of specific genetic variants on repair phenotype and cancer risk has not yet been clarified... The control group included 120 women with no breast cancer and no family history.",A,XRCC1,XRCC1,0.543478261
1129,bc_id1174,CANCER,RAD51,16475125,B,"DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil",2005,,"Polymorphisms have been identified in several DNA repair genes, such as XRCC1, XPD, XRCC3, and RAD51, but the influence of specific genetic variants on repair phenotype and cancer risk has not yet been clarified... The control group included 120 women with no breast cancer and no family history.",A,RAD51,RAD51,0.615384615
1130,bc_id1175,CANCER,XRCC3,16475125,B,"DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil",2005,,"Polymorphisms have been identified in several DNA repair genes, such as XRCC1, XPD, XRCC3, and RAD51, but the influence of specific genetic variants on repair phenotype and cancer risk has not yet been clarified... The control group included 120 women with no breast cancer and no family history.",A,XRCC3,XRCC3,0.461538462
1131,bc_id1176,CANCER,ESR1,16477637,B,Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk,2006,,Genetic variants in the steroid hormone receptor genes ESR1 and PGR (belonging to the nuclear receptor superfamily) could therefore modify sporadic breast cancer susceptibility.,A,ESR1,ESR1,0.586956522
1132,bc_id1177,CANCER,PGR,16477637,B,Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk,2006,,Genetic variants in the steroid hormone receptor genes ESR1 and PGR (belonging to the nuclear receptor superfamily) could therefore modify sporadic breast cancer susceptibility.,A,PGR,PGR,0.5
1133,bc_id1178,CANCER,BRCA1,16477874,B,Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer,2005,,"Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and/or progression of breast cancer. The lack of detectable BRCA1 germ-line mutations in most cases suggests that there are probably additional, as yet unidentified genes predisposing to this disease.",A,BRCA1,BRCA1,0.60944206
1134,bc_id1179,CANCER,RAD51,16477874,B,Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer,2005,,"Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and/or progression of breast cancer. The lack of detectable BRCA1 germ-line mutations in most cases suggests that there are probably additional, as yet unidentified genes predisposing to this disease.",A,RAD51,RAD51,0.615384615
1135,bc_id1180,CANCER,XRCC2,16485136,N,Polymorphisms in DNA double-strand break repair genes and risk of breast cancer,2006,"the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.","We evaluated the association between 19 polymorphisms in seven genes in this pathway (XRCC2, XRCC3, BRCA2, ZNF350, BRIP1, XRCC4, LIG4) and breast cancer risk in two population-based studies in USA (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.",N,XRCC2,XRCC2,0.454545455
1136,bc_id1181,CANCER,XRCC3,16485136,N,Polymorphisms in DNA double-strand break repair genes and risk of breast cancer,2006,"the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.","We evaluated the association between 19 polymorphisms in seven genes in this pathway (XRCC2, XRCC3, BRCA2, ZNF350, BRIP1, XRCC4, LIG4) and breast cancer risk in two population-based studies in USA (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.",Y,XRCC3,XRCC3,0.269230769
1137,bc_id1182,CANCER,ZNF350,16485136,N,Polymorphisms in DNA double-strand break repair genes and risk of breast cancer,2006,"the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.","We evaluated the association between 19 polymorphisms in seven genes in this pathway (XRCC2, XRCC3, BRCA2, ZNF350, BRIP1, XRCC4, LIG4) and breast cancer risk in two population-based studies in USA (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.",Y,ZNF350,ZNF350,0.333333333
1138,bc_id1183,CANCER,LIG4,16485136,N,Polymorphisms in DNA double-strand break repair genes and risk of breast cancer,2006,"the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.","We evaluated the association between 19 polymorphisms in seven genes in this pathway (XRCC2, XRCC3, BRCA2, ZNF350, BRIP1, XRCC4, LIG4) and breast cancer risk in two population-based studies in USA (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.",N,LIG4,LIG4,0.5
1139,bc_id1184,CANCER,BRCA2,16485136,N,Polymorphisms in DNA double-strand break repair genes and risk of breast cancer,2006,"the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.","We evaluated the association between 19 polymorphisms in seven genes in this pathway (XRCC2, XRCC3, BRCA2, ZNF350, BRIP1, XRCC4, LIG4) and breast cancer risk in two population-based studies in USA (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.",Y,BRCA2,BRCA2,0.324175824
1140,bc_id1185,CANCER,BRIP1,16485136,N,Polymorphisms in DNA double-strand break repair genes and risk of breast cancer,2006,"the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.","We evaluated the association between 19 polymorphisms in seven genes in this pathway (XRCC2, XRCC3, BRCA2, ZNF350, BRIP1, XRCC4, LIG4) and breast cancer risk in two population-based studies in USA (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.",N,BRIP1,BRIP1,0.3
1141,bc_id1186,CANCER,XRCC4,16485136,N,Polymorphisms in DNA double-strand break repair genes and risk of breast cancer,2006,"the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.","We evaluated the association between 19 polymorphisms in seven genes in this pathway (XRCC2, XRCC3, BRCA2, ZNF350, BRIP1, XRCC4, LIG4) and breast cancer risk in two population-based studies in USA (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... the genetic variants evaluated are unlikely to have a substantial overall association with breast cancer risk; however, weak associations are possible for XRCC3 (T241M and IVS7-14A>G), BRCA2 N372H, and ZNF350 S472P. Evaluation of potential underlying gene-gene interactions or associations in population subgroups will require even larger sample sizes.",N,XRCC4,XRCC4,0.2
1142,bc_id1187,CANCER,HSD17B1,16489054,B,Haplotype Analysis of the HSD17B1 Gene and Risk of Breast Cancer,2006,,We found no evidence of association between common HSD17B1 haplotypes or htSNPs and overall risk of breast cancer.,N,HSD17B1,HSD17B1,0.363636364
1143,bc_id1188,CANCER,TP53,16489069,B,"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.",2006,,"These results, obtained on the largest series analyzed thus far, show that TP53 mutations identified by gene sequencing have an independent prognostic value in breast cancer and could have potential uses in clinical practice.",Y,TP53,TP53,0.367816092
1144,bc_id1189,CANCER,PTGS2,16489098,Y,The Cyclooxygenase-2 (PTGS2) 8473T>C Polymorphism is Associated with Breast Cancer Risk,2006,,We conclude that the homozygous PTGS2 8473-CC genotype may be associated with breast cancer risk.,A,PTGS2,PTGS2,0.583333333
1145,bc_id1190,CANCER,ESR1,16492926,B,"Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China.",2006,,"We examined whether CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI genetic polymorphisms could increase the risk of breast cancer among Chinese women and gene-gene joint effect on the breast cancer risk in a subset from a population-based case-control study conducted in urban Shanghai from January 1, 1998 and November 31, 2001. PCR-RFLP method based on buccal cells was used to examine the three candidate polymorphisms in 282 breast cancer cases and 298 controls.",Y,ERalpha,ESR1,0.282608696
1146,bc_id1191,CANCER,CYP1A1,16492926,B,"Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China.",2006,,"We examined whether CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI genetic polymorphisms could increase the risk of breast cancer among Chinese women and gene-gene joint effect on the breast cancer risk in a subset from a population-based case-control study conducted in urban Shanghai from January 1, 1998 and November 31, 2001. PCR-RFLP method based on buccal cells was used to examine the three candidate polymorphisms in 282 breast cancer cases and 298 controls.",Y,CYP1A1,CYP1A1,0.304347826
1147,bc_id1192,CANCER,CHEK2,16492927,B,The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.,2006,30 cases and one control carried the 1100delC allele.,These data supporting the biological relevance of CHEK2 in breast carcinogenesis suggest that further studies examining the joint roles of CHEK2*1100delC carrier status and radiation exposure may be warranted.,Y,CHEK2,CHEK2,0.383333333
1148,bc_id1193,CANCER,APEX1,16492928,N,Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer,2006,"our results do not support that the polymorphisms evaluated in six BER pathway genes play a major role in breast carcinogenesis, particularly in Caucasian populations.","We evaluated whether genetic variation in six BER pathway genes (XRCC1, ADPRT, APEX1, OGG1, LIG3, and MUTYH) is associated with breast cancer risk in two large population-based case-control studies in the United States (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... Using data from U.S. study participants with mouthwash DNA, we found no significant overall association between breast cancer risk and XRCC1 R280H and R194W, ADPRT V726W, APEX1 D148E, OGG1 S326C, LIG3 R780H, or MUTYH 5' untranslated region.",N,APEX1,APEX1,0.5
1149,bc_id1194,CANCER,LIG3,16492928,N,Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer,2006,"our results do not support that the polymorphisms evaluated in six BER pathway genes play a major role in breast carcinogenesis, particularly in Caucasian populations.","We evaluated whether genetic variation in six BER pathway genes (XRCC1, ADPRT, APEX1, OGG1, LIG3, and MUTYH) is associated with breast cancer risk in two large population-based case-control studies in the United States (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... Using data from U.S. study participants with mouthwash DNA, we found no significant overall association between breast cancer risk and XRCC1 R280H and R194W, ADPRT V726W, APEX1 D148E, OGG1 S326C, LIG3 R780H, or MUTYH 5' untranslated region.",N,LIG3,LIG3,1
1150,bc_id1195,CANCER,MUTYH,16492928,N,Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer,2006,"our results do not support that the polymorphisms evaluated in six BER pathway genes play a major role in breast carcinogenesis, particularly in Caucasian populations.","We evaluated whether genetic variation in six BER pathway genes (XRCC1, ADPRT, APEX1, OGG1, LIG3, and MUTYH) is associated with breast cancer risk in two large population-based case-control studies in the United States (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... Using data from U.S. study participants with mouthwash DNA, we found no significant overall association between breast cancer risk and XRCC1 R280H and R194W, ADPRT V726W, APEX1 D148E, OGG1 S326C, LIG3 R780H, or MUTYH 5' untranslated region.",N,MUTYH,MUTYH,0.666666667
1151,bc_id1196,CANCER,OGG1,16492928,N,Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer,2006,"our results do not support that the polymorphisms evaluated in six BER pathway genes play a major role in breast carcinogenesis, particularly in Caucasian populations.","We evaluated whether genetic variation in six BER pathway genes (XRCC1, ADPRT, APEX1, OGG1, LIG3, and MUTYH) is associated with breast cancer risk in two large population-based case-control studies in the United States (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... Using data from U.S. study participants with mouthwash DNA, we found no significant overall association between breast cancer risk and XRCC1 R280H and R194W, ADPRT V726W, APEX1 D148E, OGG1 S326C, LIG3 R780H, or MUTYH 5' untranslated region.",N,OGG1,OGG1,0.333333333
1152,bc_id1197,CANCER,PARP1,16492928,N,Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer,2006,"our results do not support that the polymorphisms evaluated in six BER pathway genes play a major role in breast carcinogenesis, particularly in Caucasian populations.","We evaluated whether genetic variation in six BER pathway genes (XRCC1, ADPRT, APEX1, OGG1, LIG3, and MUTYH) is associated with breast cancer risk in two large population-based case-control studies in the United States (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... Using data from U.S. study participants with mouthwash DNA, we found no significant overall association between breast cancer risk and XRCC1 R280H and R194W, ADPRT V726W, APEX1 D148E, OGG1 S326C, LIG3 R780H, or MUTYH 5' untranslated region.",N,ADPRT,PARP1,0.333333333
1153,bc_id1198,CANCER,XRCC1,16492928,N,Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer,2006,"our results do not support that the polymorphisms evaluated in six BER pathway genes play a major role in breast carcinogenesis, particularly in Caucasian populations.","We evaluated whether genetic variation in six BER pathway genes (XRCC1, ADPRT, APEX1, OGG1, LIG3, and MUTYH) is associated with breast cancer risk in two large population-based case-control studies in the United States (3,368 cases and 2,880 controls) and Poland (1,995 cases and 2,296 controls)... Using data from U.S. study participants with mouthwash DNA, we found no significant overall association between breast cancer risk and XRCC1 R280H and R194W, ADPRT V726W, APEX1 D148E, OGG1 S326C, LIG3 R780H, or MUTYH 5' untranslated region.",N,XRCC1,XRCC1,0.217391304
1154,bc_id1199,CANCER,DNMT3B,16501248,B,Genetic variants in epigenetic genes and breast cancer risk,2006,,"To evaluate this hypothesis, we examined common variants in 12 genes coding for DNA methyltransferases (DNMT), histone acetyltransferases, histone deacetyltransferases, histone methyltrasferases and methyl-CpG binding domain proteins, for association with breast cancer in a large case-control study (N cases = 4474 and N controls = 4580)... No statistically significant association was found... The most significant result was for DNMT3b-c31721t (P-trend = 0.124 after adjusting for multiple testing)... However, a trend was observed: homozygotes for the rare alleles of the EHMT1, EHMT2 and PRDM2 had a mean value for both trimethylation of K9 and K27 of histone H3 remarkably different to the homozygotes for the common alleles.",Y,DNMT3b-c31721t,DNMT3B,0.25
1155,bc_id1200,CANCER,EHMT1,16501248,B,Genetic variants in epigenetic genes and breast cancer risk,2006,,"To evaluate this hypothesis, we examined common variants in 12 genes coding for DNA methyltransferases (DNMT), histone acetyltransferases, histone deacetyltransferases, histone methyltrasferases and methyl-CpG binding domain proteins, for association with breast cancer in a large case-control study (N cases = 4474 and N controls = 4580)... No statistically significant association was found... The most significant result was for DNMT3b-c31721t (P-trend = 0.124 after adjusting for multiple testing)... However, a trend was observed: homozygotes for the rare alleles of the EHMT1, EHMT2 and PRDM2 had a mean value for both trimethylation of K9 and K27 of histone H3 remarkably different to the homozygotes for the common alleles.",N,EHMT1,EHMT1,1
1156,bc_id1201,CANCER,EHMT2,16501248,B,Genetic variants in epigenetic genes and breast cancer risk,2006,,"To evaluate this hypothesis, we examined common variants in 12 genes coding for DNA methyltransferases (DNMT), histone acetyltransferases, histone deacetyltransferases, histone methyltrasferases and methyl-CpG binding domain proteins, for association with breast cancer in a large case-control study (N cases = 4474 and N controls = 4580)... No statistically significant association was found... The most significant result was for DNMT3b-c31721t (P-trend = 0.124 after adjusting for multiple testing)... However, a trend was observed: homozygotes for the rare alleles of the EHMT1, EHMT2 and PRDM2 had a mean value for both trimethylation of K9 and K27 of histone H3 remarkably different to the homozygotes for the common alleles.",N,EHMT2,EHMT2,1
1157,bc_id1202,CANCER,PRDM2,16501248,B,Genetic variants in epigenetic genes and breast cancer risk,2006,,"To evaluate this hypothesis, we examined common variants in 12 genes coding for DNA methyltransferases (DNMT), histone acetyltransferases, histone deacetyltransferases, histone methyltrasferases and methyl-CpG binding domain proteins, for association with breast cancer in a large case-control study (N cases = 4474 and N controls = 4580)... No statistically significant association was found... The most significant result was for DNMT3b-c31721t (P-trend = 0.124 after adjusting for multiple testing)... However, a trend was observed: homozygotes for the rare alleles of the EHMT1, EHMT2 and PRDM2 had a mean value for both trimethylation of K9 and K27 of histone H3 remarkably different to the homozygotes for the common alleles.",N,PRDM2,PRDM2,1
1158,bc_id1203,CANCER,CDH1,16502042,B,Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway,2006,,"The invasion-suppressor gene, E-Cadherin (E-Cad), has recently been identified as a downstream target gene regulated by the ER-MTA3 pathway via the transcriptional repressor, Snail, and the ER-MTA3-Snail-E-Cad pathway has therefore been evoked to explain the clinical observation that ER expression in breast cancer is generally associated with a better clinical outcome.",Y,E-Cadherin,CDH1,0.142857143
1159,bc_id1204,CANCER,ESR1,16502042,B,Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway,2006,,"Since E-Cad may play an initiating role during breast tumorigenesis, we hypothesized that this ER-signaling pathway may also determine susceptibility to breast cancer, and examined this in a multigenic case-control study of 468 incident breast cancer patients and 470 healthy controls by genotyping the single nucleotide polymorphisms (SNPs) in five genes (ER, MTA3, Snail, E-Cad, and MTA1) in the ER-signaling pathways... These epidemiological findings highlight the role of newly identified novel ER-related pathways in breast cancer development and provide a more comprehensive picture of the tumorigenic effect of estrogen in breast cancer development.",Y,ER,ESR1,0.282608696
1160,bc_id1205,CANCER,MTA3,16502042,B,Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway,2006,,"Since E-Cad may play an initiating role during breast tumorigenesis, we hypothesized that this ER-signaling pathway may also determine susceptibility to breast cancer, and examined this in a multigenic case-control study of 468 incident breast cancer patients and 470 healthy controls by genotyping the single nucleotide polymorphisms (SNPs) in five genes (ER, MTA3, Snail, E-Cad, and MTA1) in the ER-signaling pathways... These epidemiological findings highlight the role of newly identified novel ER-related pathways in breast cancer development and provide a more comprehensive picture of the tumorigenic effect of estrogen in breast cancer development.",Y,MTA3,MTA3,1
1161,bc_id1206,CANCER,SNAI1,16502042,B,Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway,2006,,"Since E-Cad may play an initiating role during breast tumorigenesis, we hypothesized that this ER-signaling pathway may also determine susceptibility to breast cancer, and examined this in a multigenic case-control study of 468 incident breast cancer patients and 470 healthy controls by genotyping the single nucleotide polymorphisms (SNPs) in five genes (ER, MTA3, Snail, E-Cad, and MTA1) in the ER-signaling pathways... These epidemiological findings highlight the role of newly identified novel ER-related pathways in breast cancer development and provide a more comprehensive picture of the tumorigenic effect of estrogen in breast cancer development.",Y,Snail,SNAI1,1
1162,bc_id1207,CANCER,MTA1,16502042,B,Breast cancer risk associated with genotypic polymorphism of the genes involved in the estrogen-receptor-signaling pathway,2006,,"Since E-Cad may play an initiating role during breast tumorigenesis, we hypothesized that this ER-signaling pathway may also determine susceptibility to breast cancer, and examined this in a multigenic case-control study of 468 incident breast cancer patients and 470 healthy controls by genotyping the single nucleotide polymorphisms (SNPs) in five genes (ER, MTA3, Snail, E-Cad, and MTA1) in the ER-signaling pathways... These epidemiological findings highlight the role of newly identified novel ER-related pathways in breast cancer development and provide a more comprehensive picture of the tumorigenic effect of estrogen in breast cancer development.",Y,MTA1,MTA1,1
1163,bc_id1208,CANCER,HFE,16503999,B,HFE H63D mutation frequency shows an increase in Turkish women with breast cancer.,2006,Our results suggest that HFE H63D mutation frequencies were increased in the breast cancer patients in comparison to those in the general population.,Our results suggest that HFE H63D mutation frequencies were increased in the breast cancer patients in comparison to those in the general population.,Y,HFE,HFE,0.333333333
1164,bc_id1209,CANCER,XRCC1,16510609,B,XRCC1 genotype and breast cancer: functional studies and epidemiologic data show interactions between XRCC1 codon 280 His and smoking.,2006,,"In the CBCS, positive associations were observed between breast cancer and smoking dose for participants with XRCC1 codon 194 Arg/Arg (P(trend) = 0.046), 399 Arg/Arg (P(trend) = 0.012), and 280 His/His or His/Arg (P(trend) = 0.047) genotypes.",Y,XRCC1,XRCC1,0.239130435
1165,bc_id1210,CANCER,CTLA4,16527605,B,Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer,2006,,These results suggest that CTLA4 promoter variants participate in the progression of breast cancer rather than in its initial development.,Y,CTLA4,CTLA4,0.666666667
1166,bc_id1211,CANCER,TMPRSS6,16533768,B,Refinement of the 22q12-q13 breast cancer--associated region,2006,,Our results suggest that matriptase-2 gene is associated with breast cancer risk in the Eastern Finnish population.,Y,matriptase-2,TMPRSS6,1
1167,bc_id1212,CANCER,AHR,16538170,Y,Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk,2006,"the results from our study suggest that the AhR Lys554Arg polymorphism may be a genetic susceptibility factor for breast cancer, whereas CYP1A2*1F, which is a potentially functional single nucleotide polymorphism, may not be related to breast cancer risk.","the results from our study suggest that the AhR Lys554Arg polymorphism may be a genetic susceptibility factor for breast cancer, whereas CYP1A2*1F, which is a potentially functional single nucleotide polymorphism, may not be related to breast cancer risk.",A,AhR,AHR,0.4
1168,bc_id1213,CANCER,CYP1A2,16538170,N,Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk,2006,"the results from our study suggest that the AhR Lys554Arg polymorphism may be a genetic susceptibility factor for breast cancer, whereas CYP1A2*1F, which is a potentially functional single nucleotide polymorphism, may not be related to breast cancer risk.","the results from our study suggest that the AhR Lys554Arg polymorphism may be a genetic susceptibility factor for breast cancer, whereas CYP1A2*1F, which is a potentially functional single nucleotide polymorphism, may not be related to breast cancer risk.",N,CYP1A2*1F,CYP1A2,0.416666667
1169,bc_id1214,CANCER,NOS3,16538535,B,Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer,2006,,"In our series, presence of the mutant exon7 Nos3 polymorphism was associated with an increased risk for breast cancer in Caucasian women.",Y,Nos3,NOS3,0.538461538
1170,bc_id1215,CANCER,CHEK2,16539695,N,CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum,2006,"In summary, our data suggest that the CHEK2 1100delC is not a major cause of double primary breast and colorectal cancer in Sweden, which suggests that this patient group should not routinely be screened for the CHEK2 1100delC variant.","In summary, our data suggest that the CHEK2 1100delC is not a major cause of double primary breast and colorectal cancer in Sweden, which suggests that this patient group should not routinely be screened for the CHEK2 1100delC variant.",N,CHEK2,CHEK2,0.233333333
1171,bc_id1216,CANCER,BRCA1,16541315,B,BRCA1-positive breast cancers in young women from Poland.,2006,,"The proportion of cases with a BRCA1 mutation was 5.7%. The hereditary proportions were higher than this for women with breast cancer diagnosed before age 40 (9%), for women with cancer of medullary or atypical medullary histology (28%), for those with bilateral cancer (29%) or with a family history of breast or ovarian cancer (13%). It is reasonable to offer genetic testing to women with early-onset breast cancer in Poland.",A,BRCA1,BRCA1,0.60944206
1172,bc_id1217,CANCER,BRCA2,16541324,B,"Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians.",2006,,X,X,X,X,0
1173,bc_id1218,CANCER,BRCA1,16541324,B,"Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians.",2006,,X,X,X,X,0
1174,bc_id1219,CANCER,BRCA1,16563154,N,Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers,2006,We found no evidence that the MDM2 SNP309 accelerates tumour development in carriers of known pathogenic germline mutations of BRCA1.,"Incidence of malignancy in female BRCA1 carriers was not significantly higher in SNP309 carriers than in wildtype (T/T) individuals (72.7% vs. 75.6%, p = 1.00). Mean age of diagnosis of first breast cancer was 41.2 years in the SNP309 G/G genotype carriers, 38.6 years in those with the SNP309 G/T genotype and 39.0 years in wildtype subjects (p = 0.80)... We found no evidence that the MDM2 SNP309 accelerates tumour development in carriers of known pathogenic germline mutations of BRCA1.",N,BRCA1,BRCA1,0.064377682
1175,bc_id1220,CANCER,MDM2,16563154,N,Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers,2006,We found no evidence that the MDM2 SNP309 accelerates tumour development in carriers of known pathogenic germline mutations of BRCA1.,"Incidence of malignancy in female BRCA1 carriers was not significantly higher in SNP309 carriers than in wildtype (T/T) individuals (72.7% vs. 75.6%, p = 1.00). Mean age of diagnosis of first breast cancer was 41.2 years in the SNP309 G/G genotype carriers, 38.6 years in those with the SNP309 G/T genotype and 39.0 years in wildtype subjects (p = 0.80)... We found no evidence that the MDM2 SNP309 accelerates tumour development in carriers of known pathogenic germline mutations of BRCA1.",N,MDM2,MDM2,0.444444444
1176,bc_id1221,CANCER,BRCA2,16563180,B,Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.,2006,Carrying a BRCA1 or BRCA2 mutation is not a risk factor for spontaneous abortions and spontaneous abortions do not appear to influence the risk of breast cancer in carriers of BRCA1 or BRCA2 mutations.,X,X,X,X,0
1177,bc_id1222,CANCER,BRCA1,16563180,B,Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.,2006,Carrying a BRCA1 or BRCA2 mutation is not a risk factor for spontaneous abortions and spontaneous abortions do not appear to influence the risk of breast cancer in carriers of BRCA1 or BRCA2 mutations.,X,X,X,X,0
1178,bc_id1223,CANCER,SIPA1,16563182,Y,Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer,2006,Our findings imply that SIPA1 germline polymorphisms are associated with aggressive disease behavior in the cohort examined.,The aim of this study was to determine whether single nucleotide polymorphisms (SNPs) within the human SIPA1 gene are associated with metastasis and other disease characteristics in breast cancer... Our findings imply that SIPA1 germline polymorphisms are associated with aggressive disease behavior in the cohort examined.,Y,SIPA1,SIPA1,0.25
1179,bc_id1224,CANCER,ARL11,16570116,B,Cancer Familial Aggregation (CFA) and G446A polymorphism in ARLTS1 gene,2006,,"The results of this study suggest that the G446A in ARLTS1 gene is probably not associated with an increased risk of sporadic breast cancer, prostate cancer, melanoma, thyroid papillary cancer or laryngeal cancer.",N,ARLTS1,ARL11,0.333333333
1180,bc_id1226,CANCER,XRCC1,16596326,B,"An intronic polymorphism associated with increased XRCC1 expression, reduced apoptosis and familial breast cancer.",2006,,"XRCC1 IVS10+141G>A is an intronic polymorphism that is associated with XRCC1 expression, apoptosis and familial breast cancer. It may occur within an intronic regulatory sequence.",Y,XRCC1,XRCC1,0.239130435
1181,bc_id1225,CANCER,POLB,16596326,B,"An intronic polymorphism associated with increased XRCC1 expression, reduced apoptosis and familial breast cancer.",2006,,X,X,X,X,0
1182,bc_id1227,CANCER,COMT,16596327,B,"Catechol-O-methyltransferase haplotypes and breast cancer among women on Long Island, New York.",2006,,"In this report of COMT haplotypes and breast cancer, we found some evidence that additional genetic variability beyond the Ex4-12 G>A SNP contributes to risk of breast cancer among a small subgroup of women; however, these results need to be replicated in additional studies.",Y,COMT,COMT,0.276595745
1183,bc_id1228,CANCER,CYP1A1,16599372,B,Potential differences in breast cancer risk factors based on CYP1A1 MspI and African-American-specific genotypes.,2006,,Our study results suggest that some risk factors for breast cancer are dependent upon CYP1A1 genotype.,Y,CYP1A1,CYP1A1,0.304347826
1184,bc_id1229,CANCER,CYP19A1,16604491,N,Effect of R264C polymorphism in CYP19A1 gene on BRCA1/2-negative hereditary breast cancer from Shanghai population of China.,2006,R264C polymorphism in CYP19A1 gene is not a candidate locus for low penetrance breast cancer susceptibility in Shanghai group of Chinese population and not recommended in clinical genetic test.,R264C polymorphism in CYP19A1 gene is not a candidate locus for low penetrance breast cancer susceptibility in Shanghai group of Chinese population and not recommended in clinical genetic test.,N,CYP19A1,CYP19A1,0.181818182
1185,bc_id1230,CANCER,GHRH,16606630,B,Polymorphisms in genes involved in GH1 release and their association with breast cancer risk,2006,,X,X,X,X,0
1186,bc_id1231,CANCER,GHRHR,16606630,B,Polymorphisms in genes involved in GH1 release and their association with breast cancer risk,2006,,X,X,X,X,0
1187,bc_id1232,CANCER,GHRL,16606630,B,Polymorphisms in genes involved in GH1 release and their association with breast cancer risk,2006,,X,X,X,X,0
1188,bc_id1233,CANCER,GHSR,16606630,B,Polymorphisms in genes involved in GH1 release and their association with breast cancer risk,2006,,X,X,X,X,0
1189,bc_id1234,CANCER,SST,16606630,B,Polymorphisms in genes involved in GH1 release and their association with breast cancer risk,2006,,"We investigated single nucleotide polymorphisms (SNPs) in the GHRH, GHRHR, GHRL, GHSR, SST and SSTR2 gene regions in a Polish and a German cohort of 798 breast cancer cases and 1011 controls. Our study revealed an association of a novel TC repeat polymorphism in the SST promoter with a decreased breast cancer risk in the Polish study population [odds ratio (OR), 0.65; 95% confidence interval (CI), 0.44-0.96].",Y,SST,SST,0.5
1190,bc_id1235,CANCER,SSTR2,16606630,B,Polymorphisms in genes involved in GH1 release and their association with breast cancer risk,2006,,X,X,X,X,0
1191,bc_id1236,CANCER,COMT,16608396,B,Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma,2006,GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.,"Three latent classification GoM extreme type groups represented the data: (a) fibroadenoma, and infrequent SRD5A2 and VDR alleles; (b) postmenopausal breast cancer, and infrequent CYP1A1-1 and CYP1A1-2 alleles (both over-represented infrequent alleles for CYP17, CYP19-3, and COMT); and (c) women at intrinsically low risk. Carriage of the respective multilocus genotypes increased risk 25-fold. We conclude that GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.",A,COMT,COMT,0.425531915
1192,bc_id1237,CANCER,CYP17A1,16608396,B,Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma,2006,GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.,"Three latent classification GoM extreme type groups represented the data: (a) fibroadenoma, and infrequent SRD5A2 and VDR alleles; (b) postmenopausal breast cancer, and infrequent CYP1A1-1 and CYP1A1-2 alleles (both over-represented infrequent alleles for CYP17, CYP19-3, and COMT); and (c) women at intrinsically low risk. Carriage of the respective multilocus genotypes increased risk 25-fold. We conclude that GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.",A,CYP17,CYP17A1,0.466666667
1193,bc_id1238,CANCER,CYP19A1,16608396,B,Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma,2006,GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.,"Three latent classification GoM extreme type groups represented the data: (a) fibroadenoma, and infrequent SRD5A2 and VDR alleles; (b) postmenopausal breast cancer, and infrequent CYP1A1-1 and CYP1A1-2 alleles (both over-represented infrequent alleles for CYP17, CYP19-3, and COMT); and (c) women at intrinsically low risk. Carriage of the respective multilocus genotypes increased risk 25-fold. We conclude that GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.",A,CYP19-3,CYP19A1,0.484848485
1194,bc_id1239,CANCER,CYP1A1,16608396,B,Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma,2006,GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.,"Three latent classification GoM extreme type groups represented the data: (a) fibroadenoma, and infrequent SRD5A2 and VDR alleles; (b) postmenopausal breast cancer, and infrequent CYP1A1-1 and CYP1A1-2 alleles (both over-represented infrequent alleles for CYP17, CYP19-3, and COMT); and (c) women at intrinsically low risk. Carriage of the respective multilocus genotypes increased risk 25-fold. We conclude that GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.",A,CYP1A1-2,CYP1A1,0.456521739
1195,bc_id1240,CANCER,SRD5A2,16608396,B,Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma,2006,GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.,"Three latent classification GoM extreme type groups represented the data: (a) fibroadenoma, and infrequent SRD5A2 and VDR alleles; (b) postmenopausal breast cancer, and infrequent CYP1A1-1 and CYP1A1-2 alleles (both over-represented infrequent alleles for CYP17, CYP19-3, and COMT); and (c) women at intrinsically low risk. Carriage of the respective multilocus genotypes increased risk 25-fold. We conclude that GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.",A,SRD5A2,SRD5A2,0.666666667
1196,bc_id1241,CANCER,VDR,16608396,B,Multilocus genotypes spanning estrogen metabolism associated with breast cancer and fibroadenoma,2006,GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.,"Three latent classification GoM extreme type groups represented the data: (a) fibroadenoma, and infrequent SRD5A2 and VDR alleles; (b) postmenopausal breast cancer, and infrequent CYP1A1-1 and CYP1A1-2 alleles (both over-represented infrequent alleles for CYP17, CYP19-3, and COMT); and (c) women at intrinsically low risk. Carriage of the respective multilocus genotypes increased risk 25-fold. We conclude that GoM latent classification may be useful to identify genetic risk sets and estimate risk for individuals.",A,VDR,VDR,0.538461538
1197,bc_id1242,CANCER,TP53,16609366,B,p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients.,2006,"The present report indicates that the codon 72 polymorphism in the p53 gene may be a predictor of tamoxifen response, suggesting that breast cancer patients lacking the Pro72 allele might be candidates for other therapies.","The present report indicates that the codon 72 polymorphism in the p53 gene may be a predictor of tamoxifen response, suggesting that breast cancer patients lacking the Pro72 allele might be candidates for other therapies.",A,p53,TP53,0.482758621
1198,bc_id1243,CANCER,VEGFA,16613616,B,Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort,2006,Our findings provide limited support for the hypothesis that the -2578C and -1154G VEGF alleles are associated with increased risk for invasive but not in situ breast cancer in postmenopausal women.,Our findings provide limited support for the hypothesis that the -2578C and -1154G VEGF alleles are associated with increased risk for invasive but not in situ breast cancer in postmenopausal women.,A,VEGF,VEGFA,0.416666667
1199,bc_id1244,CANCER,NAT2,16614098,B,Is the association between cigarette smoking and breast cancer modified by genotype? A review of epidemiologic studies and meta-analysis.,2006,"however, interpretation of the available literature is complicated by methodologic limitations, including small sample sizes, varying definitions of smoking, and difficulties involving single nucleotide polymorphism selection, which likely have contributed to the inconsistent findings.",X,X,X,X,0
1200,bc_id1245,CANCER,PGR,16614108,Y,Association of the progesterone receptor gene with breast cancer risk,2006,"the 660L allele may be associated with a moderately increased risk of breast cancer, but that other common SNPs in the PGR gene are unlikely to be associated with a substantial risk of breast cancer.","the 660L allele may be associated with a moderately increased risk of breast cancer, but that other common SNPs in the PGR gene are unlikely to be associated with a substantial risk of breast cancer.",A,PGR,PGR,0.5
1201,bc_id1246,CANCER,OGG1,16614128,B,OGG1 polymorphisms and breast cancer risk.,2006,", although we found some differences between the three OGG1 SNPs and breast cancer risk among moderate alcohol drinkers and women with higher BMI, replication of these results is needed to rule out spurious findings.","although we found some differences between the three OGG1 SNPs and breast cancer risk among moderate alcohol drinkers and women with higher BMI, replication of these results is needed to rule out spurious findings.",A,OGG1,OGG1,0.444444444
1202,bc_id1247,CANCER,BRCA2,16622123,B,"Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).",2006,,BRCA1 and BRCA2 mutation carriers older than 40 years show a similar reduction in breast cancer risk with increasing parity as non-carriers.,Y,BRCA2,BRCA2,0.324175824
1203,bc_id1248,CANCER,BRCA1,16622123,B,"Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).",2006,,BRCA1 and BRCA2 mutation carriers older than 40 years show a similar reduction in breast cancer risk with increasing parity as non-carriers.,Y,BRCA1,BRCA1,0.326180258
1204,bc_id1249,CANCER,ATM,16622469,B,ATM haplotypes and breast cancer risk in Jewish high-risk women,2006,,We conclude that a specific ATM SNP and a specific haplotype are associated with increased breast cancer risk in high-risk non-Ashkenazi Jews.,Y,ATM,ATM,0.333333333
1205,bc_id1250,CANCER,RAD51,16624550,B,A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women,2006,,"One of the haplotypes (TGTA - coined haplotype 3) was present in 7.3% (19/260 haplotypes) of controls (n=130) and in 16.8% (40/238 haplotypes) of high-risk breast cancer patients (n=119, P=0.001). A specific RAD51 haplotype is more prevalent among non-Ashkenazi Jewish high-risk women than in average-risk population.",A,RAD51,RAD51,0.615384615
1206,bc_id1251,CANCER,GSTA1,16624829,B,Effects of glutathione S-transferase A1 (GSTA1) genotype and potential modifiers on breast cancer risk,2006,,These data indicate that GSTA1 genotypes related to reduced GSTA1 expression are associated with increased breast cancer primarily among women with lower consumption of cruciferous vegetables and among current smokers.,Y,GSTA1,GSTA1,0.6
1207,bc_id1252,CANCER,MTHFR,16630166,B,Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis.,2006,,The methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms have been linked to the risk of developing breast cancer.,Y,MTHFR,MTHFR,0.269230769
1208,bc_id1253,CANCER,SULT1A1,16637266,Y,Association of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women,2006,,No association was observed between any of the SULT1A1 genotypes and breast cancer risk or phenotypes. Our data suggest that UGT1A1 but not SULT1A1 genotype might be important for breast cancer risk and phenotype in Russian women.,N,SULT1A1,SULT1A1,0.290322581
1209,bc_id1254,CANCER,UGT1A1,16637266,Y,Association of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women,2006,,Our data suggest that UGT1A1 but not SULT1A1 genotype might be important for breast cancer risk and phenotype in Russian women.,A,UGT1A1,UGT1A1,0.7
1210,bc_id1255,CANCER,TP53,16644204,B,"BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.",2006,,"Pathological mutations in BRCA1, BRCA2 and TP53 are associated with an increased risk of breast cancer.",Y,TP53,TP53,0.367816092
1211,bc_id1256,CANCER,BRCA2,16644204,B,"BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.",2006,,"Pathological mutations in BRCA1, BRCA2 and TP53 are associated with an increased risk of breast cancer.",Y,BRCA2,BRCA2,0.324175824
1212,bc_id1257,CANCER,BRCA1,16644204,B,"BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.",2006,,"Pathological mutations in BRCA1, BRCA2 and TP53 are associated with an increased risk of breast cancer.",Y,BRCA1,BRCA1,0.326180258
1213,bc_id1258,CANCER,BRCA2,16648044,B,Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.,2006,,X,X,X,X,0
1214,bc_id1259,CANCER,BRCA1,16648044,B,Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.,2006,,X,X,X,X,0
1215,bc_id1260,CANCER,ATM,16652348,B,The ATM missense mutation p.Ser49Cys (c.146C&gt;G) and the risk of breast cancer.,2006,,"These analyses provide the most convincing evidence thus far that missense mutations in ATM, particularly p.S49C, may be breast cancer susceptibility alleles.",A,ATM,ATM,0.422222222
1216,bc_id1261,CANCER,CHEK2,16671833,B,Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk.,2006,"Notwithstanding the involvement of the CHEK2 gene in breast cancer aetiology, we show that common polymorphisms do not influence postmenopausal breast cancer risk.","Notwithstanding the involvement of the CHEK2 gene in breast cancer aetiology, we show that common polymorphisms do not influence postmenopausal breast cancer risk.",N,CHEK2,CHEK2,0.233333333
1217,bc_id1262,CANCER,BARD1,16672066,B,SNP-SNP interactions in breast cancer susceptibility,2006,"The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.","Our study suggests cross talk between the SNPs of the DNA repair and immune system (XPD-[Lys751Gln] and IL10-[G(-1082)A]), cell cycle and estrogen metabolism (CCND1-[Pro241Pro] and COMT-[Met108/158Val]), cell cycle and DNA repair (BARD1-[Pro24Ser] and XPD-[Lys751Gln]), and within carcinogen metabolism (GSTP1-[Ile105Val] and COMT-[Met108/158Val]) pathways...  The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.",A,BARD1-[Pro24Ser],BARD1,0.454545455
1218,bc_id1263,CANCER,CCND1,16672066,B,SNP-SNP interactions in breast cancer susceptibility,2006,"The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.","Our study suggests cross talk between the SNPs of the DNA repair and immune system (XPD-[Lys751Gln] and IL10-[G(-1082)A]), cell cycle and estrogen metabolism (CCND1-[Pro241Pro] and COMT-[Met108/158Val]), cell cycle and DNA repair (BARD1-[Pro24Ser] and XPD-[Lys751Gln]), and within carcinogen metabolism (GSTP1-[Ile105Val] and COMT-[Met108/158Val]) pathways...  The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.",A,CCND1-[Pro241Pro],CCND1,0.5
1219,bc_id1264,CANCER,COMT,16672066,B,SNP-SNP interactions in breast cancer susceptibility,2006,"The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.","Our study suggests cross talk between the SNPs of the DNA repair and immune system (XPD-[Lys751Gln] and IL10-[G(-1082)A]), cell cycle and estrogen metabolism (CCND1-[Pro241Pro] and COMT-[Met108/158Val]), cell cycle and DNA repair (BARD1-[Pro24Ser] and XPD-[Lys751Gln]), and within carcinogen metabolism (GSTP1-[Ile105Val] and COMT-[Met108/158Val]) pathways...  The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.",A,COMT-[Met108/158Val],COMT,0.425531915
1220,bc_id1265,CANCER,ERCC2,16672066,B,SNP-SNP interactions in breast cancer susceptibility,2006,"The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.","Our study suggests cross talk between the SNPs of the DNA repair and immune system (XPD-[Lys751Gln] and IL10-[G(-1082)A]), cell cycle and estrogen metabolism (CCND1-[Pro241Pro] and COMT-[Met108/158Val]), cell cycle and DNA repair (BARD1-[Pro24Ser] and XPD-[Lys751Gln]), and within carcinogen metabolism (GSTP1-[Ile105Val] and COMT-[Met108/158Val]) pathways...  The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.",A,XPD-[Lys751Gln],ERCC2,0.6875
1221,bc_id1266,CANCER,GSTP1,16672066,B,SNP-SNP interactions in breast cancer susceptibility,2006,"The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.","Our study suggests cross talk between the SNPs of the DNA repair and immune system (XPD-[Lys751Gln] and IL10-[G(-1082)A]), cell cycle and estrogen metabolism (CCND1-[Pro241Pro] and COMT-[Met108/158Val]), cell cycle and DNA repair (BARD1-[Pro24Ser] and XPD-[Lys751Gln]), and within carcinogen metabolism (GSTP1-[Ile105Val] and COMT-[Met108/158Val]) pathways...  The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.",A,GSTP1-[Ile105Val],GSTP1,0.485714286
1222,bc_id1267,CANCER,IL10,16672066,B,SNP-SNP interactions in breast cancer susceptibility,2006,"The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.","Our study suggests cross talk between the SNPs of the DNA repair and immune system (XPD-[Lys751Gln] and IL10-[G(-1082)A]), cell cycle and estrogen metabolism (CCND1-[Pro241Pro] and COMT-[Met108/158Val]), cell cycle and DNA repair (BARD1-[Pro24Ser] and XPD-[Lys751Gln]), and within carcinogen metabolism (GSTP1-[Ile105Val] and COMT-[Met108/158Val]) pathways...  The importance of these pathways and their communication in breast cancer predisposition has been emphasized previously, but their biological interactions through SNPs have not been described.",A,IL10-[G(-1082)A],IL10,0.625
1223,bc_id1268,CANCER,FANCD2,16679306,B,FANCD2 associated with sporadic breast cancer risk,2006,,Our data indicate that a relationship between FANCD2 and sporadic breast cancer risk may exist.,A,FANCD2,FANCD2,1
1224,bc_id1269,CANCER,RB1,16685266,B,Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population,2006,,The RB1 gene is not known to contain any coding SNPs with allele frequencies > or = 5% but several intronic variants are in perfect linkage disequilibrium with the associated SNPs. Replication studies are needed to confirm the associations with breast cancer.,A,RB1,RB1,0.5
1225,bc_id1270,CANCER,ERCC2,16685590,B,XPD common variants and their association with melanoma and breast cancer risk.,2006,,"Additionally we examined the prevalence of three additional XPD variants, Gly156Gly, Leu485Pro and Arg112His amongst the 421 unselected melanoma patients. All of the variants when evaluated singularly were found not to be associated either with melanoma or breast cancer risk in younger or older patients.",N,XPD,ERCC2,0.1875
1226,bc_id1271,CANCER,IL8,16698420,B,Genetic Variation in IL-8 Associated with Increased Risk and Poor Prognosis of Breast Carcinoma,2006,,The polymorphism in the promoter region of the IL-8 gene may not only represent a marker for the increased risk of breast carcinoma but also predict the clinical outcome.,A,IL-8,IL8,0.2
1227,bc_id1272,CANCER,CYP17A1,16702327,Y,CYP17 Genotype Modifies the Association between Lignan Supply and Premenopausal Breast Cancer Risk in Humans,2006,,Our results suggest that CYP17 genotype modifies the protective effect of lignans on premenopausal breast cancer risk.,Y,CYP17,CYP17A1,0.266666667
1228,bc_id1273,CANCER,PTEN,16702386,N,Common Genetic Variation at PTEN and Risk of Sporadic Breast and Prostate Cancer,2006,our results show that common variants in PTEN do not substantially influence risk of these two common cancers.,"We found no strong association with any common haplotype in relation to breast or prostate cancer risk. In summary, our results show that common variants in PTEN do not substantially influence risk of these two common cancers.",N,PTEN,PTEN,0.166666667
1229,bc_id1274,CANCER,EP300,16704985,Y,"Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer",2006,,"We tested the hypothesis that non-conservative, putative functional amino acid exchanges in PPARGC1A, PPARGC1B and EP300 act as low-penetrance familial breast cancer risk factors... Our results indicate for the first time the importance of inherited variants in the estrogen receptor coactivator genes PPARGC1A and PPARGC1B for familial breast cancer susceptibility.",Y,EP300,EP300,1
1230,bc_id1275,CANCER,PPARGC1A,16704985,Y,"Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer",2006,,"We tested the hypothesis that non-conservative, putative functional amino acid exchanges in PPARGC1A, PPARGC1B and EP300 act as low-penetrance familial breast cancer risk factors... Our results indicate for the first time the importance of inherited variants in the estrogen receptor coactivator genes PPARGC1A and PPARGC1B for familial breast cancer susceptibility.",Y,PPARGC1A,PPARGC1A,1
1231,bc_id1276,CANCER,PPARGC1B,16704985,Y,"Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer",2006,,"We tested the hypothesis that non-conservative, putative functional amino acid exchanges in PPARGC1A, PPARGC1B and EP300 act as low-penetrance familial breast cancer risk factors... Our results indicate for the first time the importance of inherited variants in the estrogen receptor coactivator genes PPARGC1A and PPARGC1B for familial breast cancer susceptibility.",Y,PPARGC1B,PPARGC1B,1
1232,bc_id1277,CANCER,BRCA1,16713266,B,Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan,2006,,X,X,X,X,0
1233,bc_id1278,CANCER,BRCA2,16713266,B,Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan,2006,,X,X,X,X,0
1234,bc_id1279,CANCER,COMT,16713266,B,Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan,2006,,X,X,X,X,0
1235,bc_id1280,CANCER,CYP1A1,16713266,B,Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan,2006,,X,X,X,X,0
1236,bc_id1281,CANCER,RAD51,16713266,B,Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan,2006,,X,X,X,X,0
1237,bc_id1282,CANCER,NAT2,16713266,B,Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan,2006,,X,X,X,X,0
1238,bc_id1283,CANCER,NBN,16714331,Y,Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women <= 55 years,2006,,These findings suggest that NBS1 polymorphisms and haplotypes may contribute to the etiology of sporadic breast cancer in young non-Hispanic white women.,A,NBS1,NBN,0.571428571
1239,bc_id1284,CANCER,IL6,16721634,B,Interleukin 6 G-174 C polymorphism and breast cancer risk.,2007,,"Our data suggest that the IL-6 G-174 C polymorphism does not seem to play a role in breast cancer risk, although its role as a prognostic factor remains to be studied.",N,IL-6,IL6,0.428571429
1240,bc_id1285,CANCER,NAT2,16721725,B,"Tobacco smoking, NAT2 acetylation genotype and breast cancer risk.",2006,", our data indicate that passive smoking is not associated with breast cancer risk; however, active smoking might be associated with an increased risk for early onset breast cancers.","NAT2 slow vs. rapid/intermediate acetylation genotype was not related to breast cancer risk (0.99 (0.87-1.13)), and did not significantly modify the smoking relationships.",N,NAT2,NAT2,0.37037037
1241,bc_id1286,CANCER,TYMS,16723031,B,Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population,2006,These findings suggest that the TS3\-UTR del6 polymorphism may play a role in the etiology of breast cancer. Further larger population-based studies as well as functional evaluation of the variants are warranted to confirm our findings.,"To test the hypothesis that polymorphisms of the TYMS gene are associated with risk of breast cancer, we genotyped these two polymorphisms in a case-control study of 432 incident cases with invasive breast cancer and 473 cancer-free controls in a Chinese population...  These findings suggest that the TS3'-UTR del6 polymorphism may play a role in the etiology of breast cancer.",A,TYMS,TYMS,0.7
1242,bc_id1287,PHARMACOGENOMIC,ESR2,16723304,B,Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer,2006,,PvuII and XbaI polymorphisms of the estrogen receptor-alpha gene (ERalpha) and RsaI and AluI polymorphisms of the estrogen receptor-beta gene (ERbeta) have been associated with breast cancer.,Y,ERbeta,ESR2,0.333333333
1243,bc_id1288,CANCER,BRCA1,16724249,B,Low prevalence of BRCA1 exon rearrangements in familial and young sporadic breast cancer patients.,2007,,"Additionally, we detected a duplication of exons 18-19 in an early onset sporadic breast cancer patient from a panel of 100 patients tested. These data indicate that in the absence of any founder mutations, screening for BRCA1 exon rearrangements does not significantly increase the overall BRCA1 mutation detection rate in patients referred to a genetics clinic because of either a family history and/or an early onset of disease.",A,BRCA1,BRCA1,0.60944206
1244,bc_id1289,CANCER,BRCA1,16737811,B,High frequency of BRCA1 5382insC mutation in Russian breast cancer patients.,2006,,"The presented data confirm a noticeable contribution of BRCA1 5382insC mutation in BC development in Russia, that may justify an extended BRCA1 5382insC testing within this population.",Y,BRCA1,BRCA1,0.326180258
1245,bc_id1290,CANCER,IGHMBP2,16752224,B,IGHMBP2 Thr671Ala polymorphism might be a modifier for the effects of cigarette smoking and PAH-DNA adducts to breast cancer risk,2006,,Smokers carrying the IGHMBP2 variant-G allele had no significant increased breast cancer risk compared with non-smoking women with the AA genotype.,N,IGHMBP2,IGHMBP2,1
1246,bc_id1291,CANCER,APOE,16752225,B,Association between the apolipoprotein E genotypes and breast cancer patients in Taiwanese.,2006,,"Our findings demonstrated that the APOE genotypes were not associated with breast cancer patients, and epsilon2 allele tended to induce breast cancer on the left site among those patients in pre-menopause.",N,APOE,APOE,0.666666667
1247,bc_id1292,CANCER,CHEK2,16758118,B,CHEK2 1100delC mutation is frequent among Russian breast cancer patients,2006,,"This study was aimed to assess the role of CHEK2 1100delC mutation in breast cancer (BC) predisposition in Russia. The 1100delC allele was detected in 14/660 (2.1%) unilateral BC cases and in 8/155 (5.2%) patients with the bilateral form of the disease, but only in 1/448 (0.2%) middle-aged control females and in none of 373 elderly tumor-free women.",A,CHEK2,CHEK2,0.383333333
1248,bc_id1293,CANCER,GSTM1,16758119,B,Interaction of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferase M1 to breast cancer in Taiwanese woman without smoking and drinking habits.,2006,,Our findings indicated a gene-gene interaction between CYP2E1 and GSTM1 was accessible to developing breast cancer in Taiwanese women without the habits of cigarette smoking and alcohol consumption even though independent effects of CYP2E1 and GSTM1 were weak or non-significant and suggest that environmental carcinogen besides cigarette and alcohol consumption could induce breast cancer.,A,GSTM1,GSTM1,0.339622642
1249,bc_id1294,CANCER,CYP2E1,16758119,B,Interaction of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferase M1 to breast cancer in Taiwanese woman without smoking and drinking habits.,2006,,Our findings indicated a gene-gene interaction between CYP2E1 and GSTM1 was accessible to developing breast cancer in Taiwanese women without the habits of cigarette smoking and alcohol consumption even though independent effects of CYP2E1 and GSTM1 were weak or non-significant and suggest that environmental carcinogen besides cigarette and alcohol consumption could induce breast cancer.,A,CYP2E1,CYP2E1,1
1250,bc_id1295,CANCER,BARD1,16768547,Y,The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland,2006,"Our findings suggest that BARD1 Cys557Ser is an ancient variant that confers risk of single and multiple primary breast cancers, and this risk extends to carriers of the BRCA2 999del5 mutation.","Our findings suggest that BARD1 Cys557Ser is an ancient variant that confers risk of single and multiple primary breast cancers, and this risk extends to carriers of the BRCA2 999del5 mutation.",Y,BARD1,BARD1,0.363636364
1251,bc_id1296,CANCER,BRCA2,16769276,Y,The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy,2006,BRCA1 and BRCA2 mutations are common (9%) among unselected young breast cancer patients undergoing BCT.,X,X,X,X,0
1252,bc_id1297,CANCER,RCA1,16769276,B,The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy,2006,BRCA1 and BRCA2 mutations are common (9%) among unselected young breast cancer patients undergoing BCT.,X,X,X,X,0
1253,bc_id1298,CANCER,NBN,16770759,B,Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland,2006,,"Recent studies have demonstrated that heterozygous carriers of the NBS1 657del5 mutation have an increased risk for familial and bilateral breast cancer, but similar studies in consecutive breast cancer patients were inconclusive.",A,NBS1,NBN,0.571428571
1254,bc_id1299,CANCER,VEGFA,16775174,B,Population-Based Case-Control Study of VEGF Gene Polymorphisms and Breast Cancer Risk among Chinese Women,2006,,Our study suggests that the VEGF C936T polymorphism might be a susceptibility factor for breast cancer among Chinese women.,A,VEGF,VEGFA,0.416666667
1255,bc_id1300,PHARMACOGENOMIC,PON1,16775186,Y,Association of Polymorphisms in the Paraoxonase 1 Gene with Breast Cancer Incidence in the CPS-II Nutrition Cohort,2006,,"These results suggest that genetic variation in PON1, particularly at the L55M SNP, may be associated with increased risk of breast cancer in postmenopausal women. Furthermore, NSAID use seems to modify this risk.",A,PON1,PON1,1
1256,bc_id1301,CANCER,MTHFR,16777985,B,"Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan.",2006,,"The MTHFR 677T and 1298C variant alleles were associated with decreased risk for breast cancer [adjusted ORs were 0.81 (95% CI: 0.54-1.21) and 0.57 (95% CI: 0.36-0.89) for 677CT + TT genotypes and 1298AC + CC genotypes, respectively]. Furthermore, compound heterozygote and homozygote variants (677CT + TT and 1298AC + CC) had greater reduced risk (adjusted OR: 0.11, 95% CI: 0.03-0.43) among women with lower plasma folate levels.",Y,MTHFR,MTHFR,0.269230769
1257,bc_id1302,CANCER,MGMT,16788379,Y,Polymorphisms in O6-methylguanine DNA methyltransferase and breast cancer risk,2006,These data suggest that the Leu84Phe polymorphism affect the capacity of MGMT to inhibit estrogen receptor-mediated cell proliferation and is associated with$$$ breast cancer risk.,These data suggest that the Leu84Phe polymorphism affect the capacity of MGMT to inhibit estrogen receptor-mediated cell proliferation and is associated with breast cancer risk.,Y,MGMT,MGMT,0.5
1258,bc_id1303,CANCER,ESR1,16791482,B,Genetic determinants of bone mass do not relate with breast cancer risk in US white and African-American women.,2006,Our data suggest that the polymorphisms investigated had no effect on risk of breast cancer in this population.,"Thus, we found no evidence to support our hypothesis that breast cancer cases and controls would have a different distribution of ER and VDR genotypes. Furthermore, the polymorphisms were not associated with differences in bone mass and its relationship with breast cancer risk.",N,ER,ESR1,0.130434783
1259,bc_id1304,CANCER,VDR,16791482,B,Genetic determinants of bone mass do not relate with breast cancer risk in US white and African-American women.,2006,Our data suggest that the polymorphisms investigated had no effect on risk of breast cancer in this population.,"Thus, we found no evidence to support our hypothesis that breast cancer cases and controls would have a different distribution of ER and VDR genotypes. Furthermore, the polymorphisms were not associated with differences in bone mass and its relationship with breast cancer risk.",N,VDR,VDR,0.192307692
1260,bc_id1305,CANCER,AR,16791593,B,"Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer",2006,Our results confirm previous reports regarding an association between longer CAG repeats and breast cancer.,"Case-control studies have reported inconsistent results concerning the association between polymorphisms in the androgen and estrogen receptor (ER) genes and breast cancer. While several studies investigated the association between the androgen receptor (AR) gene, CAG repeat and breast cancer, for the CA and TA repeats in the ER genes there are considerably fewer studies (one for CA and none for TA)... Our results confirm previous reports regarding an association between longer CAG repeats and breast cancer. In addition to that, we found that the combination of long CAG, short TA and CA repeats are strongly associated with breast cancer.",Y,AR,AR,0.291666667
1261,bc_id1306,CANCER,ESR1,16791593,B,"Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer",2006,Our results confirm previous reports regarding an association between longer CAG repeats and breast cancer.,"Case-control studies have reported inconsistent results concerning the association between polymorphisms in the androgen and estrogen receptor (ER) genes and breast cancer. While several studies investigated the association between the androgen receptor (AR) gene, CAG repeat and breast cancer, for the CA and TA repeats in the ER genes there are considerably fewer studies (one for CA and none for TA)... Our results confirm previous reports regarding an association between longer CAG repeats and breast cancer. In addition to that, we found that the combination of long CAG, short TA and CA repeats are strongly associated with breast cancer.",Y,ER,ESR1,0.282608696
1262,bc_id1307,CANCER,ESR2,16791593,B,"Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer",2006,Our results confirm previous reports regarding an association between longer CAG repeats and breast cancer.,"Case-control studies have reported inconsistent results concerning the association between polymorphisms in the androgen and estrogen receptor (ER) genes and breast cancer. While several studies investigated the association between the androgen receptor (AR) gene, CAG repeat and breast cancer, for the CA and TA repeats in the ER genes there are considerably fewer studies (one for CA and none for TA)... Our results confirm previous reports regarding an association between longer CAG repeats and breast cancer. In addition to that, we found that the combination of long CAG, short TA and CA repeats are strongly associated with breast cancer.",Y,ER,ESR2,0.333333333
1263,bc_id1308,CANCER,HLA-DQB1,16799707,B,HLA Class II Polymorphism,2006,,Comparison of allele and haplotype distribution between patients and 70 female control subjects reveals a negative association between HLADRB1* 07-DQB1*02 and the incidence of breast cancer in the Tunisian population.,Y,HLADRB1* 07-DQB1*02,HLA-DQB1,0.5
1264,bc_id1309,CANCER,HLA-DRB1,16799707,B,HLA Class II Polymorphism,2006,,Comparison of allele and haplotype distribution between patients and 70 female control subjects reveals a negative association between HLADRB1* 07-DQB1*02 and the incidence of breast cancer in the Tunisian population.,Y,HLADRB1* 07-DQB1*02,HLA-DRB1,1
1265,bc_id1310,CANCER,CDKN1A,16804901,Y,Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women,2006,,"Although the exact biological mechanism remains to be explored, our findings suggest possible involvement of CDKN1A and CDKN1B variants in the etiology of breast cancer.",A,CDKN1A,CDKN1A,0.5
1266,bc_id1311,CANCER,CDKN1B,16804901,Y,Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women,2006,,"Although the exact biological mechanism remains to be explored, our findings suggest possible involvement of CDKN1A and CDKN1B variants in the etiology of breast cancer.",A,CDKN1B,CDKN1B,0.714285714
1267,bc_id1312,CANCER,KDR,16807673,B,Polymorphisms in the KDR and POSTN Genes,2006,,"Although a major effect of the SNPs in the KDR and the POSTN genes on breast cancer susceptibility and prognosis was excluded, the effect of the POSTN C-33G SNP on prognosis needs further characterization.",N,KDR,KDR,0.5
1268,bc_id1313,CANCER,POSTN,16807673,B,Polymorphisms in the KDR and POSTN Genes,2006,,"Although a major effect of the SNPs in the KDR and the POSTN genes on breast cancer susceptibility and prognosis was excluded, the effect of the POSTN C-33G SNP on prognosis needs further characterization.",A,POSTN,POSTN,1
1269,bc_id1314,CANCER,CYP1A1,16807674,B,A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.,2007,,"The results obtained from the present investigation thus suggest that probably CYP1A1 (M1, M2, M3, and M4) polymorphism alone does not play a significant role in the breast cancer risk in north Indian women.",N,CYP1A1,CYP1A1,0.239130435
1270,bc_id1315,CANCER,COL18A1,16807676,Y,A high risk of occurrence of sporadic breast cancer in individuals with the 104NN polymorphism of the COL18A1 gene,2006,,"We investigated the influence of the polymorphism D104N of the COL18A1 gene, encoding endostatin, on the occurrence of sporadic breast cancer in 181 patients and 448 controls. The homozygous 104NN polymorphism was found in five patients but was absent in controls (2.8% vs 0.0%; P = 0.002). Individuals with this genotype had a significantly increased risk for disease.",Y,COL18A1,COL18A1,1
1271,bc_id1316,CANCER,NOS3,16807677,N,Lack of Association Between NOS3 Glu298Asp and Breast Cancer Risk,2006,,Different studies provide data suggesting that the endothelial cell nitric oxide synthase (NOS3) expression in peritumoral microvessels might be a prognostic indicator in breast cancer patients.,A,NOS3,NOS3,0.461538462
1272,bc_id1317,CANCER,CYP1B1,16808847,Y,Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease,2006,"The results indicate that specific polymorphisms in the CYP1B1, ESR1, and ESR2 genes may play a role in progression of BBD to breast cancer among Caucasian women.","The results indicate that specific polymorphisms in the CYP1B1, ESR1, and ESR2 genes may play a role in progression of BBD to breast cancer among Caucasian women.",A,CYP1B1,CYP1B1,0.384615385
1273,bc_id1318,CANCER,ESR1,16808847,Y,Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease,2006,"The results indicate that specific polymorphisms in the CYP1B1, ESR1, and ESR2 genes may play a role in progression of BBD to breast cancer among Caucasian women.","The results indicate that specific polymorphisms in the CYP1B1, ESR1, and ESR2 genes may play a role in progression of BBD to breast cancer among Caucasian women.",A,ESR1,ESR1,0.586956522
1274,bc_id1319,CANCER,ESR2,16808847,Y,Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease,2006,"The results indicate that specific polymorphisms in the CYP1B1, ESR1, and ESR2 genes may play a role in progression of BBD to breast cancer among Caucasian women.","The results indicate that specific polymorphisms in the CYP1B1, ESR1, and ESR2 genes may play a role in progression of BBD to breast cancer among Caucasian women.",A,ESR2,ESR2,0.533333333
1275,bc_id1320,CANCER,CYP2D6,16815318,B,Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.,2006,CYP2D6 genotype and concomitant potent CYP2D6 inhibitors are highly associated with endoxifen plasma concentration and may have an impact on the response to tamoxifen therapy.,We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of CYP2D6 genotype and concomitant medications on endoxifen plasma concentrations... CYP2D6 genotype and concomitant potent CYP2D6 inhibitors are highly associated with endoxifen plasma concentration and may have an impact on the response to tamoxifen therapy.,A,CYP2D6,CYP2D6,0.590909091
1276,bc_id1321,CANCER,F5,16818854,B,Effect of Factor V Leiden and prothrombin G20210--&gt;A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.,2006,"Venous thromboembolic disease in the BCPT women is associated with tamoxifen use and body mass index, but not with FVL and PT20210 mutations.",X,X,X,X,0
1277,bc_id1322,CANCER,F2,16818854,B,Effect of Factor V Leiden and prothrombin G20210--&gt;A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.,2006,"Venous thromboembolic disease in the BCPT women is associated with tamoxifen use and body mass index, but not with FVL and PT20210 mutations.",X,X,X,X,0
1278,bc_id1323,CANCER,TP53,16818855,Y,Association of Breast Cancer Outcome With Status of p53 and MDM2 SNP309,2006,A strong interaction between SNP309 status and tumor p53 status appears to modify the association between p53 status and breast cancer survival.,"Tumor p53 status was not associated with breast cancer survival among carriers of the variant MDM2 SNP309 allele (G/T or G/G), which is consistent with a dominant effect of the variant allele.",N,p53,TP53,0.149425287
1279,bc_id1324,CANCER,MDM2,16818855,N,Association of Breast Cancer Outcome With Status of p53 and MDM2 SNP309,2006,A strong interaction between SNP309 status and tumor p53 status appears to modify the association between p53 status and breast cancer survival.,"Tumor p53 status was not associated with breast cancer survival among carriers of the variant MDM2 SNP309 allele (G/T or G/G), which is consistent with a dominant effect of the variant allele.",A,MDM2,MDM2,0.444444444
1280,bc_id1325,CANCER,NOS3,16821086,B,"Genetic Polymorphisms of eNOS, Hormone Receptor Status, and Survival of Breast Cancer",2006,,"Women carriers of the eNOS -786C allele had significantly increased hazards of breast cancer recurrence or death, compared with women having the TT genotype (HR = 2.1, 95% CI = 1.03-4.33); risks increased up to 3-fold in ER positive cases (HR = 3.2, 95% CI = 0.95-10.50). The hazard was also increased in eNOS 894T carriers, however, it did not reach statistical significance (HR = 1.8, 95% CI = 0.85-3.93).",Y,eNOS,NOS3,0.538461538
1281,bc_id1326,CANCER,FGFR4,16822847,Y,FGFR4 Arg388 Allele Is Associated With Resistance to Adjuvant Therapy in Primary Breast Cancer,2006,"According to this study, FGFR4 Arg388 genotype is a marker for breast cancer progression in patients with adjuvant systemic therapy, particularly chemotherapy, and thus may indicate therapy resistance.","According to this study, FGFR4 Arg388 genotype is a marker for breast cancer progression in patients with adjuvant systemic therapy, particularly chemotherapy, and thus may indicate therapy resistance.",Y,FGFR4,FGFR4,0.6
1282,bc_id1327,CANCER,AGTR1,16823505,B,Differential roles of Angiotensinogen and Angiotensin Receptor type 1 polymorphisms in breast cancer risk.,2007,,"Our results suggest that AGT plays a role in breast cancer risk in postmenopausal women, whereas the role of AGTR1 needs further studying.",A,AGTR1,AGTR1,0.5
1283,bc_id1328,CANCER,ERCC2,16823510,N,"Breast Cancer Risk is not Associated with Polymorphic Forms of Xeroderma Pigmentosum Genes in a Cohort of Women from Washington County, Maryland",2006,These results suggest that polymorphisms of XP genes are not likely to be significant risk factors for women within the general population.,"Five single nucleotide polymorphisms (SNPs) among four XP genes (XPC, XPD, XPF and XPG) were genotyped from DNA samples collected at baseline, and then analyzed by conditional logistic regression for association with the incidence of breast cancer. 321 cases were individually matched to 321 controls, by age and menopausal status...  No significant associations were found between breast cancer risk and any of the XP genotypes.",N,XPD,ERCC2,0.1875
1284,bc_id1329,CANCER,ERCC4,16823510,N,"Breast Cancer Risk is not Associated with Polymorphic Forms of Xeroderma Pigmentosum Genes in a Cohort of Women from Washington County, Maryland",2006,These results suggest that polymorphisms of XP genes are not likely to be significant risk factors for women within the general population.,"Five single nucleotide polymorphisms (SNPs) among four XP genes (XPC, XPD, XPF and XPG) were genotyped from DNA samples collected at baseline, and then analyzed by conditional logistic regression for association with the incidence of breast cancer. 321 cases were individually matched to 321 controls, by age and menopausal status...  No significant associations were found between breast cancer risk and any of the XP genotypes.",N,XPF,ERCC4,0.25
1285,bc_id1330,CANCER,ERCC5,16823510,N,"Breast Cancer Risk is not Associated with Polymorphic Forms of Xeroderma Pigmentosum Genes in a Cohort of Women from Washington County, Maryland",2006,These results suggest that polymorphisms of XP genes are not likely to be significant risk factors for women within the general population.,"Five single nucleotide polymorphisms (SNPs) among four XP genes (XPC, XPD, XPF and XPG) were genotyped from DNA samples collected at baseline, and then analyzed by conditional logistic regression for association with the incidence of breast cancer. 321 cases were individually matched to 321 controls, by age and menopausal status...  No significant associations were found between breast cancer risk and any of the XP genotypes.",N,XPG,ERCC5,0.166666667
1286,bc_id1331,CANCER,XPC,16823510,N,"Breast Cancer Risk is not Associated with Polymorphic Forms of Xeroderma Pigmentosum Genes in a Cohort of Women from Washington County, Maryland",2006,These results suggest that polymorphisms of XP genes are not likely to be significant risk factors for women within the general population.,"Five single nucleotide polymorphisms (SNPs) among four XP genes (XPC, XPD, XPF and XPG) were genotyped from DNA samples collected at baseline, and then analyzed by conditional logistic regression for association with the incidence of breast cancer. 321 cases were individually matched to 321 controls, by age and menopausal status...  No significant associations were found between breast cancer risk and any of the XP genotypes.",N,XPC,XPC,0.285714286
1287,bc_id1332,CANCER,BARD1,16825437,Y,Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 cancer cases,2006,These results provide further evidence that BARD1 Cys557Ser confers a slightly increased risk of breast cancer in women.,These results provide further evidence that BARD1 Cys557Ser confers a slightly increased risk of breast cancer in women.,Y,BARD1,BARD1,0.363636364
1288,bc_id1333,CANCER,XRCC1,16829685,B,"The XRCC1 -77T-&gt;C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage.",2006,,X,X,X,X,0
1289,bc_id1334,CANCER,CHEK2,16830057,B,Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland.,2006,"the 1100delC mutation of the CHEK2 gene contributes little to the overall breast cancer burden in Poland, including familial cases of this malignancy.",X,X,X,X,0
1290,bc_id1335,CANCER,ATM,16832357,B,ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles,2006,,There was no evidence that other classes of ATM variant confer a risk of breast cancer.,N,ATM,ATM,0.244444444
1291,bc_id1336,CANCER,XRCC4,16835328,Y,A Role for XRCC4 in Age at Diagnosis and Breast Cancer Risk,2006,,"Our results suggest that XRCC4 may play a role in the age at diagnosis and risk of breast cancer in non-BRCA1/2, heritable breast cancer cases.",A,XRCC4,XRCC4,0.4
1292,bc_id1337,CANCER,TP53,16835330,B,p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study.,2006,,The results of this study suggest that p53 protein accumulation and nonpolymorphic intronic changes in p53 are associated with increased risk of progression to breast cancer in women with benign breast disease.,Y,p53,TP53,0.367816092
1293,bc_id1338,CANCER,BRCA1,16837909,B,Analysis of RAD51 polymorphism and BRCA1 mutations in polish women with breast cancer,2006,Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and=or progression of breast cancer.,In present study one Ex20insC mutations of BRCA1 gene was identified in women with breast cancer... Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and=or progression of breast cancer.,Y,BRCA1,BRCA1,0.326180258
1294,bc_id1339,CANCER,RAD51,16837909,N,Analysis of RAD51 polymorphism and BRCA1 mutations in polish women with breast cancer,2006,Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and=or progression of breast cancer.,Our study implies that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and=or progression of breast cancer.,N,RAD51,RAD51,0.153846154
1295,bc_id1340,CANCER,IL6,16842617,B,Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.,2006,"Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.","Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.",N,IL6,IL6,0.428571429
1296,bc_id1341,CANCER,IL4R,16842617,B,Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.,2006,"Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.","Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.",N,IL4R,IL4R,1
1297,bc_id1342,CANCER,IL1RN,16842617,B,Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.,2006,"Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.","Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.",N,IL1RN,IL1RN,0.25
1298,bc_id1343,CANCER,IL1B,16842617,B,Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.,2006,"Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.","Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.",N,IL1B,IL1B,0.4
1299,bc_id1344,CANCER,IL1A,16842617,B,Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.,2006,"Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.","Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.",N,IL1A,IL1A,0.5
1300,bc_id1345,CANCER,IL10,16842617,B,Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.,2006,"Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.","Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 do not appear to play a significant overall role in breast cancer susceptibility or severity.",N,IL10,IL10,0.25
1301,bc_id1346,CANCER,CYP1B1,16847423,B,Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women,2006,,The present study provides strong evidence against the existence of a substantial overall association between common genetic variation in CYP1B1 and breast cancer risk.,N,CYP1B1,CYP1B1,0.256410256
1302,bc_id1347,CANCER,AURKA,16849685,N,Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk,2006,,"STK15 may be a low-penetrance breast cancer susceptibility gene, and several reports suggest that women who are homozygous for the polymorphic variant F31I have an increased risk of breast cancer.",A,STK15,AURKA,0.5
1303,bc_id1348,CANCER,SOD2,16859522,Y,Association between Manganese Superoxide Dismutase Promoter Gene Polymorphism and Breast Cancer Survival,2006,"The MnSOD -102 variant allele appears to be associated with an improved recurrence-free survival in all patients, and more dramatically in subjects who received adjuvant radiation therapy.","Manganese superoxide dismutase (MnSOD) plays a critical role in the detoxification of mitochondrial reactive oxygen species, constituting a major cellular defense mechanism against agents that induce oxidative stress. A genetic polymorphism in the mitochondrial targeting sequence of this gene has been associated with increased cancer risk and survival in breast cancer.",Y,MnSOD,SOD2,0.25
1304,bc_id1349,CANCER,CYP2D6,16864175,B,The association of CYP2D6 *10 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women.,2007,,Our results suggest that CYP2D6 *10 mutant 188T/T genotype displays a non-significant increased risk for breast cancer.,N,CYP2D6,CYP2D6,0.136363636
1305,bc_id1350,CANCER,TP53,16864176,B,LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.,2007,", we find a highly significant prognostic value of TP53 mutations but find a possible prognostic value of the Arg72Pro polymorphism only related to LOH.",Mutations in the TP53 gene are a well-documented strong prognostic factor in breast cancer.,Y,TP53,TP53,0.367816092
1306,bc_id1351,CANCER,GPX1,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,GPX1,GPX1,0.4
1307,bc_id1352,CANCER,GPX4,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,GPX4,GPX4,0.666666667
1308,bc_id1353,CANCER,GSR,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,GSR,GSR,1
1309,bc_id1354,CANCER,SOD1,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,SOD1,SOD1,1
1310,bc_id1355,CANCER,SOD2,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,SOD2,SOD2,0.375
1311,bc_id1356,CANCER,TXN,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,TXN,TXN,1
1312,bc_id1357,CANCER,TXN2,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,TXN2,TXN2,1
1313,bc_id1358,CANCER,TXNRD2,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,TXNRD2,TXNRD2,1
1314,bc_id1359,CANCER,CAT,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,CAT,CAT,0.4
1315,bc_id1360,CANCER,TXNRD1,16868544,B,Interactions between genes involved in the antioxidant defence system and breast cancer risk,2006,,"The 10 genes are SOD1, SOD2, GPX1, GPX4, GSR, CAT, TXN, TXN2, TXNRD1 and TXNRD2. In all, 2271 cases and 2280 controls were used to examine gene-gene interactions between 52 single nucleotide polymorphisms (SNPs) that are hypothesised to tag all common variants in the 10 genes... We found no evidence of an association with breast cancer with our multilocus approach.",N,TXNRD1,TXNRD1,1
1316,bc_id1361,CANCER,CYP17A1,16875543,B,"Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women",2006,This study indicated that the polymorphisms of estrogen-metabolizing genes were related to breast cancer.,X,X,X,X,0
1317,bc_id1362,CANCER,CYP19A1,16875543,B,"Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women",2006,This study indicated that the polymorphisms of estrogen-metabolizing genes were related to breast cancer.,Data from multivariate analysis showed that the allele of SULT1A1 His and CYP19 (TTTA)10 was positively associated with the risk of breast cancer.,Y,CYP19,CYP19A1,0.333333333
1318,bc_id1363,CANCER,SULT1A1,16875543,B,"Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women",2006,This study indicated that the polymorphisms of estrogen-metabolizing genes were related to breast cancer.,Data from multivariate analysis showed that the allele of SULT1A1 His and CYP19 (TTTA)10 was positively associated with the risk of breast cancer.,Y,SULT1A1,SULT1A1,0.322580645
1319,bc_id1364,CANCER,CHEK2,16880452,B,Increased risk of breast cancer associated with CHEK2*1100delC.,2007,,CHEK2*1100delC heterozygosity is associated with a three-fold risk of breast cancer in women in the general population.,Y,CHEK2*1100delC,CHEK2,0.383333333
1320,bc_id1365,CANCER,CHEK2,16883537,B,CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China.,2006,CHEK2 c.,CHEK2 c.1100delC is rare variant for Chinese population and may not contribute to predisposition for hereditary breast cancer in Shanghai.,A,CHEK2 c.1100delC,CHEK2,0.383333333
1321,bc_id1366,CANCER,TGFB2,16885354,B,A Novel Functional Polymorphism in the Transforming Growth Factor-{beta}2 Gene Promoter and Tumor Progression in Breast Cancer,2006,,X,X,X,X,0
1322,bc_id1367,CANCER,ESR1,16886637,B,The estrogen receptor alpha C975G variant in familial and sporadic breast cancer: a case-control study.,2006,The results of this study indicated that the common C975G variant may have an effect on familial breast cancer susceptibility.,The estrogen receptor alpha (ESR1) mediates the effect of estrogen in target tissues. Estrogen is important in breast cancer development and several polymorphic variants in the ESR1 gene have been investigated for association with breast cancer...  The results of this study indicated that the common C975G variant may have an effect on familial breast cancer susceptibility.,A,ESR1,ESR1,0.586956522
1323,bc_id1368,CANCER,BRCA2,16912212,B,Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.,2006,,These results provide first-time prevalence estimates for BRCA1/BRCA2 in breast cancer cases among understudied racial and age groups and show key predictors of mutation carrier status for both White and Black women and women of a wide age spectrum with breast cancer in the general population.,A,BRCA1/BRCA2,BRCA2,0.576923077
1324,bc_id1369,CANCER,BRCA1,16912212,B,Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.,2006,,These results provide first-time prevalence estimates for BRCA1/BRCA2 in breast cancer cases among understudied racial and age groups and show key predictors of mutation carrier status for both White and Black women and women of a wide age spectrum with breast cancer in the general population.,A,BRCA1/BRCA2,BRCA1,0.60944206
1325,bc_id1370,CANCER,ATM,16914028,N,ATM variants and cancer risk in breast cancer patients from Southern Finland,2006,"Altogether, our results suggest very minor effect, if any, of ATM genetic variants on familial breast cancer in Southern Finland.","Altogether, our results suggest very minor effect, if any, of ATM genetic variants on familial breast cancer in Southern Finland.",Y,ATM,ATM,0.333333333
1326,bc_id1371,CANCER,CHEK2,16914568,B,CHEK2-positive breast cancers in young Polish women.,2006,,Three founder alleles in CHEK2 contribute to early-onset breast cancer in Poland. Breast tumors which arise in carriers of CHEK2 mutations seem to be similar to those of breast cancers in the population at large.,Y,CHEK2,CHEK2,0.383333333
1327,bc_id1372,CANCER,XRCC1,16924699,N,Association of single nucleotide polymorphisms and haplotypes in DNA repair gene XRCC1 with susceptibility of breast cancer.,2006,"XRCC1 C26304T, G27466A and G28152A SNPs may not be associated with the susceptibility of breast cancer.","XRCC1 C26304T, G27466A and G28152A SNPs may not be associated with the susceptibility of breast cancer.",A,XRCC1,XRCC1,0.543478261
1328,bc_id1373,CANCER,TOPBP1,16930991,B,Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer,2006,,"Based on its biological significance, we reasoned that TopBP1 is a plausible susceptibility gene for hereditary breast and/or ovarian cancer and therefore screened affected index cases from 125 Finnish cancer families for germline changes by conformation sensitive gel electrophoresis (CSGE).",Y,TopBP1,TOPBP1,0.5
1329,bc_id1374,CANCER,BRCA2,16931905,B,Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic.,2006,"In this retrospective analysis, heterozygous BRCA1 and BRCA2 mutations were not a risk factor for childhood cancer in hereditary breast cancer families.","In this retrospective analysis, heterozygous BRCA1 and BRCA2 mutations were not a risk factor for childhood cancer in hereditary breast cancer families.",N,BRCA2,BRCA2,0.098901099
1330,bc_id1375,CANCER,BRCA1,16931905,B,Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic.,2006,"In this retrospective analysis, heterozygous BRCA1 and BRCA2 mutations were not a risk factor for childhood cancer in hereditary breast cancer families.","In this retrospective analysis, heterozygous BRCA1 and BRCA2 mutations were not a risk factor for childhood cancer in hereditary breast cancer families.",N,BRCA1,BRCA1,0.064377682
1331,bc_id1376,CANCER,SOD2,16933053,Y,"Manganese superoxide dismutase Ala-9Val polymorphism, environmental modifiers, and risk of breast cancer in a German population",2006,"The MnSOD Ala-9Val polymorphism may contribute to an increase in breast cancer risk in the context of high alcohol consumption, however the polymorphism is not an overall risk factor for breast cancer in this primarily premenopausal population.",X,X,X,X,0
1332,bc_id1377,CANCER,SOD2,16945136,Y,GenexGene interaction between MnSOD and GPX-1 and breast cancer risk,2006,Polymorphisms in the GPX-1 and MnSOD genes are associated with an increased risk of breast cancer.,X,X,X,X,0
1333,bc_id1378,CANCER,GPX1,16945136,Y,GenexGene interaction between MnSOD and GPX-1 and breast cancer risk,2006,Polymorphisms in the GPX-1 and MnSOD genes are associated with an increased risk of breast cancer.,X,X,X,X,0
1334,bc_id1379,CANCER,TP73,16950799,Y,Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival,2006,,Our results suggest that the GC/GC genotype is significantly associated with poor prognosis in breast cancer and raise the possibility that analysis of p73 polymorphism may provide useful prognostic information for breast cancer patients.,A,p73,TP73,1
1335,bc_id1380,CANCER,AKAP10,16956908,Y,The functional genetic variant Ile646Val located in the kinase binding domain of the A kinase anchoring protein 10 is associated with familial breast cancer,2006,,"Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).",Y,AKAP10,AKAP10,1
1336,bc_id1381,CANCER,AKAP13,16956908,N,The functional genetic variant Ile646Val located in the kinase binding domain of the A kinase anchoring protein 10 is associated with familial breast cancer,2006,,"Here, we discovered that carriers of both variants, AKAP10 Ile646Val and AKAP13 Lys526Gln, are at a further enhanced breast cancer risk (OR=2.41, 95% CI 1.30-4.46, P=0.005).",Y,AKAP13,AKAP13,1
1337,bc_id1382,CANCER,ATM,16958054,B,Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T&gt;G and c.1066-6T&gt;G (IVS10-6T&gt;G) from the Breast Cancer Family Registry.,2006,,"These findings suggest that although the more common c.1066-6T>G variant is not associated with breast cancer, the rare ATM c.7271T>G variant is associated with a substantially elevated risk.",A,ATM,ATM,0.422222222
1338,bc_id1383,CANCER,PPARG,16959787,B,"Peroxisome profilerator-activated receptor{gamma}2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes",2006,,"Non-users of NSAID, who were carriers of the variant allele of PPARgamma2 Pro12Ala, were at lower risk of breast cancer (IRR=0.44; 95% CI=0.26-0.73) compared with non-users carrying wild-type alleles (P for interaction=0.03). No effects were found for IL6 G-174C, IL8 T-251A and COX2 T8473C.",A,PPARgamma2,PPARG,0.4
1339,bc_id1384,CANCER,PTGS2,16959787,B,"Peroxisome profilerator-activated receptor{gamma}2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes",2006,,"Non-users of NSAID, who were carriers of the variant allele of PPARgamma2 Pro12Ala, were at lower risk of breast cancer (IRR=0.44; 95% CI=0.26-0.73) compared with non-users carrying wild-type alleles (P for interaction=0.03). No effects were found for IL6 G-174C, IL8 T-251A and COX2 T8473C.",N,COX2,PTGS2,0.333333333
1340,bc_id1385,CANCER,IL8,16959787,B,"Peroxisome profilerator-activated receptor{gamma}2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes",2006,,"Non-users of NSAID, who were carriers of the variant allele of PPARgamma2 Pro12Ala, were at lower risk of breast cancer (IRR=0.44; 95% CI=0.26-0.73) compared with non-users carrying wild-type alleles (P for interaction=0.03). No effects were found for IL6 G-174C, IL8 T-251A and COX2 T8473C.",N,IL8,IL8,0.4
1341,bc_id1386,CANCER,IL6,16959787,B,"Peroxisome profilerator-activated receptor{gamma}2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes",2006,,"Non-users of NSAID, who were carriers of the variant allele of PPARgamma2 Pro12Ala, were at lower risk of breast cancer (IRR=0.44; 95% CI=0.26-0.73) compared with non-users carrying wild-type alleles (P for interaction=0.03). No effects were found for IL6 G-174C, IL8 T-251A and COX2 T8473C.",N,IL6,IL6,0.428571429
1342,bc_id1387,CANCER,XRCC3,16963196,B,No association between XRCC1 and XRCC3 gene polymorphisms and breast cancer risk: Iowa Women's Health Study.,2006,These results suggest that independently these polymorphisms of XRCC1 and XRCC3 genes do not contribute significantly to the genetic susceptibility of breast cancer.,These results suggest that independently these polymorphisms of XRCC1 and XRCC3 genes do not contribute significantly to the genetic susceptibility of breast cancer.,N,XRCC3,XRCC3,0.269230769
1343,bc_id1388,CANCER,XRCC1,16963196,B,No association between XRCC1 and XRCC3 gene polymorphisms and breast cancer risk: Iowa Women's Health Study.,2006,These results suggest that independently these polymorphisms of XRCC1 and XRCC3 genes do not contribute significantly to the genetic susceptibility of breast cancer.,These results suggest that independently these polymorphisms of XRCC1 and XRCC3 genes do not contribute significantly to the genetic susceptibility of breast cancer.,N,XRCC1,XRCC1,0.217391304
1344,bc_id1389,CANCER,COMT,16969494,B,"Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD)",2006,,"In this study, we evaluated the frequency of different polymorphisms related with estrogen metabolism [COMT Val158Met, CYP17 (5'UTR, T27C); HSD17beta1 Gly313Ser and MnSOD Val16Ala] in a breast cancer resistant population, the Xavante Indians, and the frequencies were compared with the ones reported in other populations where breast cancer case-control studies dealing with these polymorphisms have been carried out... The results obtained did not reveal a significant association between individual genotypes and breast cancer risk.",N,COMT,COMT,0.29787234
1345,bc_id1390,CANCER,CYP17A1,16969494,B,"Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD)",2006,,"In this study, we evaluated the frequency of different polymorphisms related with estrogen metabolism [COMT Val158Met, CYP17 (5'UTR, T27C); HSD17beta1 Gly313Ser and MnSOD Val16Ala] in a breast cancer resistant population, the Xavante Indians, and the frequencies were compared with the ones reported in other populations where breast cancer case-control studies dealing with these polymorphisms have been carried out... The results obtained did not reveal a significant association between individual genotypes and breast cancer risk.",N,CYP17,CYP17A1,0.266666667
1346,bc_id1391,CANCER,HSD17B1,16969494,B,"Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD)",2006,,"In this study, we evaluated the frequency of different polymorphisms related with estrogen metabolism [COMT Val158Met, CYP17 (5'UTR, T27C); HSD17beta1 Gly313Ser and MnSOD Val16Ala] in a breast cancer resistant population, the Xavante Indians, and the frequencies were compared with the ones reported in other populations where breast cancer case-control studies dealing with these polymorphisms have been carried out... The results obtained did not reveal a significant association between individual genotypes and breast cancer risk.",N,HSD17beta1,HSD17B1,0.363636364
1347,bc_id1392,CANCER,SOD2,16969494,B,"Breast cancer risk and polymorphisms in genes involved in metabolism of estrogens (CYP17, HSD17beta1, COMT and MnSOD)",2006,,X,X,X,X,0
1348,bc_id1393,CANCER,AR,16987421,N,A comprehensive analysis of the AR gene and risk of breast cancer,2006,"Among postmenopausal Caucasian women, common variants of the AR gene are not associated with risk of breast cancer.","Among postmenopausal Caucasian women, common variants of the AR gene are not associated with risk of breast cancer.",N,AR,AR,0.25
1349,bc_id1394,CANCER,CDKN2A,16988943,Y,"MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk",2006,the results of this population-based study show herein that MC1R variants are associated with increased melanoma risk in the Polish population. The risk of disease seems to be increased additively for patients harbouring also the CDKN2A common variant A148T.,"We found no association with the MC1R variants and breast cancer risk. In conclusion, the results of this population-based study show herein that MC1R variants are associated with increased melanoma risk in the Polish population. The risk of disease seems to be increased additively for patients harbouring also the CDKN2A common variant A148T.",A,CDKN2A,CDKN2A,0.625
1350,bc_id1395,CANCER,MC1R,16988943,Y,"MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk",2006,the results of this population-based study show herein that MC1R variants are associated with increased melanoma risk in the Polish population. The risk of disease seems to be increased additively for patients harbouring also the CDKN2A common variant A148T.,"We found no association with the MC1R variants and breast cancer risk. In conclusion, the results of this population-based study show herein that MC1R variants are associated with increased melanoma risk in the Polish population. The risk of disease seems to be increased additively for patients harbouring also the CDKN2A common variant A148T.",N,MC1R,MC1R,1
1351,bc_id1396,PHARMACOGENOMIC,DPYD,17000685,B,Pharmacogenetics of capecitabine in advanced breast cancer patients,2006,The present data suggest that 3RG3RG breast cancer patients are not good candidates for capecitabine therapy.,X,X,X,X,0
1352,bc_id1397,PHARMACOGENOMIC,MTHFR,17000685,B,Pharmacogenetics of capecitabine in advanced breast cancer patients,2006,The present data suggest that 3RG3RG breast cancer patients are not good candidates for capecitabine therapy.,X,X,X,X,0
1353,bc_id1398,PHARMACOGENOMIC,TYMS,17000685,B,Pharmacogenetics of capecitabine in advanced breast cancer patients,2006,The present data suggest that 3RG3RG breast cancer patients are not good candidates for capecitabine therapy.,X,X,X,X,0
1354,bc_id1399,CANCER,BRCA1,17004108,B,The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation,2006,,X,X,X,X,0
1355,bc_id1400,CANCER,PHB,17004108,B,The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation,2006,,"To investigate whether the PHB 3'UTR polymorphism acts as a modifier of hereditary breast cancer risk we performed a case-control study among female BRCA1 mutation carriers, which included 258 cases and 258 controls who were unaffected by ovarian cancer, in situ breast carcinoma or any other type of cancer... Our results suggest that the PHB 3'UTR T allele increases the risk of breast cancer in patients who are already at increased risk of disease.",A,PHB,PHB,0.2
1356,bc_id1401,CANCER,CYP19A1,17004113,N,A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches,2006,These analyses suggest that variants of CYP19 are not associated with risk of breast cancer.,These analyses suggest that variants of CYP19 are not associated with risk of breast cancer.,N,CYP19,CYP19A1,0.181818182
1357,bc_id1402,CANCER,RAD51,17007294,N,The G/C polymorphism of RAD51 gene in breast cancer,2006,"Our study implies that it is possible that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and/or progression of breast cancer but further researches, conducted on larger population, are needed to clarify this point.","Our study implies that it is possible that the G/C polymorphism of the RAD51 gene may not be directly involved in the development and/or progression of breast cancer but further researches, conducted on larger population, are needed to clarify this point.",A,RAD51,RAD51,0.615384615
1358,bc_id1403,CANCER,IGF1,17010055,B,Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.,2007,,"BRCA1/2 mutations predispose to early-onset breast cancer, especially after oral contraceptive (OC) use and pregnancy...  High IGF-1 levels are linked to an increased risk of early-onset breast cancer and to larger breast volumes in the general population.",Y,IGF-1,IGF1,0.35
1359,bc_id1404,CANCER,BRCA2,17010055,B,Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.,2007,,"BRCA1/2 mutations predispose to early-onset breast cancer, especially after oral contraceptive (OC) use and pregnancy...  High IGF-1 levels are linked to an increased risk of early-onset breast cancer and to larger breast volumes in the general population.",Y,BRCA1/2,BRCA2,0.324175824
1360,bc_id1405,CANCER,BRCA1,17010055,B,Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.,2007,,X,X,X,X,0
1361,bc_id1406,CANCER,BRCA2,17018160,B,Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.,2006,,"BRCA1 and BRCA2 mutations appear to account for a lower proportion of breast cancer patients at increased risk of harboring such mutations in Northern India (6/204, 2.9%) than has been reported in other populations.",Y,BRCA2,BRCA2,0.324175824
1362,bc_id1407,CANCER,BRCA1,17018160,B,Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.,2006,,"BRCA1 and BRCA2 mutations appear to account for a lower proportion of breast cancer patients at increased risk of harboring such mutations in Northern India (6/204, 2.9%) than has been reported in other populations.",Y,BRCA1,BRCA1,0.326180258
1363,bc_id1408,CANCER,ERCC4,17018596,B,ERCC4 Associated with Breast Cancer Risk,2006,,This study suggests that common intronic variation in ERCC4 is associated with protection from breast cancer.,Y,ERCC4,ERCC4,0.25
1364,bc_id1409,CANCER,COMT,17018638,B,Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk.,2006,", our data does not support a substantial overall association between COMT haplotypes and breast cancer.",our data does not support a substantial overall association between COMT haplotypes and breast cancer.,N,COMT,COMT,0.29787234
1365,bc_id1410,CANCER,ADH1C,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1366,bc_id1411,CANCER,AURKA,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1367,bc_id1412,CANCER,CASP8,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,"Data from up to 12 studies were pooled for each SNP (ADH1C I350V, AURKA F31I, BRCA2 N372H, CASP8 D302H, ERCC2 D312N, IGFBP3 -202 c>a, LIG4 D501D, PGR V660L, SOD2 V16A, TGFB1 L10P, TP53 R72P, XRCC1 R399Q, XRCC2 R188H, XRCC3 T241M, XRCC3 5' UTR, and XRCC3 IVS7-14)... For five SNPs--CASP8 D302H, IGFBP3 -202 c>a, PGR V660L, SOD2 V16A, and TGFB1 L10P--the associations with breast cancer were of borderline statistical significance (P = .016, .060, .047, .056, and .0088 respectively).",A,CASP8,CASP8,0.285714286
1368,bc_id1413,CANCER,ERCC2,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1369,bc_id1414,CANCER,LIG4,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1370,bc_id1415,CANCER,PGR,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,"Data from up to 12 studies were pooled for each SNP (ADH1C I350V, AURKA F31I, BRCA2 N372H, CASP8 D302H, ERCC2 D312N, IGFBP3 -202 c>a, LIG4 D501D, PGR V660L, SOD2 V16A, TGFB1 L10P, TP53 R72P, XRCC1 R399Q, XRCC2 R188H, XRCC3 T241M, XRCC3 5' UTR, and XRCC3 IVS7-14)... For five SNPs--CASP8 D302H, IGFBP3 -202 c>a, PGR V660L, SOD2 V16A, and TGFB1 L10P--the associations with breast cancer were of borderline statistical significance (P = .016, .060, .047, .056, and .0088 respectively).",A,PGR,PGR,0.5
1371,bc_id1416,CANCER,SOD2,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,"Data from up to 12 studies were pooled for each SNP (ADH1C I350V, AURKA F31I, BRCA2 N372H, CASP8 D302H, ERCC2 D312N, IGFBP3 -202 c>a, LIG4 D501D, PGR V660L, SOD2 V16A, TGFB1 L10P, TP53 R72P, XRCC1 R399Q, XRCC2 R188H, XRCC3 T241M, XRCC3 5' UTR, and XRCC3 IVS7-14)... For five SNPs--CASP8 D302H, IGFBP3 -202 c>a, PGR V660L, SOD2 V16A, and TGFB1 L10P--the associations with breast cancer were of borderline statistical significance (P = .016, .060, .047, .056, and .0088 respectively).",A,SOD2,SOD2,0.375
1372,bc_id1417,CANCER,TGFB1,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,"Data from up to 12 studies were pooled for each SNP (ADH1C I350V, AURKA F31I, BRCA2 N372H, CASP8 D302H, ERCC2 D312N, IGFBP3 -202 c>a, LIG4 D501D, PGR V660L, SOD2 V16A, TGFB1 L10P, TP53 R72P, XRCC1 R399Q, XRCC2 R188H, XRCC3 T241M, XRCC3 5' UTR, and XRCC3 IVS7-14)... For five SNPs--CASP8 D302H, IGFBP3 -202 c>a, PGR V660L, SOD2 V16A, and TGFB1 L10P--the associations with breast cancer were of borderline statistical significance (P = .016, .060, .047, .056, and .0088 respectively).",A,TGFB1,TGFB1,0.518518519
1373,bc_id1418,CANCER,TP53,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1374,bc_id1419,CANCER,XRCC1,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1375,bc_id1420,CANCER,XRCC2,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1376,bc_id1421,CANCER,XRCC3,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1377,bc_id1422,CANCER,BRCA2,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1378,bc_id1423,CANCER,IGFBP3,17018785,B,Commonly studied single-nucleotide polymorphisms and breast cancer,2006,Pooling data within a large consortium has helped to clarify associations of SNPs with breast cancer.,X,X,X,X,0
1379,bc_id1424,CANCER,BRCA2,17021353,B,"BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.",2006,We found no evidence overall that use of oral contraceptives for at least 1 year is associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers before age 50.,We found no evidence overall that use of oral contraceptives for at least 1 year is associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers before age 50.,N,BRCA2,BRCA2,0.098901099
1380,bc_id1425,CANCER,BRCA1,17021353,B,"BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.",2006,We found no evidence overall that use of oral contraceptives for at least 1 year is associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers before age 50.,We found no evidence overall that use of oral contraceptives for at least 1 year is associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers before age 50.,N,BRCA1,BRCA1,0.064377682
1381,bc_id1426,CANCER,ACE,17023764,B,Association between the polymorphism of the angiotensin-converting enzyme gene and tumor size of breast cancer in premenopausal patients.,2006,,"Thus, ACE may influence the local tumor growth of breast cancer in premenopausal patients.",A,ACE,ACE,0.571428571
1382,bc_id1427,CANCER,BARD1,17028982,Y,Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility,2006,,These findings indicate that the potentially functional polymorphisms Pro24Ser and Arg378Ser in BARD1 may jointly contribute to the susceptibility of breast cancer.,A,BARD1,BARD1,0.454545455
1383,bc_id1428,CANCER,CDT1,17029205,N,The association of polymorphisms of CDT1 and GMNN gene with the risk of breast cancer in Chinese women,2006,"These findings suggest that the CDT1 838G/A and GMNN 387C/A polymorphisms may not play a major role in the etiology of breast cancer, but CDT1 variant may have a potential role only in genetically susceptible women.","These findings suggest that the CDT1 838G/A and GMNN 387C/A polymorphisms may not play a major role in the etiology of breast cancer, but CDT1 variant may have a potential role only in genetically susceptible women.",A,CDT1,CDT1,1
1384,bc_id1429,CANCER,GMNN,17029205,N,The association of polymorphisms of CDT1 and GMNN gene with the risk of breast cancer in Chinese women,2006,"These findings suggest that the CDT1 838G/A and GMNN 387C/A polymorphisms may not play a major role in the etiology of breast cancer, but CDT1 variant may have a potential role only in genetically susceptible women.","These findings suggest that the CDT1 838G/A and GMNN 387C/A polymorphisms may not play a major role in the etiology of breast cancer, but CDT1 variant may have a potential role only in genetically susceptible women.",A,GMNN,GMNN,1
1385,bc_id1430,CANCER,BRIP1,17033622,B,Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles,2006,,"Thus, inactivating truncating mutations of BRIP1, similar to those in BRCA2, cause Fanconi anemia in biallelic carriers and confer susceptibility to breast cancer in monoallelic carriers.",Y,BRIP1,BRIP1,0.2
1386,bc_id1431,CANCER,MMP1,17033924,B,Promoter polymorphisms in matrix metalloproteinases and their inhibitors,2006,,"In this, so far largest case-control study, we genotyped eight SNPs in the MMP1, MMP2, MMP3, MMP9, MMP13, RECK and TIMP3 genes in a well-characterized breast cancer series of 959 cases and 952 controls from Sweden. Even though we did not correct for multiple comparisons, only a few associations were noted.",A,MMP1,MMP1,0.833333333
1387,bc_id1432,CANCER,MMP2,17033924,B,Promoter polymorphisms in matrix metalloproteinases and their inhibitors,2006,,"In this, so far largest case-control study, we genotyped eight SNPs in the MMP1, MMP2, MMP3, MMP9, MMP13, RECK and TIMP3 genes in a well-characterized breast cancer series of 959 cases and 952 controls from Sweden. Even though we did not correct for multiple comparisons, only a few associations were noted.",A,MMP2,MMP2,0.5
1388,bc_id1433,CANCER,MMP3,17033924,B,Promoter polymorphisms in matrix metalloproteinases and their inhibitors,2006,,"In this, so far largest case-control study, we genotyped eight SNPs in the MMP1, MMP2, MMP3, MMP9, MMP13, RECK and TIMP3 genes in a well-characterized breast cancer series of 959 cases and 952 controls from Sweden. Even though we did not correct for multiple comparisons, only a few associations were noted.",A,MMP3,MMP3,0.666666667
1389,bc_id1434,CANCER,RECK,17033924,B,Promoter polymorphisms in matrix metalloproteinases and their inhibitors,2006,,"In this, so far largest case-control study, we genotyped eight SNPs in the MMP1, MMP2, MMP3, MMP9, MMP13, RECK and TIMP3 genes in a well-characterized breast cancer series of 959 cases and 952 controls from Sweden. Even though we did not correct for multiple comparisons, only a few associations were noted.",A,RECK,RECK,1
1390,bc_id1435,CANCER,TIMP3,17033924,B,Promoter polymorphisms in matrix metalloproteinases and their inhibitors,2006,,"In this, so far largest case-control study, we genotyped eight SNPs in the MMP1, MMP2, MMP3, MMP9, MMP13, RECK and TIMP3 genes in a well-characterized breast cancer series of 959 cases and 952 controls from Sweden. Even though we did not correct for multiple comparisons, only a few associations were noted.",A,TIMP3,TIMP3,1
1391,bc_id1436,CANCER,MMP13,17033924,B,Promoter polymorphisms in matrix metalloproteinases and their inhibitors,2006,,"In this, so far largest case-control study, we genotyped eight SNPs in the MMP1, MMP2, MMP3, MMP9, MMP13, RECK and TIMP3 genes in a well-characterized breast cancer series of 959 cases and 952 controls from Sweden. Even though we did not correct for multiple comparisons, only a few associations were noted.",A,MMP13,MMP13,1
1392,bc_id1437,CANCER,MMP9,17033924,B,Promoter polymorphisms in matrix metalloproteinases and their inhibitors,2006,,"In this, so far largest case-control study, we genotyped eight SNPs in the MMP1, MMP2, MMP3, MMP9, MMP13, RECK and TIMP3 genes in a well-characterized breast cancer series of 959 cases and 952 controls from Sweden. Even though we did not correct for multiple comparisons, only a few associations were noted.",A,MMP9,MMP9,1
1393,bc_id1438,CANCER,TGFB1,17035001,B,Transforming-growth factor beta1 Leu10Pro polymorphism and breast cancer morbidity.,2007,,Our data suggest that the TGF-beta1 Leu10Pro polymorphism might play a role in breast cancer risk.,A,TGF-beta1,TGFB1,0.518518519
1394,bc_id1439,CANCER,IGFBP1,17035411,B,Haplotype-Based Association Studies of IGFBP1 and IGFBP3 with Prostate and Breast Cancer Risk,2006,,Our results suggest that common genetic variation in the IGFBP1 and IGFBP3 genes do not substantially influence prostate and breast cancer susceptibility.,N,IGFBP1,IGFBP1,1
1395,bc_id1440,CANCER,IGFBP3,17035411,B,Haplotype-Based Association Studies of IGFBP1 and IGFBP3 with Prostate and Breast Cancer Risk,2006,,Our results suggest that common genetic variation in the IGFBP1 and IGFBP3 genes do not substantially influence prostate and breast cancer susceptibility.,N,IGFBP3,IGFBP3,0.214285714
1396,bc_id1441,CANCER,BRCA1,17039264,B,Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study.,2007,,"In conclusion, the BRCA1-Gln356 allele presents risk factor in the onset and progression of breast cancer in Czech population and its use as a possible screening tool should be considered.",Y,BRCA1-Gln356,BRCA1,0.326180258
1397,bc_id1442,CANCER,IGF1,17051426,B,"Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States",2006,Our data suggest that associations between insulin-related genes and breast cancer risk among women living in the Southwestern United States may be dependent on estrogen exposure and may differ by ethnicity.,"We examine the 19 CA repeat of the IGF1 gene, the -202 C > A IGFBP3, the G972R IRS, and the G1057D IRS2 polymorphisms among 1,175 non-Hispanic white (NHW) and 576 Hispanic newly diagnosed breast cancer cases and 1,330 NHW and 727 Hispanic controls living in Arizona, Colorado, New Mexico, and Utah... Our data suggest that associations between insulin-related genes and breast cancer risk among women living in the Southwestern United States may be dependent on estrogen exposure and may differ by ethnicity.",A,IGF1,IGF1,0.25
1398,bc_id1443,CANCER,IRS1,17051426,B,"Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States",2006,Our data suggest that associations between insulin-related genes and breast cancer risk among women living in the Southwestern United States may be dependent on estrogen exposure and may differ by ethnicity.,X,X,X,X,0
1399,bc_id1444,CANCER,IRS2,17051426,B,"Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States",2006,Our data suggest that associations between insulin-related genes and breast cancer risk among women living in the Southwestern United States may be dependent on estrogen exposure and may differ by ethnicity.,"We examine the 19 CA repeat of the IGF1 gene, the -202 C > A IGFBP3, the G972R IRS, and the G1057D IRS2 polymorphisms among 1,175 non-Hispanic white (NHW) and 576 Hispanic newly diagnosed breast cancer cases and 1,330 NHW and 727 Hispanic controls living in Arizona, Colorado, New Mexico, and Utah... Our data suggest that associations between insulin-related genes and breast cancer risk among women living in the Southwestern United States may be dependent on estrogen exposure and may differ by ethnicity.",A,IRS2,IRS2,0.666666667
1400,bc_id1445,CANCER,IGFBP3,17051426,B,"Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States",2006,Our data suggest that associations between insulin-related genes and breast cancer risk among women living in the Southwestern United States may be dependent on estrogen exposure and may differ by ethnicity.,"We examine the 19 CA repeat of the IGF1 gene, the -202 C > A IGFBP3, the G972R IRS, and the G1057D IRS2 polymorphisms among 1,175 non-Hispanic white (NHW) and 576 Hispanic newly diagnosed breast cancer cases and 1,330 NHW and 727 Hispanic controls living in Arizona, Colorado, New Mexico, and Utah... Our data suggest that associations between insulin-related genes and breast cancer risk among women living in the Southwestern United States may be dependent on estrogen exposure and may differ by ethnicity.",A,IGFBP3,IGFBP3,0.428571429
1401,bc_id1446,CANCER,CYP1B1,17053044,B,Meta- and Pooled Analyses of the Cytochrome P-450 1B1 Val432Leu Polymorphism and Breast Cancer,2006,,"No association between the CYP1B1 Val432Leu polymorphism and breast cancer was observed in Asians (for Val/Val and Val/Leu combined, odds ratio (OR) = 1.0, 95% confidence interval (CI): 0.8, 1.2).",N,CYP1B1,CYP1B1,0.256410256
1402,bc_id1447,CANCER,MMP3,17058024,B,A multigenic approach to predict breast cancer risk,2006,,"CART analysis of the data identified the heterozygous vascular endothelial growth factor (VEGF) and matrix metalloproteinase 3 (MMP3) genotype and homozygous cyclooxygenase-2 (PTGS2) mutant as the initial splits, indicating that these genotypes exert the greatest impact on the classification process. Breast cancer patients were primarily indicated by 30 distinct genetic profiles.",A,MMP3,MMP3,0.666666667
1403,bc_id1448,CANCER,PTGS2,17058024,B,A multigenic approach to predict breast cancer risk,2006,,"CART analysis of the data identified the heterozygous vascular endothelial growth factor (VEGF) and matrix metalloproteinase 3 (MMP3) genotype and homozygous cyclooxygenase-2 (PTGS2) mutant as the initial splits, indicating that these genotypes exert the greatest impact on the classification process. Breast cancer patients were primarily indicated by 30 distinct genetic profiles.",A,PTGS2,PTGS2,0.583333333
1404,bc_id1449,CANCER,VEGFA,17058024,B,A multigenic approach to predict breast cancer risk,2006,,"CART analysis of the data identified the heterozygous vascular endothelial growth factor (VEGF) and matrix metalloproteinase 3 (MMP3) genotype and homozygous cyclooxygenase-2 (PTGS2) mutant as the initial splits, indicating that these genotypes exert the greatest impact on the classification process. Breast cancer patients were primarily indicated by 30 distinct genetic profiles.",A,VEGF,VEGFA,0.416666667
1405,bc_id1450,CANCER,BRCA2,17061047,B,Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.,2007,,X,X,X,X,0
1406,bc_id1451,CANCER,BRCA1,17061047,B,Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.,2007,,X,X,X,X,0
1407,bc_id1452,CANCER,CDKN1A,17062672,Y,The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer,2006,,"The finding of an association between locally advanced breast cancer and one particular polymorphism of the p21 gene suggests this polymorphism to be related to tumor behavior, including enhanced growth rate. If confirmed in other studies, this may add significant information to our understanding of the biology as well as of the clinical behaviour of locally advanced breast cancers.",Y,p21,CDKN1A,0.25
1408,bc_id1453,CANCER,SERPINE1,17062678,Y,Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival,2006,The PAI-1 4G/5G polymorphism may be a prognostic marker for young and middle-aged Chinese breast cancer patients.,The PAI-1 4G/5G polymorphism may be a prognostic marker for young and middle-aged Chinese breast cancer patients.,A,PAI-1,SERPINE1,1
1409,bc_id1454,CANCER,IGF1,17063263,N,"Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women",2006,no significant association was noted between any of the 19 polymorphisms and survival.,X,X,X,X,0
1410,bc_id1455,CANCER,IGFALS,17063263,N,"Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women",2006,no significant association was noted between any of the 19 polymorphisms and survival.,X,X,X,X,0
1411,bc_id1456,CANCER,IGFBP3,17063263,N,"Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women",2006,no significant association was noted between any of the 19 polymorphisms and survival.,"Nineteen functional or potentially functional polymorphisms were evaluated in the IGF-1, IGF-1R, IGFALS, and IGFBP3 genes... Taken together, these data suggest that polymorphisms in the IGF-1R and IGFBP3 genes may be associated with altered survival among subgroups of breast cancer patients defined by menopausal status.",A,IGFBP3,IGFBP3,0.428571429
1412,bc_id1457,CANCER,IGF1R,17063263,N,"Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women",2006,no significant association was noted between any of the 19 polymorphisms and survival.,"Nineteen functional or potentially functional polymorphisms were evaluated in the IGF-1, IGF-1R, IGFALS, and IGFBP3 genes... Taken together, these data suggest that polymorphisms in the IGF-1R and IGFBP3 genes may be associated with altered survival among subgroups of breast cancer patients defined by menopausal status.",A,IGF-1R,IGF1R,0.5
1413,bc_id1458,CANCER,CYP1B1,17063266,B,"CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population",2006,,No statistically significant overall associations were found between the CYP1A1 and CYP1B1 genotypes and breast cancer risk... Our results suggest that the CYP1B1 polymorphism may be an important modifier of breast cancer risk in Finnish Caucasian women who have been exposed to tobacco smoke and/or carry the NAT2 slow acetylator genotype.,A,CYP1B1,CYP1B1,0.384615385
1414,bc_id1459,CANCER,NAT2,17063266,B,"CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population",2006,,X,X,X,X,0
1415,bc_id1460,CANCER,CYP1A1,17063266,B,"CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population",2006,,No statistically significant overall associations were found between the CYP1A1 and CYP1B1 genotypes and breast cancer risk.,N,CYP1A1,CYP1A1,0.239130435
1416,bc_id1461,CANCER,BRCA2,17063270,B,Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.,2007,", BRCA1 and BRCA2 mutations are not uncommon in Brazilian women with breast cancer.",BRCA1 and BRCA2 mutations are not uncommon in Brazilian women with breast cancer.,Y,BRCA2,BRCA2,0.324175824
1417,bc_id1462,CANCER,BRCA1,17063270,B,Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.,2007,", BRCA1 and BRCA2 mutations are not uncommon in Brazilian women with breast cancer.",BRCA1 and BRCA2 mutations are not uncommon in Brazilian women with breast cancer.,Y,BRCA1,BRCA1,0.326180258
1418,bc_id1463,CANCER,XRCC1,17063276,B,DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility,2006,,"We analysed DNA samples from 285 breast cancer patients and 442 control subjects, for XRCC1 Arg399Gln, XPD Lys751Gln, RAD51 G135C and XRCC3 Thr241Met polymorphisms using PCR-RFLP... Our results suggest XRCC1 Arg399Gln and XRCC3 Thr241Met DNA repair polymorphisms as important biomarkers to sporadic breast cancer susceptibility, as well as, RAD51 G135C polymorphism as a real risk modifier in familial breast cancer cases.",Y,XRCC1,XRCC1,0.239130435
1419,bc_id1464,CANCER,ERCC2,17063276,B,DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility,2006,,X,X,X,X,0
1420,bc_id1465,CANCER,RAD51,17063276,B,DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility,2006,,"We analysed DNA samples from 285 breast cancer patients and 442 control subjects, for XRCC1 Arg399Gln, XPD Lys751Gln, RAD51 G135C and XRCC3 Thr241Met polymorphisms using PCR-RFLP... Our results suggest XRCC1 Arg399Gln and XRCC3 Thr241Met DNA repair polymorphisms as important biomarkers to sporadic breast cancer susceptibility, as well as, RAD51 G135C polymorphism as a real risk modifier in familial breast cancer cases.",Y,RAD51,RAD51,0.230769231
1421,bc_id1466,CANCER,XRCC3,17063276,B,DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility,2006,,"We analysed DNA samples from 285 breast cancer patients and 442 control subjects, for XRCC1 Arg399Gln, XPD Lys751Gln, RAD51 G135C and XRCC3 Thr241Met polymorphisms using PCR-RFLP... Our results suggest XRCC1 Arg399Gln and XRCC3 Thr241Met DNA repair polymorphisms as important biomarkers to sporadic breast cancer susceptibility, as well as, RAD51 G135C polymorphism as a real risk modifier in familial breast cancer cases.",Y,XRCC3,XRCC3,0.269230769
1422,bc_id1467,CANCER,XRCC3,17063279,B,Genetic polymorphism of XRCC3 Thr241Met and breast cancer risk: case-control study in Korean women and meta-analysis of 12 studies.,2007,,"In conclusion, although the genetic polymorphism of XRCC3 Thr(241)Met was unlikely to have a substantial overall association in Korean women, the meta-analysis of studies, including ours, provided that Thr/Met and Met/Met was weakly increased the risk of breast cancer compare to Thr/Thr genotype.",A,XRCC3,XRCC3,0.461538462
1423,bc_id1468,CANCER,NOS3,17063466,Y,Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years,2006,The results suggest that eNOS polymorphisms (especially -786T>C) may play a role in the development of sporadic breast cancer.,The results suggest that eNOS polymorphisms (especially -786T>C) may play a role in the development of sporadic breast cancer.,A,eNOS,NOS3,0.461538462
1424,bc_id1469,CANCER,DMBT1,17066405,B,Single nucleotide polymorphisms in the DMBT1 promoter and the progression of breast cancer,2007,,ANF,ANF,ANF,ANF,0
1425,bc_id1470,CANCER,DSS1,17066443,B,Mutations in the BRCA2 interacting DSS1 are not a risk factor for male breast cancer,2007,,ANF,ANF,ANF,ANF,0
1426,bc_id1471,CANCER,MTHFR,17069650,B,Association of MTHFR gene polymorphisms with breast cancer survival.,2006,"We found that the MTHFR SNPs, C677T and A1298C, were associated with breast cancer survival.","We found that the MTHFR SNPs, C677T and A1298C, were associated with breast cancer survival.",Y,MTHFR,MTHFR,0.269230769
1427,bc_id1472,CANCER,MBL2,17071626,B,The mannose-binding lectin (MBL2) haplotype and breast cancer: an association study in African-American and Caucasian women.,2007,,"In conclusion, this study presents preliminary evidence that common genetic variants in the 3'-UTR of MBL2 might influence the risk for breast cancer in AA women, probably in interaction with the 5' secretor haplotypes that are associated with high concentrations of MBL.",A,MBL2,MBL2,1
1428,bc_id1473,CANCER,MDM2,17080308,Y,MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling,2006,"our data suggest that MDM2 SNP309 accelerates familial breast carcinogenesis, but that this acceleration is not influenced by estrogen signaling.","our data suggest that MDM2 SNP309 accelerates familial breast carcinogenesis, but that this acceleration is not influenced by estrogen signaling.",Y,MDM2,MDM2,0.111111111
1429,bc_id1474,CANCER,MT-ND3,17081685,B,Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer,2006,"drawn of mt10398A allele providing a risk towards cancer is confirmed in a case-control comparison study of 124 sporadic breast cancer patients and 273 controls; and 55 squamous cell carcinoma of esophagus, ESCC, and 163 controls, matched for age, ethnicity and sex from north India. It is further apparent from the study that such a mtDNA polymorphism background provides a higher risk for the cancers of the tissues which could be affected by environmental insults directly as in the ESCC, observed with a high acquired (somatic) rate of mutation in p53 when compared to the breast cancer, suggesting that the mtDNA variants that arose as energetic adaptations, influence our health differentially under different environment conditions and a given genetic background of the mt genome.",X,X,X,X,0
1430,bc_id1475,CANCER,HLA-C,17085834,B,HLA alleles in pre-menopausal breast cancer patients from western India.,2006,of this study provide directions to further analyse role of immunogenetic mechanisms governing innate and adaptive immune responses contributing to modulation of risk for breast cancer.,X,X,X,X,0
1431,bc_id1476,CANCER,HLA-B,17085834,B,HLA alleles in pre-menopausal breast cancer patients from western India.,2006,of this study provide directions to further analyse role of immunogenetic mechanisms governing innate and adaptive immune responses contributing to modulation of risk for breast cancer.,X,X,X,X,0
1432,bc_id1477,CANCER,BRCA2,17100994,B,Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.,2006,,X,X,X,X,0
1433,bc_id1478,CANCER,BRCA1,17100994,B,Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.,2006,,X,X,X,X,0
1434,bc_id1479,CANCER,MTHFR,17105984,B,Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk.,2006,A lack of dietary folate intake is not associated with the risk of breast cancer.,there was no evidence of an interaction between folate intake and MTHFR genotype on breast cancer risk.,N,MTHFR,MTHFR,0.326923077
1435,bc_id1480,CANCER,TCF7L2,17109766,B,Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study.,2006,Our results suggest a possible influence of TCF7L2 rs12255372 on the risk of familial BC.,Our results suggest a possible influence of TCF7L2 rs12255372 on the risk of familial BC.,A,TCF7L2,TCF7L2,1
1436,bc_id1481,CANCER,AURKA,17113223,B,Breast cancer risk associated with AURKA 91T-->A polymorphism in relation to BRCA mutations,2006,,"In this study 759 breast cancer patients, including 9 BRCA1 and 98 BRCA2 mutation carriers, and 653 mutation-negative unaffected controls were genotyped for the AURKA 91T -->A polymorphism. Individuals homozygous for the 91A allele were found to be at increased risk of breast cancer compared to 91T homozygotes (OR=1.87; 95% CI=1.09-3.21).",Y,AURKA,AURKA,0.25
1437,bc_id1482,CANCER,CHEK2,17113724,B,Large genomic BRCA2 rearrangements and male breast cancer.,2007,Large genomic BRCA2 rearrangements were not found among our 36 Finnish male breast cancer patients.,X,X,X,X,0
1438,bc_id1483,CANCER,BRCA2,17113724,B,Large genomic BRCA2 rearrangements and male breast cancer.,2007,Large genomic BRCA2 rearrangements were not found among our 36 Finnish male breast cancer patients.,"No genomic mutations of BRCA2 nor CHEK2*1100delC point mutations, also included in the assay, were found in this study... Large genomic BRCA2 rearrangements were not found among our 36 Finnish male breast cancer patients.",N,BRCA2,BRCA2,0.098901099
1439,bc_id1484,CANCER,TP53,17113725,B,Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk.,2007,,"TP53 codon 72 polymorphism might be implicated in breast carcinogenesis, with the Arg/Arg genotype being associated with an increased susceptibility for this malignancy.",A,TP53,TP53,0.482758621
1440,bc_id1485,PHARMACOGENOMIC,XRCC1,17116943,Y,"Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer",2006,"XRCC1-01, XRCC3-01, and CCND1-01 may be predictive of survival outcome in patients with MBC treated with DNA damaging chemotherapy.",X,X,X,X,0
1441,bc_id1486,PHARMACOGENOMIC,XRCC3,17116943,Y,"Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer",2006,"XRCC1-01, XRCC3-01, and CCND1-01 may be predictive of survival outcome in patients with MBC treated with DNA damaging chemotherapy.",X,X,X,X,0
1442,bc_id1487,PHARMACOGENOMIC,CCND1,17116943,Y,"Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer",2006,"XRCC1-01, XRCC3-01, and CCND1-01 may be predictive of survival outcome in patients with MBC treated with DNA damaging chemotherapy.",X,X,X,X,0
1443,bc_id1488,CANCER,C17orf37,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,C17ORF37,MIEN1,1
1444,bc_id1489,CANCER,ERBB2,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,ERBB2,ERBB2,0.261904762
1445,bc_id1490,CANCER,GRB7,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,GRB7,GRB7,1
1446,bc_id1491,CANCER,IKZF3,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,ZNFN1A3,IKZF3,1
1447,bc_id1492,CANCER,NEUROD2,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,NEUROD2,NEUROD2,1
1448,bc_id1493,CANCER,PERLD1,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,CAB2,PGAP3,1
1449,bc_id1494,CANCER,PNMT,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,PNMT,PNMT,1
1450,bc_id1495,CANCER,PPARBP,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,PPARBP,MED1,1
1451,bc_id1496,CANCER,PPP1R1B,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,PPP1R1B,PPP1R1B,1
1452,bc_id1497,CANCER,STARD3,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,STARD3,STARD3,1
1453,bc_id1498,CANCER,TCAP,17117180,N,HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer,2006,we found no association between common genetic variation in the 17q21 ERBB2 amplicon and breast cancer risk in British women.,"We used a genetic association study design to determine if common genetic variation (frequency>or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk... We observed no association between any of the genotypes or associated haplotypes and disease risk.",N,TCAP,TCAP,1
1454,bc_id1500,CANCER,SERPINE1,17119035,B,Prognostic Value of PAI1 in Invasive Breast Cancer,2006,,"Thus, local factors, such as CTGF and genomic amplification, seem to be more important than germ line genetic variation in influencing PAI1 expression and its untoward effects in breast cancer.",A,PAI1,SERPINE1,1
1455,bc_id1501,CANCER,CYP19A1,17119036,B,Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.,2006,,These results suggest that polymorphisms in the CYP19A1 gene may have effects on breast cancer prognosis.,A,CYP19A1,CYP19A1,0.484848485
1456,bc_id1502,CANCER,POLB,17131038,Y,Polymorphisms of the DNA polymerase beta gene in breast cancer,2006,"Polbeta may play a role in the breast carcinogenesis and the Lys289Met polymorphism of the polbeta gene may be considered as an independent, early, molecular diagnostic marker in breast cancer.","Polbeta may play a role in the breast carcinogenesis and the Lys289Met polymorphism of the polbeta gene may be considered as an independent, early, molecular diagnostic marker in breast cancer.",A,Polbeta,POLB,1
1457,bc_id1503,CANCER,ATM,17132159,N,"Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival",2006,"Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.","Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.",N,ATM,ATM,0.244444444
1458,bc_id1504,CANCER,CHEK2,17132159,N,"Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival",2006,"Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.","Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.",N,CHEK2,CHEK2,0.233333333
1459,bc_id1505,CANCER,ERBB2,17132159,N,"Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival",2006,"Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.","Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.",N,ERBB2,ERBB2,0.261904762
1460,bc_id1506,CANCER,CHEK2,17132695,Y,Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation,2006,"Our study, which is representative for the premenopausal breast cancer population, reveals approximately 4% CHEK2*1100delC carriers have an increased risk of second breast cancer and a worse long-term recurrence-free survival rate. Their identification at time of diagnosis and prolonged intensive follow-up should be considered to optimize clinical management",X,X,X,X,0
1461,bc_id1507,CANCER,BRCA1,17151928,B,Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers,2006,,"The role of allele variants 677T and 1298C (MTHFR gene) and 2756G (MS gene) has been investigated as potentially modifying factors of BRCA gene penetrance, evaluated as age at first diagnosis of cancer, in 484 BRCA1/BRCA2 carriers and in 108 sporadic breast cancer cases as a control group... The presence of 677T allele confers an increased risk of breast cancer in BRCA1 carriers (P = 0.007) and the presence of 1298C allele confers an increased risk of breast cancer in sporadic cases (P = 0.015).",A,BRCA1/BRCA2,BRCA1,0.60944206
1462,bc_id1508,CANCER,BRCA2,17151928,B,Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers,2006,,"The role of allele variants 677T and 1298C (MTHFR gene) and 2756G (MS gene) has been investigated as potentially modifying factors of BRCA gene penetrance, evaluated as age at first diagnosis of cancer, in 484 BRCA1/BRCA2 carriers and in 108 sporadic breast cancer cases as a control group... The presence of 677T allele confers an increased risk of breast cancer in BRCA1 carriers (P = 0.007) and the presence of 1298C allele confers an increased risk of breast cancer in sporadic cases (P = 0.015).",Y,BRCA1/BRCA2,BRCA2,0.324175824
1463,bc_id1509,CANCER,MS,17151928,B,Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers,2006,,X,X,X,X,0
1464,bc_id1510,CANCER,MTHFR,17151928,B,Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers,2006,,"The role of allele variants 677T and 1298C (MTHFR gene) and 2756G (MS gene) has been investigated as potentially modifying factors of BRCA gene penetrance, evaluated as age at first diagnosis of cancer, in 484 BRCA1/BRCA2 carriers and in 108 sporadic breast cancer cases as a control group... The presence of 677T allele confers an increased risk of breast cancer in BRCA1 carriers (P = 0.007) and the presence of 1298C allele confers an increased risk of breast cancer in sporadic cases (P = 0.015).",Y,MTHFR,MTHFR,0.269230769
1465,bc_id1511,CANCER,MTR,17151928,B,Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers,2006,,X,X,X,X,0
1466,bc_id1512,CANCER,CHEK2,17164383,B,A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers,2006,,"Our results suggest that the risk of cancer associated with CHEK2 1100delC mutations is restricted to breast cancer, although we cannot rule out a small increase in overall cancer risk.",Y,CHEK2,CHEK2,0.383333333
1467,bc_id1513,CANCER,CYP11A1,17178901,B,A Systematic Assessment of Common Genetic Variation in CYP11A and Risk of Breast Cancer,2006,,"Based on these findings, CYP11A deserves further consideration as a candidate breast cancer susceptibility gene.",A,CYP11A,CYP11A1,0.75
1468,bc_id1514,CANCER,PTGS2,17181859,B,"Genetic polymorphisms in the cyclooxygenase-2 gene, use of NSAIDs and breast cancer risk",2006,These data provide modest evidence that the C allele of COX-2 .8473 may interact with NSAIDs to reduce risk for hormone receptor positive breast cancer.,These data provide modest evidence that the C allele of COX-2 .8473 may interact with NSAIDs to reduce risk for hormone receptor positive breast cancer.,A,COX-2,PTGS2,0.583333333
1469,bc_id1515,CANCER,FAS,17183065,B,Functional Polymorphisms in FAS and FASL Contribute to Increased Apoptosis of Tumor Infiltration Lymphocytes and Risk of Breast Cancer,2006,,These findings indicate that functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.,Y,FAS,FAS,0.25
1470,bc_id1516,CANCER,FASLG,17183065,B,Functional Polymorphisms in FAS and FASL Contribute to Increased Apoptosis of Tumor Infiltration Lymphocytes and Risk of Breast Cancer,2006,,These findings indicate that functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.,Y,FASL,FASLG,0.333333333
1471,bc_id1517,CANCER,GNAS,17186357,Y,The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma,2006,,Our results suggest that the GNAS1 T393C SNP is a novel genetic host factor for disease progression in patients with invasive breast carcinoma.,Y,GNAS1,GNAS,1
1472,bc_id1518,CANCER,AR,17187234,B,"ESR1, AR, body size, and breast cancer risk in Hispanic and non-Hispanic white women living in the Southwestern United States.",2007,,"However, they provide only minor support for the role of the AR and ESR1 gene in the etiology of breast cancer.",A,AR,AR,0.458333333
1473,bc_id1519,CANCER,ESR1,17187234,B,"ESR1, AR, body size, and breast cancer risk in Hispanic and non-Hispanic white women living in the Southwestern United States.",2007,,"However, they provide only minor support for the role of the AR and ESR1 gene in the etiology of breast cancer.",A,ESR1,ESR1,0.586956522
1474,bc_id1521,CANCER,BUB1,17210994,B,Breast Cancer Risk Associated with Genotypic Polymorphism of the Mitotic Checkpoint Genes,2007,,"We therefore speculated that the genes TTK, MAD2L1, BUB1, BUB1B and PTTG1 (Securin), jointly implicated in the regulation of mitotic checkpoint, might be associated with breast tumorigenesis... Support for these hypotheses came from the observations that (i) two SNPs in TTK and PTTG1 were associated with breast cancer risk; (ii) haplotype and haplotype combination analyses in TTK, BUB1B and PTTG1 revealed a strong association with breast cancer risk; (iii) a trend to an increased risk of breast cancer was found in women harboring a greater number of putative high-risk genotypes/haplotypes of mitotic checkpoint genes and (iv) a significant interaction between high-risk genotypes/haplotypes and reproductive risk factors in determining breast cancer risk was defined.",Y,BUB1,BUB1,1
1475,bc_id1522,CANCER,BUB1B,17210994,B,Breast Cancer Risk Associated with Genotypic Polymorphism of the Mitotic Checkpoint Genes,2007,,"We therefore speculated that the genes TTK, MAD2L1, BUB1, BUB1B and PTTG1 (Securin), jointly implicated in the regulation of mitotic checkpoint, might be associated with breast tumorigenesis... Support for these hypotheses came from the observations that (i) two SNPs in TTK and PTTG1 were associated with breast cancer risk; (ii) haplotype and haplotype combination analyses in TTK, BUB1B and PTTG1 revealed a strong association with breast cancer risk; (iii) a trend to an increased risk of breast cancer was found in women harboring a greater number of putative high-risk genotypes/haplotypes of mitotic checkpoint genes and (iv) a significant interaction between high-risk genotypes/haplotypes and reproductive risk factors in determining breast cancer risk was defined.",Y,BUB1B,BUB1B,0.5
1476,bc_id1523,CANCER,MAD2L1,17210994,B,Breast Cancer Risk Associated with Genotypic Polymorphism of the Mitotic Checkpoint Genes,2007,,"We therefore speculated that the genes TTK, MAD2L1, BUB1, BUB1B and PTTG1 (Securin), jointly implicated in the regulation of mitotic checkpoint, might be associated with breast tumorigenesis... Support for these hypotheses came from the observations that (i) two SNPs in TTK and PTTG1 were associated with breast cancer risk; (ii) haplotype and haplotype combination analyses in TTK, BUB1B and PTTG1 revealed a strong association with breast cancer risk; (iii) a trend to an increased risk of breast cancer was found in women harboring a greater number of putative high-risk genotypes/haplotypes of mitotic checkpoint genes and (iv) a significant interaction between high-risk genotypes/haplotypes and reproductive risk factors in determining breast cancer risk was defined.",Y,MAD2L1,MAD2L1,0.5
1477,bc_id1524,CANCER,PTTG1,17210994,B,Breast Cancer Risk Associated with Genotypic Polymorphism of the Mitotic Checkpoint Genes,2007,,"We therefore speculated that the genes TTK, MAD2L1, BUB1, BUB1B and PTTG1 (Securin), jointly implicated in the regulation of mitotic checkpoint, might be associated with breast tumorigenesis... Support for these hypotheses came from the observations that (i) two SNPs in TTK and PTTG1 were associated with breast cancer risk; (ii) haplotype and haplotype combination analyses in TTK, BUB1B and PTTG1 revealed a strong association with breast cancer risk; (iii) a trend to an increased risk of breast cancer was found in women harboring a greater number of putative high-risk genotypes/haplotypes of mitotic checkpoint genes and (iv) a significant interaction between high-risk genotypes/haplotypes and reproductive risk factors in determining breast cancer risk was defined.",Y,PTTG1,PTTG1,1
1478,bc_id1525,CANCER,TTK,17210994,B,Breast Cancer Risk Associated with Genotypic Polymorphism of the Mitotic Checkpoint Genes,2007,,"We therefore speculated that the genes TTK, MAD2L1, BUB1, BUB1B and PTTG1 (Securin), jointly implicated in the regulation of mitotic checkpoint, might be associated with breast tumorigenesis... Support for these hypotheses came from the observations that (i) two SNPs in TTK and PTTG1 were associated with breast cancer risk; (ii) haplotype and haplotype combination analyses in TTK, BUB1B and PTTG1 revealed a strong association with breast cancer risk; (iii) a trend to an increased risk of breast cancer was found in women harboring a greater number of putative high-risk genotypes/haplotypes of mitotic checkpoint genes and (iv) a significant interaction between high-risk genotypes/haplotypes and reproductive risk factors in determining breast cancer risk was defined.",Y,TTK,TTK,0.5
1479,bc_id1526,CANCER,MDM2,17214373,N,Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk,2006,,"A case-control study of 223 females diagnosed with breast cancer and 149 female controls sampled from the Turkish population was carried out and the T/G MDM2-SNP309 genotype of participants was determined... There was no significant association of the G/G or G/T genotypes with breast cancer risk (odds ratio (OR) 1.14, 95% confidence interval (CI) 0.59-2.22, and OR 1.20, 95% CI 0.67-2.12, respectively).",N,MDM2-SNP309,MDM2,0.444444444
1480,bc_id1527,CANCER,PTGS2,17214885,N,A polymorphism in the 3' UTR of PTGS2 is not associated with an increase in breast cancer risk,2007,"Although this polymorphism may be associated with a decrease in breast cancer risk among Caucasian women, we provide strong evidence that it is not associated with an increased risk of breast cancer.","polymorphisms in PTGS2 are associated with breast cancer risk, using logistic regression analyses.",Y,PTGS2,PTGS2,0.083333333
1481,bc_id1529,CANCER,TNF,17216494,B,Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk.,2007,,"Data from 5,269 cases and 4,982 controls suggested that the rs361525 A allele, located in the TNF promoter region, was associated with a modest increase in breast cancer risk.",Y,TNF,TNF,0.333333333
1482,bc_id1530,CANCER,BRCA2,17217814,N,Prevalence of Val158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer,2006,"Val158Met polymorphism in COMT gene could be a candidate for low penetrance breast cancer susceptibility in Shanghai population, especially among premenopausal women and early-onset breast cancer patients.",X,X,X,X,0
1483,bc_id1531,CANCER,BRCA1,17217814,N,Prevalence of Val158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer,2006,"Val158Met polymorphism in COMT gene could be a candidate for low penetrance breast cancer susceptibility in Shanghai population, especially among premenopausal women and early-onset breast cancer patients.",X,X,X,X,0
1484,bc_id1532,CANCER,COMT,17217814,Y,Prevalence of Val158Met polymorphism in COMT gene on non-BRCA1/2 hereditary breast cancer,2006,"Val158Met polymorphism in COMT gene could be a candidate for low penetrance breast cancer susceptibility in Shanghai population, especially among premenopausal women and early-onset breast cancer patients.","A total of 114 patients with BRCA1/BRCA 2 negative hereditary breast cancer from independent families and 121 age-matched healthy controls were analyzed...  Val158Met polymorphism in COMT gene could be a candidate for low penetrance breast cancer susceptibility in Shanghai population, especially among premenopausal women and early-onset breast cancer patients.",A,COMT,COMT,0.425531915
1485,bc_id1533,CANCER,ITGB3,17220212,Y,Integrin {beta}3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk,2007,,"The results revealed that the ITGB3_Leu33Pro polymorphism was associated with a 2.5-fold increased risk of ovarian cancer, whereas no association with breast cancer risk was found.",N,ITGB3,ITGB3,0.666666667
1486,bc_id1534,CANCER,PTPRT,17223850,B,Mutational analysis of PTPRT phosphatase domains in common human cancers,2007,,"Here, we performed a mutational analysis of the PTPRT phosphatase domain by polymerase chain reaction-based single-strand conformation polymorphism (PCR-SSCP) assay in 345 cases of common human cancers, including colon carcinomas, hepatocellular carcinomas, acute leukemias, gastric carcinomas, breast carcinomas and non-small cell lung cancers... The data suggested that alterations of the PTPRT-mediated signaling pathway by PTPRT phosphatase domain mutation may not play a critical role in the development of common human cancers.",A,PTPRT,PTPRT,1
1487,bc_id1535,PHARMACOGENOMIC,CYP1B1,17224914,B,Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer,2007,,"We found no association between ABCB1, ABCG2, CYP1B1, CYP3A4, CYP3A5 and CYP2C8 genotypes and paclitaxel clearance. However, patients homozygous for the CYP1B1*3 allele had a significantly longer progression-free survival than patients with at least one Valine allele (P=0.037)...  Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele.",A,CYP1B1,CYP1B1,0.384615385
1488,bc_id1536,PHARMACOGENOMIC,CYP2C8,17224914,B,Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer,2007,,"We found no association between ABCB1, ABCG2, CYP1B1, CYP3A4, CYP3A5 and CYP2C8 genotypes and paclitaxel clearance. However, patients homozygous for the CYP1B1*3 allele had a significantly longer progression-free survival than patients with at least one Valine allele (P=0.037)...  Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele.",N,CYP2C8,CYP2C8,0.5
1489,bc_id1537,PHARMACOGENOMIC,CYP3A4,17224914,B,Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer,2007,,"We found no association between ABCB1, ABCG2, CYP1B1, CYP3A4, CYP3A5 and CYP2C8 genotypes and paclitaxel clearance. However, patients homozygous for the CYP1B1*3 allele had a significantly longer progression-free survival than patients with at least one Valine allele (P=0.037)...  Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele.",N,CYP3A4,CYP3A4,0.363636364
1490,bc_id1538,PHARMACOGENOMIC,CYP3A5,17224914,B,Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer,2007,,"We found no association between ABCB1, ABCG2, CYP1B1, CYP3A4, CYP3A5 and CYP2C8 genotypes and paclitaxel clearance. However, patients homozygous for the CYP1B1*3 allele had a significantly longer progression-free survival than patients with at least one Valine allele (P=0.037)...  Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele.",N,CYP3A5,CYP3A5,0.4
1491,bc_id1539,CANCER,CYP17A1,17235448,B,CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients,2007,,The present findings suggest that CYP17 A2 allele gene polymorphism might play a significant role in breast cancer development in young Indian women.,A,CYP17,CYP17A1,0.466666667
1492,bc_id1540,CANCER,AIP,17242703,B,"Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers",2007,,"These results suggest that somatic AIP mutations are not common in CRC, breast, and prostate cancers.",N,AIP,AIP,1
1493,bc_id1541,PHARMACOGENOMIC,CYP2D6,17244352,B,"Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients",2007,The metabolism of tamoxifen is complex and the mechanisms responsible for the resistance are unlikely to be explained by a single polymorphism; instead it is a combination of several mechanisms.,Tamoxifen therapy reduces the risk of recurrence and prolongs the survival of oestrogen-receptor-positive patients with breast cancer... The prognostic evaluation performed in the total population revealed a significantly better disease-free survival in patients homozygous for CYP2D6*4.,Y,CYP2D6*4,CYP2D6,0.272727273
1494,bc_id1542,PHARMACOGENOMIC,CYP3A5,17244352,B,"Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients",2007,The metabolism of tamoxifen is complex and the mechanisms responsible for the resistance are unlikely to be explained by a single polymorphism; instead it is a combination of several mechanisms.,"Tamoxifen therapy reduces the risk of recurrence and prolongs the survival of oestrogen-receptor-positive patients with breast cancer... The prognostic evaluation performed in the total population revealed a significantly better disease-free survival in patients homozygous for CYP2D6*4. For CYP3A5, SULT1A1 and UGT2B15 no prognostic significance was observed.",N,CYP3A5,CYP3A5,0.4
1495,bc_id1543,PHARMACOGENOMIC,SULT1A1,17244352,B,"Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients",2007,The metabolism of tamoxifen is complex and the mechanisms responsible for the resistance are unlikely to be explained by a single polymorphism; instead it is a combination of several mechanisms.,"Tamoxifen therapy reduces the risk of recurrence and prolongs the survival of oestrogen-receptor-positive patients with breast cancer... The prognostic evaluation performed in the total population revealed a significantly better disease-free survival in patients homozygous for CYP2D6*4. For CYP3A5, SULT1A1 and UGT2B15 no prognostic significance was observed.",N,SULT1A1,SULT1A1,0.290322581
1496,bc_id1544,PHARMACOGENOMIC,UGT2B15,17244352,B,"Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients",2007,The metabolism of tamoxifen is complex and the mechanisms responsible for the resistance are unlikely to be explained by a single polymorphism; instead it is a combination of several mechanisms.,"Tamoxifen therapy reduces the risk of recurrence and prolongs the survival of oestrogen-receptor-positive patients with breast cancer... The prognostic evaluation performed in the total population revealed a significantly better disease-free survival in patients homozygous for CYP2D6*4. For CYP3A5, SULT1A1 and UGT2B15 no prognostic significance was observed.",N,UGT2B15,UGT2B15,0.333333333
1497,bc_id1545,CANCER,CYP24A1,17244366,N,"Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer",2007,We found no overall association between selected vitamin D pathway genes and postmenopausal breast cancer risk.,X,X,X,X,0
1498,bc_id1546,CANCER,GC,17244366,N,"Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer",2007,We found no overall association between selected vitamin D pathway genes and postmenopausal breast cancer risk.,X,X,X,X,0
1499,bc_id1547,CANCER,VDR,17244366,N,"Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer",2007,We found no overall association between selected vitamin D pathway genes and postmenopausal breast cancer risk.,"We conducted a nested case-control study within the Cancer Prevention Study II Nutrition Cohort of associations between breast cancer and four VDR single-nucleotide polymorphisms (SNPs), Bsm1,Apa1,Taq1, and Fok1, a poly(A) microsatellite, and associated haplotypes (baTL and BAtS). We also examined one SNP in the 24-hydroxylase gene (CYP24A1) and two in the vitamin D-binding protein (group-specific component [GC]) gene... However, certain VDR gene polymorphisms were associated with lower risk in women consuming high levels of calcium, suggesting that dietary factors may modify associations by VDR genotype.",Y,VDR,VDR,0.269230769
1500,bc_id1548,CANCER,BRCA2,17250666,B,Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus.,2007,,These results show that the prevalence of BRCA1 and BRCA2 mutations in Cypriot women diagnosed with early-onset breast cancer is high.,Y,BRCA2,BRCA2,0.324175824
1501,bc_id1549,CANCER,BRCA1,17250666,B,Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus.,2007,,These results show that the prevalence of BRCA1 and BRCA2 mutations in Cypriot women diagnosed with early-onset breast cancer is high.,Y,BRCA1,BRCA1,0.326180258
1502,bc_id1550,CANCER,CHEK2,17250914,Y,Breast cancer in patients carrying a germ-line CHEK2 mutation,2007,Heterozygosity for a germline CHEK2 mutation appears to represent an adverse prognostic factor in patients with early-stage breast cancer. If confirmed in larger studies these data may serve as a basis for future surveillance and treatment strategies taking into account individual germline mutational status.,Heterozygosity for a germline CHEK2 mutation appears to represent an adverse prognostic factor in patients with early-stage breast cancer.,Y,CHEK2,CHEK2,0.383333333
1503,bc_id1551,CANCER,NOS3,17259657,B,"Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking, and risk of postmenopausal breast cancer",2007,,"NOS3 genotypes appeared to be associated with risk of post-menopausal breast cancer among smokers, supporting the hypothesis that subgroups of women based upon genetic profiles may be at higher risk of breast cancer when exposed to tobacco smoke.",Y,NOS3,NOS3,0.538461538
1504,bc_id1552,CANCER,MPO,17259657,B,"Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking, and risk of postmenopausal breast cancer",2007,,X,X,X,X,0
1505,bc_id1553,CANCER,MTHFR,17260091,B,Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis.,2007,Our study lends support to a positive association between the MTHFR variant homozygous allele 677TT and breast cancer risk.,Our study lends support to a positive association between the MTHFR variant homozygous allele 677TT and breast cancer risk.,Y,MTHFR,MTHFR,0.269230769
1506,bc_id1554,CANCER,HSD17B2,17260097,B,A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer,2007,,No mutation was detected and therefore mutations in HSD17B2 do not explain why some breast tumours exhibit low 17HSD type 2 expression.,N,HSD17B2,HSD17B2,1
1507,bc_id1555,CANCER,IFNG,17261759,B,Cytokine Gene Polymorphisms and Breast Cancer Susceptibility,2006,further studies involving larger numbers of subjects are required.,"TNF-alpha (-308G/A), TGF-beta1 (+869C/T), IL-10 (-1117G/A; -854C/T; -627C/A), and IFN-gamma (874T/A) single nucleotide polymorphisms (SNPs) were identified by sequence-specific primers (SSP)-PCR or restriction fragment length polymorphism (RFLP)-PCR. Genotype or haplotype distributions for each polymorphisms were consistent with the HWE in these populations... Data obtained in this study indicate that none of the cytokine SNPs studied is likely to have predisposing or protective effects on BC susceptibility.",A,IFN-gamma,IFNG,0.75
1508,bc_id1556,CANCER,IL10,17261759,B,Cytokine Gene Polymorphisms and Breast Cancer Susceptibility,2006,further studies involving larger numbers of subjects are required.,"TNF-alpha (-308G/A), TGF-beta1 (+869C/T), IL-10 (-1117G/A; -854C/T; -627C/A), and IFN-gamma (874T/A) single nucleotide polymorphisms (SNPs) were identified by sequence-specific primers (SSP)-PCR or restriction fragment length polymorphism (RFLP)-PCR. Genotype or haplotype distributions for each polymorphisms were consistent with the HWE in these populations... Data obtained in this study indicate that none of the cytokine SNPs studied is likely to have predisposing or protective effects on BC susceptibility.",A,IL-10,IL10,0.625
1509,bc_id1557,CANCER,TGFB1,17261759,B,Cytokine Gene Polymorphisms and Breast Cancer Susceptibility,2006,further studies involving larger numbers of subjects are required.,"TNF-alpha (-308G/A), TGF-beta1 (+869C/T), IL-10 (-1117G/A; -854C/T; -627C/A), and IFN-gamma (874T/A) single nucleotide polymorphisms (SNPs) were identified by sequence-specific primers (SSP)-PCR or restriction fragment length polymorphism (RFLP)-PCR. Genotype or haplotype distributions for each polymorphisms were consistent with the HWE in these populations... Data obtained in this study indicate that none of the cytokine SNPs studied is likely to have predisposing or protective effects on BC susceptibility.",A,TGF-beta1,TGFB1,0.518518519
1510,bc_id1558,CANCER,TNF,17261759,B,Cytokine Gene Polymorphisms and Breast Cancer Susceptibility,2006,further studies involving larger numbers of subjects are required.,"TNF-alpha (-308G/A), TGF-beta1 (+869C/T), IL-10 (-1117G/A; -854C/T; -627C/A), and IFN-gamma (874T/A) single nucleotide polymorphisms (SNPs) were identified by sequence-specific primers (SSP)-PCR or restriction fragment length polymorphism (RFLP)-PCR. Genotype or haplotype distributions for each polymorphisms were consistent with the HWE in these populations... Data obtained in this study indicate that none of the cytokine SNPs studied is likely to have predisposing or protective effects on BC susceptibility.",A,TNF-alpha,TNF,0.4
1511,bc_id1559,CANCER,NOS3,17262178,Y,Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement,2007,,Our results suggest that genetic polymorphisms in NOS3 modify individual susceptibility to invasive breast cancer with lymph node involvement in Korean women.,Y,NOS3,NOS3,0.538461538
1512,bc_id1561,CANCER,ADRB3,17264845,B,The ADRB3 Trp64Arg variant and obesity in African-American breast cancer cases.,2007,,X,X,X,X,0
1513,bc_id1562,CANCER,ADH1B,17268812,B,"Alcohol metabolism, alcohol intake, and breast cancer risk",2007,,Neither alcohol drinking nor alcohol metabolizing ADH1B and ADH1C genotypes were associated with breast cancer risk.,N,ADH1B,ADH1B,0.6
1514,bc_id1563,CANCER,ADH1C,17268812,B,"Alcohol metabolism, alcohol intake, and breast cancer risk",2007,,Neither alcohol drinking nor alcohol metabolizing ADH1B and ADH1C genotypes were associated with breast cancer risk.,N,ADH1C,ADH1C,0.5
1515,bc_id1564,CANCER,ESR1,17268813,B,Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women.,2007,,No other statistically significant associations were observed between ESR1 haplotypes from the same four SNPs and the risk of breast cancer in older Caucasian women.,N,ESR1,ESR1,0.130434783
1516,bc_id1565,CANCER,BUB1B,17268814,B,Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk,2007,,"In the present study we examined the effect of promoter and coding single nucleotide polymorphisms (SNPs) in six major spindle checkpoint genes (BUB1B, BUB3, CENPE, MAD2L1, MAD2L2, TTK) on familial breast cancer (BC) risk... Therefore, our results indicate that the investigated SNPs in the mitotic checkpoint genes do not affect the risk of familial BC.",N,BUB1B,BUB1B,0.5
1517,bc_id1566,CANCER,BUB3,17268814,B,Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk,2007,,"In the present study we examined the effect of promoter and coding single nucleotide polymorphisms (SNPs) in six major spindle checkpoint genes (BUB1B, BUB3, CENPE, MAD2L1, MAD2L2, TTK) on familial breast cancer (BC) risk... Therefore, our results indicate that the investigated SNPs in the mitotic checkpoint genes do not affect the risk of familial BC.",N,BUB3,BUB3,1
1518,bc_id1567,CANCER,CENPE,17268814,B,Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk,2007,,"In the present study we examined the effect of promoter and coding single nucleotide polymorphisms (SNPs) in six major spindle checkpoint genes (BUB1B, BUB3, CENPE, MAD2L1, MAD2L2, TTK) on familial breast cancer (BC) risk... Therefore, our results indicate that the investigated SNPs in the mitotic checkpoint genes do not affect the risk of familial BC.",N,CENPE,CENPE,1
1519,bc_id1568,CANCER,MAD2L2,17268814,B,Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk,2007,,"In the present study we examined the effect of promoter and coding single nucleotide polymorphisms (SNPs) in six major spindle checkpoint genes (BUB1B, BUB3, CENPE, MAD2L1, MAD2L2, TTK) on familial breast cancer (BC) risk... Therefore, our results indicate that the investigated SNPs in the mitotic checkpoint genes do not affect the risk of familial BC.",N,MAD2L2,MAD2L2,1
1520,bc_id1569,CANCER,TTK,17268814,B,Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk,2007,,"In the present study we examined the effect of promoter and coding single nucleotide polymorphisms (SNPs) in six major spindle checkpoint genes (BUB1B, BUB3, CENPE, MAD2L1, MAD2L2, TTK) on familial breast cancer (BC) risk... Therefore, our results indicate that the investigated SNPs in the mitotic checkpoint genes do not affect the risk of familial BC.",N,TTK,TTK,0.5
1521,bc_id1570,CANCER,MAD2L1,17268814,B,Genetic variation in the major mitotic checkpoint genes does not affect familial breast cancer risk,2007,,"In the present study we examined the effect of promoter and coding single nucleotide polymorphisms (SNPs) in six major spindle checkpoint genes (BUB1B, BUB3, CENPE, MAD2L1, MAD2L2, TTK) on familial breast cancer (BC) risk... Therefore, our results indicate that the investigated SNPs in the mitotic checkpoint genes do not affect the risk of familial BC.",N,MAD2L1,MAD2L1,0.5
1522,bc_id1571,CANCER,TP53,17284368,B,Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women.,2007,,Mutation in codon 72 of TP53 gene was not associated with breast cancer in Iranian patients.,N,TP53,TP53,0.149425287
1523,bc_id1572,CANCER,ATM,17293864,N,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,ATM,ATM,0.333333333
1524,bc_id1573,CANCER,CASP8,17293864,Y,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,CASP8,CASP8,0.642857143
1525,bc_id1574,CANCER,ICAM5,17293864,N,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,ICAM5,ICAM5,1
1526,bc_id1575,CANCER,IGFBP3,17293864,N,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,IGFBP3,IGFBP3,0.357142857
1527,bc_id1576,CANCER,NUMA1,17293864,N,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,NUMA1,NUMA1,0.5
1528,bc_id1577,CANCER,SOD2,17293864,N,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,SOD2,SOD2,0.25
1529,bc_id1578,CANCER,TGFB1,17293864,N,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,TGFB1,TGFB1,0.185185185
1530,bc_id1579,CANCER,ADH1B,17293864,N,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,ADH1B,ADH1B,0.2
1531,bc_id1580,CANCER,CDKN1A,17293864,N,A common coding variant in CASP8 is associated with breast cancer risk,2007,,"We genotyped nine SNPs for which there was some prior evidence of an association with breast cancer: CASP8 D302H (rs1045485), IGFBP3 -202 C --> A (rs2854744), SOD2 V16A (rs1799725), TGFB1 L10P (rs1982073), ATM S49C (rs1800054), ADH1B 3' UTR A --> G (rs1042026), CDKN1A S31R (rs1801270), ICAM5 V301I (rs1056538) and NUMA1 A794G (rs3750913)...  These results demonstrate that common breast cancer susceptibility alleles with small effects on risk can be identified, given sufficiently powerful studies.",Y,CDKN1A,CDKN1A,0.25
1532,bc_id1581,CANCER,ADH1B,17295732,N,"Alcohol Dehydrogenase Genetic Polymorphisms, Low-to-Moderate Alcohol Consumption, and Risk of Breast Cancer",2007,In this study low levels of alcohol are associated with a modest increase in breast cancer risk that is not altered by known functional allelic variants of the ADH1B and 1C gene.,In this study low levels of alcohol are associated with a modest increase in breast cancer risk that is not altered by known functional allelic variants of the ADH1B and 1C gene.,N,ADH1B,ADH1B,0.6
1533,bc_id1582,CANCER,ADH1C,17295732,N,"Alcohol Dehydrogenase Genetic Polymorphisms, Low-to-Moderate Alcohol Consumption, and Risk of Breast Cancer",2007,In this study low levels of alcohol are associated with a modest increase in breast cancer risk that is not altered by known functional allelic variants of the ADH1B and 1C gene.,In this study low levels of alcohol are associated with a modest increase in breast cancer risk that is not altered by known functional allelic variants of the ADH1B and 1C gene.,N,ADH1B and 1C,ADH1C,0.5
1534,bc_id1583,CANCER,MTUS1,17301065,B,Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk,2007,,"A recent study has characterized 100 CNVs including a deletion in the mitochondrial tumor suppressor gene 1 (MTUS1) lacking the coding exon 4. MTUS1 maps to chromosome 8p, a region frequently deleted and associated with disease progression in human cancers, including breast cancer (BC).",Y,MTUS1,MTUS1,1
1535,bc_id1584,CANCER,WRN,17301258,B,Genetic Variation in the Premature Aging Gene WRN,2007,,"This study provides support for the tumorigenic role of WRN in breast cancer development, suggesting that breast cancer can be driven by the aging associated with variant WRN, the tumorigenic contribution of which might be enhanced as a result of increased cell growth due to estrogen exposure.",Y,WRN,WRN,0.666666667
1536,bc_id1585,CANCER,RAD51,17301259,B,The RAD51 135 G&gt;C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.,2007,", the RAD51 C allele seems to protect against both breast and ovarian cancer in women harboring BRCA1 mutations.",the RAD51 C allele seems to protect against both breast and ovarian cancer in women harboring BRCA1 mutations.,Y,RAD51,RAD51,0.230769231
1537,bc_id1586,CANCER,BRCA1,17301259,B,The RAD51 135 G&gt;C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.,2007,", the RAD51 C allele seems to protect against both breast and ovarian cancer in women harboring BRCA1 mutations.",the RAD51 C allele seems to protect against both breast and ovarian cancer in women harboring BRCA1 mutations.,Y,BRCA1,BRCA1,0.326180258
1538,bc_id1587,CANCER,GSTP1,17301692,Y,ABCB1 and GST polymorphisms associated with TP53 status in breast cancer,2007,An association between polymorphisms in GSTP1 and ABCB1 and risk of acquiring intratumoral TP53 mutations suggests the existence of putative predisposing genotype backgrounds.,X,X,X,X,0
1539,bc_id1588,CANCER,ABCB1,17301692,Y,ABCB1 and GST polymorphisms associated with TP53 status in breast cancer,2007,An association between polymorphisms in GSTP1 and ABCB1 and risk of acquiring intratumoral TP53 mutations suggests the existence of putative predisposing genotype backgrounds.,"The goal of this study was to characterize the genetic variation in the ABCB1, GSTM1, GSTT1 and GSTP1 genes, as well as the haplotype structure in the ABCB1 gene... Multifactor dimensionality reduction showed that carriers of the combined GG genotype for GSTP1 and the GG for ABCB1 exon 11 had the highest chance of acquiring a mutation in the TP53 gene (P<0.02). Haplotype analysis of ABCB1 revealed a significantly different distribution of haplotypes between the breast cancer cases and the controls (P<0.01).",Y,ABCB1,ABCB1,0.1875
1540,bc_id1589,CANCER,GSTM1,17301692,N,ABCB1 and GST polymorphisms associated with TP53 status in breast cancer,2007,An association between polymorphisms in GSTP1 and ABCB1 and risk of acquiring intratumoral TP53 mutations suggests the existence of putative predisposing genotype backgrounds.,X,X,X,X,0
1541,bc_id1590,CANCER,GSTT1,17301692,N,ABCB1 and GST polymorphisms associated with TP53 status in breast cancer,2007,An association between polymorphisms in GSTP1 and ABCB1 and risk of acquiring intratumoral TP53 mutations suggests the existence of putative predisposing genotype backgrounds.,X,X,X,X,0
1542,bc_id1591,CANCER,SERPINE1,17309181,B,Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer,2006,"We suggest that this polymorphism may contribute to an inherited predisposition to the development of breast cancer, however further studies with larger series from diverse ethnic populations are needed to confirm our results.","The distribution of the PAI-1 4G/5G genotypes was significantly different between the two groups (p<0.05)... We suggest that this polymorphism may contribute to an inherited predisposition to the development of breast cancer, however further studies with larger series from diverse ethnic populations are needed to confirm our results.",A,PAI-1,SERPINE1,1
1543,bc_id1592,CANCER,IGF1,17311016,B,Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women,2007,,X,X,X,X,0
1544,bc_id1593,CANCER,CBS,17311260,B,Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk,2007,this report does not support a substantial overall association between the evaluated polymorphisms in the one-carbon metabolism pathway and breast cancer risk.,"we investigated the association between breast cancer risk and 13 polymorphisms in 6 one-carbon metabolism genes (MTHFR, MTR, MTRR, CBS, SHMT1 and SLC19A1). Data suggested an association between a nonsynonymous change in the gene coding for methionine synthase (MTR D919G) and reduced breast cancer risk...  We found no significant associations between other variants and breast cancer risk, including MTHFR A222V or E429A. Meta-analyses including published studies of MTHFR A222V (8,330 cases and 10,825 controls) and E429A (6,521 cases and 8,515 controls) supported the lack of an overall association; however, studies suggested an increase in risk among premenopausal women.",N,CBS,CBS,1
1545,bc_id1594,CANCER,MTR,17311260,B,Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk,2007,this report does not support a substantial overall association between the evaluated polymorphisms in the one-carbon metabolism pathway and breast cancer risk.,"we investigated the association between breast cancer risk and 13 polymorphisms in 6 one-carbon metabolism genes (MTHFR, MTR, MTRR, CBS, SHMT1 and SLC19A1). Data suggested an association between a nonsynonymous change in the gene coding for methionine synthase (MTR D919G) and reduced breast cancer risk...  We found no significant associations between other variants and breast cancer risk, including MTHFR A222V or E429A. Meta-analyses including published studies of MTHFR A222V (8,330 cases and 10,825 controls) and E429A (6,521 cases and 8,515 controls) supported the lack of an overall association; however, studies suggested an increase in risk among premenopausal women.",Y,MTR,MTR,0.444444444
1546,bc_id1595,CANCER,MTRR,17311260,B,Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk,2007,this report does not support a substantial overall association between the evaluated polymorphisms in the one-carbon metabolism pathway and breast cancer risk.,"we investigated the association between breast cancer risk and 13 polymorphisms in 6 one-carbon metabolism genes (MTHFR, MTR, MTRR, CBS, SHMT1 and SLC19A1). Data suggested an association between a nonsynonymous change in the gene coding for methionine synthase (MTR D919G) and reduced breast cancer risk...  We found no significant associations between other variants and breast cancer risk, including MTHFR A222V or E429A. Meta-analyses including published studies of MTHFR A222V (8,330 cases and 10,825 controls) and E429A (6,521 cases and 8,515 controls) supported the lack of an overall association; however, studies suggested an increase in risk among premenopausal women.",N,MTRR,MTRR,0.666666667
1547,bc_id1596,CANCER,SHMT1,17311260,B,Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk,2007,this report does not support a substantial overall association between the evaluated polymorphisms in the one-carbon metabolism pathway and breast cancer risk.,"we investigated the association between breast cancer risk and 13 polymorphisms in 6 one-carbon metabolism genes (MTHFR, MTR, MTRR, CBS, SHMT1 and SLC19A1). Data suggested an association between a nonsynonymous change in the gene coding for methionine synthase (MTR D919G) and reduced breast cancer risk...  We found no significant associations between other variants and breast cancer risk, including MTHFR A222V or E429A. Meta-analyses including published studies of MTHFR A222V (8,330 cases and 10,825 controls) and E429A (6,521 cases and 8,515 controls) supported the lack of an overall association; however, studies suggested an increase in risk among premenopausal women.",N,SHMT1,SHMT1,0.6
1548,bc_id1597,CANCER,MTHFR,17311260,B,Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk,2007,this report does not support a substantial overall association between the evaluated polymorphisms in the one-carbon metabolism pathway and breast cancer risk.,"we investigated the association between breast cancer risk and 13 polymorphisms in 6 one-carbon metabolism genes (MTHFR, MTR, MTRR, CBS, SHMT1 and SLC19A1). Data suggested an association between a nonsynonymous change in the gene coding for methionine synthase (MTR D919G) and reduced breast cancer risk...  We found no significant associations between other variants and breast cancer risk, including MTHFR A222V or E429A. Meta-analyses including published studies of MTHFR A222V (8,330 cases and 10,825 controls) and E429A (6,521 cases and 8,515 controls) supported the lack of an overall association; however, studies suggested an increase in risk among premenopausal women.",N,MTHFR,MTHFR,0.326923077
1549,bc_id1598,CANCER,SLC19A1,17311260,B,Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk,2007,this report does not support a substantial overall association between the evaluated polymorphisms in the one-carbon metabolism pathway and breast cancer risk.,"we investigated the association between breast cancer risk and 13 polymorphisms in 6 one-carbon metabolism genes (MTHFR, MTR, MTRR, CBS, SHMT1 and SLC19A1). Data suggested an association between a nonsynonymous change in the gene coding for methionine synthase (MTR D919G) and reduced breast cancer risk...  We found no significant associations between other variants and breast cancer risk, including MTHFR A222V or E429A. Meta-analyses including published studies of MTHFR A222V (8,330 cases and 10,825 controls) and E429A (6,521 cases and 8,515 controls) supported the lack of an overall association; however, studies suggested an increase in risk among premenopausal women.",N,SLC19A1,SLC19A1,1
1550,bc_id1599,CANCER,TP53,17319790,B,Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population.,2007,,Our results indicate that both BstUI and MspI p53 polymormphisms might play the role in the breast cancer development especially in women younger than 50 years.,A,p53,TP53,0.482758621
1551,bc_id1600,CANCER,CYP19A1,17325027,B,Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.,2007,,"Thus, although genetic variation in CYP19A1 produces measurable differences in estrogen levels among postmenopausal women, the magnitude of the change was insufficient to contribute detectably to breast cancer.",A,CYP19A1,CYP19A1,0.484848485
1552,bc_id1601,CANCER,NBN,17333333,N,BARD1 and breast cancer in Poland,2007,There was no clear association between the presence of the BARD1 Cys557Ser allele and breast cancer in Poland.,"The risk associated with the BARD1 variant was not significantly greater in women with familial cancer (OR = 1.5; 95% CI = 0.8-2.7), or with an inherited mutation in BRCA1 (OR = 0.9; 95% CI = 0.4-2.2), CHEK2 (OR = 1.0; 95% CI = 0.5-2.1), or NBS1 (OR = 1.3; 95% CI = 0.2-10.2). Modest associations were observed among the subgroups of women with very early onset breast cancer (OR = 2.9; 95% CI = 1.2-7.1) and with medullary breast cancer (OR = 1.8; 95% CI = 0.9-3.7).",A,NBS1,NBN,0.571428571
1553,bc_id1602,CANCER,CHEK2,17333333,N,BARD1 and breast cancer in Poland,2007,There was no clear association between the presence of the BARD1 Cys557Ser allele and breast cancer in Poland.,"The risk associated with the BARD1 variant was not significantly greater in women with familial cancer (OR = 1.5; 95% CI = 0.8-2.7), or with an inherited mutation in BRCA1 (OR = 0.9; 95% CI = 0.4-2.2), CHEK2 (OR = 1.0; 95% CI = 0.5-2.1), or NBS1 (OR = 1.3; 95% CI = 0.2-10.2). Modest associations were observed among the subgroups of women with very early onset breast cancer (OR = 2.9; 95% CI = 1.2-7.1) and with medullary breast cancer (OR = 1.8; 95% CI = 0.9-3.7).",A,CHEK2,CHEK2,0.383333333
1554,bc_id1603,CANCER,BARD1,17333333,N,BARD1 and breast cancer in Poland,2007,There was no clear association between the presence of the BARD1 Cys557Ser allele and breast cancer in Poland.,"The risk associated with the BARD1 variant was not significantly greater in women with familial cancer (OR = 1.5; 95% CI = 0.8-2.7), or with an inherited mutation in BRCA1 (OR = 0.9; 95% CI = 0.4-2.2), CHEK2 (OR = 1.0; 95% CI = 0.5-2.1), or NBS1 (OR = 1.3; 95% CI = 0.2-10.2). Modest associations were observed among the subgroups of women with very early onset breast cancer (OR = 2.9; 95% CI = 1.2-7.1) and with medullary breast cancer (OR = 1.8; 95% CI = 0.9-3.7).",A,BARD1,BARD1,0.454545455
1555,bc_id1604,CANCER,ATM,17333338,B,Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.,2008,,"We found no statistically significant differences in the overall frequency of ATM variants, nor any specific variant type or group, between African-American women who had been diagnosed with breast cancer compared with an age-matched cohort of African-American women who did not have breast cancer.",N,ATM,ATM,0.244444444
1556,bc_id1605,CANCER,BRCA2,17333338,B,Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.,2008,,X,X,X,X,0
1557,bc_id1606,CANCER,BRCA1,17333338,B,Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.,2008,,X,X,X,X,0
1558,bc_id1607,CANCER,CHEK2,17333477,B,"Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.",2007,,"BRCA1 5382insC mutation was detected in 29 (9.6%) patients, CHEK2 1100delC in 9 (3.0%), BRCA1 4153delA in 3 (1.0%), CHEK2 IVS2+1G>A in 2 (0.7%), and BRCA1 185delAG, BRCA2 6174delT and NBS1 657del5 in 1 (0.3%) patient each. No cases with BRCA1 300T>G (C61G) mutation was identified. The obtained data suggest that a significant fraction of hereditary BC cases in Russia can be diagnosed using only a limited number of simple PCR tests.",A,CHEK2,CHEK2,0.383333333
1559,bc_id1608,CANCER,BRCA2,17333477,B,"Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.",2007,,"BRCA1 5382insC mutation was detected in 29 (9.6%) patients, CHEK2 1100delC in 9 (3.0%), BRCA1 4153delA in 3 (1.0%), CHEK2 IVS2+1G>A in 2 (0.7%), and BRCA1 185delAG, BRCA2 6174delT and NBS1 657del5 in 1 (0.3%) patient each. No cases with BRCA1 300T>G (C61G) mutation was identified. The obtained data suggest that a significant fraction of hereditary BC cases in Russia can be diagnosed using only a limited number of simple PCR tests.",A,BRCA2,BRCA2,0.576923077
1560,bc_id1609,CANCER,BRCA1,17333477,B,"Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.",2007,,"BRCA1 5382insC mutation was detected in 29 (9.6%) patients, CHEK2 1100delC in 9 (3.0%), BRCA1 4153delA in 3 (1.0%), CHEK2 IVS2+1G>A in 2 (0.7%), and BRCA1 185delAG, BRCA2 6174delT and NBS1 657del5 in 1 (0.3%) patient each. No cases with BRCA1 300T>G (C61G) mutation was identified. The obtained data suggest that a significant fraction of hereditary BC cases in Russia can be diagnosed using only a limited number of simple PCR tests.",A,BRCA1,BRCA1,0.60944206
1561,bc_id1610,CANCER,GSTT1,17336217,B,Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy.,2007,"The results of this study have illustrated the impact of hypofractionation on the level of adverse effects and indicated that the specific alleles of GSTP1, M1, and T1 studied here may be significant in determining the level of adverse effects after radiotherapy.",X,X,X,X,0
1562,bc_id1611,CANCER,GSTP1,17336217,B,Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy.,2007,"The results of this study have illustrated the impact of hypofractionation on the level of adverse effects and indicated that the specific alleles of GSTP1, M1, and T1 studied here may be significant in determining the level of adverse effects after radiotherapy.",X,X,X,X,0
1563,bc_id1612,CANCER,GSTM1,17336217,B,Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy.,2007,"The results of this study have illustrated the impact of hypofractionation on the level of adverse effects and indicated that the specific alleles of GSTP1, M1, and T1 studied here may be significant in determining the level of adverse effects after radiotherapy.",X,X,X,X,0
1564,bc_id1613,CANCER,ATM,17341484,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,"Rare inactivating mutations in BRCA1, BRCA2, ATM, TP53 and CHEK2 confer relative risks for breast cancer between about 2 and more than 10, but more common variants in these genes are generally considered of little or no clinical significance.",A,ATM,ATM,0.422222222
1565,bc_id1614,CANCER,BRCA1,17341484,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,"Rare inactivating mutations in BRCA1, BRCA2, ATM, TP53 and CHEK2 confer relative risks for breast cancer between about 2 and more than 10, but more common variants in these genes are generally considered of little or no clinical significance.",A,BRCA1,BRCA1,0.60944206
1566,bc_id1615,CANCER,BRCA2,17341484,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,"Rare inactivating mutations in BRCA1, BRCA2, ATM, TP53 and CHEK2 confer relative risks for breast cancer between about 2 and more than 10, but more common variants in these genes are generally considered of little or no clinical significance.",A,BRCA2,BRCA2,0.576923077
1567,bc_id1616,CANCER,CHEK2,17341484,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,"Rare inactivating mutations in BRCA1, BRCA2, ATM, TP53 and CHEK2 confer relative risks for breast cancer between about 2 and more than 10, but more common variants in these genes are generally considered of little or no clinical significance.",A,CHEK2,CHEK2,0.383333333
1568,bc_id1617,CANCER,TP53,17341484,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,"Rare inactivating mutations in BRCA1, BRCA2, ATM, TP53 and CHEK2 confer relative risks for breast cancer between about 2 and more than 10, but more common variants in these genes are generally considered of little or no clinical significance.",A,TP53,TP53,0.482758621
1569,bc_id1618,CANCER,BRIP1,17342202,N,Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer,2007,It is unlikely that common variants in BRIP1 contribute significantly to breast cancer susceptibility.,It is unlikely that common variants in BRIP1 contribute significantly to breast cancer susceptibility.,N,BRIP1,BRIP1,0.3
1570,bc_id1619,CANCER,INS,17348446,B,Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer,2007,"Our results suggest that polymorphisms in these energy regulation candidate genes may be associated with risk of breast cancer, but replication in larger studies is needed.",X,X,X,X,0
1571,bc_id1620,CANCER,INSR,17348446,B,Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer,2007,"Our results suggest that polymorphisms in these energy regulation candidate genes may be associated with risk of breast cancer, but replication in larger studies is needed.",X,X,X,X,0
1572,bc_id1621,CANCER,PPARG,17348446,B,Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer,2007,"Our results suggest that polymorphisms in these energy regulation candidate genes may be associated with risk of breast cancer, but replication in larger studies is needed.","The studied SNPs were INS+1127 PstI (rs3842752), INSR H1085H (rs1799817) and PPARy Prol2Ala (rs1801282)... A marginally significant increased risk of breast cancer was observed among women homozygous for the Ala allele of PPARgamma Pro12Ala.",Y,PPARgamma,PPARG,0.2
1573,bc_id1622,CANCER,ATM,17351744,B,ATM allelic variants associated to hereditary breast cancer in 94 Chilean women,2007,,"We found no statistically significant differences in the overall frequency of ATM variants, nor any specific variant type or group, between African-American women who had been diagnosed with breast cancer compared with an age-matched cohort of African-American women who did not have breast cancer. ATM, therefore, does not appear to represent a breast cancer susceptibility gene in the general African-American population.",N,ATM,ATM,0.244444444
1574,bc_id1624,CANCER,TP53,17369602,B,p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.,2007,,"Preclinical data indicate that p-53 gene mutations predict resistance to doxorubicin (A) but not to docetaxel (Taxotere) (T). In the TAX 303 trial, A and T have been compared with advanced breast cancer patients... p-53 gene analysis indicates that gene mutations may compromise the efficacy of A while they do not interfere with the antitumor activity of T; and (ii) the evaluation of multiple molecular markers including p-53 and proliferation markers as topo II protein levels looks more promising in predicting response to anthracyclines.",A,p-53,TP53,0.482758621
1575,bc_id1625,CANCER,ACACA,17372234,B,Haplotype-Based Analysis of Common Variation in the Acetyl-CoA Carboxylase {alpha} Gene and Breast Cancer Risk,2007,,"However, they suggest a possible role of the ACC-alpha common sequence variants in susceptibility to breast cancer and encourage studies of other genes involved in fatty acid synthesis.",Y,ACC-alpha,ACACA,0.5
1576,bc_id1626,CANCER,CYP1A1,17372239,B,Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology,2007,,"We evaluated seven main effects and 21 first-order interactions in African Americans and European Americans for genotypes at COMT, CYP1A1, CYP1A2, CYP1B1, CYP3A4, SULT1A1, and SULT1E1 in 878 breast cancer cases and 1,409 matched random digit-dialed controls.In European Americans, we observed main effect associations of genotypes containing any CYP1A1*2C (odds ratio, 1.71; 95% confidence interval, 1.09-2.67) and breast cancer.",Y,CYP1A1,CYP1A1,0.304347826
1577,bc_id1627,CANCER,CYP1A2,17372239,B,Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology,2007,,"We evaluated seven main effects and 21 first-order interactions in African Americans and European Americans for genotypes at COMT, CYP1A1, CYP1A2, CYP1B1, CYP3A4, SULT1A1, and SULT1E1 in 878 breast cancer cases and 1,409 matched random digit-dialed controls.In European Americans, we observed main effect associations of genotypes containing any CYP1A1*2C (odds ratio, 1.71; 95% confidence interval, 1.09-2.67) and breast cancer. No significant main effects were observed in African Americans.",N,CYP1A2,CYP1A2,0.416666667
1578,bc_id1628,CANCER,CYP1B1,17372239,B,Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology,2007,,"We evaluated seven main effects and 21 first-order interactions in African Americans and European Americans for genotypes at COMT, CYP1A1, CYP1A2, CYP1B1, CYP3A4, SULT1A1, and SULT1E1 in 878 breast cancer cases and 1,409 matched random digit-dialed controls.In European Americans, we observed main effect associations of genotypes containing any CYP1A1*2C (odds ratio, 1.71; 95% confidence interval, 1.09-2.67) and breast cancer. No significant main effects were observed in African Americans.",N,CYP1B1,CYP1B1,0.256410256
1579,bc_id1629,CANCER,CYP3A4,17372239,B,Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology,2007,,"We evaluated seven main effects and 21 first-order interactions in African Americans and European Americans for genotypes at COMT, CYP1A1, CYP1A2, CYP1B1, CYP3A4, SULT1A1, and SULT1E1 in 878 breast cancer cases and 1,409 matched random digit-dialed controls.In European Americans, we observed main effect associations of genotypes containing any CYP1A1*2C (odds ratio, 1.71; 95% confidence interval, 1.09-2.67) and breast cancer. No significant main effects were observed in African Americans.",N,CYP3A4,CYP3A4,0.363636364
1580,bc_id1630,CANCER,SULT1A1,17372239,B,Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology,2007,,"We evaluated seven main effects and 21 first-order interactions in African Americans and European Americans for genotypes at COMT, CYP1A1, CYP1A2, CYP1B1, CYP3A4, SULT1A1, and SULT1E1 in 878 breast cancer cases and 1,409 matched random digit-dialed controls.In European Americans, we observed main effect associations of genotypes containing any CYP1A1*2C (odds ratio, 1.71; 95% confidence interval, 1.09-2.67) and breast cancer. No significant main effects were observed in African Americans.",N,SULT1A1,SULT1A1,0.290322581
1581,bc_id1631,CANCER,SULT1E1,17372239,B,Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology,2007,,"We evaluated seven main effects and 21 first-order interactions in African Americans and European Americans for genotypes at COMT, CYP1A1, CYP1A2, CYP1B1, CYP3A4, SULT1A1, and SULT1E1 in 878 breast cancer cases and 1,409 matched random digit-dialed controls.In European Americans, we observed main effect associations of genotypes containing any CYP1A1*2C (odds ratio, 1.71; 95% confidence interval, 1.09-2.67) and breast cancer. No significant main effects were observed in African Americans.",N,SULT1E1,SULT1E1,0.5
1582,bc_id1632,CANCER,COMT,17372239,B,Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology,2007,,"We evaluated seven main effects and 21 first-order interactions in African Americans and European Americans for genotypes at COMT, CYP1A1, CYP1A2, CYP1B1, CYP3A4, SULT1A1, and SULT1E1 in 878 breast cancer cases and 1,409 matched random digit-dialed controls.In European Americans, we observed main effect associations of genotypes containing any CYP1A1*2C (odds ratio, 1.71; 95% confidence interval, 1.09-2.67) and breast cancer. No significant main effects were observed in African Americans.",N,COMT,COMT,0.29787234
1583,bc_id1633,CANCER,MTHFR,17372271,B,Polymorphisms of One-carbon Metabolizing Genes and Risk of Breast Cancer in a Population-based Study,2007,,"Results from RTREE analyses indicate that MTHFR and TYMS are the two leading rate-limiting enzymes in the pathway, consistent with our epidemiological findings. Our findings underscore the importance of one-carbon metabolism in breast cancer etiology.",A,MTHFR,MTHFR,0.403846154
1584,bc_id1634,CANCER,TYMS,17372271,B,Polymorphisms of One-carbon Metabolizing Genes and Risk of Breast Cancer in a Population-based Study,2007,,"Results from RTREE analyses indicate that MTHFR and TYMS are the two leading rate-limiting enzymes in the pathway, consistent with our epidemiological findings. Our findings underscore the importance of one-carbon metabolism in breast cancer etiology.",A,TYMS,TYMS,0.7
1585,bc_id1635,CANCER,DPYD,17375478,B,Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese,2005,,X,X,X,X,0
1586,bc_id1636,CANCER,IL1B,17385677,B,"Functional polymorphism of thymidylate synthase, but not of the COMT and IL-1B genes, is associated with breast cancer.",2007,,Our data do not provide evidence for an association between the polymorphic variants of the IL-1B and COMT genes and breast cancer risk.,N,IL-1B,IL1B,0.4
1587,bc_id1637,CANCER,COMT,17385677,B,"Functional polymorphism of thymidylate synthase, but not of the COMT and IL-1B genes, is associated with breast cancer.",2007,,Our data do not provide evidence for an association between the polymorphic variants of the IL-1B and COMT genes and breast cancer risk.,N,COMT,COMT,0.29787234
1588,bc_id1638,CANCER,TP53,17387621,B,The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies,2007,,The two major proteins along this pathway are p53 and its negative regulator MDM2...  Neither SNP is independently associated with overall breast cancer risk.,N,p53,TP53,0.149425287
1589,bc_id1639,CANCER,MDM2,17387621,B,The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies,2007,,The two major proteins along this pathway are p53 and its negative regulator MDM2...  Neither SNP is independently associated with overall breast cancer risk.,N,MDM2,MDM2,0.444444444
1590,bc_id1640,CANCER,ATM,17393301,B,The spectrum of ATM missense variants and their contribution to contralateral breast cancer.,2008,,"Heterozygous carriers of ATM mutations are at increased risk of breast cancer. In this case-control study, we evaluated the significance of germline ATM missense variants to the risk of contralateral breast cancer (CBC).",Y,ATM,ATM,0.333333333
1591,bc_id1641,CANCER,BRCA1,17405295,B,"Analysis of loss of heterozygosity and microsatellite instability RAD52, RAD54 and RAD54B gene and BRCA1 gene mutation in breast cancer",2006,The results suggest that the microsatellite instability and LOH seems to be important in the development sporadic breast cancer.,"The results suggest that the microsatellite instability and LOH seems to be important in the development sporadic breast cancer. The lack of detectable BRCA1 germ-line mutations in most cases suggests that there are probably additional, as yet unidentified genes predisposing to this disease.",A,BRCA1,BRCA1,0.60944206
1592,bc_id1642,CANCER,ATM,17409195,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,ANF,ANF,ANF,ANF,0
1593,bc_id1643,CANCER,BRCA2,17409195,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,ANF,ANF,ANF,ANF,0
1594,bc_id1644,CANCER,CHEK2,17409195,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,ANF,ANF,ANF,ANF,0
1595,bc_id1645,CANCER,TP53,17409195,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,ANF,ANF,ANF,ANF,0
1596,bc_id1646,CANCER,BRCA1,17409195,B,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility",2007,,ANF,ANF,ANF,ANF,0
1597,bc_id1648,CANCER,DHFR,17413111,B,A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users,2007,"The DHFR 19-bp deletion polymorphism affects the transcription of DHFR gene in humans. Multivitamin supplements may place a subgroup of women (ie, those with the -19-bp allele) at elevated risk of developing breast cancer.","The DHFR 19-bp deletion polymorphism affects the transcription of DHFR gene in humans. Multivitamin supplements may place a subgroup of women (ie, those with the -19-bp allele) at elevated risk of developing breast cancer.",A,DHFR,DHFR,1
1598,bc_id1649,CANCER,IL6,17416766,B,"IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States.",2007,,These data suggest that IL6 is associated with breast cancer risk and modifies the association between estrogen and aspirin and breast cancer risk.,Y,IL6,IL6,0.285714286
1599,bc_id1650,CANCER,EPHX1,17416769,B,A Systematic Approach to Analysing Gene-Gene Interactions,2007,Detoxification gene polymorphisms may interact with each other to result in small groups of individuals at modestly increased risk.,"We undertook a case-control study in an Australian Caucasian population-based sample of 1,246 cases and 664 controls to assess the roles of detoxification gene polymorphisms EPHX T>C Tyr(113)His, GSTT1 deletion, GSTM1 deletion, and GSTP1 A>G Ile(105)Val on risk of breast cancer.... Detoxification gene polymorphisms may interact with each other to result in small groups of individuals at modestly increased risk.",A,EPHX,EPHX1,1
1600,bc_id1651,CANCER,GSTM1,17416769,B,A Systematic Approach to Analysing Gene-Gene Interactions,2007,Detoxification gene polymorphisms may interact with each other to result in small groups of individuals at modestly increased risk.,"We undertook a case-control study in an Australian Caucasian population-based sample of 1,246 cases and 664 controls to assess the roles of detoxification gene polymorphisms EPHX T>C Tyr(113)His, GSTT1 deletion, GSTM1 deletion, and GSTP1 A>G Ile(105)Val on risk of breast cancer.... Detoxification gene polymorphisms may interact with each other to result in small groups of individuals at modestly increased risk.",A,GSTM1,GSTM1,0.339622642
1601,bc_id1652,CANCER,GSTP1,17416769,B,A Systematic Approach to Analysing Gene-Gene Interactions,2007,Detoxification gene polymorphisms may interact with each other to result in small groups of individuals at modestly increased risk.,"We undertook a case-control study in an Australian Caucasian population-based sample of 1,246 cases and 664 controls to assess the roles of detoxification gene polymorphisms EPHX T>C Tyr(113)His, GSTT1 deletion, GSTM1 deletion, and GSTP1 A>G Ile(105)Val on risk of breast cancer.... Detoxification gene polymorphisms may interact with each other to result in small groups of individuals at modestly increased risk.",A,GSTP1,GSTP1,0.485714286
1602,bc_id1653,CANCER,GSTT1,17416769,B,A Systematic Approach to Analysing Gene-Gene Interactions,2007,Detoxification gene polymorphisms may interact with each other to result in small groups of individuals at modestly increased risk.,"We undertook a case-control study in an Australian Caucasian population-based sample of 1,246 cases and 664 controls to assess the roles of detoxification gene polymorphisms EPHX T>C Tyr(113)His, GSTT1 deletion, GSTM1 deletion, and GSTP1 A>G Ile(105)Val on risk of breast cancer.... Detoxification gene polymorphisms may interact with each other to result in small groups of individuals at modestly increased risk.",A,GSTT1,GSTT1,0.289473684
1603,bc_id1654,CANCER,CYP1A1,17427032,B,Cytochrome P450 1A1 (CYP1A1) T3801C and A2455G polymorphisms in breast cancer risk: a meta-analysis.,2007,,Larger scale primary studies are required to further evaluate the interaction of CYP1A1 polymorphisms and breast cancer risk in specific populations.,A,CYP1A1,CYP1A1,0.456521739
1604,bc_id1655,CANCER,ATM,17428320,B,Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.,2007,"This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy; that is, over and above the risk associated with their carrier status.","We evaluated the contribution of germline mutations in the DDRP genes BRCA1, BRCA2, CHEK2 and ATM to the risk of radiation-induced contralateral breast cancer (CBC)... This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy",Y,ATM,ATM,0.333333333
1605,bc_id1656,CANCER,CHEK2,17428320,B,Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.,2007,"This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy; that is, over and above the risk associated with their carrier status.","We evaluated the contribution of germline mutations in the DDRP genes BRCA1, BRCA2, CHEK2 and ATM to the risk of radiation-induced contralateral breast cancer (CBC)... This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy",Y,CHEK2,CHEK2,0.383333333
1606,bc_id1657,CANCER,BRCA2,17428320,B,Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.,2007,"This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy; that is, over and above the risk associated with their carrier status.","We evaluated the contribution of germline mutations in the DDRP genes BRCA1, BRCA2, CHEK2 and ATM to the risk of radiation-induced contralateral breast cancer (CBC)... This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy",Y,BRCA2,BRCA2,0.324175824
1607,bc_id1658,CANCER,BRCA1,17428320,B,Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.,2007,"This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy; that is, over and above the risk associated with their carrier status.","We evaluated the contribution of germline mutations in the DDRP genes BRCA1, BRCA2, CHEK2 and ATM to the risk of radiation-induced contralateral breast cancer (CBC)... This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy",Y,BRCA1,BRCA1,0.326180258
1608,bc_id1659,CANCER,BRCA1,17428325,N,"Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk",2007,It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.,"Certain rare, familial mutations in the ATM, BRCA1, BRCA2, CHEK2 or TP53 genes increase susceptibility to breast cancer but it has not, until now, been clear whether common polymorphic variants in the same genes also increase risk.",A,BRCA1,BRCA1,0.60944206
1609,bc_id1660,CANCER,BRCA2,17428325,N,"Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk",2007,It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.,"Certain rare, familial mutations in the ATM, BRCA1, BRCA2, CHEK2 or TP53 genes increase susceptibility to breast cancer but it has not, until now, been clear whether common polymorphic variants in the same genes also increase risk.",A,BRCA2,BRCA2,0.576923077
1610,bc_id1661,CANCER,CHEK2,17428325,N,"Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk",2007,It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.,"Certain rare, familial mutations in the ATM, BRCA1, BRCA2, CHEK2 or TP53 genes increase susceptibility to breast cancer but it has not, until now, been clear whether common polymorphic variants in the same genes also increase risk.",A,CHEK2,CHEK2,0.383333333
1611,bc_id1662,CANCER,TP53,17428325,N,"Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk",2007,It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.,"Certain rare, familial mutations in the ATM, BRCA1, BRCA2, CHEK2 or TP53 genes increase susceptibility to breast cancer but it has not, until now, been clear whether common polymorphic variants in the same genes also increase risk.",A,TP53,TP53,0.482758621
1612,bc_id1663,CANCER,ATM,17428325,N,"Common variants in the ATM, BRCA1, BRCA2, CHEK2 & TP53 cancer susceptibility genes are unlikely to increase breast cancer risk",2007,It is unlikely that there are any other common variants in these genes conferring measurably increased risks of breast cancer in our study population.,"Certain rare, familial mutations in the ATM, BRCA1, BRCA2, CHEK2 or TP53 genes increase susceptibility to breast cancer but it has not, until now, been clear whether common polymorphic variants in the same genes also increase risk.",A,ATM,ATM,0.422222222
1613,bc_id1664,CANCER,LEPR,17428620,Y,"Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease",2007,The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.,"No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk... The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.",A,LEPR,LEPR,0.285714286
1614,bc_id1665,CANCER,PON1,17428620,Y,"Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease",2007,The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.,"No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk... The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.",A,PON1,PON1,1
1615,bc_id1666,CANCER,PON2,17428620,N,"Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease",2007,The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.,"No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk... The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.",N,PON2,PON2,1
1616,bc_id1667,CANCER,PPARG,17428620,N,"Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease",2007,The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.,"No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk... The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.",N,PPARG,PPARG,0.4
1617,bc_id1668,CANCER,TNF,17428620,N,"Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease",2007,The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.,"No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk... The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.",N,TNF,TNF,0.266666667
1618,bc_id1669,CANCER,LPL,17428620,N,"Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease",2007,The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.,"No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk... The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.",N,LPL,LPL,1
1619,bc_id1670,CANCER,AHR,17429315,N,Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival,2007,Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.,"No apparent association was found for any of the other six single nucleotide polymorphisms evaluated in the AhR, CYP1A1, CYP1A2, and CYP1B1 genes... Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.",N,AhR,AHR,0.4
1620,bc_id1671,CANCER,COMT,17429315,Y,Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival,2007,Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.,"No apparent association was found for any of the other six single nucleotide polymorphisms evaluated in the AhR, CYP1A1, CYP1A2, and CYP1B1 genes... Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.",A,COMT,COMT,0.425531915
1621,bc_id1672,CANCER,CYP1A1,17429315,Y,Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival,2007,Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.,"No apparent association was found for any of the other six single nucleotide polymorphisms evaluated in the AhR, CYP1A1, CYP1A2, and CYP1B1 genes... Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.",A,CYP1A1,CYP1A1,0.456521739
1622,bc_id1673,CANCER,CYP1A2,17429315,N,Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival,2007,Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.,"No apparent association was found for any of the other six single nucleotide polymorphisms evaluated in the AhR, CYP1A1, CYP1A2, and CYP1B1 genes... Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.",N,CYP1A2,CYP1A1,0.239130435
1623,bc_id1674,CANCER,CYP1B1,17429315,N,Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival,2007,Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.,"No apparent association was found for any of the other six single nucleotide polymorphisms evaluated in the AhR, CYP1A1, CYP1A2, and CYP1B1 genes... Results from this study suggest that rs4680 in the COMT gene and rs4646903 in the CYP1A1 gene may be genetic markers for breast cancer prognosis in Chinese women.",N,CYP1B1,CYP1A2,0.416666667
1624,bc_id1675,CANCER,ATM,17431766,B,Two-stage case-control study of common ATM gene variants in relation to breast cancer risk.,2007,,Our study reveals no apparent association of common ATM variants with breast cancer risk and underscores the importance of replication using independent samples to reduce type I errors in association studies of low-penetrance genetic factors.,N,ATM,ATM,0.244444444
1625,bc_id1676,CANCER,POR,17440066,Y,A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in african americans,2007,,These data suggest that African Americans harbor an allele at the POR locus that may increase breast cancer risk.,A,POR,POR,1
1626,bc_id1677,PHARMACOGENOMIC,CDKN1A,17443496,B,Mutations and polymorphisms of the p21B transcript in breast cancer,2007,,"p21(WAF1/CIP1), transcribed from the CDKN1A locus, plays a key role executing p53-induced growth arrest... Our findings do not suggest mutations or polymorphisms of p21B to play a major role with respect to either breast cancer risk or sensitivity towards chemotherapy.",N,CDKN1A,CDKN1A,0.25
1627,bc_id1678,CANCER,TP53,17449902,B,Genetic variation in TP53 and risk of breast cancer in a population-based case control study.,2007,,These results indicate that common variation in the TP53 gene could modify the risk of invasive breast cancer.,A,TP53,TP53,0.482758621
1628,bc_id1679,CANCER,CASP10,17450141,N,A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers,2007,,"We tested whether genetic variants in CASP8, CASP10 and CFLAR, three genes important for death receptor-induced cell killing residing in tandem order on chromosome 2q33, are associated with cancer susceptibility... Case-control analyses of 4,995 individuals with cancer and 4,972 controls in a Chinese population showed that this genetic variant is associated with reduced susceptibility to multiple cancers, including lung, esophageal, gastric, colorectal, cervical and breast cancers, acting in an allele dose-dependent manner.",Y,CASP10,CASP10,0.666666667
1629,bc_id1680,CANCER,CASP8,17450141,Y,A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers,2007,,"We tested whether genetic variants in CASP8, CASP10 and CFLAR, three genes important for death receptor-induced cell killing residing in tandem order on chromosome 2q33, are associated with cancer susceptibility... Case-control analyses of 4,995 individuals with cancer and 4,972 controls in a Chinese population showed that this genetic variant is associated with reduced susceptibility to multiple cancers, including lung, esophageal, gastric, colorectal, cervical and breast cancers, acting in an allele dose-dependent manner.",Y,CASP8,CASP8,0.642857143
1630,bc_id1681,CANCER,CFLAR,17450141,N,A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers,2007,,"We tested whether genetic variants in CASP8, CASP10 and CFLAR, three genes important for death receptor-induced cell killing residing in tandem order on chromosome 2q33, are associated with cancer susceptibility... Case-control analyses of 4,995 individuals with cancer and 4,972 controls in a Chinese population showed that this genetic variant is associated with reduced susceptibility to multiple cancers, including lung, esophageal, gastric, colorectal, cervical and breast cancers, acting in an allele dose-dependent manner.",Y,CFLAR,CFLAR,1
1631,bc_id1682,CANCER,ERBB2,17452776,Y,655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations,2007,these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.,"In conclusion, these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.",Y,ERBB2,ERBB2,0.285714286
1632,bc_id1683,CANCER,BRCA1,17452776,N,655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations,2007,these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.,X,X,X,X,0
1633,bc_id1684,CANCER,NPAS2,17453337,B,Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk,2007,,"This is the first evidence demonstrating a role of the circadian gene NPAS2 in human breast cancer, suggesting that genetic variations in circadian genes might be a novel panel of biomarkers for breast cancer risk.",Y,NPAS2,NPAS2,1
1634,bc_id1685,CANCER,MTHFR,17453338,B,Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis.,2008,,"Our data show a trend for a higher MTHFR 677T allele frequency in breast cancer cases (61.9%) than in controls (51.5%, P = 0.082) supporting the results of previous studies.",Y,MTHFR,MTHFR,0.269230769
1635,bc_id1686,CANCER,ESR1,17453340,B,Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk.,2008,Our results suggest that the ESR1 polymorphisms do not play a role in breast cancer risk in Caucasian postmenopausal women.,Our results suggest that the ESR1 polymorphisms do not play a role in breast cancer risk in Caucasian postmenopausal women.,N,ESR1,ESR1,0.130434783
1636,bc_id1687,CANCER,CYP1B1,17458695,Y,CYP1B1 and predisposition to breast cancer in Poland,2007,The CYP1B1 gene appears to influence breast cancer susceptibility in Poland.,The CYP1B1 gene appears to influence breast cancer susceptibility in Poland.,Y,CYP1B1,CYP1B1,0.358974359
1637,bc_id1688,CANCER,VEGFA,17471570,B,Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity,2007,,There was no association between the individual polymorphisms and circulating VEGF levels in healthy volunteers and VEGF expression on the breast cancer micro array.,N,VEGF,VEGFA,0.333333333
1638,bc_id1689,CANCER,PTGS2,17479405,B,Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population,2007,,These findings indicate that these three variants in the regulatory regions of COX-2 may contribute to the etiology of breast cancer.,A,COX-2,PTGS2,0.583333333
1639,bc_id1690,CANCER,HLA-DQA1,17484621,N,HLA-DQA1 and -DQB1 allele typing in southern Taiwanese women with breast cancer,2007,We have established a significant lack of HLA-DQA1 and -DQB1 association with breast cancer in southern Taiwanese women. The results of this study may provide information for further clarification of the etiology of breast cancer in this region.,We have established a significant lack of HLA-DQA1 and -DQB1 association with breast cancer in southern Taiwanese women. The results of this study may provide information for further clarification of the etiology of breast cancer in this region.,N,HLA-DQA1,HLA-DQA1,1
1640,bc_id1691,CANCER,HLA-DQB1,17484621,N,HLA-DQA1 and -DQB1 allele typing in southern Taiwanese women with breast cancer,2007,We have established a significant lack of HLA-DQA1 and -DQB1 association with breast cancer in southern Taiwanese women. The results of this study may provide information for further clarification of the etiology of breast cancer in this region.,We have established a significant lack of HLA-DQA1 and -DQB1 association with breast cancer in southern Taiwanese women. The results of this study may provide information for further clarification of the etiology of breast cancer in this region.,N,HLA-DQA1 and -DQB1,HLA-DQB1,0.25
1641,bc_id1692,CANCER,BRCA1,17492376,B,Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.,2008,,Breast cancers among BRCA1 carriers frequently do not exhibit sensitivity to docetaxel in the neo-adjuvant setting.,A,BRCA1,BRCA1,0.60944206
1642,bc_id1693,CANCER,BACH1,17504528,B,BRIP1 (BACH1) variants and familial breast cancer risk,2007,We found no effect of the putatively functional BRIP1 variants -64G>A and Pro919Ser on the risk of familial BC.,We found no effect of the putatively functional BRIP1 variants -64G>A and Pro919Ser on the risk of familial BC.,N,BRIP1,BACH1,0.5
1643,bc_id1694,CANCER,CYP1A2,17507615,Y,The CYP1A2 Genotype Modifies the Association Between Coffee Consumption and Breast Cancer Risk Among BRCA1 Mutation Carriers,2007,,The CYP1A2 genotype did not affect breast cancer risk.,N,CYP1A2,CYP1A2,0.416666667
1644,bc_id1695,CANCER,NAT2,17512776,B,Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients,2007,"it was found that oxygen radical generation occurred within carcinoma cells, but the role of polymorphism of specific genes in the development of breast cancer should be evaluated.","However, it was found that breast cancer was not significantly influenced by CYP1A1, CYP1M1 or NAT2 polymorphisms.",N,NAT2,NAT2,0.37037037
1645,bc_id1696,CANCER,S100A1,17512776,B,Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients,2007,"it was found that oxygen radical generation occurred within carcinoma cells, but the role of polymorphism of specific genes in the development of breast cancer should be evaluated.",X,X,X,X,0
1646,bc_id1697,CANCER,CYP1A1,17512776,B,Urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients,2007,"it was found that oxygen radical generation occurred within carcinoma cells, but the role of polymorphism of specific genes in the development of breast cancer should be evaluated.","However, it was found that breast cancer was not significantly influenced by CYP1A1, CYP1M1 or NAT2 polymorphisms.",N,CYP1A1,CYP1A1,0.239130435
1647,bc_id1698,CANCER,ATM,17517479,B,Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy.,2007,,"Sequence variants located in the ATM gene, in particular the 5557 G-->A polymorphism, may predict for late adverse radiation responses in breast cancer patients.",A,ATM,ATM,0.422222222
1648,bc_id1699,CANCER,NR3C1,17522428,Y,"Association of progesterone receptor gene polymorphism (PROGINS) with endometriosis, uterine fibroids and breast cancer",2007,,X,X,X,X,0
1649,bc_id1700,CANCER,PGR,17522428,B,"Association of progesterone receptor gene polymorphism (PROGINS) with endometriosis, uterine fibroids and breast cancer.",2007,,This indicates that PROGINS can be considered as a predisposing risk marker for breast cancer but not for endometriosis and uterine fibroids.,Y,PROGINS,PGR,0.142857143
1650,bc_id1701,CANCER,TNFRSF10C,17522430,B,Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women,2007,,X,X,X,X,0
1651,bc_id1702,CANCER,TNFRSF10D,17522430,B,Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women,2007,,X,X,X,X,0
1652,bc_id1703,CANCER,FGFR2,17529967,Y,Genome-wide association study identifies novel breast cancer susceptibility loci,2007,,"We used 227,876 SNPs that were estimated to correlate with 77% of known common SNPs in Europeans at r2 > 0.5. SNPs in five novel independent loci exhibited strong and consistent evidence of association with breast cancer (P < 10(-7)). Four of these contain plausible causative genes (FGFR2, TNRC9, MAP3K1 and LSP1).",Y,FGFR2,FGFR2,0.708333333
1653,bc_id1704,CANCER,LSP1,17529967,Y,Genome-wide association study identifies novel breast cancer susceptibility loci,2007,,"We used 227,876 SNPs that were estimated to correlate with 77% of known common SNPs in Europeans at r2 > 0.5. SNPs in five novel independent loci exhibited strong and consistent evidence of association with breast cancer (P < 10(-7)). Four of these contain plausible causative genes (FGFR2, TNRC9, MAP3K1 and LSP1).",Y,LSP1,LSP1,0.555555556
1654,bc_id1705,CANCER,MAP3K1,17529967,Y,Genome-wide association study identifies novel breast cancer susceptibility loci,2007,,"We used 227,876 SNPs that were estimated to correlate with 77% of known common SNPs in Europeans at r2 > 0.5. SNPs in five novel independent loci exhibited strong and consistent evidence of association with breast cancer (P < 10(-7)). Four of these contain plausible causative genes (FGFR2, TNRC9, MAP3K1 and LSP1).",Y,MAP3K1,MAP3K1,0.636363636
1655,bc_id1706,CANCER,FGFR2,17529973,Y,A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer,2007,results from the GWAS are available online in a form that should speed the identification of additional risk loci.,"We identified four SNPs in intron 2 of FGFR2 (which encodes a receptor tyrosine kinase and is amplified or overexpressed in some breast cancers) that were highly associated with breast cancer and confirmed this association in 1,776 affected individuals and 2,072 controls from three additional studies.",Y,FGFR2,FGFR2,0.708333333
1656,bc_id1708,CANCER,NAT2,17535831,Y,A Meta-Analysis of the Association of N-Acetyltransferase 2 Gene (NAT2) Variants with Breast Cancer,2007,,These results suggest that there is no overall association between the NAT2 slow- or rapid-acetylation phenotype and breast cancer risk.,N,NAT2,NAT2,0.37037037
1657,bc_id1709,PHARMACOGENOMIC,MDM2,17537232,B,Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients,2007,The Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients.,X,X,X,X,0
1658,bc_id1710,PHARMACOGENOMIC,TP53,17537232,Y,Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients,2007,The Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients.,"The genotypes of TP53 codon 72 and MDM2 SNP309 were defined among 557 primary Japanese breast cancer patients (median follow-up, 61.7 months)... The Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients.",Y,TP53,TP53,0.367816092
1659,bc_id1711,CANCER,MT-ND2,17541740,B,Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases,2007,,X,X,X,X,0
1660,bc_id1712,CANCER,TP53,17541742,B,Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.,2008,,"Neither of the TP53 mutations was detected in 381 French Canadian women with breast cancer diagnosed before 50 years of age not selected for family history of cancer. In all, germline TP53 mutations were identified in two of 52 (3.8%) cancer families, suggesting that TP53 is not a major contributor to BRCA1 and BRCA2 mutation-negative breast and/or ovarian cancer families of French Canadian descent.",N,TP53,TP53,0.149425287
1661,bc_id1713,CANCER,BRCA1,17541742,B,Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.,2008,,X,X,X,X,0
1662,bc_id1714,CANCER,EGFR,17548322,B,Epidermal growth factor receptor mutation in non-small cell lung cancer and breast cancer.,2007,,Mutational analysis for EGFR exons 19 and 21 was performed in 75 NSCLC and 10 breast cancer patients... EGFR mutation rate in Chinese NSCLC patients was higher than that in Caucasians. Our data indicated that Chinese adenocarcinoma patients could benefit from TK inhibitor Gefitinib.,A,EGFR,EGFR,0.571428571
1663,bc_id1715,CANCER,MTHFR,17548676,Y,Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence,2007,,"The presence of at least one variant from both the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C SNPs was also associated with increased risk (OR, 2.16; 95% CI, 1.34-3.48 for 677 CT + TT/1,298 AC + CC)... Our findings indicate that genetic variation in multiple one-carbon metabolism genes may influence risk of postmenopausal breast cancer and may involve changes in methyl donor synthesis.",Y,MTHFR,MTHFR,0.269230769
1664,bc_id1716,CANCER,ALDH1L1,17548676,Y,Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence,2007,,X,X,X,X,0
1665,bc_id1717,CANCER,CBS,17548676,Y,Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence,2007,,X,X,X,X,0
1666,bc_id1718,CANCER,MTHFD1,17548676,Y,Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence,2007,,"The nonsynonymous R134K SNP in methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthase [MTHFD1; odds ratio (OR), 1.40; 95% confidence interval (95% CI), 1.06-1.85 for CT + TT] and an intronic SNP in formyltetrahydrofolate dehydrogenase (FTHFD; OR, 2.23; 95% CI, 1.09-4.54 for CC) were associated with a significant increase in risk... Our findings indicate that genetic variation in multiple one-carbon metabolism genes may influence risk of postmenopausal breast cancer and may involve changes in methyl donor synthesis.",Y,MTHFD1,MTHFD1,0.333333333
1667,bc_id1719,CANCER,ABCB1,17549370,Y,A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women,2007,,Our findings suggest that the MDR-1C3435T polymorphism occurs in high incidence among women with breast carcinoma where C allele carriers have increased risk of developing cancer when exposed to toxic substances.,Y,MDR-1C3435T,ABCB1,0.1875
1668,bc_id1720,CANCER,CDKN1B,17550142,B,P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer,2007,"the polymorphic variant at codon 109 of p27 gene may not be a marker for determining patients\ risk of developing breast cancer but it may be a potential genetic marker for poor prognosis, thereby a marker for tumor prognosis.","In conclusion, the polymorphic variant at codon 109 of p27 gene may not be a marker for determining patients' risk of developing breast cancer but it may be a potential genetic marker for poor prognosis, thereby a marker for tumor prognosis.",A,p27,CDKN1B,0.714285714
1669,bc_id1721,CANCER,ESR1,17553133,B,Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation.,2007,These preliminary results suggest that OCs may interact with the ESR1 A908G mutant receptor to drive the development of some breast tumors.,These preliminary results suggest that OCs may interact with the ESR1 A908G mutant receptor to drive the development of some breast tumors.,A,ESR1,ESR1,0.586956522
1670,bc_id1722,CANCER,BRCA1,17557253,Y,Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang.,2007,The mutation of BRCA1 gene may be related to Uigur women breast cancer and bilateral breast cancer.,The mutation of BRCA1 gene may be related to Uigur women breast cancer and bilateral breast cancer.,A,BRCA1,BRCA1,0.60944206
1671,bc_id1723,CANCER,XRCC1,17558308,B,Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.,2007,,The DNA repair enzyme XRCC1 is a potential treatment predictor for the outcome and survival of anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of invasive breast cancer.,Y,XRCC1,XRCC1,0.239130435
1672,bc_id1724,CANCER,CASP14,17558860,B,Mutational analysis of caspase-14 gene in common carcinomas,2007,"These data indicate that caspase-14 gene is rarely mutated in colorectal carcinomas, but not mutated in gastric, lung, breast and hepatocellular carcinomas. The data also suggest that the caspase-14 mutation may not be a direct target of inactivation in tumorigenesis of common carcinomas.","These data indicate that caspase-14 gene is rarely mutated in colorectal carcinomas, but not mutated in gastric, lung, breast and hepatocellular carcinomas. The data also suggest that the caspase-14 mutation may not be a direct target of inactivation in tumorigenesis of common carcinomas.",N,caspase-14,CASP14,1
1673,bc_id1725,CANCER,PARP1,17560163,B,Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients,2007,,The present study implies that genetic variants of PARP-1 may contribute to breast cancerogenesis and that PARP-1 htSNP c.852T>C (Ala284Ala) may influence hormonal therapy of breast cancer.,A,PARP-1,PARP1,0.666666667
1674,bc_id1726,CANCER,ABCB1,17560460,B,MDR1 C3435T Polymorphism in Patients with Breast Cancer,2007,Results of the present study demonstrated a 1.,X,X,X,X,0
1675,bc_id1727,CANCER,IGF1,17561390,B,IGF-1 CA repeat variant and breast cancer risk in postmenopausal women.,2007,,"The meta-analysis using the random-effects model gave a pooled OR of 1.26 (95% CI=0.95-1.82) for IGF-I CA(19) non-carriers versus CA(19) homozygous carriers. According to these results, the IGF-I CA(19) promoter polymorphism is not likely to predict the risk of breast cancer.",N,IGF-I,IGF1,0.4
1676,bc_id1728,CANCER,COMT,17562079,B,"A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives",2007,,"The genotypes of estrogen receptor alpha (ERalpha), aromatase (CYP19), and catechol-O-methyltransferase (COMT) genes were analyzed by direct DNA-sequencing... Our findings suggest that polymorphism of genes involving estrogen-metabolizing pathway, estrogen- biosynthesizing pathway and estrogen receptor pathway may play an important role in the etiology of BRCA1/2 negative breast cancer with hereditary predisposing factors.",A,COMT,COMT,0.425531915
1677,bc_id1729,CANCER,CYP19A1,17562079,B,"A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives",2007,,"The genotypes of estrogen receptor alpha (ERalpha), aromatase (CYP19), and catechol-O-methyltransferase (COMT) genes were analyzed by direct DNA-sequencing... Our findings suggest that polymorphism of genes involving estrogen-metabolizing pathway, estrogen- biosynthesizing pathway and estrogen receptor pathway may play an important role in the etiology of BRCA1/2 negative breast cancer with hereditary predisposing factors.",A,CYP19,CYP19A1,0.484848485
1678,bc_id1730,CANCER,ESR1,17562079,B,"A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives",2007,,"The genotypes of estrogen receptor alpha (ERalpha), aromatase (CYP19), and catechol-O-methyltransferase (COMT) genes were analyzed by direct DNA-sequencing... Our findings suggest that polymorphism of genes involving estrogen-metabolizing pathway, estrogen- biosynthesizing pathway and estrogen receptor pathway may play an important role in the etiology of BRCA1/2 negative breast cancer with hereditary predisposing factors.",A,ERalpha,ESR1,0.586956522
1679,bc_id1731,CANCER,CDKN1B,17567920,B,Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis,2007,"Further work is recommended to understand the potential functional role of these specific non-synonymous amino acid changes and a larger, more comprehensive investigation of genetic variation in these genes (e.g., using a tagSNP approach) in combination with other relevant genes is needed as well as consideration for treatment effects when assessing their po",We found no evidence to suggest that p27-V109G alone or in combination with cMyc-N11S was associated with survival. Age at onset and first-degree family history of breast or ovarian cancer did not significantly modify the association of these polymorphisms with breast cancer risk.,N,p27-V109G,CDKN1B,0.285714286
1680,bc_id1732,CANCER,MYC,17567920,B,Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis,2007,"Further work is recommended to understand the potential functional role of these specific non-synonymous amino acid changes and a larger, more comprehensive investigation of genetic variation in these genes (e.g., using a tagSNP approach) in combination with other relevant genes is needed as well as consideration for treatment effects when assessing their po",We found no evidence to suggest that p27-V109G alone or in combination with cMyc-N11S was associated with survival. Age at onset and first-degree family history of breast or ovarian cancer did not significantly modify the association of these polymorphisms with breast cancer risk.,N,cMyc-N11S,MYC,0.5
1681,bc_id1733,CANCER,TP53,17574348,B,p53 genotypes and haplotypes associated with risk of breast cancer.,2007,,"Several polymorphisms have been reported in the p53 gene. Some of these are within the coding region and may affect the function of the p53 protein, others are within introns or non-coding regions, and their significance is unclear... We conclude that two haplotypes harboring the intron 3 polymorphic (+16bp) allele are associated with a higher risk of breast cancer in the Turkish population.",Y,p53,TP53,0.367816092
1682,bc_id1734,CANCER,CYP11A1,17575134,B,Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk,2007,,"Among genes controlling endogenous estrogen metabolism, CYP11A1 harbors common variants that may influence expression to significantly modify risk of breast cancer.",A,CYP11A1,CYP11A1,0.75
1683,bc_id1735,PHARMACOGENOMIC,MTHFR,17581305,B,Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy,2007,,This study shows that genotyping the TS or the MTHFR gene is of little value in the individual assessment of the use of adjuvant therapy in breast cancer patients.,A,MTHFR,MTHFR,0.403846154
1684,bc_id1736,PHARMACOGENOMIC,TYMS,17581305,B,Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy,2007,,This study shows that genotyping the TS or the MTHFR gene is of little value in the individual assessment of the use of adjuvant therapy in breast cancer patients.,A,TS,TYMS,0.7
1685,bc_id1737,CANCER,BRCA2,17582599,B,Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.,2007,,X,X,X,X,0
1686,bc_id1738,CANCER,BRCA1,17582599,B,Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.,2007,,X,X,X,X,0
1687,bc_id1739,CANCER,MTHFR,17584018,B,GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment.,2007,,Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline-based treatment of breast cancer.,A,MTHFR,MTHFR,0.403846154
1688,bc_id1740,CANCER,GSTP1,17584018,B,GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment.,2007,,Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline-based treatment of breast cancer.,A,GSTP1,GSTP1,0.485714286
1689,bc_id1741,CANCER,COL18A1,17587451,Y,Endostatin gene variation and protein levels in breast cancer susceptibility and severity,2007,The Endostatin 4349A allele is associated with$$$ invasive breast cancer.,The Endostatin 4349A allele is associated with invasive breast cancer.,Y,Endostatin,COL18A1,1
1690,bc_id1742,CANCER,COMT,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,COMT,COMT,0.425531915
1691,bc_id1743,CANCER,CYP19A1,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,CYP19A1,CYP19A1,0.484848485
1692,bc_id1744,CANCER,CYP1A1,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,CYP1A1,CYP1A1,0.456521739
1693,bc_id1745,CANCER,CYP1B1,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,CYP1B1,CYP1B1,0.384615385
1694,bc_id1746,CANCER,GSTP1,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,GSTP1,GSTP1,0.485714286
1695,bc_id1747,CANCER,HSD17B1,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,HSD17B1,HSD17B1,0.454545455
1696,bc_id1748,CANCER,PPARG,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,PPARG2,PPARG,0.4
1697,bc_id1749,CANCER,SOD2,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,SOD2,SOD2,0.375
1698,bc_id1750,CANCER,SRD5A2,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,SRD5A2,SRD5A2,0.666666667
1699,bc_id1751,CANCER,CYP17A1,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,CYP17A1,CYP17A1,0.466666667
1700,bc_id1752,CANCER,EPHX1,17588204,B,Breast cancer,2007,,"Of these CYP17A1, CYP19A1, EPHX1, HSD17B1, SRD5A2, and PPARG2 participate in biosynthesis, CYP1A1, CYP1B1, COMT, GSTP1, and SOD2 in catabolism and detoxification... The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.",A,EPHX1,EPHX1,1
1701,bc_id1753,CANCER,BRCA2,17592676,B,Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.,2007,"Despite this negative finding, our study, to the best of our knowledge, is one of the first to comprehensively screen for mutations, including large genomic rearrangement mutations, in BRCA1 and BRCA2 in men with breast cancer in the United States.","Despite this negative finding, our study, to the best of our knowledge, is one of the first to comprehensively screen for mutations, including large genomic rearrangement mutations, in BRCA1 and BRCA2 in men with breast cancer in the United States.",A,BRCA2,BRCA2,0.576923077
1702,bc_id1754,CANCER,BRCA1,17592676,B,Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.,2007,"Despite this negative finding, our study, to the best of our knowledge, is one of the first to comprehensively screen for mutations, including large genomic rearrangement mutations, in BRCA1 and BRCA2 in men with breast cancer in the United States.","Despite this negative finding, our study, to the best of our knowledge, is one of the first to comprehensively screen for mutations, including large genomic rearrangement mutations, in BRCA1 and BRCA2 in men with breast cancer in the United States.",A,BRCA1,BRCA1,0.60944206
1703,bc_id1755,CANCER,PGR,17592773,B,Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies.,2008,,"We conclude that the leucine allele of the V660L SNP may be associated with a small increase in breast cancer risk, while the other four PGR SNPs, +44C/T (rs518162), +331G/A (rs10895068), H770H (rs1042839) and Q886Q (rs500760), do not substantially increase breast cancer risk.",N,PGR,PGR,0.357142857
1704,bc_id1756,CANCER,ESR1,17594514,B,"Active and passive smoking, IL6, ESR1, and breast cancer risk",2007,,Those with the ESR1 Xba1 AA genotype had a threefold increased risk of breast cancer if they smoked>or=15 pack-years relative to non-smokers (P interaction 0.01).,Y,ESR1,ESR1,0.282608696
1705,bc_id1757,CANCER,MTR,17595805,B,Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes,2007,The present study indicates the significance of multiple low-penetrance alleles of functionally-related folate-metabolizing genes interactive with an estrogenic environment in breast tumorigenesis.,X,X,X,X,0
1706,bc_id1758,CANCER,MTHFR,17595805,B,Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes,2007,The present study indicates the significance of multiple low-penetrance alleles of functionally-related folate-metabolizing genes interactive with an estrogenic environment in breast tumorigenesis.,"The polymorphisms in serine hydroxymethyltransferase (SHMT1 C1420T), 5,10-methylenetetrahydrofolate reductase (MTHFR C677T), and methionine synthase (MS A2756G) genes were examined using polymerase chain reaction-restriction fragment length polymorphism... The present study indicates the significance of multiple low-penetrance alleles of functionally-related folate-metabolizing genes interactive with an estrogenic environment in breast tumorigenesis.",A,MTHFR,MTHFR,0.403846154
1707,bc_id1759,CANCER,SHMT1,17595805,B,Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes,2007,The present study indicates the significance of multiple low-penetrance alleles of functionally-related folate-metabolizing genes interactive with an estrogenic environment in breast tumorigenesis.,"The polymorphisms in serine hydroxymethyltransferase (SHMT1 C1420T), 5,10-methylenetetrahydrofolate reductase (MTHFR C677T), and methionine synthase (MS A2756G) genes were examined using polymerase chain reaction-restriction fragment length polymorphism... The present study indicates the significance of multiple low-penetrance alleles of functionally-related folate-metabolizing genes interactive with an estrogenic environment in breast tumorigenesis.",A,SHMT1,SHMT1,0.2
1708,bc_id1761,PHARMACOGENOMIC,DCK,17602053,N,An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients,2007,RRM1 haplotype showed an association with susceptibility to gemcitabine monotherapy in breast cancer patients.,X,X,X,X,0
1709,bc_id1762,PHARMACOGENOMIC,DCTD,17602053,N,An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients,2007,RRM1 haplotype showed an association with susceptibility to gemcitabine monotherapy in breast cancer patients.,X,X,X,X,0
1710,bc_id1763,PHARMACOGENOMIC,RRM1,17602053,Y,An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients,2007,RRM1 haplotype showed an association with susceptibility to gemcitabine monotherapy in breast cancer patients.,"SNPs in deoxycytidine kinase (dCK), deoxycytidine monophosphate deaminase (DCTD), and ribonucleotide reductase M1 polypeptide (RRM1) were analyzed with genomic DNA of 10 breast cancer cell lines, 74 peripheral blood mononuclear cell (PBMC) samples from advanced breast cancer patients treated with gemcitabine, and 56 PBMC samples from healthy volunteers... RRM1 haplotype showed an association with susceptibility to gemcitabine monotherapy in breast cancer patients.",Y,RRM1,RRM1,1
1711,bc_id1764,CANCER,CYP1A1,17603290,B,Cytochrome P450 1A1 (CYP1A1) polymorphisms and breast cancer risk in Korean women.,2007,,The results obtained suggest that the CYP1A1 MspI polymorphisms could affect susceptibility to breast cancer.,A,CYP1A1,CYP1A1,0.456521739
1712,bc_id1765,CANCER,SERPINE1,17616807,Y,PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer,2007,,Our finding suggests that genotyping PAI-1 -675 4G/5G may help in clinical prognosis of breast cancer.,A,PAI-1,SERPINE1,1
1713,bc_id1766,CANCER,GSTP1,17624589,B,Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women.,2008,,Our results suggest that GSTM1 and GSTP1 genotypes do not individually influence susceptibility to breast cancer or fibrocystic breast conditions.,N,GSTP1,GSTP1,0.085714286
1714,bc_id1767,CANCER,GSTM1,17624589,B,Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women.,2008,,Our results suggest that GSTM1 and GSTP1 genotypes do not individually influence susceptibility to breast cancer or fibrocystic breast conditions.,N,GSTM1,GSTM1,0.20754717
1715,bc_id1768,CANCER,TP53,17624591,B,"Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York.",2008,"These results should be confirmed in larger studies, but suggest that cigarette smoking may influence breast cancer risk through interaction with p53.","These results should be confirmed in larger studies, but suggest that cigarette smoking may influence breast cancer risk through interaction with p53.",A,p53,TP53,0.482758621
1716,bc_id1769,CANCER,CDKN2A,17624602,B,"BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.",2008,Our findings show that few patients with BC and CMM who lacked family histories of these cancers are carriers of deleterious germline mutations in four of the five genes we examined.,"Deleterious mutations were identified in 6 patients: two carriers of a BRCA1 germline mutation, two carriers of TP53 germline mutations (one of which also harbored a BRCA2 deleterious mutation, the other one a BRCA2 unclassified variant), and two carriers of a CDKN2A germline mutation. In addition, 6 variants of unknown signification were identified in BRCA1 or BRCA2 genes. Regarding family history, 3/13 (23%) patients with a positive family history of BC or CMM were carriers of a germline mutation, whereas only 3/69 (4%) patients without family history were carriers of a germline mutation.",A,CDKN2A,CDKN2A,0.625
1717,bc_id1770,CANCER,TP53,17624602,B,"BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.",2008,Our findings show that few patients with BC and CMM who lacked family histories of these cancers are carriers of deleterious germline mutations in four of the five genes we examined.,"Deleterious mutations were identified in 6 patients: two carriers of a BRCA1 germline mutation, two carriers of TP53 germline mutations (one of which also harbored a BRCA2 deleterious mutation, the other one a BRCA2 unclassified variant), and two carriers of a CDKN2A germline mutation. In addition, 6 variants of unknown signification were identified in BRCA1 or BRCA2 genes. Regarding family history, 3/13 (23%) patients with a positive family history of BC or CMM were carriers of a germline mutation, whereas only 3/69 (4%) patients without family history were carriers of a germline mutation.",A,TP53,TP53,0.482758621
1718,bc_id1771,CANCER,BRCA2,17624602,B,"BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.",2008,Our findings show that few patients with BC and CMM who lacked family histories of these cancers are carriers of deleterious germline mutations in four of the five genes we examined.,"Deleterious mutations were identified in 6 patients: two carriers of a BRCA1 germline mutation, two carriers of TP53 germline mutations (one of which also harbored a BRCA2 deleterious mutation, the other one a BRCA2 unclassified variant), and two carriers of a CDKN2A germline mutation. In addition, 6 variants of unknown signification were identified in BRCA1 or BRCA2 genes. Regarding family history, 3/13 (23%) patients with a positive family history of BC or CMM were carriers of a germline mutation, whereas only 3/69 (4%) patients without family history were carriers of a germline mutation.",A,BRCA2,BRCA2,0.576923077
1719,bc_id1772,CANCER,BRCA1,17624602,B,"BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.",2008,Our findings show that few patients with BC and CMM who lacked family histories of these cancers are carriers of deleterious germline mutations in four of the five genes we examined.,"Deleterious mutations were identified in 6 patients: two carriers of a BRCA1 germline mutation, two carriers of TP53 germline mutations (one of which also harbored a BRCA2 deleterious mutation, the other one a BRCA2 unclassified variant), and two carriers of a CDKN2A germline mutation. In addition, 6 variants of unknown signification were identified in BRCA1 or BRCA2 genes. Regarding family history, 3/13 (23%) patients with a positive family history of BC or CMM were carriers of a germline mutation, whereas only 3/69 (4%) patients without family history were carriers of a germline mutation.",A,BRCA1,BRCA1,0.60944206
1720,bc_id1773,CANCER,BRCA2,17625123,B,Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.,2007,,X,X,X,X,0
1721,bc_id1774,CANCER,BRCA1,17625123,B,Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.,2007,,X,X,X,X,0
1722,bc_id1775,CANCER,AURKA,17627006,B,AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.,2007,", the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers.",the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers.,N,AURKA,AURKA,0.25
1723,bc_id1776,CANCER,BRCA2,17627006,B,AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.,2007,", the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers.",X,X,X,X,0
1724,bc_id1777,CANCER,BRCA1,17627006,B,AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.,2007,", the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers.",X,X,X,X,0
1725,bc_id1778,CANCER,GPX1,17634480,B,Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.,2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,X,X,X,X,0
1726,bc_id1779,CANCER,GPX4,17634480,B,"We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer... These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.",2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,"We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer... These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.",Y,GPX4,GPX4,0.333333333
1727,bc_id1780,CANCER,TXNRD2,17634480,B,Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.,2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,X,X,X,X,0
1728,bc_id1781,CANCER,TXN2,17634480,B,Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.,2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,X,X,X,X,0
1729,bc_id1782,CANCER,CAT,17634480,B,Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.,2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,X,X,X,X,0
1730,bc_id1783,CANCER,TXN,17634480,B,Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.,2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,X,X,X,X,0
1731,bc_id1784,CANCER,TXNRD1,17634480,B,Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.,2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,X,X,X,X,0
1732,bc_id1785,CANCER,SOD2,17634480,B,Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.,2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,X,X,X,X,0
1733,bc_id1786,CANCER,SOD1,17634480,B,Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.,2007,These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.,X,X,X,X,0
1734,bc_id1787,CANCER,BRCA2,17635951,B,"Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.",2007,,X,X,X,X,0
1735,bc_id1788,CANCER,BRCA1,17635951,B,"Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.",2007,,X,X,X,X,0
1736,bc_id1789,CANCER,VEGFA,17636397,B,"Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian """"tumor of breast tissue: incidence, genetics, and environmental risk factors"""" study.",2008,Our findings do not support the hypothesis that VEGF polymorphisms are associated with breast cancer risk.,Our findings do not support the hypothesis that VEGF polymorphisms are associated with breast cancer risk.,N,VEGF,VEGFA,0.333333333
1737,bc_id1790,CANCER,PTEN,17636424,B,Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.,2008,,These results suggest that PTEN germline mutations are rare and are unlikely to account for a significant proportion of familial breast cancer cases in the French Canadian population.,A,PTEN,PTEN,0.666666667
1738,bc_id1791,CANCER,BRCA2,17636424,B,Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.,2008,,"Alleles in PTEN and other breast cancer susceptibility genes would be responsible for approximately 25% of the familial component of breast cancer risk, BRCA1 and BRCA2 being the two major genes responsible for this inherited risk.",A,BRCA2,BRCA2,0.576923077
1739,bc_id1792,CANCER,BRCA1,17636424,B,Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.,2008,,"Alleles in PTEN and other breast cancer susceptibility genes would be responsible for approximately 25% of the familial component of breast cancer risk, BRCA1 and BRCA2 being the two major genes responsible for this inherited risk.",A,BRCA1,BRCA1,0.60944206
1740,bc_id1793,CANCER,JAK2,17639043,B,Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer.,2007,,"In this study, we investigated whether genetic variation in the JAK2 gene and the STAT gene region (STAT3, STAT5A and STAT5B) is associated with breast cancer (BC) risk... Haplotypes in the JAK2 gene were not associated with the risk of BC.",N,JAK2,JAK2,1
1741,bc_id1794,CANCER,STAT5A,17639043,B,Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer.,2007,,"In this study, we investigated whether genetic variation in the JAK2 gene and the STAT gene region (STAT3, STAT5A and STAT5B) is associated with breast cancer (BC) risk... Haplotypes in the JAK2 gene were not associated with the risk of BC. In the STAT gene region, the rare haplotype CAGCC containing the variant alleles of each single nucleotide polymorphism (SNP) was associated with an increased risk odds ratio (OR = 5.83, 95% confidence interval (CI) 1.51-26.28).",A,STAT5A,STAT5A,1
1742,bc_id1795,CANCER,STAT5B,17639043,B,Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer.,2007,,"In this study, we investigated whether genetic variation in the JAK2 gene and the STAT gene region (STAT3, STAT5A and STAT5B) is associated with breast cancer (BC) risk... Haplotypes in the JAK2 gene were not associated with the risk of BC. In the STAT gene region, the rare haplotype CAGCC containing the variant alleles of each single nucleotide polymorphism (SNP) was associated with an increased risk odds ratio (OR = 5.83, 95% confidence interval (CI) 1.51-26.28).",A,STAT5B,STAT5B,1
1743,bc_id1796,CANCER,STAT3,17639043,B,Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer.,2007,,"In this study, we investigated whether genetic variation in the JAK2 gene and the STAT gene region (STAT3, STAT5A and STAT5B) is associated with breast cancer (BC) risk... Haplotypes in the JAK2 gene were not associated with the risk of BC. In the STAT gene region, the rare haplotype CAGCC containing the variant alleles of each single nucleotide polymorphism (SNP) was associated with an increased risk odds ratio (OR = 5.83, 95% confidence interval (CI) 1.51-26.28).",A,STAT,STAT,1
1744,bc_id1797,CANCER,BRCA2,17640379,B,Origin and distribution of the BRCA2-8765delAG mutation in breast cancer.,2007,,Screening for the BRCA2-8765delAG variant among unselected and consecutively-collected breast cancer patients originating from the entire Sardinia revealed that such a mutation is present in the northern part of the island only [9/648 (1.4%) among cases from North Sardinia versus 0/493 among cases from South Sardinia].,A,BRCA2,BRCA2,0.576923077
1745,bc_id1798,CANCER,CDH1,17660459,B,Germline E-cadherin mutations in familial lobular breast cancer.,2007,Germline CDH1 mutations can be associated with invasive LBC in the absence of diffuse gastric cancer.,Germline CDH1 mutations can be associated with invasive LBC in the absence of diffuse gastric cancer.,A,CDH1,CDH1,0.428571429
1746,bc_id1799,CANCER,CHEK2,17661168,B,BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.,2008,,"Overall, our data suggest that screening of BRCA1/2 rearrangements is not advantageous in MBC cases not belonging to high-risk breast cancer families and that common CHEK2 mutations play an irrelevant role in MBC predisposition in Italy.",A,CHEK2,CHEK2,0.383333333
1747,bc_id1800,CANCER,BRCA1,17680524,B,[5589del8: the recurrent mutation of BRCA1 gene in Chinese breast cancer patients],2007,,Three cases were found with BRCA1 5589del8 mutation out of 247 hereditary-predisposing breast cancer patients (70 patients in previous study and 177 patients in current study) and 2 cases with BRCA1 5589del8 mutation out of 426 sporadic breast cancer patients.,A,BRCA1,BRCA1,0.60944206
1748,bc_id1801,CANCER,ERCC4,17682675,B,[Polymorphisms in XRCC1 and ERCC4/XPF DNA repair genes and associations with breast cancer risk in women],2007,,The results suggest that the Arg194Trp andArg399Gln polymorphism of XRCC1 gene as well as Arg415Gln polymorphism in ERCC4/XPF may not be linked with appearance and development of breast cancer.,A,ERCC4/XPF,ERCC4,0.5
1749,bc_id1802,CANCER,XRCC1,17682675,B,[Polymorphisms in XRCC1 and ERCC4/XPF DNA repair genes and associations with breast cancer risk in women],2007,,The results suggest that the Arg194Trp andArg399Gln polymorphism of XRCC1 gene as well as Arg415Gln polymorphism in ERCC4/XPF may not be linked with appearance and development of breast cancer.,A,XRCC1,XRCC1,0.543478261
1750,bc_id1803,CANCER,ATP1B2,17683073,B,"Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer.",2007,", this comprehensive evaluation of common genetic variation in TP53 and its flanking genes found no significant overall associations between SNPs in TP53 and breast cancer risk.","We investigated the association of common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, with risk for breast cancer... In conclusion, this comprehensive evaluation of common genetic variation in TP53 and its flanking genes found no significant overall associations between SNPs in TP53 and breast cancer risk.",N,ATP1B2,ATP1B2,1
1751,bc_id1804,CANCER,WDR79,17683073,B,"Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer.",2007,", this comprehensive evaluation of common genetic variation in TP53 and its flanking genes found no significant overall associations between SNPs in TP53 and breast cancer risk.","In conclusion, this comprehensive evaluation of common genetic variation in TP53 and its flanking genes found no significant overall associations between SNPs in TP53 and breast cancer risk. However, data suggested that common variation in TP53 or WDR79 could be associated with ER negative breast cancers.",A,WDR79,WDR79,1
1752,bc_id1805,CANCER,TP53,17683073,B,"Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer.",2007,", this comprehensive evaluation of common genetic variation in TP53 and its flanking genes found no significant overall associations between SNPs in TP53 and breast cancer risk.","In conclusion, this comprehensive evaluation of common genetic variation in TP53 and its flanking genes found no significant overall associations between SNPs in TP53 and breast cancer risk. However, data suggested that common variation in TP53 or WDR79 could be associated with ER negative breast cancers.",A,TP53,TP53,0.482758621
1753,bc_id1806,CANCER,GSTT1,17683074,B,"Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer.",2008,,X,X,X,X,0
1754,bc_id1807,CANCER,GSTP1,17683074,B,"Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer.",2008,,X,X,X,X,0
1755,bc_id1808,CANCER,GSTM1,17683074,B,"Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer.",2008,,X,X,X,X,0
1756,bc_id1809,CANCER,TP53,17683074,B,"Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer.",2008,,"We analyzed polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and p53 mutations in 323 breast tumor samples... Our results suggest that gene-smoking and gene-gene interactions may impact the prevalence of p53 mutations in breast tumors.",A,p53,TP53,0.482758621
1757,bc_id1810,CANCER,BRCA2,17686308,B,[Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers],2007,"Mutations in BRCA1 may play an important role in evaluation of sick risk, earlier diagnosis and gene therapy of breast cancer in southern Chinese populations.","No mutation was detected in the BRCA2 and controls... Mutations in BRCA1 may play an important role in evaluation of sick risk, earlier diagnosis and gene therapy of breast cancer in southern Chinese populations.",N,BRCA2,BRCA2,0.098901099
1758,bc_id1811,CANCER,BRCA1,17686308,B,[Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers],2007,"Mutations in BRCA1 may play an important role in evaluation of sick risk, earlier diagnosis and gene therapy of breast cancer in southern Chinese populations.","No mutation was detected in the BRCA2 and controls... Mutations in BRCA1 may play an important role in evaluation of sick risk, earlier diagnosis and gene therapy of breast cancer in southern Chinese populations.",A,BRCA1,BRCA1,0.60944206
1759,bc_id1812,CANCER,ERBB2,17687647,B,ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study.,2008,,"In a serious of biochemical analyses, we found that the Ile655Val substitution did not alter ErbB2 and its downstream signaling molecule activity. These study results suggest that Ile655Val polymorphism of the ERBB2 gene do not alter its activity and may not be associated with increased breast cancer risk among Chinese women.",A,ERBB2,ERBB2,0.452380952
1760,bc_id1813,CANCER,LHCGR,17692113,B,GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients.,2008,the LHR insLQ and GnRH 16Ser alleles are independently associated with shorter DFS in premenopausal patients.,"We conclude that the LHR insLQ and GnRH 16Ser alleles are independently associated with shorter DFS in premenopausal patients. When validated, these findings may provide a lead in the development of tailored treatment for breast cancer patients carrying both polymorphisms.",A,LHR,LHCGR,0.666666667
1761,bc_id1814,CANCER,GNRH1,17692113,B,GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients.,2008,the LHR insLQ and GnRH 16Ser alleles are independently associated with shorter DFS in premenopausal patients.,"We conclude that the LHR insLQ and GnRH 16Ser alleles are independently associated with shorter DFS in premenopausal patients. When validated, these findings may provide a lead in the development of tailored treatment for breast cancer patients carrying both polymorphisms.",A,GnRH,GNRH1,0.5
1762,bc_id1815,CANCER,GSTT1,17693660,B,"Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk.",2007,", we found associations between specific combinations of three GST gene polymorphisms and breast cancer risk but these did not modify the association between cruciferous vegetable intake and breast cancer.",X,X,X,X,0
1763,bc_id1816,CANCER,GSTP1,17693660,B,"Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk.",2007,", we found associations between specific combinations of three GST gene polymorphisms and breast cancer risk but these did not modify the association between cruciferous vegetable intake and breast cancer.",X,X,X,X,0
1764,bc_id1817,CANCER,GSTM1,17693660,B,"Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk.",2007,", we found associations between specific combinations of three GST gene polymorphisms and breast cancer risk but these did not modify the association between cruciferous vegetable intake and breast cancer.",X,X,X,X,0
1765,bc_id1818,CANCER,GSTP1,17696741,B,"Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India.",2008,,"A nonsignificant elevation in breast cancer risk was observed among women who had the GSTM1 Null genotype (OR=1.24; 95% CI=0.83-1.84), the p53 Arg/Arg genotype (OR=1.28; 95% CI=0.81-2.03) and the Pro/Arg genotype (OR=1.49; 95% CI=0.99-2.25), and the GSTP1 Val/Val genotype (OR=1.1; 95% CI=0.64-1.91).",Y,GSTP1,GSTP1,0.428571429
1766,bc_id1819,CANCER,GSTM1,17696741,B,"Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India.",2008,,"A nonsignificant elevation in breast cancer risk was observed among women who had the GSTM1 Null genotype (OR=1.24; 95% CI=0.83-1.84), the p53 Arg/Arg genotype (OR=1.28; 95% CI=0.81-2.03) and the Pro/Arg genotype (OR=1.49; 95% CI=0.99-2.25), and the GSTP1 Val/Val genotype (OR=1.1; 95% CI=0.64-1.91).",Y,GSTM1,GSTM1,0.452830189
1767,bc_id1820,CANCER,TP53,17696741,B,"Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India.",2008,,"A nonsignificant elevation in breast cancer risk was observed among women who had the GSTM1 Null genotype (OR=1.24; 95% CI=0.83-1.84), the p53 Arg/Arg genotype (OR=1.28; 95% CI=0.81-2.03) and the Pro/Arg genotype (OR=1.49; 95% CI=0.99-2.25), and the GSTP1 Val/Val genotype (OR=1.1; 95% CI=0.64-1.91).",Y,p53,TP53,0.367816092
1768,bc_id1821,CANCER,XRCC3,17701750,B,The XRCC3 Thr241Met polymorphism and breast cancer risk: a case-control study in a Thai population.,2007,,Our findings suggest that the XRCC3 Thr241Met polymorphism is likely to play a modifying role in the individual susceptibility to breast cancer among Thai women as already shown for women of European ancestry.,A,XRCC3,XRCC3,0.461538462
1769,bc_id1822,CANCER,CHEK2,17705858,B,CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer.,2007,"In conclusion, CHEK2 1100delC exists in the Swedish population.","In conclusion, CHEK2 1100delC exists in the Swedish population. The prevalence is increased in familial breast cancer and the variant seems to influence age at onset.",A,CHEK2 1100delC,CHEK2,0.383333333
1770,bc_id1823,CANCER,LHCGR,17709176,B,Polymorphic variations in exon 10 of the luteinizing hormone receptor: functional consequences and associations with breast cancer.,2007,", although functional changes of the LHR 291Ser candidate allele were observed, no associations with breast cancer were found, while the LHR 312Asn allele can be regarded as a weak breast cancer risk allele.","In conclusion, although functional changes of the LHR 291Ser candidate allele were observed, no associations with breast cancer were found, while the LHR 312Asn allele can be regarded as a weak breast cancer risk allele.",A,LHR,LHCGR,0.666666667
1771,bc_id1824,CANCER,MDM2,17719241,B,Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women.,2008,,The results indicate protective associations of p53 Arg72Pro heterozygous variant with postmenopausal and MDM-2 SNP309G along with p53 Arg72Pro heterozygous variant with premenopausal breast cancer risk.,Y,MDM-2,MDM2,0.111111111
1772,bc_id1825,CANCER,TP53,17719241,B,Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women.,2008,,The results indicate protective associations of p53 Arg72Pro heterozygous variant with postmenopausal and MDM-2 SNP309G along with p53 Arg72Pro heterozygous variant with premenopausal breast cancer risk.,Y,p53,TP53,0.367816092
1773,bc_id1826,CANCER,NOS3,17726138,B,"Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer.",2007,,"A significant dose trend (P trend = 0.04), however, was observed for total number of putative ""at-risk"" alleles (Nrf T, NQO1 T, NOS T, and HO-1 LL and LM genotypes), with those carrying three or more at-risk alleles having an odds ratio (OR) of 1.56 [95% confidence interval (95% CI), 0.97-2.51] compared with those having none... These results indicate that women with genotypes resulting in potentially higher levels of iron-generated oxidative stress may be at increased risk of breast cancer and that this association may be most relevant among women with high iron intake.",A,NOS,NOS3,0.461538462
1774,bc_id1827,CANCER,NFE2L2,17726138,B,"Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer.",2007,,"A significant dose trend (P trend = 0.04), however, was observed for total number of putative ""at-risk"" alleles (Nrf T, NQO1 T, NOS T, and HO-1 LL and LM genotypes), with those carrying three or more at-risk alleles having an odds ratio (OR) of 1.56 [95% confidence interval (95% CI), 0.97-2.51] compared with those having none... These results indicate that women with genotypes resulting in potentially higher levels of iron-generated oxidative stress may be at increased risk of breast cancer and that this association may be most relevant among women with high iron intake.",A,NrF,NFE2L2,1
1775,bc_id1828,CANCER,HMOX1,17726138,B,"Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer.",2007,,"A significant dose trend (P trend = 0.04), however, was observed for total number of putative ""at-risk"" alleles (Nrf T, NQO1 T, NOS T, and HO-1 LL and LM genotypes), with those carrying three or more at-risk alleles having an odds ratio (OR) of 1.56 [95% confidence interval (95% CI), 0.97-2.51] compared with those having none... These results indicate that women with genotypes resulting in potentially higher levels of iron-generated oxidative stress may be at increased risk of breast cancer and that this association may be most relevant among women with high iron intake.",A,HO-1,HMOX1,1
1776,bc_id1829,CANCER,NQO1,17726138,B,"Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer.",2007,,"A significant dose trend (P trend = 0.04), however, was observed for total number of putative ""at-risk"" alleles (Nrf T, NQO1 T, NOS T, and HO-1 LL and LM genotypes), with those carrying three or more at-risk alleles having an odds ratio (OR) of 1.56 [95% confidence interval (95% CI), 0.97-2.51] compared with those having none... These results indicate that women with genotypes resulting in potentially higher levels of iron-generated oxidative stress may be at increased risk of breast cancer and that this association may be most relevant among women with high iron intake.",A,NQO1,NQO1,0.25
1777,bc_id1830,CANCER,AR,17728127,B,Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene.,2007,,"In conclusion, our results indicate that longer CAG(n)/GGN(n) combinations increase the risk of BC and suggest that CAG and GGN AR polymorphisms should be considered in order to assess the BC risk.",Y,AR,AR,0.291666667
1778,bc_id1831,CANCER,NR1I2,17761971,B,Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.,2007,,X,X,X,X,0
1779,bc_id1832,CANCER,CYP2D6,17761971,B,Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.,2007,,"Plasma concentrations of tamoxifen and its metabolites were measured. Common alleles of CYP2D6 and PXR were identified in 202 patients treated with tamoxifen 20 mg daily for more than 8 weeks....CYP2D6*10/*10 is associated with lower steady-state plasma concentrations of active tamoxifen metabolites, which could possibly influence the clinical outcome by tamoxifen in Asian breast cancer patients.",A,CYP2D6*10/*10,CYP2D6,0.590909091
1780,bc_id1833,CANCER,PRKDC,17764108,B,"Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists.",2008,,"In multivariable analyses, WRN V114I (rs2230009) significantly modified the association between cumulative occupational breast dose and risk of breast cancer (adjusted for personal diagnostic exposure) (p = 0.04) and BRCA1 D652N (rs4986850), PRKDC IVS15 + 6C > T (rs1231202), PRKDC IVS34 + 39T > C (rs8178097) and PRKDC IVS31 - 634C > A (rs10109984) significantly altered the personal diagnostic radiation exposure-response relationship (adjusted for occupational dose) (p < or = 0.05).",A,PRKDC,PRKDC,1
1781,bc_id1834,CANCER,WRN,17764108,B,"Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists.",2008,,"In multivariable analyses, WRN V114I (rs2230009) significantly modified the association between cumulative occupational breast dose and risk of breast cancer (adjusted for personal diagnostic exposure) (p = 0.04) and BRCA1 D652N (rs4986850), PRKDC IVS15 + 6C > T (rs1231202), PRKDC IVS34 + 39T > C (rs8178097) and PRKDC IVS31 - 634C > A (rs10109984) significantly altered the personal diagnostic radiation exposure-response relationship (adjusted for occupational dose) (p < or = 0.05).",A,WRN,WRN,0.333333333
1782,bc_id1835,CANCER,BRCA1,17764108,B,"Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists.",2008,,"In multivariable analyses, WRN V114I (rs2230009) significantly modified the association between cumulative occupational breast dose and risk of breast cancer (adjusted for personal diagnostic exposure) (p = 0.04) and BRCA1 D652N (rs4986850), PRKDC IVS15 + 6C > T (rs1231202), PRKDC IVS34 + 39T > C (rs8178097) and PRKDC IVS31 - 634C > A (rs10109984) significantly altered the personal diagnostic radiation exposure-response relationship (adjusted for occupational dose) (p < or = 0.05).",A,BRCA1,BRCA1,0.60944206
1783,bc_id1836,CANCER,BRCA2,17767707,B,"Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.",2007,"Overall, our findings, although based on a relatively small series, suggest that the BRCA2 HH homozygous genotype might be positively associated with an increased risk of MBC in men younger than 60 years.","To evaluate the genotype specific risk of the BRCA2 N372H variant, MBC carriers of germ-line BRCA1/2 mutations were excluded from the analyses... Overall, our findings, although based on a relatively small series, suggest that the BRCA2 HH homozygous genotype might be positively associated with an increased risk of MBC in men younger than 60 years.",A,BRCA2,BRCA2,0.576923077
1784,bc_id1837,CANCER,BRCA1,17767707,B,"Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.",2007,"Overall, our findings, although based on a relatively small series, suggest that the BRCA2 HH homozygous genotype might be positively associated with an increased risk of MBC in men younger than 60 years.",X,X,X,X,0
1785,bc_id1838,CANCER,CTLA4,17825114,B,Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population.,2007,,These results suggest that polymorphisms of the CTLA-4 gene may modify individual susceptibility to and progression of breast cancer in Chinese Han women.,A,CTLA-4,CTLA4,0.333333333
1786,bc_id1839,CANCER,CYP3A4,17827444,B,Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.,2007,,"The authors evaluated interactions between CHRT use and progestin metabolism genotypes at CYP3A4 and the progesterone receptor (PGR) and their effects on breast cancer risk using the population-based Women's Insights and Shared Experiences (WISE) Study (1999-2002) of postmenopausal Caucasian women (522 breast cancer cases, 708 controls)... Breast cancer risk in women who have used CHRT may be influenced by genetic factors involved in progestin metabolism.",A,CYP3A4,CYP3A4,0.363636364
1787,bc_id1840,CANCER,TGFBR1,17848193,B,TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses Health Study.,2008,Polymorphisms in the promoter region of TGFB1 are not likely to be associated with large increases in breast cancer risk overall among Caucasian women.,"No overall associations between the L10P polymorphism of TGFB1 or the TGFBR1 microsatellite were detected. However, we observed an inverse association between the -509 C/T polymorphism of TGFB1 (p-trend = 0.04), which was stronger and more significant among women with estrogen receptor positive breast cancer.",N,TGFBR1,TGFBR1,0.666666667
1788,bc_id1841,CANCER,TGFB1,17848193,B,TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses Health Study.,2008,Polymorphisms in the promoter region of TGFB1 are not likely to be associated with large increases in breast cancer risk overall among Caucasian women.,"No overall associations between the L10P polymorphism of TGFB1 or the TGFBR1 microsatellite were detected. However, we observed an inverse association between the -509 C/T polymorphism of TGFB1 (p-trend = 0.04), which was stronger and more significant among women with estrogen receptor positive breast cancer.",Y,TGFB1,TGFB1,0.185185185
1789,bc_id1842,CANCER,POT1,17848914,B,Genetic variation in five genes important in telomere biology and risk for breast cancer.,2007,", our data do not support substantial overall associations between SNPs in telomere pathway genes and breast cancer risk.","In a population-based study of 1995 breast cancer cases and 2296 controls from Poland, 24 SNPs representing common variation in POT1, TEP1, TERF1, TERF2 and TERT were genotyped... We did not identify any significant associations between individual SNPs or haplotypes and breast cancer risk; however, data suggested that three correlated SNPs in TERT (-1381C>T, -244C>T, and Ex2-659G>A) may be associated with reduced risk of breast cancer among individuals with a family history of breast cancer (odds ratios 0.73, 0.66, and 0.57, 95% confidence intervals 0.53-1.00, 0.46-0.95 and 0.39-0.84, respectively).",N,POT1,POT1,0.666666667
1790,bc_id1843,CANCER,TERT,17848914,B,Genetic variation in five genes important in telomere biology and risk for breast cancer.,2007,", our data do not support substantial overall associations between SNPs in telomere pathway genes and breast cancer risk.","In a population-based study of 1995 breast cancer cases and 2296 controls from Poland, 24 SNPs representing common variation in POT1, TEP1, TERF1, TERF2 and TERT were genotyped... We did not identify any significant associations between individual SNPs or haplotypes and breast cancer risk; however, data suggested that three correlated SNPs in TERT (-1381C>T, -244C>T, and Ex2-659G>A) may be associated with reduced risk of breast cancer among individuals with a family history of breast cancer (odds ratios 0.73, 0.66, and 0.57, 95% confidence intervals 0.53-1.00, 0.46-0.95 and 0.39-0.84, respectively).",N,TERT,TERT,0.5
1791,bc_id1844,CANCER,TERF1,17848914,B,Genetic variation in five genes important in telomere biology and risk for breast cancer.,2007,", our data do not support substantial overall associations between SNPs in telomere pathway genes and breast cancer risk.","In a population-based study of 1995 breast cancer cases and 2296 controls from Poland, 24 SNPs representing common variation in POT1, TEP1, TERF1, TERF2 and TERT were genotyped... We did not identify any significant associations between individual SNPs or haplotypes and breast cancer risk; however, data suggested that three correlated SNPs in TERT (-1381C>T, -244C>T, and Ex2-659G>A) may be associated with reduced risk of breast cancer among individuals with a family history of breast cancer (odds ratios 0.73, 0.66, and 0.57, 95% confidence intervals 0.53-1.00, 0.46-0.95 and 0.39-0.84, respectively).",N,TERF1,TERF1,1
1792,bc_id1845,CANCER,TERF2,17848914,B,Genetic variation in five genes important in telomere biology and risk for breast cancer.,2007,", our data do not support substantial overall associations between SNPs in telomere pathway genes and breast cancer risk.","In a population-based study of 1995 breast cancer cases and 2296 controls from Poland, 24 SNPs representing common variation in POT1, TEP1, TERF1, TERF2 and TERT were genotyped... We did not identify any significant associations between individual SNPs or haplotypes and breast cancer risk; however, data suggested that three correlated SNPs in TERT (-1381C>T, -244C>T, and Ex2-659G>A) may be associated with reduced risk of breast cancer among individuals with a family history of breast cancer (odds ratios 0.73, 0.66, and 0.57, 95% confidence intervals 0.53-1.00, 0.46-0.95 and 0.39-0.84, respectively).",N,TERF2,TERF2,1
1793,bc_id1846,CANCER,TEP1,17848914,B,Genetic variation in five genes important in telomere biology and risk for breast cancer.,2007,", our data do not support substantial overall associations between SNPs in telomere pathway genes and breast cancer risk.","In a population-based study of 1995 breast cancer cases and 2296 controls from Poland, 24 SNPs representing common variation in POT1, TEP1, TERF1, TERF2 and TERT were genotyped... We did not identify any significant associations between individual SNPs or haplotypes and breast cancer risk; however, data suggested that three correlated SNPs in TERT (-1381C>T, -244C>T, and Ex2-659G>A) may be associated with reduced risk of breast cancer among individuals with a family history of breast cancer (odds ratios 0.73, 0.66, and 0.57, 95% confidence intervals 0.53-1.00, 0.46-0.95 and 0.39-0.84, respectively).",N,TEP1,TEP1,1
1794,bc_id1847,CANCER,TGFBR1,17848956,B,TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.,2007,,"Two common variants in transforming growth factor-beta receptor 1 (TGFBR1), TGFBR1(*)6A and Int7G24A, A allele, have been shown to act as low-penetrance tumour susceptibility alleles in several common cancers, including breast cancer.",Y,TGFBR1,TGFBR1,0.166666667
1795,bc_id1848,CANCER,ACE,17850737,B,Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with breast cancer and effects on prognostic factors.,2007,,"The aims of the present study were to investigate the distribution of the insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene in breast cancer patients and the association between ACE genotypes and clinicopathologic features, as well as their effects on prognosis... These results suggest that the DD genotype may accompany poor prognostic factors and influence the tumor course.",A,ACE,ACE,0.571428571
1796,bc_id1849,CANCER,MMP2,17851253,B,Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population.,2008,,"The data suggest that MMP-2 -1306C>T polymorphism strongly contributes to the development of BC in the population studied, especially among women 50 years old and younger.",Y,MMP-2,MMP2,0.5
1797,bc_id1850,CANCER,H2AFX,17851762,B,Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged &lt;or=55 years.,2008,,"We found that significantly increased risk of breast cancer was associated with variant genotypes in the H2AFX promoter: adjusted odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.38-2.34 for -1654AG/GG; OR = 1.40, 95% CI = 1.07-1.83 for -1420GA/AA; and OR = 1.65, 95% CI = 1.26-2.16 for -1187TC/CC. Furthermore, the number of variant alleles in the promoter haplotypes was associated with increased risks of breast cancer in a dose-response manner (OR = 6.08, 95% CI = 3.25-11.38; OR = 6.83, 95% CI = 3.83-12.18; and OR = 23.61, 95% CI = 3.95-140.99 for one, two, and three variant alleles, respectively) (P (trend) \ < 0.0001).",Y,H2AFX,H2AFX,0.5
1798,bc_id1851,CANCER,BRCA2,17851763,B,The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.,2008,,"We recommended the BRCA1 and BRCA2 genetic analysis could be done for high-risk breast cancer patient in Chinese population, especially for those with both early-onset breast cancer and affected relatives.",A,BRCA2,BRCA2,0.576923077
1799,bc_id1852,CANCER,BRCA1,17851763,B,The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.,2008,,"We recommended the BRCA1 and BRCA2 genetic analysis could be done for high-risk breast cancer patient in Chinese population, especially for those with both early-onset breast cancer and affected relatives.",A,BRCA1,BRCA1,0.60944206
1800,bc_id1853,CANCER,AR,17855696,B,Associations between androgen and Vitamin D receptor microsatellites and postmenopausal breast cancer.,2007,,"Our data do not support major roles for AR or VDR polymorphism as breast cancer risk factors. However, we did find an interaction between VDR genotype and parity that remains to be corroborated.",N,AR,AR,0.25
1801,bc_id1854,CANCER,VDR,17855696,B,Associations between androgen and Vitamin D receptor microsatellites and postmenopausal breast cancer.,2007,,"Our data do not support major roles for AR or VDR polymorphism as breast cancer risk factors. However, we did find an interaction between VDR genotype and parity that remains to be corroborated.",A,VDR,VDR,0.538461538
1802,bc_id1856,CANCER,RAD51,17889711,B,RAD51 135G&gt;C polymorphism and risk of familial breast cancer in a South American population.,2007,,"Thus, we propose that RAD51 135G>C polymorphism presents an increased risk of familial BC in women with age < 50 years at diagnosis, and this polymorphism may be a BC risk variant. This finding should be confirmed in other populations.",Y,RAD51,RAD51,0.230769231
1803,bc_id1857,CANCER,VEGFA,17891484,B,Association of polymorphisms of angiogenesis genes with breast cancer.,2008,,There is an association of the VEGF-2578A and -1498C alleles with increased breast cancer risk. This association remains significant when adjusted for Gail score-related risk factors.,Y,VEGF-2578A,VEGFA,0.25
1804,bc_id1858,CANCER,CASP8,17891485,B,The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study.,2008,,The present result indicates that the CASP8 -652 6N del variant has no significant effect on BC risk in Europeans.,N,CASP8,CASP8,0.071428571
1805,bc_id1859,CANCER,SHMT1,17896178,B,"Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan.",2008,", our study provides support to account for the preferential role of cSHMT polymorphism to lower risk of female breast cancer, and such reduced risk would be more significant in carriers with the polymorphisms of MS and MTHFR genes.","In conclusion, our study provides support to account for the preferential role of cSHMT polymorphism to lower risk of female breast cancer, and such reduced risk would be more significant in carriers with the polymorphisms of MS and MTHFR genes.",Y,cSHMT,SHMT1,0.2
1806,bc_id1860,CANCER,NBN,17899368,B,I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer.,2008,is that heterozygous germline mutation I171V in NBS1 gene is a significant risk factor for breast cancer development.,"The treatment's results however were unexpectedly satisfactory, that is why further investigations are necessary to assess the role of I171V mutation in NBS1 gene as a prognostic and predictive factor for breast cancer.",A,NBS1,NBN,0.571428571
1807,bc_id1861,CANCER,AR,17904846,B,"Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer.",2008,", an association for breast cancer risk between short (SS) alleles for the repeat variants of the ESR2 and AR genes was found in women of Greek descent.","In conclusion, an association for breast cancer risk between short (SS) alleles for the repeat variants of the ESR2 and AR genes was found in women of Greek descent.",Y,AR,AR,0.291666667
1808,bc_id1862,CANCER,ESR2,17904846,B,"Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer.",2008,", an association for breast cancer risk between short (SS) alleles for the repeat variants of the ESR2 and AR genes was found in women of Greek descent.","In conclusion, an association for breast cancer risk between short (SS) alleles for the repeat variants of the ESR2 and AR genes was found in women of Greek descent.",Y,ESR2,ESR2,0.333333333
1809,bc_id1863,CANCER,ESR1,17904846,B,"Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer.",2008,", an association for breast cancer risk between short (SS) alleles for the repeat variants of the ESR2 and AR genes was found in women of Greek descent.","To determine the possible contribution of genetic variation in the ESR1 (ER-alpha), ESR2 (ER-beta) and AR genes in breast cancer risk the -1174(TA)(7-27), c. 1092+3607(CA)(10-26) and c. 172(CAG)(6-40) repeat variants were studied in a case-control study of 79 women with sporadic breast cancer and 155 controls. No significant difference was observed in the frequency distribution of -1174(TA)(7-27) in the ESR1 gene between patients and controls, while a significant difference was observed for repeat polymorphisms c. 1092+3607(CA)(10-26) in the ESR2 gene and c. 172(CAG)(6-40) in the AR gene (p0.0001). ",N,ESR1,ESR1,0.130434783
1810,bc_id1864,CANCER,BCL2,17908970,B,The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C&gt;A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.,2007,,Immunohistochemical Bcl-2 expression was significantly associated with the clinical outcome of lymph node-positive but not of lymph node-negative breast cancer patients.,A,Bcl-2,BCL2,1
1811,bc_id1865,CANCER,MDM2,17909070,B,Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.,2007,", in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.","In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.",N,MDM2,MDM2,0.444444444
1812,bc_id1866,CANCER,TP53,17909070,B,Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.,2007,", in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.","In conclusion, in this large collaborative study, we did not find an association of MDM2 SNP309 and TP53 R72P, separately or in interaction, with breast cancer.",N,TP53,TP53,0.149425287
1813,bc_id1867,CANCER,UGT1A1,17909964,B,Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans.,2008,,"In contrast with previous studies, we found low-activity TA repeat alleles were protective against breast cancer among premenopausal indigenous Africans, suggesting that the role of UGT1A1 in breast cancer development may vary by population, presumably due to different environmental and genetic modifier effects.",A,UGT1A1,UGT1A1,0.7
1814,bc_id1868,CANCER,ERBB2,17918664,B,Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.,2007,,Alterations of c-erbB-2 (neu or HER-2) proto-oncogene have been associated with carcinogenesis and poor prognosis of breast cancer.,Y,HER-2,ERBB2,0.285714286
1815,bc_id1869,CANCER,OGG1,17922186,B,Polymorphisms in three base excision repair genes and breast cancer risk in Thai women.,2008,", our data suggest that Thai women with a certain XRCC1 diplotype or homozygous for two or three variant alleles of XRCC1, OGG1, and APEX1 are likely to have an increased susceptibility to breast cancer.","In conclusion, our data suggest that Thai women with a certain XRCC1 diplotype or homozygous for two or three variant alleles of XRCC1, OGG1, and APEX1 are likely to have an increased susceptibility to breast cancer.",Y,OGG1,OGG1,0.222222222
1816,bc_id1870,CANCER,APEX1,17922186,B,Polymorphisms in three base excision repair genes and breast cancer risk in Thai women.,2008,", our data suggest that Thai women with a certain XRCC1 diplotype or homozygous for two or three variant alleles of XRCC1, OGG1, and APEX1 are likely to have an increased susceptibility to breast cancer.","In conclusion, our data suggest that Thai women with a certain XRCC1 diplotype or homozygous for two or three variant alleles of XRCC1, OGG1, and APEX1 are likely to have an increased susceptibility to breast cancer.",Y,APEX1,APEX1,0.166666667
1817,bc_id1871,CANCER,XRCC1,17922186,B,Polymorphisms in three base excision repair genes and breast cancer risk in Thai women.,2008,", our data suggest that Thai women with a certain XRCC1 diplotype or homozygous for two or three variant alleles of XRCC1, OGG1, and APEX1 are likely to have an increased susceptibility to breast cancer.","In conclusion, our data suggest that Thai women with a certain XRCC1 diplotype or homozygous for two or three variant alleles of XRCC1, OGG1, and APEX1 are likely to have an increased susceptibility to breast cancer.",Y,XRCC1,XRCC1,0.239130435
1818,bc_id1872,CANCER,CYP1B1,17922187,B,The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer.,2008,,We conclude that the CYP1B1_1358_A>G polymorphism has an impact on ERalpha status in breast cancer in that the CYP1B1_1358_GG genotype known to encode higher CYP1B1 activity is associated with ERalpha negativity.,Y,CYP1B1,CYP1B1,0.358974359
1819,bc_id1873,CANCER,MPO,17922231,B,"Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer.",2008,,"SNPs in the SOD2 (SOD2-01, Val16Ala), MPO (MPO-02, -463 promoter variant) and GSTP1 [GSTP1-01 (Ile105Val), GSTP1-02 (Ala114Val)] genes were examined in DNA isolated from cryopreserved blood products using genotyping assays... These results suggest that SNPs in genes involved in drug metabolism may influence survival outcome for patients with MBC receiving HDC and ASCT.",A,MPO,MPO,0.571428571
1820,bc_id1874,CANCER,GSTP1,17922231,B,"Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer.",2008,,"SNPs in the SOD2 (SOD2-01, Val16Ala), MPO (MPO-02, -463 promoter variant) and GSTP1 [GSTP1-01 (Ile105Val), GSTP1-02 (Ala114Val)] genes were examined in DNA isolated from cryopreserved blood products using genotyping assays... These results suggest that SNPs in genes involved in drug metabolism may influence survival outcome for patients with MBC receiving HDC and ASCT.",A,GSTP1,GSTP1,0.485714286
1821,bc_id1875,CANCER,SOD2,17922231,B,"Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer.",2008,,"SNPs in the SOD2 (SOD2-01, Val16Ala), MPO (MPO-02, -463 promoter variant) and GSTP1 [GSTP1-01 (Ile105Val), GSTP1-02 (Ala114Val)] genes were examined in DNA isolated from cryopreserved blood products using genotyping assays... These results suggest that SNPs in genes involved in drug metabolism may influence survival outcome for patients with MBC receiving HDC and ASCT.",A,SOD2,SOD2,0.375
1822,bc_id1876,CANCER,BRCA1,17922413,B,[BRCA1 germ line mutations in Chinese early-onset breast cancer patients],2007,,"It seems reasonable to give genetic consultations and genetic test of BRCA1 gene to early-onset breast cancer patients in China, especially for those with breast/ovarian cancer family history.",A,BRCA1,BRCA1,0.60944206
1823,bc_id1878,CANCER,IL1A,17932347,B,"Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists.",2007,,X,X,X,X,0
1824,bc_id1879,CANCER,CASP8,17932347,B,"Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists.",2007,,X,X,X,X,0
1825,bc_id1880,CANCER,RAD50,17932350,B,Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.,2007,,X,X,X,X,0
1826,bc_id1881,CANCER,NBN,17932350,B,Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.,2007,,X,X,X,X,0
1827,bc_id1882,CANCER,MRE11A,17932350,B,Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.,2007,,X,X,X,X,0
1828,bc_id1883,CANCER,ERCC5,17932351,B,"Polymorphisms in nucleotide excision repair genes, polycyclic aromatic hydrocarbon-DNA adducts, and breast cancer risk.",2007,,X,X,X,X,0
1829,bc_id1884,CANCER,ERCC2,17932351,B,"Polymorphisms in nucleotide excision repair genes, polycyclic aromatic hydrocarbon-DNA adducts, and breast cancer risk.",2007,,"We examined polymorphisms in ERCC1 (3'-untranslated region 8092C/A), XPA (5'-untranslated region -4G/A), XPD (Asp(312)Asn in exon 10), XPF (Arg(415)Gln in exon 8), and XPG (Asp(1104)His in exon 15) in 1,053 breast cancer cases and 1,102 population-based controls. The presence of at least one variant allele in XPD was associated with a 25% increase in the odds ratio [OR, 1.25; 95% confidence interval (95% CI), 1.04-1.50] for breast cancer... We found no association between XPA, XPF, and XPG genotypes, PAH-DNA adducts, and breast cancer risk.",A,XPD,ERCC2,0.6875
1830,bc_id1885,CANCER,ERCC1,17932351,B,"Polymorphisms in nucleotide excision repair genes, polycyclic aromatic hydrocarbon-DNA adducts, and breast cancer risk.",2007,,X,X,X,X,0
1831,bc_id1886,CANCER,XPA,17932351,B,"Polymorphisms in nucleotide excision repair genes, polycyclic aromatic hydrocarbon-DNA adducts, and breast cancer risk.",2007,,"We found no association between XPA, XPF, and XPG genotypes, PAH-DNA adducts, and breast cancer risk.",N,XPA,XPA,1
1832,bc_id1887,CANCER,VDR,17934201,B,"Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population.",2007,,No associations were found for women with medium or dark pigmentation. Localized breast cancer was not associated with sun exposure or VDR genotype.,N,VDR,VDR,0.192307692
1833,bc_id1888,CANCER,ESR2,17935138,B,Haplotypes of the estrogen receptor beta gene and breast cancer risk.,2008,,These data suggest that inherited variants in ESR2 (while possibly conferring a small increased risk of breast cancer) are not associated with appreciable (OR > 1.2) changes in breast cancer risk among Caucasian women.,N,ESR2,ESR2,0.133333333
1834,bc_id1889,CANCER,XRCC1,17935911,B,Menopausal age and XRCC1 gene polymorphisms: role in breast cancer risk.,2008,Our results suggest that menopausal age together with Arg194Trp and Arg399Gln XRCC1 gene polymorphisms might be involved in individual susceptibility to breast cancer.,Our results suggest that menopausal age together with Arg194Trp and Arg399Gln XRCC1 gene polymorphisms might be involved in individual susceptibility to breast cancer.,A,XRCC1,XRCC1,0.543478261
1835,bc_id1890,CANCER,PTEN,17936563,B,A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.,2007,,"Oncogenic mutants of PIK3CA (activator of the same pathway and frequently mutated in breast cancer) also conferred resistance to trastuzumab in cell culture. In a cohort of 55 breast cancer patients, activation of the PI3K pathway, as judged by the presence of oncogenic PIK3CA mutations or low PTEN expression, was associated with poor prognosis after trastuzumab therapy, and the combined analysis of PTEN and PIK3CA identified twice as many patients at increased risk for progression compared to PTEN alone.",A,PTEN,PTEN,0.666666667
1836,bc_id1891,CANCER,PIK3CA,17936563,B,A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.,2007,,"Oncogenic mutants of PIK3CA (activator of the same pathway and frequently mutated in breast cancer) also conferred resistance to trastuzumab in cell culture. In a cohort of 55 breast cancer patients, activation of the PI3K pathway, as judged by the presence of oncogenic PIK3CA mutations or low PTEN expression, was associated with poor prognosis after trastuzumab therapy, and the combined analysis of PTEN and PIK3CA identified twice as many patients at increased risk for progression compared to PTEN alone.",A,PIK3CA,PIK3CA,0.466666667
1837,bc_id1892,CANCER,EGF,17940864,B,"EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women.",2008,,These findings indicated that plasma EGF levels served as a protective marker against breast cancer in our study and EGF G-1380A variant might be a modifier on it. Further studies are warranted to verify these findings.,A,EGF,EGF,0.333333333
1838,bc_id1893,CANCER,CASP8,17940865,B,"CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk.",2008,,Our results thus suggest that the CASP8 5'-UTR C > T are associated with breast cancer risks and the effect may be modified by estrogen and progesterone receptor status.,Y,CASP8,CASP8,0.642857143
1839,bc_id1894,CANCER,BRCA2,17945002,B,Implication of BRCA2 -26G&gt;A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg&gt;Pro polymorphism.,2008,,"Our study shows that -26 5' UTR polymorphism in BRCA2 can modulate the fine-tuned regulation of the multifunctional gene BRCA2 and renders risk or protection according to the genotype status in the sporadic form of breast cancer, which is further influenced by the germline genetic backgrounds of codon 72 polymorphism of p53.",A,BRCA2,BRCA2,0.576923077
1840,bc_id1895,CANCER,IL8RB,17949231,B,Association of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer.,2008,,"In conclusion, IL-8 -251T/A polymorphism is associated with development of invasive ductal carcinoma type of breast cancer while CXCR2 +1208C/T polymorphism may affect the disease progression.",Y,IL-8,IL8RB,1
1841,bc_id1896,CANCER,IL8,17949231,B,Association of interleukin-8 (IL-8 or CXCL8) -251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer.,2008,,"In conclusion, IL-8 -251T/A polymorphism is associated with development of invasive ductal carcinoma type of breast cancer while CXCR2 +1208C/T polymorphism may affect the disease progression.",Y,IL-8,IL8,0.4
1842,bc_id1897,CANCER,UGT1A1,17949292,B,Genetic polymorphisms in the UGT1A1 gene and breast cancer risk in Greek women.,2008,,"The polymorphism A(TA)nTAA in the promoter region of UGT1A1 gene was studied using the Fragment Analysis Software of an automated DNA sequencer and three genotypes (homozygous 7/7, heterozygous 6/7, and normal homozygous 6/6) were identified. No significant associations were observed between the 7/7 genotype and breast cancer risk, indicating that further studies in Caucasian women are needed to elucidate the role of UGT1A1 polymorphism in breast cancer risk.",N,UGT1A1,UGT1A1,0.2
1843,bc_id1898,CANCER,BRCA2,17952592,B,"Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.",2008,,X,X,X,X,0
1844,bc_id1899,CANCER,BRCA1,17952592,B,"Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.",2008,,X,X,X,X,0
1845,bc_id1900,CANCER,NBN,17957789,B,Nijmegen Breakage Syndrome mutations and risk of breast cancer.,2008,,The combined data are in line with an about 3-fold increase in breast cancer risk for female NBS heterozygotes (OR 3.1; 95%CI 1.4-6.6) and indicate that the 657del5 deletion and perhaps the R215W substitution contribute to inherited breast cancer susceptibility in Central and Eastern Europe.,A,NBS,NBN,0.571428571
1846,bc_id1901,CANCER,FASLG,17962219,B,Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk.,2007,,"In addition, lactation history significantly modified the association between FAS1377 and FAS670 genetic variants and breast cancer risk (OR = 1.46, 95% CI = 1.04-2.06 and OR = 1.71, 95% CI = 1.13-1.58, respectively, in those who ever lactated compared with those who did not with the wild-type alleles). Overall, this study suggests that the risk of breast cancer may be elevated among women with polymorphisms in the FAS gene and detectable PAH-DNA adducts.",A,FAS,FASLG,0.666666667
1847,bc_id1902,CANCER,FAS,17962219,B,Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk.,2007,,"In addition, lactation history significantly modified the association between FAS1377 and FAS670 genetic variants and breast cancer risk (OR = 1.46, 95% CI = 1.04-2.06 and OR = 1.71, 95% CI = 1.13-1.58, respectively, in those who ever lactated compared with those who did not with the wild-type alleles). Overall, this study suggests that the risk of breast cancer may be elevated among women with polymorphisms in the FAS gene and detectable PAH-DNA adducts.",A,FAS,FAS,0.75
1848,bc_id1903,CANCER,TGFB1,17965799,B,Association of breast cancer and cytokine gene polymorphism in Turkish women.,2007,,"The distribution of IFN-gamma +874, TNF-alpha 308, and TGF-beta1 codon 10-25 genotypes failed to show any statistical significant association with the development of breast cancer.",N,TGF-beta1,TGFB1,0.296296296
1849,bc_id1904,CANCER,BARD1,17972171,B,BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.,2008,,"In addition, three variants previously reported to be pathogenic in other populations are likely to represent benign polymorphisms and therefore we conclude that BARD1 is unlikely to represent a high-penetrance breast cancer susceptibility gene.",N,BARD1,BARD1,0.181818182
1850,bc_id1905,CANCER,BRCA2,17972172,B,Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.,2008,These results indicate that smoking is associated with increased risk of breast cancer before age 50 years in BRCA1 and BRCA2 mutation carriers.,These results indicate that smoking is associated with increased risk of breast cancer before age 50 years in BRCA1 and BRCA2 mutation carriers.,A,BRCA2,BRCA2,0.576923077
1851,bc_id1906,CANCER,BRCA1,17972172,B,Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.,2008,These results indicate that smoking is associated with increased risk of breast cancer before age 50 years in BRCA1 and BRCA2 mutation carriers.,These results indicate that smoking is associated with increased risk of breast cancer before age 50 years in BRCA1 and BRCA2 mutation carriers.,A,BRCA1,BRCA1,0.60944206
1852,bc_id1907,CANCER,MMP8,17974962,B,Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis.,2007,,The data suggest that MMP8 gene variation may influence breast cancer prognosis and support the notion that MMP8 has an inhibitory effect on cancer metastasis.,A,MMP8,MMP8,1
1853,bc_id1908,CANCER,CYP19A1,17975727,B,A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.,2008,,Our results suggest that premenopausal women carrying the G allele at CYP19 rs1008805 have increased risk of breast cancer.,Y,CYP19,CYP19A1,0.333333333
1854,bc_id1909,CANCER,GNB3,17978878,B,A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients.,2008,the homozygous GNB3 825 TT genotype may be protective against development of bone metastasis in breast cancer patients.,We conclude that the homozygous GNB3 825 TT genotype may be protective against development of bone metastasis in breast cancer patients.,A,GNB3,GNB3,0.333333333
1855,bc_id1910,CANCER,XRCC1,17987379,B,"Genetic polymorphisms of XRCC1 (codon 399) and susceptibility to breast cancer in Iranian women, a case-control study.",2008,,"Using PCR-based method, the XRCC1 Arg399Gln polymorphism was determined... In the dominant effect of the Gln allele (comparison between Gln/Gln+Arg/Gln vs. Arg/Arg), Gln/Gln+Arg/Gln genotypes was not associated with the risk of breast cancer (OR = 0.95, 95% CI:0.63-1.42, P = 0.799).",N,XRCC1,XRCC1,0.217391304
1856,bc_id1911,CANCER,MAP3K1,17997823,B,"Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.",2008,Some recently discovered genomic variants associated with a mildly increased risk of breast cancer are also associated with breast cancer characteristics or family history of breast cancer and ovarian cancer.,Heterozygote carriers and minor allele homozygote carriers for SNP rs889312 in the MAP3K1 gene were less likely to be lymph node positive at breast cancer diagnosis (P = 0.044) relative to major allele homozygote carriers.,N,MAP3K1,MAP3K1,0.090909091
1857,bc_id1912,CANCER,LSP1,17997823,B,"Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.",2008,Some recently discovered genomic variants associated with a mildly increased risk of breast cancer are also associated with breast cancer characteristics or family history of breast cancer and ovarian cancer.,X,X,X,X,0
1858,bc_id1913,CANCER,TOX3,17997823,B,"Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.",2008,Some recently discovered genomic variants associated with a mildly increased risk of breast cancer are also associated with breast cancer characteristics or family history of breast cancer and ovarian cancer.,X,X,X,X,0
1859,bc_id1914,CANCER,FGFR2,17997823,B,"Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.",2008,Some recently discovered genomic variants associated with a mildly increased risk of breast cancer are also associated with breast cancer characteristics or family history of breast cancer and ovarian cancer.,X,A,FGFR2,FGFR2,0.25
1860,bc_id1915,CANCER,RAD51,17999359,B,RAD51 135G--&gt;C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.,2007,,X,A,RAD51,RAD51,0.615384615
1861,bc_id1916,CANCER,BRCA2,17999359,B,RAD51 135G--&gt;C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.,2007,,X,X,X,X,0
1862,bc_id1917,CANCER,BRCA1,17999359,B,RAD51 135G--&gt;C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.,2007,,X,X,X,X,0
1863,bc_id1918,CANCER,XRCC6,18000863,B,Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity.,2008,", our results provide preliminary evidence that the variant allele of c.",X,Y,XRCC6Ku70,XRCC6,1
1864,bc_id1919,CANCER,XRCC5,18000863,B,Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity.,2008,", our results provide preliminary evidence that the variant allele of c.",X,Y,XRCC5Ku80,XRCC5,0.5
1865,bc_id1920,CANCER,LEPR,18004080,B,The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer.,2008,Our study suggests an association between serum leptin concentration and tumor progression.,X,X,X,X,0
1866,bc_id1921,CANCER,MMP9,18006768,B,Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.,2007,,X,A,MMP-9,MMP9,1
1867,bc_id1922,CANCER,MMP7,18006768,B,Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.,2007,,X,A,MMP-7,MMP7,0.75
1868,bc_id1923,CANCER,MMP3,18006768,B,Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.,2007,,X,A,MMP-3,MMP3,0.666666667
1869,bc_id1924,CANCER,MMP13,18006768,B,Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.,2007,,X,A,MMP-13,MMP13,1
1870,bc_id1925,CANCER,MMP12,18006768,B,Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.,2007,,X,A,MMP-12,MMP12,1
1871,bc_id1926,CANCER,MMP1,18006768,B,Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.,2007,,X,A,MMP-1,MMP1,0.833333333
1872,bc_id1927,CANCER,GATA3,18006915,B,Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status.,2007,", data from two independent study populations showed two intronic variants in GATA3 associated with overall decreases in breast cancer risk and suggested heterogeneity of these associations by ER status.",X,Y,GATA3,GATA3,0.5
1873,bc_id1928,CANCER,CYP3A5,18024866,B,Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.,2007,,X,A,CYP3A5,CYP3A5,0.4
1874,bc_id1929,CANCER,CYP2D6,18024866,Y,Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.,2007,,X,Y,CYP2D6,CYP2D6,0.272727273
1875,bc_id1930,CANCER,CYP2C9,18024866,B,Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.,2007,,X,A,CYP2C9,CYP2C9,1
1876,bc_id1931,CANCER,CYP2C19,18024866,Y,Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.,2007,,X,Y,CYP2C19,CYP2C19,0.2
1877,bc_id1932,CANCER,CYP2B6,18024866,B,Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.,2007,,X,A,CYP2B6,CYP2B6,0.5
1878,bc_id1933,CANCER,BRCA2,18042939,B,Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.,2007,,X,A,BRCA2,BRCA2,0.576923077
1879,bc_id1934,CANCER,BRCA1,18042939,B,Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.,2007,,X,A,BRCA1,BRCA1,0.60944206
1880,bc_id1935,CANCER,CCND1,18043898,B,Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.,2008,,X,Y,CCND1,CCND1,0.1875
1881,bc_id1936,CANCER,ERCC2,18044339,B,[Polymorphism Lys751Gln of XPD gene and breast cancer risk in women],2007,The results suggest that the Lys751Gln polymorphism of XPD gene may not be linked with appearance and development of breast cancer.,X,A,XPD,ERCC2,0.6875
1882,bc_id1937,CANCER,CYP19A1,18049890,B,"Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.",2008,"SNPs rs10046 and rs4646 may influence the HER2 status of breast cancer tumors, and rs10046 genotypes are associated with an altered DFS.",X,X,X,X,0
1883,bc_id1938,CANCER,NBN,18049891,B,NBS1 variant I171V and breast cancer risk.,2008,the I171V substitution is unlikely to constitute a strong risk factor for breast cancer in our study populations.,X,A,NBS1,NBN,0.571428571
1884,bc_id1939,CANCER,PRL,18053149,B,A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.,2008,"In this comprehensive analysis covering 59 kb of the PRL locus and 210 kb of the PRLR locus, we found no significant association between common variation in these candidate genes and breast cancer risk or plasma PRL levels.",X,N,PRL,PRL,0.5
1885,bc_id1940,CANCER,PRLR,18053149,B,A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.,2008,"In this comprehensive analysis covering 59 kb of the PRL locus and 210 kb of the PRLR locus, we found no significant association between common variation in these candidate genes and breast cancer risk or plasma PRL levels.","In this comprehensive analysis covering 59 kb of the PRL locus and 210 kb of the PRLR locus, we found no significant association between common variation in these candidate genes and breast cancer risk or plasma PRL levels.",N,PRLR,PRLR,0.333333333
1886,bc_id1941,CANCER,PALB2,18053174,B,Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.,2008,We have identified a novel truncating mutation in PALB2.,"Although mutations are infrequent, PALB2 can be added to the list of breast cancer susceptibility genes for which founder mutations have been identified in the French-Canadian population.",Y,PALB2,PALB2,0.25
1887,bc_id1942,CANCER,XPC,18053706,B,Xeroderma pigmentosum complementation group C genotypes/diplotypes play no independent or interaction role with polycyclic aromatic hydrocarbons-DNA adducts for breast cancer risk.,2008,,These data suggest that XPCs have neither independent effects nor interactions with cigarette smoking and PAH-DNA adducts for breast cancer risk. Further studies with multiple genetic polymorphisms in NER pathway are warranted.,A,XPCs,XPC,0.571428571
1888,bc_id1943,CANCER,FANCA,18056155,B,Comprehensive association testing of common genetic variation in DNA repair pathway genes in relationship with breast cancer risk in multiple populations.,2008,,"A variant in the FANCA gene (rs1061646, 0.15-0.68 frequency across populations) was associated with risk in the initial study (P = 0.0052), and in the replication studies (P = 0.032). In a combined analysis (8556 cases and 9605 controls), this SNP yielded an 8% increase in risk per allele. Combinations of coding variants in these genes were not associated with breast cancer and together, these data suggest that common variation in these DNA repair pathway genes are not strongly associated with breast cancer risk.",N,FANCA,FANCA,0.5
1889,bc_id1944,CANCER,CHEK2,18058223,B,Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations.,2008,,We analyzed the CHEK2 gene segment coding for FHA domain in 673 unselected breast cancer patients and 683 controls from the Czech Republic using the denaturant high-performance liquid chromatography. The found frequency of predominant FHA alteration I157T did not differ between breast cancer patients (19/673; 2.82%) and controls (17/683; 2.49%; P=0.71).,N,CHEK2,CHEK2,0.233333333
1890,bc_id1945,CANCER,RAD51L3,18058226,B,The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women.,2008,,"A rare missense variant in the RAD51D gene, E233G (c.A>G), has been reported to be more prevalent in breast cancer cases from specific multiple-case breast cancer families, with an odds ratio of 2.6 (95% confidence interval (CI): 1.12-6.03)...",Y,RAD51D,RAD51L3,1
1891,bc_id1946,CANCER,GSTT1,18058229,N,"TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.",2008,,"A case (n=250)-control (n=500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP's) in GSTM1 (Present/Null); GSTP1 (Ile105Val), p53 (Arg72Pro), TGFbeta1 (Leu10Pro), c-erbB2 (Ile655Val), and GSTT1 (Null/Present) in breast cancer... This study suggests that SNP's can help predict breast cancer risk in south Indian women and that TGFbeta1 (Pro/Pro) allele is associated with a better pCR in the primary tumour.",A,GSTT1,GSTT1,0.289473684
1892,bc_id1947,CANCER,GSTP1,18058229,N,"TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.",2008,,"A case (n=250)-control (n=500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP's) in GSTM1 (Present/Null); GSTP1 (Ile105Val), p53 (Arg72Pro), TGFbeta1 (Leu10Pro), c-erbB2 (Ile655Val), and GSTT1 (Null/Present) in breast cancer... This study suggests that SNP's can help predict breast cancer risk in south Indian women and that TGFbeta1 (Pro/Pro) allele is associated with a better pCR in the primary tumour.",A,GSTP1,GSTP1,0.485714286
1893,bc_id1948,CANCER,GSTM1,18058229,N,"TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.",2008,,"A case (n=250)-control (n=500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP's) in GSTM1 (Present/Null); GSTP1 (Ile105Val), p53 (Arg72Pro), TGFbeta1 (Leu10Pro), c-erbB2 (Ile655Val), and GSTT1 (Null/Present) in breast cancer... This study suggests that SNP's can help predict breast cancer risk in south Indian women and that TGFbeta1 (Pro/Pro) allele is associated with a better pCR in the primary tumour.",A,GSTM1,GSTM1,0.339622642
1894,bc_id1949,CANCER,TP53,18058229,Y,"TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.",2008,,"A case (n=250)-control (n=500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP's) in GSTM1 (Present/Null); GSTP1 (Ile105Val), p53 (Arg72Pro), TGFbeta1 (Leu10Pro), c-erbB2 (Ile655Val), and GSTT1 (Null/Present) in breast cancer... This study suggests that SNP's can help predict breast cancer risk in south Indian women and that TGFbeta1 (Pro/Pro) allele is associated with a better pCR in the primary tumour.",Y,p53,TP53,0.367816092
1895,bc_id1950,CANCER,TGFB1,18058229,Y,"TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.",2008,,"A case (n=250)-control (n=500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP's) in GSTM1 (Present/Null); GSTP1 (Ile105Val), p53 (Arg72Pro), TGFbeta1 (Leu10Pro), c-erbB2 (Ile655Val), and GSTT1 (Null/Present) in breast cancer... This study suggests that SNP's can help predict breast cancer risk in south Indian women and that TGFbeta1 (Pro/Pro) allele is associated with a better pCR in the primary tumour.",Y,TGFbeta1,TGFB1,0.185185185
1896,bc_id1951,CANCER,RAGE,18058469,B,Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer.,2007,,Decreased sRAGE levels in patients with breast cancer may contribute to the progression of the disease.,A,sRAGE,RAGE,1
1897,bc_id1952,CANCER,ERBB2,18062925,B,A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.,2008,Our results indicate that the Val carrier was associated with increased risks in patients with breast cancer in Taiwan.,"he HER2 polymorphism at codon 655 was analyzed in 424 patients with breast cancer and 318 controls by using the polymerase chain reaction methodology, followed by the restriction fragment-length polymorphism (PCR-RFLP) analysis... Our results indicate that the Val carrier was associated with increased risks in patients with breast cancer in Taiwan.",Y,HER2,ERBB2,0.285714286
1898,bc_id1953,CANCER,VDR,18067661,B,Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women.,2008,Our results provide additional support for an increased risk for breast cancer in postmenopausal Caucasian women with the BsmI bb genotype and shed light on possible differential effects by menopausal status and race.,X,X,X,X,0
1899,bc_id1954,CANCER,CLSPN,18077083,B,Germline alterations in the CLSPN gene in breast cancer families.,2008,,X,X,X,X,0
1900,bc_id1955,CANCER,GSTT1,18080216,B,"Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival.",2009,,"Interestingly, GSTM1 deletion was found to be significantly associated only with familial breast cancer (OR = 2.0; 95%CI = 1.252-3.128) while GSTT1 was associated only with sporadic breast cancer (OR = 2.3; 95%CI = 1.336-3.970).",Y,GSTT1,GSTT1,0.578947368
1901,bc_id1956,CANCER,GSTP1,18080216,B,"Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival.",2009,,"Interestingly, GSTM1 deletion was found to be significantly associated only with familial breast cancer (OR = 2.0; 95%CI = 1.252-3.128) while GSTT1 was associated only with sporadic breast cancer (OR = 2.3; 95%CI = 1.336-3.970). GSTP1 Ile105Val polymorphism was associated neither with sporadic nor familial breast cancer susceptibility (P value > 0.05).",N,GSTP1,GSTP1,0.085714286
1902,bc_id1957,CANCER,GSTM1,18080216,B,"Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival.",2009,,"Interestingly, GSTM1 deletion was found to be significantly associated only with familial breast cancer (OR = 2.0; 95%CI = 1.252-3.128) while GSTT1 was associated only with sporadic breast cancer (OR = 2.3; 95%CI = 1.336-3.970). GSTP1 Ile105Val polymorphism was associated neither with sporadic nor familial breast cancer susceptibility (P value > 0.05).",Y,GSTM1,GSTM1,0.452830189
1903,bc_id1958,CANCER,LCT,18080747,B,"The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer.",2008,,ANF,ANF,ANF,ANF,0
1904,bc_id1959,CANCER,BRCA1,18080788,B,"Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk.",2009,,X,X,X,X,0
1905,bc_id1960,CANCER,RRP1B,18081427,B,"Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis.",2007,,"Furthermore, a gene signature induced by ectopic expression of Rrp1b in tumor cells predicted survival in a human breast cancer gene expression dataset.",A,Rrp1b,RRP1B,1
1906,bc_id1961,CANCER,NAT2,18090909,B,"Meat consumption, N-acetyl transferase 1 and 2 polymorphism and risk of breast cancer in Danish postmenopausal women.",2008,,"Compared with slow acetylators, the IRR (95% confidence interval) among fast N-acetyl transferase 1 acetylators was 1.43 (1.03-1.99) and 1.13 (0.83-1.54) among intermediate/fast N-acetyl transferase 2 acetylators. Interaction analyses revealed that the positive associations between total meat intake and red meat intake and breast cancer risk were confined to intermediate/fast N-acetyl transferase 2 acetylators (Pinteraction = 0.03 and 0.04). Our findings support an association between meat consumption and breast cancer risk and that N-acetyl transferase 2 polymorphism has a modifying effect on the association, indicating that the association is confined to only genetically susceptible women.",Y,N-acetyl transferase 2,NAT2,0.37037037
1907,bc_id1962,CANCER,NAT1,18090909,B,"Meat consumption, N-acetyl transferase 1 and 2 polymorphism and risk of breast cancer in Danish postmenopausal women.",2008,,X,X,X,X,0
1908,bc_id1963,CANCER,BRCA2,18092194,B,Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.,2008,,"The family history selection criteria most likely to indicate the presence of deleterious BRCA1/2 mutations are breast cancer <or=35 years (P = 0.012), two first-degree relatives with breast cancer <or=50 years (P = 0.022), and male breast cancer (P = 0.047).",Y,BRCA1/2,BRCA2,0.324175824
1909,bc_id1964,CANCER,BRCA1,18092194,B,Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.,2008,,"The family history selection criteria most likely to indicate the presence of deleterious BRCA1/2 mutations are breast cancer <or=35 years (P = 0.012), two first-degree relatives with breast cancer <or=50 years (P = 0.022), and male breast cancer (P = 0.047).",Y,BRCA1/2,BRCA1,0.326180258
1910,bc_id1965,CANCER,MTHFR,18095031,B,"Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.",2008,"The results of the present study highly suggest that GSTP1, MDR1, and MTHFR genotypes could be prognostic factors for Taiwanese patients with breast cancer.","The results of the present study highly suggest that GSTP1, MDR1, and MTHFR genotypes could be prognostic factors for Taiwanese patients with breast cancer.",A,MTHFR,MTHFR,0.403846154
1911,bc_id1966,CANCER,GSTP1,18095031,B,"Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.",2008,"The results of the present study highly suggest that GSTP1, MDR1, and MTHFR genotypes could be prognostic factors for Taiwanese patients with breast cancer.","The results of the present study highly suggest that GSTP1, MDR1, and MTHFR genotypes could be prognostic factors for Taiwanese patients with breast cancer.",A,GSTP1,GSTP1,0.485714286
1912,bc_id1967,CANCER,ABCB1,18095031,B,"Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.",2008,"The results of the present study highly suggest that GSTP1, MDR1, and MTHFR genotypes could be prognostic factors for Taiwanese patients with breast cancer.",X,X,X,X,0
1913,bc_id1968,CANCER,TYMS,18095031,B,"Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.",2008,"The results of the present study highly suggest that GSTP1, MDR1, and MTHFR genotypes could be prognostic factors for Taiwanese patients with breast cancer.","The results showed that the genotype distribution of GSTP1 A313G, MTHFR C677T, and TS 3R3R in Taiwanese subjects differed significantly from the distribution in Caucasians... The results of the present study highly suggest that GSTP1, MDR1, and MTHFR genotypes could be prognostic factors for Taiwanese patients with breast cancer.",A,TS,TYMS,0.7
1914,bc_id1969,CANCER,PLCG2,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1915,bc_id1970,CANCER,PER1,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1916,bc_id1971,CANCER,ABL1,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1917,bc_id1972,CANCER,MS4A1,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1918,bc_id1973,CANCER,MLF2,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1919,bc_id1974,CANCER,ARHGEF2,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1920,bc_id1975,CANCER,SMAD3,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1921,bc_id1976,CANCER,JUND,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1922,bc_id1977,CANCER,IL4R,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1923,bc_id1978,CANCER,HNRPDL,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1924,bc_id1979,CANCER,THEM2,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1925,bc_id1980,CANCER,EPM2AIP1,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1926,bc_id1981,CANCER,TOMM40,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1927,bc_id1982,CANCER,PLD3,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1928,bc_id1983,CANCER,MAGED2,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1929,bc_id1984,CANCER,ELMO1,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1930,bc_id1985,CANCER,LSM2,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1931,bc_id1986,CANCER,VNN2,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1932,bc_id1987,CANCER,STIP1,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1933,bc_id1988,CANCER,BRCA2,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,"Breast Cancer Whole Genome Association Scan to be nominally associated with breast cancer risk. Irradiation responsive genes whose expression correlated with BRCA1 and/or BRCA2 mutation status were more likely to be tagged by risk-associated SNPs in the CGEMS dataset (BRCA1, P = 0.0005; BRCA2, P = 0.01).",Y,BRCA2,BRCA2,0.324175824
1934,bc_id1989,CANCER,BRCA1,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,"Breast Cancer Whole Genome Association Scan to be nominally associated with breast cancer risk. Irradiation responsive genes whose expression correlated with BRCA1 and/or BRCA2 mutation status were more likely to be tagged by risk-associated SNPs in the CGEMS dataset (BRCA1, P = 0.0005; BRCA2, P = 0.01).",Y,BRCA1,BRCA1,0.326180258
1935,bc_id1990,CANCER,SLC20A1,18095154,B,Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1936,bc_id1992,CANCER,BRCA2,18158280,B,"Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.",2008,,"To evaluate the potential contribution of mutations in the BRCA1 and BRCA2 genes to male breast cancer (MBC), we expanded a previous study to screen a total of 261 Israeli men diagnosed with breast carcinoma. A total of 21 BRCA2 6174delT and 8 BRCA1 185delAG mutations were found.",Y,BRCA2,BRCA2,0.324175824
1937,bc_id1993,CANCER,BRCA1,18158280,B,"Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.",2008,,"To evaluate the potential contribution of mutations in the BRCA1 and BRCA2 genes to male breast cancer (MBC), we expanded a previous study to screen a total of 261 Israeli men diagnosed with breast carcinoma. A total of 21 BRCA2 6174delT and 8 BRCA1 185delAG mutations were found.",Y,BRCA1,BRCA1,0.326180258
1938,bc_id1994,CANCER,HIF1A,18160046,B,Rare variant of hypoxia-inducible factor-1alpha (HIF-1A) and breast cancer risk in Korean women.,2008,,Our findings support the hypothesis that the HIF-1Alpha P582S variant may confer susceptibility to subgroups of breast cancer in Korean women.,A,HIF-1Alpha,HIF1A,0.666666667
1939,bc_id1995,CANCER,EGFR,18161656,B,(AC) dinucleotide repeat polymorphism in intron 1 of human EGFR shows ethnic specificities and high evidence for association with breast cancer.,2008,,"A polymorphic AC repeat in intron 1 of the EGFR gene was genotyped on 352 healthy individuals and 118 women with breast cancer sampled from the Kuwaiti and Tunisian populations... Strong evidence for such an association was found for allele 18 when considered alone (chi2=27.04, corrected p=0.0000016, OR=3.94) or with longer alleles (>17 repeats) (chi2=20.21, p=0.0005, OR=2.30).",Y,EGFR,EGFR,0.285714286
1940,bc_id1996,CANCER,VEGFA,18171601,B,The VEGF_936_C&gt;T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women.,2007,,"The vascular endothelial growth factor (VEGF) plays a crucial role in the initiation of angiogenesis, which is an important stage in tumor development. A functional 936_C>T polymorphism in the VEGF gene and its association with sporadic breast cancer risk has been analyzed in various studies yielding conflicting results... The results revealed an association of the CT+TT genotypes with a reduced breast cancer risk (OR(adj) 0.63, 95% CI, 0.41-0.98; OR(clustered) 0.63, 95% CI, 0.48-0.83), and a potential effect on ovarian cancer risk (OR(adj) 0.62, 95% CI, 0.33-1.18; OR(clustered) 0.62, 95% CI, 0.47-0.83). Thus, the 936_C>T polymorphism appears to modify disease risks in BRCA1 carriers.",Y,VEGF,VEGFA,0.25
1941,bc_id1997,CANCER,CHEK2,18172190,B,"CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.",2008,,"Because the cumulative risk of breast cancer at age 70 years among familial patient cases for CHEK2*1100delC heterozygotes is almost as high as that for BRCA1 and BRCA2 mutation heterozygotes, genotyping for CHEK2*1100delC should be considered together with BRCA1 and BRCA2 mutation screening in women with a family history of breast cancer.",Y,CHEK2*1100delC,CHEK2,0.383333333
1942,bc_id1998,CANCER,BRCA2,18172190,B,"CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.",2008,,"Because the cumulative risk of breast cancer at age 70 years among familial patient cases for CHEK2*1100delC heterozygotes is almost as high as that for BRCA1 and BRCA2 mutation heterozygotes, genotyping for CHEK2*1100delC should be considered together with BRCA1 and BRCA2 mutation screening in women with a family history of breast cancer.",Y,BRCA2,BRCA2,0.324175824
1943,bc_id1999,CANCER,BRCA1,18172190,B,"CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.",2008,,"Because the cumulative risk of breast cancer at age 70 years among familial patient cases for CHEK2*1100delC heterozygotes is almost as high as that for BRCA1 and BRCA2 mutation heterozygotes, genotyping for CHEK2*1100delC should be considered together with BRCA1 and BRCA2 mutation screening in women with a family history of breast cancer.",Y,BRCA1,BRCA1,0.326180258
1944,bc_id2000,CANCER,RASSF1,18172292,B,RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers.,2008,,Our data suggest that the presence of the RASSF1A A133S polymorphism is associated with breast cancer pathogenesis in general and modifies breast cancer age of onset in BRCA1/2 mutations carriers.,Y,RASSF1,RASSF1,0.666666667
1945,bc_id2001,CANCER,CDC20,18172292,B,RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1946,bc_id2002,CANCER,BRCA2,18172292,B,RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1947,bc_id2003,CANCER,BRCA1,18172292,B,RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers.,2008,,X,X,X,X,0
1948,bc_id2004,CANCER,MTRR,18174236,B,One-carbon metabolism-related gene polymorphisms and risk of breast cancer.,2008,,Our findings indicated that the MTHFR and MTRR polymorphisms were associated with individual susceptibility to breast cancer among postmenopausal women.,Y,MTRR,MTRR,0.333333333
1949,bc_id2005,CANCER,MTR,18174236,B,One-carbon metabolism-related gene polymorphisms and risk of breast cancer.,2008,,"Functional polymorphisms in genes encoding one-carbon metabolism enzymes, methylenetetrahydrofolate reductase (MTHFR C677T), methionine synthase (MTR A2756G), methionine synthase reductase (MTRR A66G) and thymidylate synthase (TS), influence folate metabolism, but epidemiological studies have yielded inconsistent findings... In addition, interaction between the MTRR A66G polymorphism and folate intake for risk of postmenopausal breast cancer was observed (interaction P = 0.008). Our findings indicated that the MTHFR and MTRR polymorphisms were associated with individual susceptibility to breast cancer among postmenopausal women.",A,MTR,MTR,0.222222222
1950,bc_id2006,CANCER,MTHFR,18174236,B,One-carbon metabolism-related gene polymorphisms and risk of breast cancer.,2008,,Our findings indicated that the MTHFR and MTRR polymorphisms were associated with individual susceptibility to breast cancer among postmenopausal women.,Y,MTHFR,MTHFR,0.269230769
1951,bc_id2007,CANCER,TYMS,18174236,B,One-carbon metabolism-related gene polymorphisms and risk of breast cancer.,2008,,X,X,X,X,0
1952,bc_id2009,CANCER,CDKN2C,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDKN2C,CDKN2C,1
1953,bc_id2010,CANCER,CDKN2D,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDKN2D,CDKN2D,1
1954,bc_id2011,CANCER,CDKN2B,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDKN2A/CDKN2B,CDKN2B,1
1955,bc_id2012,CANCER,CDKN2A,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDKN2A/CDKN2B,CDKN2A,0.625
1956,bc_id2013,CANCER,CDKN1B,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDKNIB,CDKN1B,0.714285714
1957,bc_id2014,CANCER,CDKN1A,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDKN1A,CDKN1A,0.5
1958,bc_id2015,CANCER,CDK4,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDK4,CDK4,1
1959,bc_id2016,CANCER,CDK6,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDK6,CDK6,1
1960,bc_id2017,CANCER,CDK2,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CDK2,CDK2,1
1961,bc_id2018,CANCER,CCNE1,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CCNE1,CCNE1,1
1962,bc_id2019,CANCER,CCND2,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CCND2,CCND2,1
1963,bc_id2020,CANCER,CCND3,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CCND3,CCND3,1
1964,bc_id2021,CANCER,CCND1,18174243,B,Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.,2008,,"Seventy-nine tag SNPs were used to evaluate 240 common SNPs found in the genes: CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKNIB, CDKN2A/CDKN2B, CDKN2C and CDKN2D... The combined effects of the cell cycle genes considered here provide evidence for a significant association with breast cancer risk in a global test (P-heterogeneity = 0.010, P-trend = 0.048). Further large-scale studies are needed to confirm these results.",A,CCND1,CCND1,0.5
1965,bc_id2022,CANCER,BRCA2,18175183,B,Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment.,2008,,The BRCA1/BRCA2 gene mutation carriers and low-risk women have different mammographic parenchymal patterns. It is expected that women identified as high risk by computerized feature analyses might potentially be more aggressively screened for breast cancer.,A,BRCA1/BRCA2,BRCA2,0.576923077
1966,bc_id2023,CANCER,BRCA1,18175183,B,Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment.,2008,,The BRCA1/BRCA2 gene mutation carriers and low-risk women have different mammographic parenchymal patterns. It is expected that women identified as high risk by computerized feature analyses might potentially be more aggressively screened for breast cancer.,A,BRCA1/BRCA2,BRCA1,0.60944206
1967,bc_id2024,CANCER,CHEK2,18175216,B,The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.,2008,,"In the present study, we evaluated the role of a CHEK2 1100delC as a susceptibility mutation of breast cancer in the Korean population. However, our results suggest that this mutation is absent or may be very infrequent in Korean patients with breast cancer who have high risk of BRCA1 and BRCA2 mutation, making its screening irrelevant from the practical point view.",N,CHEK2,CHEK2,0.233333333
1968,bc_id2025,CANCER,BRCA2,18175216,B,The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.,2008,,X,X,X,X,0
1969,bc_id2026,CANCER,BRCA2,18182601,B,Variation of breast cancer risk among BRCA1/2 carriers.,2008,There exists broad variation in breast cancer risk among carriers of BRCA1 and BRCA2 mutations.,"Among the 1394 participants with unilateral breast cancer, 73 (5.2%) were identified as carriers of deleterious mutations (42 with BRCA1 and 31 with BRCA2). There exists broad variation in breast cancer risk among carriers of BRCA1 and BRCA2 mutations.",A,BRCA2,BRCA2,0.576923077
1970,bc_id2027,CANCER,BRCA1,18182601,B,Variation of breast cancer risk among BRCA1/2 carriers.,2008,There exists broad variation in breast cancer risk among carriers of BRCA1 and BRCA2 mutations.,"Among the 1394 participants with unilateral breast cancer, 73 (5.2%) were identified as carriers of deleterious mutations (42 with BRCA1 and 31 with BRCA2). There exists broad variation in breast cancer risk among carriers of BRCA1 and BRCA2 mutations.",A,BRCA1,BRCA1,0.60944206
1971,bc_id2028,CANCER,PIK3CA,18183466,B,PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.,2008,PIK3CA mutations are common in invasive ductal carcinomas of the breast.,PIK3CA mutations are common in invasive ductal carcinomas of the breast.,Y,PIK3CA,PIK3CA,0.4
1972,bc_id2029,CANCER,NAT2,18187392,Y,"Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis.",2008,Our results show that cigarette smoking is associated with an increase in breast cancer risk among women with NAT2 slow acetylation genotypes.,Our results show that cigarette smoking is associated with an increase in breast cancer risk among women with NAT2 slow acetylation genotypes.,A,NAT2,NAT2,0.259259259
1973,bc_id2030,CANCER,XRCC2,18188695,B,"Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus.",2008,,No significant associations were observed between the other three SNPs and breast cancer. This study suggests that genetic variation in SNPs in XRCC1 and XRCC2 genes may influence breast cancer susceptibility.,A,XRCC2,XRCC2,0.272727273
1974,bc_id2031,CANCER,XRCC1,18188695,B,"Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus.",2008,,No significant associations were observed between the other three SNPs and breast cancer. This study suggests that genetic variation in SNPs in XRCC1 and XRCC2 genes may influence breast cancer susceptibility.,A,XRCC1,XRCC1,0.543478261
1975,bc_id2032,CANCER,COMT,18194538,B,Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk.,2008,"Using two independent Caucasian populations, we have shown a stronger combined effect of the two commonly occurring CCND1 and COMT genotypes in the context of breast cancer predisposition.","Using two independent Caucasian populations, we have shown a stronger combined effect of the two commonly occurring CCND1 and COMT genotypes in the context of breast cancer predisposition.",Y,COMT,COMT,0.276595745
1976,bc_id2033,CANCER,CCND1,18194538,B,Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk.,2008,"Using two independent Caucasian populations, we have shown a stronger combined effect of the two commonly occurring CCND1 and COMT genotypes in the context of breast cancer predisposition.","Using two independent Caucasian populations, we have shown a stronger combined effect of the two commonly occurring CCND1 and COMT genotypes in the context of breast cancer predisposition.",Y,CCND1,CCND1,0.1875
1977,bc_id2034,CANCER,ERCC2,18196582,B,"Polymorphisms in XPC and ERCC2 genes, smoking and breast cancer risk.",2008,,"Analyses of the ERCC2 Lys751Gln polymorphism did not show an association with breast cancer risk, either overall or at younger ages.",N,ERCC2,ERCC2,0.1875
1978,bc_id2035,CANCER,XPC,18196582,B,"Polymorphisms in XPC and ERCC2 genes, smoking and breast cancer risk.",2008,,The results suggest that breast cancer risk is related to the XPC haplotype tagged by the XPC-PAT+/+ insertion-deletion polymorphism in intron 9. Further study of the XPC haplotypes and their interactions with smoking in relation to breast cancer risk is needed.,Y,XPC,XPC,0.142857143
1979,bc_id2036,CANCER,CYP19A1,18199708,B,Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.,2008,,Further studies are needed to explore CYP19A1 gene-environment interactions in relation to breast cancer risk.,A,CYP19A1,CYP19A1,0.484848485
1980,bc_id2037,CANCER,IL6,18199986,B,Interleukin-6 -174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study.,2007,,The -174G/C IL-6 polymorphism is not a risk factor of major importance for breast cancer in the Ukrainian population.,N,IL-6,IL6,0.428571429
1981,bc_id2038,CANCER,RFC1,18204969,B,Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer.,2008,These data do not support the hypothesis that genetic variation in genes involved in the metabolism of folate are implicated in the etiology of breast cancer.,"We observed no association between the MTHFR, RFC, MS and MTRR genotypes and the risk of breast cancer.",N,RFC,RFC1,1
1982,bc_id2039,CANCER,MTRR,18204969,B,Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer.,2008,These data do not support the hypothesis that genetic variation in genes involved in the metabolism of folate are implicated in the etiology of breast cancer.,"We observed no association between the MTHFR, RFC, MS and MTRR genotypes and the risk of breast cancer.",N,MTRR,MTRR,0.666666667
1983,bc_id2040,CANCER,MTR,18204969,B,Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer.,2008,These data do not support the hypothesis that genetic variation in genes involved in the metabolism of folate are implicated in the etiology of breast cancer.,X,X,X,X,0
1984,bc_id2041,CANCER,MTHFR,18204969,B,Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer.,2008,These data do not support the hypothesis that genetic variation in genes involved in the metabolism of folate are implicated in the etiology of breast cancer.,"We observed no association between the MTHFR, RFC, MS and MTRR genotypes and the risk of breast cancer.",N,MTHFR,MTHFR,0.326923077
1985,bc_id2042,CANCER,BRCA1,18205043,B,Early radiation exposures and BRCA1-associated breast cancer in young women from Poland.,2008,,X,X,X,X,0
1986,bc_id2043,CANCER,IGFBP5,18210156,B,Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.,2008,,This study is the first to report associations between genetic variants in IGFBP2 and IGFBP5 and breast cancer risk.,Y,IGFBP5,IGFBP5,0.5
1987,bc_id2044,CANCER,IGFBP2,18210156,B,Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.,2008,,This study is the first to report associations between genetic variants in IGFBP2 and IGFBP5 and breast cancer risk.,Y,IGFBP2,IGFBP2,1
1988,bc_id2045,CANCER,CXCL12,18223219,B,Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer.,2008,,X,X,X,X,0
1989,bc_id2046,CANCER,TP53,18230179,B,Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer.,2008,"Our findings suggest TP53 PIN3 Ins16bp polymorphism as a real risk modifier in breast cancer disease, either in sporadic and familial breast cancer.","Our findings suggest TP53 PIN3 Ins16bp polymorphism as a real risk modifier in breast cancer disease, either in sporadic and familial breast cancer.",Y,TP53,TP53,0.367816092
1990,bc_id2047,CANCER,PEMT,18230680,B,Choline metabolism and risk of breast cancer in a population-based study.,2008,,The CHDH minor T allele was also associated with an increased risk (OR: 1.19; 95% CI: 1.00-1.41) compared with the major G allele. The BHMT rs3733890 polymorphism was also examined but was found not to be associated with breast cancer risk. We observed a significant interaction between dietary betaine intake and the PEMT rs7926 polymorphism (P(interaction)=0.04). Our findings suggest that choline metabolism may play an important role in breast cancer etiology.,Y,PEMT,PEMT,1
1991,bc_id2048,CANCER,CHDH,18230680,B,Choline metabolism and risk of breast cancer in a population-based study.,2008,,The CHDH minor T allele was also associated with an increased risk (OR: 1.19; 95% CI: 1.00-1.41) compared with the major G allele. The BHMT rs3733890 polymorphism was also examined but was found not to be associated with breast cancer risk. We observed a significant interaction between dietary betaine intake and the PEMT rs7926 polymorphism (P(interaction)=0.04).,Y,CHDH,CHDH,1
1992,bc_id2049,CANCER,BHMT,18230680,B,Choline metabolism and risk of breast cancer in a population-based study.,2008,, The BHMT rs3733890 polymorphism was also examined but was found not to be associated with breast cancer risk.,N,BHMT,BHMT,1
1993,bc_id2050,CANCER,ERBB2,18237245,N,Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.,2008,,"Our findings suggest that the polymorphic alleles of HER2 and CCND1 may not play an important role as genetic markers for breast cancer risk, but presence of Val allele may be useful for tumor prognosis.",A,HER2,ERBB2,0.452380952
1994,bc_id2051,CANCER,CCND1,18237245,N,Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.,2008,,"Our findings suggest that the polymorphic alleles of HER2 and CCND1 may not play an important role as genetic markers for breast cancer risk, but presence of Val allele may be useful for tumor prognosis.",A,CCND1,CCND1,0.5
1995,bc_id2052,CANCER,ERBB2,18237248,B,The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.,2008,,"Furthermore, they provide clinical evidence that HER-2 Ile655Val SNP does affect serum HER-2 levels and it can be regarded as a predictive biomarker for breast cancer patients with poor prognosis.",Y,HER-2,ERBB2,0.285714286
1996,bc_id2053,CANCER,IL6,18239642,B,Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk.,2008,,These data suggest that IL-6 genotypes may influence breast cancer risk in conjunction with central adiposity.,A,IL-6,IL6,0.285714286
1997,bc_id2054,CANCER,TP53,18248785,B,"Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.",2008,,X,X,X,X,0
1998,bc_id2055,CANCER,CHEK2,18253122,B,Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.,2008,,We found no significant associations between the CHEK2*1100delC mutation and CBC overall or among those treated with RT.,N,CHEK2*1100delC,CHEK2,0.233333333
1999,bc_id2056,CANCER,ND3,18262047,N,Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women.,2008,,X,X,X,X,0
2000,bc_id2057,CANCER,ATM,18264724,B,Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer.,2008,,The ATM genotype was weakly associated with the risk for breast cancer (P = 0.04 for the overall test).,Y,ATM,ATM,0.333333333
2001,bc_id2058,CANCER,UIMC1,18270812,B,Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.,2009,,Our analysis suggests that RAP80 and CCDC98 do not play an important role as high penetrance breast cancer susceptibility genes.,N,RAP80,UIMC1,0.666666667
2002,bc_id2059,CANCER,CCDC98,18270812,B,Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.,2009,,Our analysis suggests that RAP80 and CCDC98 do not play an important role as high penetrance breast cancer susceptibility genes.,N,CCDC98,CCDC98,0.5
2003,bc_id2060,CANCER,ESR1,18271972,B,ESR1 and EGF genetic variation in relation to breast cancer risk and survival.,2008,"Our results do not support a strong association between common variants in the ESR1 and EGF genes and breast cancer risk, tumour characteristics or survival.","Our results do not support a strong association between common variants in the ESR1 and EGF genes and breast cancer risk, tumour characteristics or survival.",N,ESR1,ESR1,0.130434783
2004,bc_id2061,CANCER,EGF,18271972,B,ESR1 and EGF genetic variation in relation to breast cancer risk and survival.,2008,"Our results do not support a strong association between common variants in the ESR1 and EGF genes and breast cancer risk, tumour characteristics or survival.","Our results do not support a strong association between common variants in the ESR1 and EGF genes and breast cancer risk, tumour characteristics or survival.",N,EGF,EGF,0.333333333
2005,bc_id2062,CANCER,MDM4,18279506,B,Mutation analysis of the MDM4 gene in German breast cancer patients.,2008,there is no evidence for a major role of MDM4 coding variants in the inherited susceptibility towards breast cancer in German patients.,We conclude that there is no evidence for a major role of MDM4 coding variants in the inherited susceptibility towards breast cancer in German patients.,N,MDM4,MDM4,0.5
2006,bc_id2063,CANCER,HIF1A,18279708,B,Single nucleotide polymorphisms in the hypoxia-inducible factor-1alpha (HIF-1alpha) gene in human sporadic breast cancer.,2008,,Our results suggest that none of the polymorphisms studied in the HIF-1alpha gene influence susceptibility to sporadic breast cancer.,N,HIF-1alpha,HIF1A,0.333333333
2007,bc_id2064,CANCER,MDM2,18281248,B,MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population.,2008,,"Hence, we examined if MDM2 and p53 polymorphisms would be determinants of the early onset phenomenon in Chinese women... Together, the data suggest that though the MDM2 SNP309 G allele is a risk factor for breast cancer, it does not accelerate, but delays the onset of the sporadic disease in Chinese women, highlighting that differences in ethnicity and family history may influence the role of MDM2 SNP309 in cancer susceptibility.",A,MDM2,MDM2,0.444444444
2008,bc_id2065,CANCER,TP53,18281248,B,MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population.,2008,,"Hence, we examined if MDM2 and p53 polymorphisms would be determinants of the early onset phenomenon in Chinese women... Together, the data suggest that though the MDM2 SNP309 G allele is a risk factor for breast cancer, it does not accelerate, but delays the onset of the sporadic disease in Chinese women, highlighting that differences in ethnicity and family history may influence the role of MDM2 SNP309 in cancer susceptibility.",A,p53,TP53,0.482758621
2009,bc_id2066,CANCER,CYP17A1,18281250,B,"Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project.",2008,there were no associations between the CYP17 genotype and breast cancer risk.,there were no associations between the CYP17 genotype and breast cancer risk.,N,CYP17,CYP17A1,0.266666667
2010,bc_id2067,CANCER,BRCA2,18284688,B,Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.,2008,The results suggest that the five classification methods yielded similar results.,X,X,X,X,0
2011,bc_id2068,CANCER,BRCA1,18284688,B,Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.,2008,The results suggest that the five classification methods yielded similar results.,"Polyphen was particularly better at isolating BRCA1 UV carriers likely to have a family history of breast cancer or ovarian cancer, and may therefore help to classify BRCA1 UVs. Our study suggests that these methods may not be as successful in classifying BRCA2 UVs.",A,BRCA1,BRCA1,0.60944206
2012,bc_id2069,CANCER,BRCA2,18286383,B,Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba.,2009,", BRCA1 and BRCA2 mutations are not uncommon in Cuban women with breast cancer, but the absence of founder mutations precludes the development of a rapid and inexpensive clinical screening test.","In summary, BRCA1 and BRCA2 mutations are not uncommon in Cuban women with breast cancer, but the absence of founder mutations precludes the development of a rapid and inexpensive clinical screening test.",A,BRCA2,BRCA2,0.576923077
2013,bc_id2070,CANCER,BRCA1,18286383,B,Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba.,2009,", BRCA1 and BRCA2 mutations are not uncommon in Cuban women with breast cancer, but the absence of founder mutations precludes the development of a rapid and inexpensive clinical screening test.","In summary, BRCA1 and BRCA2 mutations are not uncommon in Cuban women with breast cancer, but the absence of founder mutations precludes the development of a rapid and inexpensive clinical screening test.",A,BRCA1,BRCA1,0.60944206
2014,bc_id2071,CANCER,BRCA2,18288416,B,Disease family history and modification of breast cancer risk in common BRCA2 variants.,2008,", the analysis of some BRCA2 variants could help to identify women at a higher risk of developing breast cancer who could be candidates for chemoprevention protocols.","The BRCA2 N372H polymorphism was associated with a 2.29-fold (95% CI, 1.16-4.49; P=0.016) increased risk in the subgroup of high-risk families with no BRCA1/2 mutations. Conversely, the BRCA1 Q356R and BRCA2 203G>A polymorphisms did not show any significant associations with breast cancer risk.",Y,BRCA2,BRCA2,0.324175824
2015,bc_id2072,CANCER,BRCA1,18288416,B,Disease family history and modification of breast cancer risk in common BRCA2 variants.,2008,", the analysis of some BRCA2 variants could help to identify women at a higher risk of developing breast cancer who could be candidates for chemoprevention protocols.","The BRCA2 N372H polymorphism was associated with a 2.29-fold (95% CI, 1.16-4.49; P=0.016) increased risk in the subgroup of high-risk families with no BRCA1/2 mutations. Conversely, the BRCA1 Q356R and BRCA2 203G>A polymorphisms did not show any significant associations with breast cancer risk.",N,BRCA1,BRCA1,0.064377682
2016,bc_id2073,CANCER,CYP2D6,18294285,B,Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.,2008,,The present study suggests that the CYP2D6 genotype should be considered when selecting adjuvant hormonal therapy for breast cancer patients.,A,CYP2D6,CYP2D6,0.590909091
2017,bc_id2074,CANCER,ABCB1,18300948,B,Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.,2008,,ABCB1 SNPs may affect function of P-glycoprotein by influencing the expression level and modify breast cancer prognosis.,A,ABCB1,ABCB1,0.6875
2018,bc_id2075,CANCER,ESR1,18301357,B,Analysis of the ERalpha germline PvuII marker in breast cancer risk.,2008,The PvuII T allele may be a germline risk factor for familial forms of breast cancer and is associated with a specific subset of immunohistochemical tumor phenotype.,"Different biomarkers mapping estrogen receptor alpha (ESR1) have been associated with breast cancer risk, although the size of the effect is not consistent among different reports.",Y,ESR1,ESR1,0.282608696
2019,bc_id2076,CANCER,PALB2,18302019,B,Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.,2009,,Our results rule out a major contribution of FANCB to hereditary breast cancer... We show evidence that PALB2 loss of function might also conform to the inactivation model of a classic tumor-suppressor gene and present data that adds to the clinically relevant discussion about the existence of a PALB2-breast cancer phenotype.,A,PALB2,PALB2,0.583333333
2020,bc_id2077,CANCER,FANCB,18302019,B,Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.,2009,,Our results rule out a major contribution of FANCB to hereditary breast cancer... We show evidence that PALB2 loss of function might also conform to the inactivation model of a classic tumor-suppressor gene and present data that adds to the clinically relevant discussion about the existence of a PALB2-breast cancer phenotype.,N,FANCB,FANCB,0.5
2021,bc_id2078,CANCER,UIMC1,18306035,B,Germline RAP80 mutations and susceptibility to breast cancer.,2009,", we did not find truncating mutations of the RAP80 gene to be a cause of familial breast cancer.",we did not find truncating mutations of the RAP80 gene to be a cause of familial breast cancer.,N,RAP80,UIMC1,0.666666667
2022,bc_id2079,CANCER,GSTP1,18326615,B,"Cruciferous vegetables, the GSTP1 Ile105Val genetic polymorphism, and breast cancer risk.",2008,Cruciferous vegetable intake consistent with high isothiocyanate exposure may reduce breast cancer risk.,X,X,X,X,0
2023,bc_id2080,CANCER,NUMA1,18331640,B,Comprehensive analysis of NuMA variation in breast cancer.,2008,Our results do not support the role of NuMA variants as breast cancer susceptibility alleles.,Our results do not support the role of NuMA variants as breast cancer susceptibility alleles.,N,NuMA,NUMA1,0.5
2024,bc_id2081,CANCER,AKAP9,18334708,B,Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis.,2008,,"We extended the analysis of AKAP9 M463I, which is in strong linkage disequilibrium with AKAP9 N2792S, to 9523 breast cancer patients and 13770 healthy control subjects from seven independent European and Australian breast cancer studies.",Y,AKAP9,AKAP9,1
2025,bc_id2082,CANCER,MPO,18340529,B,"A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk.",2009,from this study suggest that exogenous and endogenous modulators of oxidative stress may modify the association between the MPO polymorphism and breast cancer risk.,from this study suggest that exogenous and endogenous modulators of oxidative stress may modify the association between the MPO polymorphism and breast cancer risk.,A,MPO,MPO,0.571428571
2026,bc_id2083,CANCER,FCGR3A,18347005,B,Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.,2008,,Prospective studies are needed to confirm the role of Fc gamma R polymorphisms in predicting clinical outcome of patients with breast cancer treated with trastuzumab-based therapy.,A,Fc gamma,FCGR3A,1
2027,bc_id2084,CANCER,FCGR2B,18347005,B,Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.,2008,,Prospective studies are needed to confirm the role of Fc gamma R polymorphisms in predicting clinical outcome of patients with breast cancer treated with trastuzumab-based therapy.,A,Fc gamma,FCGR2B,1
2028,bc_id2085,CANCER,FCGR2A,18347005,B,Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.,2008,,Prospective studies are needed to confirm the role of Fc gamma R polymorphisms in predicting clinical outcome of patients with breast cancer treated with trastuzumab-based therapy.,A,Fc gamma,FCGR2A,1
2029,bc_id2086,CANCER,TP53,18348141,B,Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status.,2008,,"We conclude that the effect of p53 codon 72 genotype on breast cancer survival is dependent on p53 gene status, the P/P variant is strongly associated with poor prognosis among patients with a wild-type p53 tumor.",Y,p53,TP53,0.367816092
2030,bc_id2087,CANCER,ERBB2,18348656,B,Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.,2008,,X,X,X,X,0
2031,bc_id2089,CANCER,GADD45A,18350249,B,Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer.,2008,,X,X,X,X,0
2032,bc_id2090,CANCER,CYP1A1,18351133,B,Association of CYP1A1 polymorphisms with breast cancer in North Indian women.,2008,,"In the present case control study four CYP1A1 gene polymorphisms, m1 (T6235C), m2 (A4889G), m3 T5639C), and m4 (C4887A) were studied for their association with BC conjointly with the known risk factors such as age, menopausal status, diet, and life style... No significant association was observed between m1 and m3 polymorphisms and BC risk in all the subjects as well as when stratified into pre- and postmenopausal subjects.",N,CYP1A1,CYP1A1,0.239130435
2033,bc_id2091,CANCER,MAP3K1,18355772,B,Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2008,,"A recent genome-wide association study has shown that common alleles at single nucleotide polymorphisms (SNPs) in FGFR2 (rs2981582), TNRC9 (rs3803662), and MAP3K1 (rs889312) are associated with increased breast cancer risks in the general population... The differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCA2 carriers point to differences in the biology of BRCA1 and BRCA2 breast cancer tumors and confirm the distinct nature of breast cancer in BRCA1 mutation carriers.",Y,MAP3K1,MAP3K1,0.636363636
2034,bc_id2092,CANCER,TOX3,18355772,B,Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2008,,"A recent genome-wide association study has shown that common alleles at single nucleotide polymorphisms (SNPs) in FGFR2 (rs2981582), TNRC9 (rs3803662), and MAP3K1 (rs889312) are associated with increased breast cancer risks in the general population... The differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCA2 carriers point to differences in the biology of BRCA1 and BRCA2 breast cancer tumors and confirm the distinct nature of breast cancer in BRCA1 mutation carriers.",Y,TNRC9,TOX3,0.5
2035,bc_id2093,CANCER,FGFR2,18355772,B,Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2008,,"A recent genome-wide association study has shown that common alleles at single nucleotide polymorphisms (SNPs) in FGFR2 (rs2981582), TNRC9 (rs3803662), and MAP3K1 (rs889312) are associated with increased breast cancer risks in the general population... The differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCA2 carriers point to differences in the biology of BRCA1 and BRCA2 breast cancer tumors and confirm the distinct nature of breast cancer in BRCA1 mutation carriers.",Y,FGFR2,FGFR2,0.708333333
2036,bc_id2094,CANCER,BRCA2,18355772,B,Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2008,,"A recent genome-wide association study has shown that common alleles at single nucleotide polymorphisms (SNPs) in FGFR2 (rs2981582), TNRC9 (rs3803662), and MAP3K1 (rs889312) are associated with increased breast cancer risks in the general population... The differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCA2 carriers point to differences in the biology of BRCA1 and BRCA2 breast cancer tumors and confirm the distinct nature of breast cancer in BRCA1 mutation carriers.",A,BRCA2,BRCA2,0.576923077
2037,bc_id2095,CANCER,BRCA1,18355772,B,Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2008,,"A recent genome-wide association study has shown that common alleles at single nucleotide polymorphisms (SNPs) in FGFR2 (rs2981582), TNRC9 (rs3803662), and MAP3K1 (rs889312) are associated with increased breast cancer risks in the general population... The differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCA2 carriers point to differences in the biology of BRCA1 and BRCA2 breast cancer tumors and confirm the distinct nature of breast cancer in BRCA1 mutation carriers.",A,BRCA1,BRCA1,0.60944206
2038,bc_id2096,CANCER,APEX1,18357393,N,Prevalence of BER gene polymorphisms in sporadic breast cancer.,NA,,X,X,X,X,0
2039,bc_id2097,CANCER,PARP1,18357393,N,Prevalence of BER gene polymorphisms in sporadic breast cancer.,NA,,X,X,X,X,0
2040,bc_id2098,CANCER,XRCC1,18357393,Y,Prevalence of BER gene polymorphisms in sporadic breast cancer.,NA,,"Using PCR-RFLP procedures, the XRCC1 gene was examined for Arg194Trp and Arg399Gln, APE1 for Asp148Glu, LIG3alpha for Arg780His and PARP1 for Pro377Ser mutations... Thus, the Gln allele was significantly more frequent in breast cancer cases (allele frequency, 0.52) than in controls (allele frequency, 0.35), suggesting that XRCC1 399Gln may enhance the risk of breast cancer.",A,XRCC1,XRCC1,0.543478261
2041,bc_id2099,CANCER,PIK3CA,18371219,B,PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.,2008,,PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapies in ER-positive and ER-negative breast tumors.,N,PIK3CA,PIK3CA,0.133333333
2042,bc_id2100,CANCER,GHSR,18375957,B,"Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (",2008,,X,X,X,X,0
2043,bc_id2101,CANCER,GHRL,18375957,B,"Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (",2008,,"A number of GHRL and GHSR polymorphisms were associated with body mass index (BMI) and height (P between <0.01 and 0.04)... Furthermore, we have observed evidence for association of GHRL polymorphisms with circulating IGF-I levels and with breast cancer risk.",Y,GHRL,GHRL,0.5
2044,bc_id2102,CANCER,ABCB1,18377430,B,Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.,2008,"the present exploratory study suggests that the three high frequency linked polymorphisms in the ABCB1 gene might be functionally important with regards to the altered pharmacokinetics of doxorubicin in Asian breast cancer patients, resulting in signifi","In conclusion, the present exploratory study suggests that the three high frequency linked polymorphisms in the ABCB1 gene might be functionally important with regards to the altered pharmacokinetics of doxorubicin in Asian breast cancer patients, resulting in significantly increased exposure levels and reduced clearance.",A,ABCB1,ABCB1,0.6875
2045,bc_id2103,CANCER,CHEK2,18381420,B,Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.,2008,,"We estimate that the CHEK2 1100delC allele is associated with an odds ratio of 2.6 for breast cancer, which corresponds to a lifetime risk of approximately 24% in Ontario.",Y,CHEK2,CHEK2,0.383333333
2046,bc_id2104,CANCER,XRCC4,18383855,Y,A new single nucleotide polymorphism in XRCC4 gene is associated with breast cancer susceptibility in Taiwanese patients.,2008,,Our findings suggest that the heterozygous and homozygous T allele of the XRCC4 G-1394T may be associated with the development of breast cancer and may be a useful biomarker for anticancer prevention and intervention.,A,XRCC4,XRCC4,0.4
2047,bc_id2105,CANCER,ATM,18384426,B,ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.,2008,,"These are the initial results concerning the prevalence of germline mutations in the ATM gene among BC cases in a Spanish population, and they suggest that ATM mutations can confer increased susceptibility to early-onset BC.",Y,ATM,ATM,0.333333333
2048,bc_id2106,CANCER,GSTT1,18392488,B,[Polymorphisms GSTM1 and GSTT1 and sporadic breast cancer mammographic features],2008,GSTM1 homozygous deletion was associated with high mammographic density.,X,X,X,X,0
2049,bc_id2107,CANCER,GSTM1,18392488,B,[Polymorphisms GSTM1 and GSTT1 and sporadic breast cancer mammographic features],2008,GSTM1 homozygous deletion was associated with high mammographic density.,To evaluate the occurrence of homozygous deletions of the GSTM1 and GSTT1 genes in women with sporadic breast cancer and in women without cancer and to compare breast cancer mammographic features between patients with and without these deletions... GSTM1 homozygous deletion was associated with high mammographic density.,Y,GSTM1,GSTM1,0.452830189
2050,bc_id2108,CANCER,ABCB1,18393221,B,Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer.,2008,,We evaluated the presence of single nucleotide polymorphism (SNP) C3435T of the MDR-1 gene and its correlation with the response to primary chemotherapy using the RECIST criteria. Forty-one Brazilian women with stages II and III breast cancer using the PCR-RFLP analysis were evaluated.,A,MDR-1,ABCB1,0.6875
2051,bc_id2109,CANCER,BRCA2,18393245,B,[Analysis of BRCA2 gene mutations among familial and/or early-onset breast cancer patients in eastern Shandong of China],2008,,"BRCA2 may play an important role in the familial breast cancer in eastern Shandong Chinese population, but not in the early-onset breast cancer.",A,BRCA2,BRCA2,0.576923077
2052,bc_id2110,CANCER,CYP1A2,18398030,B,Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status.,2008,,These findings raise the hypothesis that coffee slows the growth of ER-positive tumors in patients with CYP1A2*1F A/A and may have implications for breast cancer if confirmed.,A,CYP1A2*1F,CYP1A2,0.5
2053,bc_id2111,CANCER,PTPRN2,18398821,B,"Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.",2008,,X,X,X,X,0
2054,bc_id2112,CANCER,KPNB1,18398821,B,"Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.",2008,,X,X,X,X,0
2055,bc_id2113,CANCER,JMY,18398821,B,"Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.",2008,,X,X,X,X,0
2056,bc_id2114,CANCER,CWF19L2,18398821,B,"Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.",2008,,X,X,X,X,0
2057,bc_id2115,CANCER,CHST3,18398821,B,"Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.",2008,,X,X,X,X,0
2058,bc_id2116,CANCER,CNTNAP4,18398821,B,"Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.",2008,,X,X,X,X,0
2059,bc_id2117,CANCER,ADAMTS18,18398821,B,"Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.",2008,,X,X,X,X,0
2060,bc_id2118,CANCER,SPOCK2,18398821,B,"Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients.",2008,,X,X,X,X,0
2061,bc_id2119,CANCER,CYP2D6,18407954,B,Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.,2008,,Human cytochrome P450 2D6 (CYP2D6) genotype may affect the efficacy of tamoxifen treatment in Caucasian women with breast cancer.,A,CYP2D6,CYP2D6,0.590909091
2062,bc_id2120,CANCER,NQO1,18407955,B,Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).,2008,,X,X,X,X,0
2063,bc_id2121,CANCER,LTA,18409070,B,Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population.,2009,,TNF-LTA locus could serve as an important biomarker for breast cancer predisposition in Indian population.,A,TNF-LTA,LTA,0.75
2064,bc_id2122,CANCER,TNF,18409070,B,Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population.,2009,,TNF-LTA locus could serve as an important biomarker for breast cancer predisposition in Indian population.,A,TNF-LTA,TNF,0.4
2065,bc_id2124,CANCER,GSTA1,18414193,B,Polymorphisms of glutathione S-transferase A1 and O1 and breast cancer among postmenopausal Danish women.,2008,,X,X,X,X,0
2066,bc_id2125,CANCER,GSTO1,18414193,B,Polymorphisms of glutathione S-transferase A1 and O1 and breast cancer among postmenopausal Danish women.,2008,,"Two of the family members, GSTA1 and GSTO1, have only been considered in a very limited number of studies... The study suggests that postmenopausal carriers of the GSTO1 *B/*B genotype may be at increased risk of especially estrogen receptor positive breast cancer.",A,GSTO1,GSTO1,0.666666667
2067,bc_id2126,CANCER,BRIP1,18414782,B,Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.,2008,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,BRCA1,BRIP1,0.5
2068,bc_id2127,CANCER,FGFR1,18415014,B,Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.,2009,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,FGFRnAA,FGFR1,1
2069,bc_id2128,CANCER,ERCC2,18415014,B,Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.,2009,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,XPD,ERCC2,0.6875
2070,bc_id2129,CANCER,CYP1B1,18415014,B,Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.,2009,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,CYP1B1,CYP1B1,0.384615385
2071,bc_id2130,CANCER,CDKN2A,18415014,B,Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.,2009,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,CDKN2A,CDKN2A,0.625
2072,bc_id2131,CANCER,CHEK2,18415014,B,Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.,2009,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,CHEK2,CHEK2,0.383333333
2073,bc_id2132,CANCER,TP53,18415014,B,Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.,2009,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,p53,TP53,0.482758621
2074,bc_id2133,CANCER,TNR,18415014,B,Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.,2009,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,TNRnTT,TNR,1
2075,bc_id2134,CANCER,BRCA1,18415014,B,Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.,2009,,"Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition... The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.",A,BRCA1,BRCA1,0.60944206
2076,bc_id2135,CANCER,ERCC2,18415712,B,Polymorphisms of the XRCC1 and XPD genes and breast cancer risk: a case-control study.,2008,,"For the single nucleotide polymorphisms in XRCC1 exon 10 (Arg399Gln, G/A) and XPD exon 23 (Lys751Gln, A/C), no remarkable differences for genotype distribution and allele frequencies were observed between BC group and control group in the study... The data indicate a possible role for XPD (Arg156Arg, C/A) polymorphisms in BC susceptibility.",A,XPD,ERCC2,0.6875
2077,bc_id2136,CANCER,XRCC1,18415712,B,Polymorphisms of the XRCC1 and XPD genes and breast cancer risk: a case-control study.,2008,,X,X,X,X,0
2078,bc_id2137,CANCER,TNF,18416134,B,[Polymorphisms of tumor necrosis factor genes in sporadic and hereditary breast cancer],2008,,"It was suggested that polymorphism of 308 (G/A) TNFalpha and TNFa depended, first of all, on patterns of breast and, secondly, on the elevated TNFalpha expression as a factor of pathogenesis of hereditary breast cancer.",A,TNFalpha,TNF,0.4
2079,bc_id2138,CANCER,VDR,18419802,B,Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk.,2008,Our results support potential effects of VDR polymorphisms on postmenopausal breast cancer risk and possible differential effects of receptor status of the tumour.,No differences in serum 25(OD)D concentrations by VDR genotype were observed. None of the analyzed polymorphisms was associated with overall risk for postmenopausal breast cancer.,N,VDR,VDR,0.192307692
2080,bc_id2139,CANCER,GSTT1,18425393,B,"Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.",2008,,"In Caucasian women, the combined GSTP1 105IV/VV and CYP1B1 119AA genotypes resulted in a near 2-fold increase in risk (OR=1.96; 95% CI=1.04-3.72) and the three way combination of GSTP1 105IV/VV, CYP1B1 119AS/SS and GSTT1 null genotypes resulted in an almost 4-fold increase in risk (OR=3.97; 95% CI=1.27-12.40). These results suggest the importance of estrogen/carcinogen metabolic enzymes in the etiology of breast cancer, especially in women before the age of 60, as well as preventative measures such as smoking cessation.",Y,GSTT1,GSTT1,0.578947368
2081,bc_id2140,CANCER,GSTP1,18425393,B,"Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.",2008,,"In Caucasian women, the combined GSTP1 105IV/VV and CYP1B1 119AA genotypes resulted in a near 2-fold increase in risk (OR=1.96; 95% CI=1.04-3.72) and the three way combination of GSTP1 105IV/VV, CYP1B1 119AS/SS and GSTT1 null genotypes resulted in an almost 4-fold increase in risk (OR=3.97; 95% CI=1.27-12.40). These results suggest the importance of estrogen/carcinogen metabolic enzymes in the etiology of breast cancer, especially in women before the age of 60, as well as preventative measures such as smoking cessation.",Y,GSTP1,GSTP1,0.428571429
2082,bc_id2141,CANCER,GSTM1,18425393,B,"Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.",2008,,X,X,X,X,0
2083,bc_id2142,CANCER,CYP1B1,18425393,B,"Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.",2008,,"In Caucasian women, the combined GSTP1 105IV/VV and CYP1B1 119AA genotypes resulted in a near 2-fold increase in risk (OR=1.96; 95% CI=1.04-3.72) and the three way combination of GSTP1 105IV/VV, CYP1B1 119AS/SS and GSTT1 null genotypes resulted in an almost 4-fold increase in risk (OR=3.97; 95% CI=1.27-12.40). These results suggest the importance of estrogen/carcinogen metabolic enzymes in the etiology of breast cancer, especially in women before the age of 60, as well as preventative measures such as smoking cessation.",Y,CYP1B1,CYP1B1,0.358974359
2084,bc_id2143,CANCER,BRCA2,18429825,B,"Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.",2008,,"BRCA1 and BRCA2, two breast cancer susceptibility genes, are essential to maintain chromosomal integrity. ... Genotype containing the (CA)(17) allele in the 13q12-13 region was found to be associated with an increased breast cancer risk. The results indicate that dinucleotide CA repeat polymorphism at RAD51 and BRCA2 gene regions might be associated with genetic susceptibility to breast cancer.",A,BRCA2,BRCA2,0.576923077
2085,bc_id2144,CANCER,BRCA1,18429825,B,"Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.",2008,,"BRCA1 and BRCA2, two breast cancer susceptibility genes, are essential to maintain chromosomal integrity. ... Genotype containing the (CA)(17) allele in the 13q12-13 region was found to be associated with an increased breast cancer risk. The results indicate that dinucleotide CA repeat polymorphism at RAD51 and BRCA2 gene regions might be associated with genetic susceptibility to breast cancer.",A,BRCA1,BRCA1,0.60944206
2086,bc_id2145,CANCER,RAD51,18429825,B,"Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.",2008,,"BRCA1 and BRCA2, two breast cancer susceptibility genes, are essential to maintain chromosomal integrity. ... Genotype containing the (CA)(17) allele in the 13q12-13 region was found to be associated with an increased breast cancer risk. The results indicate that dinucleotide CA repeat polymorphism at RAD51 and BRCA2 gene regions might be associated with genetic susceptibility to breast cancer.",A,RAD51,RAD51,0.615384615
2087,bc_id2146,CANCER,BRCA2,18431501,B,BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history.,2008,"Here, we report a total of 14 BRCA1 and 17 BRCA2 sequence alterations, of which eight are novel (3 BRCA1 and 5 BRCA2).","Given that hereditary breast carcinoma is primarily due to germline mutations in one of two breast cancer susceptibility genes, BRCA1 and BRCA2, we have characterised the spectrum of BRCA mutations in a cohort of 37 individuals with early-onset disease (<or=40 years) and no reported family history... Here, we report a total of 14 BRCA1 and 17 BRCA2 sequence alterations, of which eight are novel (3 BRCA1 and 5 BRCA2).",A,BRCA2,BRCA2,0.576923077
2088,bc_id2147,CANCER,BRCA1,18431501,B,BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history.,2008,"Here, we report a total of 14 BRCA1 and 17 BRCA2 sequence alterations, of which eight are novel (3 BRCA1 and 5 BRCA2).","Given that hereditary breast carcinoma is primarily due to germline mutations in one of two breast cancer susceptibility genes, BRCA1 and BRCA2, we have characterised the spectrum of BRCA mutations in a cohort of 37 individuals with early-onset disease (<or=40 years) and no reported family history... Here, we report a total of 14 BRCA1 and 17 BRCA2 sequence alterations, of which eight are novel (3 BRCA1 and 5 BRCA2).",A,BRCA1,BRCA1,0.60944206
2089,bc_id2148,CANCER,BRCA2,18431737,B,"MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.",2008,we advise restricting BRCA1 MLPA screening to those subgroups that revealed LGRs and recommend BRCA2 MLPA screening only for families presenting with cooccurrence of female and male breast cancer.,"In summary, we advise restricting BRCA1 MLPA screening to those subgroups that revealed LGRs and recommend BRCA2 MLPA screening only for families presenting with cooccurrence of female and male breast cancer.",A,BRCA2,BRCA2,0.576923077
2090,bc_id2149,CANCER,BRCA1,18431737,B,"MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.",2008,we advise restricting BRCA1 MLPA screening to those subgroups that revealed LGRs and recommend BRCA2 MLPA screening only for families presenting with cooccurrence of female and male breast cancer.,"In summary, we advise restricting BRCA1 MLPA screening to those subgroups that revealed LGRs and recommend BRCA2 MLPA screening only for families presenting with cooccurrence of female and male breast cancer.",A,BRCA1,BRCA1,0.60944206
2091,bc_id2150,CANCER,ATM,18433505,Y,Association of common ATM variants with familial breast cancer in a South American population.,2008,,"In this study, a full mutation analysis of the ATM gene was carried out in patients from 137 Chilean breast cancer families, of which 126 were BRCA1/2 negatives and 11 BRCA1/2 positives... The IVS24-9 T/(-T), IVS38-8 T/C, 5557 G/A composite genotype alone or in combination with certain genetic background and/or environmental factors, could modify the cancer risk by increasing genetic instability or by altering the effect of the normal DNA damage response.",A,ATM,ATM,0.422222222
2092,bc_id2151,CANCER,BRCA2,18434071,B,Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.,2008,Prevalent atypical or malignant lesions are relatively a common finding in PM specimens in asymptomatic women with hereditary increased risk of breast cancer.,X,X,X,X,0
2093,bc_id2152,CANCER,BRCA1,18434071,B,Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.,2008,Prevalent atypical or malignant lesions are relatively a common finding in PM specimens in asymptomatic women with hereditary increased risk of breast cancer.,X,X,X,X,0
2094,bc_id2153,CANCER,MAP3K1,18437204,B,Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.,2008,,"A three-stage genome-wide association study recently identified single nucleotide polymorphisms (SNPs) in five loci (fibroblast growth receptor 2 (FGFR2), trinucleotide repeat containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), 8q24, and lymphocyte-specific protein 1 (LSP1)) associated with breast cancer risk.",Y,MAP3K1,MAP3K1,0.636363636
2095,bc_id2154,CANCER,LSP1,18437204,B,Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.,2008,,"A three-stage genome-wide association study recently identified single nucleotide polymorphisms (SNPs) in five loci (fibroblast growth receptor 2 (FGFR2), trinucleotide repeat containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), 8q24, and lymphocyte-specific protein 1 (LSP1)) associated with breast cancer risk.",Y,LSP1,LSP1,0.555555556
2096,bc_id2155,CANCER,TOX3,18437204,B,Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.,2008,,"A three-stage genome-wide association study recently identified single nucleotide polymorphisms (SNPs) in five loci (fibroblast growth receptor 2 (FGFR2), trinucleotide repeat containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), 8q24, and lymphocyte-specific protein 1 (LSP1)) associated with breast cancer risk.",Y,TNRC9,TOX3,0.5
2097,bc_id2156,CANCER,FGFR2,18437204,B,Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.,2008,,"A three-stage genome-wide association study recently identified single nucleotide polymorphisms (SNPs) in five loci (fibroblast growth receptor 2 (FGFR2), trinucleotide repeat containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), 8q24, and lymphocyte-specific protein 1 (LSP1)) associated with breast cancer risk.",Y,FGFR2,FGFR2,0.708333333
2098,bc_id2157,CANCER,SHBG,18437557,B,Molecular mechanisms of the D327N SHBG protective role on breast cancer development after estrogen exposure.,2009,,X,X,X,X,0
2099,bc_id2159,CANCER,ERBB2,18438707,B,HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis.,2009,,"So our analyses suggest HER2 codon 655 Val allele is weakly associated with an increased risk of breast cancer, and SNP at HER2 codon 655 could be considered as a susceptibility biomarker for breast cancer for Asian females or women age 45 years or younger.",A,HER2,ERBB2,0.452380952
2100,bc_id2160,CANCER,EGFR,18443966,B,Association between the length of a CA dinucleotide repeat in the EGFR and risk of breast cancer.,2008,,X,X,X,X,0
2101,bc_id2161,CANCER,CYP2D6,18445827,B,Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.,2008,,"Endocrine therapy tailored to CYP2D6 genotype could be considered for women who are newly diagnosed with breast cancer, particularly those who have with concerns about either the relative toxicity or the increased cost of aromatase inhibitors.",A,CYP2D6,CYP2D6,0.590909091
2102,bc_id2162,CANCER,PALB2,18446436,B,The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.,2009,,PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.,A,PALB2,PALB2,0.583333333
2103,bc_id2163,CANCER,PGC,18447628,B,Overall survival in women with breast cancer: the influence of pepsinogen C gene polymorphism.,2008,,"We hypothesize that PGC polymorphism can be a predictive biomarker in breast cancer, contributing to an individual profile of great interest in clinical oncology.",A,PGC,PGC,1
2104,bc_id2164,CANCER,ADIPOR1,18451143,B,Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk.,2008,,"One ADIPOR1 SNP (rs7539542), which modulates expression of adiponectin receptor 1 mRNA, was also associated with breast cancer risk (OR, 0.51; 95% CI, 0.28-0.92).",Y,ADIPOR1,ADIPOR1,0.5
2105,bc_id2165,CANCER,ADIPOQ,18451143,B,Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk.,2008,,"Two ADIPOQ SNPs (rs2241766 and rs1501299), which have been associated with circulating levels of adiponectin, were associated with breast cancer risk [rs1501299*GG: odd ratios (OR), 1.80; 95% confidence interval (95% CI), 1.14-2.85; rs2241766*TG: OR, 0.61; 95% CI, 0.46-0.80].",Y,ADIPOQ,ADIPOQ,0.5
2106,bc_id2166,CANCER,MUTYH,18454351,B,Mutations of the MYH gene do not substantially contribute to the risk of breast cancer.,2009,Carriers of the MYH Y165C or G382D mutant alleles do not appear to be at increased risk for breast cancer.,Carriers of the MYH Y165C or G382D mutant alleles do not appear to be at increased risk for breast cancer.,N,MYH,MUTYH,0.666666667
2107,bc_id2167,CANCER,ERCC2,18459458,B,XPD Lys751Gln polymorphism analysis in women with sporadic breast cancer.,2008,,In present work we investigated the association between XPD Lys751Gln polymorphism and breast cancer progression... The results support the hypothesis that the Lys751Gln polymorphism of XPD gene may be associated with the incidence of breast cancer.,A,XPD,ERCC2,0.6875
2108,bc_id2168,CANCER,GLG1,18463975,B,A pilot genome-wide association study of early-onset breast cancer.,2009,,"However, haplotype association tests, using 90730 tag-SNPs, suggested two regions in GLG1 and UGT1 genes retaining significance even after Bonferroni correction. Nevertheless, without systematic replication, findings from this pilot study, especially the associations of breast cancer in relation to specific SNPs, should be interpreted with great caution.",A,GLG1,GLG1,1
2109,bc_id2169,CANCER,UGT1A,18463975,B,A pilot genome-wide association study of early-onset breast cancer.,2009,,"However, haplotype association tests, using 90730 tag-SNPs, suggested two regions in GLG1 and UGT1 genes retaining significance even after Bonferroni correction. Nevertheless, without systematic replication, findings from this pilot study, especially the associations of breast cancer in relation to specific SNPs, should be interpreted with great caution.",A,UGT1,UGT1A,1
2110,bc_id2170,CANCER,ICAM1,18474291,B,Intercellular adhesion molecule-1 genetic markers (+241G/A and +469A/G) in Iranian women with breast cancer.,2008,,These findings indicate that individuals carrying the A allele of the ICAM1 gene as well as the A/G haplotype may have a higher risk of developing breast cancer.,A,ICAM1,ICAM1,1
2111,bc_id2171,CANCER,XRCC1,18481169,B,"Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures.",2009,,"We identified 36 eligible studies, in relation to the Arg399Gln polymorphism of XRCC1 and risk of breast cancer... In Asian countries the Arg/Gln versus Arg/Arg (OR = 0.98, 95% CI: 0.88-1.10) and Gln/Gln+Arg/Gln versus Arg/Arg (OR = 1.05, 95% CI: 0.95-1.18) were not associated with increased risk of breast cancer.",N,XRCC1,XRCC1,0.217391304
2112,bc_id2172,CANCER,BARD1,18481171,B,The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis.,2009,the BARD1 Cys557Ser variant is not associated with breast cancer risk.,the BARD1 Cys557Ser variant is not associated with breast cancer risk.,N,BARD1,BARD1,0.181818182
2113,bc_id2173,CANCER,FGFR2,18483326,B,FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations.,2008,,The identification of population-specific risk haplotypes in FGFR2 is likely to help identify causal variants for breast cancer.,A,FGFR2,FGFR2,0.25
2114,bc_id2174,CANCER,HSD17B1,18483327,B,Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.,2008,,"No associations between CYP11A1, CYP17A1, and HSD17B1 genotypes and risk of fibrocystic breast conditions were observed. Our findings support the possibility that common allelic variation at the CYP11A1 D15S520 locus alters breast cancer risk in Chinese women.",N,HSD17B1,HSD17B1,0.363636364
2115,bc_id2175,CANCER,CYP17A1,18483327,B,Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.,2008,,"No associations between CYP11A1, CYP17A1, and HSD17B1 genotypes and risk of fibrocystic breast conditions were observed. Our findings support the possibility that common allelic variation at the CYP11A1 D15S520 locus alters breast cancer risk in Chinese women.",N,CYP17A1,CYP17A1,0.266666667
2116,bc_id2176,CANCER,CYP11A1,18483327,B,Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.,2008,,"No associations between CYP11A1, CYP17A1, and HSD17B1 genotypes and risk of fibrocystic breast conditions were observed. Our findings support the possibility that common allelic variation at the CYP11A1 D15S520 locus alters breast cancer risk in Chinese women.",A,CYP11A1,CYP11A1,0.75
2117,bc_id2177,CANCER,CAT,18483329,B,Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.,2008,,Our findings suggest that CAT genotype modifies the effect of HRT use on breast cancer risk and that HRT may affect risk by affecting oxidative stress.,A,CAT,CAT,0.4
2118,bc_id2178,CANCER,BRCA2,18483851,B,Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.,2009,,X,X,X,X,0
2119,bc_id2179,CANCER,BRCA1,18483851,B,Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.,2009,,X,X,X,X,0
2120,bc_id2180,CANCER,BACH1,18483852,B,Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.,2009,,"The proper interaction between BRIP1/BACH1 and BRCA1 protein has been found to be crucial for BRCA1-mediated DNA double-strand break repair and BRIP1/BACH1 mutations were estimated to confer a relative risk for breast cancer of 2.0 in western populations... Altogether, the results of our study indicated that germline mutations in BRIP1/BACH were extremely rare in Chinese population and there was no evidence for the recommendation of BRIP1/BACH1 for genetic testing in Chinese.",A,BRIP1/BACH,BACH1,0.5
2121,bc_id2181,CANCER,BRIP1,18483852,B,Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.,2009,,"The proper interaction between BRIP1/BACH1 and BRCA1 protein has been found to be crucial for BRCA1-mediated DNA double-strand break repair and BRIP1/BACH1 mutations were estimated to confer a relative risk for breast cancer of 2.0 in western populations... Altogether, the results of our study indicated that germline mutations in BRIP1/BACH were extremely rare in Chinese population and there was no evidence for the recommendation of BRIP1/BACH1 for genetic testing in Chinese.",A,BRIP1/BACH,BRIP1,0.5
2122,bc_id2182,CANCER,CHEK2,18484200,B,Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.,2008,,The CHEK2.1100delC mutation may be a rare variant in Chinese populations and may not contribute to predisposition for familial breast cancer in China.,A,CHEK2.1100delC,CHEK2,0.383333333
2123,bc_id2183,CANCER,PHB,18494604,N,Lack of association between prohibitin 3' untranslated region C--&gt;T polymorphism and breast cancer in a Turkish population.,2008,,The prohibitin T variant is not associated with the risk of breast cancer in Turkish women.,N,prohibitin T,PHB,0.4
2124,bc_id2184,CANCER,CYP1B1,18497059,B,"Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia.",2008,,"We estimated the frequency of CYP1A1, CYP1A2, CYP1B1, CYP19, and SULT1A1 allelic variants in a female population of the Novosibirsk district and their association with the elevated risk of breast (BC), ovarian (OC), and endometrial (EC) cancers... In conclusion, these results support the hypothesis that susceptibility gene alleles of estrogen-metabolizing enzymes may differentially influence risk for woman hormone-dependent cancers.",A,CYP1B1,CYP1B1,0.384615385
2125,bc_id2185,CANCER,CYP1A2,18497059,B,"Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia.",2008,,"We estimated the frequency of CYP1A1, CYP1A2, CYP1B1, CYP19, and SULT1A1 allelic variants in a female population of the Novosibirsk district and their association with the elevated risk of breast (BC), ovarian (OC), and endometrial (EC) cancers... In conclusion, these results support the hypothesis that susceptibility gene alleles of estrogen-metabolizing enzymes may differentially influence risk for woman hormone-dependent cancers.",A,CYP1A2,CYP1A2,0.5
2126,bc_id2186,CANCER,CYP1A1,18497059,B,"Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia.",2008,,"We estimated the frequency of CYP1A1, CYP1A2, CYP1B1, CYP19, and SULT1A1 allelic variants in a female population of the Novosibirsk district and their association with the elevated risk of breast (BC), ovarian (OC), and endometrial (EC) cancers... In conclusion, these results support the hypothesis that susceptibility gene alleles of estrogen-metabolizing enzymes may differentially influence risk for woman hormone-dependent cancers.",A,CYP1A1,CYP1A1,0.456521739
2127,bc_id2187,CANCER,CYP19A1,18497059,B,"Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia.",2008,,"We estimated the frequency of CYP1A1, CYP1A2, CYP1B1, CYP19, and SULT1A1 allelic variants in a female population of the Novosibirsk district and their association with the elevated risk of breast (BC), ovarian (OC), and endometrial (EC) cancers... In conclusion, these results support the hypothesis that susceptibility gene alleles of estrogen-metabolizing enzymes may differentially influence risk for woman hormone-dependent cancers.",A,CYP19,CYP19A1,0.484848485
2128,bc_id2188,CANCER,SULT1A1,18497059,B,"Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia.",2008,,"We estimated the frequency of CYP1A1, CYP1A2, CYP1B1, CYP19, and SULT1A1 allelic variants in a female population of the Novosibirsk district and their association with the elevated risk of breast (BC), ovarian (OC), and endometrial (EC) cancers... In conclusion, these results support the hypothesis that susceptibility gene alleles of estrogen-metabolizing enzymes may differentially influence risk for woman hormone-dependent cancers.",A,SULT1A1,SULT1A1,0.387096774
2129,bc_id2189,CANCER,ATM,18497957,B,Contribution of mutations in ATM to breast cancer development in the Czech population.,2008,,"Thus, the association of the c.1066-6T>G mutation with familial breast cancer remains uncertain. Loss of the wild-type ATM allele has not been detected in the tumor samples from heterozygous carriers of the ATM mutation. Our experiments did not detect the hypermethylation of the ATM promoter in any of the DNA samples from tumor tissues.",N,ATM,ATM,0.244444444
2130,bc_id2190,CANCER,MTHFR,18498051,B,Dihydrofolate reductase (DHRF) 19-bp intron-1 deletion and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in breast cancer.,2009,,ANF,ANF,ANF,ANF,0
2131,bc_id2191,CANCER,DHFR,18498051,B,Dihydrofolate reductase (DHRF) 19-bp intron-1 deletion and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in breast cancer.,2009,,ANF,ANF,ANF,ANF,0
2132,bc_id2192,CANCER,CDKN2D,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2133,bc_id2193,CANCER,CDKN2C,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2134,bc_id2194,CANCER,CDKN2B,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2135,bc_id2195,CANCER,CDKN2A,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2136,bc_id2196,CANCER,CDKN1B,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2137,bc_id2197,CANCER,CDKN1A,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2138,bc_id2198,CANCER,CDK6,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2139,bc_id2199,CANCER,CDK4,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2140,bc_id2200,CANCER,CDK2,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2141,bc_id2201,CANCER,CCNE1,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2142,bc_id2202,CANCER,CCND3,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.","We examined associations between common germline genetic variation in 13 genes involved in cell cycle control (CCND1, CCND2, CCND3, CCNE1, CDK2 [p33], CDK4, CDK6, CDKN1A [p21, Cip1], CDKN1B [p27, Kip1], CDKN2A [p16], CDKN2B [p15], CDKN2C [p18], and CDKN2D [p19]) and survival among women diagnosed with invasive breast cancer participating in the SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity) breast cancer study... It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer. Further study is required to validate this finding.",A,CCND3,CCND3,1
2143,bc_id2203,CANCER,CCND2,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2144,bc_id2204,CANCER,CCND1,18507837,B,Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.,2008,"It is possible that CCND3 rs2479717, or another variant it tags, is associated with prognosis after a diagnosis of breast cancer.",X,X,X,X,0
2145,bc_id2205,CANCER,BRCA2,18509731,B,"Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.",2008,The results of this study suggest that the use of fertility medications does not adversely affect the risk of breast cancer among BRCA mutation carriers.,X,X,X,X,0
2146,bc_id2206,CANCER,BRCA1,18509731,B,"Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.",2008,The results of this study suggest that the use of fertility medications does not adversely affect the risk of breast cancer among BRCA mutation carriers.,X,X,X,X,0
2147,bc_id2207,CANCER,NQO1,18511948,B,NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.,2008,,"We propose a model of defective anthracycline response in NQO1-deficient breast tumors, along with increased genomic instability promoted by elevated reactive oxygen species (ROS), and suggest that the NQO1 genotype is a prognostic and predictive marker for breast cancer.",Y,NQO1,NQO1,0.5
2148,bc_id2208,CANCER,BRCA1,18512148,B,BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer.,2009,,Our study suggests that Chinese women with a family history of breast cancer whose tumors are diagnosed before age of 40 would be a suitable candidate for BRCA1 testing; and BRCA1 tumors in Chinese women exhibit an aggressive phenotype.,Y,BRCA1,BRCA1,0.326180258
2149,bc_id2209,CANCER,CYP2C19,18521743,Y,CYP2C19*17 is associated with decreased breast cancer risk.,2009,,Since CYP2C19*17 defines an ultra rapid metabolizer phenotype we suggest that an increased catabolism of estrogens by CYP2C19 may lead to decreased estrogen levels and therefore reduces breast cancer risk.,A,CYP2C19,CYP2C19,0.8
2150,bc_id2210,CANCER,GSTT1,18521819,B,"Relation of glutathione S-transferase T1, M1 and P1 genotypes and breast cancer risk.",2008,,X,X,X,X,0
2151,bc_id2211,CANCER,GSTP1,18521819,B,"Relation of glutathione S-transferase T1, M1 and P1 genotypes and breast cancer risk.",2008,,X,X,X,X,0
2152,bc_id2212,CANCER,GSTM1,18521819,B,"Relation of glutathione S-transferase T1, M1 and P1 genotypes and breast cancer risk.",2008,,X,X,X,X,0
2153,bc_id2213,CANCER,TGFB1,18523885,N,No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.,2009,These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.,These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.,N,TGFB1,TGFB1,0.296296296
2154,bc_id2214,CANCER,BRCA2,18523885,N,No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.,2009,These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.,X,X,X,X,0
2155,bc_id2215,CANCER,BRCA1,18523885,N,No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.,2009,These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.,X,X,X,X,0
2156,bc_id2216,CANCER,GSTT1,18542066,B,"Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers.",2008,,"In conclusion, our results indicate significantly elevated risk for BC in carriers of BRCA2 mutations with GSTP1-Val allele with dosage effect, as implicated by higher risk in homozygous Val carriers. The GSTM1- and GSTT1-null allele did not seem to have a major effect.",N,GSTT1,GSTT1,0.131578947
2157,bc_id2217,CANCER,GSTP1,18542066,B,"Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers.",2008,,"In conclusion, our results indicate significantly elevated risk for BC in carriers of BRCA2 mutations with GSTP1-Val allele with dosage effect, as implicated by higher risk in homozygous Val carriers. The GSTM1- and GSTT1-null allele did not seem to have a major effect.",Y,GSTP1,GSTP1,0.428571429
2158,bc_id2218,CANCER,GSTM1,18542066,B,"Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers.",2008,,"In conclusion, our results indicate significantly elevated risk for BC in carriers of BRCA2 mutations with GSTP1-Val allele with dosage effect, as implicated by higher risk in homozygous Val carriers. The GSTM1- and GSTT1-null allele did not seem to have a major effect.",N,GSTM1,GSTM1,0.20754717
2159,bc_id2219,CANCER,CDKN1B,18543099,N,No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,,"The 95% confidence intervals for per allele risk estimates excluded a twofold risk, indicating that common CDKN1B polymorphisms do not markedly modify breast cancer risk among BRCA1 or BRCA2 carriers.",N,CDKN1B,CDKN1B,0.285714286
2160,bc_id2220,CANCER,BRCA2,18543099,N,No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,,X,X,X,X,0
2161,bc_id2221,CANCER,BRCA1,18543099,N,No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,,X,X,X,X,0
2162,bc_id2222,CANCER,MDM2,18547962,B,MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk.,2008,"Our data clearly show neither association between SNP309 and cancer risk, nor the responsibility of G allele for increased MDM2 or decreased of p53 protein levels in human primary breast tumors.",X,X,X,X,0
2163,bc_id2223,CANCER,ITGB5,18550570,B,Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.,2008,,"We examined the effect of single-nucleotide polymorphisms (SNPs) in predicted miRNA target sites of six integrin genes (ITGA3, ITGA6, ITGAv, ITGB3, ITGB4 and ITGB5) on breast cancer (BC) risk and clinical outcome... None of the SNPs was significantly associated with BC risk.",N,ITGB5,ITGB5,1
2164,bc_id2224,CANCER,ITGB4,18550570,B,Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.,2008,,"We examined the effect of single-nucleotide polymorphisms (SNPs) in predicted miRNA target sites of six integrin genes (ITGA3, ITGA6, ITGAv, ITGB3, ITGB4 and ITGB5) on breast cancer (BC) risk and clinical outcome... None of the SNPs was significantly associated with BC risk.",N,ITGB4,ITGB4,1
2165,bc_id2225,CANCER,ITGB3,18550570,B,Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.,2008,,"We examined the effect of single-nucleotide polymorphisms (SNPs) in predicted miRNA target sites of six integrin genes (ITGA3, ITGA6, ITGAv, ITGB3, ITGB4 and ITGB5) on breast cancer (BC) risk and clinical outcome... None of the SNPs was significantly associated with BC risk.",N,ITGB3,ITGB3,0.666666667
2166,bc_id2226,CANCER,ITGAV,18550570,B,Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.,2008,,"We examined the effect of single-nucleotide polymorphisms (SNPs) in predicted miRNA target sites of six integrin genes (ITGA3, ITGA6, ITGAv, ITGB3, ITGB4 and ITGB5) on breast cancer (BC) risk and clinical outcome... None of the SNPs was significantly associated with BC risk.",N,ITGAv,ITGAV,1
2167,bc_id2227,CANCER,ITGA6,18550570,B,Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.,2008,,"We examined the effect of single-nucleotide polymorphisms (SNPs) in predicted miRNA target sites of six integrin genes (ITGA3, ITGA6, ITGAv, ITGB3, ITGB4 and ITGB5) on breast cancer (BC) risk and clinical outcome... None of the SNPs was significantly associated with BC risk.",N,ITGA6,ITGA6,1
2168,bc_id2228,CANCER,ITGA3,18550570,B,Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.,2008,,"We examined the effect of single-nucleotide polymorphisms (SNPs) in predicted miRNA target sites of six integrin genes (ITGA3, ITGA6, ITGAv, ITGB3, ITGB4 and ITGB5) on breast cancer (BC) risk and clinical outcome... None of the SNPs was significantly associated with BC risk.",N,ITGA3,ITGA3,1
2169,bc_id2229,CANCER,ERCC4,18551366,B,Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk.,2009,,Four variants were associated with breast cancer risk with a significance level of <0.01; two in the XPF gene and two in the XRCC3 gene.,Y,XPF,ERCC4,0.25
2170,bc_id2230,CANCER,XRCC3,18551366,B,Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk.,2009,,Four variants were associated with breast cancer risk with a significance level of <0.01; two in the XPF gene and two in the XRCC3 gene.,Y,XRCC3,XRCC3,0.269230769
2171,bc_id2231,CANCER,MRE11A,18553220,B,DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus.,2009,,This study suggests that genetic variants in BRCA2 and MRE11A are associated with breast cancer risk.,Y,MRE11A,MRE11A,1
2172,bc_id2232,CANCER,BRCA2,18553220,B,DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus.,2009,,This study suggests that genetic variants in BRCA2 and MRE11A are associated with breast cancer risk.,Y,BRCA2,BRCA2,0.324175824
2173,bc_id2233,CANCER,GC,18559548,B,"The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status.",2008,,Our results provide evidence for a serum 25(OH)D-independent effect of Gc2 allele carrier status in postmenopausal breast cancer.,Y,Gc2,GC,1
2174,bc_id2234,CANCER,AR,18562955,B,"Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility.",2008,,"These data suggest that longer AR (CAG)n repeat alleles may confer an increased risk of breast cancer among particular subsets of individuals, although these findings need replication in other populations.",A,AR,AR,0.458333333
2175,bc_id2235,CANCER,GSTT1,18574688,B,Detection and relevance of germline genetic polymorphisms in glutathione S-transferases (GSTs) in breast cancer patients from northern Indian population.,2009,The findings of this study are in line with previously published reports that show an overall association with GSTM1 and GSTP1 polymorphisms with breast cancer risk.,"Our results suggest that the variants in low penetrance genes such as GSTM1, GSTT1 and GSTP1 are associated with an increased breast cancer risk thereby suggesting their contribution in the etiology of breast cancer.",Y,GSTT1,GSTT1,0.578947368
2176,bc_id2236,CANCER,GSTP1,18574688,B,Detection and relevance of germline genetic polymorphisms in glutathione S-transferases (GSTs) in breast cancer patients from northern Indian population.,2009,The findings of this study are in line with previously published reports that show an overall association with GSTM1 and GSTP1 polymorphisms with breast cancer risk.,"Our results suggest that the variants in low penetrance genes such as GSTM1, GSTT1 and GSTP1 are associated with an increased breast cancer risk thereby suggesting their contribution in the etiology of breast cancer.",Y,GSTP1,GSTP1,0.428571429
2177,bc_id2237,CANCER,GSTM1,18574688,B,Detection and relevance of germline genetic polymorphisms in glutathione S-transferases (GSTs) in breast cancer patients from northern Indian population.,2009,The findings of this study are in line with previously published reports that show an overall association with GSTM1 and GSTP1 polymorphisms with breast cancer risk.,"Our results suggest that the variants in low penetrance genes such as GSTM1, GSTT1 and GSTP1 are associated with an increased breast cancer risk thereby suggesting their contribution in the etiology of breast cancer.",Y,GSTM1,GSTM1,0.452830189
2178,bc_id2238,CANCER,RNASEL,18575592,B,"Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer.",2008,"we have discovered an increased risk, a heterozygous advantage and thereby a protective effect linked to the RNASEL SNP rs3738579.","In conclusion, we have discovered an increased risk, a heterozygous advantage and thereby a protective effect linked to the RNASEL SNP rs3738579. This effect is found for patients diagnosed with carcinoma of the uterine cervix, HNSCC, and breast cancer thus pointing at RNASEL as a general marker for cancer risk and not restricted to familial prostate cancer.",Y,RNASEL,RNASEL,0.5
2179,bc_id2239,CANCER,PPARA,18586686,B,Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study.,2008,,Our results are the first to evaluate the relationship between PPARA and breast cancer incidence and suggest that replication in an independent cohort is warranted.,A,PPARA,PPARA,1
2180,bc_id2240,CANCER,VDR,18587672,B,Vitamin D receptor variants and breast cancer risk in the Polish population.,2009,this study has identified an association between the VDR gene and early onset breast cancer risk in the Polish population.,"In summary, this study has identified an association between the VDR gene and early onset breast cancer risk in the Polish population.",Y,VDR,VDR,0.269230769
2181,bc_id2241,CANCER,PPP1R13L,18588689,B,Linkage disequilibrium mapping of a breast cancer susceptibility locus near RAI/PPP1R13L/iASPP.,2008,,"We tested an additional 44 of these for association with disease and found a new tandem repeat marker, called RAI-3'd1, located downstream of the transcribed region of RAI, which was more strongly associated with breast cancer than any other marker we have tested (RR = 2.44 (1.41-4.23, p = 0.0008, all cases; RR = 6.29 (1.49-26.6), p = 0.01, cases up to 55 years of age).",Y,RAI,PPP1R13L,1
2182,bc_id2242,CANCER,IGFBP3,18596909,B,"IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).",2008,the impact of genetic variation in IGF1 and IGFBP3 on circulating IGF levels does not appear to substantially influence breast cancer risk substantially among primarily Caucasian postmenopausal women.,"Linkage disequilibrium and haplotype patterns were characterized in the regions surrounding IGF1 and the genes coding for two of its binding proteins, IGFBP1 and IGFBP3... In summary, the impact of genetic variation in IGF1 and IGFBP3 on circulating IGF levels does not appear to substantially influence breast cancer risk substantially among primarily Caucasian postmenopausal women.",N,IGFBP3,IGFBP3,0.214285714
2183,bc_id2243,CANCER,IGFBP1,18596909,B,"IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).",2008,the impact of genetic variation in IGF1 and IGFBP3 on circulating IGF levels does not appear to substantially influence breast cancer risk substantially among primarily Caucasian postmenopausal women.,X,X,X,X,0
2184,bc_id2244,CANCER,IGF1,18596909,B,"IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).",2008,the impact of genetic variation in IGF1 and IGFBP3 on circulating IGF levels does not appear to substantially influence breast cancer risk substantially among primarily Caucasian postmenopausal women.,"Linkage disequilibrium and haplotype patterns were characterized in the regions surrounding IGF1 and the genes coding for two of its binding proteins, IGFBP1 and IGFBP3... In summary, the impact of genetic variation in IGF1 and IGFBP3 on circulating IGF levels does not appear to substantially influence breast cancer risk substantially among primarily Caucasian postmenopausal women.",N,IGF1,IGF1,0.4
2185,bc_id2245,CANCER,IRS2,18611262,B,"Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.",2009,"Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.","Tagging single nucleotide polymorphisms (SNPs) were selected to capture common variation across seven candidate genes that encode adipose-related proteins: ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1... Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.",A,IRS2,IRS2,0.666666667
2186,bc_id2246,CANCER,IRS1,18611262,B,"Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.",2009,"Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.","Tagging single nucleotide polymorphisms (SNPs) were selected to capture common variation across seven candidate genes that encode adipose-related proteins: ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1... Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.",A,IRS1,IRS1,0.333333333
2187,bc_id2247,CANCER,HSD11B1,18611262,B,"Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.",2009,"Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.","Tagging single nucleotide polymorphisms (SNPs) were selected to capture common variation across seven candidate genes that encode adipose-related proteins: ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1... Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.",A,HSD11B1,HSD11B1,1
2188,bc_id2248,CANCER,ADRB3,18611262,B,"Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.",2009,"Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.","Tagging single nucleotide polymorphisms (SNPs) were selected to capture common variation across seven candidate genes that encode adipose-related proteins: ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1... Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.",A,ADRB3,ADRB3,1
2189,bc_id2249,CANCER,ADRB2,18611262,B,"Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.",2009,"Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.","Tagging single nucleotide polymorphisms (SNPs) were selected to capture common variation across seven candidate genes that encode adipose-related proteins: ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1... Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.",A,ADRB2,ADRB2,1
2190,bc_id2250,CANCER,GHRL,18611262,B,"Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.",2009,"Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.","Tagging single nucleotide polymorphisms (SNPs) were selected to capture common variation across seven candidate genes that encode adipose-related proteins: ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1... Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.",A,GHRL,GHRL,0.5
2191,bc_id2251,CANCER,SHC1,18611262,B,"Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.",2009,"Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.","Tagging single nucleotide polymorphisms (SNPs) were selected to capture common variation across seven candidate genes that encode adipose-related proteins: ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1... Our findings suggest that these tagging SNPs in HSD11B1 and IRS2 mark regions of the genome that may harbor risk alleles for breast cancer, and these associations are probably independent of adiposity.",A,SHC1,SHC1,0.5
2192,bc_id2252,CANCER,TP53,18612219,B,Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer.,2008,We provide a molecular explanation for the association of the arginine allele with tumor aggressiveness and treatment resistance in advanced breast cancer.,"Tumors at advanced stages grow in vivo in a hypoxic environment, and we mimicked such conditions in vitro using p53 null breast cancer cells transfected with either the arginine or proline allele. We also analyzed in vivo the p53 codon 72 genotype status of advanced breast cancer patients... We provide a molecular explanation for the association of the arginine allele with tumor aggressiveness and treatment resistance in advanced breast cancer.",A,p53,TP53,0.482758621
2193,bc_id2253,CANCER,IL6,18617366,B,Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings.,2008,,X,X,X,X,0
2194,bc_id2254,CANCER,IL1B,18617366,B,Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings.,2008,,"We examined single nucleotide polymorphisms (SNPs) in the promoters of cytokine genes as genetic risk factors for cytokine-related fatigue in 33 fatigued and 14 non-fatigued breast cancer survivors, focusing on promoter sequence polymorphisms in IL1B and IL6 associated with differential expression of proinflammatory cytokines... Associations between fatigue status and IL1B genotype remained significant after covariate adjustment for demographic, biobehavioral and treatment-related factors.",Y,IL1B,IL1B,0.2
2195,bc_id2255,CANCER,GSTT1,18618215,B,Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes.,2008,in our population only GSTP1 was associated with breast cancer risk.,"In this study we examine the role of the genes CYP1A1, CYP17, CYP2D6, GSTM1, GSTP1 and GSTT1 in breast cancer risk in Brazilian women... In conclusion, in our population only GSTP1 was associated with breast cancer risk. However, when the genes were tested in combination, a significant association in the breast cancer risk was observed.",A,GSTT1,GSTT1,0.289473684
2196,bc_id2256,CANCER,GSTP1,18618215,B,Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes.,2008,in our population only GSTP1 was associated with breast cancer risk.,"In this study we examine the role of the genes CYP1A1, CYP17, CYP2D6, GSTM1, GSTP1 and GSTT1 in breast cancer risk in Brazilian women... In conclusion, in our population only GSTP1 was associated with breast cancer risk. However, when the genes were tested in combination, a significant association in the breast cancer risk was observed.",Y,GSTP1,GSTP1,0.428571429
2197,bc_id2257,CANCER,GSTM1,18618215,B,Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes.,2008,in our population only GSTP1 was associated with breast cancer risk.,"In this study we examine the role of the genes CYP1A1, CYP17, CYP2D6, GSTM1, GSTP1 and GSTT1 in breast cancer risk in Brazilian women... In conclusion, in our population only GSTP1 was associated with breast cancer risk. However, when the genes were tested in combination, a significant association in the breast cancer risk was observed.",A,GSTM1,GSTM1,0.339622642
2198,bc_id2258,CANCER,CYP2D6,18618215,B,Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes.,2008,in our population only GSTP1 was associated with breast cancer risk.,"In this study we examine the role of the genes CYP1A1, CYP17, CYP2D6, GSTM1, GSTP1 and GSTT1 in breast cancer risk in Brazilian women... In conclusion, in our population only GSTP1 was associated with breast cancer risk. However, when the genes were tested in combination, a significant association in the breast cancer risk was observed.",A,CYP2D6,CYP2D6,0.590909091
2199,bc_id2259,CANCER,CYP1A1,18618215,B,Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes.,2008,in our population only GSTP1 was associated with breast cancer risk.,"In this study we examine the role of the genes CYP1A1, CYP17, CYP2D6, GSTM1, GSTP1 and GSTT1 in breast cancer risk in Brazilian women... In conclusion, in our population only GSTP1 was associated with breast cancer risk. However, when the genes were tested in combination, a significant association in the breast cancer risk was observed.",A,CYP1A1,CYP1A1,0.456521739
2200,bc_id2260,CANCER,CYP17A1,18618215,B,Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes.,2008,in our population only GSTP1 was associated with breast cancer risk.,"In this study we examine the role of the genes CYP1A1, CYP17, CYP2D6, GSTM1, GSTP1 and GSTT1 in breast cancer risk in Brazilian women... In conclusion, in our population only GSTP1 was associated with breast cancer risk. However, when the genes were tested in combination, a significant association in the breast cancer risk was observed.",A,CYP17,CYP17A1,0.466666667
2201,bc_id2261,CANCER,BRCA2,18627636,B,Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.,2009,,"A total of 187 breast cancer patients with either early-onset breast cancer (at age </= 40 years) or a personal and/or family history of breast or ovarian cancer were comprehensively tested by full sequencing of both BRCA1 and BRCA2... Twenty-seven deleterious mutations were detected (14 in BRCA1 and 13 in BRCA2), only one of which was found in two unrelated individuals (BRCA2 490 delCT). In addition, 47 variants of uncertain clinical significance were identified (16 in BRCA1 and 31 in BRCA2). Notably, many mutations are novel (13 of the 30 BRCA1 mutations and 24 of the 44 BRCA2).",A,BRCA2,BRCA2,0.576923077
2202,bc_id2262,CANCER,BRCA1,18627636,B,Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.,2009,,"A total of 187 breast cancer patients with either early-onset breast cancer (at age </= 40 years) or a personal and/or family history of breast or ovarian cancer were comprehensively tested by full sequencing of both BRCA1 and BRCA2... Twenty-seven deleterious mutations were detected (14 in BRCA1 and 13 in BRCA2), only one of which was found in two unrelated individuals (BRCA2 490 delCT). In addition, 47 variants of uncertain clinical significance were identified (16 in BRCA1 and 31 in BRCA2). Notably, many mutations are novel (13 of the 30 BRCA1 mutations and 24 of the 44 BRCA2).",A,BRCA1,BRCA1,0.60944206
2203,bc_id2263,CANCER,PGR,18628428,B,"Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.",2008,,X,X,X,X,0
2204,bc_id2264,CANCER,CYP1B1,18628428,B,"Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.",2008,,"Statistically significant interactions between CYP1A1 Ile(462)Val (P(interaction) = 0.04), CYP1A1 MspI (P(interaction) = 0.003), CYP1B1 Val(432)Leu (P(interaction) = 0.007), CYP1B1 Asn(453)Ser (P(interaction) = 0.04) and PGR Val(660)Leu (P(interaction) = 0.01), and E+P use were observed... Risk of breast cancer increased little with increasing years of E+P use among women with at least one CYP1B1 Val(432) allele; a large increase in risk was seen among women homozygous for CYP1B1 Leu(432).",Y,CYP1B1,CYP1B1,0.358974359
2205,bc_id2265,CANCER,CYP1A1,18628428,B,"Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.",2008,,X,X,X,X,0
2206,bc_id2266,CANCER,CYP19A1,18629629,B,Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.,2009,,"This study provides evidence that polymorphisms CYP17 rs743572, CYP19 rs10046 and ER-alpha rs3798577 are associated with breast cancer risk among Chinese women.",Y,CYP19,CYP19A1,0.333333333
2207,bc_id2267,CANCER,CYP17A1,18629629,B,Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.,2009,,"This study provides evidence that polymorphisms CYP17 rs743572, CYP19 rs10046 and ER-alpha rs3798577 are associated with breast cancer risk among Chinese women.",Y,CYP17,CYP17A1,0.266666667
2208,bc_id2268,CANCER,F5,18632446,B,Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis.,2006,,X,X,X,X,0
2209,bc_id2269,CANCER,F2,18632446,B,Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis.,2006,,X,X,X,X,0
2210,bc_id2270,CANCER,COMT,18632656,B,Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.,2008,,"These studies showed that two SNPs in the COMT distal promoter were associated with breast cancer risk reduction in two of three case control studies, compatible with the results of functional genomic experiments, suggesting a role for MB-COMT in breast cancer risk.",A,MB-COMT,COMT,0.425531915
2211,bc_id2271,CANCER,GPC1,18634034,B,Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women.,2009,,X,X,X,X,0
2212,bc_id2272,CANCER,MYH7B,18634034,B,Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women.,2009,,X,X,X,X,0
2213,bc_id2273,CANCER,TP53,18640791,B,The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.,2008,,"The Ins16bp and Arg72Pro polymorphisms of p53 were implicated in breast cancer and recently it has been shown that these polymorphisms could have an effect when combined as specific haplotypes.... These observations suggested that neither the Ins16bp or Arg72Pro polymorphisms considered separately, nor any related haplotype, were associated with breast cancer risk in BRCA-mutation negative familial cases.",N,p53,TP53,0.149425287
2214,bc_id2274,CANCER,BRCA2,18645608,B,"BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.",2008,"we observed a much higher frequency of BRCA1 mutations among young breast cancer patients than observed in Europe, suggesting biological differences and that the inclusion criterea for analysis in Western Europe may not be applicable for the Northern Af","In Western populations, 5 to 10 % of breast cancer cases can be attributed to major genetic factors such as BRCA1 and BRCA2, while this attribution is not yet well defined among Africans... In conclusion, we observed a much higher frequency of BRCA1 mutations among young breast cancer patients than observed in Europe, suggesting biological differences and that the inclusion criterea for analysis in Western Europe may not be applicable for the Northern African population.",A,BRCA2,BRCA2,0.576923077
2215,bc_id2275,CANCER,BRCA1,18645608,B,"BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases.",2008,"we observed a much higher frequency of BRCA1 mutations among young breast cancer patients than observed in Europe, suggesting biological differences and that the inclusion criterea for analysis in Western Europe may not be applicable for the Northern Af","In Western populations, 5 to 10 % of breast cancer cases can be attributed to major genetic factors such as BRCA1 and BRCA2, while this attribution is not yet well defined among Africans... In conclusion, we observed a much higher frequency of BRCA1 mutations among young breast cancer patients than observed in Europe, suggesting biological differences and that the inclusion criterea for analysis in Western Europe may not be applicable for the Northern African population.",Y,BRCA1,BRCA1,0.326180258
2216,bc_id2276,CANCER,MMP7,18648013,B,Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality.,2008,,Results from our study suggest that common MMP-7 genetic polymorphisms may contribute to breast cancer susceptibility.,A,MMP-7,MMP7,0.75
2217,bc_id2277,CANCER,BRCA2,18662409,B,Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals.,2008,"After screening of 66 patients with family history and 64 sporadic breast cancer patients, 2 deleterious mutations (c.","Germline mutations in the susceptibility genes BRCA1 and BRCA2 in hereditary breast/ovarian cancer, though low in prevalence, are highly penetrant and show geographical variations. There have been only a few reports from Asia on mutations in BRCA1/2 genes and none from Sri Lanka.",A,BRCA2,BRCA2,0.576923077
2218,bc_id2278,CANCER,BRCA1,18662409,B,Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals.,2008,"After screening of 66 patients with family history and 64 sporadic breast cancer patients, 2 deleterious mutations (c.","Germline mutations in the susceptibility genes BRCA1 and BRCA2 in hereditary breast/ovarian cancer, though low in prevalence, are highly penetrant and show geographical variations. There have been only a few reports from Asia on mutations in BRCA1/2 genes and none from Sri Lanka.",A,BRCA1,BRCA1,0.60944206
2219,bc_id2279,CANCER,BRCA2,18663943,B,[Several risk factors of breast cancer development and prognosis of its course],2008,,The article presents some risk factors of breast cancer development and prognosis of the disease in Ukrainian patients. The frequency of 5382ins and 185delAG mutations in gene BRCA 1 and mutations of 6174delT in gene BRCA 2 was detected in the group of patients from Ukraine.,Y,BRCA 2,BRCA2,0.324175824
2220,bc_id2280,CANCER,BRCA1,18663943,B,[Several risk factors of breast cancer development and prognosis of its course],2008,,The article presents some risk factors of breast cancer development and prognosis of the disease in Ukrainian patients. The frequency of 5382ins and 185delAG mutations in gene BRCA 1 and mutations of 6174delT in gene BRCA 2 was detected in the group of patients from Ukraine.,Y,BRCA 1,BRCA1,0.326180258
2221,bc_id2281,CANCER,LEPR,18668212,B,"Associations among lipids, leptin, and leptin receptor gene Gin223Arg polymorphisms and breast cancer in China.",2009,,"And, it also suggested that LEPR gene Gln223Arg polymorphisms, elevated leptin, insulin, TG, FCH, APOA1, WHR, and reduced APOB should play a major role in the development of breast cancer.",Y,LEPR,LEPR,0.285714286
2222,bc_id2282,CANCER,PCNA,18669164,B,Association of polymorphisms in base excision repair genes with the risk of breast cancer: a case-control study in North Indian women.,2008,,X,X,X,X,0
2223,bc_id2283,CANCER,FEN1,18669164,B,Association of polymorphisms in base excision repair genes with the risk of breast cancer: a case-control study in North Indian women.,2008,,X,X,X,X,0
2224,bc_id2284,CANCER,XRCC1,18669164,B,Association of polymorphisms in base excision repair genes with the risk of breast cancer: a case-control study in North Indian women.,2008,,"The present case-control study with 390 north Indian women (155 breast cancer cases and 235 controls) was aimed to investigate the association of seven nonsynonymous BER gene polymorphisms viz. rs1130409/T1865G (APEX1), rs1799782/T22142C (XRCC1), rs25487/G23990A (XRCC1), rs4989588/T3337A (FEN1), rs4989586/ G3259A (FEN1), rs4989587/C3315T (FEN1), and rs1050525/G6941T (PCNA) with breast cancer susceptibility... The results indicate that the polymorphisms rs1130409 (APEX1) and rs25487 (XRCC1) might be involved in contributing towards breast cancer susceptibility, while rs1799782 (XRCC1) might have protective influence.",A,XRCC1,XRCC1,0.543478261
2225,bc_id2285,CANCER,MTHFR,18669903,B,"Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study.",2008,,"In a nested case-control study of 380 women with incident breast cancer and 662 controls within the Singapore Chinese Health Study, we found no association between either green tea intake or gene polymorphisms of MTHFR (C677T and A1298C) and TYMS (1494 ins/del) and breast cancer risk.",N,MTHFR,MTHFR,0.326923077
2226,bc_id2286,CANCER,TYMS,18669903,B,"Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study.",2008,,"In a nested case-control study of 380 women with incident breast cancer and 662 controls within the Singapore Chinese Health Study, we found no association between either green tea intake or gene polymorphisms of MTHFR (C677T and A1298C) and TYMS (1494 ins/del) and breast cancer risk.",N,TYMS,TYMS,0.3
2227,bc_id2287,CANCER,NME1,18676749,B,Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival.,2008,Promoter polymorphisms in the NME1 gene may alter its expression and influence breast cancer survival.,Promoter polymorphisms in the NME1 gene may alter its expression and influence breast cancer survival.,A,NME1,NME1,1
2228,bc_id2288,CANCER,BRCA1,18679828,B,Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.,2009,BRCA1 Y101X is the first reported recurrent mutation occurring in patients of African ancestry for which prevalence has been determined.,"The BRCA1 Y101X mutation was detected in four Yoruban patients with no documented family history of breast cancer among a cohort of 365 (1.1, 95% C.I. = 0.43-2.78%) unrelated Yoruban breast cancer patients... BRCA1 Y101X is the first reported recurrent mutation occurring in patients of African ancestry for which prevalence has been determined. Identification of this mutation in a woman of European ancestry with strong family history of breast/ovarian suggests further that this mutation occurred once, probably many generations ago.",A,BRCA1,BRCA1,0.60944206
2229,bc_id2289,CANCER,UIMC1,18695986,B,"Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases.",2009,"Overall, it seems unlikely that moderate to highly penetrant alleles of either RAP80 or Abraxas, confer a significantly high relative risk of breast cancer.","Overall, it seems unlikely that moderate to highly penetrant alleles of either RAP80 or Abraxas, confer a significantly high relative risk of breast cancer.",A,RAP80,UIMC1,0.333333333
2230,bc_id2290,CANCER,CCDC98,18695986,B,"Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases.",2009,"Overall, it seems unlikely that moderate to highly penetrant alleles of either RAP80 or Abraxas, confer a significantly high relative risk of breast cancer.","Overall, it seems unlikely that moderate to highly penetrant alleles of either RAP80 or Abraxas, confer a significantly high relative risk of breast cancer.",A,Abraxas,CCDC98,0.5
2231,bc_id2291,CANCER,POLD1,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,POLD1,POLD1,1
2232,bc_id2292,CANCER,NBN,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,NBS1,NBN,0.571428571
2233,bc_id2293,CANCER,MSH6,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,MSH6,MSH6,1
2234,bc_id2294,CANCER,MSH3,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,MSH3,MSH3,1
2235,bc_id2295,CANCER,MLH1,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,MLH1,MLH1,1
2236,bc_id2296,CANCER,APEX1,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,APE1,APEX1,0.333333333
2237,bc_id2297,CANCER,ERCC5,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,ERCC5,ERCC5,0.666666667
2238,bc_id2298,CANCER,ERCC4,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,ERCC4,ERCC4,0.5
2239,bc_id2299,CANCER,ERCC2,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,ERCC2,ERCC2,0.6875
2240,bc_id2300,CANCER,ADPRTL4,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,ADPRT,ADPRTL4,1
2241,bc_id2301,CANCER,XRCC3,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,XRCC3,XRCC3,0.461538462
2242,bc_id2302,CANCER,XRCC1,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,XRCC1,XRCC1,0.543478261
2243,bc_id2303,CANCER,XPC,18701435,B,Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.,2008,,"we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M... Our results suggest that combined nsSNPs in multiple DNA repair pathways may contribute to breast cancer risk and larger studies are warranted to further evaluate polygenic models of DNA repair in breast cancer risk.",A,XPC,XPC,0.571428571
2244,bc_id2304,CANCER,ATM,18701470,B,Variants in the ATM gene associated with a reduced risk of contralateral breast cancer.,2008,,"ATM, a serine-threonine kinase, controls the cellular response to DNA double-strand breaks, and has been implicated in breast cancer risk.",Y,ATM,ATM,0.333333333
2245,bc_id2305,CANCER,BRCA2,18703817,B,The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.,2008,,X,X,X,X,0
2246,bc_id2306,CANCER,BRCA1,18703817,B,The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.,2008,,X,X,X,X,0
2247,bc_id2307,CANCER,CHEK2,18706089,B,Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.,2008,"The novel CHEK2 missense variant identified in this study, R406H, is unlikely to contribute to breast cancer risk in French Canadian women.","The novel CHEK2 missense variant identified in this study, R406H, is unlikely to contribute to breast cancer risk in French Canadian women.",N,CHEK2,CHEK2,0.233333333
2248,bc_id2308,CANCER,AXIN2,18708403,B,Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.,2008,,"Here, we report a comprehensive study of the contribution of genetic variation in six genes encoding the beta-catenin destruction complex (APC, AXIN1, AXIN2, CSNK1D, CSNK1E, and GSK3B) to breast cancer using a Mayo Clinic Breast Cancer Case-Control Study... The combination of our findings and numerous genetic and functional studies showing that APC and AXIN2 perform crucial tumor suppressor functions suggest that further investigation of the contribution of AXIN2 and APC SNPs to breast cancer risk are needed.",A,AXIN2,AXIN2,1
2249,bc_id2309,CANCER,AXIN1,18708403,B,Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.,2008,,X,X,X,X,0
2250,bc_id2310,CANCER,APC,18708403,B,Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.,2008,,"Here, we report a comprehensive study of the contribution of genetic variation in six genes encoding the beta-catenin destruction complex (APC, AXIN1, AXIN2, CSNK1D, CSNK1E, and GSK3B) to breast cancer using a Mayo Clinic Breast Cancer Case-Control Study... The combination of our findings and numerous genetic and functional studies showing that APC and AXIN2 perform crucial tumor suppressor functions suggest that further investigation of the contribution of AXIN2 and APC SNPs to breast cancer risk are needed.",A,APC,APC,1
2251,bc_id2311,CANCER,GSK3B,18708403,B,Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.,2008,,X,X,X,X,0
2252,bc_id2312,CANCER,CSNK1E,18708403,B,Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.,2008,,X,X,X,X,0
2253,bc_id2313,CANCER,CSNK1D,18708403,B,Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.,2008,,X,X,X,X,0
2254,bc_id2314,CANCER,TRNL2,18709563,B,Mitochondrial DNA variant interactions modify breast cancer risk.,2008,,X,X,X,X,0
2255,bc_id2315,CANCER,ND3,18709563,B,Mitochondrial DNA variant interactions modify breast cancer risk.,2008,,X,X,X,X,0
2256,bc_id2316,CANCER,ND1,18709563,B,Mitochondrial DNA variant interactions modify breast cancer risk.,2008,,X,X,X,X,0
2257,bc_id2317,CANCER,ND5,18709563,B,Mitochondrial DNA variant interactions modify breast cancer risk.,2008,,X,X,X,X,0
2258,bc_id2318,CANCER,CYTB,18709563,B,Mitochondrial DNA variant interactions modify breast cancer risk.,2008,,X,X,X,X,0
2259,bc_id2319,CANCER,RNR1,18709563,B,Mitochondrial DNA variant interactions modify breast cancer risk.,2008,,X,X,X,X,0
2260,bc_id2320,CANCER,TP53,18714570,B,Study of p53 codon 72 polymorphism in patients with breast cancer.,2008,,"According to our results, the TP53 polymorphism, at the 347 residue, is not associated with any clinicopathological findings of patients with breast cancer.",N,TP53,TP53,0.149425287
2261,bc_id2321,CANCER,VDR,18719092,B,"Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population.",2008,"support the idea that vitamin D, through its signalling pathway, can affect breast cancer risk.",They also suggest that variability in observed associations between VDR FokI and breast cancer from different studies may partly be explained by the proportion of study subjects with a family history of breast cancer.,A,VDR,VDR,0.538461538
2262,bc_id2322,CANCER,ERBB2,18721072,B,The influence of HER2 genotypes as molecular markers on breast cancer outcome.,2008,results of this study suggest that polymorphisms of the HER2 gene may be important susceptibility biomarkers for breast cancer risk among older women.,"In conclusion, results of this study suggest that polymorphisms of the HER2 gene may be important susceptibility biomarkers for breast cancer risk among older women.",A,HER2,ERBB2,0.452380952
2263,bc_id2323,CANCER,CDKN2A,18725978,B,CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.,2008,,X,X,X,X,0
2264,bc_id2324,CANCER,CHEK2,18725978,B,CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.,2008,,X,X,X,X,0
2265,bc_id2325,CANCER,TP53,18725978,B,CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.,2008,,X,X,X,X,0
2266,bc_id2326,CANCER,ERCC2,18752184,B,The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer.,2008,"the XRCC1 genotype was found to be associated with ductal carcinoma histotypes and XPD genotype with low histological grade, which is the most frequent pattern of sporadic breast carcinomas.","The aim of the present study was to investigate a possible association between DNA repair gene polymorphisms (XRCC1, XPD, XRCC3, and RAD51) with histological type, grade and hormone receptor expression in a series of breast cancers... In conclusion, the XRCC1 genotype was found to be associated with ductal carcinoma histotypes and XPD genotype with low histological grade, which is the most frequent pattern of sporadic breast carcinomas.",A,XPD,ERCC2,0.6875
2267,bc_id2327,CANCER,XRCC3,18752184,B,The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer.,2008,"the XRCC1 genotype was found to be associated with ductal carcinoma histotypes and XPD genotype with low histological grade, which is the most frequent pattern of sporadic breast carcinomas.",X,X,X,X,0
2268,bc_id2328,CANCER,XRCC1,18752184,B,The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer.,2008,"the XRCC1 genotype was found to be associated with ductal carcinoma histotypes and XPD genotype with low histological grade, which is the most frequent pattern of sporadic breast carcinomas.","The aim of the present study was to investigate a possible association between DNA repair gene polymorphisms (XRCC1, XPD, XRCC3, and RAD51) with histological type, grade and hormone receptor expression in a series of breast cancers... In conclusion, the XRCC1 genotype was found to be associated with ductal carcinoma histotypes and XPD genotype with low histological grade, which is the most frequent pattern of sporadic breast carcinomas.",Y,XRCC1,XRCC1,0.239130435
2269,bc_id2329,CANCER,RAD51,18752184,B,The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer.,2008,"the XRCC1 genotype was found to be associated with ductal carcinoma histotypes and XPD genotype with low histological grade, which is the most frequent pattern of sporadic breast carcinomas.",X,X,X,X,0
2270,bc_id2330,CANCER,CHEK2,18759107,B,CHEK2 1100delC and male breast cancer in the Netherlands.,2009,,"Our data suggest that, in the Netherlands, CHEK2 1100delC is associated with an increased risk for MBC.",Y,CHEK2,CHEK2,0.383333333
2271,bc_id2331,CANCER,BRCA1,18759965,B,Contribution of BRCA1 germline mutation in patients with sporadic breast cancer.,2008,,Hereditary artifacts in BRCA1 gene have a significant contributory role in familial cases of breast cancer.,Y,BRCA1,BRCA1,0.326180258
2272,bc_id2332,CANCER,ERCC6,18767034,B,Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists.,2008,,"we examined whether risk of breast cancer conferred by radiation was modified by nucleotide excision gene polymorphisms ERCC2 (XPD) rs13181, ERCC4 (XPF) rs1800067 and rs1800124, ERCC5 (XPG) rs1047769 and rs17655; and ERCC6 rs2228526... These results suggest that common variants in nucleotide excision repair genes may modify the association between occupational radiation exposure and breast cancer risk.",A,ERCC6,ERCC6,1
2273,bc_id2333,CANCER,ERCC5,18767034,B,Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists.,2008,,"we examined whether risk of breast cancer conferred by radiation was modified by nucleotide excision gene polymorphisms ERCC2 (XPD) rs13181, ERCC4 (XPF) rs1800067 and rs1800124, ERCC5 (XPG) rs1047769 and rs17655; and ERCC6 rs2228526... These results suggest that common variants in nucleotide excision repair genes may modify the association between occupational radiation exposure and breast cancer risk.",A,ERCC5,ERCC5,0.666666667
2274,bc_id2334,CANCER,ERCC4,18767034,B,Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists.,2008,,"we examined whether risk of breast cancer conferred by radiation was modified by nucleotide excision gene polymorphisms ERCC2 (XPD) rs13181, ERCC4 (XPF) rs1800067 and rs1800124, ERCC5 (XPG) rs1047769 and rs17655; and ERCC6 rs2228526... These results suggest that common variants in nucleotide excision repair genes may modify the association between occupational radiation exposure and breast cancer risk.",A,ERCC4,ERCC4,0.5
2275,bc_id2335,CANCER,ERCC2,18767034,B,Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists.,2008,,"we examined whether risk of breast cancer conferred by radiation was modified by nucleotide excision gene polymorphisms ERCC2 (XPD) rs13181, ERCC4 (XPF) rs1800067 and rs1800124, ERCC5 (XPG) rs1047769 and rs17655; and ERCC6 rs2228526... These results suggest that common variants in nucleotide excision repair genes may modify the association between occupational radiation exposure and breast cancer risk.",A,ERCC2,ERCC2,0.6875
2276,bc_id2336,CANCER,F5,18777205,B,Factor V Leiden and prothrombin G20210A polymorphisms are not associated with disease-free survival in breast cancer.,2009,,ANF,ANF,ANF,ANF,0
2277,bc_id2337,CANCER,F2,18777205,B,Factor V Leiden and prothrombin G20210A polymorphisms are not associated with disease-free survival in breast cancer.,2009,,ANF,ANF,ANF,ANF,0
2278,bc_id2338,CANCER,BRCA2,18779615,B,Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.,2008,,"These results suggest that tumors associated with BRCA1 mutations may be divided into two distinct groups, triple-negative and non-triple-negative groups. Future studies should seek to determine whether patients with BRCA1 mutations and triple-negative breast cancer respond to treatment better than BRCA-negative patients with similar tumor pathology.",A,BRCA,BRCA2,0.576923077
2279,bc_id2339,CANCER,BRCA1,18779615,B,Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.,2008,,"These results suggest that tumors associated with BRCA1 mutations may be divided into two distinct groups, triple-negative and non-triple-negative groups. Future studies should seek to determine whether patients with BRCA1 mutations and triple-negative breast cancer respond to treatment better than BRCA-negative patients with similar tumor pathology.",A,BRCA1,BRCA1,0.60944206
2280,bc_id2340,CANCER,BRCA1,18782836,B,Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women.,2009,This comprehensive study of BRCA1 promoter polymorphisms found four variants that altered promoter activity and with the most significant contribution from c.,"This comprehensive study of BRCA1 promoter polymorphisms found four variants that altered promoter activity and with the most significant contribution from c.-2265C-->T, which could affect susceptibility to breast cancer in the Chinese population. Its significance in other populations remains to be investigated.",A,BRCA1,BRCA1,0.60944206
2281,bc_id2341,CANCER,MAP3K1,18785201,B,Novel breast cancer risk alleles and endometrial cancer risk.,2008,,X,X,X,X,0
2282,bc_id2342,CANCER,FGFR2,18785201,B,Novel breast cancer risk alleles and endometrial cancer risk.,2008,,X,X,X,X,0
2283,bc_id2343,CANCER,CYP2D6,18794105,B,Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.,2008,Poor metabolizer status for CYP2D6 predicts worse overall survival in patients with familial breast cancer.,"We conducted a case note review and genotyping for the CYP2D6*3, CYP2D6*4, CYP2D6*5, and CYP2D6*41 alleles in 115 patients (47 BRCA1, 68 BRCA2) with familial breast cancer who had been treated with 20-mg tamoxifen following surgery... Poor metabolizer status for CYP2D6 predicts worse overall survival in patients with familial breast cancer.",Y,CYP2D6,CYP2D6,0.272727273
2284,bc_id2344,CANCER,BRCA2,18794105,B,Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.,2008,Poor metabolizer status for CYP2D6 predicts worse overall survival in patients with familial breast cancer.,"We conducted a case note review and genotyping for the CYP2D6*3, CYP2D6*4, CYP2D6*5, and CYP2D6*41 alleles in 115 patients (47 BRCA1, 68 BRCA2) with familial breast cancer who had been treated with 20-mg tamoxifen following surgery... Poor metabolizer status for CYP2D6 predicts worse overall survival in patients with familial breast cancer.",A,BRCA2,BRCA2,0.576923077
2285,bc_id2345,CANCER,BRCA1,18794105,B,Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.,2008,Poor metabolizer status for CYP2D6 predicts worse overall survival in patients with familial breast cancer.,"We conducted a case note review and genotyping for the CYP2D6*3, CYP2D6*4, CYP2D6*5, and CYP2D6*41 alleles in 115 patients (47 BRCA1, 68 BRCA2) with familial breast cancer who had been treated with 20-mg tamoxifen following surgery... Poor metabolizer status for CYP2D6 predicts worse overall survival in patients with familial breast cancer.",A,BRCA1,BRCA1,0.60944206
2286,bc_id2346,CANCER,PALB2,18794107,B,Association of common PALB2 polymorphisms with breast cancer risk: a case-control study.,2008,,Our data suggest that the variants of PALB2 confer low-penetrance breast cancer susceptibility in a Chinese population.,Y,PALB2,PALB2,0.25
2287,bc_id2347,CANCER,PIK3CA,18798071,B,PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance.,2008,,Mutations in PIK3CA and alterations of BRCA1 expression are common in breast cancer and have been correlated with altered sensitivity to taxanes in human cancer cell lines and with outcome of patients.,Y,PIK3CA,PIK3CA,0.4
2288,bc_id2348,CANCER,MMP7,18798254,B,Genetic polymorphisms in the MMP-7 gene and breast cancer survival.,2009,,"Thus, common MMP-7 genetic polymorphisms were found to be significant determinants of survival among Chinese women with breast cancer.",Y,MMP-7,MMP7,0.25
2289,bc_id2349,CANCER,BRCA2,18807178,B,Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.,2009,,"Three risk assessment models, Penn II, Myriad and BRCApro, were applied to 212 familial breast cancer patients who had undergone BRCA1/2 mutation analysis. Sensitivity, specificity, positive and negative predictive values, likelihood ratios and area under the receiver operator characteristic (ROC) curve were calculated for each model... : Three models had the similar impact on the pre-test probability of BRCA mutation. But at a 10% cutoff point, BRCApro had the best BRCA mutation carrier prediction value.",A,BRCA1/2,BRCA2,0.576923077
2290,bc_id2350,CANCER,BRCA1,18807178,B,Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.,2009,,"Three risk assessment models, Penn II, Myriad and BRCApro, were applied to 212 familial breast cancer patients who had undergone BRCA1/2 mutation analysis. Sensitivity, specificity, positive and negative predictive values, likelihood ratios and area under the receiver operator characteristic (ROC) curve were calculated for each model... : Three models had the similar impact on the pre-test probability of BRCA mutation. But at a 10% cutoff point, BRCApro had the best BRCA mutation carrier prediction value.",A,BRCA1/2,BRCA1,0.60944206
2291,bc_id2351,CANCER,ATM,18807267,Y,A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer.,2009,,X,X,X,X,0
2292,bc_id2352,CANCER,BRCA1,18812548,B,Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.,2008,"Among postmenopausal women with a BRCA1 mutation, HT use was not associated with increased risk of breast cancer; indeed, in this population, it was associated with a decreased risk.",X,X,X,X,0
2293,bc_id2353,CANCER,CYP1A2,18813311,B,Coffee intake and CYP1A2*1F genotype predict breast volume in young women: implications for breast cancer.,2008,,"As breast volume may be associated with heart cancer risk, we studied the relationship between breast volume, CYP1A2*1F and coffee intake. Among healthy premenopausal non-hormone users, 3+ cups per day was associated with lower volume only in C-allele carriers (P(interaction)=0.02), which is consistent with reports that coffee protects only C-allele carriers against breast cancer.",A,CYP1A2*1F,CYP1A2,0.5
2294,bc_id2354,CANCER,CCND1,18819000,B,CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis.,2009,,"The results suggest that CCND1 G870A polymorphism may contribute to breast cancer development, especially in Caucasians.",A,CCND1,CCND1,0.5
2295,bc_id2355,CANCER,BRCA2,18819001,B,BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy.,2009,our results may have important implications on clinical management for this rare disease.,"MBC appears to be biologically similar to breast cancer in females, however the phenotypic characteristics of BRCA1/2-related MBCs are not yet well elucidated.",A,BRCA1/2,BRCA2,0.576923077
2296,bc_id2356,CANCER,BRCA1,18819001,B,BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy.,2009,our results may have important implications on clinical management for this rare disease.,"MBC appears to be biologically similar to breast cancer in females, however the phenotypic characteristics of BRCA1/2-related MBCs are not yet well elucidated.",A,BRCA1/2,BRCA1,0.60944206
2297,bc_id2357,IMMUNE,PTGS2,18819034,B,"Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.",2009,,X,X,X,X,0
2298,bc_id2358,IMMUNE,ABCB1,18819034,B,"Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population.",2009,,X,X,X,X,0
2299,bc_id2359,CANCER,HSD17B1,18820009,B,"Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.",2008,,X,X,X,X,0
2300,bc_id2360,CANCER,ESR1,18820009,B,"Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.",2008,,"We compared genetic polymorphisms of ERalpha, estrogen metabolism genes (CYP17A1, CYP19A1, HSD17B1 COASY, CYP1B1 and COMT), and p53 between ER-positive and -negative female Japanese breast cancer patients, and analyzed whether these polymorphisms affected the frequency of ER-positive breast cancer... Our study demonstrated genetic polymorphisms of ERalpha, CYP19A1, COMT and p53 genes frequently occur in ER-positive breast cancer in premenopausal Japanese women.",A,ERalpha,ESR1,0.586956522
2301,bc_id2361,CANCER,COASY,18820009,B,"Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.",2008,,X,X,X,X,0
2302,bc_id2362,CANCER,CYP1B1,18820009,B,"Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.",2008,,X,X,X,X,0
2303,bc_id2363,CANCER,CYP19A1,18820009,B,"Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.",2008,,"We compared genetic polymorphisms of ERalpha, estrogen metabolism genes (CYP17A1, CYP19A1, HSD17B1 COASY, CYP1B1 and COMT), and p53 between ER-positive and -negative female Japanese breast cancer patients, and analyzed whether these polymorphisms affected the frequency of ER-positive breast cancer... Our study demonstrated genetic polymorphisms of ERalpha, CYP19A1, COMT and p53 genes frequently occur in ER-positive breast cancer in premenopausal Japanese women.",Y,CYP19A1,CYP19A1,0.333333333
2304,bc_id2364,CANCER,CYP17A1,18820009,B,"Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.",2008,,X,X,X,X,0
2305,bc_id2365,CANCER,COMT,18820009,B,"Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.",2008,,"We compared genetic polymorphisms of ERalpha, estrogen metabolism genes (CYP17A1, CYP19A1, HSD17B1 COASY, CYP1B1 and COMT), and p53 between ER-positive and -negative female Japanese breast cancer patients, and analyzed whether these polymorphisms affected the frequency of ER-positive breast cancer... Our study demonstrated genetic polymorphisms of ERalpha, CYP19A1, COMT and p53 genes frequently occur in ER-positive breast cancer in premenopausal Japanese women.",Y,COMT,COMT,0.276595745
2306,bc_id2366,CANCER,TP53,18820009,B,"Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers.",2008,,"We compared genetic polymorphisms of ERalpha, estrogen metabolism genes (CYP17A1, CYP19A1, HSD17B1 COASY, CYP1B1 and COMT), and p53 between ER-positive and -negative female Japanese breast cancer patients, and analyzed whether these polymorphisms affected the frequency of ER-positive breast cancer... Our study demonstrated genetic polymorphisms of ERalpha, CYP19A1, COMT and p53 genes frequently occur in ER-positive breast cancer in premenopausal Japanese women.",Y,p53,TP53,0.367816092
2307,bc_id2368,CANCER,VEGFA,18824714,B,Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.,2008,Our data support an association between VEGF genotype and median OS as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer.,X,X,X,X,0
2308,bc_id2369,CANCER,TGFB1,18827819,B,TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival.,2008,,"The study suggests a complex role of TGF-beta1 in breast cancer progression, which supports the finding of in vitro studies that TGF-beta1 has conflicting effects on tumour growth and metastasis.",A,TGF-beta1,TGFB1,0.518518519
2309,bc_id2370,CANCER,BRCA1,18835712,B,Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations.,2008,,"These results suggest that somatic mutations of BRCA1 are infrequent in sporadic breast cancer, and nucleotide alterations were more easily observed in the breast cancer tissue DNA. It is likely that there are other important susceptibility genes that remain to be identified in patients with sporadic breast cancer.",A,BRCA1,BRCA1,0.60944206
2310,bc_id2371,CANCER,ABCB1,18836089,B,Association of the ABCB1 gene polymorphisms 2677G&gt;T/A and 3435C&gt;T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.,2009,ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic breast cancer patients.,ABCB1 genotypes may be a predictor of paclitaxel activity as well as a prognostic factor in metastatic breast cancer patients.,A,ABCB1,ABCB1,0.6875
2311,bc_id2372,CANCER,ESR1,18837888,B,HER-2/neu Ile655Val polymorphism and the risk of breast cancer.,2008,,The results of this study suggest that a significant gene-gene interaction between ESR1325C (previously reported) and HER-2/neu Ile655Val variants may jointly contribute to a higher risk of breast cancer.,A,ESR1325C,ESR1,0.586956522
2312,bc_id2373,CANCER,ERBB2,18837888,B,HER-2/neu Ile655Val polymorphism and the risk of breast cancer.,2008,,The results of this study suggest that a significant gene-gene interaction between ESR1325C (previously reported) and HER-2/neu Ile655Val variants may jointly contribute to a higher risk of breast cancer.,A,HER-2,ERBB2,0.452380952
2313,bc_id2374,CANCER,ESR1,18837889,B,Estrogen receptor alpha gene polymorphism and breast cancer.,2008,,This study found significant evidence that polymorphism within the low penetrance ESR1 is associated with breast cancer susceptibility in women of 50 years or younger. There is also an indication that G allele is protective (compared to C allele).,Y,ESR1,ESR1,0.282608696
2314,bc_id2375,CANCER,ESR1,18839613,B,[The analysis of estrogen receptor alpha (ER-alpha) gene Pvull and Xbal polymorphisms in postmenopausal women with breast cancer],2008,,The results suggest that the Pvull polymorphism of ER-alpha gene as well as Xbal polymorphism may not be linked with appearance and development of breast cancer.,A,ER-alpha,ESR1,0.586956522
2315,bc_id2376,CANCER,MTRR,18842997,B,Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.,2008,,X,X,X,X,0
2316,bc_id2377,CANCER,MTR,18842997,B,Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.,2008,,"Viable cell growth, MDI, and polymorphism frequency in MTRR (A66G and C524T) and MTHFR (A1298C and A1793G) did not differ among the study groups; however, MDI tended to be higher in BRCA carriers with breast cancer than those without and was significantly increased in MTHFR 677T allele carriers relative to wild-type carriers (P=0.017). The presence of MTR A2756G mutant allele and MTHFR C677T mutant allele in carriers was associated with increased breast cancer risk [odds ration, 3.2 (P=0.16; 95% confidence interval, 0.76-13.9) and 3.9 (P=0.09; 95% confidence interval, 0.93-16.3), respectively]. The results of this study support the hypothesis that defects in methionine metabolism may be associated with breast cancer risk in BRCA carriers.",Y,MTR,MTR,0.444444444
2317,bc_id2378,CANCER,MTHFR,18842997,B,Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.,2008,,"Viable cell growth, MDI, and polymorphism frequency in MTRR (A66G and C524T) and MTHFR (A1298C and A1793G) did not differ among the study groups; however, MDI tended to be higher in BRCA carriers with breast cancer than those without and was significantly increased in MTHFR 677T allele carriers relative to wild-type carriers (P=0.017). The presence of MTR A2756G mutant allele and MTHFR C677T mutant allele in carriers was associated with increased breast cancer risk [odds ration, 3.2 (P=0.16; 95% confidence interval, 0.76-13.9) and 3.9 (P=0.09; 95% confidence interval, 0.93-16.3), respectively]. The results of this study support the hypothesis that defects in methionine metabolism may be associated with breast cancer risk in BRCA carriers.",Y,MTHFR,MTHFR,0.269230769
2318,bc_id2379,CANCER,BRCA2,18842997,B,Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.,2008,,"Viable cell growth, MDI, and polymorphism frequency in MTRR (A66G and C524T) and MTHFR (A1298C and A1793G) did not differ among the study groups; however, MDI tended to be higher in BRCA carriers with breast cancer than those without and was significantly increased in MTHFR 677T allele carriers relative to wild-type carriers (P=0.017). The presence of MTR A2756G mutant allele and MTHFR C677T mutant allele in carriers was associated with increased breast cancer risk [odds ration, 3.2 (P=0.16; 95% confidence interval, 0.76-13.9) and 3.9 (P=0.09; 95% confidence interval, 0.93-16.3), respectively]. The results of this study support the hypothesis that defects in methionine metabolism may be associated with breast cancer risk in BRCA carriers.",A,BRCA,BRCA2,0.576923077
2319,bc_id2380,CANCER,BRCA1,18842997,B,Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer.,2008,,"Viable cell growth, MDI, and polymorphism frequency in MTRR (A66G and C524T) and MTHFR (A1298C and A1793G) did not differ among the study groups; however, MDI tended to be higher in BRCA carriers with breast cancer than those without and was significantly increased in MTHFR 677T allele carriers relative to wild-type carriers (P=0.017). The presence of MTR A2756G mutant allele and MTHFR C677T mutant allele in carriers was associated with increased breast cancer risk [odds ration, 3.2 (P=0.16; 95% confidence interval, 0.76-13.9) and 3.9 (P=0.09; 95% confidence interval, 0.93-16.3), respectively]. The results of this study support the hypothesis that defects in methionine metabolism may be associated with breast cancer risk in BRCA carriers.",A,BRCA,BRCA1,0.60944206
2320,bc_id2381,CANCER,ALOX5AP,18843019,B,"5-lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic acid, and risk for breast cancer.",2008,,"Among women consuming <or=17.4 g/d of linoleic acid, ALOX5AP -4900 genotype was not associated with breast cancer risk (age- and race-adjusted odds ratio, 0.9; 95% confidence interval, 0.7-1.2).",N,ALOX5AP,ALOX5AP,1
2321,bc_id2382,CANCER,HSD17B1,18843021,B,HSD17B1 genetic variants and hormone receptor-defined breast cancer.,2008,"it is unlikely that common genetic variation in HSD17B1 is associated with a moderate modulation in breast cancer risk overall; however, we cannot exclude the possibility of a very weak effect.",Associations between HSD17B1 genotypes and risk for ER- breast cancer were inconsistent across studies and should be studied further.,A,HSD17B1,HSD17B1,0.454545455
2322,bc_id2383,CANCER,FGFR2,18845558,B,Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women.,2008,,"These findings indicate that genetic variants in FGFR2 may contribute to breast cancer occurrence in Chinese women, possibly through pathways related to estrogen and/or progesterone.",A,FGFR2,FGFR2,0.25
2323,bc_id2384,CANCER,TNF,18846826,B,[Tumor necrosis factor gene polymorphisms in breast cancer patients],2008,,Analysis of microsatellite TNFalpha marker and (-308(G/A) polymorphisms in promoter of TNFalpha gene was conducted in 167 patients with various types of sporadic breast cancer (BC) as well as in 139 healthy Russian donors. It was shown that frequency of allele 7 in TNFalpha microsatellite marker was significantly higher in BC patients than in healthy donors (17.9% versus 10.4%; P = 0.02) mainly due to the patients with invasive ductal BC (19.2% versus 10.4%; P = 0.008).,Y,TNFalpha,TNF,0.333333333
2324,bc_id2385,CANCER,CHEK2,18930998,B,Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.,2009,Our study suggests that the risk of breast cancer in carriers of a deleterious CHEK2 mutation is increased if the second allele is the I157T missense variant.,Our study suggests that the risk of breast cancer in carriers of a deleterious CHEK2 mutation is increased if the second allele is the I157T missense variant. ,Y,CHEK2,CHEK2,0.383333333
2325,bc_id2386,CANCER,BRCA1,18930998,B,Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.,2009,Our study suggests that the risk of breast cancer in carriers of a deleterious CHEK2 mutation is increased if the second allele is the I157T missense variant.,"Our study suggests that the risk of breast cancer in carriers of a deleterious CHEK2 mutation is increased if the second allele is the I157T missense variant. However, the presence of a CHEK2 mutation in women with a BRCA1 mutation may not increase their risk beyond that of the BRCA1 mutation alone. These suggestive findings need to be verified in other studies.",A,BRCA1,BRCA1,0.60944206
2326,bc_id2387,CANCER,HIF1A,18949419,B,The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer.,2008,,"In our study, we investigated whether polymorphisms of the HIF-1alpha gene may account for the expression patterns of HIF-1alpha protein and impact of clinical progression in breast cancer.",A,HIF-1alpha,HIF1A,0.666666667
2327,bc_id2388,CANCER,TP53,18949740,B,TP53 mutations in breast cancer: association with ductal histology and early relapse of disease.,2009,TP53 mutations correlated only with nodal status and ductal histology.,X,X,X,X,0
2328,bc_id2389,CANCER,EGFR,18950515,B,Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.,2009,"TNBCs have an aggressive clinical course, and EGFR and BRCA1 might be candidate therapeutic targets in this disease.","TNBC patients had shorter disease-free survival than non-TNBC in node-negative breast cancers... TNBCs have an aggressive clinical course, and EGFR and BRCA1 might be candidate therapeutic targets in this disease.",A,EGFR,EGFR,0.571428571
2329,bc_id2390,CANCER,RAD1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2330,bc_id2391,CANCER,RAD17,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2331,bc_id2392,CANCER,BCCIP,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2332,bc_id2393,CANCER,BARD1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2333,bc_id2394,CANCER,BAP1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2334,bc_id2395,CANCER,PRKDC,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2335,bc_id2396,CANCER,BACH1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2336,bc_id2397,CANCER,PPARGC1A,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2337,bc_id2398,CANCER,PLK1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2338,bc_id2399,CANCER,ATR,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2339,bc_id2400,CANCER,PCAF,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2340,bc_id2401,CANCER,NRXN2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2341,bc_id2402,CANCER,NRIP1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2342,bc_id2403,CANCER,ATM,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2343,bc_id2404,CANCER,NMI,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2344,bc_id2405,CANCER,ATF1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2345,bc_id2406,CANCER,NFKBIA,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2346,bc_id2407,CANCER,NCOR2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2347,bc_id2408,CANCER,NBN,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2348,bc_id2409,CANCER,MYT1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2349,bc_id2410,CANCER,ABL1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2350,bc_id2411,CANCER,MYC,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2351,bc_id2412,CANCER,MSH6,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2352,bc_id2413,CANCER,MSH2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2353,bc_id2414,CANCER,MRE11A,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2354,bc_id2415,CANCER,MEF2C,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2355,bc_id2416,CANCER,MDM2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2356,bc_id2417,CANCER,MAPK9,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2357,bc_id2418,CANCER,MAPK8,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2358,bc_id2419,CANCER,LMO4,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2359,bc_id2420,CANCER,ATRIP,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2360,bc_id2421,CANCER,MED1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2361,bc_id2422,CANCER,JUN,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2362,bc_id2423,CANCER,HUS1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2363,bc_id2424,CANCER,HDAC2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2364,bc_id2425,CANCER,GTF2F1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2365,bc_id2426,CANCER,GTF2E1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2366,bc_id2427,CANCER,GTF2A1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2367,bc_id2428,CANCER,GADD45A,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2368,bc_id2429,CANCER,FANCG,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2369,bc_id2430,CANCER,FANCF,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2370,bc_id2431,CANCER,FANCE,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2371,bc_id2432,CANCER,FANCD2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2372,bc_id2433,CANCER,FANCC,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2373,bc_id2434,CANCER,FANCA,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2374,bc_id2435,CANCER,ESR1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2375,bc_id2436,CANCER,ERCC3,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2376,bc_id2437,CANCER,ERBB2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2377,bc_id2438,CANCER,EP300,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2378,bc_id2439,CANCER,EHF,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2379,bc_id2440,CANCER,AMAC1L3,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2380,bc_id2441,CANCER,PELP1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2381,bc_id2442,CANCER,CYR61,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2382,bc_id2443,CANCER,SHARPIN,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2383,bc_id2444,CANCER,CARM1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2384,bc_id2445,CANCER,ACAD10,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2385,bc_id2446,CANCER,CLCA2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2386,bc_id2447,CANCER,CHEK1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2387,bc_id2448,CANCER,GRIP1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2388,bc_id2449,CANCER,SCGB3A1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2389,bc_id2450,CANCER,GIPC3,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2390,bc_id2451,CANCER,C11ORF30,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2391,bc_id2452,CANCER,CDKN2D,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2392,bc_id2453,CANCER,CDKN1A,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2393,bc_id2454,CANCER,CDC34,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2394,bc_id2455,CANCER,CDC2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2395,bc_id2456,CANCER,EMG1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2396,bc_id2457,CANCER,ZNF350,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2397,bc_id2458,CANCER,CHEK2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2398,bc_id2459,CANCER,CCND2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2399,bc_id2460,CANCER,CCND1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2400,bc_id2461,CANCER,YWHAH,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2401,bc_id2462,CANCER,YWHAQ,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2402,bc_id2463,CANCER,WEE1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2403,bc_id2464,CANCER,TP73,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2404,bc_id2465,CANCER,TP53,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2405,bc_id2466,CANCER,TBP,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2406,bc_id2467,CANCER,STAT1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2407,bc_id2468,CANCER,SRA1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2408,bc_id2469,CANCER,BRCA2,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2409,bc_id2470,CANCER,BRCA1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2410,bc_id2471,CANCER,SHFM1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2411,bc_id2472,CANCER,RPS6KA1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2412,bc_id2473,CANCER,RAD50,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2413,bc_id2474,CANCER,RAD51,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2414,bc_id2475,CANCER,RB1,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2415,bc_id2476,CANCER,RBBP8,18950845,B,Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study.,2009,SNPs located at the gene HUS1 are good candidates for further investigation in independent association studies and functional assays.,X,X,X,X,0
2416,bc_id2478,CANCER,IL1B,18953879,B,[Association of cytokine gene polymorphisms with cachexia related to sporadic female breast cancer],2008,TNF2 plays an important role in the susceptibility of cachexia in breast cancer.,X,X,X,X,0
2417,bc_id2479,CANCER,IL10,18953879,B,[Association of cytokine gene polymorphisms with cachexia related to sporadic female breast cancer],2008,TNF2 plays an important role in the susceptibility of cachexia in breast cancer.,X,X,X,X,0
2418,bc_id2480,CANCER,TNF,18953879,B,[Association of cytokine gene polymorphisms with cachexia related to sporadic female breast cancer],2008,TNF2 plays an important role in the susceptibility of cachexia in breast cancer.,"Logistic regression analysis indicated TNF2 as a risk factor for cachexia in breast cancer ( OR = 2.333, 95% CI: 1.085-5.017).",Y,TNF-beta,TNF,0.333333333
2419,bc_id2481,CANCER,VEGFA,18972599,B,Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C&gt;T) gene and patients with stomach cancer.,2008,,NR,NR,NR,NR,0
2420,bc_id2482,CANCER,BLM,18974064,B,Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility.,2009,,Our results suggest a contribution of BLM and RAD51 to breast cancer development and provide support for the tumorigenic significance of the functional interaction between these two HR proteins.,A,BLM,BLM,0.5
2421,bc_id2483,CANCER,RAD51,18974064,B,Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility.,2009,,Our results suggest a contribution of BLM and RAD51 to breast cancer development and provide support for the tumorigenic significance of the functional interaction between these two HR proteins.,A,RAD51,RAD51,0.615384615
2422,bc_id2484,CANCER,OGG1,18977234,B,"Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients.",2008,,"In the present work we determined the level of basal (total endogenous) and endogenous oxidative DNA damage as well as polymorphism of the DNA repair genes: RAD51 (135 G/C), XRCC3 (Thr241Met), OGG1 (Ser326Cys) and XPD (Lys751Gln) in peripheral blood lymphocytes of 41 breast cancer patients and 48 healthy individuals... Our results suggest that the polymorphism of the RAD51, OGG1 and XPD genes may be linked with breast cancer by the modulation of the cellular response to oxidative stress and these polymorphisms may be considered as markers in breast cancer along with the genetic or/and environmental indicators of oxidative stress.",A,OGG1,OGG1,0.444444444
2423,bc_id2485,CANCER,ERCC2,18977234,B,"Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients.",2008,,"In the present work we determined the level of basal (total endogenous) and endogenous oxidative DNA damage as well as polymorphism of the DNA repair genes: RAD51 (135 G/C), XRCC3 (Thr241Met), OGG1 (Ser326Cys) and XPD (Lys751Gln) in peripheral blood lymphocytes of 41 breast cancer patients and 48 healthy individuals... Our results suggest that the polymorphism of the RAD51, OGG1 and XPD genes may be linked with breast cancer by the modulation of the cellular response to oxidative stress and these polymorphisms may be considered as markers in breast cancer along with the genetic or/and environmental indicators of oxidative stress.",A,XPD,ERCC2,0.6875
2424,bc_id2486,CANCER,XRCC3,18977234,B,"Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients.",2008,,X,X,X,X,0
2425,bc_id2487,CANCER,RAD51,18977234,B,"Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients.",2008,,"In the present work we determined the level of basal (total endogenous) and endogenous oxidative DNA damage as well as polymorphism of the DNA repair genes: RAD51 (135 G/C), XRCC3 (Thr241Met), OGG1 (Ser326Cys) and XPD (Lys751Gln) in peripheral blood lymphocytes of 41 breast cancer patients and 48 healthy individuals... Our results suggest that the polymorphism of the RAD51, OGG1 and XPD genes may be linked with breast cancer by the modulation of the cellular response to oxidative stress and these polymorphisms may be considered as markers in breast cancer along with the genetic or/and environmental indicators of oxidative stress.",A,RAD51,RAD51,0.615384615
2426,bc_id2488,CANCER,NR1I2,18981011,B,PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients.,2008,,X,X,X,X,0
2427,bc_id2489,CANCER,ABCB1,18981011,B,PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients.,2008,,X,X,X,X,0
2428,bc_id2490,CANCER,CYP3A4,18981011,B,PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients.,2008,,X,X,X,X,0
2429,bc_id2491,CANCER,IL13,18989750,B,Interleukin13 haplotypes and susceptibility of Iranian women to breast cancer.,2009,,"Despite observing no association between breast cancer and the single SNPs, results of this investigation suggest that the presence of CCA haplotype of IL13 gene may be associated with susceptibility of Iranian women to breast cancer.",A,IL13,IL13,1
2430,bc_id2492,CANCER,BRCA2,18990759,B,Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.,2008,,X,X,X,X,0
2431,bc_id2493,CANCER,BRCA1,18990759,B,Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.,2008,,X,X,X,X,0
2432,bc_id2494,CANCER,ATM,18990761,B,Breast cancer incidence and the effect of cigarette smoking in heterozygous carriers of mutations in the ataxia-telangiectasia gene.,2008,,X,X,X,X,0
2433,bc_id2496,CANCER,PTTG1,19008095,B,Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study.,2009,,X,X,X,X,0
2434,bc_id2497,CANCER,NEK2,19008095,B,Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study.,2009,,X,X,X,X,0
2435,bc_id2498,CANCER,ZWILCH,19008095,B,Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study.,2009,,X,X,X,X,0
2436,bc_id2499,CANCER,CENPF,19008095,B,Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study.,2009,,"We investigated whether putatively functional single nucleotide polymorphisms (SNPs) in genes related to CIN (CENPF, ESPL1, NEK2, PTTG1, ZWILCH, ZWINT) affect breast cancer (BC) risk and clinical outcome in a Swedish cohort of 749 incident BC cases with detailed clinical data and up to 15 years of follow-up and 1493 matched controls... As there is increasing evidence that CENPF is associated with poor prognosis in patients with primary BC, further independent studies are needed to clarify the importance of genetic variation in the CENPF gene in the clinic.",A,CENPF,CENPF,1
2437,bc_id2500,CANCER,ESPL1,19008095,B,Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study.,2009,,X,X,X,X,0
2438,bc_id2501,CANCER,ZWINT,19008095,B,Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study.,2009,,X,X,X,X,0
2439,bc_id2502,CANCER,CBR3,19016765,B,CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.,2008,,X,X,X,X,0
2440,bc_id2503,CANCER,CBR1,19016765,B,CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.,2008,,"The present study aimed to identify polymorphic genes encoding carbonyl reductases (CBR1, CBR3) and investigate their influence on doxorubicin disposition in Asian breast cancer patients... No significant influence of CBR3 polymorphisms on the pharmacokinetics of doxorubicin were observed in Asian cancer patients. The present exploratory study shows that CBR1 D2 diplotypes correlate with significantly higher exposure levels of doxorubicin, suggesting the possibility of lowered intracellular conversion to doxorubicinol in these patients.",A,CBR1,CBR1,1
2441,bc_id2504,CANCER,LEPR,19017403,B,Leptin receptor Gln223Arg polymorphism and breast cancer risk in Nigerian women: a case control study.,2009,Our results suggest that the LEPR Gln223Arg polymorphism in the extracellular domain of the LEPR receptor gene is associated with a modestly increased risk of premenopausal breast cancer in Nigerian women.,Our results suggest that the LEPR Gln223Arg polymorphism in the extracellular domain of the LEPR receptor gene is associated with a modestly increased risk of premenopausal breast cancer in Nigerian women.,Y,LEPR,LEPR,0.285714286
2442,bc_id2505,CANCER,CHEK2,19021634,B,Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.,2009,,Women with a CHEK2 mutation face a fourfold increase in the risk of ER-positive breast cancer and might be candidates for tamoxifen chemoprevention.,Y,CHEK2,CHEK2,0.383333333
2443,bc_id2506,CANCER,GSTT1,19024313,B,[Using MSR model to analyze the impact of gene-gene interaction with related to the genetic polymorphism of metabolism enzymes on the risk of breast cancer],2008,,The variant genotypes of CYP1A1 Msp I and GSTT1/M1 were identified by PCR-RFLP and multiplex PCR assays... The gene-gene interaction with related to the genetic polymorphism of metabolism enzymes (CYP1A1 and GSTT1) may increase the risk of breast cancer by disturbing the metabolism of estrogen.,A,GSTT1,GSTT1,0.289473684
2444,bc_id2507,CANCER,GSTM1,19024313,B,[Using MSR model to analyze the impact of gene-gene interaction with related to the genetic polymorphism of metabolism enzymes on the risk of breast cancer],2008,,The variant genotypes of CYP1A1 Msp I and GSTT1/M1 were identified by PCR-RFLP and multiplex PCR assays... The gene-gene interaction with related to the genetic polymorphism of metabolism enzymes (CYP1A1 and GSTT1) may increase the risk of breast cancer by disturbing the metabolism of estrogen.,A,GSTT1/M1,GSTM1,0.339622642
2445,bc_id2508,CANCER,CYP1A1,19024313,B,[Using MSR model to analyze the impact of gene-gene interaction with related to the genetic polymorphism of metabolism enzymes on the risk of breast cancer],2008,,The variant genotypes of CYP1A1 Msp I and GSTT1/M1 were identified by PCR-RFLP and multiplex PCR assays... The gene-gene interaction with related to the genetic polymorphism of metabolism enzymes (CYP1A1 and GSTT1) may increase the risk of breast cancer by disturbing the metabolism of estrogen.,A,CYP1A1,CYP1A1,0.456521739
2446,bc_id2509,CANCER,MAP3K1,19028704,B,Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.,2009,,These results confirm that FGFR2 and MAP3K1 are involved in breast cancer susceptibility and confer their effects primarily in ER+ and PR+ tumors.,Y,MAP3K1,MAP3K1,0.636363636
2447,bc_id2510,CANCER,FGFR2,19028704,B,Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.,2009,,These results confirm that FGFR2 and MAP3K1 are involved in breast cancer susceptibility and confer their effects primarily in ER+ and PR+ tumors.,Y,FGFR2,FGFR2,0.708333333
2448,bc_id2511,CANCER,ESR1,19028706,Y,A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women.,2009,,"According to in silico analysis, ESR1_rs2747648 affects the binding capacity of miR-453, which is stronger when the C allele is present. In contrast, the T allele attenuates the binding of miR-453, which might lead to a reduced miRNA-mediated ESR1 repression, in consequence higher ESR1 protein levels and an increased breast cancer risk.",A,ESR1,ESR1,0.586956522
2449,bc_id2512,CANCER,CHEK2,19030985,B,Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.,2009,,"These data suggest that the BRCA2 T1915M polymorphism alone might be associated with a reduced risk of breast cancer, but among CHEK2 mutation carriers, it may lead to an unexpectedly high risk.",Y,CHEK2,CHEK2,0.383333333
2450,bc_id2513,CANCER,BRCA2,19030985,B,Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.,2009,,"These data suggest that the BRCA2 T1915M polymorphism alone might be associated with a reduced risk of breast cancer, but among CHEK2 mutation carriers, it may lead to an unexpectedly high risk.",A,BRCA2,BRCA2,0.576923077
2451,bc_id2514,CANCER,LUM,19036156,B,Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies.,2009,,"We hypothesized that genetic variation in the decorin (DCN) and lumican (LUM) genes may contribute to breast cancer... Although LUM rs2268578 was associated with breast cancer in the Mayo Clinic study, particularly estrogen receptor-positive breast cancer, weaker and modest associations were observed in the SEARCH sample. These modest associations will require larger samples to adequately assess the importance of this polymorphism in breast cancer.",A,LUM,LUM,1
2452,bc_id2515,CANCER,DCN,19036156,B,Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies.,2009,,"We hypothesized that genetic variation in the decorin (DCN) and lumican (LUM) genes may contribute to breast cancer... Although LUM rs2268578 was associated with breast cancer in the Mayo Clinic study, particularly estrogen receptor-positive breast cancer, weaker and modest associations were observed in the SEARCH sample. These modest associations will require larger samples to adequately assess the importance of this polymorphism in breast cancer.",A,DCN,DCN,1
2453,bc_id2516,CANCER,MDM2,19046423,B,Association of the germline TP53 R337H mutation with breast cancer in southern Brazil.,2009,"These results demonstrate that the R337H mutation can significantly increase the risk of breast cancer in carriers, which likely depends on additional cooperating genetic factors.",We conducted a case-control study to determine the prevalence of the R337H mutation by sequencing TP53 exon 10 in 123 women with breast cancer and 223 age- and sex-matched control subjects from southern Brazil. Fisher's test was used to compare the prevalence of the R337H... Polymorphisms were identified within the TP53 (R72P and Ins16) and MDM2 (SNP309) genes that may further diminish TP53 tumor suppressor activity.,A,MDM2,MDM2,0.444444444
2454,bc_id2517,CANCER,TP53,19046423,B,Association of the germline TP53 R337H mutation with breast cancer in southern Brazil.,2009,"These results demonstrate that the R337H mutation can significantly increase the risk of breast cancer in carriers, which likely depends on additional cooperating genetic factors.",We conducted a case-control study to determine the prevalence of the R337H mutation by sequencing TP53 exon 10 in 123 women with breast cancer and 223 age- and sex-matched control subjects from southern Brazil. Fisher's test was used to compare the prevalence of the R337H... These findings are also important for understanding how low-penetrant mutant TP53 alleles can differentially influence tumor susceptibility.,A,TP53,TP53,0.482758621
2455,bc_id2518,CANCER,CSH1,19047151,B,Do placental genes affect maternal breast cancer? Association between offspring's CGB5 and CSH1 gene variants and maternal breast cancer risk.,2008,,X,X,X,X,0
2456,bc_id2519,CANCER,CGB5,19047151,B,Do placental genes affect maternal breast cancer? Association between offspring's CGB5 and CSH1 gene variants and maternal breast cancer risk.,2008,,"We conducted a case-control study to examine the association between polymorphisms in a woman's placental (i.e., her offspring's) homologous chorionic gonadotrophin beta5 (CGB5) and CSH1 genes and her post-pregnancy breast cancer risk... The findings suggest that placental CGB5 genotype may be predictive of maternal post-pregnancy breast cancer risk among women who give birth early in life.",A,CGB5,CGB5,1
2457,bc_id2520,CANCER,CYP2D6,19047159,B,A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.,2008,,X,X,X,X,0
2458,bc_id2521,CANCER,RRAS2,19047159,B,A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.,2008,,Immunohistochemical analyses of breast tumors revealed a higher TC21 expression in ER-negative compared with ER-positive tumors...Our functional and patient-based results suggest that the TC21 -582C>T polymorphism improves prediction of tamoxifen treatment outcome in breast cancer.,A,TC21,RRAS2,1
2459,bc_id2522,CANCER,TP53,19048399,B,Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer.,2009,"presence of proline allele at codon 72 alone, and its special combinations with other two polymorphisms appear to be a significant risk factor for breast cancer.",Determination of well-known p53 polymorphisms might be a good predictor for breast cancer development especially in women younger than 50 years.,A,p53,TP53,0.482758621
2460,bc_id2523,CANCER,MIR30C2,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2461,bc_id2524,CANCER,MIR920,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2462,bc_id2525,CANCER,MIR17,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2463,bc_id2526,CANCER,MIR20A,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2464,bc_id2527,CANCER,MIR24-2,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2465,bc_id2528,CANCER,MIR29B2,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2466,bc_id2529,CANCER,MIR223,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2467,bc_id2530,CANCER,MIR24-1,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2468,bc_id2531,CANCER,MIR191,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2469,bc_id2532,CANCER,MIR21,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2470,bc_id2533,CANCER,MIR125A,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2471,bc_id2534,CANCER,MIR128-1,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2472,bc_id2535,CANCER,MIR128-2,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2473,bc_id2536,CANCER,MIR29B1,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2474,bc_id2537,CANCER,MIR30C1,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2475,bc_id2538,CANCER,MIR146A,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2476,bc_id2539,CANCER,MIR125B1,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2477,bc_id2540,CANCER,MIR125B2,19048628,B,Novel genetic variants in microRNA genes and familial breast cancer.,2009,,X,X,X,X,0
2478,bc_id2541,CANCER,ERCC2,19051060,B,Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an Indian report.,2009,,"Variant genotypes XRCC1 Arg/Gln or Gln/Gln and XPD Lys/Gln or Gln/Gln increased both familial and sporadic breast cancer susceptibility... However, when the intra group risk was compared, the risk due to the XPD polymorphic genotypes Lys/Gln or Gln/Gln was significantly lower among familial breast cancer patients compared to sporadic breast cancer patients [OR = 0.61; 95%CI = 0.39-0.94; p value = 0.024) whereas the risk implied by XRCC1 variant genotype was not significantly different between the familial and nonfamilial groups of breast cancer patients [OR = 0.97; 95%CI = 0.63-1.49; p value = 0.882].",A,XPD,ERCC2,0.6875
2479,bc_id2542,CANCER,XRCC1,19051060,B,Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an Indian report.,2009,,"Variant genotypes XRCC1 Arg/Gln or Gln/Gln and XPD Lys/Gln or Gln/Gln increased both familial and sporadic breast cancer susceptibility... However, when the intra group risk was compared, the risk due to the XPD polymorphic genotypes Lys/Gln or Gln/Gln was significantly lower among familial breast cancer patients compared to sporadic breast cancer patients [OR = 0.61; 95%CI = 0.39-0.94; p value = 0.024) whereas the risk implied by XRCC1 variant genotype was not significantly different between the familial and nonfamilial groups of breast cancer patients [OR = 0.97; 95%CI = 0.63-1.49; p value = 0.882].",Y,XRCC1,XRCC1,0.239130435
2480,bc_id2543,CANCER,CYP19A1,19064562,B,"Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.",2008,,"Our findings suggest that CYP19A1 variation may enhance breast cancer development in some women, but further confirmation is warranted.",A,CYP19A1,CYP19A1,0.484848485
2481,bc_id2544,CANCER,BARD1,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2482,bc_id2545,CANCER,ATRX,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2483,bc_id2546,CANCER,ATR,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2484,bc_id2547,CANCER,NBN,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",The ancestral haplotypes of NBS1 and CHEK1 also showed some evidence of association with breast cancer risk and this may bring us onto the question of efficacy of the study: ,A,NBS1,NBN,0.571428571
2485,bc_id2548,CANCER,MRE11A,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2486,bc_id2549,CANCER,BRIP1,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects."," The BRIP1 gene has been shown to contain
rare truncating mutations associated with breast cancer
susceptibility and Fanconis anemia (27, 54), a chromosome instability disorder partly characterized by a
predisposition to cancer, so it is notable that we now
have evidence of common variants affecting cancer
outcome.",Y,BRIP1,BRIP1,0.2
2487,bc_id2550,CANCER,CHEK1,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",The ancestral haplotypes of NBS1 and CHEK1 also showed some evidence of association with breast cancer risk and this may bring us onto the question of efficacy of the study: ,A,CHEK1,CHEK1,0.5
2488,bc_id2551,CANCER,XRCC3,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2489,bc_id2552,CANCER,XRCC2,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.","None of these tagging SNPs was associated with breast cancer risk, with the exception of XRCC2 rs3218536, R188H.",Y,XRCC2,XRCC2,0.272727273
2490,bc_id2553,CANCER,RAD50,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2491,bc_id2554,CANCER,RAD51,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2492,bc_id2555,CANCER,RAD51C,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2493,bc_id2556,CANCER,RAD52,19064565,B,Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk.,2008,"there was little evidence of breast cancer susceptibility with any of the SNPs studied, but larger studies would be needed to confirm subgroup effects.",X,X,X,X,0
2494,bc_id2557,CANCER,SHBG,19064566,B,Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women.,2008,At least 3 SNPs showed associations with SHBG levels that were highly significant but relatively small in magnitude.,"At least 3 SNPs showed associations with SHBG levels that were highly significant but relatively small in magnitude. rs6257 is a potential breast cancer susceptibility variant, but relationships between the genetic determinants of SHBG levels and breast cancer are complex.",A,SHBG,SHBG,0.666666667
2495,bc_id2558,CANCER,HMMR,19064580,B,Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer.,2008,,"We have examined the association of these single nucleotide polymorphisms, together with others tagging the HMMR gene, in a larger, European case-control study and find no association of any of them with risk of breast cancer.",N,HMMR,HMMR,1
2496,bc_id2559,CANCER,PHB,19071013,B,Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?,2009,,"We genotyped seven SNPs in six distinct genes (PHB, RAD51, ITGB3, TGFB1, VEGF, MTHFR) in 1100 unselected Polish breast cancer patients and 1100 controls. The frequencies of genotypes were similar in cases and controls... The PHB 1630 C/T single nucleotide polymorphism was associated with breast cancers with clinical features typical for BRCA1-positive tumours and is deserving of further study.",Y,PHB,PHB,0.4
2497,bc_id2560,CANCER,MTHFR,19071013,B,Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?,2009,,X,X,X,X,0
2498,bc_id2561,CANCER,ITGB3,19071013,B,Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?,2009,,X,X,X,X,0
2499,bc_id2562,CANCER,VEGFA,19071013,B,Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?,2009,,"We genotyped seven SNPs in six distinct genes (PHB, RAD51, ITGB3, TGFB1, VEGF, MTHFR) in 1100 unselected Polish breast cancer patients and 1100 controls. The frequencies of genotypes were similar in cases and controls... The PHB 1630 C/T single nucleotide polymorphism was associated with breast cancers with clinical features typical for BRCA1-positive tumours and is deserving of further study.",N,VEGF,VEGFA,0.333333333
2500,bc_id2563,CANCER,TGFB1,19071013,B,Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?,2009,,X,X,X,X,0
2501,bc_id2564,CANCER,RAD51,19071013,B,Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?,2009,,X,X,X,X,0
2502,bc_id2565,CANCER,IGK@,19072568,B,The polymorphisms on Igkappa gene are related to susceptibility of breast cancer and gastric cancer.,2008,,"The phenomenon of immunoglobulin (Ig) expression in cancer cells has been discovered recently; the Ig protein expressed and secreted in cancer cells was found to be in favor of tumor growth...Our results suggested that the 5658-G allele and 3635-C allele were risk factors for both gastric cancer (odds ratio [OR]: 1.64 and 1.67, respectively) and breast cancer (OR: 1.94 and 1.56, respectively).",Y,Igkappa,IGK,1
2503,bc_id2566,CANCER,GATA3,19082709,N,No evidence that GATA3 rs570613 SNP modifies breast cancer risk.,2009,"there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.","We found no association between this SNP and breast cancer risk in BCAC cases overall (OR(per-allele) = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (OR(per-allele) = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RR(per-allele) = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RR(per-allele) = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.",N,GATA3,GATA3,0.5
2504,bc_id2567,CANCER,BRCA2,19082709,N,No evidence that GATA3 rs570613 SNP modifies breast cancer risk.,2009,"there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.",X,X,X,X,0
2505,bc_id2568,CANCER,BRCA1,19082709,N,No evidence that GATA3 rs570613 SNP modifies breast cancer risk.,2009,"there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women.",X,X,X,X,0
2506,bc_id2569,CANCER,BRCA2,19087709,B,[BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases],2008,,X,X,X,X,0
2507,bc_id2570,CANCER,BRCA1,19087709,B,[BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases],2008,,X,X,X,X,0
2508,bc_id2571,CANCER,SIPA1,19089925,B,Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis.,2009,,Our results do not support a relationship between SIPA1 polymorphisms and breast cancer risk or subsequent survival.,N,SIPA1,SIPA1,0.25
2509,bc_id2572,CANCER,PGR,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2510,bc_id2573,CANCER,ATM,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,"We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors... Stratifying POSH cases by tumour characteristics identified SNPs in FGFR2 and TOX3 associated with ER-positive disease and SNPs in ATM associated with ER-negative disease.",A,ATM,ATM,0.422222222
2511,bc_id2574,CANCER,MMP9,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2512,bc_id2575,CANCER,MMP7,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,"We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors.",A,MMP7,MMP7,0.75
2513,bc_id2576,CANCER,MMP2,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2514,bc_id2577,CANCER,MDM2,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2515,bc_id2578,CANCER,MAP3K1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,"We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors.",A,MAP3K1,MAP3K1,0.272727273
2516,bc_id2579,CANCER,LSP1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,"We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors.",A,LSP1,LSP1,0.444444444
2517,bc_id2580,CANCER,RHOC,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2518,bc_id2581,CANCER,TOX3,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,"We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors.",A,TOX3,TOX3,0.5
2519,bc_id2582,CANCER,AR,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2520,bc_id2583,CANCER,ITGB4,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2521,bc_id2584,CANCER,IL6,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2522,bc_id2585,CANCER,IGF1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2523,bc_id2586,CANCER,GATA3,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2524,bc_id2587,CANCER,FN1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2525,bc_id2588,CANCER,FGFR2,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2526,bc_id2589,CANCER,ESR1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,"We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors.",A,ESR1,ESR1,0.586956522
2527,bc_id2590,CANCER,ERBB2,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2528,bc_id2591,CANCER,DAPK1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,"We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors.",A,DAPK1,DAPK1,1
2529,bc_id2592,CANCER,CYP1B1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2530,bc_id2593,CANCER,ADH1B,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2531,bc_id2594,CANCER,CASP8,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,"We confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors.",A,CASP8,CASP8,0.285714286
2532,bc_id2595,CANCER,VEGFA,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2533,bc_id2596,CANCER,TWIST1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2534,bc_id2597,CANCER,TP53,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2535,bc_id2598,CANCER,TNF,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2536,bc_id2599,CANCER,TGFB1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2537,bc_id2600,CANCER,BRCA1,19094228,B,The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer.,2009,We have demonstrated that several SNPs are associated with survival.,X,X,X,X,0
2538,bc_id2601,CANCER,GSTT1,19103108,B,"[A case-control study on serum organochlorines residues, genetic polymorphisms of glutathione S-transferase T1 and the risks of breast cancer]",2008,,Genetic and environmental hazard factors had a co-effect on the development of breast cancer while genetic polymorphisms of GSTT1 and DDT/HCH expressed an interaction to breast cancer.,Y,GSTT1,GSTT1,0.578947368
2539,bc_id2602,CANCER,APOE,19103187,B,Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients.,2009,These findings indicate that the effects of tamoxifen on plasma triglyceride levels are modified by APOE polymorphism.,"These findings indicate that the effects of tamoxifen on plasma triglyceride levels are modified by APOE polymorphism. Breast cancer patients with APOE4 allele have low plasma triglyceride levels when receiving tamoxifen therapy. Therefore, we suggest that APOE gene polymorphism is a critical validation before tamoxifen treatment in breast cancer patients.",A,APOE,APOE,0.333333333
2540,bc_id2603,CANCER,VDR,19105801,B,Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.,2009,"In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.","In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.",Y,VDR,VDR,0.269230769
2541,bc_id2604,CANCER,NAT2,19116874,B,"Meat consumption, heterocyclic amines, NAT2, and the risk of breast cancer.",2009,,"There were no statistically significant interactions with NAT2 genotype. Results do not support an important association of HCAs with breast cancer risk, although potential biases in case-control studies should be considered.",N,NAT2,NAT2,0.37037037
2542,bc_id2605,CANCER,MUC1,19121298,B,MUC1 568 A/G genotype-dependent cancer antigen 15-3 levels in breast cancer patients.,2009,,X,X,X,X,0
2543,bc_id2606,CANCER,CHEK2,19124502,B,"Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.",2009,,"however, further population-based evidence is needed on the effect of CHEK2 1100delC and other moderate penetrance alleles in women with a family history of breast cancer.",A,CHEK2,CHEK2,0.383333333
2544,bc_id2607,CANCER,PTPRJ,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2545,bc_id2608,CANCER,PTGS2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2546,bc_id2609,CANCER,PTGS1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2547,bc_id2610,CANCER,PTGIS,19124506,Y,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2548,bc_id2611,CANCER,PTGES,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2549,bc_id2612,CANCER,PTGDS,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2550,bc_id2613,CANCER,BARD1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2551,bc_id2614,CANCER,PPP1R1B,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2552,bc_id2615,CANCER,PPP1CB,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2553,bc_id2616,CANCER,ATR,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2554,bc_id2617,CANCER,NUMA1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2555,bc_id2618,CANCER,NR1I2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2556,bc_id2619,CANCER,ATM,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2557,bc_id2620,CANCER,NEUROD2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2558,bc_id2621,CANCER,NBN,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2559,bc_id2622,CANCER,ABL1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2560,bc_id2623,CANCER,MTHFR,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2561,bc_id2624,CANCER,MRE11A,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2562,bc_id2625,CANCER,MMP2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2563,bc_id2626,CANCER,MMP13,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2564,bc_id2627,CANCER,MDM2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2565,bc_id2628,CANCER,MBD2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2566,bc_id2629,CANCER,LIG4,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2567,bc_id2630,CANCER,P5.8,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2568,bc_id2631,CANCER,PTGDS,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2569,bc_id2632,CANCER,IKZF3,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2570,bc_id2633,CANCER,IL10,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2571,bc_id2634,CANCER,IGF2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2572,bc_id2635,CANCER,IGF1R,19124506,Y,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2573,bc_id2636,CANCER,IGF1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2574,bc_id2637,CANCER,ICAM5,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2575,bc_id2638,CANCER,HDAC2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2576,bc_id2639,CANCER,GSTM1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2577,bc_id2640,CANCER,GSR,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2578,bc_id2641,CANCER,GRB7,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2579,bc_id2642,CANCER,GPX4,19124506,Y,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2580,bc_id2643,CANCER,GPX1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2581,bc_id2644,CANCER,ESR2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2582,bc_id2645,CANCER,EP300,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2583,bc_id2646,CANCER,EGF,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2584,bc_id2647,CANCER,E2F5,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2585,bc_id2648,CANCER,MUS81,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2586,bc_id2649,CANCER,DNMT1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2587,bc_id2650,CANCER,C17orf37,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2588,bc_id2651,CANCER,CYP19A1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2589,bc_id2652,CANCER,ADH1A,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2590,bc_id2653,CANCER,CSTF1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2591,bc_id2654,CANCER,FBXL20,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2592,bc_id2655,CANCER,CRKRS,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2593,bc_id2656,CANCER,ITGB1BP1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2594,bc_id2657,CANCER,PERLD1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2595,bc_id2658,CANCER,CREBBP,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2596,bc_id2659,CANCER,COMT,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2597,bc_id2660,CANCER,BRIP1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2598,bc_id2661,CANCER,ADAM17,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2599,bc_id2662,CANCER,CHEK1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2600,bc_id2663,CANCER,PCNXL3,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2601,bc_id2664,CANCER,TXNRD2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2602,bc_id2665,CANCER,C11ORF30,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2603,bc_id2666,CANCER,CDKN2D,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2604,bc_id2667,CANCER,CDKN2C,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2605,bc_id2668,CANCER,CDKN2B,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2606,bc_id2669,CANCER,TXN2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2607,bc_id2670,CANCER,CDK4,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2608,bc_id2671,CANCER,CDK2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2609,bc_id2672,CANCER,STARD3,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2610,bc_id2673,CANCER,RAD54B,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2611,bc_id2674,CANCER,FBXW7,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2612,bc_id2675,CANCER,CCNE1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2613,bc_id2676,CANCER,CCND3,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2614,bc_id2677,CANCER,CCND2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2615,bc_id2678,CANCER,CAT,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2616,bc_id2679,CANCER,CASP8,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2617,bc_id2680,CANCER,FBXO10,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2618,bc_id2681,CANCER,XRCC3,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2619,bc_id2682,CANCER,VEGFA,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2620,bc_id2683,CANCER,TXNRD1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2621,bc_id2684,CANCER,TXN,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2622,bc_id2685,CANCER,TP53,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2623,bc_id2686,CANCER,FASLG,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2624,bc_id2687,CANCER,KLF11,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2625,bc_id2688,CANCER,TGFB1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2626,bc_id2689,CANCER,STS,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2627,bc_id2690,CANCER,STEAP1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2628,bc_id2691,CANCER,SOD2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2629,bc_id2692,CANCER,SOD1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2630,bc_id2693,CANCER,BRCA2,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2631,bc_id2694,CANCER,BRCA1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2632,bc_id2695,CANCER,SIPA1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2633,bc_id2696,CANCER,SETDB1,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2634,bc_id2697,CANCER,RAD50,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2635,bc_id2698,CANCER,RAD51,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2636,bc_id2699,CANCER,RAD51C,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2637,bc_id2700,CANCER,RAD52,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2638,bc_id2701,CANCER,RELA,19124506,N,Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer.,2009,,X,X,X,X,0
2639,bc_id2703,CANCER,VDR,19124512,B,Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.,2009,"Although the evidence for independent contributions of these variants to breast cancer susceptibility remains equivocal, future large studies should integrate genetic variation in VDR with biomarkers of vitamin D status.","Although the evidence for independent contributions of these variants to breast cancer susceptibility remains equivocal, future large studies should integrate genetic variation in VDR with biomarkers of vitamin D status.",A,VDR,VDR,0.538461538
2640,bc_id2704,CANCER,ESR1,19126777,B,Association of ESR1 gene tagging SNPs with breast cancer risk.,2009,,"SNP rs3020314, tagging a region of ESR1 intron 4, is associated with an increase in breast cancer susceptibility with a dominant mode of action in European populations.",Y,ESR1,ESR1,0.282608696
2641,bc_id2705,CANCER,PTGS2,19138835,B,A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer.,2009,,We conclude that the homozygous PTGS2 169-GG genotype may be associated with breast cancer risk.,A,PTGS2,PTGS2,0.583333333
2642,bc_id2706,CANCER,BRCA2,19139771,B,Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer.,2009,The reliable information of penetrance is considered important in genetic counseling.,We estimated the penetrance of breast cancer in carriers of BRCA1/2 specific gene mutations based on the modified kin-cohort method... Three hundred and forty-five probands were examined for specific mutations of BRCA1/2 genes. The estimated penetrance for the age groups among BRCA1/2 carriers was 31.9% (<50 years) and 46.2% (> or =50 years).,A,BRCA1/2,BRCA2,0.576923077
2643,bc_id2707,CANCER,BRCA1,19139771,B,Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer.,2009,The reliable information of penetrance is considered important in genetic counseling.,We estimated the penetrance of breast cancer in carriers of BRCA1/2 specific gene mutations based on the modified kin-cohort method... Three hundred and forty-five probands were examined for specific mutations of BRCA1/2 genes. The estimated penetrance for the age groups among BRCA1/2 carriers was 31.9% (<50 years) and 46.2% (> or =50 years).,A,BRCA1,BRCA1,0.60944206
2644,bc_id2708,CANCER,MDM2,19144119,Y,Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.,2009,Findings based on the current sample size suggest that the MDM2 SNP309 GG genotype may be associated with both the risk of breast cancer and an earlier age of onset in Taiwanese women.,Findings based on the current sample size suggest that the MDM2 SNP309 GG genotype may be associated with both the risk of breast cancer and an earlier age of onset in Taiwanese women.,A,MDM2,MDM2,0.444444444
2645,bc_id2709,CANCER,VDR,19145484,B,Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis.,2009,,Several polymorphisms in the vitamin D receptor (VDR) gene have been reported to influence breast cancer risk.,Y,VDR,VDR,0.269230769
2646,bc_id2710,CANCER,CTNNB1,19145675,B,beta-catenin gene mutation in invasive ductal breast cancer.,2009,,"Our results suggest that genetic defects in beta-catenin is not common in invasive ductal breast cancers, whereas mutations in other components of the Wnt signaling pathway should be considered.",N,beta-catenin,CTNNB1,0.5
2647,bc_id2711,CANCER,ABCB1,19151448,B,Polymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expression.,2008,,"breast cancer patients with positive Her-2 expression do not always respond to Anthracycline, it means that only patients with T/T genotype at position 3435 located in exon 26 of MDR1 gene have clinical response, while patients have C/T genotype do not show clinical response. MDR-1 polymorphism C3435T in exon 26 may co-determine resistance to chemotherapy and provide useful information to individual therapy.",A,MDR1,ABCB1,0.6875
2648,bc_id2712,CANCER,IL18,19152241,B,Association of interleukin-18 gene promoter polymorphisms with breast cancer.,2009,,This is the first report investigating the contribution of IL-18 gene promoter polymorphisms to breast cancer. These results suggest contrast effects of IL-18 gene in cancer induction and progression.,A,IL-18,IL18,1
2649,bc_id2713,CANCER,CYP2D6,19156902,B,"Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.",2009,,"Neither the CYP2D6 10/10 genotype nor the CYP2C19 genotype is likely to have a clinically significant impact on prognosis, endometrial thickness, BMD, or total cholesterol levels in Japanese patients with breast cancer who are treated with adjuvant tamoxifen.",A,CYP2D6,CYP2D6,0.590909091
2650,bc_id2714,CANCER,CYP2C19,19156902,B,"Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.",2009,,"Neither the CYP2D6 10/10 genotype nor the CYP2C19 genotype is likely to have a clinically significant impact on prognosis, endometrial thickness, BMD, or total cholesterol levels in Japanese patients with breast cancer who are treated with adjuvant tamoxifen.",A,CYP2C19,CYP2C19,0.8
2651,bc_id2715,CANCER,BRCA2,19165595,B,Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity.,2009,,The results of this study suggest that the combination of BRCA mutations and vegetable and fruit diversity may be associated with a reduced risk of BC.,A,BRCA,BRCA2,0.576923077
2652,bc_id2716,CANCER,BRCA1,19165595,B,Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity.,2009,,The results of this study suggest that the combination of BRCA mutations and vegetable and fruit diversity may be associated with a reduced risk of BC.,A,BRCA,BRCA1,0.60944206
2653,bc_id2717,CANCER,BRCA1,19176458,B,Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers.,2009,,"For BRCA1 mutation carriers, the estimated lifetime risk of radiation-induced breast cancer mortality per 10,000 women resulting from annual mammography was 26 (95% confidence interval [CI] = 14 to 49) for screening at age 25-29 years, 20 (95% CI = 11 to 39) for screening at age 30-34 years, and 13 (95% CI = 7 to 23) for screening at age 35-39 years.",A,BRCA1,BRCA1,0.60944206
2654,bc_id2718,CANCER,NME1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2655,bc_id2719,CANCER,NCOR2,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2656,bc_id2720,CANCER,NCOR1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2657,bc_id2721,CANCER,NCOA3,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2658,bc_id2722,CANCER,NCOA2,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2659,bc_id2723,CANCER,NCOA1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2660,bc_id2724,CANCER,MPG,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2661,bc_id2725,CANCER,MED1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,"We sequenced the coding exons of 17 genes (EP300, CCND1, NME1, NCOA1, NCOA2, NCOA3, SMARCA4, SMARCA2, CARM1, FOXA1, MPG, NCOR1, NCOR2, CALCOCO1, PRMT1, PPARBP and CREBBP) Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.",N,PPARBP,MED1,1
2662,bc_id2726,CANCER,PRMT1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2663,bc_id2727,CANCER,FOXA1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2664,bc_id2728,CANCER,EP300,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2665,bc_id2729,CANCER,CALCOCO1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2666,bc_id2730,CANCER,CREBBP,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2667,bc_id2731,CANCER,CARM1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2668,bc_id2732,CANCER,CCND1,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2669,bc_id2733,CANCER,SMARCA4,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2670,bc_id2734,CANCER,SMARCA2,19183483,B,Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.,2009,Our findings suggest that common coding variation in these candidate genes do not make a substantial contribution to breast cancer risk in the general population.,X,X,X,X,0
2671,bc_id2735,CANCER,HGF,19188684,B,Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer.,2009,,We found that 51% of African Americans and 15% of individuals of mixed European descent with breast cancer harbor a truncated DATE variant (25As or fewer) in their breast tumors and that the truncated allele is associated with cancer incidence and aberrant HGF expression.,A,HGF,HGF,1
2672,bc_id2736,CANCER,CYP2D6,19189210,B,Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.,2010,,X,X,X,X,0
2673,bc_id2737,CANCER,CYP2D6,19189212,B,The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.,2009,,X,X,X,X,0
2674,bc_id2738,CANCER,RAD50,19190165,B,Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population.,2009,,"Rad50 was analyzed in its entirety for 231 familial cases, with no clearly deleterious mutations detected. These data together suggest that although founder mutations may make Rad50 a significant breast cancer risk factor in certain populations, it is not a factor in others.",A,RAD50,RAD50,0.5
2675,bc_id2739,CANCER,EGFR,19190167,B,A two-stage case-control study of EGFR polymorphisms and breast cancer risk.,2009,,ANF,ANF,ANF,ANF,0
2676,bc_id2740,CANCER,MMP2,19196101,B,Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.,2009,,X,X,X,X,0
2677,bc_id2741,CANCER,KITLG,19196101,B,Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.,2009,,X,X,X,X,0
2678,bc_id2742,CANCER,CXCR4,19196101,B,Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.,2009,,"Similarly, the SNP barcode of rs12812942-rs2228014-rs3025039 (CD4-CXCR4-VEGF) and rs12812942-rs3136685-rs2228014-rs1801157 (CD4- CCR7-CXCR4-CXCL12) with specific genotype patterns (AT-CC-CC and AT-AG-CC-GG) among three and four combinational SNPs were significantly low in breast cancer occurrence.",Y,CXCR4,CXCR4,1
2679,bc_id2743,CANCER,CD4,19196101,B,Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.,2009,,"Similarly, the SNP barcode of rs12812942-rs2228014-rs3025039 (CD4-CXCR4-VEGF) and rs12812942-rs3136685-rs2228014-rs1801157 (CD4- CCR7-CXCR4-CXCL12) with specific genotype patterns (AT-CC-CC and AT-AG-CC-GG) among three and four combinational SNPs were significantly low in breast cancer occurrence.",Y,CD4,CD4,1
2680,bc_id2744,CANCER,CCR7,19196101,B,Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.,2009,,"Similarly, the SNP barcode of rs12812942-rs2228014-rs3025039 (CD4-CXCR4-VEGF) and rs12812942-rs3136685-rs2228014-rs1801157 (CD4- CCR7-CXCR4-CXCL12) with specific genotype patterns (AT-CC-CC and AT-AG-CC-GG) among three and four combinational SNPs were significantly low in breast cancer occurrence.",Y,CCR7,CCR7,1
2681,bc_id2745,CANCER,VEGFA,19196101,B,Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.,2009,,"Similarly, the SNP barcode of rs12812942-rs2228014-rs3025039 (CD4-CXCR4-VEGF) and rs12812942-rs3136685-rs2228014-rs1801157 (CD4- CCR7-CXCR4-CXCL12) with specific genotype patterns (AT-CC-CC and AT-AG-CC-GG) among three and four combinational SNPs were significantly low in breast cancer occurrence.",A,VEGF,VEGFA,0.416666667
2682,bc_id2746,CANCER,CXCL12,19196101,B,Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.,2009,,"Similarly, the SNP barcode of rs12812942-rs2228014-rs3025039 (CD4-CXCR4-VEGF) and rs12812942-rs3136685-rs2228014-rs1801157 (CD4- CCR7-CXCR4-CXCL12) with specific genotype patterns (AT-CC-CC and AT-AG-CC-GG) among three and four combinational SNPs were significantly low in breast cancer occurrence.",Y,CXCL12,CXCL12,0.333333333
2683,bc_id2747,CANCER,HLA-DRB1,19196481,B,High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study.,2009,"Our results reveal the role of the MHC genes in the pathophysiology of breast cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation.",X,X,X,X,0
2684,bc_id2748,CANCER,HLA-DQA1,19196481,B,High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study.,2009,"Our results reveal the role of the MHC genes in the pathophysiology of breast cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation.",X,X,X,X,0
2685,bc_id2749,CANCER,HLA-C,19196481,B,High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study.,2009,"Our results reveal the role of the MHC genes in the pathophysiology of breast cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation.",X,X,X,X,0
2686,bc_id2750,CANCER,HLA-B,19196481,B,High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study.,2009,"Our results reveal the role of the MHC genes in the pathophysiology of breast cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation.","HLA-A frequencies that we were able to observe that there was no difference between both groups from the statistical viewpoint. HLA-B*1501 was found three times more common in the case group (OR, 3.714; p = 0.031). HLA-Cw is not a marker neither for risk, nor protection for the disease, because we did not find significant statistical differences between the two groups... Our results reveal the role of the MHC genes in the pathophysiology of breast cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation.",A,HLA-B*1501,HLA-B,0.5
2687,bc_id2751,CANCER,HLA-A,19196481,B,High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study.,2009,"Our results reveal the role of the MHC genes in the pathophysiology of breast cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation.","HLA-A frequencies that we were able to observe that there was no difference between both groups from the statistical viewpoint. HLA-B*1501 was found three times more common in the case group (OR, 3.714; p = 0.031). HLA-Cw is not a marker neither for risk, nor protection for the disease, because we did not find significant statistical differences between the two groups... Our results reveal the role of the MHC genes in the pathophysiology of breast cancer, suggesting that in the development of breast cancer exists a disorder of immune regulation.",A,HLA-A,HLA-A,1
2688,bc_id2752,CANCER,BARD1,19197335,B,"Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.",2009,,"Given the high susceptibility conferred by the two major breast cancer predisposition genes, BRCA1 and BRCA2 and the implication of these genes in many key cellular processes, assessment of genes encoding BRCA1-interacting proteins as plausible breast cancer candidate genes is thus attractive... Although no deleterious truncating germline mutations or aberrant spliced mRNA species were identified, a total of 10, 4, 11 and 6 variants were found in the AURKA, BAP1, BARD1 and DHX9 genes, respectively.",A,BARD1,BARD1,0.454545455
2689,bc_id2753,CANCER,BAP1,19197335,B,"Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.",2009,,"Given the high susceptibility conferred by the two major breast cancer predisposition genes, BRCA1 and BRCA2 and the implication of these genes in many key cellular processes, assessment of genes encoding BRCA1-interacting proteins as plausible breast cancer candidate genes is thus attractive... Although no deleterious truncating germline mutations or aberrant spliced mRNA species were identified, a total of 10, 4, 11 and 6 variants were found in the AURKA, BAP1, BARD1 and DHX9 genes, respectively.",A,BAP1,BAP1,1
2690,bc_id2754,CANCER,DHX9,19197335,B,"Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.",2009,,"Given the high susceptibility conferred by the two major breast cancer predisposition genes, BRCA1 and BRCA2 and the implication of these genes in many key cellular processes, assessment of genes encoding BRCA1-interacting proteins as plausible breast cancer candidate genes is thus attractive... Although no deleterious truncating germline mutations or aberrant spliced mRNA species were identified, a total of 10, 4, 11 and 6 variants were found in the AURKA, BAP1, BARD1 and DHX9 genes, respectively.",A,DHX9,DHX9,1
2691,bc_id2755,CANCER,AURKA,19197335,B,"Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.",2009,,"Given the high susceptibility conferred by the two major breast cancer predisposition genes, BRCA1 and BRCA2 and the implication of these genes in many key cellular processes, assessment of genes encoding BRCA1-interacting proteins as plausible breast cancer candidate genes is thus attractive... Although no deleterious truncating germline mutations or aberrant spliced mRNA species were identified, a total of 10, 4, 11 and 6 variants were found in the AURKA, BAP1, BARD1 and DHX9 genes, respectively.",A,AURKA,AURKA,0.5
2692,bc_id2756,CANCER,WRN,19205873,Y,A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women.,2009,,"In this case-control study of 1,004 breast cancer cases and 1,008 controls, we tested the hypothesis that non-conservative amino acid exchanges in WRN (leu1074Phe), BLM (Met298Thr) and BRCA1 (Pro871Leu) are independently or jointly associated with the risk of breast cancer in Chinese women.",Y,WRN,WRN,0.666666667
2693,bc_id2757,CANCER,BRCA1,19205873,B,A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women.,2009,,"In this case-control study of 1,004 breast cancer cases and 1,008 controls, we tested the hypothesis that non-conservative amino acid exchanges in WRN (leu1074Phe), BLM (Met298Thr) and BRCA1 (Pro871Leu) are independently or jointly associated with the risk of breast cancer in Chinese women.",Y,BRCA1,BRCA1,0.326180258
2694,bc_id2758,CANCER,BLM,19205873,B,A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women.,2009,,"In this case-control study of 1,004 breast cancer cases and 1,008 controls, we tested the hypothesis that non-conservative amino acid exchanges in WRN (leu1074Phe), BLM (Met298Thr) and BRCA1 (Pro871Leu) are independently or jointly associated with the risk of breast cancer in Chinese women.",Y,BLM,BLM,0.5
2695,bc_id2759,CANCER,CYP1B1,19208203,B,Cytochrome P450 1B1 Val432Leu polymorphism and breast cancer risk in Nigerian women: a case control study.,2009,Our results suggest that the codon 432 polymorphism of the CYP1B1 gene is associated with increased risk of breast cancer and is particularly involved in breast cancer risk in premenopausal women of African descent.,Our results suggest that the codon 432 polymorphism of the CYP1B1 gene is associated with increased risk of breast cancer and is particularly involved in breast cancer risk in premenopausal women of African descent.,Y,CYP1B1,CYP1B1,0.358974359
2696,bc_id2760,CANCER,CCR5,19212663,B,CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development.,2009,,"In the present study, a higher percentage of breast cancer patients presented homozygous genotype for Arg and wild-type for CCR5 than the control subjects.",Y,CCR5,CCR5,1
2697,bc_id2761,CANCER,NQO1,19214744,B,CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.,2010,,"In the present study we investigate the relevance of RAD51 -135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations... Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.",A,NQO1*2,NQO1,0.25
2698,bc_id2762,CANCER,CASP8,19214744,B,CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.,2010,,"In the present study we investigate the relevance of RAD51 -135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations... Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.",Y,CASP8,CASP8,0.642857143
2699,bc_id2763,CANCER,TP53,19214744,B,CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.,2010,,"In the present study we investigate the relevance of RAD51 -135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations... Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.",A,TP53,TP53,0.482758621
2700,bc_id2764,CANCER,BRCA2,19214744,B,CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.,2010,,"In the present study we investigate the relevance of RAD51 -135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations... Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.",A,BRCA2,BRCA2,0.576923077
2701,bc_id2765,CANCER,BRCA1,19214744,B,CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.,2010,,"In the present study we investigate the relevance of RAD51 -135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations... Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.",A,BRCA1,BRCA1,0.60944206
2702,bc_id2766,CANCER,RAD51,19214744,B,CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.,2010,,"In the present study we investigate the relevance of RAD51 -135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations... Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.",A,RAD51,RAD51,0.615384615
2703,bc_id2767,CANCER,CYP3A4,19214745,Y,"Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists.",2009,,"In multivariate analyses, we observed a significantly decreased risk of breast cancer associated with the CYP3A4 M445T minor allele (rs4986910, OR = 0.3; 95% CI 0.1-0.9). We found a borderline increased breast cancer risk with having both minor alleles of CYP1B1 V432L (rs1056836, CC vs. GG, OR = 1.2; 95% CI 0.9-1.6).",Y,CYP3A4,CYP3A4,0.272727273
2704,bc_id2768,CANCER,CYP1B1,19214745,Y,"Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists.",2009,,"Assuming a recessive model, the minor allele of CYP1B1 V432L significantly increased the dose-response relationship between personal diagnostic X-ray exposure and breast cancer risk, adjusted for cumulative occupational radiation dose (p (interaction) = 0.03) and had a similar joint effect for cumulative occupational radiation dose adjusted for personal diagnostic X-ray exposure (p (interaction) = 0.06).",Y,CYP1B1,CYP1B1,0.358974359
2705,bc_id2769,CANCER,ESR1,19219042,B,Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1.,2009,,"We further investigated four replicated loci in a third set of samples comprising 3,472 cases and 900 controls. SNP rs2046210 at 6q25.1, located upstream of the gene encoding estrogen receptor alpha (ESR1), showed strong and consistent association with breast cancer across all three stages.",Y,ESR1,ESR1,0.282608696
2706,bc_id2770,CANCER,XRCC6,19219618,B,"A polymorphism in the promoter region of Ku70/XRCC6, associated with breast cancer risk and oestrogen exposure.",2009,,"These results show that the variant allele of c.-1310 C>G, located in the Ku70 promoter, is a risk allele for breast cancer.",Y,Ku70,XRCC6,1
2707,bc_id2771,CANCER,FGFR2,19223389,B,FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation.,2009,,"Our results demonstrate that the association of SNPs in FGFR2 with BC risk extends to women of African American ethnicity, and illustrate the utility of combining association analysis in datasets of diverse ethnic groups with functional experiments to identify disease susceptibility variants.",Y,FGFR2,FGFR2,0.708333333
2708,bc_id2772,CANCER,ODC1,19225907,B,Genetic polymorphism in ornithine decarboxylase and risk of breast cancer.,2010,,"Ornithine decarboxylase (ODC), the first enzyme in the biosynthesis of polyamines, has increased activity in breast cancer tissue compared with benign and normal tissues.",Y,ODC,ODC1,1
2709,bc_id2773,CANCER,MDM2,19226467,B,Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.,2009,,DNA from breast cancer patients was obtained for analysis of one of the three common BRCA1/2 mutations and MDM2 SNP309... MDM2SNP309G/G main effect on BRCA1/2 positive mutation carriers is linked to its effect on patients survival.,A,MDM2,MDM2,0.444444444
2710,bc_id2774,CANCER,BRCA2,19226467,B,Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.,2009,,DNA from breast cancer patients was obtained for analysis of one of the three common BRCA1/2 mutations and MDM2 SNP309... MDM2SNP309G/G main effect on BRCA1/2 positive mutation carriers is linked to its effect on patients survival.,A,BRCA1/2,BRCA2,0.576923077
2711,bc_id2775,CANCER,BRCA1,19226467,B,Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.,2009,,DNA from breast cancer patients was obtained for analysis of one of the three common BRCA1/2 mutations and MDM2 SNP309... MDM2SNP309G/G main effect on BRCA1/2 positive mutation carriers is linked to its effect on patients survival.,A,BRCA1,BRCA1,0.60944206
2712,bc_id2776,CANCER,GSTM1,19228880,B,A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer.,2009,has been reached and no clear risk pattern has yet to emerge for GSTM1.,We recommend that a more complicated role for GSTM1 should be considered in breast cancer risk prediction.,Y,GSTM1,GSTM1,0.452830189
2713,bc_id2777,CANCER,CYP3A5,19229255,B,"Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians.",2009,,"Although we found no significant association in the three populations combined, subgroup analyses revealed statistically significant associations of CYP1A2*1F in NJB, and CYP1B1 Leu(432)Val and CYP3A5*3 in JJ with breast cancer risk... Compared to women with the AA genotype in CYP1A2*1F, the odds ratio (OR) (95% confidence interval (CI)) for NJB with the CC genotype was 0.54 (0.32-0.90); that for JJ with Leu/Val+Val/Val versus Leu/Leu genotype in CYP1B1 Leu(432)Val was 0.68 (0.48-0.97); and that for JJ with (*)3/(*)1+(*)1/(*)1 versus (*)3/(*)3 genotype in CYP3A5*3 was 1.49 (1.10-2.04). Our findings provide further evidence that genetic polymorphisms related to estrogen metabolism may play a role in the development of breast cancer.",A,CYP3A5*3,CYP3A5,0.4
2714,bc_id2778,CANCER,CYP1B1,19229255,B,"Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians.",2009,,"Although we found no significant association in the three populations combined, subgroup analyses revealed statistically significant associations of CYP1A2*1F in NJB, and CYP1B1 Leu(432)Val and CYP3A5*3 in JJ with breast cancer risk... Compared to women with the AA genotype in CYP1A2*1F, the odds ratio (OR) (95% confidence interval (CI)) for NJB with the CC genotype was 0.54 (0.32-0.90); that for JJ with Leu/Val+Val/Val versus Leu/Leu genotype in CYP1B1 Leu(432)Val was 0.68 (0.48-0.97); and that for JJ with (*)3/(*)1+(*)1/(*)1 versus (*)3/(*)3 genotype in CYP3A5*3 was 1.49 (1.10-2.04). Our findings provide further evidence that genetic polymorphisms related to estrogen metabolism may play a role in the development of breast cancer.",A,CYP1B1,CYP1B1,0.384615385
2715,bc_id2779,CANCER,CYP1A2,19229255,B,"Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians.",2009,,"Although we found no significant association in the three populations combined, subgroup analyses revealed statistically significant associations of CYP1A2*1F in NJB, and CYP1B1 Leu(432)Val and CYP3A5*3 in JJ with breast cancer risk... Compared to women with the AA genotype in CYP1A2*1F, the odds ratio (OR) (95% confidence interval (CI)) for NJB with the CC genotype was 0.54 (0.32-0.90); that for JJ with Leu/Val+Val/Val versus Leu/Leu genotype in CYP1B1 Leu(432)Val was 0.68 (0.48-0.97); and that for JJ with (*)3/(*)1+(*)1/(*)1 versus (*)3/(*)3 genotype in CYP3A5*3 was 1.49 (1.10-2.04). Our findings provide further evidence that genetic polymorphisms related to estrogen metabolism may play a role in the development of breast cancer.",A,CYP1A2*1F,CYP1A2,0.5
2716,bc_id2780,CANCER,CYP1A1,19229255,B,"Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians.",2009,,"Although we found no significant association in the three populations combined, subgroup analyses revealed statistically significant associations of CYP1A2*1F in NJB, and CYP1B1 Leu(432)Val and CYP3A5*3 in JJ with breast cancer risk... Compared to women with the AA genotype in CYP1A2*1F, the odds ratio (OR) (95% confidence interval (CI)) for NJB with the CC genotype was 0.54 (0.32-0.90); that for JJ with Leu/Val+Val/Val versus Leu/Leu genotype in CYP1B1 Leu(432)Val was 0.68 (0.48-0.97); and that for JJ with (*)3/(*)1+(*)1/(*)1 versus (*)3/(*)3 genotype in CYP3A5*3 was 1.49 (1.10-2.04). Our findings provide further evidence that genetic polymorphisms related to estrogen metabolism may play a role in the development of breast cancer.",A,CYP1A2*1F,CYP1A1,0.456521739
2717,bc_id2781,CANCER,BRCA2,19229607,B,Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk.,2009,,"However, both SNPs, BRCA2 Ser2414Ser (7242A > G) and Ser455Ser (1365A > G), showed no association with breast cancer risk. This indicates that these codon-usage-changing SNPs have no major impact on familial breast cancer risk.",N,BRCA2,BRCA2,0.098901099
2718,bc_id2782,CANCER,IGF1,19229608,B,Family-based genetic association study of insulin-like growth factor I microsatellite markers and premenopausal breast cancer risk.,2009,,The associations we found could be due to chance as many comparisons were made. Our results do not strongly support an association between these IGF1 variants and breast cancer risk.,N,IGF1,IGF1,0.4
2719,bc_id2783,CANCER,BRCA2,19232099,B,Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia.,2009,,Germline mutations in BRCA1 or BRCA2 genes have been demonstrated to increase the risk of developing breast cancer.,Y,BRCA2,BRCA2,0.324175824
2720,bc_id2784,CANCER,BRCA1,19232099,B,Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia.,2009,,Germline mutations in BRCA1 or BRCA2 genes have been demonstrated to increase the risk of developing breast cancer.,Y,BRCA1,BRCA1,0.326180258
2721,bc_id2785,CANCER,MAP3K1,19232126,B,Association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort.,2009,The available data suggest that the effects of most of these polymorphisms on breast cancer are not mediated by mammographic density.,X,X,X,X,0
2722,bc_id2786,CANCER,LSP1,19232126,B,Association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort.,2009,The available data suggest that the effects of most of these polymorphisms on breast cancer are not mediated by mammographic density.,X,X,X,X,0
2723,bc_id2787,CANCER,TOX3,19232126,B,Association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort.,2009,The available data suggest that the effects of most of these polymorphisms on breast cancer are not mediated by mammographic density.,"Eight polymorphisms (rs2981582 in FGFR2, rs3803662 and rs12443621in TOX3, rs3817198 in LSP1, rs981782 and rs10941679 near HCN1/MRPS30, rs889312 in MAP3K1, and rs13387042 at 2q) were examined... The polymorphism rs12443621 in TOX3 was associated with percent dense area; women with at least one G allele (previously associated with increased breast cancer risk) had 3% to 4% higher densities than women with two A alleles. The polymorphism rs10941679 near HCN1/MRPS30 was also associated with percent dense area; women who were homozygous for the G allele (previously associated with increased breast cancer risk) had 4% to 5% lower densities than women with at least one A allele.",Y,TOX3,TOX3,0.5
2724,bc_id2788,CANCER,HCN1,19232126,B,Association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort.,2009,The available data suggest that the effects of most of these polymorphisms on breast cancer are not mediated by mammographic density.,"Eight polymorphisms (rs2981582 in FGFR2, rs3803662 and rs12443621in TOX3, rs3817198 in LSP1, rs981782 and rs10941679 near HCN1/MRPS30, rs889312 in MAP3K1, and rs13387042 at 2q) were examined... The polymorphism rs12443621 in TOX3 was associated with percent dense area; women with at least one G allele (previously associated with increased breast cancer risk) had 3% to 4% higher densities than women with two A alleles. The polymorphism rs10941679 near HCN1/MRPS30 was also associated with percent dense area; women who were homozygous for the G allele (previously associated with increased breast cancer risk) had 4% to 5% lower densities than women with at least one A allele.",Y,HCN1/MRPS30,HCN1,1
2725,bc_id2789,CANCER,FGFR2,19232126,B,Association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort.,2009,The available data suggest that the effects of most of these polymorphisms on breast cancer are not mediated by mammographic density.,X,X,X,X,0
2726,bc_id2790,CANCER,CYP3A4,19242060,B,Novel mutations of CYP3A4 in fine needle aspiration cytology samples of breast cancer patients and its clinical correlations.,2009,,This is the first report of these two novel point mutations in CYP3A4 gene. These mutations in the gene in respective patients were found to relate to drug response in invasive ductal carcinomas of breast cancer.,Y,CYP3A4,CYP3A4,0.272727273
2727,bc_id2791,CANCER,BRCA1,19246281,B,[Analysis of BRCA1 gene mutations in patients with early-onset breast cancer and their affected relatives in Guangdong province],2009,,"The incidence of BRCA1 mutation is significantly lower in patients with early-onset breast cancer and their affected relatives in Guangdong province than in the Western populations. The novel mutation identified in BRCA1 gene may represent a mutation characteristic of the patients in Guangdong province. BRCA1 gene mutations may not have any relation with the expression of ER, PR, HER2 and ALN.",A,BRCA1,BRCA1,0.60944206
2728,bc_id2792,CANCER,FASN,19252981,B,Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk.,2009,,"In this study we were not able to find any statistically significant association between the SNPs in the FAS, ChREBP and SREPB-1 genes and an increased risk of breast cancer overall and by subgroups of age, menopausal status, hormone replacement therapy (HRT) use or BMI. On the other hand, we found that two SNPs in FASN were associated with BMI.",N,FAS,FASN,1
2729,bc_id2793,CANCER,MLXIPL,19252981,B,Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk.,2009,,"In this study we were not able to find any statistically significant association between the SNPs in the FAS, ChREBP and SREPB-1 genes and an increased risk of breast cancer overall and by subgroups of age, menopausal status, hormone replacement therapy (HRT) use or BMI. On the other hand, we found that two SNPs in FASN were associated with BMI.",N,ChREBP,MLXIPL,1
2730,bc_id2794,CANCER,SREBF1,19252981,B,Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk.,2009,,X,X,X,X,0
2731,bc_id2795,CANCER,BRCA2,19253839,B,[Association of polymorphisms of N372H in BRCA2 gene and 135G/C in RAD51 gene and breast cancers],2008,"The genotype HH of the N372H locus in BRCA2 is associated with breast cancers, which might be a genetic risk factor for breast cancers in Chinese populations.","The genotype HH of the N372H locus in BRCA2 is associated with breast cancers, which might be a genetic risk factor for breast cancers in Chinese populations.",A,BRCA2,BRCA2,0.576923077
2732,bc_id2796,CANCER,RAD51,19253839,B,[Association of polymorphisms of N372H in BRCA2 gene and 135G/C in RAD51 gene and breast cancers],2008,"The genotype HH of the N372H locus in BRCA2 is associated with breast cancers, which might be a genetic risk factor for breast cancers in Chinese populations.",X,X,X,X,0
2733,bc_id2797,CANCER,NOS3,19255063,B,"Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk.",2009,,"In contrast, among women with low vegetable and fruit intake (< median), the low-risk CAT CC (OR = 1.33, 95% CI = 0.89-1.99), NOS3 TT (OR = 2.93, 95% CI = 1.38-6.22) and MPO AA (OR = 2.09, 95% CI = 0.73-5.95) genotypes appeared to be associated with raised breast cancer risk, with significantly increased risks observed in those with > or = 4 low-risk alleles compared with participants with < or = 2 low-risk alleles (OR = 1.77, 95% CI = 1.05-2.99, P-interaction = 0.006).",Y,NOS3,NOS3,0.538461538
2734,bc_id2798,CANCER,MPO,19255063,B,"Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk.",2009,,"In contrast, among women with low vegetable and fruit intake (< median), the low-risk CAT CC (OR = 1.33, 95% CI = 0.89-1.99), NOS3 TT (OR = 2.93, 95% CI = 1.38-6.22) and MPO AA (OR = 2.09, 95% CI = 0.73-5.95) genotypes appeared to be associated with raised breast cancer risk, with significantly increased risks observed in those with > or = 4 low-risk alleles compared with participants with < or = 2 low-risk alleles (OR = 1.77, 95% CI = 1.05-2.99, P-interaction = 0.006).",Y,MPO,MPO,0.428571429
2735,bc_id2799,CANCER,HMOX1,19255063,B,"Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk.",2009,,X,X,X,X,0
2736,bc_id2800,CANCER,CAT,19255063,B,"Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk.",2009,,"In contrast, among women with low vegetable and fruit intake (< median), the low-risk CAT CC (OR = 1.33, 95% CI = 0.89-1.99), NOS3 TT (OR = 2.93, 95% CI = 1.38-6.22) and MPO AA (OR = 2.09, 95% CI = 0.73-5.95) genotypes appeared to be associated with raised breast cancer risk, with significantly increased risks observed in those with > or = 4 low-risk alleles compared with participants with < or = 2 low-risk alleles (OR = 1.77, 95% CI = 1.05-2.99, P-interaction = 0.006).",Y,CAT,CAT,0.2
2737,bc_id2801,CANCER,FOXP3,19264232,B,FOXP3 germline polymorphisms are not associated with risk of breast cancer.,2009,,The analysis of reconstructed haplotypes based on the three FOXP3 htSNPs did not identify any haplotypes associated with breast cancer.,N,FOXP3,FOXP3,1
2738,bc_id2802,CANCER,ND3,19266278,B,Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland.,2009,,X,X,X,X,0
2739,bc_id2803,CANCER,IL1RN,19267917,B,The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study.,2009,Carriage of the mutant alleles of IL1RN was independently associated with shortened disease free and overall survival rates in Caucasian patients with breast cancer.,"Presence of the homozygous mutant genotype of the IL1A -889 and IL1B +3953 gene polymorphism was associated with overall survival in the univariate (p = 0.004 and p = 0.002, respectively), but not in the multivariate analysis. No association was observed between all possible haplotype combinations and overall survival... Carriage of the mutant alleles of IL1RN was independently associated with shortened disease free and overall survival rates in Caucasian patients with breast cancer.",A,IL1RN,IL1RN,0.5
2740,bc_id2804,CANCER,IL1B,19267917,B,The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study.,2009,Carriage of the mutant alleles of IL1RN was independently associated with shortened disease free and overall survival rates in Caucasian patients with breast cancer.,"Presence of the homozygous mutant genotype of the IL1A -889 and IL1B +3953 gene polymorphism was associated with overall survival in the univariate (p = 0.004 and p = 0.002, respectively), but not in the multivariate analysis. No association was observed between all possible haplotype combinations and overall survival... Carriage of the mutant alleles of IL1RN was independently associated with shortened disease free and overall survival rates in Caucasian patients with breast cancer.",A,IL1B,IL1B,0.4
2741,bc_id2805,CANCER,IL1A,19267917,B,The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study.,2009,Carriage of the mutant alleles of IL1RN was independently associated with shortened disease free and overall survival rates in Caucasian patients with breast cancer.,"Presence of the homozygous mutant genotype of the IL1A -889 and IL1B +3953 gene polymorphism was associated with overall survival in the univariate (p = 0.004 and p = 0.002, respectively), but not in the multivariate analysis. No association was observed between all possible haplotype combinations and overall survival... Carriage of the mutant alleles of IL1RN was independently associated with shortened disease free and overall survival rates in Caucasian patients with breast cancer.",A,IL1A,IL1A,0.5
2742,bc_id2806,CANCER,PTGS2,19276290,B,Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.,2009,"Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.","Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.",N,PTGS2,PTGS2,0.333333333
2743,bc_id2807,CANCER,PTGS1,19276290,B,Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.,2009,"Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.","Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.",N,PTGS1,PTGS1,1
2744,bc_id2808,CANCER,PTGIS,19276290,B,Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.,2009,"Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.","Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.",A,PTGIS,PTGIS,1
2745,bc_id2809,CANCER,PTGES,19276290,B,Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.,2009,"Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.","Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.",N,PTGES,PTGES,1
2746,bc_id2810,CANCER,PTGDS,19276290,B,Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.,2009,"Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.","Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.",N,PTGDS,PTGDS,1
2747,bc_id2812,CANCER,TBXAS1,19276290,B,Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.,2009,"Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.","Specific PTGIS and TBXAS1 variants may affect breast cancer susceptibility, but common variants in PTGS1, PTGS2, PTGES, PTGDS, and PGDS have no major role in breast cancer susceptibility.",A,TBXAS1,TBXAS1,1
2748,bc_id2813,CANCER,CCND1,19287456,B,Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.,2009,,"Aberrant expression of cyclin D1 protein is a common feature of breast cancer. However, the CCND1 gene encodes two gene products, cyclin D1a and cyclin D1b, which have discrete mechanisms of regulation and impact on cell behavior... Thus, specific cyclin D1 isoforms are associated with discrete forms of breast cancer and high cyclin D1b protein levels hold prognostic potential.",A,CCND1,CCND1,0.5
2749,bc_id2814,CANCER,NAT2,19287511,B,Analysis association between mitochondrial genome instability and xenobiotic metabolizing genes in human breast cancer.,2009,,X,X,X,X,0
2750,bc_id2815,CANCER,GSTT1,19287511,B,Analysis association between mitochondrial genome instability and xenobiotic metabolizing genes in human breast cancer.,2009,,X,X,X,X,0
2751,bc_id2816,CANCER,GSTM1,19287511,B,Analysis association between mitochondrial genome instability and xenobiotic metabolizing genes in human breast cancer.,2009,,X,X,X,X,0
2752,bc_id2818,CANCER,CYP1B1,19293312,B,Association of CYP1B1 haplotypes and breast cancer risk in Caucasian women.,2009,suggest that genetic variation in CYP1B1 has at most a minor influence on breast cancer susceptibility among Caucasian women.,suggest that genetic variation in CYP1B1 has at most a minor influence on breast cancer susceptibility among Caucasian women.,Y,CYP1B1,CYP1B1,0.358974359
2753,bc_id2819,CANCER,ESR2,19298602,B,"Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians.",2009,,"Epidemiologic studies have shown an inverse association between isoflavones and breast cancer risk. Because isoflavones bind estrogen receptors, we hypothesized that polymorphisms in the estrogen receptor genes might modify the association between isoflavone intake and breast cancer risk.",A,estrogen receptors,ESR2,0.533333333
2754,bc_id2820,CANCER,ESR1,19298602,B,"Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians.",2009,,"Epidemiologic studies have shown an inverse association between isoflavones and breast cancer risk. Because isoflavones bind estrogen receptors, we hypothesized that polymorphisms in the estrogen receptor genes might modify the association between isoflavone intake and breast cancer risk.",A,estrogen receptors,ESR1,0.586956522
2755,bc_id2821,CANCER,BRCA2,19298662,B,The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.,2009,,X,X,X,X,0
2756,bc_id2822,CANCER,BRCA1,19298662,B,The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.,2009,,X,X,X,X,0
2757,bc_id2823,CANCER,PTHLH,19304784,B,Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.,2009,"we found that rs4954956 was associated with increased ovarian cancer risk, particularly for serous ovarian cancer.",X,X,X,X,0
2758,bc_id2824,CANCER,LOC643714,19304784,B,Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.,2009,"we found that rs4954956 was associated with increased ovarian cancer risk, particularly for serous ovarian cancer.",X,X,X,X,0
2759,bc_id2825,CANCER,MRPL23,19304784,B,Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.,2009,"we found that rs4954956 was associated with increased ovarian cancer risk, particularly for serous ovarian cancer.",X,X,X,X,0
2760,bc_id2826,CANCER,BRCA2,19307946,B,Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.,2009,,"Breast conservation after induction treatment was higher in BRmut+ tumors, and clinical response was related to aggressive tumor features correlated with BRCA1/2 mutations. This suggests that impaired repair mechanisms related to the BRCA1/2 mutations increased the chemosensitivity and radiosensitivity of large breast cancers. Further studies will need to determine the long-term outcome in these patients.",A,BRCA1/2,BRCA2,0.576923077
2761,bc_id2827,CANCER,BRCA1,19307946,B,Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.,2009,,"Breast conservation after induction treatment was higher in BRmut+ tumors, and clinical response was related to aggressive tumor features correlated with BRCA1/2 mutations. This suggests that impaired repair mechanisms related to the BRCA1/2 mutations increased the chemosensitivity and radiosensitivity of large breast cancers. Further studies will need to determine the long-term outcome in these patients.",A,BRCA1/2,BRCA1,0.60944206
2762,bc_id2828,CANCER,C1ORF38,19308812,B,Single nucleotide polymorphisms in human gene icb-1 and breast cancer susceptibility.,2009,,"Analysis of allele positivity revealed that AG or GG genotypes were significantly less frequent in breast cancer patients, suggesting that presence of G allele might have protective effects. Our data suggest that SNP rs1467465 of human gene icb-1 might affect breast cancer susceptibility.",A,icb-1,C1ORF38,1
2763,bc_id2830,CANCER,CASP8,19318553,B,A breast cancer risk haplotype in the caspase-8 gene.,2009,,"One such variant in the caspase-8 (CASP8) gene, D302H (rs1045485), has been confirmed to be associated with breast cancer risk, although the functional effect of this polymorphism (if any) is not yet clear.",Y,CASP8,CASP8,0.642857143
2764,bc_id2831,CANCER,ESR2,19321582,B,The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes.,2009,,"Seven polymorphisms in ESR1 (rs827422, rs1709184, rs2347867, rs3020328, rs72207, rs2982896, and rs2234693) and 5 polymorphisms in ESR2 (rs915057, rs1269056, rs1256033, rs3020450, and rs3020443) were selected... None of the other polymorphisms seem to modify the association between enterolactone and breast cancer.",N,ESR2,ESR2,0.133333333
2765,bc_id2832,CANCER,ESR1,19321582,B,The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes.,2009,,"Seven polymorphisms in ESR1 (rs827422, rs1709184, rs2347867, rs3020328, rs72207, rs2982896, and rs2234693) and 5 polymorphisms in ESR2 (rs915057, rs1269056, rs1256033, rs3020450, and rs3020443) were selected... None of the other polymorphisms seem to modify the association between enterolactone and breast cancer.",N,ESR1,ESR1,0.130434783
2766,bc_id2833,CANCER,COX11,19330027,B,Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.,2009,,"To identify additional loci, we tested over 800 promising associations from this GWAS in a further two stages involving 37,012 cases and 40,069 controls from 33 studies in the CGEMS collaboration and Breast Cancer Association Consortium. We found strong evidence for additional susceptibility loci on 3p (rs4973768: per-allele OR = 1.11, 95% CI = 1.08-1.13, P = 4.1 x 10(-23)) and 17q (rs6504950: per-allele OR = 0.95, 95% CI = 0.92-0.97, P = 1.4 x 10(-8)). Potential causative genes include SLC4A7 and NEK10 on 3p and COX11 on 17q.",Y,COX11,COX11,1
2767,bc_id2834,CANCER,NEK10,19330027,B,Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.,2009,,"To identify additional loci, we tested over 800 promising associations from this GWAS in a further two stages involving 37,012 cases and 40,069 controls from 33 studies in the CGEMS collaboration and Breast Cancer Association Consortium. We found strong evidence for additional susceptibility loci on 3p (rs4973768: per-allele OR = 1.11, 95% CI = 1.08-1.13, P = 4.1 x 10(-23)) and 17q (rs6504950: per-allele OR = 0.95, 95% CI = 0.92-0.97, P = 1.4 x 10(-8)). Potential causative genes include SLC4A7 and NEK10 on 3p and COX11 on 17q.",Y,NEK10,NEK10,1
2768,bc_id2835,CANCER,SLC4A7,19330027,B,Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.,2009,,"To identify additional loci, we tested over 800 promising associations from this GWAS in a further two stages involving 37,012 cases and 40,069 controls from 33 studies in the CGEMS collaboration and Breast Cancer Association Consortium. We found strong evidence for additional susceptibility loci on 3p (rs4973768: per-allele OR = 1.11, 95% CI = 1.08-1.13, P = 4.1 x 10(-23)) and 17q (rs6504950: per-allele OR = 0.95, 95% CI = 0.92-0.97, P = 1.4 x 10(-8)). Potential causative genes include SLC4A7 and NEK10 on 3p and COX11 on 17q.",Y,SLC4A7,SLC4A7,1
2769,bc_id2836,CANCER,NOTCH2,19330030,B,A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).,2009,,X,X,X,X,0
2770,bc_id2837,CANCER,FCGR1B,19330030,B,A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).,2009,,X,X,X,X,0
2771,bc_id2838,CANCER,RAD51L1,19330030,B,A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).,2009,,X,X,X,X,0
2772,bc_id2839,CANCER,ABCB1,19332043,B,"Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.",2009,There could be correlations between certain side effects of docetaxel treatment and polymorphisms of these metabolic enzymes.,X,X,X,X,0
2773,bc_id2840,CANCER,CYP3A5,19332043,B,"Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.",2009,There could be correlations between certain side effects of docetaxel treatment and polymorphisms of these metabolic enzymes.,X,X,X,X,0
2774,bc_id2841,CANCER,CYP3A4,19332043,B,"Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.",2009,There could be correlations between certain side effects of docetaxel treatment and polymorphisms of these metabolic enzymes.,X,X,X,X,0
2775,bc_id2842,CANCER,PALB2,19333784,B,PALB2 sequence variants in young South African breast cancer patients.,2010,,Our study reports that deleterious mutations in PALB2 account for approximately 2% (1/48) of South African early-onset breast cancer.,A,PALB2,PALB2,0.583333333
2776,bc_id2843,CANCER,ERBB2,19336545,B,Heritable variation of ERBB2 and breast cancer risk.,2009,,"In contrast, we observed no association of ERBB2 single nucleotide polymorphism haplotypes with breast cancer predisposition.",N,ERBB2,ERBB2,0.261904762
2777,bc_id2844,CANCER,MTHFR,19336565,B,"Folate intake, methylenetetrahydrofolate reductase polymorphisms, and breast cancer risk in women from the Malmo Diet and Cancer cohort.",2009,,"In conclusion, a positive association between DFE and breast cancer was observed in MTHFR 677CT/TT-1298AA women but an inverse association was observed in 677CT-1298AC women. The 677T allele was associated with higher breast cancer risk in women above 55 years of age.",A,MTHFR,MTHFR,0.403846154
2778,bc_id2845,CANCER,CYP1A1,19346634,B,Association of CYP1A1*2 polymorphisms with breast cancer risk: a case control study.,2009,,"In conclusion, our results suggest a significant correlation between CYP1A1*2 expression and the occurrence of breast cancer.",Y,CYP1A1*2,CYP1A1,0.304347826
2779,bc_id2846,CANCER,NQO2,19351655,B,"Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53.",2009,,"Taken together, the data presented here strongly suggest that NQO2 is a susceptibility gene for breast carcinogenesis.",Y,NQO2,NQO2,1
2780,bc_id2847,CANCER,BRCA1,19366445,B,Survival in Norwegian BRCA1 mutation carriers with breast cancer.,2009,,"Our findings confirm the serious prognosis of BRCA1-associated breast cancer even when diagnosed at an early stage, and that type of treatment does not influence prognosis.",Y,BRCA1,BRCA1,0.326180258
2781,bc_id2848,CANCER,CYP19A1,19366906,B,BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.,2009,,The present study suggests that the CYP19 Val(80) polymorphism and a haplotype that includes this polymorphism are associated with increased breast cancer risk in young women with BRCA1 mutations.,Y,CYP19,CYP19A1,0.333333333
2782,bc_id2849,CANCER,BRCA1,19366906,B,BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.,2009,,The present study suggests that the CYP19 Val(80) polymorphism and a haplotype that includes this polymorphism are associated with increased breast cancer risk in young women with BRCA1 mutations.,A,BRCA1,BRCA1,0.60944206
2783,bc_id2850,CANCER,APEX1,19367277,B,Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.,2009,,"Breast cancer patients who received radiotherapy after breast-conserving surgery were examined for late complications of radiotherapy after a median follow-up time of 51 months. Polymorphisms in genes involved in DNA repair (APEX1, XRCC1, XRCC2, XRCC3, XPD) and damage response (TP53, P21) were determined.",A,APEX1,APEX1,0.333333333
2784,bc_id2851,CANCER,ERCC2,19367277,B,Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.,2009,,"Breast cancer patients who received radiotherapy after breast-conserving surgery were examined for late complications of radiotherapy after a median follow-up time of 51 months. Polymorphisms in genes involved in DNA repair (APEX1, XRCC1, XRCC2, XRCC3, XPD) and damage response (TP53, P21) were determined.",A,XPD,ERCC2,0.6875
2785,bc_id2852,CANCER,CDKN1A,19367277,B,Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.,2009,,"Breast cancer patients who received radiotherapy after breast-conserving surgery were examined for late complications of radiotherapy after a median follow-up time of 51 months. Polymorphisms in genes involved in DNA repair (APEX1, XRCC1, XRCC2, XRCC3, XPD) and damage response (TP53, P21) were determined.",A,P21,CDKN1A,0.5
2786,bc_id2853,CANCER,XRCC3,19367277,B,Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.,2009,,"Breast cancer patients who received radiotherapy after breast-conserving surgery were examined for late complications of radiotherapy after a median follow-up time of 51 months. Polymorphisms in genes involved in DNA repair (APEX1, XRCC1, XRCC2, XRCC3, XPD) and damage response (TP53, P21) were determined.",A,XRCC3,XRCC3,0.461538462
2787,bc_id2854,CANCER,XRCC2,19367277,B,Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.,2009,,"Breast cancer patients who received radiotherapy after breast-conserving surgery were examined for late complications of radiotherapy after a median follow-up time of 51 months. Polymorphisms in genes involved in DNA repair (APEX1, XRCC1, XRCC2, XRCC3, XPD) and damage response (TP53, P21) were determined.",A,XRCC2,XRCC2,0.272727273
2788,bc_id2855,CANCER,XRCC1,19367277,B,Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.,2009,,"Breast cancer patients who received radiotherapy after breast-conserving surgery were examined for late complications of radiotherapy after a median follow-up time of 51 months. Polymorphisms in genes involved in DNA repair (APEX1, XRCC1, XRCC2, XRCC3, XPD) and damage response (TP53, P21) were determined.",A,XRCC1,XRCC1,0.543478261
2789,bc_id2856,CANCER,TP53,19367277,B,Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer.,2009,,"Breast cancer patients who received radiotherapy after breast-conserving surgery were examined for late complications of radiotherapy after a median follow-up time of 51 months. Polymorphisms in genes involved in DNA repair (APEX1, XRCC1, XRCC2, XRCC3, XPD) and damage response (TP53, P21) were determined.",A,TP53,TP53,0.482758621
2790,bc_id2857,CANCER,CNTNAP1,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,CNTNAP1,CNTNAP1,1
2791,bc_id2858,CANCER,NOS1,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,NOS1,NOS1,1
2792,bc_id2859,CANCER,NCF4,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,NCF4,NCF4,1
2793,bc_id2860,CANCER,NCF2,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,NCF2,NCF2,1
2794,bc_id2861,CANCER,MBP,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,MBP,MBP,1
2795,bc_id2862,CANCER,CD93,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,C1QR1,CD93,1
2796,bc_id2863,CANCER,KLKB1,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,KLKB1,KLKB1,1
2797,bc_id2864,CANCER,KLK4,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,KLK4,KLK4,1
2798,bc_id2865,CANCER,KLK2,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,KLK2,KLK2,1
2799,bc_id2866,CANCER,ITGB2,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,ITGB2,ITGB2,1
2800,bc_id2867,CANCER,ALOX12B,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,ALOX12B,ALOX12B,1
2801,bc_id2868,CANCER,FCER1A,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,FCER1A,FCER1A,1
2802,bc_id2869,CANCER,CTNNB1,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,CTNNB1,CTNNB1,0.5
2803,bc_id2870,CANCER,IRAK3,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,IRAK3,IRAK3,1
2804,bc_id2871,CANCER,OR10J3,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,OR10J3,OR10J3,1
2805,bc_id2872,CANCER,STAT6,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,STAT6,STAT6,1
2806,bc_id2873,CANCER,CCL1,19372141,B,Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.,2009,This study suggests that common genetic variants in the OR10J3 and FCER1A be strongly associated with breast cancer risk among Korean women.,"Both SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.",Y,CCL1,CCL1,1
2807,bc_id2874,CANCER,CHEK2,19372713,B,"Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.",2009,,"In patients with CHEK2 gene mutations, breast cancer occurred 2.1-3.8 years earlier than in patients without mutations in the CHEK2 gene.",Y,CHEK2,CHEK2,0.383333333
2808,bc_id2875,CANCER,GSTT1,19376514,B,Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.,2009,,X,X,X,X,0
2809,bc_id2876,CANCER,GSTP1,19376514,B,Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.,2009,,X,X,X,X,0
2810,bc_id2877,CANCER,GSTM1,19376514,B,Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.,2009,,X,X,X,X,0
2811,bc_id2878,CANCER,GSTA1,19376514,B,Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.,2009,,X,X,X,X,0
2812,bc_id2879,CANCER,CYP3A5,19376514,B,Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.,2009,,X,X,X,X,0
2813,bc_id2880,CANCER,CYP3A4,19376514,B,Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.,2009,,X,X,X,X,0
2814,bc_id2881,CANCER,CYP2B6,19376514,B,Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.,2009,,X,X,X,X,0
2815,bc_id2882,CANCER,PON1,19379515,B,"CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study.",2009,"Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and GLO1 could be associated with the risk for BC.","Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and GLO1 could be associated with the risk for BC.",A,PON1,PON1,1
2816,bc_id2883,CANCER,GSTP1,19379515,B,"CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study.",2009,"Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and GLO1 could be associated with the risk for BC.","Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and GLO1 could be associated with the risk for BC.",A,GSTP1,GSTP1,0.485714286
2817,bc_id2884,CANCER,GLO1,19379515,B,"CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study.",2009,"Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and GLO1 could be associated with the risk for BC.","Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and GLO1 could be associated with the risk for BC.",A,GLO1,GLO1,1
2818,bc_id2885,CANCER,CYP17A1,19379515,B,"CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study.",2009,"Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and GLO1 could be associated with the risk for BC.","Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and GLO1 could be associated with the risk for BC.",A,CYP17,CYP17A1,0.466666667
2819,bc_id2886,CANCER,TERT,19380022,B,A functional promoter polymorphism in the TERT gene does not affect inherited susceptibility to breast cancer.,2009,,"In our attempt to identify functional polymorphisms in the TERT gene and their effect on breast cancer risk, we sequenced the promoter of the gene and identified three single nucleotide polymorphisms (SNPs) with a frequency of at least 10%. One of these SNPs, rs2853669 (-244 T > C), has been shown to affect telomerase activity and telomere length. Recently, this SNP has been suggested to affect familial breast cancer risk.",Y,TERT,TERT,0.5
2820,bc_id2888,CANCER,PALB2,19383810,Y,The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.,2009,The PALB2 1592delT mutation has a strong effect on familial breast cancer risk.,The PALB2 1592delT mutation has a strong effect on familial breast cancer risk.,Y,PALB2,PALB2,0.25
2821,bc_id2889,CANCER,GSTT1,19383894,B,Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk.,2009,,X,X,X,X,0
2822,bc_id2890,CANCER,GSTP1,19383894,B,Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk.,2009,,"In a population-based case-control study of breast cancer, 891 cases and 878 controls were genotyped for six functional SNPs in the COMT, CYP1B1, GSTM1, GSTP1, and GSTT1 genes... With the exception of GSTP1 and possibly CYP1B1*2, our findings do not provide support for the role of genetic variation in the catechol estrogen metabolism pathway and breast cancer risk in postmenopausal women.",A,GSTP1,GSTP1,0.485714286
2823,bc_id2891,CANCER,GSTM1,19383894,B,Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk.,2009,,X,X,X,X,0
2824,bc_id2892,CANCER,CYP1B1,19383894,B,Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk.,2009,,"In a population-based case-control study of breast cancer, 891 cases and 878 controls were genotyped for six functional SNPs in the COMT, CYP1B1, GSTM1, GSTP1, and GSTT1 genes... With the exception of GSTP1 and possibly CYP1B1*2, our findings do not provide support for the role of genetic variation in the catechol estrogen metabolism pathway and breast cancer risk in postmenopausal women.",A,CYP1B1,CYP1B1,0.384615385
2825,bc_id2893,CANCER,COMT,19383894,B,Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk.,2009,,X,X,X,X,0
2826,bc_id2894,CANCER,ABCB1,19388849,B,Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population.,2009,,Our results suggest that C3435T MDR1 polymorphism was not associated with the susceptibility to breast cancer in the population studied.,N,MDR1,ABCB1,0.125
2827,bc_id2895,CANCER,EGF,19388850,B,"Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease.",2009,,A lower risk for breast cancer in GG carriers might be explained through EGF receptor internalization promoted by EGF.,Y,EGF,EGF,0.333333333
2828,bc_id2896,CANCER,MTR,19389261,B,"Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Brazilian women.",2009,"MTHFR polymorphisms and dietary intake of folate, vitamin B6, and vitamin B12 had no overall association with breast cancer risk.","MTHFR polymorphisms and dietary intake of folate, vitamin B6, and vitamin B12 had no overall association with breast cancer risk. However, increased risk was observed in total women with the MTR 2756GG genotype and in premenopausal women with high folate intake.",Y,MTR,MTR,0.444444444
2829,bc_id2897,CANCER,MTHFR,19389261,B,"Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Brazilian women.",2009,"MTHFR polymorphisms and dietary intake of folate, vitamin B6, and vitamin B12 had no overall association with breast cancer risk.","MTHFR polymorphisms and dietary intake of folate, vitamin B6, and vitamin B12 had no overall association with breast cancer risk. However, increased risk was observed in total women with the MTR 2756GG genotype and in premenopausal women with high folate intake.",N,MTHFR,MTHFR,0.326923077
2830,bc_id2898,CANCER,BRCA1,19390427,B,Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.,2009,,X,X,X,X,0
2831,bc_id2899,CANCER,ND3,19390621,B,"The mitochondrial A10398G polymorphism, interaction with alcohol consumption, and breast cancer risk.",2009,,X,X,X,X,0
2832,bc_id2900,CANCER,TGFBR1,19390964,B,The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer.,2010,,"In conclusion, our study shows that there is no association between TGFBR1*6A and breast cancer risk.",N,TGFBR1*6A,TGFBR1,0.666666667
2833,bc_id2901,CANCER,LOC643714,19398914,B,TNRC9/LOC643714 polymorphisms are not associated with breast cancer risk in Chinese women.,2009,,None of these three SNPs of TNRC9/LOC643714 gene is associated with individual susceptibility to breast cancer in Chinese women.,N,LOC643714,LOC643714,0.333333333
2834,bc_id2902,CANCER,CHEK2,19399639,B,"CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.",2010,,"The variant was not found in any patients in this cohort, suggesting that CHEK2*1100delC is rare in our population, and unlikely to contribute significantly to risk to breast cancer among the Malay, Chinese and Indian ethnic groups in Malaysia.",A,CHEK2*1100delC,CHEK2,0.383333333
2835,bc_id2903,CANCER,ERBB2,19401546,B,Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.,2009,,X,X,X,X,0
2836,bc_id2904,CANCER,TOP2A,19401546,B,Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.,2009,,X,X,X,X,0
2837,bc_id2905,CANCER,TP53,19403344,B,Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution.,2009,,The role of mutant TP53 in the progression of breast cancer is less clear and may vary between subtypes.,A,TP53,TP53,0.482758621
2838,bc_id2906,CANCER,ATM,19404735,B,ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.,2010,,X,X,X,X,0
2839,bc_id2907,CANCER,PGR,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2840,bc_id2908,CANCER,HSD17B2,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2841,bc_id2909,CANCER,HSD17B1,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2842,bc_id2910,CANCER,AHR,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,"Forty single nucleotide polymorphisms (SNPs) in the CYP1A1, CYP1A2, CYP1B1, CYP17, CYP19, CYP2C9, CYP2C19, AhR, ESR1, PGR, ERRG, COMT, HSD17B1, HSD17B2, EPHX1 and NQO1 genes were genotyped... These findings suggest that CYP1A2, CYP2C19, AhR, ERRG and CYP17 polymorphisms may play an important role in estrogen metabolism and modify individual susceptibility to breast cancer in Thai women.",A,AhR,AHR,0.4
2843,bc_id2911,CANCER,ESRRG,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,"Forty single nucleotide polymorphisms (SNPs) in the CYP1A1, CYP1A2, CYP1B1, CYP17, CYP19, CYP2C9, CYP2C19, AhR, ESR1, PGR, ERRG, COMT, HSD17B1, HSD17B2, EPHX1 and NQO1 genes were genotyped... These findings suggest that CYP1A2, CYP2C19, AhR, ERRG and CYP17 polymorphisms may play an important role in estrogen metabolism and modify individual susceptibility to breast cancer in Thai women.",A,ERRG,ESRRG,1
2844,bc_id2912,CANCER,ESR1,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2845,bc_id2913,CANCER,NQO1,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2846,bc_id2914,CANCER,CYP2C9,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2847,bc_id2915,CANCER,CYP2C19,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,"Forty single nucleotide polymorphisms (SNPs) in the CYP1A1, CYP1A2, CYP1B1, CYP17, CYP19, CYP2C9, CYP2C19, AhR, ESR1, PGR, ERRG, COMT, HSD17B1, HSD17B2, EPHX1 and NQO1 genes were genotyped... These findings suggest that CYP1A2, CYP2C19, AhR, ERRG and CYP17 polymorphisms may play an important role in estrogen metabolism and modify individual susceptibility to breast cancer in Thai women.",A,CYP2C19,CYP2C19,0.8
2848,bc_id2916,CANCER,CYP1B1,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2849,bc_id2917,CANCER,CYP1A2,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,"Forty single nucleotide polymorphisms (SNPs) in the CYP1A1, CYP1A2, CYP1B1, CYP17, CYP19, CYP2C9, CYP2C19, AhR, ESR1, PGR, ERRG, COMT, HSD17B1, HSD17B2, EPHX1 and NQO1 genes were genotyped... These findings suggest that CYP1A2, CYP2C19, AhR, ERRG and CYP17 polymorphisms may play an important role in estrogen metabolism and modify individual susceptibility to breast cancer in Thai women.",A,CYP1A2,CYP1A2,0.5
2850,bc_id2918,CANCER,CYP1A1,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2851,bc_id2919,CANCER,CYP19A1,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2852,bc_id2920,CANCER,CYP17A1,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,"Forty single nucleotide polymorphisms (SNPs) in the CYP1A1, CYP1A2, CYP1B1, CYP17, CYP19, CYP2C9, CYP2C19, AhR, ESR1, PGR, ERRG, COMT, HSD17B1, HSD17B2, EPHX1 and NQO1 genes were genotyped... These findings suggest that CYP1A2, CYP2C19, AhR, ERRG and CYP17 polymorphisms may play an important role in estrogen metabolism and modify individual susceptibility to breast cancer in Thai women.",A,CYP17,CYP17A1,0.466666667
2853,bc_id2921,CANCER,COMT,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2854,bc_id2922,CANCER,EPHX1,19415745,B,Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.,2009,,X,X,X,X,0
2855,bc_id2923,CANCER,CYP2D6,19421167,B,Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.,2009,,The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer... These data suggest that presence of active CYP2D6 alleles may predict for higher likelihood of tamoxifen discontinuation.,A,CYP2D6,CYP2D6,0.590909091
2856,bc_id2924,CANCER,PGR,19423537,B,Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.,2009,"our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.","In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.",N,PGR,PGR,0.357142857
2857,bc_id2925,CANCER,ERCC4,19423537,B,Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.,2009,"our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.","In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.",N,ERCC4,ERCC4,0.25
2858,bc_id2926,CANCER,CASP10,19423537,B,Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.,2009,"our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.","In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.",N,CASP10,CASP10,0.333333333
2859,bc_id2927,CANCER,TNF,19423537,B,Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.,2009,"our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.","In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.",N,TNF,TNF,0.266666667
2860,bc_id2928,CANCER,BID,19423537,B,Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.,2009,"our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.","In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.",N,BID,BID,1
2861,bc_id2929,CANCER,GSTP1,19424636,B,eRF3a/GSPT1 12-GGC allele increases the susceptibility for breast cancer development.,2009,,"The eukaryotic Release Factor 3 (eRF3) is a GTPase that associates with eRF1 in a complex that mediates translation termination. eRF3a/GSPT1 first exon contains a (GGC)n expansion coding for proteins with different N-terminal extremities. Herein we show that the longer allele (12-GGC) is present in 5.1% (7/137) of the breast cancer patients analysed and is absent in the control population (0/135), corresponding to an increased risk for cancer development, as revealed by Odds Ratio analysis.",A,GSPT1,GSTP1,0.485714286
2862,bc_id2930,CANCER,GSTT1,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",Y,GSTT1,GSTT1,0.578947368
2863,bc_id2931,CANCER,GSTP1,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,GSTP1,GSTP1,0.485714286
2864,bc_id2932,CANCER,GSTM3,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,GSTM3,GSTM3,0.666666667
2865,bc_id2933,CANCER,GSTM1,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,GSTM1,GSTM1,0.339622642
2866,bc_id2934,CANCER,CYP3A7,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,CYP3A7,CYP3A7,1
2867,bc_id2935,CANCER,CYP3A5,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,CYP3A5,CYP3A5,0.4
2868,bc_id2936,CANCER,CYP3A4,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,CYP3A4,CYP3A4,0.363636364
2869,bc_id2937,CANCER,CYP2C9,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,CYP2C9,CYP2C9,1
2870,bc_id2938,CANCER,CYP2C19,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,CYP2C19,CYP2C19,0.8
2871,bc_id2939,CANCER,CYP1B1,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,CYP1B1,CYP1B1,0.384615385
2872,bc_id2940,CANCER,CYP1A2,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,CYP1A2,CYP1A2,0.5
2873,bc_id2941,CANCER,CYP1A1,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,CYP1A1,CYP1A1,0.456521739
2874,bc_id2942,CANCER,COMT,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,COMT,COMT,0.425531915
2875,bc_id2943,CANCER,UGT2B7,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,UGT2B7,UGT2B7,1
2876,bc_id2944,CANCER,UGT1A6,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,UGT1A6,UGT1A6,1
2877,bc_id2945,CANCER,UGT1A1,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,UGT1A1,UGT1A1,0.7
2878,bc_id2946,CANCER,SULT1A1,19424794,B,Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.,2010,,"Twenty-eight polymorphisms in eight genes of phase I (CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP3A7) and nine genes of phase II enzymes (COMT, GSTM1, GSTM3, GSTP1, GSTT1, SULT1A1, UGT1A1, UGT1A6, UGT2B7) were genotyped... The finding regarding GSTT1 was still statistically significant after corrections for multiple comparisons. Postmenopausal breast cancer risk associated with hormone therapy may be modified by genetically determined variations in phase I and II enzymes involved in steroid hormone metabolism.",A,SULT1A1,SULT1A1,0.387096774
2879,bc_id2947,CANCER,XRCC3,19426727,B,Polymorphism of the homologous recombination repair genes RAD51 and XRCC3 in breast cancer.,2009,,"Our results suggest that the variability of the DNA homologous recombination repair genes RAD51 and XRCC3 may play a role in breast cancer occurrence and progression, but this role may be underlined by a mutual interaction between these genes.",A,XRCC3,XRCC3,0.461538462
2880,bc_id2948,CANCER,RAD51,19426727,B,Polymorphism of the homologous recombination repair genes RAD51 and XRCC3 in breast cancer.,2009,,"Our results suggest that the variability of the DNA homologous recombination repair genes RAD51 and XRCC3 may play a role in breast cancer occurrence and progression, but this role may be underlined by a mutual interaction between these genes.",A,RAD51,RAD51,0.615384615
2881,bc_id2949,CANCER,ESR2,19429453,B,Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility.,2009,,Our data suggest that a SNP in the promoter region of ESR2 gene might be able to affect breast cancer risk.,A,ESR2,ESR2,0.533333333
2882,bc_id2950,CANCER,TIMP3,19431211,B,Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival.,2009,,Genetic variation in the TIMP-2 and TIMP-3 genes may contribute to individual differences in breast cancer susceptibility and survival.,A,TIMP-3,TIMP3,1
2883,bc_id2951,CANCER,TIMP2,19431211,B,Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival.,2009,,Genetic variation in the TIMP-2 and TIMP-3 genes may contribute to individual differences in breast cancer susceptibility and survival.,A,TIMP-2,TIMP2,1
2884,bc_id2952,CANCER,IGF2R,19435860,B,IGF2R missense single-nucleotide polymorphisms and breast cancer risk: the multiethnic cohort study.,2009,,None of these missense SNPs were significantly associated with breast cancer risk. Our findings provide no evidence that missense SNPs in IGF2R influence breast cancer susceptibility.,N,IGF2R,IGF2R,1
2885,bc_id2953,CANCER,IL6,19435922,Y,"Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.",2009,"Patients with estrogen receptor-positive tumors and genotypes 597 GG or 174 GG had significantly worse disease-free survival, whereas the 373 8A12T repeat appeared to be protective. The presence of at least one copy of the haplotype ([-597G, -572G, -373[10A/11T], -174G]) was associated with worse disease-free survival (HR, 1.46; P = 0.04). Kaplan-Meier plots show that all patients in this group relapsed by 24 months from diagnosis.","Interleukin-6 modulates immune response, estrogen production, and growth pathways in breast cancer.",Y,Interleukin-6,IL6,0.285714286
2886,bc_id2954,CANCER,GSTT1,19440493,B,"PAH-DNA adducts, cigarette smoking, GST polymorphisms, and breast cancer risk.",2009,"We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.","We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.",Y,GSTT1,GSTT1,0.578947368
2887,bc_id2955,CANCER,GSTP1,19440493,B,"PAH-DNA adducts, cigarette smoking, GST polymorphisms, and breast cancer risk.",2009,"We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.","We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.",Y,GSTP1,GSTP1,0.428571429
2888,bc_id2956,CANCER,GSTM1,19440493,B,"PAH-DNA adducts, cigarette smoking, GST polymorphisms, and breast cancer risk.",2009,"We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.","We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.",Y,GSTM1,GSTM1,0.452830189
2889,bc_id2957,CANCER,GSTA1,19440493,B,"PAH-DNA adducts, cigarette smoking, GST polymorphisms, and breast cancer risk.",2009,"We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.","We found little statistical evidence that PAHs interacted with GSTT1, GSTM1, GSTP1, and GSTA1 polymorphisms to further increase breast cancer risk.",Y,GSTA1,GSTA1,0.6
2890,bc_id2958,CANCER,XRCC1,19446452,B,XRCC1 gene polymorphisms and breast cancer risk in different populations: a meta-analysis.,2009,,"We performed a meta-analysis to investigate the role of XRCC1 polymorphisms Arg194Trp, Arg280His and Arg399Gln in breast cancer... These findings suggest that polymorphisms Arg280His and Arg399Gln may modify breast cancer risk differently in Caucasian and Asian populations.",A,XRCC1,XRCC1,0.543478261
2891,bc_id2959,CANCER,GZMB,19446661,B,Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.,2009,,X,X,X,X,0
2892,bc_id2961,CANCER,MMP2,19454611,B,Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility.,2009,,"Together, these findings support a role for MMP-2 genetic variation in breast cancer susceptibility.",Y,MMP-2,MMP2,0.5
2893,bc_id2962,CANCER,PRKCA,19454617,B,Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.,2009,These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.,"We investigated 60 polymorphisms in the TUBD1, SEPT4, PRKCA, TBX2, TBX4, TEX14, TLK2, YPEL2, and PPM1E genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic... These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.",A,PRKCA,PRKCA,1
2894,bc_id2964,CANCER,PPM1E,19454617,B,Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.,2009,These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.,"We investigated 60 polymorphisms in the TUBD1, SEPT4, PRKCA, TBX2, TBX4, TEX14, TLK2, YPEL2, and PPM1E genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic... These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.",A,PPM1E,PPM1E,1
2895,bc_id2965,CANCER,YPEL2,19454617,B,Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.,2009,These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.,"We investigated 60 polymorphisms in the TUBD1, SEPT4, PRKCA, TBX2, TBX4, TEX14, TLK2, YPEL2, and PPM1E genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic... These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.",A,YPEL2,YPEL2,1
2896,bc_id2966,CANCER,TUBD1,19454617,B,Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.,2009,These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.,"We investigated 60 polymorphisms in the TUBD1, SEPT4, PRKCA, TBX2, TBX4, TEX14, TLK2, YPEL2, and PPM1E genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic... These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.",A,TUBD1,TUBD1,1
2897,bc_id2967,CANCER,TLK2,19454617,B,Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.,2009,These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.,"We investigated 60 polymorphisms in the TUBD1, SEPT4, PRKCA, TBX2, TBX4, TEX14, TLK2, YPEL2, and PPM1E genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic... These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.",A,TLK2,TLK2,1
2898,bc_id2968,CANCER,TEX14,19454617,B,Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.,2009,These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.,"We investigated 60 polymorphisms in the TUBD1, SEPT4, PRKCA, TBX2, TBX4, TEX14, TLK2, YPEL2, and PPM1E genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic... These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.",A,TEX14,TEX14,1
2899,bc_id2969,CANCER,TBX4,19454617,B,Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.,2009,These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.,"We investigated 60 polymorphisms in the TUBD1, SEPT4, PRKCA, TBX2, TBX4, TEX14, TLK2, YPEL2, and PPM1E genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic... These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.",A,TBX4,TBX4,1
2900,bc_id2970,CANCER,TBX2,19454617,B,Genetic variation in the chromosome 17q23 amplicon and breast cancer risk.,2009,These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.,"We investigated 60 polymorphisms in the TUBD1, SEPT4, PRKCA, TBX2, TBX4, TEX14, TLK2, YPEL2, and PPM1E genes from this amplicon for association with breast cancer risk among 798 Caucasian breast cancer cases and 843 unaffected Caucasian controls from the Mayo Clinic... These findings suggest that single polymorphisms and combinations of polymorphisms within candidate oncogenes from the 17q23 amplicon may influence risk of breast cancer overall and possibly specific molecular subtypes of breast tumors.",A,TBX2,TBX2,1
2901,bc_id2971,CANCER,HSD17B7,19460435,B,"Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.",2009,,"This study screened for mutations in HSD17B7 and HSD17B12 genes, which encode enzymes involved in estradiol biosynthesis and in AKR1C3, which codes for 17beta-HSD type 5 enzyme involved in androgen and progesterone metabolism, to assess whether high penetrance allelic variants in these genes could be involved in breast cancer susceptibility. Mutation screening of 50 breast cancer cases from non-BRCA1/2 high-risk French Canadian families failed to identify germline likely high-risk mutations in HSD17B7, HSD17B12 and AKR1C3 genes.",N,HSD17B7,HSD17B7,1
2902,bc_id2972,CANCER,AKR1C3,19460435,B,"Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.",2009,,"This study screened for mutations in HSD17B7 and HSD17B12 genes, which encode enzymes involved in estradiol biosynthesis and in AKR1C3, which codes for 17beta-HSD type 5 enzyme involved in androgen and progesterone metabolism, to assess whether high penetrance allelic variants in these genes could be involved in breast cancer susceptibility. Mutation screening of 50 breast cancer cases from non-BRCA1/2 high-risk French Canadian families failed to identify germline likely high-risk mutations in HSD17B7, HSD17B12 and AKR1C3 genes.",N,AKR1C3,AKR1C3,0.5
2903,bc_id2973,CANCER,HSD17B12,19460435,B,"Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.",2009,,"This study screened for mutations in HSD17B7 and HSD17B12 genes, which encode enzymes involved in estradiol biosynthesis and in AKR1C3, which codes for 17beta-HSD type 5 enzyme involved in androgen and progesterone metabolism, to assess whether high penetrance allelic variants in these genes could be involved in breast cancer susceptibility. Mutation screening of 50 breast cancer cases from non-BRCA1/2 high-risk French Canadian families failed to identify germline likely high-risk mutations in HSD17B7, HSD17B12 and AKR1C3 genes.",N,HSD17B12,HSD17B12,1
2904,bc_id2974,CANCER,PGR,19462450,B,#ERROR!,2009,,This finding adds to the evidence that the PR has an important etiologic role in breast cancer and should be evaluated in future studies.,Y,PR,PGR,0.142857143
2905,bc_id2975,CANCER,XRCC1,19465687,B,"XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a meta-analysis.",2009,,Larger scale primary studies are required to further evaluate the interaction of XRCC1 polymorphisms and breast cancer risk in specific populations.,A,XRCC1,XRCC1,0.543478261
2906,bc_id2976,CANCER,ERCC2,19466538,B,The polymorphism of DNA repair gene ERCC2/XPD Arg156Arg and susceptibility to breast cancer in a Chinese population.,2009,,Our findings do not suggest that ERCC2/XPD Arg156Arg contributes to breast cancer susceptibility in a Chinese population.,N,ERCC2,ERCC2,0.1875
2907,bc_id2977,CANCER,FGFR2,19469636,B,"CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.",2009,,"A case-control (n= 250-500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP's) in CYP17 (T34C), CYP19 (Trp39Arg) and FGFR2(C906T)... There was no significant association between the risk of breast cancer and FGFR2 (C906T).",N,FGFR2,FGFR2,0.041666667
2908,bc_id2978,CANCER,CYP19A1,19469636,B,"CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.",2009,,X,X,X,X,0
2909,bc_id2979,CANCER,CYP17A1,19469636,B,"CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.",2009,,"A case-control (n= 250-500) study was undertaken to investigate the role of Single Nucleotide Polymorphisms (SNP's) in CYP17 (T34C), CYP19 (Trp39Arg) and FGFR2(C906T)... There was no significant association between the risk of breast cancer and FGFR2 (C906T). These results suggest that the CYP17 TT/CC genotype is associated with decreased risk for breast cancer, especially in post menopausal women.",Y,CYP17,CYP17A1,0.266666667
2910,bc_id2980,CANCER,GSTT1,19469640,B,Glutathione s-transferase polymorphisms in breast cancers of Thai patients.,2009,,X,X,X,X,0
2911,bc_id2981,CANCER,GSTP1,19469640,B,Glutathione s-transferase polymorphisms in breast cancers of Thai patients.,2009,,"While GST genotypes may not be associated with susceptibility, a GSTP1 polymorphism (Ile105Val) may be related to progression of breast cancer.",A,GSTP1,GSTP1,0.485714286
2912,bc_id2982,CANCER,GSTM1,19469640,B,Glutathione s-transferase polymorphisms in breast cancers of Thai patients.,2009,,X,X,X,X,0
2913,bc_id2983,CANCER,PTEN,19471547,B,Pharmacogenomic profiling of the PI3K/PTEN pathway in sporadic breast cancer.,2009,Loss of PTEN function in breast cancer can occur either by mutation or reduction of PTEN expression in almost half of sporadic breast tumors.,Loss of PTEN function in breast cancer can occur either by mutation or reduction of PTEN expression in almost half of sporadic breast tumors.,A,PTEN,PTEN,0.666666667
2914,bc_id2984,CANCER,DIRAS3,19482475,B,NOEY2 mutations in primary breast cancers and breast hyperplasia.,The mutations of human NOEY2 were identified in human breast cancers and the corresponding adjacent breast tissues.,The mutations of human NOEY2 were identified in human breast cancers and the corresponding adjacent breast tissues.,The mutations of human NOEY2 were identified in human breast cancers and the corresponding adjacent breast tissues.,Y,NOEY2,DIRAS3,1
2915,bc_id2985,CANCER,BRIP1,19484476,B,"Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women.",2009,,X,X,X,X,0
2916,bc_id2986,CANCER,ZNF350,19484476,B,"Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women.",2009,,BRCA1-interacting protein C-terminal helicase 1 (BRIP1) and zinc finger protein 350 (ZNF350) work with BRCA1 in tumor suppression procedures... BRCA1 and ZNF350 may jointly contribute to individuals' susceptibility of breast cancer in Chinese women.,A,ZNF350,ZNF350,0.333333333
2917,bc_id2987,CANCER,BRCA1,19484476,B,"Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women.",2009,,BRCA1-interacting protein C-terminal helicase 1 (BRIP1) and zinc finger protein 350 (ZNF350) work with BRCA1 in tumor suppression procedures... BRCA1 and ZNF350 may jointly contribute to individuals' susceptibility of breast cancer in Chinese women. Further functional studies are warranted to validate our findings.,A,BRCA1,BRCA1,0.60944206
2918,bc_id2988,CANCER,BRCA1,19489266,B,[Relationship between mutation of BRCA1 and susceptibility to early onset of breast cancer],2009,,Patients with breast cancer aged < or = 35 have BRCA1 mutations located in the exon 11 mainly.,Y,BRCA1,BRCA1,0.326180258
2919,bc_id2989,CANCER,BRCA2,19491284,B,Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups.,2009,,"A total of 333 eligible women, 166 CA, 66 AA and 101 KO underwent complete sequencing of BRCA1/2 genes... VUS were predominantly in BRCA2 and AA had markedly higher frequency of VUS (38%) compared with CA (10%) and KO (12%). At 10-year follow-up from the time of initial diagnosis of breast cancer, the risk of secondary malignancies was similar among WT (14%) and VUS (16%), but markedly higher among DEL (39%).",A,BRCA1/2,BRCA2,0.576923077
2920,bc_id2990,CANCER,BRCA1,19491284,B,Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups.,2009,,"A total of 333 eligible women, 166 CA, 66 AA and 101 KO underwent complete sequencing of BRCA1/2 genes... VUS were predominantly in BRCA2 and AA had markedly higher frequency of VUS (38%) compared with CA (10%) and KO (12%). At 10-year follow-up from the time of initial diagnosis of breast cancer, the risk of secondary malignancies was similar among WT (14%) and VUS (16%), but markedly higher among DEL (39%).",A,BRCA1/2,BRCA1,0.60944206
2921,bc_id2991,CANCER,BRCA2,19491894,B,Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.,2009,,Specific BRCA1 and BRCA2 mutations or different mutation frequencies have been identified in specific populations and ethnic groups... These results suggest that a low-cost genetic screening for only the four prominent BRCA1 mutations may be advisable to all early-onset breast cancer patients of Greek origin.,A,BRCA2,BRCA2,0.576923077
2922,bc_id2992,CANCER,BRCA1,19491894,B,Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.,2009,,Specific BRCA1 and BRCA2 mutations or different mutation frequencies have been identified in specific populations and ethnic groups... These results suggest that a low-cost genetic screening for only the four prominent BRCA1 mutations may be advisable to all early-onset breast cancer patients of Greek origin.,A,BRCA1,BRCA1,0.60944206
2923,bc_id2993,CANCER,SMAD7,19505925,N,No breast cancer association for transforming growth factor-beta pathway colorectal cancer single nucleotide polymorphisms.,2009,,"SMAD7 and GREM1 are signaling components on the transforming growth factor-beta pathway, which regulates normal mammary gland development and has been implicated in breast tumor invasion and metastasis... None of these single nucleotide polymorphisms were associated with breast cancer risk in our study and the 95% confidence limits of our data, pooled with data from the Cancer Genetic Markers of Susceptibility study, exclude per allele ORs of <0.94 or >1.08.",N,SMAD7,SMAD7,1
2924,bc_id2994,CANCER,CRAC1,19505925,N,No breast cancer association for transforming growth factor-beta pathway colorectal cancer single nucleotide polymorphisms.,2009,,"SMAD7 and GREM1 are signaling components on the transforming growth factor-beta pathway, which regulates normal mammary gland development and has been implicated in breast tumor invasion and metastasis.Three variants within SMAD7 and two variants in CRAC1 (a colorectal cancer-associated region on chromosome 15 in which GREM1 is located) have been associated with colorectal cancer risks [odds ratios (OR), 0.85-1.26; all P < 10(-7)]... None of these single nucleotide polymorphisms were associated with breast cancer risk in our study and the 95% confidence limits of our data, pooled with data from the Cancer Genetic Markers of Susceptibility study, exclude per allele ORs of <0.94 or >1.08.",N,CRAC1,CRAC1,1
2925,bc_id2995,CANCER,GREM1,19505925,N,No breast cancer association for transforming growth factor-beta pathway colorectal cancer single nucleotide polymorphisms.,2009,,"SMAD7 and GREM1 are signaling components on the transforming growth factor-beta pathway, which regulates normal mammary gland development and has been implicated in breast tumor invasion and metastasis.Three variants within SMAD7 and two variants in CRAC1 (a colorectal cancer-associated region on chromosome 15 in which GREM1 is located) have been associated with colorectal cancer risks [odds ratios (OR), 0.85-1.26; all P < 10(-7)]... None of these single nucleotide polymorphisms were associated with breast cancer risk in our study and the 95% confidence limits of our data, pooled with data from the Cancer Genetic Markers of Susceptibility study, exclude per allele ORs of <0.94 or >1.08.",N,GREM1,GREM1,1
2926,bc_id2996,CANCER,CYP1B1,19514368,B,[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations],2009,,X,X,X,X,0
2927,bc_id2997,CANCER,CYP19A1,19514368,B,[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations],2009,,X,X,X,X,0
2928,bc_id2998,CANCER,COMT,19514368,B,[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations],2009,,X,X,X,X,0
2929,bc_id2999,CANCER,BRCA1,19514368,B,[Analysis of polymorphisms in genes of insulin receptor substrate-1 and enzymes involved in estrogen biosynthesis and metabolism among breast cancer patients with BRCA1 mutations],2009,,X,X,X,X,0
2930,bc_id3000,CANCER,TP53,19521985,B,FAK overexpression and p53 mutations are highly correlated in human breast cancer.,2009,,This is the first analysis demonstrating a high correlation between FAK expression and p53 mutations in a population-based series of breast tumors.,Y,p53,TP53,0.367816092
2931,bc_id3001,CANCER,NBN,19523210,B,Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer.,2009,,"Our analysis of NBN sequence variations indicated that potential NBN alterations are present, albeit at a low frequency, in our cohort of high-risk breast cancer cases.",A,NBN,NBN,0.571428571
2932,bc_id3002,CANCER,SOD2,19526139,B,Associations of polymorphic variant of MnSOD gene with breast cancer in residents of the Altai Region.,2009,,X,X,X,X,0
2933,bc_id3003,CANCER,FGFR2,19536173,B,Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia.,2009,,"Thus, in addition to the confirmation of association of FGFR2 with the BC risk in this new population, our study has suggested that rs7895676 is not likely to represent the causative variant.",Y,FGFR2,FGFR2,0.708333333
2934,bc_id3004,CANCER,ATR,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,ATR,ATR,0.333333333
2935,bc_id3005,CANCER,ATM,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,ATM,ATM,0.422222222
2936,bc_id3006,CANCER,FANCI,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,FANCI,FANCI,0.5
2937,bc_id3007,CANCER,PALB2,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,PALB2,PALB2,0.583333333
2938,bc_id3008,CANCER,H2AFX,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,H2AX,H2AFX,0.5
2939,bc_id3009,CANCER,FANCG,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,"(FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N)",FANCG,1
2940,bc_id3010,CANCER,FANCF,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,"(FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N)",FANCF,1
2941,bc_id3011,CANCER,FANCE,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,"(FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N)",FANCE,1
2942,bc_id3012,CANCER,FANCD2,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,FANCD2,FANCD2,1
2943,bc_id3013,CANCER,FANCB,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,FANC-B,FANCB,0.5
2944,bc_id3014,CANCER,FANCC,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,FANCC,FANCC,1
2945,bc_id3015,CANCER,FANCM,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,"(FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N)",FANCM,0.5
2946,bc_id3016,CANCER,BRIP1,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,BRIP1,BRIP1,0.5
2947,bc_id3017,CANCER,USP1,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"In a previous case-control association study analysing FANCA, FANCD2 and FANCL, we reported an association between FANCD2 and sporadic breast cancer (BC) risk (OR = 1.35)... A total of 61 SNPs in ten FA genes (FANC-B, -C, -D1, -E, -F, -G, -I, -J, -M, -N) and five FA related genes (ATM, ATR, BRCA1, H2AX and USP1) were studied in a total of 547 consecutive and nonrelated sporadic BC cases and 552 unaffected controls from the Spanish population. Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM. Survival association with SNPs on FANCC and BRCA2/FANCD1 genes were also reported. Sub-group analyses revealed associations between SNPs on FANCI and ATM and nodal metastasis status and between FANCJ/BRIP1 and FANCN/PALB2 and PR- status.",A,USP1,USP1,1
2948,bc_id3018,CANCER,BRCA1,19536649,B,The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.,2009,,"Some of these proteins also confer susceptibility to hereditary breast and ovarian cancer (HBOC), since FANCD1 is the BRCA2 breast cancer susceptibility gene, and FANCN/PALB2 and FANCJ/BRIP1 explain 2% of non-BRCA1/2 HBOC families. Thus, there is an important connection between FA and BRCA pathways... Association analyses reported marginal statistically significant results with the minor allele of intronic SNPs in three genes: BRCA1, BRCA2/FANCD1, and ATM.",A,BRCA1,BRCA1,0.60944206
2949,bc_id3019,CANCER,FAS,19538884,B,[Prognostic role of apoptosis-related gene Fas-1377 and -670 polymorphisms in breast cancer],2009,,"Among breast cancer patients without lymph node metastasis, patients with Fas-1377 AA genotype may have a worse survival, while patients with Fas-1377 GA or GG genotype may not be so.",A,Fas-1377,FAS,0.75
2950,bc_id3020,CANCER,GSTT1,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,X,X,X,X,0
2951,bc_id3021,CANCER,GSTP1,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,"The 10 SNP loci were polymorphic of different frequency in the breast cancer patients. The combinations with GSTP1 genotypes and GSTM1 genotypes were related to anthracycline-based chemotherapy efficacy (P = 0.037), and the low GSTs activity group (GSTP1 variant allele + GSTM1 null) showed the best effects (85.7%). GSTM1 genotypes and their combinations with GSTP1 and/or CYP3A5*3 genotypes were related to taxane-based therapy efficacy (P < 0.05 for all), and both the low GSTs activity group and the drug slow-metabolising group (low GSTs activity group + CYP3A5*3 wild allele) showed better effects (100%).",A,GSTP1,GSTP1,0.485714286
2952,bc_id3022,CANCER,GSTM1,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,"The 10 SNP loci were polymorphic of different frequency in the breast cancer patients. The combinations with GSTP1 genotypes and GSTM1 genotypes were related to anthracycline-based chemotherapy efficacy (P = 0.037), and the low GSTs activity group (GSTP1 variant allele + GSTM1 null) showed the best effects (85.7%). GSTM1 genotypes and their combinations with GSTP1 and/or CYP3A5*3 genotypes were related to taxane-based therapy efficacy (P < 0.05 for all), and both the low GSTs activity group and the drug slow-metabolising group (low GSTs activity group + CYP3A5*3 wild allele) showed better effects (100%).",A,GSTM1,GSTM1,0.339622642
2953,bc_id3023,CANCER,CYP3A5,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,"The 10 SNP loci were polymorphic of different frequency in the breast cancer patients. The combinations with GSTP1 genotypes and GSTM1 genotypes were related to anthracycline-based chemotherapy efficacy (P = 0.037), and the low GSTs activity group (GSTP1 variant allele + GSTM1 null) showed the best effects (85.7%). GSTM1 genotypes and their combinations with GSTP1 and/or CYP3A5*3 genotypes were related to taxane-based therapy efficacy (P < 0.05 for all), and both the low GSTs activity group and the drug slow-metabolising group (low GSTs activity group + CYP3A5*3 wild allele) showed better effects (100%).",A,CYP3A5*3,CYP3A5,0.4
2954,bc_id3024,CANCER,CYP3A4,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,X,X,X,X,0
2955,bc_id3025,CANCER,CYP2C9,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,X,X,X,X,0
2956,bc_id3026,CANCER,CAT,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,X,X,X,X,0
2957,bc_id3027,CANCER,ACTB,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,X,X,X,X,0
2958,bc_id3028,CANCER,TP53,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,X,X,X,X,0
2959,bc_id3029,CANCER,SOD2,19538885,B,[Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer],2009,,X,X,X,X,0
2960,bc_id3030,CANCER,IGF1,19543094,B,Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.,2009,,The IGF-1 gene seems to be associated with breast cancer risk in premenopausal Ashkenazi Jewish women who are not carriers of mutations in BRCA1/2 genes.,Y,IGF-1,IGF1,0.35
2961,bc_id3031,CANCER,GH1,19543094,B,Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.,2009,,The GH1 polymorphism did not influence the risk of breast cancer in our study population.,N,GH1,GH1,0.75
2962,bc_id3032,CANCER,IL4,19544973,B,Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women.,2009,,IL-1RN and IL-4 polymorphisms alone or in combination are not associated with risk of breast cancer in Indian patients.,N,IL-4,IL4,0.5
2963,bc_id3033,CANCER,IL1RN,19544973,B,Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women.,2009,,IL-1RN and IL-4 polymorphisms alone or in combination are not associated with risk of breast cancer in Indian patients. The association of IL-1RN with malignant stages may indicate its possible role in progression of breast cancer. Further studies in other population are needed to confirm our findings and to elucidate the role of IL-1RN in progression of breast cancer.,A,IL-1RN,IL1RN,0.5
2964,bc_id3034,CANCER,PGR,19551860,B,"Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.",2009,,X,X,X,X,0
2965,bc_id3035,CANCER,ESR1,19551860,B,"Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.",2009,,X,X,X,X,0
2966,bc_id3036,CANCER,CYP19A1,19551860,B,"Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.",2009,,X,X,X,X,0
2967,bc_id3037,CANCER,COMT,19551860,B,"Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.",2009,,"We examined associations between germline polymorphisms in 6 genes involved in the steroid hormone metabolism and signaling pathway (COMT, CYP19A1, ESR1, PGR, SULT1E1, STS) and survival among women with breast cancer participating in SEARCH, a population-based case-control study... A correlated SNP in COMT, rs4860, has recently been associated with breast cancer prognosis in Chinese women in a dominant model.",A,COMT,COMT,0.425531915
2968,bc_id3038,CANCER,STS,19551860,B,"Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.",2009,,X,X,X,X,0
2969,bc_id3039,CANCER,SULT1E1,19551860,B,"Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer.",2009,,X,X,X,X,0
2970,bc_id3040,CANCER,MTHFR,19557016,B,"MTHFR polymorphisms, dietary folate intake and breast cancer risk in Chinese women.",2009,,The findings of this study suggest that MTHFR genetic polymorphisms and dietary intake of folate may modify susceptibility to breast cancer.,A,MTHFR,MTHFR,0.403846154
2971,bc_id3041,CANCER,BRCA2,19564533,B,Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.,2009,,X,X,X,X,0
2972,bc_id3042,CANCER,BRCA1,19564533,B,Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.,2009,,"BRCA2-associated breast cancer is more sensitive to standard first-line chemotherapy for metastatic breast cancer in comparison with sporadic breast cancer, especially to anthracyclines. For BRCA1-associated breast cancer no statistically significant higher sensitivity was observed.",A,BRCA1,BRCA1,0.60944206
2973,bc_id3044,CANCER,TP53,19567506,B,Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.,2009,"Strict enforcement of study criteria would have minimally improved the power of the study, whereas testing for BRCA1/2 in advance would have substantially increased the detection rates.",X,X,X,X,0
2974,bc_id3045,CANCER,BRCA1,19567506,B,Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.,2009,"Strict enforcement of study criteria would have minimally improved the power of the study, whereas testing for BRCA1/2 in advance would have substantially increased the detection rates.",X,X,X,X,0
2975,bc_id3046,CANCER,CDKN2A,19571771,B,Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.,2009,,The epidemiologic link between cutaneous melanoma and breast cancer is not mainly related to CDKN2A mutations.,N,CDKN2A,CDKN2A,0.25
2976,bc_id3047,CANCER,HIF1A,19580347,B,Associations between hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms and risk of developing breast cancer.,2009,,X,X,X,X,0
2977,bc_id3048,CANCER,FGFR2,19582883,B,FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan.,2009,,These findings suggest that FGFR2 intronic SNPs affect the reproductive hormone-related pathway and contribute to the development of female breast cancer in the Japanese population.,Y,FGFR2,FGFR2,0.708333333
2978,bc_id3049,CANCER,BTLA,19585237,B,Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province.,2010,,These results primarily suggested that BTLA gene polymorphisms may affect the sporadic breast cancer risk and prognosis in Chinese women in northeast of Heilongjiang Province.,A,BTLA,BTLA,1
2979,bc_id3050,CANCER,CDKN1B,19587092,B,Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes.,2009,,X,X,X,X,0
2980,bc_id3051,CANCER,FBXW7,19587092,B,Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes.,2009,,X,X,X,X,0
2981,bc_id3052,CANCER,CCNE1,19587092,B,Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes.,2009,,X,X,X,X,0
2982,bc_id3053,CANCER,SKP2,19587092,B,Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes.,2009,,Tumor levels of the cell cycle regulators cyclin E and p27 correlate strongly with survival in breast cancer patients and are specifically regulated by the ubiquitin ligases hCDC4 and SKP2... This study concludes that polymorphism of hCDC4 is a risk factor for breast cancer development by interacting with either cyclin E or FTP and may also prove useful in predicting progression of patients with high-stage and ER-negative breast cancers.,A,SKP2,SKP2,1
2983,bc_id3054,CANCER,VDR,19588543,B,Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians.,2009,,The results indicate that the VDR poly-A polymorphism is significantly associated with breast cancer risk in north Indians especially with early onset disease.,Y,VDR,VDR,0.269230769
2984,bc_id3055,CANCER,MDM2,19590949,B,Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.,2010,the association between MDM2 SNP309 and breast cancer is modified by race.,"In conclusion, the association between MDM2 SNP309 and breast cancer is modified by race. MDM2 SNP309 represents a risk factor for breast cancer in Chinese women but not in non-Chinese women. This phenomenon is analogous to that described in the context of lung cancer.",A,MDM2,MDM2,0.444444444
2985,bc_id3056,CANCER,CYP2D6,19596663,N,No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.,2009,,Our results suggest that the CYP2D6*10 genotype is unlikely to have any clinical significance for prognosis of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen alone.,N,CYP2D6*10,CYP2D6,0.136363636
2986,bc_id3057,CANCER,CYP2D6,19597703,B,Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.,2009,,They support clinical trials prospectively testing the effect of CYP2D6 genetic variability in response to tamoxifen before denying this drug to breast cancer patients only based on their CYP2D6*4 status.,A,CYP2D6,CYP2D6,0.590909091
2987,bc_id3058,CANCER,BRCA2,19597986,B,Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.,2010,,The potential effects of oral contraceptive (OC) and postmenopausal hormone (PMH) use are not well understood among BRCA1 or BRCA2 (BRCA1/2) deleterious mutation carriers with a history of breast cancer.,A,BRCA2,BRCA2,0.576923077
2988,bc_id3059,CANCER,BRCA1,19597986,B,Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.,2010,,The potential effects of oral contraceptive (OC) and postmenopausal hormone (PMH) use are not well understood among BRCA1 or BRCA2 (BRCA1/2) deleterious mutation carriers with a history of breast cancer.,A,BRCA1,BRCA1,0.60944206
2989,bc_id3060,CANCER,TP53,19602056,B,"Mutations in p53, p53 protein overexpression and breast cancer survival.",2008,,"Thus, in this population-based cohort of women with breast cancer, although p53 protein overexpression and p53 mutations were associated with each other, neither independently impacted breast cancer-specific or all-causing mortality, after considering ER/PR status.",A,p53,TP53,0.482758621
2990,bc_id3061,CANCER,ERCC2,19615095,B,Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population.,2010,showed significant association of rs13181 homozygous mutant (CC) [Odds Ratio (OR) 4.,"Results showed significant association of rs13181 homozygous mutant (CC) [Odds Ratio (OR) 4.412, 95% Confidence Interval (CI) 2.413 to 8.068], heterozygous (AC) (OR 2.086, 95% CI 1.246 to 3.492) and combined mutant (AC + CC) (OR 2.672, 95% CI 1.647 to 4.334) genotypes with predisposition to Breast cancer. Statistically significant increase in SCCHN risk was also associated with the mutant genotypes of rs13181 (ERCC2), viz. homozygous mutant (CC) (OR 1.680, 95% CI 1.014 to 2.784), heterozygous (AC) (OR 1.531, 95% CI 1.092 to 2.149) and combined mutant (AC + CC) (OR 1.560, 95% CI 1.128 to 2.158) genotypes.",Y,ERCC2,ERCC2,0.125
2991,bc_id3062,CANCER,MAP3K1,19617217,B,Breast cancer susceptibility variants alter risks in familial disease.,2010,"This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context.","This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context. The level of risk is dependent on the strength of the family history and the presence of a BRCA1/2 mutation and contributes to the understanding of the use of these variants in clinical risk prediction.",Y,MAP3K1,MAP3K1,0.636363636
2992,bc_id3063,CANCER,TOX3,19617217,B,Breast cancer susceptibility variants alter risks in familial disease.,2010,"This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context.","This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context. The level of risk is dependent on the strength of the family history and the presence of a BRCA1/2 mutation and contributes to the understanding of the use of these variants in clinical risk prediction.",Y,TOX3,TOX3,0.5
2993,bc_id3064,CANCER,FGFR2,19617217,B,Breast cancer susceptibility variants alter risks in familial disease.,2010,"This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context.","This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context. The level of risk is dependent on the strength of the family history and the presence of a BRCA1/2 mutation and contributes to the understanding of the use of these variants in clinical risk prediction.",Y,FGFR2,FGFR2,0.708333333
2994,bc_id3065,CANCER,CASP8,19617217,B,Breast cancer susceptibility variants alter risks in familial disease.,2010,"This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context.","This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context. The level of risk is dependent on the strength of the family history and the presence of a BRCA1/2 mutation and contributes to the understanding of the use of these variants in clinical risk prediction.",Y,CASP8,CASP8,0.642857143
2995,bc_id3066,CANCER,BRCA2,19617217,B,Breast cancer susceptibility variants alter risks in familial disease.,2010,"This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context.","This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context. The level of risk is dependent on the strength of the family history and the presence of a BRCA1/2 mutation and contributes to the understanding of the use of these variants in clinical risk prediction.",Y,BRCA1/2,BRCA2,0.324175824
2996,bc_id3067,CANCER,BRCA1,19617217,B,Breast cancer susceptibility variants alter risks in familial disease.,2010,"This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context.","This study confirms that susceptibility variants in FGFR2, TOX3 and MAP3K1 and on chromosome 8q are all associated with increased risk of cancer in individuals with a family history of breast cancer, whereas CASP8 is protective in this context. The level of risk is dependent on the strength of the family history and the presence of a BRCA1/2 mutation and contributes to the understanding of the use of these variants in clinical risk prediction.",Y,BRCA1/2,BRCA1,0.326180258
2997,bc_id3068,CANCER,BRCA2,19619314,B,A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.,2009,,X,X,X,X,0
2998,bc_id3069,CANCER,BRCA1,19619314,B,A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.,2009,,X,X,X,X,0
2999,bc_id3070,CANCER,ERBB2,19620488,B,Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.,2009,,"In this population of patients with early-stage breast cancer who were treated with adjuvant AC chemotherapy, TOP2A abnormalities were not associated with outcome. HER2 high-level amplification was a prognostic marker in anthracycline-treated patients.",A,HER2,ERBB2,0.452380952
3000,bc_id3071,CANCER,TOP2A,19620488,B,Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.,2009,,"In this population of patients with early-stage breast cancer who were treated with adjuvant AC chemotherapy, TOP2A abnormalities were not associated with outcome.",N,TOP2A,TOP2A,0.5
3001,bc_id3072,CANCER,TP53,19629678,B,P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies.,2009,,"The results suggested that p53 codon 72 polymorphism may contribute to susceptibility to breast cancer, especially in Europeans.",A,p53,TP53,0.482758621
3002,bc_id3073,CANCER,CASP8,19629679,B,Association of two CASP8 polymorphisms with breast cancer risk: a meta-analysis.,2010,,"CASP8 D302H was associated with reduced breast cancer risk (for H carriers: pooled OR = 0.874, 95% CI: 0.834-0.917).",Y,CASP8,CASP8,0.642857143
3003,bc_id3074,CANCER,PGR,19636371,B,"Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.",2009,,X,X,X,X,0
3004,bc_id3075,CANCER,ESR1,19636371,B,"Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.",2009,,The higher expression of HER2 in ESR1 T594T GG patients suggests the possibility that ESR1 gene polymorphisms accompanied by HER2 expression might influence the pathogenesis of breast cancers.,A,ESR1,ESR1,0.586956522
3005,bc_id3076,CANCER,ERBB2,19636371,B,"Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.",2009,,The higher expression of HER2 in ESR1 T594T GG patients suggests the possibility that ESR1 gene polymorphisms accompanied by HER2 expression might influence the pathogenesis of breast cancers.,A,HER2,ERBB2,0.452380952
3006,bc_id3077,CANCER,EGFR,19636371,B,"Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.",2009,,We found no evidence for an association between EGFR R521K polymorphism and breast cancer risk.,N,EGFR R521K,EGFR,0.142857143
3007,bc_id3078,CANCER,BCL2,19636371,B,"Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.",2009,,X,X,X,X,0
3008,bc_id3079,CANCER,CYP19A1,19639193,B,The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women.,2009,,"These results suggest that 3-bp I/D polymorphisms of the CYP19 gene may be associated with breast cancer and that the (TTTA)n repeat genotype would be useful in selecting candidates for tamoxifen therapy, as well as predicting breast cancer risk in Korean women.",A,CYP19,CYP19A1,0.484848485
3009,bc_id3080,CANCER,MDM2,19639206,B,The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer.,2009,,"No risk of breast cancer was observed for the genotypes of p53 and MDM2, however, a tendency (P=0.15) towards increased risk of early onset breast cancer was observed in carriers of two or more Pro and/or G alleles.",N,MDM2,MDM2,0.444444444
3010,bc_id3081,CANCER,TP53,19639206,B,The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer.,2009,,Our results suggest that p53 codon 72 and MDM2 SNP309 may be implicated in early onset breast cancer.,A,p53,TP53,0.482758621
3011,bc_id3082,CANCER,GSTA2,19639209,B,The role of GSTA2 polymorphisms and haplotypes in breast cancer susceptibility: a case-control study in the Portuguese population.,2009,,"Among the alpha class, GSTA1 and GSTA2 isoforms are the most widely expressed in human tissues... Our data show that the studied polymorphisms are in strong linkage disequilibrium, but no association was observed between individual GSTA2 polymorphisms and haplotypes and individual susceptibility to breast cancer.",N,GSTA2,GSTA2,1
3012,bc_id3083,CANCER,GSTA1,19639209,B,The role of GSTA2 polymorphisms and haplotypes in breast cancer susceptibility: a case-control study in the Portuguese population.,2009,,"Among the alpha class, GSTA1 and GSTA2 isoforms are the most widely expressed in human tissues... Our data show that the studied polymorphisms are in strong linkage disequilibrium, but no association was observed between individual GSTA2 polymorphisms and haplotypes and individual susceptibility to breast cancer.",A,GSTA1,GSTA1,0.4
3013,bc_id3084,CANCER,GNRHR,19640273,B,Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).,2009,Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians.,Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians.,N,GNRHR,GNRHR,1
3014,bc_id3085,CANCER,GNRH1,19640273,B,Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).,2009,Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians.,Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians.,N,GNRH1,GNRH1,0.5
3015,bc_id3086,CANCER,NPAS2,19649706,B,The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer.,2009,,These findings provide the first evidence suggesting prognostic significance of the circadian gene NPAS2 in breast cancer.,Y,NPAS2,NPAS2,1
3016,bc_id3087,CANCER,BRCA2,19649760,B,"Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.",2009,,"These results suggest that tumors associated with BRCA1 mutations are distinct from those of BRCA2-associated and non-BRCA-associated breast cancers, and that the tumors associated with BRCA2 mutations are similar to the non-BRCA-associated breast cancers. Further studies are required to determine if the prognosis is different in each of these groups and the best management strategy for each group.",A,BRCA2,BRCA2,0.576923077
3017,bc_id3088,CANCER,BRCA1,19649760,B,"Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.",2009,,"These results suggest that tumors associated with BRCA1 mutations are distinct from those of BRCA2-associated and non-BRCA-associated breast cancers, and that the tumors associated with BRCA2 mutations are similar to the non-BRCA-associated breast cancers. Further studies are required to determine if the prognosis is different in each of these groups and the best management strategy for each group.",A,BRCA1,BRCA1,0.60944206
3018,bc_id3089,CANCER,LSP1,19656774,B,"Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.",2009,,"In a previous study, we demonstrated that the minor alleles at three of these SNPs, in FGFR2, TNRC9 and MAP3K1, also confer increased risks of breast cancer for BRCA1 or BRCA2 mutation carriers... The LSP1 and 2q35 SNPs appear to interact multiplicatively on breast cancer risk for BRCA2 mutation carriers. There was no evidence that the associations vary by mutation type depending on whether the mutated protein is predicted to be stable or not.",Y,LSP1,LSP1,0.555555556
3019,bc_id3090,CANCER,FGFR2,19656774,B,"Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.",2009,,"In a previous study, we demonstrated that the minor alleles at three of these SNPs, in FGFR2, TNRC9 and MAP3K1, also confer increased risks of breast cancer for BRCA1 or BRCA2 mutation carriers... The LSP1 and 2q35 SNPs appear to interact multiplicatively on breast cancer risk for BRCA2 mutation carriers. There was no evidence that the associations vary by mutation type depending on whether the mutated protein is predicted to be stable or not.",A,FGFR2,FGFR2,0.25
3020,bc_id3091,CANCER,BRCA2,19656774,B,"Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.",2009,,"In a previous study, we demonstrated that the minor alleles at three of these SNPs, in FGFR2, TNRC9 and MAP3K1, also confer increased risks of breast cancer for BRCA1 or BRCA2 mutation carriers... The LSP1 and 2q35 SNPs appear to interact multiplicatively on breast cancer risk for BRCA2 mutation carriers. There was no evidence that the associations vary by mutation type depending on whether the mutated protein is predicted to be stable or not.",A,BRCA2,BRCA2,0.576923077
3021,bc_id3092,CANCER,BRCA1,19656774,B,"Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.",2009,,"In a previous study, we demonstrated that the minor alleles at three of these SNPs, in FGFR2, TNRC9 and MAP3K1, also confer increased risks of breast cancer for BRCA1 or BRCA2 mutation carriers... The LSP1 and 2q35 SNPs appear to interact multiplicatively on breast cancer risk for BRCA2 mutation carriers. There was no evidence that the associations vary by mutation type depending on whether the mutated protein is predicted to be stable or not.",A,BRCA1,BRCA1,0.60944206
3022,bc_id3093,CANCER,TP53,19657731,B,"Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis.",2009,,"The association of polymorphisms of tumor suppressor gene TP53 with breast cancer has widely been reported; however, the results are inconsistent.",A,TP53,TP53,0.482758621
3023,bc_id3094,CANCER,ABCB1,19661039,B,A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.,2009,Significantly higher prevalence of 3435TT genotype in exon 26 of the MDR1 gene in patients with breast cancer might suggest the possibility of increased breast cancer susceptibility.,Significantly higher prevalence of 3435TT genotype in exon 26 of the MDR1 gene in patients with breast cancer might suggest the possibility of increased breast cancer susceptibility.,A,MDR1,ABCB1,0.6875
3024,bc_id3095,CANCER,PTGS2,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3025,bc_id3096,CANCER,POLQ,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3026,bc_id3097,CANCER,POLH,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3027,bc_id3098,CANCER,NBN,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3028,bc_id3099,CANCER,MLH1,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3029,bc_id3100,CANCER,LTA,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3030,bc_id3101,CANCER,LIG4,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3031,bc_id3102,CANCER,LIG3,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3032,bc_id3103,CANCER,LIG1,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3033,bc_id3104,CANCER,IL1A,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3034,bc_id3105,CANCER,IL10,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3035,bc_id3106,CANCER,ERCC6,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3036,bc_id3107,CANCER,ERCC5,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3037,bc_id3108,CANCER,ERCC1,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3038,bc_id3109,CANCER,NQO1,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3039,bc_id3110,CANCER,CDH1,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3040,bc_id3111,CANCER,REV1,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3041,bc_id3112,CANCER,XRCC5,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3042,bc_id3113,CANCER,XRCC4,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3043,bc_id3114,CANCER,XRCC3,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3044,bc_id3115,CANCER,XRCC1,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3045,bc_id3116,CANCER,XPC,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3046,bc_id3117,CANCER,TNF,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3047,bc_id3118,CANCER,BRCA2,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3048,bc_id3119,CANCER,BRCA1,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3049,bc_id3120,CANCER,RAD51,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3050,bc_id3121,CANCER,RAD52,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3051,bc_id3122,CANCER,REV3L,19661089,B,Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.,2009,PTGS2 and ERCC5 were associated with stomach cancer risk in a Chinese population.,NR,NR,NR,NR,0
3052,bc_id3123,CANCER,ALDH2,19667493,B,Interaction of the effects of alcohol drinking and polymorphisms in alcohol-metabolizing enzymes on the risk of female breast cancer in Japan.,2009,,Our findings do not support the hypothesis that acetaldehyde is the main contributor to the carcinogenesis of alcohol-induced breast cancer.,A,acetaldehyde,ALDH2,1
3053,bc_id3124,CANCER,ADH1B,19667493,B,Interaction of the effects of alcohol drinking and polymorphisms in alcohol-metabolizing enzymes on the risk of female breast cancer in Japan.,2009,,Our findings do not support the hypothesis that acetaldehyde is the main contributor to the carcinogenesis of alcohol-induced breast cancer.,A,acetaldehyde,ADH1B,0.2
3054,bc_id3125,CANCER,PIK3CA,19671852,B,PIK3CA mutation associates with improved outcome in breast cancer.,2009,This study defines the positive prognostic significance of PIK3CA mutations.,Patients with PIK3CA mutated tumors have significant improvement in overall survival (P = 0.03) and breast cancer-specific survival (P = 0.004).,Y,PIK3CA,PIK3CA,0.4
3055,bc_id3126,CANCER,NOS3,19671875,B,Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.,2009,"Variants encoding lower activity of NOS3 may affect outcomes in breast cancer patients, with the direction of risk differing depending on chemotherapy status.","We extracted DNA from normal lymph node tissue and examined functional polymorphisms in NOS3, NQO1, NQO2, and CBR3, in relation to DFS, using Cox proportional hazard model... There were no associations between the other genotypes and DFS in either group... Variants encoding lower activity of NOS3 may affect outcomes in breast cancer patients, with the direction of risk differing depending on chemotherapy status.",A,NOS3,NOS3,0.461538462
3056,bc_id3127,CANCER,NQO2,19671875,B,Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.,2009,"Variants encoding lower activity of NOS3 may affect outcomes in breast cancer patients, with the direction of risk differing depending on chemotherapy status.",X,X,X,X,0
3057,bc_id3128,CANCER,NQO1,19671875,B,Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.,2009,"Variants encoding lower activity of NOS3 may affect outcomes in breast cancer patients, with the direction of risk differing depending on chemotherapy status.",X,X,X,X,0
3058,bc_id3129,CANCER,CBR3,19671875,B,Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.,2009,"Variants encoding lower activity of NOS3 may affect outcomes in breast cancer patients, with the direction of risk differing depending on chemotherapy status.",X,X,X,X,0
3059,bc_id3130,CANCER,CYP17A1,19672705,B,Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T&gt;C polymorphism.,2009,,We conclude that CYP17A1_-34_T > C may be part of the genetic background to contribute to postmenopausal breast cancer risk in women using estrogen monotherapy.,A,CYP17A1_-34_T,CYP17A1,0.466666667
3060,bc_id3131,CANCER,LTA,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3061,bc_id3132,CANCER,IL6,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3062,bc_id3133,CANCER,IGFBP3,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3063,bc_id3134,CANCER,IGF1,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3064,bc_id3135,CANCER,ABCB1,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,"Twenty-eight polymorphisms of 14 candidate genes including two drug and hormone transporter genes (ABCB1/MDR1 and SHBG), four genes involved in cell cycle regulation (BRCA1, P21/CDKN1A, STK15/AURKA and TP53), six cytokine genes (IGFBP3, IL6, TGFB1, TNF, LTA and IGF1), and two cytokine receptor genes (EGFR and ERBB2) were genotyped using validated methods... Our results suggest that genetic variants in ABCB1 and BRCA1 may modify the effect of HT on postmenopausal breast cancer risk.",A,ABCB1,ABCB1,0.6875
3065,bc_id3136,CANCER,ERBB2,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3066,bc_id3137,CANCER,EGFR,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3067,bc_id3138,CANCER,CDKN1A,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3068,bc_id3139,CANCER,TP53,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3069,bc_id3140,CANCER,TNF,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3070,bc_id3141,CANCER,TGFB1,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3071,bc_id3142,CANCER,AURKA,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3072,bc_id3143,CANCER,BRCA1,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,"Twenty-eight polymorphisms of 14 candidate genes including two drug and hormone transporter genes (ABCB1/MDR1 and SHBG), four genes involved in cell cycle regulation (BRCA1, P21/CDKN1A, STK15/AURKA and TP53), six cytokine genes (IGFBP3, IL6, TGFB1, TNF, LTA and IGF1), and two cytokine receptor genes (EGFR and ERBB2) were genotyped using validated methods... Our results suggest that genetic variants in ABCB1 and BRCA1 may modify the effect of HT on postmenopausal breast cancer risk.",A,BRCA1,BRCA1,0.60944206
3073,bc_id3144,CANCER,SHBG,19672706,B,Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.,2009,,X,X,X,X,0
3074,bc_id3145,CANCER,HSD17B1,19679043,B,African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer.,2009,These observations need to be confirmed in larger studies due to the limited statistical power of the study based on a small number of cases.,"In addition, African American-predominant CYP1B1 432 Val allele was significantly more often found in the cases than in the controls overall and the HSD17B1 312 Gly allele was specifically associated with premenopausal breast cancer risk (OR=3.00, 95%CI 1.29-6.99).",Y,HSD17B1,HSD17B1,0.181818182
3075,bc_id3146,CANCER,CYP1A1,19679043,B,African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer.,2009,These observations need to be confirmed in larger studies due to the limited statistical power of the study based on a small number of cases.,"The African American-specific CYP1A1 5639C allele was associated with an increased risk of breast cancer (odds ratio (OR)=2.34, 95% confidence interval (CI) 1.23-4.44) and this association with the CYP1A1 5639 locus was dependent on another polymorphism in the CYP3A4 gene (P=0.043 for the interaction).",Y,CYP1A1,CYP1A1,0.304347826
3076,bc_id3147,CANCER,SNORD50A,19683667,B,Implication of snoRNA U50 in human breast cancer.,2009,,These results suggest that noncoding snoRNA U50 plays a role in the development and/or progression of breast cancer.,Y,snoRNA,SNORD50A,1
3077,bc_id3148,CANCER,PIK3CA,19685490,B,PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.,2010,,"We concluded that >70% of breast cancers have an alteration in at least 1 component of the PI3K pathway and this might be exploited to therapeutic advantage especially in ""basal-like"" cancers.",A,PI3K,PIK3CA,0.466666667
3078,bc_id3150,CANCER,ABCC4,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3079,bc_id3151,CANCER,ABCC2,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3080,bc_id3152,CANCER,GSTT1,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3081,bc_id3153,CANCER,GSTP1,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3082,bc_id3154,CANCER,GSTM1,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3083,bc_id3155,CANCER,GSTA1,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3084,bc_id3156,CANCER,ALDH3A1,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3085,bc_id3157,CANCER,ALDH1A1,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3086,bc_id3158,CANCER,CYP3A5,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3087,bc_id3159,CANCER,CYP3A4,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3088,bc_id3160,CANCER,CYP2C9,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3089,bc_id3161,CANCER,CYP2C19,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3090,bc_id3162,CANCER,CYP2B6,19696793,B,Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.,2009,,X,X,X,X,0
3091,bc_id3163,CANCER,LEPR,19697123,B,"Common genetic variations in the LEP and LEPR genes, obesity and breast cancer incidence and survival.",2009,our results show that a common variant in LEP may be associated with the risk of developing breast cancer supporting the hypothesis that leptin is involved in breast carcinogenesis.,We found no evidence of an association with polymorphisms of either LEP or LEPR in relation to all-cause or breast cancer-specific mortality among women with breast cancer (mean follow-up time = 66.7 months).,N,LEPR,LEPR,0.428571429
3092,bc_id3164,CANCER,LEP,19697123,B,"Common genetic variations in the LEP and LEPR genes, obesity and breast cancer incidence and survival.",2009,our results show that a common variant in LEP may be associated with the risk of developing breast cancer supporting the hypothesis that leptin is involved in breast carcinogenesis.,We found no evidence of an association with polymorphisms of either LEP or LEPR in relation to all-cause or breast cancer-specific mortality among women with breast cancer (mean follow-up time = 66.7 months).,N,LEP,LEP,0.666666667
3093,bc_id3165,CANCER,ESR2,19700868,B,Oestrogen receptor beta (ERbeta) polymorphism and its influence on breast cancer risk.,2009,,ANF,ANF,ANF,ANF,0
3094,bc_id3166,CANCER,XRCC1,19701703,B,Association between polymorphisms of XRCC1 and offspring sex ratio at births in families of female breast cancer patients.,2010,,ANF,ANF,ANF,ANF,0
3095,bc_id3167,CANCER,MTR,19706843,B,Alcohol consumption and genetic variation in methylenetetrahydrofolate reductase and 5-methyltetrahydrofolate-homocysteine methyltransferase in relation to breast cancer risk.,2009,,We found no association of MTHFR or MTR genotype with risk of breast cancer.,N,MTR,MTR,0.333333333
3096,bc_id3168,CANCER,MTHFR,19706843,B,Alcohol consumption and genetic variation in methylenetetrahydrofolate reductase and 5-methyltetrahydrofolate-homocysteine methyltransferase in relation to breast cancer risk.,2009,,We found no association of MTHFR or MTR genotype with risk of breast cancer.,N,MTHFR,MTHFR,0.326923077
3097,bc_id3169,CANCER,MDM2,19707196,B,The TP53 Arg72Pro and MDM2 309G&gt;T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,,"There was no evidence that TP53 Arg72Pro or MDM2 309T>G, either singly or in combination, influence breast cancer risk in BRCA1 or BRCA2 mutation carriers.",N,MDM2,MDM2,0.444444444
3098,bc_id3170,CANCER,TP53,19707196,B,The TP53 Arg72Pro and MDM2 309G&gt;T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,,"There was no evidence that TP53 Arg72Pro or MDM2 309T>G, either singly or in combination, influence breast cancer risk in BRCA1 or BRCA2 mutation carriers.",N,TP53,TP53,0.149425287
3099,bc_id3171,CANCER,BRCA2,19707196,B,The TP53 Arg72Pro and MDM2 309G&gt;T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,,X,X,X,X,0
3100,bc_id3172,CANCER,BRCA1,19707196,B,The TP53 Arg72Pro and MDM2 309G&gt;T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,,X,X,X,X,0
3101,bc_id3173,CANCER,MTHFR,19707223,N,No association between cSHMT genotypes and the risk of breast cancer in the Nurses' Health Study.,2010,There was no evidence of an association between the cSHMT genotype and breast cancer occurrence.,X,X,X,X,0
3102,bc_id3174,CANCER,SHMT1,19707223,N,No association between cSHMT genotypes and the risk of breast cancer in the Nurses' Health Study.,2010,There was no evidence of an association between the cSHMT genotype and breast cancer occurrence.,No evidence for an association between the cSHMT genotype and breast cancer was observed. There was also no evidence of a gene-gene interaction between cSHMT and MTHFR.,N,cSHMT,SHMT1,0.6
3103,bc_id3175,CANCER,RFC1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3104,bc_id3176,CANCER,RAD52,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3105,bc_id3177,CANCER,RAD51L1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3106,bc_id3178,CANCER,RAD51C,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3107,bc_id3179,CANCER,RAD50,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3108,bc_id3180,CANCER,BARD1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3109,bc_id3181,CANCER,ATR,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3110,bc_id3182,CANCER,PCNA,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3111,bc_id3183,CANCER,ATM,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3112,bc_id3184,CANCER,ATF1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3113,bc_id3185,CANCER,NBN,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,"MUS81 rs545500 and PBOV1 rs6927706 SNPs were associated with an increased risk of developing breast cancer (OR GG vs. GC/CC = 1.21, 95% CI, 1.02-1.45; P = 0.031; OR AA vs. AG/GG = 1.53, 95% CI, 1.07-2.18; P = 0.019, respectively). Finally, haplotype-based tests identified significant associations between specific haplotypes in MRE11A and NBS1 genes and breast cancer risk. Further large-scale studies are needed to confirm these results.",Y,NBS1,NBN,0.19047619
3114,bc_id3186,CANCER,MSH6,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3115,bc_id3187,CANCER,MSH2,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3116,bc_id3188,CANCER,MRE11A,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,"MUS81 rs545500 and PBOV1 rs6927706 SNPs were associated with an increased risk of developing breast cancer (OR GG vs. GC/CC = 1.21, 95% CI, 1.02-1.45; P = 0.031; OR AA vs. AG/GG = 1.53, 95% CI, 1.07-2.18; P = 0.019, respectively). Finally, haplotype-based tests identified significant associations between specific haplotypes in MRE11A and NBS1 genes and breast cancer risk. Further large-scale studies are needed to confirm these results.",Y,MRE11A,MRE11A,1
3117,bc_id3189,CANCER,MLH1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3118,bc_id3190,CANCER,PALB2,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3119,bc_id3191,CANCER,FANCE,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3120,bc_id3192,CANCER,FANCD2,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3121,bc_id3193,CANCER,FANCC,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3122,bc_id3194,CANCER,FANCA,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3123,bc_id3195,CANCER,MUS81,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,"MUS81 rs545500 and PBOV1 rs6927706 SNPs were associated with an increased risk of developing breast cancer (OR GG vs. GC/CC = 1.21, 95% CI, 1.02-1.45; P = 0.031; OR AA vs. AG/GG = 1.53, 95% CI, 1.07-2.18; P = 0.019, respectively). Finally, haplotype-based tests identified significant associations between specific haplotypes in MRE11A and NBS1 genes and breast cancer risk. Further large-scale studies are needed to confirm these results.",Y,MUS81,MUS81,1
3124,bc_id3196,CANCER,DMC1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3125,bc_id3197,CANCER,DDB2,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3126,bc_id3198,CANCER,EME1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3127,bc_id3199,CANCER,PBOV1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,"MUS81 rs545500 and PBOV1 rs6927706 SNPs were associated with an increased risk of developing breast cancer (OR GG vs. GC/CC = 1.21, 95% CI, 1.02-1.45; P = 0.031; OR AA vs. AG/GG = 1.53, 95% CI, 1.07-2.18; P = 0.019, respectively). Finally, haplotype-based tests identified significant associations between specific haplotypes in MRE11A and NBS1 genes and breast cancer risk. Further large-scale studies are needed to confirm these results.",Y,PBOV1,PBOV1,1
3128,bc_id3200,CANCER,BRIP1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3129,bc_id3201,CANCER,CHEK1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3130,bc_id3202,CANCER,RHOBTB2,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3131,bc_id3203,CANCER,CHEK2,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3132,bc_id3204,CANCER,XPC,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3133,bc_id3205,CANCER,BRCA2,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3134,bc_id3206,CANCER,BRCA1,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3135,bc_id3207,CANCER,BLM,19714462,B,Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population.,2010,,X,X,X,X,0
3136,bc_id3208,CANCER,LEPR,19723917,N,"No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk.",2009,,"We conducted a nested case-control study using women in the American Cancer Society Cancer Prevention Study II to examine the association between postmenopausal breast cancer and variability in the genes encoding leptin, the leptin receptor, adiponectin, adiponectin receptor 1, and adiponectin receptor 2. Using 648 cases and 659 controls, we found no statistically significant (P < 0.05) associations between breast cancer risk and any of the single nucleotide polymorphisms.",N,leptin receptor,LEPR,0.428571429
3137,bc_id3209,CANCER,LEP,19723917,N,"No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk.",2009,,"We conducted a nested case-control study using women in the American Cancer Society Cancer Prevention Study II to examine the association between postmenopausal breast cancer and variability in the genes encoding leptin, the leptin receptor, adiponectin, adiponectin receptor 1, and adiponectin receptor 2. Using 648 cases and 659 controls, we found no statistically significant (P < 0.05) associations between breast cancer risk and any of the single nucleotide polymorphisms.",N,leptin,LEP,0.666666667
3138,bc_id3210,CANCER,ADIPOR2,19723917,N,"No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk.",2009,,"We conducted a nested case-control study using women in the American Cancer Society Cancer Prevention Study II to examine the association between postmenopausal breast cancer and variability in the genes encoding leptin, the leptin receptor, adiponectin, adiponectin receptor 1, and adiponectin receptor 2. Using 648 cases and 659 controls, we found no statistically significant (P < 0.05) associations between breast cancer risk and any of the single nucleotide polymorphisms.",N,adiponectin receptor 2,ADIPOR2,1
3139,bc_id3211,CANCER,ADIPOR1,19723917,N,"No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk.",2009,,"We conducted a nested case-control study using women in the American Cancer Society Cancer Prevention Study II to examine the association between postmenopausal breast cancer and variability in the genes encoding leptin, the leptin receptor, adiponectin, adiponectin receptor 1, and adiponectin receptor 2. Using 648 cases and 659 controls, we found no statistically significant (P < 0.05) associations between breast cancer risk and any of the single nucleotide polymorphisms.",N,adiponectin receptor 1,ADIPOR1,0.5
3140,bc_id3212,CANCER,ADIPOQ,19723917,N,"No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk.",2009,,"We conducted a nested case-control study using women in the American Cancer Society Cancer Prevention Study II to examine the association between postmenopausal breast cancer and variability in the genes encoding leptin, the leptin receptor, adiponectin, adiponectin receptor 1, and adiponectin receptor 2. Using 648 cases and 659 controls, we found no statistically significant (P < 0.05) associations between breast cancer risk and any of the single nucleotide polymorphisms.",N,adiponectin,ADIPOQ,0.5
3141,bc_id3213,CANCER,GADD45A,19728081,B,Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations.,2009,,"In conclusion, although germline mutations of GADD45A is not common in familial breast cancer patients, polymorphisms/haplotypes in GADD45A contribute to breast cancer risk, at least to sporadic breast cancer.",Y,GADD45A,GADD45A,1
3142,bc_id3214,CANCER,GSTT1,19731014,B,Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer.,2010,,ANF,ANF,ANF,ANF,0
3143,bc_id3215,CANCER,GSTM1,19731014,B,Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer.,2010,,ANF,ANF,ANF,ANF,0
3144,bc_id3216,CANCER,GSTO2,19731014,B,Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer.,2010,,ANF,ANF,ANF,ANF,0
3145,bc_id3217,CANCER,XRCC1,19731014,B,Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer.,2010,,ANF,ANF,ANF,ANF,0
3146,bc_id3218,CANCER,FANCI,19737859,B,"Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.",2009,,"Our results rule out a major role of FANCI, FANCL and FANCM in familial breast cancer susceptibility, suggesting that among the 13 known FA genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.",N,FANCI,FANCI,0.5
3147,bc_id3219,CANCER,FANCM,19737859,B,"Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.",2009,,"Our results rule out a major role of FANCI, FANCL and FANCM in familial breast cancer susceptibility, suggesting that among the 13 known FA genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.",N,FANCM,FANCM,0.5
3148,bc_id3220,CANCER,FANCL,19737859,B,"Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.",2009,,"Our results rule out a major role of FANCI, FANCL and FANCM in familial breast cancer susceptibility, suggesting that among the 13 known FA genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.",N,FANCL,FANCL,1
3149,bc_id3221,CANCER,PGR,19739075,B,Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.,2009,genetic variants in nuclear receptor genes may modify HT associated postmenopausal breast cancer risk.,"Thirty-three polymorphisms selected on the basis of known or putative functional relevance located in ESR1, ESR2, PGR, PXR and AR were genotyped... We conclude that genetic variants in nuclear receptor genes may modify HT-associated postmenopausal breast cancer risk.",A,PGR,PGR,0.5
3150,bc_id3222,CANCER,NR1I2,19739075,B,Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.,2009,genetic variants in nuclear receptor genes may modify HT associated postmenopausal breast cancer risk.,"Thirty-three polymorphisms selected on the basis of known or putative functional relevance located in ESR1, ESR2, PGR, PXR and AR were genotyped... We conclude that genetic variants in nuclear receptor genes may modify HT-associated postmenopausal breast cancer risk.",A,PXR,NR1I2,1
3151,bc_id3223,CANCER,AR,19739075,B,Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.,2009,genetic variants in nuclear receptor genes may modify HT associated postmenopausal breast cancer risk.,"Thirty-three polymorphisms selected on the basis of known or putative functional relevance located in ESR1, ESR2, PGR, PXR and AR were genotyped... We conclude that genetic variants in nuclear receptor genes may modify HT-associated postmenopausal breast cancer risk.",A,AR,AR,0.458333333
3152,bc_id3224,CANCER,ESR2,19739075,B,Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.,2009,genetic variants in nuclear receptor genes may modify HT associated postmenopausal breast cancer risk.,"Thirty-three polymorphisms selected on the basis of known or putative functional relevance located in ESR1, ESR2, PGR, PXR and AR were genotyped... We conclude that genetic variants in nuclear receptor genes may modify HT-associated postmenopausal breast cancer risk.",A,ESR2,ESR2,0.533333333
3153,bc_id3225,CANCER,ESR1,19739075,B,Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.,2009,genetic variants in nuclear receptor genes may modify HT associated postmenopausal breast cancer risk.,"Thirty-three polymorphisms selected on the basis of known or putative functional relevance located in ESR1, ESR2, PGR, PXR and AR were genotyped... We conclude that genetic variants in nuclear receptor genes may modify HT-associated postmenopausal breast cancer risk.",A,ESR1,ESR1,0.586956522
3154,bc_id3226,CANCER,GPER,19744559,B,GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients.,2010,,"In conclusion, the results of this study support the important role of GPR30 in breast cancer and encourage functional studies on the molecular mechanisms underlying the association of GPR30 polymorphisms with PR status and tumor growth.",Y,GPR30,GPER,1
3155,bc_id3227,CANCER,MPO,19752340,Y,Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.,2009,"These results, observed in two independent study populations, indicate that high-activity MPO genotypes are associated with better survival among women receiving cyclophosphamidecontaining therapy, particularly when followed by tamoxifen therapy.","MPO can be inhibited and/or upregulated by commonly used drugs; thus, our findings merit further investigation for optimization of therapeutics for breast cancer.",A,MPO,MPO,0.571428571
3156,bc_id3228,CANCER,ABCB1,19752884,B,MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome.,2010,,"It has been suggested that MDR1 polymorphisms contribute to the variability in cancer risk and therapeutic outcome... We also found significantly higher (P=0.019, chi(2)-test) T allele frequency in breast cancer patients (n=221) than in controls (n=113). A significantly enhanced therapeutic outcome after neoadjuvant therapy (n=38; P=0.021, Fisher's exact test) and longer time to progression after anthracycline-based chemotherapy (n=102; P=0.049, log-rank test) were observed in CC homozygotes. However, no significant association between hematologic toxicities and C3435T polymorphism was detectable.",A,MDR1,ABCB1,0.6875
3157,bc_id3229,CANCER,BRCA1,19753840,B,[Mutations in the BRCA1 gene (185delAG and 5382insC) are not present in any of the 30 breast cancer patients analyzed from eastern Colombia],2009,"Additional mutation screening techniques are necessary involving the entire BRCA1 gene, are necessary in order to better characterize the molecular epidemiology of breast cancer in Bucaramanga, Santander, Colombia.",X,X,X,X,0
3158,bc_id3230,CANCER,MTHFR,19759169,B,Increased breast cancer risk at high plasma folate concentrations among women with the MTHFR 677T allele.,2009,"and in women with other genotypes, no significant associations were observed.",Our results suggest an association of high P-folate concentration with increased risk of postmenopausal breast cancer in carriers of the 677T allele. The findings underline the importance of genetic variation of MTHFR in the complex relation between folate and cancer.,A,MTHFR,MTHFR,0.403846154
3159,bc_id3231,CANCER,ESR1,19760036,B,Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis.,2010,,These results suggest that potentially functional ESR1 polymorphisms may play a low penetrance role in breast cancer susceptibility.,A,ESR1,ESR1,0.586956522
3160,bc_id3232,CANCER,GSTT1,19760040,B,GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis.,2009,,"Cytosolic glutathione S-transferase comprises multiple isoenzymes; studies have principally examined mu-1 (GSTM1: null/present), theta-1 (GSTT1: null/present) and pi-1 (GSTP1 Ile105Val) gene polymorphisms concerning breast cancer risk... In conclusion, polymorphisms of both GSTT1 and GSTP1 genes seem associated with elevated breast cancer risk in a race-specific manner.",Y,GSTT1,GSTT1,0.578947368
3161,bc_id3233,CANCER,GSTP1,19760040,B,GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis.,2009,,"Cytosolic glutathione S-transferase comprises multiple isoenzymes; studies have principally examined mu-1 (GSTM1: null/present), theta-1 (GSTT1: null/present) and pi-1 (GSTP1 Ile105Val) gene polymorphisms concerning breast cancer risk... In conclusion, polymorphisms of both GSTT1 and GSTP1 genes seem associated with elevated breast cancer risk in a race-specific manner.",Y,GSTP1,GSTP1,0.428571429
3162,bc_id3234,CANCER,GSTM1,19760040,B,GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis.,2009,,X,X,X,X,0
3163,bc_id3235,CANCER,MDM4,19762336,B,A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer.,2009,,No association was seen in ER-positive ductal cancers suggesting that the SNP in MDM4 only has a functional association in ER-negative breast cancer.,A,MDM4,MDM4,0.5
3164,bc_id3236,CANCER,PALB2,19763819,B,"Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.",2009,,We found no evidence to suggest that PALB2 mutation is an important breast cancer predisposition gene in this population.,N,PALB2,PALB2,0.166666667
3165,bc_id3237,CANCER,BRIP1,19763819,B,"Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.",2009,,CHEK2_1100delC and BRIP1 mutations incidence in Ireland is similar to that found in other unselected breast cancer cohorts from northern European countries.,A,BRIP1,BRIP1,0.5
3166,bc_id3238,CANCER,CHEK2,19763819,B,"Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.",2009,,CHEK2_1100delC and BRIP1 mutations incidence in Ireland is similar to that found in other unselected breast cancer cohorts from northern European countries.,A,CHEK2_1100delC,CHEK2,0.383333333
3167,bc_id3239,CANCER,PALB2,19763884,B,A PALB2 germline mutation associated with hereditary breast cancer in Italy.,2009,,"This study supports the recent observation that PALB2 mutation are present, although infrequently, in familial BRCA1/BRCA2-negative breast cancer cases; moreover, it sustains latest evidences that some PALB2 mutations are associated with a substantially increased risk of breast cancer.",A,PALB2,PALB2,0.583333333
3168,bc_id3240,CANCER,SIPA1,19765277,B,Polymorphisms of the SIPA1 gene and sporadic breast cancer susceptibility.,2009,This observation indicates SNP rs3741378 as a novel potential sporadic breast cancer predisposition SNP.,"This suggests that SIPA1 may be involved in different stages of breast carcinogenesis and since this study replicates a previous study of the associated SNP, it implicates variants of the SIPA1 gene as playing a potential role in breast cancer.",A,SIPA1,SIPA1,0.5
3169,bc_id3241,CANCER,ACD,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,ACD,ACD,1
3170,bc_id3242,CANCER,TERF2IP,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,TERF2IP,TERF2IP,1
3171,bc_id3243,CANCER,POT1,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,POT1,POT1,0.666666667
3172,bc_id3244,CANCER,TNKS2,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,TNKS2,TNKS2,1
3173,bc_id3245,CANCER,TNKS,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,TNKS,TNKS,1
3174,bc_id3246,CANCER,TERT,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,TERT,TERT,0.5
3175,bc_id3247,CANCER,TERF2,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,TERF2,TERF2,1
3176,bc_id3248,CANCER,TERF1,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,TERF1,TERF1,1
3177,bc_id3249,CANCER,TEP1,19766477,B,"Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosis.",2009,,"We genotyped 14 potentially functional and most informative SNPs in nine telomere-associated genes (TERT, TEP1, TERF1, TERF2, TERF2IP, ACD, POT1, TNKS and TNKS2) in 782 incident BC cases and 1559 matched controls... None of the SNPs showed a significant correlation with survival of the breast cancer patients.",N,TEP1,TEP1,1
3178,bc_id3250,CANCER,CCND1,19779113,B,Breast cancer and cyclin D1 gene polymorphism in Turkish women.,2009,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,"The risk of breast cancer development and prognosis may be associated with genetic variation in the CCND1 genotype, which may be used as a biomarker for further studies.",A,CCND1,CCND1,0.5
3179,bc_id3251,CANCER,TP53,19787241,B,Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer.,2009,,"The association of intronic TP53 variants with an aggressive breast cancer phenotype may represent a useful predictive biomarker, particularly in patients of clinical stage I with low or intermediate risk.",A,TP53,TP53,0.482758621
3180,bc_id3253,CANCER,SETD8,19789321,Y,An miR-502-binding site single-nucleotide polymorphism in the3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset.,2009,,"These data suggest that the miR-502-binding site single-nucleotide polymorphism in the 3'-UTR of SET8 modulates SET8 expression and contributes to the early development of breast cancer, either independently or together with the TP53 codon 72 single-nucleotide polymorphism. Larger studies with multiethnic groups are warranted to validate our findings.",A,SET8,SETD8,1
3181,bc_id3254,CANCER,TP53,19789321,B,An miR-502-binding site single-nucleotide polymorphism in the3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset.,2009,,"These data suggest that the miR-502-binding site single-nucleotide polymorphism in the 3'-UTR of SET8 modulates SET8 expression and contributes to the early development of breast cancer, either independently or together with the TP53 codon 72 single-nucleotide polymorphism. Larger studies with multiethnic groups are warranted to validate our findings.",A,TP53,TP53,0.482758621
3182,bc_id3255,CANCER,MRPS30,19789366,B,Evaluation of 11 breast cancer susceptibility loci in African-American women.,2009,,X,X,X,X,0
3183,bc_id3256,CANCER,MAP3K1,19789366,B,Evaluation of 11 breast cancer susceptibility loci in African-American women.,2009,,X,X,X,X,0
3184,bc_id3257,CANCER,LSP1,19789366,B,Evaluation of 11 breast cancer susceptibility loci in African-American women.,2009,,X,X,X,X,0
3185,bc_id3258,CANCER,TOX3,19789366,B,Evaluation of 11 breast cancer susceptibility loci in African-American women.,2009,,X,X,X,X,0
3186,bc_id3259,CANCER,FGFR2,19789366,B,Evaluation of 11 breast cancer susceptibility loci in African-American women.,2009,,"Two single-nucleotide polymorphisms, rs13387042 (2q35) and rs1219648 (FGFR2 gene), were found to be associated with breast cancer risk.",Y,FGFR2,FGFR2,0.708333333
3187,bc_id3260,CANCER,ECHDC1,19789366,B,Evaluation of 11 breast cancer susceptibility loci in African-American women.,2009,,X,X,X,X,0
3188,bc_id3261,CANCER,XRCC3,19789975,B,XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis.,2009,,"Concerning Chinese populations, no consistent results were demonstrated. In conclusion, the XRCC3 Thr241Met T allele seems associated with elevated breast cancer risk in non-Chinese subjects.",Y,XRCC3,XRCC3,0.269230769
3189,bc_id3262,CANCER,TP53,19796081,B,Oligonucleotide probe array for p53 gene alteration analysis in DNA from formalin-fixed paraffin-embedded breast cancer tissues.,2009,the OPA may be safely used to identify individual genetic variations of human p53 gene in BC specimens.,"Although OPA detected fewer gene alterations than direct sequencing, the difference was not significant (P= 0.11). In conclusion, the OPA may be safely used to identify individual genetic variations of human p53 gene in BC specimens.",A,p53,TP53,0.482758621
3190,bc_id3263,CANCER,DNMT3B,19798569,B,Two-stage case-control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk.,2009,,Our data suggest that there is no apparent association of common DNMT-1 and DNMT-3B polymorphisms with the risk of breast cancer among Chinese women.,N,DNMT-3B,DNMT3B,0.5
3191,bc_id3264,CANCER,DNMT1,19798569,B,Two-stage case-control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk.,2009,,Our data suggest that there is no apparent association of common DNMT-1 and DNMT-3B polymorphisms with the risk of breast cancer among Chinese women.,N,DNMT-1,DNMT1,1
3192,bc_id3265,CANCER,KL,19802015,B,Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.,2010,,"KLOTHO and BRCA2 are located on 13q12, and we identified linkage disequilibrium between KL-VS and BRCA2 6174delT mutation. Studies in breast cancer cells showed reduced growth inhibitory activity and reduced secretion of klotho F352V compared with wild-type klotho. These data suggest KL-VS as a breast and ovarian cancer risk modifier among BRCA1 mutation carriers. If validated in additional cohorts, the presence of KL-VS may serve as a predictor of cancer risk among BRCA1 mutation carriers.",A,KLOTHO,KL,1
3193,bc_id3266,CANCER,BRCA2,19802015,B,Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.,2010,,X,X,X,X,0
3194,bc_id3267,CANCER,BRCA1,19802015,B,Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.,2010,,"KLOTHO and BRCA2 are located on 13q12, and we identified linkage disequilibrium between KL-VS and BRCA2 6174delT mutation. Studies in breast cancer cells showed reduced growth inhibitory activity and reduced secretion of klotho F352V compared with wild-type klotho. These data suggest KL-VS as a breast and ovarian cancer risk modifier among BRCA1 mutation carriers. If validated in additional cohorts, the presence of KL-VS may serve as a predictor of cancer risk among BRCA1 mutation carriers.",A,BRCA1,BRCA1,0.60944206
3195,bc_id3268,CANCER,CYP2D6,19809024,B,Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.,2009,,"Among women with breast cancer treated with tamoxifen, there was an association between CYP2D6 variation and clinical outcomes, such that the presence of 2 functional CYP2D6 alleles was associated with better clinical outcomes and the presence of nonfunctional or reduced-function alleles with worse outcomes.",Y,CYP2D6,CYP2D6,0.272727273
3196,bc_id3269,CANCER,TLR9,19810822,B,"Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer.",2009,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,N,TLR,TLR9,1
3197,bc_id3270,CANCER,TLR4,19810822,B,"Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer.",2009,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,N,TLR,TLR4,1
3198,bc_id3271,CANCER,TLR3,19810822,B,"Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer.",2009,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,N,TLR,TLR9,1
3199,bc_id3272,CANCER,TLR2,19810822,B,"Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer.",2009,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,These results suggest that polymorphisms in tested TLR genes are not likely to be associated with increased risk for developing breast cancer.,N,TLR,TLR4,1
3200,bc_id3273,CANCER,PIK3CA,19818761,B,PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.,2010,,Somatic mutations of PIK3CA are found in 20% to 40% of invasive breast cancers.,A,PIK3CA,PIK3CA,0.466666667
3201,bc_id3274,CANCER,RRP1B,19825179,B,Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study.,2009,These results validate SIPA1 and RRP1B as metastasis susceptibility genes and suggest that genotyping assays may be a useful supplement to other clinical and molecular indicators of prognosis.,"These results validate SIPA1 and RRP1B as metastasis susceptibility genes and suggest that genotyping assays may be a useful supplement to other clinical and molecular indicators of prognosis. The results also suggest that lymphatic and hematogeneous metastases are genetically distinct that may involve different mechanisms. If true, these results suggest that metastatic disease, like primary breast cancer, may be multiple diseases and that stratification of late stage patients may therefore be required to fully understand breast cancer progression and metastasis.",A,RRP1B,RRP1B,1
3202,bc_id3275,CANCER,SIPA1,19825179,B,Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study.,2009,These results validate SIPA1 and RRP1B as metastasis susceptibility genes and suggest that genotyping assays may be a useful supplement to other clinical and molecular indicators of prognosis.,"These results validate SIPA1 and RRP1B as metastasis susceptibility genes and suggest that genotyping assays may be a useful supplement to other clinical and molecular indicators of prognosis. The results also suggest that lymphatic and hematogeneous metastases are genetically distinct that may involve different mechanisms. If true, these results suggest that metastatic disease, like primary breast cancer, may be multiple diseases and that stratification of late stage patients may therefore be required to fully understand breast cancer progression and metastasis.",A,SIPA1,SIPA1,0.5
3203,bc_id3276,CANCER,DMBT1,19830809,B,Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activity.,2010,,"Promoter studies in breast cancer cells demonstrate that the risk-increasing DMBT1 -93T allele displays significantly decreased promoter activity compared to the DMBT1 -93C allele, resulting in a loss of promoter activity.",Y,DMBT1,DMBT1,1
3204,bc_id3277,CANCER,CDH1,19834798,B,E-cadherin polymorphisms and breast cancer susceptibility: a report from the Shanghai Breast Cancer Study.,2009,,"Although none of these associations retained statistical significance after correcting for the total number of polymorphisms evaluated, this study suggests that genetic variation in CDH1 may be associated with breast cancer risk, and that this relationship may vary by menopausal status.",A,CDH1,CDH1,0.428571429
3205,bc_id3278,CANCER,MTR,19838916,B,"Dietary intake of folate, vitamin B2, vitamin B6, vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Japan.",2009,dietary intake of folate and related B vitamins and genotypes of MTHFR or MTR have no overall association with breast cancer risk in Japanese women.,Neither dietary intake of folate and related B vitamins and genotypes of MTHFR or MTR have no overall association with breast cancer risk in Japanese women.,N,MTR,MTR,0.333333333
3206,bc_id3279,CANCER,MTHFR,19838916,B,"Dietary intake of folate, vitamin B2, vitamin B6, vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Japan.",2009,dietary intake of folate and related B vitamins and genotypes of MTHFR or MTR have no overall association with breast cancer risk in Japanese women.,Neither dietary intake of folate and related B vitamins and genotypes of MTHFR or MTR have no overall association with breast cancer risk in Japanese women.,N,MTHFR,MTHFR,0.326923077
3207,bc_id3280,CANCER,IRS1,19843326,B,Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.,2009,This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.,"A cohort of 1,665 adult, female mutation carriers, including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2 carriers (238 cases) were genotyped for SNPs in IGF1, IGF1 receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2, IGFBP5), and IGF receptor substrate 1 (IRS1)... Among BRCA1 carriers, significant associations were found between risk of breast cancer and LD blocks in IGF1R (global P = 0.011 for LD block 2 and global P = 0.012 for LD block 11). Among BRCA2 carriers, an LD block in IGFBP2 (global P = 0.0145) was found to be associated with the time to breast cancer diagnosis. No significant LD block associations were found for the other investigated genes among BRCA1 and BRCA2 carriers.",N,IRS1,IRS1,0.666666667
3208,bc_id3281,CANCER,IGFBP5,19843326,B,Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.,2009,This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.,"A cohort of 1,665 adult, female mutation carriers, including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2 carriers (238 cases) were genotyped for SNPs in IGF1, IGF1 receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2, IGFBP5), and IGF receptor substrate 1 (IRS1)... Among BRCA1 carriers, significant associations were found between risk of breast cancer and LD blocks in IGF1R (global P = 0.011 for LD block 2 and global P = 0.012 for LD block 11). Among BRCA2 carriers, an LD block in IGFBP2 (global P = 0.0145) was found to be associated with the time to breast cancer diagnosis. No significant LD block associations were found for the other investigated genes among BRCA1 and BRCA2 carriers.",N,IGFBP5,IGFBP5,0.5
3209,bc_id3282,CANCER,IGFBP2,19843326,B,Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.,2009,This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.,"A cohort of 1,665 adult, female mutation carriers, including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2 carriers (238 cases) were genotyped for SNPs in IGF1, IGF1 receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2, IGFBP5), and IGF receptor substrate 1 (IRS1)... Among BRCA1 carriers, significant associations were found between risk of breast cancer and LD blocks in IGF1R (global P = 0.011 for LD block 2 and global P = 0.012 for LD block 11). Among BRCA2 carriers, an LD block in IGFBP2 (global P = 0.0145) was found to be associated with the time to breast cancer diagnosis. No significant LD block associations were found for the other investigated genes among BRCA1 and BRCA2 carriers.",Y,IGFBP2,IGFBP2,1
3210,bc_id3283,CANCER,IGFBP1,19843326,B,Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.,2009,This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.,"A cohort of 1,665 adult, female mutation carriers, including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2 carriers (238 cases) were genotyped for SNPs in IGF1, IGF1 receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2, IGFBP5), and IGF receptor substrate 1 (IRS1)... Among BRCA1 carriers, significant associations were found between risk of breast cancer and LD blocks in IGF1R (global P = 0.011 for LD block 2 and global P = 0.012 for LD block 11). Among BRCA2 carriers, an LD block in IGFBP2 (global P = 0.0145) was found to be associated with the time to breast cancer diagnosis. No significant LD block associations were found for the other investigated genes among BRCA1 and BRCA2 carriers.",N,IGFBP1,IGFBP1,1
3211,bc_id3284,CANCER,IGF1R,19843326,B,Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.,2009,This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.,"A cohort of 1,665 adult, female mutation carriers, including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2 carriers (238 cases) were genotyped for SNPs in IGF1, IGF1 receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2, IGFBP5), and IGF receptor substrate 1 (IRS1)... Among BRCA1 carriers, significant associations were found between risk of breast cancer and LD blocks in IGF1R (global P = 0.011 for LD block 2 and global P = 0.012 for LD block 11). Among BRCA2 carriers, an LD block in IGFBP2 (global P = 0.0145) was found to be associated with the time to breast cancer diagnosis. No significant LD block associations were found for the other investigated genes among BRCA1 and BRCA2 carriers.",Y,IGF1R,IGF1R,0.5
3212,bc_id3285,CANCER,IGF1,19843326,B,Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.,2009,This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.,"A cohort of 1,665 adult, female mutation carriers, including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2 carriers (238 cases) were genotyped for SNPs in IGF1, IGF1 receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2, IGFBP5), and IGF receptor substrate 1 (IRS1)... Among BRCA1 carriers, significant associations were found between risk of breast cancer and LD blocks in IGF1R (global P = 0.011 for LD block 2 and global P = 0.012 for LD block 11). Among BRCA2 carriers, an LD block in IGFBP2 (global P = 0.0145) was found to be associated with the time to breast cancer diagnosis. No significant LD block associations were found for the other investigated genes among BRCA1 and BRCA2 carriers.",N,IGF1,IGF1,0.4
3213,bc_id3286,CANCER,BRCA2,19843326,B,Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.,2009,This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.,"A cohort of 1,665 adult, female mutation carriers, including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2 carriers (238 cases) were genotyped for SNPs in IGF1, IGF1 receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2, IGFBP5), and IGF receptor substrate 1 (IRS1)... Among BRCA1 carriers, significant associations were found between risk of breast cancer and LD blocks in IGF1R (global P = 0.011 for LD block 2 and global P = 0.012 for LD block 11). Among BRCA2 carriers, an LD block in IGFBP2 (global P = 0.0145) was found to be associated with the time to breast cancer diagnosis. No significant LD block associations were found for the other investigated genes among BRCA1 and BRCA2 carriers.",A,BRCA2,BRCA2,0.576923077
3214,bc_id3287,CANCER,BRCA1,19843326,B,Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.,2009,This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.,"A cohort of 1,665 adult, female mutation carriers, including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2 carriers (238 cases) were genotyped for SNPs in IGF1, IGF1 receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2, IGFBP5), and IGF receptor substrate 1 (IRS1)... Among BRCA1 carriers, significant associations were found between risk of breast cancer and LD blocks in IGF1R (global P = 0.011 for LD block 2 and global P = 0.012 for LD block 11). Among BRCA2 carriers, an LD block in IGFBP2 (global P = 0.0145) was found to be associated with the time to breast cancer diagnosis. No significant LD block associations were found for the other investigated genes among BRCA1 and BRCA2 carriers.",A,BRCA1,BRCA1,0.60944206
3215,bc_id3288,CANCER,MAP3K1,19843670,B,Association of breast cancer susceptibility variants with risk of pancreatic cancer.,2009,,X,X,X,X,0
3216,bc_id3289,CANCER,LUM,19843670,B,Association of breast cancer susceptibility variants with risk of pancreatic cancer.,2009,,X,X,X,X,0
3217,bc_id3290,CANCER,LSP1,19843670,B,Association of breast cancer susceptibility variants with risk of pancreatic cancer.,2009,,X,X,X,X,0
3218,bc_id3291,CANCER,TOX3,19843670,B,Association of breast cancer susceptibility variants with risk of pancreatic cancer.,2009,,X,X,X,X,0
3219,bc_id3292,CANCER,H19,19843670,B,Association of breast cancer susceptibility variants with risk of pancreatic cancer.,2009,,X,X,X,X,0
3220,bc_id3293,CANCER,FGFR2,19843670,B,Association of breast cancer susceptibility variants with risk of pancreatic cancer.,2009,,X,X,X,X,0
3221,bc_id3294,CANCER,CASP8,19843670,B,Association of breast cancer susceptibility variants with risk of pancreatic cancer.,2009,,X,X,X,X,0
3222,bc_id3295,CANCER,PIK3CA,19844234,B,"Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.",2009,,X,X,X,X,0
3223,bc_id3296,CANCER,PIK3CA,19844788,B,Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.,2010,,PIK3CA mutation status did not strongly interact with neoadjuvant endocrine therapy responsiveness in estrogen receptor-positive breast cancer.,N,PIK3CA,PIK3CA,0.133333333
3224,bc_id3297,CANCER,PGR,19846565,B,Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.,2009,,"In an analysis combining data from 2 population-based case-control studies of postmenopausal breast cancer (1,296 cases and 1,055 controls) conducted in Washington State in 1997-1999 and 2000-2004, the authors evaluated how 51 single nucleotide polymorphisms in 7 progesterone-related genes (AKR1C1, AKR1C2, AKR1C3, CYP3A4, SRD5A1, SRD5A2, and PGR) influenced breast cancer risk... Interpretation of these subgroup associations must await the results of similar studies conducted in other populations.",A,PGR,PGR,0.5
3225,bc_id3298,CANCER,AKR1C3,19846565,B,Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.,2009,,"In an analysis combining data from 2 population-based case-control studies of postmenopausal breast cancer (1,296 cases and 1,055 controls) conducted in Washington State in 1997-1999 and 2000-2004, the authors evaluated how 51 single nucleotide polymorphisms in 7 progesterone-related genes (AKR1C1, AKR1C2, AKR1C3, CYP3A4, SRD5A1, SRD5A2, and PGR) influenced breast cancer risk... Interpretation of these subgroup associations must await the results of similar studies conducted in other populations.",A,AKR1C3,AKR1C3,0.5
3226,bc_id3299,CANCER,AKR1C2,19846565,B,Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.,2009,,"In an analysis combining data from 2 population-based case-control studies of postmenopausal breast cancer (1,296 cases and 1,055 controls) conducted in Washington State in 1997-1999 and 2000-2004, the authors evaluated how 51 single nucleotide polymorphisms in 7 progesterone-related genes (AKR1C1, AKR1C2, AKR1C3, CYP3A4, SRD5A1, SRD5A2, and PGR) influenced breast cancer risk... Interpretation of these subgroup associations must await the results of similar studies conducted in other populations.",A,AKR1C2,AKR1C2,1
3227,bc_id3300,CANCER,AKR1C1,19846565,B,Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.,2009,,"In an analysis combining data from 2 population-based case-control studies of postmenopausal breast cancer (1,296 cases and 1,055 controls) conducted in Washington State in 1997-1999 and 2000-2004, the authors evaluated how 51 single nucleotide polymorphisms in 7 progesterone-related genes (AKR1C1, AKR1C2, AKR1C3, CYP3A4, SRD5A1, SRD5A2, and PGR) influenced breast cancer risk... Interpretation of these subgroup associations must await the results of similar studies conducted in other populations.",A,AKR1C1,AKR1C1,1
3228,bc_id3301,CANCER,CYP3A4,19846565,B,Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.,2009,,"In an analysis combining data from 2 population-based case-control studies of postmenopausal breast cancer (1,296 cases and 1,055 controls) conducted in Washington State in 1997-1999 and 2000-2004, the authors evaluated how 51 single nucleotide polymorphisms in 7 progesterone-related genes (AKR1C1, AKR1C2, AKR1C3, CYP3A4, SRD5A1, SRD5A2, and PGR) influenced breast cancer risk... Interpretation of these subgroup associations must await the results of similar studies conducted in other populations.",A,CYP3A4,CYP3A4,0.363636364
3229,bc_id3302,CANCER,SRD5A2,19846565,B,Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.,2009,,"In an analysis combining data from 2 population-based case-control studies of postmenopausal breast cancer (1,296 cases and 1,055 controls) conducted in Washington State in 1997-1999 and 2000-2004, the authors evaluated how 51 single nucleotide polymorphisms in 7 progesterone-related genes (AKR1C1, AKR1C2, AKR1C3, CYP3A4, SRD5A1, SRD5A2, and PGR) influenced breast cancer risk... Interpretation of these subgroup associations must await the results of similar studies conducted in other populations.",A,SRD5A2,SRD5A2,0.666666667
3230,bc_id3303,CANCER,SRD5A1,19846565,B,Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.,2009,,"In an analysis combining data from 2 population-based case-control studies of postmenopausal breast cancer (1,296 cases and 1,055 controls) conducted in Washington State in 1997-1999 and 2000-2004, the authors evaluated how 51 single nucleotide polymorphisms in 7 progesterone-related genes (AKR1C1, AKR1C2, AKR1C3, CYP3A4, SRD5A1, SRD5A2, and PGR) influenced breast cancer risk... Interpretation of these subgroup associations must await the results of similar studies conducted in other populations.",A,SRD5A1,SRD5A1,1
3231,bc_id3304,CANCER,EXO1,19846925,B,Association of genetic polymorphisms of EXO1 gene with risk of breast cancer in Taiwan.,2009,Our results provide evidence that the A allele of EXO1 K589E may be associated with the development of breast cancer and may be a useful biomarker for breast cancer detection and primary prevention.,Our results provide evidence that the A allele of EXO1 K589E may be associated with the development of breast cancer and may be a useful biomarker for breast cancer detection and primary prevention.,A,EXO1,EXO1,1
3232,bc_id3305,CANCER,MTHFR,19846961,B,Determinants of homocysteine levels in colorectal and breast cancer patients.,2009,,X,X,X,X,0
3233,bc_id3306,CANCER,MIR499,19847796,B,"Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases.",2010,"our data suggested lack of association between SNPs rs2910164, rs11614913 and rs3746444 and breast cancer risk, or age at breast cancer onset.","Recently, the SNPs rs11614913 in hsa-mir-196a2 and rs3746444 in hsa-mir-499 were reported to be associated with increased breast cancer risk, and the SNP rs2910164 in hsa-mir-146a was shown to have an effect on age of breast cancer diagnosis.",Y,hsa-mir-499,MIR499,1
3234,bc_id3307,CANCER,MIR196A2,19847796,B,"Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases.",2010,"our data suggested lack of association between SNPs rs2910164, rs11614913 and rs3746444 and breast cancer risk, or age at breast cancer onset.","Recently, the SNPs rs11614913 in hsa-mir-196a2 and rs3746444 in hsa-mir-499 were reported to be associated with increased breast cancer risk, and the SNP rs2910164 in hsa-mir-146a was shown to have an effect on age of breast cancer diagnosis.",Y,hsa-mir-196a2,MIR196A2,1
3235,bc_id3308,CANCER,MIR146A,19847796,B,"Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases.",2010,"our data suggested lack of association between SNPs rs2910164, rs11614913 and rs3746444 and breast cancer risk, or age at breast cancer onset.","Recently, the SNPs rs11614913 in hsa-mir-196a2 and rs3746444 in hsa-mir-499 were reported to be associated with increased breast cancer risk, and the SNP rs2910164 in hsa-mir-146a was shown to have an effect on age of breast cancer diagnosis.",Y,hsa-mir-196a2,MIR146A,1
3236,bc_id3309,CANCER,GSTM5,19856098,B,Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.,2009,,X,X,X,X,0
3237,bc_id3310,CANCER,GSTM4,19856098,B,Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.,2009,,X,X,X,X,0
3238,bc_id3311,CANCER,GSTM3,19856098,B,Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.,2009,,"In conclusion, SNPs/haplotypes in the GSTM3 gene within the GSTMs gene cluster are likely to contribute to breast cancer risk when the GSTM1 is absent. We infer that GSTM3 catalyzing ability in normal breast tissue might protect against breast carcinogenesis.",A,GSTM3,GSTM3,0.666666667
3239,bc_id3312,CANCER,GSTM2,19856098,B,Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.,2009,,X,X,X,X,0
3240,bc_id3313,CANCER,GSTM1,19856098,B,Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1.,2009,,"In conclusion, SNPs/haplotypes in the GSTM3 gene within the GSTMs gene cluster are likely to contribute to breast cancer risk when the GSTM1 is absent. We infer that GSTM3 catalyzing ability in normal breast tissue might protect against breast carcinogenesis.",N,GSTM1,GSTM1,0.20754717
3241,bc_id3314,CANCER,BRCA2,19858402,B,Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,"Contralateral breast cancer risk depends on age at first breast cancer and on the affected BRCA gene, and this risk should be considered in treatment planning.","Contralateral breast cancer risk depends on age at first breast cancer and on the affected BRCA gene, and this risk should be considered in treatment planning.",Y,BRCA,BRCA2,0.324175824
3242,bc_id3315,CANCER,BRCA1,19858402,B,Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2009,"Contralateral breast cancer risk depends on age at first breast cancer and on the affected BRCA gene, and this risk should be considered in treatment planning.","Contralateral breast cancer risk depends on age at first breast cancer and on the affected BRCA gene, and this risk should be considered in treatment planning.",Y,BRCA,BRCA1,0.326180258
3243,bc_id3316,CANCER,GSTZ1,19859803,N,"No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.",2009,,"We did not observe any breast cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in breast cancer susceptibility.",N,GSTZ1,GSTZ1,1
3244,bc_id3317,CANCER,GSTM2,19859803,N,"No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.",2009,,"We did not observe any breast cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in breast cancer susceptibility.",N,GSTM2,GSTM2,1
3245,bc_id3318,CANCER,GSTA2,19859803,N,"No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.",2009,,"We did not observe any breast cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in breast cancer susceptibility.",N,GSTA2,GSTA2,1
3246,bc_id3319,CANCER,GSTO1,19859803,N,"No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.",2009,,"We did not observe any breast cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in breast cancer susceptibility.",N,GSTO1,GSTO1,0.333333333
3247,bc_id3320,CANCER,FGFR2,19861516,B,Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.,2009,Postmenopausal women having TT genotype for SNP rs3750817 have a reduced breast cancer risk and seem to experience comparatively favorable effects of postmenopausal hormone therapy.,"Seven FGFR2 SNPs, including six in a single linkage disequilibrium region, were found to associate strongly (P < 10(-7)) with breast cancer risk.",Y,FGFR2,FGFR2,0.708333333
3248,bc_id3321,CANCER,CYP1A1,19863350,B,Possible Risk Modification by Polymorphisms of Estrogen Metabolizing Genes in Familial Breast Cancer Susceptibility in an Indian Population.,2009,,"This case control study investigated whether polymorphisms of estrogen metabolizing genes CYP1A1 MspI, CYP17 MspAI, COMT Val(158) Met, and SULT1A1 Arg(213) His have any role in familial breast cancer susceptibility risk... Our results favor a possible risk modification by estrogen metabolizing gene polymorphisms in familial breast cancer susceptibility.",A,CYP1A1,CYP1A1,0.456521739
3249,bc_id3322,CANCER,CYP17A1,19863350,B,Possible Risk Modification by Polymorphisms of Estrogen Metabolizing Genes in Familial Breast Cancer Susceptibility in an Indian Population.,2009,,"This case control study investigated whether polymorphisms of estrogen metabolizing genes CYP1A1 MspI, CYP17 MspAI, COMT Val(158) Met, and SULT1A1 Arg(213) His have any role in familial breast cancer susceptibility risk... Our results favor a possible risk modification by estrogen metabolizing gene polymorphisms in familial breast cancer susceptibility.",A,CYP17,CYP17A1,0.466666667
3250,bc_id3323,CANCER,COMT,19863350,B,Possible Risk Modification by Polymorphisms of Estrogen Metabolizing Genes in Familial Breast Cancer Susceptibility in an Indian Population.,2009,,"This case control study investigated whether polymorphisms of estrogen metabolizing genes CYP1A1 MspI, CYP17 MspAI, COMT Val(158) Met, and SULT1A1 Arg(213) His have any role in familial breast cancer susceptibility risk... Our results favor a possible risk modification by estrogen metabolizing gene polymorphisms in familial breast cancer susceptibility.",A,COMT,COMT,0.425531915
3251,bc_id3324,CANCER,SULT1A1,19863350,B,Possible Risk Modification by Polymorphisms of Estrogen Metabolizing Genes in Familial Breast Cancer Susceptibility in an Indian Population.,2009,,"This case control study investigated whether polymorphisms of estrogen metabolizing genes CYP1A1 MspI, CYP17 MspAI, COMT Val(158) Met, and SULT1A1 Arg(213) His have any role in familial breast cancer susceptibility risk... Our results favor a possible risk modification by estrogen metabolizing gene polymorphisms in familial breast cancer susceptibility.",A,SULT1A1,SULT1A1,0.387096774
3252,bc_id3325,CANCER,PALB2,19863560,B,The contribution of founder mutations to early-onset breast cancer in French-Canadian women.,2009,,"Thus, it can be concluded that a predisposing mutation in BRCA1, BRCA2, CHEK2 or PALB2 is present in approximately 6% of French-Canadian women with early-onset breast cancer.",A,PALB2,PALB2,0.583333333
3253,bc_id3326,CANCER,CHEK2,19863560,B,The contribution of founder mutations to early-onset breast cancer in French-Canadian women.,2009,,"Thus, it can be concluded that a predisposing mutation in BRCA1, BRCA2, CHEK2 or PALB2 is present in approximately 6% of French-Canadian women with early-onset breast cancer.",A,CHEK2,CHEK2,0.383333333
3254,bc_id3327,CANCER,BRCA2,19863560,B,The contribution of founder mutations to early-onset breast cancer in French-Canadian women.,2009,,"Thus, it can be concluded that a predisposing mutation in BRCA1, BRCA2, CHEK2 or PALB2 is present in approximately 6% of French-Canadian women with early-onset breast cancer.",A,BRCA2,BRCA2,0.576923077
3255,bc_id3328,CANCER,BRCA1,19863560,B,The contribution of founder mutations to early-onset breast cancer in French-Canadian women.,2009,,"Thus, it can be concluded that a predisposing mutation in BRCA1, BRCA2, CHEK2 or PALB2 is present in approximately 6% of French-Canadian women with early-onset breast cancer.",A,BRCA1,BRCA1,0.60944206
3256,bc_id3329,CANCER,BRCA2,19877382,B,Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.,2009,,"Presence of BRCA1/2 genes mutations in young women is associated with more aggressiveness of the breast cancer (their 3-years survival is 25,5% less) and absence of the ER, PR, HER-2 receptors, which is unfavorable prognostic factor in terms of hormone therapy.",Y,BRCA1/2,BRCA2,0.324175824
3257,bc_id3330,CANCER,BRCA1,19877382,B,Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.,2009,,"Presence of BRCA1/2 genes mutations in young women is associated with more aggressiveness of the breast cancer (their 3-years survival is 25,5% less) and absence of the ER, PR, HER-2 receptors, which is unfavorable prognostic factor in terms of hormone therapy.",Y,BRCA1/2,BRCA1,0.326180258
3258,bc_id3331,CANCER,BRCA2,19877752,B,Analysis of BRCA1 and BRCA2 mutations in southern Iranian Breast cancer patients.,2009,,Our results indicate that 5382insC and 185delAG mutations in BRCA1 and 6174delT in BRCA2 have much less frequency in Iranian breast cancer patients.,A,BRCA2,BRCA2,0.576923077
3259,bc_id3332,CANCER,BRCA1,19877752,B,Analysis of BRCA1 and BRCA2 mutations in southern Iranian Breast cancer patients.,2009,,Our results indicate that 5382insC and 185delAG mutations in BRCA1 and 6174delT in BRCA2 have much less frequency in Iranian breast cancer patients.,A,BRCA1,BRCA1,0.60944206
3260,bc_id3333,CANCER,MTHFR,19885596,B,"Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study.",2009,,"Allelic frequencies of these genetic variations were: TSER, (2) 0.55 and (3) 0.45 in cases, 0.49 and 0.51 respectively in controls (P=0.240); MTHFR C677T, (C) 0.63 and (T) 0.37 in cases, 0.60 and 0.40 respectively in controls (P=0.568); p53 Arg72Pro, (Arg) 0.74 and (Pro) 0.26 in cases and controls (P=0.910); MDR1 C3435T, (C) 0.52 and (T) 0.48 in cases, 0.55 and 0.45 respectively in controls (P=0.523). We did not observe any gene polymorphism as a risk factor to develop BC.",N,MTHFR,MTHFR,0.326923077
3261,bc_id3334,CANCER,ABCB1,19885596,B,"Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study.",2009,,"Allelic frequencies of these genetic variations were: TSER, (2) 0.55 and (3) 0.45 in cases, 0.49 and 0.51 respectively in controls (P=0.240); MTHFR C677T, (C) 0.63 and (T) 0.37 in cases, 0.60 and 0.40 respectively in controls (P=0.568); p53 Arg72Pro, (Arg) 0.74 and (Pro) 0.26 in cases and controls (P=0.910); MDR1 C3435T, (C) 0.52 and (T) 0.48 in cases, 0.55 and 0.45 respectively in controls (P=0.523). We did not observe any gene polymorphism as a risk factor to develop BC.",N,MDR1,ABCB1,0.125
3262,bc_id3335,CANCER,TYMS,19885596,B,"Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study.",2009,,X,X,X,X,0
3263,bc_id3336,CANCER,TP53,19885596,B,"Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study.",2009,,"Allelic frequencies of these genetic variations were: TSER, (2) 0.55 and (3) 0.45 in cases, 0.49 and 0.51 respectively in controls (P=0.240); MTHFR C677T, (C) 0.63 and (T) 0.37 in cases, 0.60 and 0.40 respectively in controls (P=0.568); p53 Arg72Pro, (Arg) 0.74 and (Pro) 0.26 in cases and controls (P=0.910); MDR1 C3435T, (C) 0.52 and (T) 0.48 in cases, 0.55 and 0.45 respectively in controls (P=0.523). We did not observe any gene polymorphism as a risk factor to develop BC.",N,p53,TP53,0.149425287
3264,bc_id3337,CANCER,XRCC3,19886181,B,XRCC1 and XRCC3 DNA repair gene polymorphisms in breast cancer women from the Lodz region of Poland.,2009,The results suggest that the Arg194Trp and Arg399Gln polymorphism of the XRCC1 gene as well as Trp241 Met polymorphism in XRCC3 may not be linked with appearance and development of breast cancer.,The results suggest that the Arg194Trp and Arg399Gln polymorphism of the XRCC1 gene as well as Trp241 Met polymorphism in XRCC3 may not be linked with appearance and development of breast cancer.,A,XRCC3,XRCC3,0.461538462
3265,bc_id3338,CANCER,XRCC1,19886181,B,XRCC1 and XRCC3 DNA repair gene polymorphisms in breast cancer women from the Lodz region of Poland.,2009,The results suggest that the Arg194Trp and Arg399Gln polymorphism of the XRCC1 gene as well as Trp241 Met polymorphism in XRCC3 may not be linked with appearance and development of breast cancer.,The results suggest that the Arg194Trp and Arg399Gln polymorphism of the XRCC1 gene as well as Trp241 Met polymorphism in XRCC3 may not be linked with appearance and development of breast cancer.,A,XRCC1,XRCC1,0.543478261
3266,bc_id3339,CANCER,PTGS2,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,"Among the target polymorphisms, the tumor necrosis factor superfamily member 10 gene polymorphism (TNFSF10 rs1131532) in a recessive model of the T allele and prostaglandin-endoperoxide synthase 2 gene polymorphism (PTGS2 rs5275) in a dominant model of the C allele were associated with survival in a log-rank test... The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.",A,PTGS2,PTGS2,0.583333333
3267,bc_id3340,CANCER,TP53,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,X,X,X,X,0
3268,bc_id3341,CANCER,FASLG,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,X,X,X,X,0
3269,bc_id3342,CANCER,TNFSF10,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,Y,TNFSF10,TNFSF10,1
3270,bc_id3343,CANCER,FAS,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,X,X,X,X,0
3271,bc_id3344,CANCER,TNFRSF1A,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,X,X,X,X,0
3272,bc_id3345,CANCER,TNFRSF10B,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,X,X,X,X,0
3273,bc_id3346,CANCER,BID,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,X,X,X,X,0
3274,bc_id3347,CANCER,RIPK1,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,X,X,X,X,0
3275,bc_id3348,CANCER,BCL2,19890662,B,TNF superfamily gene polymorphism as prognostic factor in early breast cancer.,2009,The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer.,X,X,X,X,0
3276,bc_id3349,CANCER,PPP2R5E,19890961,B,Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.,2010,,"A alpha isoform (PPP2R1A) were identified and had odds ratios of 1.63 (95% confidence interval [CI], 1.3-2.1) and 0.55 (95% CI, 0.41-0.76), respectively... The effects of haplotypes for 2 PP2A regulatory subunit genes, PP2 regulatory subunit B alpha isoform (PPP2R2A) and PP2A regulatory subunit B' epsilon isoform (PPP2R5E) on breast cancer risk were nominally significant but did not remain significant after the analysis was adjusted for multiple comparisons.",A,PPP2R5E,PPP2R5E,1
3277,bc_id3350,CANCER,PPP2R1A,19890961,B,Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.,2010,,"A alpha isoform (PPP2R1A) were identified and had odds ratios of 1.63 (95% confidence interval [CI], 1.3-2.1) and 0.55 (95% CI, 0.41-0.76), respectively... The effects of haplotypes for 2 PP2A regulatory subunit genes, PP2 regulatory subunit B alpha isoform (PPP2R2A) and PP2A regulatory subunit B' epsilon isoform (PPP2R5E) on breast cancer risk were nominally significant but did not remain significant after the analysis was adjusted for multiple comparisons.",A,PPP2R1A,PPP2R1A,1
3278,bc_id3351,CANCER,PPP2R2A,19890961,B,Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.,2010,,"A alpha isoform (PPP2R1A) were identified and had odds ratios of 1.63 (95% confidence interval [CI], 1.3-2.1) and 0.55 (95% CI, 0.41-0.76), respectively... The effects of haplotypes for 2 PP2A regulatory subunit genes, PP2 regulatory subunit B alpha isoform (PPP2R2A) and PP2A regulatory subunit B' epsilon isoform (PPP2R5E) on breast cancer risk were nominally significant but did not remain significant after the analysis was adjusted for multiple comparisons.",A,PPP2R2A,PPP2R2A,1
3279,bc_id3352,CANCER,KISS1,19895172,B,A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer.,2010,,"In conclusion, altered nucleotide sequence and repression of transcription are two potential mechanisms of suppression of the anti-metastatic effects of KiSS1 in early breast cancer: Confirmation in larger cohorts and study of functional effects of the 242C>G exon IVa mutation are warranted.",A,KiSS1,KISS1,1
3280,bc_id3353,CANCER,BRCA2,19899408,B,Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.,2009,,The contribution of BRCA1 and BRCA2 mutations to Mexican women with breast and/or ovarian cancer is not known... We found 5% of deleterious mutations in the BRCA genes.,A,BRCA2,BRCA2,0.576923077
3281,bc_id3354,CANCER,BRCA1,19899408,B,Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients.,2009,,The contribution of BRCA1 and BRCA2 mutations to Mexican women with breast and/or ovarian cancer is not known... We found 5% of deleterious mutations in the BRCA genes.,A,BRCA1,BRCA1,0.60944206
3282,bc_id3355,CANCER,GSTT1,19902106,B,Studying the association of polymorphic variants of GSTM1 and GSTT1 genes with breast cancer in female residents of Altai Krai.,2009,,"The frequency of genotype combination GSTM1""-""+GSTT1""-"" in patients with sporadic breast cancer (11.6%, 47 of 404 patients) was higher than in the control (6.1%, 16 of 263 patients; OR=2.03; 95% CI=2.09-3.83; p=0.02).",A,GSTT1,GSTT1,0.289473684
3283,bc_id3356,CANCER,GSTM1,19902106,B,Studying the association of polymorphic variants of GSTM1 and GSTT1 genes with breast cancer in female residents of Altai Krai.,2009,,"The frequency of genotype combination GSTM1""-""+GSTT1""-"" in patients with sporadic breast cancer (11.6%, 47 of 404 patients) was higher than in the control (6.1%, 16 of 263 patients; OR=2.03; 95% CI=2.09-3.83; p=0.02).",A,GSTM1,GSTM1,0.339622642
3284,bc_id3357,CANCER,BRCA2,19903338,B,Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study.,2009,The MRIBview estimates of volumetric breast density are highly correlated with mammographic dense area but are not equivalent measures; the MRI absolute dense volume shows potential as a predictor of breast cancer risk that merits further investigation.,"Mammographic percent dense area, and to a lesser extent MRI percent dense volume were lower in BRCA1 carriers (P = 0.001, P = 0.010 respectively) but there was no association with BRCA2 carrier status. The study was underpowered to detect expected associations between percent density and breast cancer, but women with absolute MRI dense volume in the upper half of the distribution had double the risk of those in the lower half (P = 0.009).",N,BRCA2,BRCA2,0.098901099
3285,bc_id3358,CANCER,BRCA1,19903338,B,Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study.,2009,The MRIBview estimates of volumetric breast density are highly correlated with mammographic dense area but are not equivalent measures; the MRI absolute dense volume shows potential as a predictor of breast cancer risk that merits further investigation.,"Mammographic percent dense area, and to a lesser extent MRI percent dense volume were lower in BRCA1 carriers (P = 0.001, P = 0.010 respectively) but there was no association with BRCA2 carrier status. The study was underpowered to detect expected associations between percent density and breast cancer, but women with absolute MRI dense volume in the upper half of the distribution had double the risk of those in the lower half (P = 0.009).",A,BRCA1,BRCA1,0.60944206
3286,bc_id3359,CANCER,VTCN1,19903360,B,B7-H4 gene polymorphisms are associated with sporadic breast cancer in a Chinese Han population.,2010,,These results suggest that B7-H4 gene polymorphism may contribute to the sporadic breast cancer risk and prognosis in Chinese Han women.,A,B7-H4,VTCN1,1
3287,bc_id3360,CANCER,NBN,19904603,B,Some common mutations of RAD50 and NBS1 in western populations do not contribute significantly to Chinese non-BRCA1/2 hereditary breast cancer.,2009,,ANF,ANF,ANF,ANF,0
3288,bc_id3361,CANCER,RAD50,19904603,B,Some common mutations of RAD50 and NBS1 in western populations do not contribute significantly to Chinese non-BRCA1/2 hereditary breast cancer.,2009,,ANF,ANF,ANF,ANF,0
3289,bc_id3362,CANCER,TP53,19911701,B,TP53 codon 72 polymorphism and breast cancer in northern Iran.,2009,,"The p53 gene is one of the most extensively studied human genes because of its role as a tumor suppressor gene... Based on these data, it is suggested that Pro allele may modify the risk of breast cancer in northern Iranian women.",A,p53,TP53,0.482758621
3290,bc_id3363,CANCER,ERCC4,19920816,B,Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).,2009,"This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.","In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers... This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.",N,ERCC4,ERCC4,0.25
3291,bc_id3364,CANCER,BRCA2,19920816,B,Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).,2009,"This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.",X,X,X,X,0
3292,bc_id3365,CANCER,BRCA1,19920816,B,Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).,2009,"This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.",X,X,X,X,0
3293,bc_id3366,CANCER,PALB2,19921424,B,Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population.,2009,,"Combined with the results of the former study, our findings further verified that some common PALB2 polymorphisms may contribute to the etiology of breast cancer in Chinese women, so other large studies are warranted to confirm these observations in different ethnic populations.",A,PALB2,PALB2,0.583333333
3294,bc_id3367,CANCER,MIR27A,19921425,Y,A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk.,2009,,"We hypothesize that the G-variant of rs895819 might impair the maturation of the oncogenic miR-27a and thus, is associated with familial breast cancer risk.",A,miR-27a,MIR27A,1
3295,bc_id3368,CANCER,GSTT1,19921428,B,"Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.",2009,,"The GSTP1, GSTM1, and GSTT1 detoxification genes all have functional polymorphisms that are common in the general population. A single study of 320 BRCA1/2 carriers previously assessed their effect in BRCA1 or BRCA2 mutation carriers. This study showed no evidence for altered risk of breast cancer for individuals with the GSTT1 and GSTM1 deletion variants, but did report that the GSTP1 Ile105Val (rs1695) variant was associated with increased breast cancer risk in carriers... There was no evidence to show that any of the polymorphisms modified disease risk for BRCA1 or BRCA2 carriers, and there was no evidence for heterogeneity between sites.",N,GSTT1,GSTT1,0.131578947
3296,bc_id3369,CANCER,GSTP1,19921428,B,"Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.",2009,,"The GSTP1, GSTM1, and GSTT1 detoxification genes all have functional polymorphisms that are common in the general population. A single study of 320 BRCA1/2 carriers previously assessed their effect in BRCA1 or BRCA2 mutation carriers. This study showed no evidence for altered risk of breast cancer for individuals with the GSTT1 and GSTM1 deletion variants, but did report that the GSTP1 Ile105Val (rs1695) variant was associated with increased breast cancer risk in carriers... There was no evidence to show that any of the polymorphisms modified disease risk for BRCA1 or BRCA2 carriers, and there was no evidence for heterogeneity between sites.",Y,GSTP1,GSTP1,0.428571429
3297,bc_id3370,CANCER,GSTM1,19921428,B,"Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.",2009,,"The GSTP1, GSTM1, and GSTT1 detoxification genes all have functional polymorphisms that are common in the general population. A single study of 320 BRCA1/2 carriers previously assessed their effect in BRCA1 or BRCA2 mutation carriers. This study showed no evidence for altered risk of breast cancer for individuals with the GSTT1 and GSTM1 deletion variants, but did report that the GSTP1 Ile105Val (rs1695) variant was associated with increased breast cancer risk in carriers... There was no evidence to show that any of the polymorphisms modified disease risk for BRCA1 or BRCA2 carriers, and there was no evidence for heterogeneity between sites.",N,GSTM1,GSTM1,0.20754717
3298,bc_id3371,CANCER,BRCA2,19921428,B,"Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.",2009,,"The GSTP1, GSTM1, and GSTT1 detoxification genes all have functional polymorphisms that are common in the general population. A single study of 320 BRCA1/2 carriers previously assessed their effect in BRCA1 or BRCA2 mutation carriers. This study showed no evidence for altered risk of breast cancer for individuals with the GSTT1 and GSTM1 deletion variants, but did report that the GSTP1 Ile105Val (rs1695) variant was associated with increased breast cancer risk in carriers... There was no evidence to show that any of the polymorphisms modified disease risk for BRCA1 or BRCA2 carriers, and there was no evidence for heterogeneity between sites.",N,BRCA2,BRCA2,0.098901099
3299,bc_id3372,CANCER,BRCA1,19921428,B,"Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.",2009,,"The GSTP1, GSTM1, and GSTT1 detoxification genes all have functional polymorphisms that are common in the general population. A single study of 320 BRCA1/2 carriers previously assessed their effect in BRCA1 or BRCA2 mutation carriers. This study showed no evidence for altered risk of breast cancer for individuals with the GSTT1 and GSTM1 deletion variants, but did report that the GSTP1 Ile105Val (rs1695) variant was associated with increased breast cancer risk in carriers... There was no evidence to show that any of the polymorphisms modified disease risk for BRCA1 or BRCA2 carriers, and there was no evidence for heterogeneity between sites.",N,BRCA1,BRCA1,0.064377682
3300,bc_id3373,CANCER,MSH6,19924528,B,Association of rare MSH6 variants with familial breast cancer.,2009,,"Together, our data suggest that rare MSH6 variants may predispose to familial breast cancer.",A,MSH6,MSH6,1
3301,bc_id3374,CANCER,MUC6,19924550,B,"A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer.",2010,"Overall, our data provide evidence that some common variations in MUC1 and MUC5AC genes contribute to an elevated risk of stomach cancer.",NR,NR,NR,NR,0
3302,bc_id3375,CANCER,MUC5AC,19924550,B,"A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer.",2010,"Overall, our data provide evidence that some common variations in MUC1 and MUC5AC genes contribute to an elevated risk of stomach cancer.",NR,NR,NR,NR,0
3303,bc_id3376,CANCER,MUC1,19924550,B,"A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer.",2010,"Overall, our data provide evidence that some common variations in MUC1 and MUC5AC genes contribute to an elevated risk of stomach cancer.",NR,NR,NR,NR,0
3304,bc_id3377,CANCER,HLA-DQB1,19927780,B,Are HLA DQB1 alleles correlated with breast cancer histopronostic parameters in Tunisia?,2009,This result may be explained by the fact that cancer is a multifactoral disease due to several interacting factors that might change from one population to another.,We have aimed to search for possible associations between HLA DQB1 alleles and the histoprognostical parameters in breast cancer in the Tunisian population... This result may be explained by the fact that cancer is a multifactoral disease due to several interacting factors that might change from one population to another.,A,HLA DQB1,HLA-DQB1,0.25
3305,bc_id3378,CANCER,ERBB2,19929405,B,HER2 Polymorphisms and Breast Cancer in Tunisian Women.,2010,,HER2 has been thought to play a critical role in both breast cancer development and progression.,A,HER2,ERBB2,0.452380952
3306,bc_id3379,CANCER,CYP2C9,19935798,B,CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.,2009,,Polymorphic variants of CYP2C8/9 may influence breast tumour characteristics and disease-free survival in tamoxifen-treated patients.,A,CYP2C8/9,CYP2C9,1
3307,bc_id3380,CANCER,CYP2C8,19935798,B,CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.,2009,,Polymorphic variants of CYP2C8/9 may influence breast tumour characteristics and disease-free survival in tamoxifen-treated patients.,A,CYP2C8/9,CYP2C8,0.5
3308,bc_id3381,CANCER,OGG1,19936841,B,Synergistic Effects of Polymorphisms in DNA Repair Genes and Endogenous Estrogen Exposure on Female Breast Cancer Risk.,2009,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,ANF,ANF,ANF,ANF,0
3309,bc_id3382,CANCER,ERCC5,19936841,B,Synergistic Effects of Polymorphisms in DNA Repair Genes and Endogenous Estrogen Exposure on Female Breast Cancer Risk.,2009,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,ANF,ANF,ANF,ANF,0
3310,bc_id3383,CANCER,ERCC4,19936841,B,Synergistic Effects of Polymorphisms in DNA Repair Genes and Endogenous Estrogen Exposure on Female Breast Cancer Risk.,2009,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,ANF,ANF,ANF,ANF,0
3311,bc_id3384,CANCER,ERCC2,19936841,B,Synergistic Effects of Polymorphisms in DNA Repair Genes and Endogenous Estrogen Exposure on Female Breast Cancer Risk.,2009,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,ANF,ANF,ANF,ANF,0
3312,bc_id3385,CANCER,XRCC1,19936841,B,Synergistic Effects of Polymorphisms in DNA Repair Genes and Endogenous Estrogen Exposure on Female Breast Cancer Risk.,2009,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,ANF,ANF,ANF,ANF,0
3313,bc_id3386,CANCER,GSTM1,19936916,B,"Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46,281 subjects.",2009,,"In conclusion, this meta-analysis suggests that the GSTM1 null genotype is a low-penetrant risk factor for developing breast cancer.",Y,GSTM1,GSTM1,0.452830189
3314,bc_id3387,CANCER,ESR1,19941161,B,Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer.,2009,our findings suggest that the combined genotypes of CDK7 and ESR1 are associated with breast cancer risk among Korean women.,"There was no significant association between breast cancer risk and the genetic polymorphisms of CCND1 and ESR1... In conclusion, our findings suggest that the combined genotypes of CDK7 and ESR1 are associated with breast cancer risk among Korean women.",Y,ESR1,ESR1,0.282608696
3315,bc_id3388,CANCER,CDK7,19941161,B,Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer.,2009,our findings suggest that the combined genotypes of CDK7 and ESR1 are associated with breast cancer risk among Korean women.,"There was no significant association between breast cancer risk and the genetic polymorphisms of CCND1 and ESR1... In conclusion, our findings suggest that the combined genotypes of CDK7 and ESR1 are associated with breast cancer risk among Korean women.",Y,CDK7,CDK7,1
3316,bc_id3389,CANCER,CCND1,19941161,B,Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer.,2009,our findings suggest that the combined genotypes of CDK7 and ESR1 are associated with breast cancer risk among Korean women.,"There was no significant association between breast cancer risk and the genetic polymorphisms of CCND1 and ESR1... In conclusion, our findings suggest that the combined genotypes of CDK7 and ESR1 are associated with breast cancer risk among Korean women.",N,CCND1,CCND1,0.3125
3317,bc_id3390,CANCER,MTHFD1,19946345,B,Association between HIC1 and RASSF1A Promoter Hypermethylation with MTHFD1 G1958A Polymorphism and Clinicopathological Features of Breast Cancer in Iranian Patients.,2009,Methylation of HIC1 and RASSF1A promoters can be used as epigenetic markers to detect the malignant progression of breast carcinoma in Iranian women patients.,X,X,X,X,0
3318,bc_id3391,CANCER,BRCA2,19949853,B,Two founder BRCA2 mutations predispose to breast cancer in young women.,2009,,The mutation spectrum of BRCA1 and BRCA2 presents a wide range of unique mutations in breast/ovarian cancer patients but recurrent mutations with founder effects have also been described.,A,BRCA2,BRCA2,0.576923077
3319,bc_id3392,CANCER,BRCA1,19949853,B,Two founder BRCA2 mutations predispose to breast cancer in young women.,2009,,The mutation spectrum of BRCA1 and BRCA2 presents a wide range of unique mutations in breast/ovarian cancer patients but recurrent mutations with founder effects have also been described.,A,BRCA1,BRCA1,0.60944206
3320,bc_id3393,CANCER,SULT1A1,19949855,B,"SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls.",2009,our results suggested that there is no significant relationship between SULT1A1 R213H polymorphism and the risk of breast cancer.,"Taken together, this meta-analysis suggests that the SULT1A1 R213H may be a low-penetrant risk factor for developing breast cancer in Asian population.",A,SULT1A1,SULT1A1,0.387096774
3321,bc_id3394,CANCER,MTHFR,19954067,B,"[MTHFR polymorphisms, dietary folate intake and risks to breast cancer]",2009,"The findings of the present study suggest that MTHFR genetic polymorphisms,and dietary intake of folate may modify susceptibility to breast cancer.","The findings of the present study suggest that MTHFR genetic polymorphisms,and dietary intake of folate may modify susceptibility to breast cancer.",A,MTHFR,MTHFR,0.403846154
3322,bc_id3395,CANCER,OGG1,19962393,B,DNA repair capacity and acute radiotherapy adverse effects in Italian breast cancer patients.,2010,,X,X,X,X,0
3323,bc_id3396,CANCER,XRCC3,19962393,B,DNA repair capacity and acute radiotherapy adverse effects in Italian breast cancer patients.,2010,,X,X,X,X,0
3324,bc_id3397,CANCER,XRCC1,19962393,B,DNA repair capacity and acute radiotherapy adverse effects in Italian breast cancer patients.,2010,,"All study subjects were genotyped for XRCC1, OGG1 and XRCC3 gene polymorphisms. In our small groups we found a positive association between XRCC1 variant allele (399Gln) and the occurrence of breast cancer [p=0.01; OR=2.41, 95%CI (1.24-4.66)]. BC patients showed a higher degree of basal (p<0.001) and X-ray induced DNA damage (p<0.01) when compared to healthy controls.",Y,XRCC1,XRCC1,0.239130435
3325,bc_id3398,CANCER,NAT2,19996973,B,"N-acetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptor-defined breast cancer.",2010,,"Our results support differing risk patterns for receptor-defined breast cancer. However, the modifying role of NAT2 for receptor-defined breast cancer is difficult to interpret in the light of complex mixtures of exposure to AHA.",A,NAT2,NAT2,0.259259259
3326,bc_id3399,CANCER,NCOR2,20003447,B,Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.,2010,,"Thus, we set out to identify novel single nucleotide polymorphisms (SNPs) within SRC-1 (NCoA1), SRC-3 (NCoA3, AIB1), NCoR (NCoR1), and SMRT (NCoR2), and test the most promising SNPs for associations with breast cancer risk... This data illustrates the importance of coregulators, especially SRC-3, in breast cancer development and suggests that more focused studies, including functional analyses, should be conducted.",A,NCoR2,NCOR2,1
3327,bc_id3400,CANCER,NCOR1,20003447,B,Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.,2010,,"Thus, we set out to identify novel single nucleotide polymorphisms (SNPs) within SRC-1 (NCoA1), SRC-3 (NCoA3, AIB1), NCoR (NCoR1), and SMRT (NCoR2), and test the most promising SNPs for associations with breast cancer risk... This data illustrates the importance of coregulators, especially SRC-3, in breast cancer development and suggests that more focused studies, including functional analyses, should be conducted.",A,NCoR1,NCOR1,1
3328,bc_id3401,CANCER,NCOA3,20003447,B,Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.,2010,,"Thus, we set out to identify novel single nucleotide polymorphisms (SNPs) within SRC-1 (NCoA1), SRC-3 (NCoA3, AIB1), NCoR (NCoR1), and SMRT (NCoR2), and test the most promising SNPs for associations with breast cancer risk... This data illustrates the importance of coregulators, especially SRC-3, in breast cancer development and suggests that more focused studies, including functional analyses, should be conducted.",Y,NCoA3,NCOA3,0.285714286
3329,bc_id3402,CANCER,NCOA1,20003447,B,Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.,2010,,"Thus, we set out to identify novel single nucleotide polymorphisms (SNPs) within SRC-1 (NCoA1), SRC-3 (NCoA3, AIB1), NCoR (NCoR1), and SMRT (NCoR2), and test the most promising SNPs for associations with breast cancer risk... This data illustrates the importance of coregulators, especially SRC-3, in breast cancer development and suggests that more focused studies, including functional analyses, should be conducted.",A,NCoA1,NCOA1,1
3330,bc_id3403,CANCER,NBN,20004634,B,"Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51.",2009,,"We genotyped 4 SNPs in 4 different HRR pathway genes, XRCC2 (Ex3+442G>A, R188H, rs3218536), XRCC3 (Ex8-5C>T, T241M, rs861539), NBS1 (Ex5-32C>G, E185Q, rs1805794) and RAD51 5'UTR (Ex1-59G>T, rs1801321), tagging 41 SNPs in these genes... The results obtained, after logistic regression analysis, did not reveal a major role of these polymorphisms on breast cancer susceptibility.",N,NBS1,NBN,0.238095238
3331,bc_id3404,CANCER,ERCC3,20004634,B,"Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51.",2009,,X,X,X,X,0
3332,bc_id3405,CANCER,XRCC2,20004634,B,"Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51.",2009,,"We genotyped 4 SNPs in 4 different HRR pathway genes, XRCC2 (Ex3+442G>A, R188H, rs3218536), XRCC3 (Ex8-5C>T, T241M, rs861539), NBS1 (Ex5-32C>G, E185Q, rs1805794) and RAD51 5'UTR (Ex1-59G>T, rs1801321), tagging 41 SNPs in these genes... The results obtained, after logistic regression analysis, did not reveal a major role of these polymorphisms on breast cancer susceptibility.",N,XRCC2,XRCC2,0.454545455
3333,bc_id3406,CANCER,RAD51,20004634,B,"Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51.",2009,,"We genotyped 4 SNPs in 4 different HRR pathway genes, XRCC2 (Ex3+442G>A, R188H, rs3218536), XRCC3 (Ex8-5C>T, T241M, rs861539), NBS1 (Ex5-32C>G, E185Q, rs1805794) and RAD51 5'UTR (Ex1-59G>T, rs1801321), tagging 41 SNPs in these genes... The results obtained, after logistic regression analysis, did not reveal a major role of these polymorphisms on breast cancer susceptibility.",N,RAD51,RAD51,0.153846154
3334,bc_id3407,CANCER,BRCA1,20008645,B,Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.,2010,A low rate of pCR was observed in women with breast cancer and a BRCA1 mutation who were treated with AT or CMF.,A low rate of pCR was observed in women with breast cancer and a BRCA1 mutation who were treated with AT or CMF.,A,BRCA1,BRCA1,0.60944206
3335,bc_id3408,CANCER,BRCA2,20010525,B,Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer.,2009,Our results suggest that variant genotypes of the Thr1915Met and Met784Val polymorphisms of the BRCA2 gene may be indicative factors in therapy of ductal breast cancer.,Our results suggest that variant genotypes of the Thr1915Met and Met784Val polymorphisms of the BRCA2 gene may be indicative factors in therapy of ductal breast cancer.,A,BRCA2,BRCA2,0.576923077
3336,bc_id3409,CANCER,CYP17A1,20013047,N,"No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects.",2009,,"In conclusion, this meta-analysis strongly suggests that CYP17 T-34C polymorphism is not associated with breast cancer risk.",N,CYP17,CYP17A1,0.266666667
3337,bc_id3410,CANCER,TP53,20015931,B,Mutations of p53 gene in breast cancer in the Egyptian Province of Dakahliya.,2009,,p53 gene mutations is potentially responsible for pathogenesis and clinical aggressiveness of breast cancer in our locality.,Y,p53,TP53,0.367816092
3338,bc_id3411,CANCER,MDM2,20021639,B,"Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.",2009,,"Within the patient group with p53-negative tumors, TP53 rare homozygous (CC) carriers had a worse survival than G-allele (GG/GC) carriers; actuarial breast cancer-specific survival 71% versus 80%, P = 0.07; HR 1.8 (1.1 to 3.1), P = 0.03... We found no evidence for a differential effect of MDM2 SNP309 by p53 protein expression on survival.",N,MDM2,MDM2,0.444444444
3339,bc_id3412,CANCER,TP53,20021639,B,"Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.",2009,,"Within the patient group with p53-negative tumors, TP53 rare homozygous (CC) carriers had a worse survival than G-allele (GG/GC) carriers; actuarial breast cancer-specific survival 71% versus 80%, P = 0.07; HR 1.8 (1.1 to 3.1), P = 0.03... We found no evidence for a differential effect of MDM2 SNP309 by p53 protein expression on survival.",A,TP53,TP53,0.482758621
3340,bc_id3413,CANCER,AATF,20025740,B,Mutation analysis of the AATF gene in breast cancer families.,2009,"To our knowledge, this is the first study reporting the mutation screening of the AATF gene in familial breast cancer cases.","To our knowledge, this is the first study reporting the mutation screening of the AATF gene in familial breast cancer cases. No evidence for the association with breast cancer was observed.",N,AATF,AATF,1
3341,bc_id3414,CANCER,MTHFR,20030812,B,MTHFR C677T and postmenopausal breast cancer risk by intakes of one-carbon metabolism nutrients: a nested case-control study.,2009,,This study provides support that the MTHFR 677TT genotype is associated with a moderate increase in risk of postmenopausal breast cancer and that this risk may be attenuated with high intakes of some one-carbon associated nutrients.,Y,MTHFR,MTHFR,0.269230769
3342,bc_id3415,CANCER,CYP1B1,20033481,N,"No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40,303 subjects.",2009,,"In conclusion, this meta-analysis provides strong evidence that CYP1B1 Val432Leu polymorphism is not associated with breast cancer risk.",N,CYP1B1,CYP1B1,0.256410256
3343,bc_id3416,CANCER,CYP17A1,20033766,N,"Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.",2009,,"In summary, the meta-analysis strongly suggests that CYP17 MspA1 polymorphism is not associated with increased breast cancer risk.",N,CYP17,CYP17A1,0.266666667
3344,bc_id3417,CANCER,PTGS2,20033767,B,Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis.,2009,,There is a need for further large studies into the role of these polymorphisms (especially rs5277) and other potentially functional polymorphisms/haplotypes in the COX-2 gene as breast cancer risk modifiers.,A,COX-2,PTGS2,0.583333333
3345,bc_id3418,CANCER,BRCA2,20033769,B,Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.,2010,,X,X,X,X,0
3346,bc_id3419,CANCER,BRCA1,20033769,B,Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.,2010,,X,X,X,X,0
3347,bc_id3420,CANCER,PIN1,20033770,Y,The functional promoter polymorphism (-842G&gt;C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger.,2009,,"In conclusion, the PIN1 polymorphisms may contribute to the etiology of sporadic breast cancer in non-Hispanic white women 55 years and younger. Further validation in large population-based studies is needed.",A,PIN1,PIN1,1
3348,bc_id3421,CANCER,TNF,20035378,Y,"TNFalpha -308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls.",2009,,"In conclusion, this meta-analysis suggests that the TNFalpha -308 G allele is a risk factor for developing breast cancer, especially for Caucasians.",Y,TNFalpha,TNF,0.333333333
3349,bc_id3422,CANCER,CYP1A1,20035380,B,Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis.,2009,,"Four single nucleotide polymorphisms in CYP1A1 have been studied concerning their potential implication in terms of breast cancer risk: T3801C, T3205C, A2455G (Ile462Val), and C2453A (Thr461Asp)... On the contrary, T3801C, T3205C, and C2453A status does not seem capable of modifying breast cancer risk.",N,CYP1A1,CYP1A1,0.239130435
3350,bc_id3423,CANCER,CYP1B1,20037207,B,Association of single nucleotide polymorphisms in CYP1B1 and COMT genes with breast cancer susceptibility in Indian women.,2009,,The results demonstrate that CYP1B1 wild type in combination with COMT heterozygous or their inverse combination offer protection against breast cancer in premenopausal Indian women.,Y,CYP1B1,CYP1B1,0.358974359
3351,bc_id3424,CANCER,COMT,20037207,B,Association of single nucleotide polymorphisms in CYP1B1 and COMT genes with breast cancer susceptibility in Indian women.,2009,,The results demonstrate that CYP1B1 wild type in combination with COMT heterozygous or their inverse combination offer protection against breast cancer in premenopausal Indian women.,Y,COMT,COMT,0.276595745
3352,bc_id3425,CANCER,IL6,20043205,N,"Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects.",2009,,"In summary, the present meta-analysis suggests that the functional polymorphism -174G > C within the IL-6 gene promoter is not associated with breast cancer risk.",N,IL-6,IL6,0.428571429
3353,bc_id3426,CANCER,CYP17A1,20043206,B,Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis.,2009,,"After these population stratifications, there was evidence indicating that a possible impact of menopausal status, age at menarche, and BMI on the association between CYP17 T34C polymorphism and the risk of breast cancer.",A,CYP17,CYP17A1,0.466666667
3354,bc_id3427,CANCER,XRCC5,20044645,B,Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan.,2009,,The T allele of Ku80 G-1401T may be associated with the development of breast cancer and may be a novel useful marker for breast cancer detection and prediction.,A,Ku80,XRCC5,0.5
3355,bc_id3428,CANCER,NAT2,20047124,B,"Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan.",2009,"In the present study, with a limited sample size of subjects with low HCA exposure, no association was found between HCA intake and stomach cancer, nor was there any evidence of any influence by genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 on the ris",NR,NR,NR,NR,0
3356,bc_id3429,CANCER,CYP1A2,20047124,B,"Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan.",2009,"In the present study, with a limited sample size of subjects with low HCA exposure, no association was found between HCA intake and stomach cancer, nor was there any evidence of any influence by genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 on the ris",NR,NR,NR,NR,0
3357,bc_id3430,CANCER,CYP1A1,20047124,B,"Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan.",2009,"In the present study, with a limited sample size of subjects with low HCA exposure, no association was found between HCA intake and stomach cancer, nor was there any evidence of any influence by genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 on the ris",NR,NR,NR,NR,0
3358,bc_id3431,CANCER,CYP19A1,20048079,B,Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.,2010,,X,X,X,X,0
3359,bc_id3432,CANCER,EGFR,20049516,B,Investigating the function of three non-synonymous SNPs in EGFR gene: structural modelling and association with breast cancer.,2010,,We also report preliminary experimental data for SNP R977C suggesting that the variant C977 might confer greater risk for breast cancer. These results contribute to an improved understanding of the EGFR dimer stability and provide new elements for understanding the relationship between EGFR and cancer.,A,EGFR,EGFR,0.571428571
3360,bc_id3433,CANCER,XRCC3,20049524,B,XRCC35'-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis.,2010,,"In conclusion, this meta-analysis suggests that the variant G allele of XRCC3 5'-UTR polymorphism is a low-penetrant risk factor for developing breast cancer, while the variant G allele of XRCC3 IVS5-14 polymorphism has a protective effect on breast cancer development.",Y,XRCC3,XRCC3,0.269230769
3361,bc_id3434,CANCER,SOD2,20052533,N,"No association between SOD2 Val16Ala polymorphism and breast cancer susceptibility: a meta-analysis based on 9,710 cases and 11,041 controls.",2010,,"Conclusively, this meta-analysis strongly suggests that SOD2 Val16Ala polymorphism is not associated with breast cancer susceptibility.",N,SOD2,SOD2,0.375
3362,bc_id3435,CANCER,CYP1A1,20052535,N,"Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk: a meta-analysis involving 25,087 subjects.",2010,,"In conclusion, this meta-analysis provides strong evidence that CYP1A1 T3801C polymorphism is not associated with breast cancer risk.",N,CYP1A1,CYP1A1,0.239130435
3363,bc_id3436,CANCER,CYP19A1,20052540,B,"Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls.",2010,,It can be concluded that potentially functional CYP19_630 3-bp del/Ins polymorphism and CYP19_681 (TTTA)(n) polymorphisms may play a low penetrance role in breast cancer susceptibility in an ethnicity-specific manner.,A,CYP19_630,CYP19A1,0.484848485
3364,bc_id3437,CANCER,CYP1A2,20054636,N,"Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects.",2010,,"In conclusion, upto date, there is still not enough evidence to indicate the association of CYP1A2-164 A/C polymorphism and breast cancer development.",N,CYP1A2-164 A/C,CYP1A2,0.416666667
3365,bc_id3438,CANCER,CYP1B1,20054638,B,Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis.,2010,,"In conclusion, this meta-analysis suggests that CYP1B1 Arg48Gly, Ala119Ser and Asn453Ser polymorphisms are not associated with breast cancer risk.",N,CYP1B1,CYP1B1,0.256410256
3366,bc_id3439,CANCER,OGG1,20054639,N,Lack of association between the hOGG1 Ser326Cys polymorphism and breast cancer risk: evidence from 11 case-control studies.,2010,,"Taken together, the results suggest that the hOGG1 Ser326Cys polymorphism is not associated with breast cancer risk.",N,hOGG1,OGG1,0.333333333
3367,bc_id3440,CANCER,XRCC3,20054644,Y,Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population.,2010,,"Our results suggested that the variability of the DNA HR repair genes XRCC3 and RAD51D may play a role in BC risk, but this role may be underlined by a mutual interaction between these genes. These findings should be confirmed in other populations.",A,XRCC3,XRCC3,0.461538462
3368,bc_id3441,CANCER,RAD51,20054644,B,Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population.,2010,,"Our results suggested that the variability of the DNA HR repair genes XRCC3 and RAD51D may play a role in BC risk, but this role may be underlined by a mutual interaction between these genes. These findings should be confirmed in other populations.",A,RAD51,RAD51,0.615384615
3369,bc_id3442,CANCER,LSP1,20054709,B,"Birth weight, breast cancer susceptibility loci, and breast cancer risk.",2010,"Although our findings require confirmation, we found suggestive evidence that genetic susceptibility modifies the positive association of birth weight with breast cancer.",X,X,X,X,0
3370,bc_id3443,CANCER,LOC643714,20054709,B,"Birth weight, breast cancer susceptibility loci, and breast cancer risk.",2010,"Although our findings require confirmation, we found suggestive evidence that genetic susceptibility modifies the positive association of birth weight with breast cancer.",X,X,X,X,0
3371,bc_id3444,CANCER,TOX3,20054709,B,"Birth weight, breast cancer susceptibility loci, and breast cancer risk.",2010,"Although our findings require confirmation, we found suggestive evidence that genetic susceptibility modifies the positive association of birth weight with breast cancer.",X,X,X,X,0
3372,bc_id3445,CANCER,FGFR2,20054709,B,"Birth weight, breast cancer susceptibility loci, and breast cancer risk.",2010,"Although our findings require confirmation, we found suggestive evidence that genetic susceptibility modifies the positive association of birth weight with breast cancer.",X,X,X,X,0
3373,bc_id3446,CANCER,FGFR2,20056625,B,Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer.,2010,,"Invasive breast cancer odds ratios for a low-fat dietary pattern, among women whose usual diets are high in fat, seem to vary with SNP rs3750817 in the FGFR2 gene.",A,FGFR2,FGFR2,0.25
3374,bc_id3447,CANCER,PINX1,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,X,X,X,X,0
3375,bc_id3448,CANCER,TERF2IP,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,X,X,X,X,0
3376,bc_id3449,CANCER,RAD18,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,X,X,X,X,0
3377,bc_id3450,CANCER,POT1,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,Y,POT1,POT1,0.333333333
3378,bc_id3451,CANCER,TNKS,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,X,X,X,X,0
3379,bc_id3452,CANCER,TERT,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,Y,TERT,TERT,0.5
3380,bc_id3453,CANCER,TERF2,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,X,X,X,X,0
3381,bc_id3454,CANCER,TERF1,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,X,X,X,X,0
3382,bc_id3455,CANCER,TERC,20056641,B,Multiple genetic variants in telomere pathway genes and breast cancer risk.,2010,Four SNPs in the TERT and POT1 genes were significantly related with overall breast cancer risk. This initial analysis provides valuable clues for further exploration of the biological role of telomere pathway genes in breast cancer.,X,X,X,X,0
3383,bc_id3456,CANCER,OGG1,20058067,B,The hOGG1 Ser326Cys polymorphism and breast cancer risk: a meta-analysis.,2010,,The meta-analysis suggested that the hOGG1 326Cys allele plays a significant protective effect to breast cancer in European women.,Y,hOGG1,OGG1,0.222222222
3384,bc_id3457,CANCER,FGFR4,20066896,B,Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development.,2010,,Our findings suggest that the polymorphic variant at codon 388 of FGFR4 gene does not confer increased risk to breast cancer development but it may be a potential genetic marker for tumor prognosis.,N,FGFR4,FGFR4,0.2
3385,bc_id3458,CANCER,CYP19A1,20072949,B,The CYP17 and CYP19 gene single nucleotide polymorphism in women with sporadic breast cancer.,2009,,"However, the distribution of the genotypes of the Trp/Arg polymorphism of CYP19 in both control and patients did not differ significantly (p > 0.05) from those predicted by the Hardy-Weinberg distribution. The results support the hypothesis that the T/C polymorphism of CYP17 gene may be associated with the incidence of breast cancer in women from Lodz region of Poland.",A,CYP19,CYP19A1,0.484848485
3386,bc_id3459,CANCER,CYP17A1,20072949,B,The CYP17 and CYP19 gene single nucleotide polymorphism in women with sporadic breast cancer.,2009,,"However, the distribution of the genotypes of the Trp/Arg polymorphism of CYP19 in both control and patients did not differ significantly (p > 0.05) from those predicted by the Hardy-Weinberg distribution. The results support the hypothesis that the T/C polymorphism of CYP17 gene may be associated with the incidence of breast cancer in women from Lodz region of Poland.",A,CYP17,CYP17A1,0.466666667
3387,bc_id3460,CANCER,PGR,20076999,B,No association between a progesterone receptor gene promoter polymorphism (+331G&gt;A) and breast cancer risk in Caucasian women: evidence from a literature-based meta-analysis.,2010,,"In conclusion, the present meta-analysis strongly suggests that +331G>A in the PgR gene is not associated with breast cancer risk.",N,PgR,PGR,0.357142857
3388,bc_id3461,CANCER,BARD1,20077502,B,Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.,2010,", we provide evidence for an increased breast cancer risk associated to specific BARD1 germline mutations.",we provide evidence for an increased breast cancer risk associated to specific BARD1 germline mutations.,Y,BARD1,BARD1,0.363636364
3389,bc_id3462,CANCER,CYP2D6,20081063,B,Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients.,2010,,X,X,X,X,0
3390,bc_id3463,CANCER,ABCB1,20082268,B,Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients.,2010,,"We observed no difference in the frequency of C3435T polymorphism between breast cancer patients and healthy controls. However, there was a significant association between MDR1 expression levels and C3435T polymorphism in the patients. C3435T polymorphism may play a role in inducing drug resistance by altering the expression level of the MDR1 gene.",A,MDR1,ABCB1,0.6875
3391,bc_id3464,CANCER,SOD2,20082851,B,Polymorphism (ALA16VAL) correlates with regional lymph node status in breast cancer.,2010,,X,X,X,X,0
3392,bc_id3465,CANCER,PGR,20082859,B,Association of a progesterone receptor gene +331 G/A polymorphism with breast cancer risk: a meta-analysis.,2010,,X,X,X,X,0
3393,bc_id3466,CANCER,IGFBP3,20084546,B,"IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls.",2010,,"In conclusion, this meta-analysis suggests that the IGFBP3 C allele is a low-penetrant risk factor for developing breast cancer.",Y,IGFBP3,IGFBP3,0.357142857
3394,bc_id3467,CANCER,UGT1A1,20087647,B,The association between TA-repeat polymorphism in the promoter region of UGT1A1 and breast cancer risk: a meta-analysis.,2010,,"In conclusion, this meta-analysis suggests that UGT1A1 A(TA)(7)TAA allele is a potential risk factor for breast cancer in Caucasians.",Y,UGT1A1,UGT1A1,0.1
3395,bc_id3468,CANCER,CYP3A4,20088394,B,"Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.",2009,"CYP1A1 polymorphisms probably predispose to an earlier onset of breast cancer and might be associated with higher c-erbB-2 protein level, but further studies on a much larger group are required to substantiate our findings.",X,X,X,X,0
3396,bc_id3469,CANCER,CYP1B1,20088394,B,"Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.",2009,"CYP1A1 polymorphisms probably predispose to an earlier onset of breast cancer and might be associated with higher c-erbB-2 protein level, but further studies on a much larger group are required to substantiate our findings.",X,X,X,X,0
3397,bc_id3470,CANCER,CYP1A1,20088394,B,"Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.",2009,"CYP1A1 polymorphisms probably predispose to an earlier onset of breast cancer and might be associated with higher c-erbB-2 protein level, but further studies on a much larger group are required to substantiate our findings.","The frequencies of CYP1A1*2A; CYP1A1*2C; CYP1B1*3; CYP3A4*1B CYP3A4*2 polymorphisms were determined in 71 patients aged 36-87, with primary breast cancer and 100 healthy individuals... CYP1A1 polymorphisms probably predispose to an earlier onset of breast cancer and might be associated with higher c-erbB-2 protein level, but further studies on a much larger group are required to substantiate our findings.",A,CYP1A1*2C,CYP1A1,0.456521739
3398,bc_id3471,CANCER,PALB2,20091115,B,Are PALB2 mutations associated with increased risk of male breast cancer?,2010,,ANF,ANF,ANF,ANF,0
3399,bc_id3472,CANCER,RAD51L1,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,We did not find significant variation in the radiation-related breast cancer risk for the variant in RAD51L1 (rs10483813) on 14q24.1 as we had hypothesized.,N,RAD51L1,RAD51L1,1
3400,bc_id3473,CANCER,PPFIBP2,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3401,bc_id3474,CANCER,NPAS2,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3402,bc_id3475,CANCER,MYCL1,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3403,bc_id3476,CANCER,LSP1,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3404,bc_id3477,CANCER,THEMIS,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3405,bc_id3478,CANCER,CLEC16A,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3406,bc_id3479,CANCER,KIAA0090,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3407,bc_id3480,CANCER,TRIT1,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3408,bc_id3481,CANCER,STXBP4,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3409,bc_id3482,CANCER,NEK10,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3410,bc_id3483,CANCER,PARD3,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3411,bc_id3484,CANCER,PRDM10,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3412,bc_id3485,CANCER,SLC4A7,20095854,B,Novel breast cancer risk alleles and interaction with ionizing radiation among U.S. radiologic technologists.,2010,,X,X,X,X,0
3413,bc_id3486,CANCER,ABCC2,20102361,B,Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.,2010,", cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.","Sixty-eight female breast cancer patients were included. All received FAC chemotherapy. Relevant genotyping was done either through restriction fragment length polymorphism or pyrosequencing. The variant allele frequencies were: 5.1% for CYP2C9*2 (430C>T), 15.4% for CYP2C9*3 (1075A>C), 27.2% for CYP2C19*2 (681G>A), 33.1% for GSTA1*B (-69C>T, -52G>A), 62.5% for ALDH3A1*2 (985C>G), 58.8% and 4.4% for ABCB1 (2677 G>T/A), 64.7% for ABCB1 3435 C>T, and 15.4%, 33.1% and 39.7% for ABCC2 (-24 C>T, 1249 G>A and 3972 C>T)... In conclusion, cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.",A,ABCC2,ABCC2,1
3414,bc_id3487,CANCER,GSTA1,20102361,B,Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.,2010,", cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.","Sixty-eight female breast cancer patients were included. All received FAC chemotherapy. Relevant genotyping was done either through restriction fragment length polymorphism or pyrosequencing. The variant allele frequencies were: 5.1% for CYP2C9*2 (430C>T), 15.4% for CYP2C9*3 (1075A>C), 27.2% for CYP2C19*2 (681G>A), 33.1% for GSTA1*B (-69C>T, -52G>A), 62.5% for ALDH3A1*2 (985C>G), 58.8% and 4.4% for ABCB1 (2677 G>T/A), 64.7% for ABCB1 3435 C>T, and 15.4%, 33.1% and 39.7% for ABCC2 (-24 C>T, 1249 G>A and 3972 C>T)... In conclusion, cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.",A,GSTA1*B,GSTA1,0.4
3415,bc_id3488,CANCER,ALDH3A1,20102361,B,Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.,2010,", cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.","Sixty-eight female breast cancer patients were included. All received FAC chemotherapy. Relevant genotyping was done either through restriction fragment length polymorphism or pyrosequencing. The variant allele frequencies were: 5.1% for CYP2C9*2 (430C>T), 15.4% for CYP2C9*3 (1075A>C), 27.2% for CYP2C19*2 (681G>A), 33.1% for GSTA1*B (-69C>T, -52G>A), 62.5% for ALDH3A1*2 (985C>G), 58.8% and 4.4% for ABCB1 (2677 G>T/A), 64.7% for ABCB1 3435 C>T, and 15.4%, 33.1% and 39.7% for ABCC2 (-24 C>T, 1249 G>A and 3972 C>T)... In conclusion, cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.",A,ALDH3A1*2,ALDH3A1,1
3416,bc_id3489,CANCER,ABCB1,20102361,B,Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.,2010,", cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.","Sixty-eight female breast cancer patients were included. All received FAC chemotherapy. Relevant genotyping was done either through restriction fragment length polymorphism or pyrosequencing. The variant allele frequencies were: 5.1% for CYP2C9*2 (430C>T), 15.4% for CYP2C9*3 (1075A>C), 27.2% for CYP2C19*2 (681G>A), 33.1% for GSTA1*B (-69C>T, -52G>A), 62.5% for ALDH3A1*2 (985C>G), 58.8% and 4.4% for ABCB1 (2677 G>T/A), 64.7% for ABCB1 3435 C>T, and 15.4%, 33.1% and 39.7% for ABCC2 (-24 C>T, 1249 G>A and 3972 C>T)... In conclusion, cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.",A,ABCB1,ABCB1,0.6875
3417,bc_id3490,CANCER,CYP2C9,20102361,B,Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.,2010,", cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.","Sixty-eight female breast cancer patients were included. All received FAC chemotherapy. Relevant genotyping was done either through restriction fragment length polymorphism or pyrosequencing. The variant allele frequencies were: 5.1% for CYP2C9*2 (430C>T), 15.4% for CYP2C9*3 (1075A>C), 27.2% for CYP2C19*2 (681G>A), 33.1% for GSTA1*B (-69C>T, -52G>A), 62.5% for ALDH3A1*2 (985C>G), 58.8% and 4.4% for ABCB1 (2677 G>T/A), 64.7% for ABCB1 3435 C>T, and 15.4%, 33.1% and 39.7% for ABCC2 (-24 C>T, 1249 G>A and 3972 C>T)... In conclusion, cyclophosphamide activation and detoxification of reactive intermediates may be altered in the Pakistani.",A,CYP2C9*3,CYP2C9,1
3418,bc_id3491,CANCER,PIK3CA,20107891,B,Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.,2010,,These data demonstrate feasibility and potential utility of cfDNA for PIK3CA mutation detection in patients with metastatic breast cancer. Studies are underway to qualify PIK3CA mutation in cfDNA as a predictive biomarker allowing patient stratification in clinical trials of mechanism-based therapeutics that target PI3K signalling pathways.,A,PIK3CA,PIK3CA,0.466666667
3419,bc_id3492,CANCER,MTR,20111902,B,"Methionine synthase A2756G polymorphism and breast cancer risk: a meta-analysis involving 18,953 subjects.",2010,,"Taken together, the results suggest that the MTR A2756G polymorphism may contribute to susceptibility to breast cancer among Europeans.",A,MTR,MTR,0.222222222
3420,bc_id3493,CANCER,ERCC2,20111903,B,Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis.,2010,,"The study provided 11,362/10,622 cases/controls for XPD K751Q and 9010/9873 cases/controls for XPD D312N, respectively... In summary, our meta-analysis suggested 312N allele might act as a recessive allele in its association with breast cancer and the 751Q allele may play a plausible role in breast cancer development whereas the ethnic background should be carefully concerned in further studies.",A,XPD,ERCC2,0.6875
3421,bc_id3494,CANCER,TP53,20127978,B,Genetic diagnosis of familial breast cancer using clonal sequencing.,2010,,X,X,X,X,0
3422,bc_id3495,CANCER,BRCA2,20127978,B,Genetic diagnosis of familial breast cancer using clonal sequencing.,2010,,"Using conventional Sanger sequencing as a reference standard, we compared the sensitivity, specificity, and capacity of the Illumina GA II platform for the detection of TP53, BRCA1, and BRCA2 mutations in established tumor cell lines and DNA from patients with germline mutations... These improvements open the possibility of BRCA1/2 testing for a wider spectrum of at-risk women, and will allow the genetic classification of tumors prior to the use of novel PARP inhibitors to treat BRCA-deficient breast cancers.",A,BRCA2,BRCA2,0.576923077
3423,bc_id3496,CANCER,BRCA1,20127978,B,Genetic diagnosis of familial breast cancer using clonal sequencing.,2010,,"Using conventional Sanger sequencing as a reference standard, we compared the sensitivity, specificity, and capacity of the Illumina GA II platform for the detection of TP53, BRCA1, and BRCA2 mutations in established tumor cell lines and DNA from patients with germline mutations... These improvements open the possibility of BRCA1/2 testing for a wider spectrum of at-risk women, and will allow the genetic classification of tumors prior to the use of novel PARP inhibitors to treat BRCA-deficient breast cancers.",A,BRCA1,BRCA1,0.60944206
3424,bc_id3497,CANCER,BRCA2,20130978,B,Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study.,2010,"For two reproductive factors previously shown to be associated with CBC risk, we observed similar associations for BRCA1/2 carriers. This suggests that reproductive variables that affect CBC risk may have similar effects in mutation carriers and non-carriers.",X,X,X,X,0
3425,bc_id3498,CANCER,BRCA1,20130978,B,Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study.,2010,"For two reproductive factors previously shown to be associated with CBC risk, we observed similar associations for BRCA1/2 carriers. This suggests that reproductive variables that affect CBC risk may have similar effects in mutation carriers and non-carriers.",X,X,X,X,0
3426,bc_id3499,CANCER,COMT,20130981,B,COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case-control studies.,2010,,"There was no between-study heterogeneity. In conclusion, COMT Val158Met polymorphism may be a low-penetrant risk factor for breast cancer development in European population.",A,COMT,COMT,0.425531915
3427,bc_id3500,CANCER,BRCA2,20130984,B,Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer.,2010,,"These improvements open the possibility of BRCA1/2 testing for a wider spectrum of at-risk women, and will allow the genetic classification of tumors prior to the use of novel PARP inhibitors to treat BRCA-deficient breast cancers.",A,BRCA1/2,BRCA2,0.576923077
3428,bc_id3501,CANCER,BRCA1,20130984,B,Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer.,2010,,"These improvements open the possibility of BRCA1/2 testing for a wider spectrum of at-risk women, and will allow the genetic classification of tumors prior to the use of novel PARP inhibitors to treat BRCA-deficient breast cancers.",A,BRCA1/2,BRCA1,0.60944206
3429,bc_id3502,CANCER,ERBB2,20130985,B,"Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.",2010,,No interaction was observed between HER2 or TOP2A status and IDD chemotherapy. TOP2A gene amplification may define a subset of HER2-amplified breast cancers that are responsible for the markedly improved chemosensitivity seen in HER2-positive breast cancer.,A,HER2,ERBB2,0.452380952
3430,bc_id3503,CANCER,TOP2A,20130985,B,"Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.",2010,,No interaction was observed between HER2 or TOP2A status and IDD chemotherapy. TOP2A gene amplification may define a subset of HER2-amplified breast cancers that are responsible for the markedly improved chemosensitivity seen in HER2-positive breast cancer.,A,TOP2A,TOP2A,0.5
3431,bc_id3504,CANCER,CYP19A1,20133979,B,CYP17 (T-34C) and CYP19 (Trp39Arg) Polymorphisms and their Cooperative Effects on Breast Cancer Susceptibility.,2010,"The results were consistent with the individual studies of CYP17 and CYP19 in the literature, however, in combined analysis of the alleles of the two genes, the frequency of high risk alleles was higher and the frequencies of low risk alleles were lower in the patient group. The CYP17 A1 + CYP19 TT haplotype may be protective for breast cancer.",The CYP17 A1 + CYP19 TT haplotype may be protective for breast cancer.,A,CYP19,CYP19A1,0.484848485
3432,bc_id3505,CANCER,CYP17A1,20133979,B,CYP17 (T-34C) and CYP19 (Trp39Arg) Polymorphisms and their Cooperative Effects on Breast Cancer Susceptibility.,2010,"The results were consistent with the individual studies of CYP17 and CYP19 in the literature, however, in combined analysis of the alleles of the two genes, the frequency of high risk alleles was higher and the frequencies of low risk alleles were lower in the patient group. The CYP17 A1 + CYP19 TT haplotype may be protective for breast cancer.",The CYP17 A1 + CYP19 TT haplotype may be protective for breast cancer.,A,CYP17 A1,CYP17A1,0.466666667
3433,bc_id3506,CANCER,BRCA2,20134318,B,Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers: Very Low Risk for Subsequent Breast Cancer.,2010,"One invasive breast cancer in 147 bilateral prophylactic mastectomies (0.7%) was detected, this makes a sentinel node procedure redundant and preoperative imaging vital. The prophylactic procedure is highly effective in preventing invasive breast cancer in BRCA1/2 mutation carriers. Since the remaining risk is less than 0.2%/woman-year, continued surveillance of the asymptomatic carriers is not warranted.","In one asymptomatic BRCA2 carrier (0.7%) an occult small invasive breast cancer was diagnosed, while in 6 asymptomatic carriers (4.0% BRCA1 and 4.3% BRCA2) and in 5 symptomatic carriers (2.5% BRCA1 and 10.7% BRCA2) DCIS was detected at prophylactic mastectomy.",A,BRCA2,BRCA2,0.576923077
3434,bc_id3507,CANCER,BRCA1,20134318,B,Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers: Very Low Risk for Subsequent Breast Cancer.,2010,"One invasive breast cancer in 147 bilateral prophylactic mastectomies (0.7%) was detected, this makes a sentinel node procedure redundant and preoperative imaging vital. The prophylactic procedure is highly effective in preventing invasive breast cancer in BRCA1/2 mutation carriers. Since the remaining risk is less than 0.2%/woman-year, continued surveillance of the asymptomatic carriers is not warranted.","In one asymptomatic BRCA2 carrier (0.7%) an occult small invasive breast cancer was diagnosed, while in 6 asymptomatic carriers (4.0% BRCA1 and 4.3% BRCA2) and in 5 symptomatic carriers (2.5% BRCA1 and 10.7% BRCA2) DCIS was detected at prophylactic mastectomy.",A,BRCA1,BRCA1,0.60944206
3435,bc_id3508,CANCER,MTHFR,20135343,B,"Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls.",2010,,It can be concluded that potentially functional MTHFR C677T polymorphism may play a low penetrance role in the development of breast cancer.,A,MTHFR,MTHFR,0.403846154
3436,bc_id3509,CANCER,BRCA2,20135344,B,Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.,2010,,"Overall, we did not observe a difference in the relative risk reduction associated with adjuvant treatment between BRCA1/BRCA2 mutation carriers and non-carriers. However, given the higher absolute CBC risk in mutation carriers, the potentially greater impact of adjuvant therapy in reducing CBC risk among mutation carriers should be considered when developing treatment plans for these patients.",A,BRCA1/BRCA2,BRCA2,0.576923077
3437,bc_id3510,CANCER,BRCA1,20135344,B,Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.,2010,,"Overall, we did not observe a difference in the relative risk reduction associated with adjuvant treatment between BRCA1/BRCA2 mutation carriers and non-carriers. However, given the higher absolute CBC risk in mutation carriers, the potentially greater impact of adjuvant therapy in reducing CBC risk among mutation carriers should be considered when developing treatment plans for these patients.",A,BRCA1/BRCA2,BRCA1,0.60944206
3438,bc_id3511,CANCER,BRCA2,20135345,B,"BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects.",2010,,"In conclusion, this meta-analysis suggests that the BRCA2 372H allele may be a low-penetrant risk factor for developing breast cancer.",A,BRCA2,BRCA2,0.576923077
3439,bc_id3512,CANCER,KDR,20135347,B,Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.,2010,,"TNB was an independent prognostic factor for decreased 5-year breast cancer specific survival (BCSS) (HR 2.0 (95% CI 1.1-3.6), P = 0.01), but not for 10-year BCSS. High VEGFR2 expression was significantly correlated to decreased BCSS in TNB patients. TNB was associated with decreased BCSS and clinicopathological characteristics of an aggressive tumor type. High VEGFR2 expression, EGFR expression, and EGFR gene copy number were significantly correlated to TNB, supporting their role as putative candidate biomarkers for selection of targeted therapy in TNB.",A,VEGFR2,KDR,0.5
3440,bc_id3513,CANCER,ERBB2,20135347,B,Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.,2010,,X,X,X,X,0
3441,bc_id3514,CANCER,EGFR,20135347,B,Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.,2010,,X,X,X,X,0
3442,bc_id3515,CANCER,OGG1,20140625,B,"Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women.",2010,"In our study, the 399-Gln allele of XRCC1 increased significantly the risk of BC and it may act as a dominant allele [Arg/Arg vs. (Gln/Gln + Arg/Gln), OR = 4.67 (95% CI 1.65-13.23), p = 0.005]. The combination of variant alleles at codon 399 and in position -77 could affect XRCC1 protein activity, impairing genome integrity and promoting cancer occurrence. Also, the number of SNPs in several genes involved in BER and HRR mechanisms made higher the risk of sporadic BC. We can conclude that genetic variants in multiple repair pathways may have a joint or additive effect in cancer risk.","XRCC1-77T-->C, XRCC1-194, OGG1 and XRCC3 were not associated with BC.",N,OGG1,OGG1,0.333333333
3443,bc_id3516,CANCER,XRCC3,20140625,B,"Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women.",2010,"In our study, the 399-Gln allele of XRCC1 increased significantly the risk of BC and it may act as a dominant allele [Arg/Arg vs. (Gln/Gln + Arg/Gln), OR = 4.67 (95% CI 1.65-13.23), p = 0.005]. The combination of variant alleles at codon 399 and in position -77 could affect XRCC1 protein activity, impairing genome integrity and promoting cancer occurrence. Also, the number of SNPs in several genes involved in BER and HRR mechanisms made higher the risk of sporadic BC. We can conclude that genetic variants in multiple repair pathways may have a joint or additive effect in cancer risk.","XRCC1-77T-->C, XRCC1-194, OGG1 and XRCC3 were not associated with BC.",N,XRCC3,XRCC3,0.269230769
3444,bc_id3517,CANCER,XRCC1,20140625,B,"Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women.",2010,"In our study, the 399-Gln allele of XRCC1 increased significantly the risk of BC and it may act as a dominant allele [Arg/Arg vs. (Gln/Gln + Arg/Gln), OR = 4.67 (95% CI 1.65-13.23), p = 0.005]. The combination of variant alleles at codon 399 and in position -77 could affect XRCC1 protein activity, impairing genome integrity and promoting cancer occurrence. Also, the number of SNPs in several genes involved in BER and HRR mechanisms made higher the risk of sporadic BC. We can conclude that genetic variants in multiple repair pathways may have a joint or additive effect in cancer risk.","XRCC1-77T-->C, XRCC1-194, OGG1 and XRCC3 were not associated with BC.",N,XRCC1,XRCC1,0.217391304
3445,bc_id3519,OTHER,UGT2B7,20142249,B,Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.,2010,Polymorphisms in SULT1A1 and the UGT1A locus may influence percent breast density in premenopausal women.,NR,NR,NR,NR,0
3446,bc_id3520,OTHER,UGT2B4,20142249,B,Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.,2010,Polymorphisms in SULT1A1 and the UGT1A locus may influence percent breast density in premenopausal women.,NR,NR,NR,NR,0
3447,bc_id3521,OTHER,UGT2B15,20142249,B,Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.,2010,Polymorphisms in SULT1A1 and the UGT1A locus may influence percent breast density in premenopausal women.,NR,NR,NR,NR,0
3448,bc_id3522,OTHER,UGT2B17,20142249,B,Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.,2010,Polymorphisms in SULT1A1 and the UGT1A locus may influence percent breast density in premenopausal women.,NR,NR,NR,NR,0
3449,bc_id3523,OTHER,UGT1A3,20142249,B,Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.,2010,Polymorphisms in SULT1A1 and the UGT1A locus may influence percent breast density in premenopausal women.,NR,NR,NR,NR,0
3450,bc_id3524,OTHER,UGT1A1,20142249,B,Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.,2010,Polymorphisms in SULT1A1 and the UGT1A locus may influence percent breast density in premenopausal women.,NR,NR,NR,NR,0
3451,bc_id3525,OTHER,SULT1A1,20142249,B,Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.,2010,Polymorphisms in SULT1A1 and the UGT1A locus may influence percent breast density in premenopausal women.,NR,NR,NR,NR,0
3452,bc_id3526,OTHER,SULT1E1,20142249,B,Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.,2010,Polymorphisms in SULT1A1 and the UGT1A locus may influence percent breast density in premenopausal women.,NR,NR,NR,NR,0
3453,bc_id3527,CANCER,MTHFR,20143151,B,"MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls.",2010,,"In conclusion, this meta-analysis suggests that the MTHFR T allele is a low-penetrant risk factor for developing breast cancer.",Y,MTHFR,MTHFR,0.269230769
3454,bc_id3528,CANCER,TGFB1,20143152,B,"TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects.",2010,,"In conclusion, this meta-analysis suggests that the TGFB1 10P allele may be a low-penetrant risk factor for developing breast cancer.",A,TGFB1,TGFB1,0.518518519
3455,bc_id3529,CANCER,SOD2,20143154,N,"Lack of association between MnSOD Val16Ala polymorphism and breast cancer risk: a meta-analysis involving 58,448 subjects.",2010,,X,X,X,X,0
3456,bc_id3530,CANCER,NBN,20143155,B,NBS1 8360G &gt; C polymorphism is associated with breast cancer risk: a meta-analysis.,2010,,"In summary, our meta-analysis strongly suggests the NBS1 8360G > C polymorphism is associated with breast cancer.",Y,NBS1,NBN,0.19047619
3457,bc_id3531,CANCER,CYP19A1,20144226,B,A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.,2010,Our study reveals that the rs4646 polymorphism identifies a subgroup of stage II-III ER/PgR [+] BC patients with poor response to neoadjuvant letrozole and poor prognosis. Testing for the rs4646 polymorphism could be a useful tool in order to orientate the treatment in elderly BC patients.,Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC).,Y,CYP19A1,CYP19A1,0.333333333
3458,bc_id3532,CANCER,MAP3K1,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,"Consistent with their breast cancer associations, rs3817198 (LSP1) and rs13281615 (8q) were associated with dense area and percent dense area (all P(x) and P(c) <0.05), and rs889312 (MAP3K1), rs2107425 (H19), and rs17468277 (CASP8) were marginally associated with dense area (some P(x) or P(c) <0.05)... These findings could help elucidate how those variants and mammographic density measures are associated with breast cancer susceptibility.",A,MAP3K1,MAP3K1,0.272727273
3459,bc_id3533,CANCER,LSP1,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,"Consistent with their breast cancer associations, rs3817198 (LSP1) and rs13281615 (8q) were associated with dense area and percent dense area (all P(x) and P(c) <0.05), and rs889312 (MAP3K1), rs2107425 (H19), and rs17468277 (CASP8) were marginally associated with dense area (some P(x) or P(c) <0.05)... These findings could help elucidate how those variants and mammographic density measures are associated with breast cancer susceptibility.",A,LSP1,LSP1,0.444444444
3460,bc_id3534,CANCER,TOX3,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,X,X,X,X,0
3461,bc_id3535,CANCER,HCN1,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,X,X,X,X,0
3462,bc_id3536,CANCER,H19,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,"Consistent with their breast cancer associations, rs3817198 (LSP1) and rs13281615 (8q) were associated with dense area and percent dense area (all P(x) and P(c) <0.05), and rs889312 (MAP3K1), rs2107425 (H19), and rs17468277 (CASP8) were marginally associated with dense area (some P(x) or P(c) <0.05)... These findings could help elucidate how those variants and mammographic density measures are associated with breast cancer susceptibility.",A,H19,H19,0.5
3463,bc_id3537,CANCER,FGFR2,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,X,X,X,X,0
3464,bc_id3538,CANCER,STXBP4,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,X,X,X,X,0
3465,bc_id3539,CANCER,NEK10,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,X,X,X,X,0
3466,bc_id3540,CANCER,CASP8,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,"Consistent with their breast cancer associations, rs3817198 (LSP1) and rs13281615 (8q) were associated with dense area and percent dense area (all P(x) and P(c) <0.05), and rs889312 (MAP3K1), rs2107425 (H19), and rs17468277 (CASP8) were marginally associated with dense area (some P(x) or P(c) <0.05)... These findings could help elucidate how those variants and mammographic density measures are associated with breast cancer susceptibility.",A,CASP8,CASP8,0.285714286
3467,bc_id3541,CANCER,SLC4A7,20145138,B,Common genetic variants associated with breast cancer and mammographic density measures that predict disease.,2010,,X,X,X,X,0
3468,bc_id3542,CANCER,FGFR4,20147743,B,FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.,2010,We provide the evidence that FGFR4 388Arg is an independent predictor of pCR following AC-Doc as NCT in PBC.,We provide the evidence that FGFR4 388Arg is an independent predictor of pCR following AC-Doc as NCT in PBC.,Y,FGFR4,FGFR4,0.6
3469,bc_id3543,CANCER,BRCA1,20149218,B,Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.,2010,BRCA1 carriers who are older at first breast cancer diagnosis are more likely to have ER+ tumors than younger BRCA1 carriers. These ER+ cancers appear pathologically intermediate between ER- BRCA1 cancers and ER+ sporadic breast cancers raising the possibility that either some ER+ BRCA1 cancers are incidental or that there is a unique mechanism by which these cancers develop.,BRCA1 carriers who are older at first breast cancer diagnosis are more likely to have ER+ tumors than younger BRCA1 carriers. These ER+ cancers appear pathologically intermediate between ER- BRCA1 cancers and ER+ sporadic breast cancers raising the possibility that either some ER+ BRCA1 cancers are incidental or that there is a unique mechanism by which these cancers develop.,A,BRCA1,BRCA1,0.60944206
3470,bc_id3544,CANCER,COMT,20150638,B,Association of COMT haplotypes and breast cancer risk in caucasian women.,2010,,These results suggest that genetic variation in COMT has no significant association with breast cancer risk among Caucasian women.,N,COMT,COMT,0.29787234
3471,bc_id3545,CANCER,HSD17B1,20151320,B,"The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects.",2010,", this study suggests that HSD17B1 312Gly allele may be a protective factor for breast cancer development in Caucasians.","In conclusion, this study suggests that HSD17B1 312Gly allele may be a protective factor for breast cancer development in Caucasians.",A,HSD17B1,HSD17B1,0.454545455
3472,bc_id3546,CANCER,BRCA2,20151938,B,BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.,2010,"The founder mutation, BRCA1 3171ins5, explains the excess of ovarian cancer after breast cancer in the region. From the relative frequency of the studied mutations found at the cancer genetic counselling clinic, it is estimated that BRCA1 gene mutations are associated with about 80-85% of the excess cases. This means that a negative screening for these mutations in similar cases may have a predictive value and could strongly reduce the risk of ovarian cancer in relatives.",X,X,X,X,0
3473,bc_id3547,CANCER,BRCA1,20151938,B,BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.,2010,"The founder mutation, BRCA1 3171ins5, explains the excess of ovarian cancer after breast cancer in the region. From the relative frequency of the studied mutations found at the cancer genetic counselling clinic, it is estimated that BRCA1 gene mutations are associated with about 80-85% of the excess cases. This means that a negative screening for these mutations in similar cases may have a predictive value and could strongly reduce the risk of ovarian cancer in relatives.","The founder mutation, BRCA1 3171ins5, explains the excess of ovarian cancer after breast cancer in the region.",A,BRCA1,BRCA1,0.60944206
3474,bc_id3548,CANCER,TGFB1,20157775,B,"TGFB1 T29C polymorphism and breast cancer risk: a meta-analysis based on 10,417 cases and 11,455 controls.",2010,,"In conclusion, the present meta-analysis suggests that the TGFB1 T29C polymorphism is not a low-penetrant risk factor for developing breast cancer.",N,TGFB1,TGFB1,0.296296296
3475,bc_id3549,CANCER,PIK3CA,20177704,B,"Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.",2010,"Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.","Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.",A,PIK3CA,PIK3CA,0.466666667
3476,bc_id3550,CANCER,ATM,20177704,B,"Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.",2010,"Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.","Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.",A,ATM,ATM,0.422222222
3477,bc_id3551,CANCER,ERBB2,20177704,B,"Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.",2010,"Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.","Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.",A,HER2,ERBB2,0.452380952
3478,bc_id3552,CANCER,TP53,20177704,B,"Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.",2010,"Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.","Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.",A,p53,TP53,0.482758621
3479,bc_id3553,CANCER,BRCA1,20177704,B,"Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.",2010,"Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.","Our data indicated that p53, BRCA1, ATM, PIK3CA, and HER2 alterations specifically correlate with clinicopathological characteristics of Bulgarian patients with breast cancer. Of these genes, only mutated p53 showed significant, though not independent, negative effect on overall survival.",A,BRCA1,BRCA1,0.60944206
3480,bc_id3554,CANCER,ABCB1,20179710,B,Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.,2010,"Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.","Germ line DNA samples from 230 patients with breast cancer on AC therapy were genotyped for the following SNPs: ABCB1 C1236T, G2677T/A and C3435T, SLC22A16 A146G, T312C, T755C and T1226C, CYP2B6*2, *8, *9, *3, *4 and *5, CYP2C9*2 and *3, CYP3A5*3 and CYP2C19*2. Clinical data on survival, toxicity, demographics and pathology were collated... Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.",Y,ABCB1,ABCB1,0.1875
3481,bc_id3555,CANCER,CYP3A5,20179710,B,Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.,2010,"Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.",X,X,X,X,0
3482,bc_id3556,CANCER,CYP2C9,20179710,B,Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.,2010,"Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.",X,X,X,X,0
3483,bc_id3557,CANCER,CYP2C19,20179710,B,Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.,2010,"Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.",X,X,X,X,0
3484,bc_id3558,CANCER,CYP2B6,20179710,B,Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.,2010,"Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.","Germ line DNA samples from 230 patients with breast cancer on AC therapy were genotyped for the following SNPs: ABCB1 C1236T, G2677T/A and C3435T, SLC22A16 A146G, T312C, T755C and T1226C, CYP2B6*2, *8, *9, *3, *4 and *5, CYP2C9*2 and *3, CYP3A5*3 and CYP2C19*2. Clinical data on survival, toxicity, demographics and pathology were collated... Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.",Y,CYP2B6,CYP2B6,0.5
3485,bc_id3559,CANCER,SLC22A16,20179710,B,Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.,2010,"Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.","Germ line DNA samples from 230 patients with breast cancer on AC therapy were genotyped for the following SNPs: ABCB1 C1236T, G2677T/A and C3435T, SLC22A16 A146G, T312C, T755C and T1226C, CYP2B6*2, *8, *9, *3, *4 and *5, CYP2C9*2 and *3, CYP3A5*3 and CYP2C19*2. Clinical data on survival, toxicity, demographics and pathology were collated... Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.",Y,SLC22A16,SLC22A16,1
3486,bc_id3560,CANCER,NAT2,20180012,B,NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis.,2010,,"In conclusion, this meta-analysis suggested that there is overall lack of association between NAT2 genotypes and breast cancer risk, however, NAT2 polymorphisms when combining with heavy smoking history may contribute to breast cancer susceptibility.",A,NAT2,NAT2,0.259259259
3487,bc_id3561,CANCER,NAT2,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,"Twenty-seven single nucleotide polymorphisms (SNPs) in the MTR, MTRR, MTHFR, TYMS, ADH1C, ALDH2, GSTP1, NAT1, NAT2, CYP2E1 DRD2, DRD3, and SLC6A4 were genotyped... Increased risk was observed for homozygotes at the MTR SNPs (rs1770449 and rs1050993) with the OR = 2.21 (95% CI 1.18-4.16) and OR = 2.24 (95% CI 1.19-4.22), respectively. A stratified analysis by menopausal status indicated the association between the NAT2 SNP (rs1799930) and breast cancer was mainly evident in premenopausal women (OR 2.70, 95% CI 1.20-6.07), while the MTRR SNP (rs162049) was significant in postmenopausal women (OR 1.61, 95% CI 1.07-2.44). Furthermore, SNPs of the genes that contribute to alcohol behavior, DRD3 (rs167770), DRD2 (rs10891556), and SLC6A4 (rs140701), were also associated with an increased risk of breast cancer.",Y,NAT2,NAT2,0.37037037
3488,bc_id3562,CANCER,NAT1,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,"Twenty-seven single nucleotide polymorphisms (SNPs) in the MTR, MTRR, MTHFR, TYMS, ADH1C, ALDH2, GSTP1, NAT1, NAT2, CYP2E1 DRD2, DRD3, and SLC6A4 were genotyped... Increased risk was observed for homozygotes at the MTR SNPs (rs1770449 and rs1050993) with the OR = 2.21 (95% CI 1.18-4.16) and OR = 2.24 (95% CI 1.19-4.22), respectively. A stratified analysis by menopausal status indicated the association between the NAT2 SNP (rs1799930) and breast cancer was mainly evident in premenopausal women (OR 2.70, 95% CI 1.20-6.07), while the MTRR SNP (rs162049) was significant in postmenopausal women (OR 1.61, 95% CI 1.07-2.44). Furthermore, SNPs of the genes that contribute to alcohol behavior, DRD3 (rs167770), DRD2 (rs10891556), and SLC6A4 (rs140701), were also associated with an increased risk of breast cancer.",A,NAT1,NAT1,0.2
3489,bc_id3563,CANCER,MTRR,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,"Twenty-seven single nucleotide polymorphisms (SNPs) in the MTR, MTRR, MTHFR, TYMS, ADH1C, ALDH2, GSTP1, NAT1, NAT2, CYP2E1 DRD2, DRD3, and SLC6A4 were genotyped... Increased risk was observed for homozygotes at the MTR SNPs (rs1770449 and rs1050993) with the OR = 2.21 (95% CI 1.18-4.16) and OR = 2.24 (95% CI 1.19-4.22), respectively. A stratified analysis by menopausal status indicated the association between the NAT2 SNP (rs1799930) and breast cancer was mainly evident in premenopausal women (OR 2.70, 95% CI 1.20-6.07), while the MTRR SNP (rs162049) was significant in postmenopausal women (OR 1.61, 95% CI 1.07-2.44). Furthermore, SNPs of the genes that contribute to alcohol behavior, DRD3 (rs167770), DRD2 (rs10891556), and SLC6A4 (rs140701), were also associated with an increased risk of breast cancer.",Y,MTRR,MTRR,0.333333333
3490,bc_id3564,CANCER,MTR,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,"Twenty-seven single nucleotide polymorphisms (SNPs) in the MTR, MTRR, MTHFR, TYMS, ADH1C, ALDH2, GSTP1, NAT1, NAT2, CYP2E1 DRD2, DRD3, and SLC6A4 were genotyped... Increased risk was observed for homozygotes at the MTR SNPs (rs1770449 and rs1050993) with the OR = 2.21 (95% CI 1.18-4.16) and OR = 2.24 (95% CI 1.19-4.22), respectively. A stratified analysis by menopausal status indicated the association between the NAT2 SNP (rs1799930) and breast cancer was mainly evident in premenopausal women (OR 2.70, 95% CI 1.20-6.07), while the MTRR SNP (rs162049) was significant in postmenopausal women (OR 1.61, 95% CI 1.07-2.44). Furthermore, SNPs of the genes that contribute to alcohol behavior, DRD3 (rs167770), DRD2 (rs10891556), and SLC6A4 (rs140701), were also associated with an increased risk of breast cancer.",Y,MTR,MTR,0.444444444
3491,bc_id3565,CANCER,MTHFR,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,X,X,X,X,0
3492,bc_id3566,CANCER,GSTP1,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,X,X,X,X,0
3493,bc_id3567,CANCER,ALDH2,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,X,X,X,X,0
3494,bc_id3568,CANCER,DRD3,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,"Twenty-seven single nucleotide polymorphisms (SNPs) in the MTR, MTRR, MTHFR, TYMS, ADH1C, ALDH2, GSTP1, NAT1, NAT2, CYP2E1 DRD2, DRD3, and SLC6A4 were genotyped... Increased risk was observed for homozygotes at the MTR SNPs (rs1770449 and rs1050993) with the OR = 2.21 (95% CI 1.18-4.16) and OR = 2.24 (95% CI 1.19-4.22), respectively. A stratified analysis by menopausal status indicated the association between the NAT2 SNP (rs1799930) and breast cancer was mainly evident in premenopausal women (OR 2.70, 95% CI 1.20-6.07), while the MTRR SNP (rs162049) was significant in postmenopausal women (OR 1.61, 95% CI 1.07-2.44). Furthermore, SNPs of the genes that contribute to alcohol behavior, DRD3 (rs167770), DRD2 (rs10891556), and SLC6A4 (rs140701), were also associated with an increased risk of breast cancer.",Y,DRD3,DRD3,1
3495,bc_id3569,CANCER,DRD2,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,"Twenty-seven single nucleotide polymorphisms (SNPs) in the MTR, MTRR, MTHFR, TYMS, ADH1C, ALDH2, GSTP1, NAT1, NAT2, CYP2E1 DRD2, DRD3, and SLC6A4 were genotyped... Increased risk was observed for homozygotes at the MTR SNPs (rs1770449 and rs1050993) with the OR = 2.21 (95% CI 1.18-4.16) and OR = 2.24 (95% CI 1.19-4.22), respectively. A stratified analysis by menopausal status indicated the association between the NAT2 SNP (rs1799930) and breast cancer was mainly evident in premenopausal women (OR 2.70, 95% CI 1.20-6.07), while the MTRR SNP (rs162049) was significant in postmenopausal women (OR 1.61, 95% CI 1.07-2.44). Furthermore, SNPs of the genes that contribute to alcohol behavior, DRD3 (rs167770), DRD2 (rs10891556), and SLC6A4 (rs140701), were also associated with an increased risk of breast cancer.",Y,DRD2,DRD2,0.5
3496,bc_id3570,CANCER,CYP2E1,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,X,X,X,X,0
3497,bc_id3571,CANCER,ADH1C,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,X,X,X,X,0
3498,bc_id3572,CANCER,TYMS,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,X,X,X,X,0
3499,bc_id3573,CANCER,SLC6A4,20180013,B,Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.,2010,,X,X,X,X,0
3500,bc_id3574,CANCER,PALB2,20180015,B,PALB2 mutations in male breast cancer: a population-based study in Central Italy.,2010,,ANF,ANF,ANF,ANF,0
3501,bc_id3575,CANCER,OGG1,20183911,B,Synergistic effects of polymorphisms in DNA repair genes and endogenous estrogen exposure on female breast cancer risk.,2010,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,"Genotyping of polymorphisms of XRCC1 (Arg194Trp and Arg399Gln), OGG1 (Ser326Cys and Arg229Gln), ERCC2 Lys751Gln, ERCC4 Ser662Pro, and ERCC5 His1104Asp was performed and used to evaluate breast cancer susceptibility... This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.",A,OGG1,OGG1,0.444444444
3502,bc_id3576,CANCER,ERCC5,20183911,B,Synergistic effects of polymorphisms in DNA repair genes and endogenous estrogen exposure on female breast cancer risk.,2010,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,"Genotyping of polymorphisms of XRCC1 (Arg194Trp and Arg399Gln), OGG1 (Ser326Cys and Arg229Gln), ERCC2 Lys751Gln, ERCC4 Ser662Pro, and ERCC5 His1104Asp was performed and used to evaluate breast cancer susceptibility... This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.",A,ERCC5,ERCC5,0.666666667
3503,bc_id3577,CANCER,ERCC4,20183911,B,Synergistic effects of polymorphisms in DNA repair genes and endogenous estrogen exposure on female breast cancer risk.,2010,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,"Genotyping of polymorphisms of XRCC1 (Arg194Trp and Arg399Gln), OGG1 (Ser326Cys and Arg229Gln), ERCC2 Lys751Gln, ERCC4 Ser662Pro, and ERCC5 His1104Asp was performed and used to evaluate breast cancer susceptibility... This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.",A,ERCC4,ERCC4,0.5
3504,bc_id3578,CANCER,ERCC2,20183911,B,Synergistic effects of polymorphisms in DNA repair genes and endogenous estrogen exposure on female breast cancer risk.,2010,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,"Genotyping of polymorphisms of XRCC1 (Arg194Trp and Arg399Gln), OGG1 (Ser326Cys and Arg229Gln), ERCC2 Lys751Gln, ERCC4 Ser662Pro, and ERCC5 His1104Asp was performed and used to evaluate breast cancer susceptibility... This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.",A,ERCC2,ERCC2,0.6875
3505,bc_id3579,CANCER,XRCC1,20183911,B,Synergistic effects of polymorphisms in DNA repair genes and endogenous estrogen exposure on female breast cancer risk.,2010,This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.,"Genotyping of polymorphisms of XRCC1 (Arg194Trp and Arg399Gln), OGG1 (Ser326Cys and Arg229Gln), ERCC2 Lys751Gln, ERCC4 Ser662Pro, and ERCC5 His1104Asp was performed and used to evaluate breast cancer susceptibility... This study demonstrates that genotype polymorphisms related to DNA damage repair confer greater susceptibility to endogenous estrogen in the development of breast cancer in women.",A,XRCC1,XRCC1,0.543478261
3506,bc_id3580,CANCER,MUTYH,20191381,B,Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer.,2010,,"Together, our results indicate that heterozygous MUTYH mutations are associated with families that include both breast cancer patients and colorectal cancer patients, independent of which tumour type is more prevalent in the family.",A,MUTYH,MUTYH,0.333333333
3507,bc_id3581,CANCER,HSD17B1,20193327,B,"[Relationship between estrogen-biosynthesis gene (CYP17, CYP19, HSD17beta1) polymorphisms and breast cancer.]",2009,The estrogen-biosynthesis genes CYP17 (T1931C) and HSD17beta1 (A1954G) polymorphism may jointly increase the risk of breast cancer.,"The main effect of CYP17, CYP19 and HSD17beta1 susceptible genotypes were not correlated to breast cancer (OR approximately 1, P > 0.05)... The estrogen-biosynthesis genes CYP17 (T1931C) and HSD17beta1 (A1954G) polymorphism may jointly increase the risk of breast cancer.",A,HSD17beta1,HSD17B1,0.454545455
3508,bc_id3582,CANCER,CYP19A1,20193327,B,"[Relationship between estrogen-biosynthesis gene (CYP17, CYP19, HSD17beta1) polymorphisms and breast cancer.]",2009,The estrogen-biosynthesis genes CYP17 (T1931C) and HSD17beta1 (A1954G) polymorphism may jointly increase the risk of breast cancer.,"The main effect of CYP17, CYP19 and HSD17beta1 susceptible genotypes were not correlated to breast cancer (OR approximately 1, P > 0.05)... The estrogen-biosynthesis genes CYP17 (T1931C) and HSD17beta1 (A1954G) polymorphism may jointly increase the risk of breast cancer.",N,CYP19,CYP19A1,0.181818182
3509,bc_id3583,CANCER,CYP17A1,20193327,B,"[Relationship between estrogen-biosynthesis gene (CYP17, CYP19, HSD17beta1) polymorphisms and breast cancer.]",2009,The estrogen-biosynthesis genes CYP17 (T1931C) and HSD17beta1 (A1954G) polymorphism may jointly increase the risk of breast cancer.,"The main effect of CYP17, CYP19 and HSD17beta1 susceptible genotypes were not correlated to breast cancer (OR approximately 1, P > 0.05)... The estrogen-biosynthesis genes CYP17 (T1931C) and HSD17beta1 (A1954G) polymorphism may jointly increase the risk of breast cancer.",A,CYP17,CYP17A1,0.466666667
3510,bc_id3584,CANCER,NAT2,20197243,B,"Smoking (active and passive), N-acetyltransferase 2, and risk of breast cancer.",2010,"These findings suggest that passive and active smoking may be related to breast cancer, and the effect may be differentially modified by NAT2 phenotype. Further research into the genetic modification of a breast cancer-smoking relationship may help to reconcile earlier discrepant findings.","These findings suggest that passive and active smoking may be related to breast cancer, and the effect may be differentially modified by NAT2 phenotype. Further research into the genetic modification of a breast cancer-smoking relationship may help to reconcile earlier discrepant findings.",A,NAT2,NAT2,0.259259259
3511,bc_id3585,CANCER,PTGS2,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,PTGS2,PTGS2,0.333333333
3512,bc_id3586,CANCER,MTHFR,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,MTHFR,MTHFR,0.326923077
3513,bc_id3587,CANCER,MMP3,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,MMP3,MMP3,0.333333333
3514,bc_id3588,CANCER,MMP1,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,MMP1,MMP1,0.166666667
3515,bc_id3589,CANCER,VEGF,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,VEGF,VEGF,0.5
3516,bc_id3590,CANCER,ITGB3,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,ITGB3,ITGB3,0.666666667
3517,bc_id3591,CANCER,ITGA2,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,ITGA2,ITGA2,0.666666667
3518,bc_id3592,CANCER,IL10,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",A,IL10,IL10,0.625
3519,bc_id3593,CANCER,GNB3,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,X,X,X,X,0
3520,bc_id3594,CANCER,CCND1,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,CCND1,CCND1,0.3125
3521,bc_id3595,CANCER,FASLG,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",A,FAS,FASLG,0.666666667
3522,bc_id3596,CANCER,FAS,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",A,FAS,FAS,0.75
3523,bc_id3597,CANCER,TGFB1,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,TGFB1,TGFB1,0.296296296
3524,bc_id3598,CANCER,SULT1A1,20204402,B,Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.,2010,Our data suggest that the FAS 1377G&gt;A and IL10 592C&gt;A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.,"No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival... Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.",N,SULT1A1,SULT1A1,0.290322581
3525,bc_id3599,CANCER,ERCC2,20204500,B,"XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.",2010,,"In conclusion, this meta-analysis suggests that the XPD 751Gln allele is a low-penetrant risk factor for developing breast cancer.",Y,XPD,ERCC2,0.125
3526,bc_id3600,CANCER,BRCA2,20204502,B,"Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.",2010,,"We show that the incidence of breast and ovarian cancer in BRCA2 mutation carriers and of ovarian cancer in BRCA1 mutation carriers is still high after 60 years. This may justify intensive breast screening as well as oophorectomy even after age 60. The risk of contralateral breast cancer rises approximately 3% per year, which may affect preventive choices.",A,BRCA2,BRCA2,0.576923077
3527,bc_id3601,CANCER,BRCA1,20204502,B,"Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.",2010,,"We show that the incidence of breast and ovarian cancer in BRCA2 mutation carriers and of ovarian cancer in BRCA1 mutation carriers is still high after 60 years. This may justify intensive breast screening as well as oophorectomy even after age 60. The risk of contralateral breast cancer rises approximately 3% per year, which may affect preventive choices.",A,BRCA1,BRCA1,0.60944206
3528,bc_id3602,CANCER,NOS3,20204503,B,The association between two polymorphisms of eNOS and breast cancer risk: a meta-analysis.,2010,significantly decreased risk was observed for E298D (for EE vs.,"In conclusion, this meta-analysis suggests that both eNOS E298D and -786T>C polymorphisms are associated with reduced breast cancer risk.",Y,eNOS,NOS3,0.538461538
3529,bc_id3603,CANCER,LOC643714,20213080,B,Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.,2010,,X,X,X,X,0
3530,bc_id3604,CANCER,PALB2,20213081,B,PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.,2010,,X,X,X,X,0
3531,bc_id3605,CANCER,NAT2,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3532,bc_id3606,CANCER,NAT1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3533,bc_id3607,CANCER,HSD3B1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3534,bc_id3608,CANCER,HSD17B7,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3535,bc_id3609,CANCER,HSD17B4,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3536,bc_id3610,CANCER,HSD17B3,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3537,bc_id3611,CANCER,HSD17B2,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3538,bc_id3612,CANCER,HSD17B1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3539,bc_id3613,CANCER,HSD11B2,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3540,bc_id3614,CANCER,HSD11B1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3541,bc_id3615,CANCER,GSTP1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3542,bc_id3616,CANCER,AKR1C4,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3543,bc_id3617,CANCER,HSD17B8,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3544,bc_id3618,CANCER,NQO1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3545,bc_id3619,CANCER,CYP3A5,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3546,bc_id3620,CANCER,CYP3A4,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3547,bc_id3621,CANCER,CYP1B1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3548,bc_id3622,CANCER,CYP1A2,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3549,bc_id3623,CANCER,CYP1A1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3550,bc_id3624,CANCER,CYP19A1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3551,bc_id3625,CANCER,CYP17A1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3552,bc_id3626,CANCER,CYP11B2,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3553,bc_id3627,CANCER,CYP11A1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3554,bc_id3628,CANCER,COMT,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3555,bc_id3629,CANCER,CYP11B1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3556,bc_id3630,CANCER,UGT2B4,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3557,bc_id3631,CANCER,UGT2B11,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3558,bc_id3632,CANCER,UGT1A9,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3559,bc_id3633,CANCER,UGT1A1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3560,bc_id3634,CANCER,SULT2B1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3561,bc_id3635,CANCER,SULT2A1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3562,bc_id3636,CANCER,SULT1A2,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3563,bc_id3637,CANCER,SULT1A1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3564,bc_id3638,CANCER,STS,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3565,bc_id3639,CANCER,SULT1E1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3566,bc_id3640,CANCER,SRD5A2,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3567,bc_id3641,CANCER,SRD5A1,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3568,bc_id3642,CANCER,SOD2,20214802,B,Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.,2010,"Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen metabolic pathway are associated with mammographic density in postmenopausal women.",X,X,X,X,0
3569,bc_id3643,CANCER,BRCA2,20219108,B,Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.,2010,"Patients belonging to a population with a high probability of being BRCA1 carriers had a better prognosis than those with sporadic BC. Considering these results, women who previously had BC and had survived ten years could be selected for BRCA1 analysis among family members at high risk of hereditary BC during genetic counselling. Since only 30% of patients with a high probability of having hereditary BC have BRCA1 mutations, selecting women with a long term survival among this population could increase the rate of positive analyses, avoiding the use of expensive tests.",X,X,X,X,0
3570,bc_id3644,CANCER,BRCA1,20219108,B,Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.,2010,"Patients belonging to a population with a high probability of being BRCA1 carriers had a better prognosis than those with sporadic BC. Considering these results, women who previously had BC and had survived ten years could be selected for BRCA1 analysis among family members at high risk of hereditary BC during genetic counselling. Since only 30% of patients with a high probability of having hereditary BC have BRCA1 mutations, selecting women with a long term survival among this population could increase the rate of positive analyses, avoiding the use of expensive tests.",One thousand eleven patients at H and IS increased risk were tested for BRCA1/2 mutations... Patients belonging to a population with a high probability of being BRCA1 carriers had a better prognosis than those with sporadic BC.,A,BRCA1,BRCA1,0.60944206
3571,bc_id3645,CANCER,TGFB1,20232138,B,"Association of TGFB1 -509 C&gt;T polymorphism with breast cancer: evidence from a meta-analysis involving 23,579 subjects.",2010,,"Taken together, our results demonstrated that TGFB1 -509 T allele was associated with a reduced risk to develop breast cancer and this allele appeared to act in an additive mode.",Y,TGFB1,TGFB1,0.185185185
3572,bc_id3646,CANCER,TP53,20233677,B,"Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer.",2010,"Our data revealed an association between the G/C genotype and the (NoIns-C) haplotype and the risk of familial breast cancer in Tunisian women. However, these observations need to be confirmed due to the limited statistical power of our study and the small number of cases.",The G13964C intronic variant was significantly associated with familial breast cancer risk (p=0.0018) while the genotypic distribution was similar for p53 Arg72Pro and Ins16bp in patients and controls.,N,p53,TP53,0.149425287
3573,bc_id3647,CANCER,CRY2,20233903,B,"The Core Circadian Gene Cryptochrome 2 Influences Breast Cancer Risk, Possibly by Mediating Hormone Signaling.",2010,,These findings suggest a role for CRY2 in breast tumorigenesis and provide further evidence that the circadian system may be an important modulator of hormone-related cancer susceptibility.,A,CRY2,CRY2,1
3574,bc_id3648,CANCER,TP53,20234365,B,"Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.",2010,Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those patients aged &lt; or =30 years to be tested.,X,X,X,X,0
3575,bc_id3649,CANCER,BRCA2,20234365,B,"Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.",2010,Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those patients aged &lt; or =30 years to be tested.,X,X,X,X,0
3576,bc_id3650,CANCER,BRCA1,20234365,B,"Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.",2010,Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those patients aged &lt; or =30 years to be tested.,X,X,X,X,0
3577,bc_id3651,CANCER,PTEN,20300775,B,PTEN mutation spectrum in breast cancers and breast hyperplasia.,2010,"The incidence of PTEN mutations is relatively high in patients with sporadic breast cancer in the region of Yunnan, China and exists at the early stage of breast cancer development. The PTEN mutations have significant effect on the expression silencing of PTEN protein indicating the important role of PTEN mutation in carcinogenesis of breast cancers.","The incidence of PTEN mutations is relatively high in patients with sporadic breast cancer in the region of Yunnan, China and exists at the early stage of breast cancer development. The PTEN mutations have significant effect on the expression silencing of PTEN protein indicating the important role of PTEN mutation in carcinogenesis of breast cancers.",A,PTEN,PTEN,0.666666667
3578,bc_id3652,CANCER,FGFR2,20300826,B,Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis.,2010,,This meta-analysis suggests that FGFR2 is likely an important genetic marker contributing to susceptibility of breast cancer.,Y,FGFR2,FGFR2,0.708333333
3579,bc_id3653,CANCER,ATM,20305132,B,"Radiation Exposure, the ATM Gene, and Contralateral Breast Cancer in the Women's Environmental Cancer and Radiation Epidemiology Study.",2010,"Women who carry rare deleterious ATM missense variants and who are treated with radiation may have an elevated risk of developing contralateral breast cancer. However, the rarity of these deleterious missense variants in human populations implies that ATM mutations could account for only a small portion of second primary breast cancers.","Women who carry rare deleterious ATM missense variants and who are treated with radiation may have an elevated risk of developing contralateral breast cancer. However, the rarity of these deleterious missense variants in human populations implies that ATM mutations could account for only a small portion of second primary breast cancers.",A,ATM,ATM,0.422222222
3580,bc_id3654,CANCER,GPX1,20306294,B,GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis.,2010,,"In conclusion, this meta-analysis strongly suggests that GPX1 Pro198Leu polymorphism is not associated with breast cancer risk in Caucasians, and an elevated risk in Africans needs large-scale investigations to confirm.",A,GPX1,GPX1,0.4
3581,bc_id3655,CANCER,TGFB1,20309626,B,Transforming growth factor-beta1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case-control studies.,2010,,It can be concluded that potentially functional TGF-Beta1 T869C polymorphism may play a low penetrance role in breast cancer susceptibility in an ethnicity-specific manner.,A,TGF-Beta1,TGFB1,0.518518519
3582,bc_id3656,CANCER,BRCA2,20309627,B,Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.,2010,,Our data suggest that the risk for breast cancer among BRCA1 or BRCA2 carriers may be modified by reproductive characteristics and alcohol use.,A,BRCA2,BRCA2,0.576923077
3583,bc_id3657,CANCER,BRCA1,20309627,B,Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.,2010,,Our data suggest that the risk for breast cancer among BRCA1 or BRCA2 carriers may be modified by reproductive characteristics and alcohol use.,A,BRCA1,BRCA1,0.60944206
3584,bc_id3658,CANCER,LOC643714,20332101,B,Fine Scale mapping of the breast cancer 16q12 locus.,2010,,"Recent genome-wide association studies have identified a breast cancer susceptibility locus on 16q12 with an unknown biological basis. We used a set of single nucleotide polymorphism (SNP) markers to generate a fine-scale map and narrowed the region of association to a 133 kb DNA segment containing the largely uncharacterized hypothetical gene LOC643714, a short intergenic region and the 5' end of TOX3.",A,LOC643714,LOC643714,0.666666667
3585,bc_id3659,CANCER,TOX3,20332101,B,Fine Scale mapping of the breast cancer 16q12 locus.,2010,,"Recent genome-wide association studies have identified a breast cancer susceptibility locus on 16q12 with an unknown biological basis. We used a set of single nucleotide polymorphism (SNP) markers to generate a fine-scale map and narrowed the region of association to a 133 kb DNA segment containing the largely uncharacterized hypothetical gene LOC643714, a short intergenic region and the 5' end of TOX3.",A,TOX3,TOX3,0.5
3586,bc_id3660,CANCER,ARHGAP10,20332263,B,A Genome-Wide Association Study of Prognosis in Breast Cancer.,2010,"Our data suggest that it is unlikely that there are common germline variants with large effect sizes for breast cancer survival overall (hazard ratio &gt;2). Instead, it is plausible that common variants associated with survival could be specific to tumor subtypes or treatment approaches. New studies, sufficiently powered, are needed to discover new regions associated with survival overall or by subtype or treatment subgroups.","We genotyped the 10 most statistically significant loci (most significant single-nucleotide polymorphism located in ARHGAP10; P = 2.28 x 10(-7)) in 4,335 women diagnosed with invasive breast cancer (38,148 years at risk) in the SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity) breast cancer study... We did not identify any common germline variants associated with breast cancer survival overall.",N,ARHGAP10,ARHGAP10,1
3587,bc_id3661,CANCER,C1QA,20332777,B,Common germ-line polymorphism of C1QA and breast cancer survival.,2010,"Our study results show that rs172378 is linked to a cis-regulatory element affecting gene expression and that allelic preferential expression is altered in tumour samples, but do not support an association between genetic variation in C1QA and breast cancer survival.","Our study results show that rs172378 is linked to a cis-regulatory element affecting gene expression and that allelic preferential expression is altered in tumour samples, but do not support an association between genetic variation in C1QA and breast cancer survival.",N,C1QA,C1QA,0.5
3588,bc_id3662,CANCER,CDKN1A,20349127,B,"The p21 Ser31Arg polymorphism and breast cancer risk: a meta-analysis involving 51,236 subjects.",2010,,X,X,X,X,0
3589,bc_id3663,CANCER,TGFB1,20349130,B,"Transforming growth factorbeta1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.",2010,,"Conclusively, this meta-analysis strongly suggests that TGFB1 L10P polymorphism may play a low penetrance role in breast cancer susceptibility in Caucasian. Large well-designed epidemiological studies will be necessary to validate the risk identified in the current meta-analysis.",A,TGFB1,TGFB1,0.518518519
3590,bc_id3664,CANCER,ADH1C,20350778,B,Interaction between ADH1C Arg(272)Gln and alcohol intake in relation to breast cancer risk suggests that ethanol is the causal factor in alcohol related breast cancer.,2010,,"Among variant allele carriers of ADH1C Arg(272)Gln, alcohol intake increased the risk of breast cancer with 14% (95% CI: 1.04-1.24) per 10g alcohol/day, but not among homozygous wild type carriers (p for interaction=0.06). Thus, slow oxidation of ethanol seemed to be associated with breast cancer risk.",A,ADH1C,ADH1C,0.166666667
3591,bc_id3665,CANCER,AR,20353269,B,"Interaction between estrogens and androgen receptor genes microsatellites, prostate-specific antigen and androgen receptor expressions in breast cancer.",2010,,"We assessed the polymorphic tandem repeats lengths by genotyping, followed by high-resolution denaturing polyacrylamide gel electrophoresis in 163 breast cancers. Immunohistochemistry was performed to assess the expressions of AR, PSA, ER, PR and HER2/neu proteins. Our results showed that PSA was correlated with the length of CA repeats in the 3'-untranslated region of ERbeta, shorter CA repeats being correlated with PSA expression (p=0.03). AR immunoexpression was correlated with CAG repeats on AR gene, higher number of repeats being linked to a higher AR immunoexpression (p=0.04).",A,AR,AR,0.458333333
3592,bc_id3666,CANCER,ESR1,20353269,B,"Interaction between estrogens and androgen receptor genes microsatellites, prostate-specific antigen and androgen receptor expressions in breast cancer.",2010,,X,X,X,X,0
3593,bc_id3667,CANCER,RAD51,20358297,B,"ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.",2011,,"Analysis of these genes may provide important information on the risk factors affecting carcinogenesis. Variations in the ARLTS1, RAD51 and MDM2 genes have been associated with increased risk of different cancer types but for breast cancer the results are not consistent.",A,RAD51,RAD51,0.615384615
3594,bc_id3668,CANCER,MDM2,20358297,B,"ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.",2011,,"Analysis of these genes may provide important information on the risk factors affecting carcinogenesis. Variations in the ARLTS1, RAD51 and MDM2 genes have been associated with increased risk of different cancer types but for breast cancer the results are not consistent.",A,MDM2,MDM2,0.444444444
3595,bc_id3669,CANCER,ARL11,20358297,B,"ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.",2011,,"Analysis of these genes may provide important information on the risk factors affecting carcinogenesis. Variations in the ARLTS1, RAD51 and MDM2 genes have been associated with increased risk of different cancer types but for breast cancer the results are not consistent.",A,ARLTS1,ARL11,0.333333333
3596,bc_id3670,CANCER,TGFB1,20361250,B,Association of a TGF-beta1 gene -509 C/T polymorphism with breast cancer risk: a meta-analysis.,2010,,"Conclusively, this meta-analysis suggests that the TGF-_1 gene -509 T allele polymorphism does not decrease breast cancer risk.",N,TGF-_1,TGFB1,0.296296296
3597,bc_id3671,CANCER,RASSF1,20361264,B,RASSF1A polymorphism in familial breast cancer.,2010,,"Subset analysis demonstrated no association in the BRCA1 (P = 0.26), BRCA2 (P = 0.16) or BRCA negative (P = 0.30) samples. Hence, the RASSF1A p.A331S polymorphism is not confirmed as a significant germline contributor to familial breast cancer susceptibility.",N,RASSF1,RASSF1,0.333333333
3598,bc_id3672,CANCER,BRCA2,20361264,B,RASSF1A polymorphism in familial breast cancer.,2010,,X,X,X,X,0
3599,bc_id3673,CANCER,BRCA1,20361264,B,RASSF1A polymorphism in familial breast cancer.,2010,,X,X,X,X,0
3600,bc_id3674,CANCER,FGFR2,20364400,B,Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer.,2010,,"In conclusion, this meta-analysis suggests that rs2981582, rs1219648, and rs2420946 polymorphisms in FGFR2 are associated with elevated BC risk.",Y,FGFR2,FGFR2,0.708333333
3601,bc_id3675,CANCER,SLC6A3,20367960,B,[Association analysis between polymorphism of dopamine transporter variable number tandem repeat and breast cancer with abnormal Hilit.],2010,The 10-repeats allele and 10/10 genotype of 40 bp VNTR polymorphism of DAT1 may increase the risk of breast cancer with Uighur medicine abnormal Hilit in Chinese Han population from Xinjiang province and it is not correlated with the susceptibility to breast cancer with Uighur medicine abnormal Sapra Hilit.,The 10-repeats allele and 10/10 genotype of 40 bp VNTR polymorphism of DAT1 may increase the risk of breast cancer with Uighur medicine abnormal Hilit in Chinese Han population from Xinjiang province and it is not correlated with the susceptibility to breast cancer with Uighur medicine abnormal Sapra Hilit.,A,DAT1,SLC6A3,1
3602,bc_id3676,CANCER,BRCA2,20368571,B,Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.,2010,The risks of subsequent contralateral breast cancer are substantial for women who carry a BRCA1/BRCA2 mutation. These findings have important clinical relevance regarding the assessment of BRCA1/BRCA2 status in patients with breast cancer and the counseling and clinical management of patients found to carry a mutation.,The risks of subsequent contralateral breast cancer are substantial for women who carry a BRCA1/BRCA2 mutation. These findings have important clinical relevance regarding the assessment of BRCA1/BRCA2 status in patients with breast cancer and the counseling and clinical management of patients found to carry a mutation.,A,BRCA2,BRCA2,0.576923077
3603,bc_id3677,CANCER,BRCA1,20368571,B,Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.,2010,The risks of subsequent contralateral breast cancer are substantial for women who carry a BRCA1/BRCA2 mutation. These findings have important clinical relevance regarding the assessment of BRCA1/BRCA2 status in patients with breast cancer and the counseling and clinical management of patients found to carry a mutation.,The risks of subsequent contralateral breast cancer are substantial for women who carry a BRCA1/BRCA2 mutation. These findings have important clinical relevance regarding the assessment of BRCA1/BRCA2 status in patients with breast cancer and the counseling and clinical management of patients found to carry a mutation.,A,BRCA1,BRCA1,0.60944206
3604,bc_id3678,CANCER,MTHFR,20371218,B,"TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.",2010,Our data indicate that breast cancer patients with the C/C variant may present multifocal tumour most frequently.,"The distribution of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms was investigated in 80 consecutive breast cancer patients treated with adjuvant chemotherapy... Our data indicate that breast cancer patients with the C/C variant may present multifocal tumour most frequently.",A,MTHFR,MTHFR,0.403846154
3605,bc_id3679,CANCER,ABCB1,20371218,B,"TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.",2010,Our data indicate that breast cancer patients with the C/C variant may present multifocal tumour most frequently.,X,X,X,X,0
3606,bc_id3680,CANCER,TYMS,20371218,B,"TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.",2010,Our data indicate that breast cancer patients with the C/C variant may present multifocal tumour most frequently.,"The distribution of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms was investigated in 80 consecutive breast cancer patients treated with adjuvant chemotherapy... Our data indicate that breast cancer patients with the C/C variant may present multifocal tumour most frequently.",A,TYMS,TYMS,0.7
3607,bc_id3681,CANCER,BRCA2,20376556,B,Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis.,2010,,"This study aimed to compare overall and disease-free breast cancer survival rates between BRCA1/2 mutation carriers and non-carriers for short-term and long-term outcomes separately... Our results suggest that BRCA1 mutation decreases short-term and long-term OSRs and short-term PFSR, however, BRCA2 mutation does not affect either short-term or long-term survival rate, which is attributed to the different carcinogenic pathways for BRCA1 and BRCA2.",A,BRCA2,BRCA2,0.576923077
3608,bc_id3682,CANCER,BRCA1,20376556,B,Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis.,2010,,"This study aimed to compare overall and disease-free breast cancer survival rates between BRCA1/2 mutation carriers and non-carriers for short-term and long-term outcomes separately... Our results suggest that BRCA1 mutation decreases short-term and long-term OSRs and short-term PFSR, however, BRCA2 mutation does not affect either short-term or long-term survival rate, which is attributed to the different carcinogenic pathways for BRCA1 and BRCA2.",A,BRCA1,BRCA1,0.60944206
3609,bc_id3683,CANCER,ERCC2,20379847,B,"Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer.",2010,", our results suggest null associations of both polymorphisms in the overall and the Caucasian subgroups, although some effects can be suggested for relatively smaller minority studies.","Several polymorphisms in the ERCC2 gene have been described, including the commonly occurring Lys751Gln and Asp312Asn polymorphisms. Studies investigating the association of these polymorphisms with breast cancer risk produced controversial results.",A,ERCC2,ERCC2,0.6875
3610,bc_id3684,CANCER,ERBB2,20380571,B,P53 Codon 72 and HER2 Codon 655 Polymorphisms in Turkish Breast Cancer Patients.,2010,,"With the exception of association between the P53 codon 72 polymorphism and tumor stages (p = 0.026), there was no significant association between the studied polymorphisms and clinicopathological characteristics. The P53 gene codon 72 Arg/Pro and Her2 gene Ile655Val polymorphisms were not associated with the risk of breast cancer in Turkish women.",N,Her2,ERBB2,0.261904762
3611,bc_id3685,CANCER,TP53,20380571,B,P53 Codon 72 and HER2 Codon 655 Polymorphisms in Turkish Breast Cancer Patients.,2010,,The P53 gene codon 72 Arg/Pro and Her2 gene Ile655Val polymorphisms were not associated with the risk of breast cancer in Turkish women.,N,P53,TP53,0.149425287
3612,bc_id3686,CANCER,KRAS,20385028,B,Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.,2010,"This study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which overexpress EGFR in about 60% of all cases.","This study indicates that KRAS mutations are very infrequent in triple-negative breast tumors and that EGFR inhibitors may be of potential benefit in the treatment of basal-like breast tumors, which overexpress EGFR in about 60% of all cases.",A,KRAS,KRAS,1
3613,bc_id3687,CANCER,RAD51,20396943,B,"RAD51 135G&gt;C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26,444 subjects.",2010,,"In summary, our meta-analysis suggested the RAD51 135G > C polymorphism may contribute to breast cancer susceptibility.",A,RAD51,RAD51,0.615384615
3614,bc_id3688,CANCER,ERBB2,20401632,B,HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies.,2010,,"In conclusion, our meta-analysis suggests that HER2 Ile 655Val polymorphism may contribute to breast cancer risk.",A,HER2,ERBB2,0.452380952
3615,bc_id3689,CANCER,CXCL12,20406099,B,CXCL12-3' G801A Polymorphism Is Not a Risk Factor for Breast Cancer.,2010,,Our investigation did not support the CXCL12-3'A gene variant as a risk factor for breast cancer incidence in a sample of the Polish population.,N,CXCL12-3',CXCL12,0.333333333
3616,bc_id3690,CANCER,LOC643714,20406955,B,Polymorphisms in the TOX3/LOC643714 Locus and Risk of Breast Cancer in African-American Women.,2010,The results narrow the locus to a smaller linkage disequilibrium block in the LOC643714 gene.,"We evaluated a total of 60 tagging SNPs throughout the TOX3/LOC643714 region in a nested case-control study of breast cancer within the Black Women's Health Study, which included 906 cases and 1,111 controls... Our results confirm the association observed in genome-wide association studies of European ancestry populations.",A,LOC643714,LOC643714,0.666666667
3617,bc_id3691,CANCER,TOX3,20406955,B,Polymorphisms in the TOX3/LOC643714 Locus and Risk of Breast Cancer in African-American Women.,2010,The results narrow the locus to a smaller linkage disequilibrium block in the LOC643714 gene.,"We evaluated a total of 60 tagging SNPs throughout the TOX3/LOC643714 region in a nested case-control study of breast cancer within the Black Women's Health Study, which included 906 cases and 1,111 controls... Our results confirm the association observed in genome-wide association studies of European ancestry populations.",A,TOX3,TOX3,0.5
3618,bc_id3692,CANCER,XRCC1,20411322,B,"Haplotype analysis of XRCC1 (at codons 194 and 399) and susceptibility to breast cancer, a meta-analysis of the literatures.",2010,,The present meta-analysis has indicated that the Arg194-Gln399 haplotype of XRCC1 might be a risk factor for breast cancer in Asian countries.,A,XRCC1,XRCC1,0.543478261
3619,bc_id3693,CANCER,BRCA2,20411323,B,Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.,2010,,"In conclusion, BRCA1/2 mutation carriers with breast cancer have similar survival whether treated with M or BCT.",A,BRCA1/2,BRCA2,0.576923077
3620,bc_id3694,CANCER,BRCA1,20411323,B,Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.,2010,,"In conclusion, BRCA1/2 mutation carriers with breast cancer have similar survival whether treated with M or BCT.",A,BRCA1/2,BRCA1,0.60944206
3621,bc_id3695,CANCER,MTRR,20411324,B,MTRR A66G polymorphism and breast cancer risk: a meta-analysis.,2010,,"In conclusion, this meta-analysis strongly suggests that MTRR A66G polymorphism is not associated with breast cancer risk, especially in Caucasians and Asians.",N,MTRR,MTRR,0.666666667
3622,bc_id3696,CANCER,BRCA1,20413709,B,A BRCA1 promoter variant (rs11655505) and breast cancer risk.,2010,Our study failed to confirm a role of rs11655505 in breast cancer risk. Larger studies are necessary to determine if there is a weak association between this SNP and breast cancer risk.,A study of Chinese women recently suggested that the minor allele of rs11655505 in the BRCA1 promoter (c.-2265C-->T) increases promoter activity and has a protective effect on breast cancer risk.,Y,BRCA1,BRCA1,0.326180258
3623,bc_id3697,CANCER,MTHFR,20417243,B,"Breast cancer risk, dietary intake, and methylenetetrahydrofolate reductase (MTHFR)single nucleotide polymorphisms.",2010,of this study suggest that theMTHFR C677T polymorphism may modify the association between dietary intake and breast cancer risk.,Results of this study suggest that theMTHFR C677T polymorphism may modify the association between dietary intake and breast cancer risk.,A,MTHFR,MTHFR,0.403846154
3624,bc_id3698,CANCER,MAP3K1,20417875,B,"Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women.",2010,,ANF,ANF,ANF,ANF,0
3625,bc_id3699,CANCER,LSP1,20417875,B,"Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women.",2010,,ANF,ANF,ANF,ANF,0
3626,bc_id3700,CANCER,TOX3,20417875,B,"Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women.",2010,,ANF,ANF,ANF,ANF,0
3627,bc_id3701,CANCER,FGFR2,20417875,B,"Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women.",2010,,ANF,ANF,ANF,ANF,0
3628,bc_id3702,CANCER,IL17A,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,X,X,X,X,0
3629,bc_id3703,CANCER,IL8,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,X,X,X,X,0
3630,bc_id3704,CANCER,IL6,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,"Five cytokines (IL-1beta, IL-5, TNF-alpha, IL-6 and IL-2) were significantly associated with disease and based on their serum levels, concentrations were higher in the cases than in the controls... Three most statistically significant SNPs were rs2069705, located in the promoter region of the interferon gamma gene (INF-gamma); rs2243248, in the promoter of IL-4 (rs2243248); and rs1800925, in the promoter of the IL-13 gene. Increased serum cytokine levels at diagnosis are indicative for immunological alterations and possibly related to genetic susceptibility markers as well. These findings might guide us to understand the presence of SNPs in cytokine genes and serum concentrations among breast cancer patients and potentially in other cancers.",A,IL-6,IL6,0.285714286
3631,bc_id3705,CANCER,IL5,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,"Five cytokines (IL-1beta, IL-5, TNF-alpha, IL-6 and IL-2) were significantly associated with disease and based on their serum levels, concentrations were higher in the cases than in the controls... Three most statistically significant SNPs were rs2069705, located in the promoter region of the interferon gamma gene (INF-gamma); rs2243248, in the promoter of IL-4 (rs2243248); and rs1800925, in the promoter of the IL-13 gene. Increased serum cytokine levels at diagnosis are indicative for immunological alterations and possibly related to genetic susceptibility markers as well. These findings might guide us to understand the presence of SNPs in cytokine genes and serum concentrations among breast cancer patients and potentially in other cancers.",A,IL-5,IL5,1
3632,bc_id3706,CANCER,IL4,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,"Five cytokines (IL-1beta, IL-5, TNF-alpha, IL-6 and IL-2) were significantly associated with disease and based on their serum levels, concentrations were higher in the cases than in the controls... Three most statistically significant SNPs were rs2069705, located in the promoter region of the interferon gamma gene (INF-gamma); rs2243248, in the promoter of IL-4 (rs2243248); and rs1800925, in the promoter of the IL-13 gene. Increased serum cytokine levels at diagnosis are indicative for immunological alterations and possibly related to genetic susceptibility markers as well. These findings might guide us to understand the presence of SNPs in cytokine genes and serum concentrations among breast cancer patients and potentially in other cancers.",A,IL-4,IL4,0.5
3633,bc_id3707,CANCER,IL2,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,"Five cytokines (IL-1beta, IL-5, TNF-alpha, IL-6 and IL-2) were significantly associated with disease and based on their serum levels, concentrations were higher in the cases than in the controls... Three most statistically significant SNPs were rs2069705, located in the promoter region of the interferon gamma gene (INF-gamma); rs2243248, in the promoter of IL-4 (rs2243248); and rs1800925, in the promoter of the IL-13 gene. Increased serum cytokine levels at diagnosis are indicative for immunological alterations and possibly related to genetic susceptibility markers as well. These findings might guide us to understand the presence of SNPs in cytokine genes and serum concentrations among breast cancer patients and potentially in other cancers.",A,IL-2,IL2,1
3634,bc_id3708,CANCER,IL1B,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,"Five cytokines (IL-1beta, IL-5, TNF-alpha, IL-6 and IL-2) were significantly associated with disease and based on their serum levels, concentrations were higher in the cases than in the controls... Three most statistically significant SNPs were rs2069705, located in the promoter region of the interferon gamma gene (INF-gamma); rs2243248, in the promoter of IL-4 (rs2243248); and rs1800925, in the promoter of the IL-13 gene. Increased serum cytokine levels at diagnosis are indicative for immunological alterations and possibly related to genetic susceptibility markers as well. These findings might guide us to understand the presence of SNPs in cytokine genes and serum concentrations among breast cancer patients and potentially in other cancers.",A,IL-1beta,IL1B,0.4
3635,bc_id3709,CANCER,IL1A,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,X,X,X,X,0
3636,bc_id3710,CANCER,IL13,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,"Five cytokines (IL-1beta, IL-5, TNF-alpha, IL-6 and IL-2) were significantly associated with disease and based on their serum levels, concentrations were higher in the cases than in the controls... Three most statistically significant SNPs were rs2069705, located in the promoter region of the interferon gamma gene (INF-gamma); rs2243248, in the promoter of IL-4 (rs2243248); and rs1800925, in the promoter of the IL-13 gene. Increased serum cytokine levels at diagnosis are indicative for immunological alterations and possibly related to genetic susceptibility markers as well. These findings might guide us to understand the presence of SNPs in cytokine genes and serum concentrations among breast cancer patients and potentially in other cancers.",A,IL-13,IL13,1
3637,bc_id3711,CANCER,IL12A,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,X,X,X,X,0
3638,bc_id3712,CANCER,IL10,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,X,X,X,X,0
3639,bc_id3713,CANCER,IFNG,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,X,X,X,X,0
3640,bc_id3714,CANCER,TNF,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,"Five cytokines (IL-1beta, IL-5, TNF-alpha, IL-6 and IL-2) were significantly associated with disease and based on their serum levels, concentrations were higher in the cases than in the controls... Three most statistically significant SNPs were rs2069705, located in the promoter region of the interferon gamma gene (INF-gamma); rs2243248, in the promoter of IL-4 (rs2243248); and rs1800925, in the promoter of the IL-13 gene. Increased serum cytokine levels at diagnosis are indicative for immunological alterations and possibly related to genetic susceptibility markers as well. These findings might guide us to understand the presence of SNPs in cytokine genes and serum concentrations among breast cancer patients and potentially in other cancers.",A,TNF-alpha,TNF,0.4
3641,bc_id3715,CANCER,TGFB1,20418110,B,Polymorphisms in cytokine genefs and serum cytokine levels among New Mexican women with and without breast cancer.,2010,,X,X,X,X,0
3642,bc_id3716,CANCER,LOC134997,20418484,B,Common variants associated with breast cancer in genome wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2010,,"Eight SNPs in BRCA1 carriers and 12 SNPs in BRCA2 carriers, representing an enrichment over the number expected, were significantly associated with breast cancer risk (P(trend) < 0.01). The minor alleles of rs6138178 in SNRPB and rs6602595 in CAMK1D displayed the strongest associations in BRCA1 carriers (HR = 0.78, 95% CI: 0.69-0.90, P(trend) = 3.6 x 10(-4) and HR = 1.25, 95% CI: 1.10-1.41, P(trend) = 4.2 x 10(-4)), whereas rs9393597 in LOC134997 and rs12652447 in FBXL7 showed the strongest associations in BRCA2 carriers (HR = 1.55, 95% CI: 1.25-1.92, P(trend) = 6 x 10(-5) and HR = 1.37, 95% CI: 1.16-1.62, P(trend) = 1.7 x 10(-4)).",A,LOC134997,LOC134997,1
3643,bc_id3717,CANCER,CAMK1D,20418484,B,Common variants associated with breast cancer in genome wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2010,,"Eight SNPs in BRCA1 carriers and 12 SNPs in BRCA2 carriers, representing an enrichment over the number expected, were significantly associated with breast cancer risk (P(trend) < 0.01). The minor alleles of rs6138178 in SNRPB and rs6602595 in CAMK1D displayed the strongest associations in BRCA1 carriers (HR = 0.78, 95% CI: 0.69-0.90, P(trend) = 3.6 x 10(-4) and HR = 1.25, 95% CI: 1.10-1.41, P(trend) = 4.2 x 10(-4)), whereas rs9393597 in LOC134997 and rs12652447 in FBXL7 showed the strongest associations in BRCA2 carriers (HR = 1.55, 95% CI: 1.25-1.92, P(trend) = 6 x 10(-5) and HR = 1.37, 95% CI: 1.16-1.62, P(trend) = 1.7 x 10(-4)).",A,CAMK1D,CAMK1D,1
3644,bc_id3718,CANCER,FBXL7,20418484,B,Common variants associated with breast cancer in genome wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2010,,"Eight SNPs in BRCA1 carriers and 12 SNPs in BRCA2 carriers, representing an enrichment over the number expected, were significantly associated with breast cancer risk (P(trend) < 0.01). The minor alleles of rs6138178 in SNRPB and rs6602595 in CAMK1D displayed the strongest associations in BRCA1 carriers (HR = 0.78, 95% CI: 0.69-0.90, P(trend) = 3.6 x 10(-4) and HR = 1.25, 95% CI: 1.10-1.41, P(trend) = 4.2 x 10(-4)), whereas rs9393597 in LOC134997 and rs12652447 in FBXL7 showed the strongest associations in BRCA2 carriers (HR = 1.55, 95% CI: 1.25-1.92, P(trend) = 6 x 10(-5) and HR = 1.37, 95% CI: 1.16-1.62, P(trend) = 1.7 x 10(-4)).",A,FBXL7,FBXL7,1
3645,bc_id3719,CANCER,SNRPB,20418484,B,Common variants associated with breast cancer in genome wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2010,,"Eight SNPs in BRCA1 carriers and 12 SNPs in BRCA2 carriers, representing an enrichment over the number expected, were significantly associated with breast cancer risk (P(trend) < 0.01). The minor alleles of rs6138178 in SNRPB and rs6602595 in CAMK1D displayed the strongest associations in BRCA1 carriers (HR = 0.78, 95% CI: 0.69-0.90, P(trend) = 3.6 x 10(-4) and HR = 1.25, 95% CI: 1.10-1.41, P(trend) = 4.2 x 10(-4)), whereas rs9393597 in LOC134997 and rs12652447 in FBXL7 showed the strongest associations in BRCA2 carriers (HR = 1.55, 95% CI: 1.25-1.92, P(trend) = 6 x 10(-5) and HR = 1.37, 95% CI: 1.16-1.62, P(trend) = 1.7 x 10(-4)).",A,SNRPB,SNRPB,1
3646,bc_id3720,CANCER,BRCA2,20418484,B,Common variants associated with breast cancer in genome wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2010,,"Eight SNPs in BRCA1 carriers and 12 SNPs in BRCA2 carriers, representing an enrichment over the number expected, were significantly associated with breast cancer risk (P(trend) < 0.01). The minor alleles of rs6138178 in SNRPB and rs6602595 in CAMK1D displayed the strongest associations in BRCA1 carriers (HR = 0.78, 95% CI: 0.69-0.90, P(trend) = 3.6 x 10(-4) and HR = 1.25, 95% CI: 1.10-1.41, P(trend) = 4.2 x 10(-4)), whereas rs9393597 in LOC134997 and rs12652447 in FBXL7 showed the strongest associations in BRCA2 carriers (HR = 1.55, 95% CI: 1.25-1.92, P(trend) = 6 x 10(-5) and HR = 1.37, 95% CI: 1.16-1.62, P(trend) = 1.7 x 10(-4)).",Y,BRCA2,BRCA2,0.324175824
3647,bc_id3721,CANCER,BRCA1,20418484,B,Common variants associated with breast cancer in genome wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.,2010,,"Eight SNPs in BRCA1 carriers and 12 SNPs in BRCA2 carriers, representing an enrichment over the number expected, were significantly associated with breast cancer risk (P(trend) < 0.01). The minor alleles of rs6138178 in SNRPB and rs6602595 in CAMK1D displayed the strongest associations in BRCA1 carriers (HR = 0.78, 95% CI: 0.69-0.90, P(trend) = 3.6 x 10(-4) and HR = 1.25, 95% CI: 1.10-1.41, P(trend) = 4.2 x 10(-4)), whereas rs9393597 in LOC134997 and rs12652447 in FBXL7 showed the strongest associations in BRCA2 carriers (HR = 1.55, 95% CI: 1.25-1.92, P(trend) = 6 x 10(-5) and HR = 1.37, 95% CI: 1.16-1.62, P(trend) = 1.7 x 10(-4)).",Y,BRCA1,BRCA1,0.326180258
3648,bc_id3722,CANCER,NOS3,20428939,B,Endothelial nitric oxide synthase (eNOS) 894 G&gt;T polymorphism is associated with breast cancer risk: a meta-analysis.,2010,,"In summary, this meta-analysis primarily suggests that eNOS 894G>T polymorphism is associated with breast cancer.",Y,eNOS,NOS3,0.538461538
3649,bc_id3723,CANCER,ESR1,20429621,B,Estrogen receptor alpha polymorphisms: correlation with clinicopathological parameters in breast cancer.,2010,", we identified four genotypes significantly correlated with either the risk or some tumor characteristics, suggesting that the main selection criteria of the investigated SNPs (frequency and the position in modulating domains of the gene) are pertinent instruments for establish correlations between the gene structure and the tumor phenotype.","Polymorphisms in estrogen receptor alpha gene (ESR1) have been previously associated with breast cancer risk; however, the results were not fully consistent.",A,ESR1,ESR1,0.586956522
3650,bc_id3724,CANCER,AR,20431938,B,Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis.,2010,,"However, larger scale primary study is required to further evaluate the interaction of AR CAG polymorphism and breast cancer risk.",A,AR,AR,0.458333333
3651,bc_id3725,CANCER,HSD17B1,20432167,B,"Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.",2010,,"Four single nucleotide polymorphisms (SNPs) in CYP17 (rs743572), CYP19 (rs10046), 17beta-HSD1 (rs605059), and SHBG (rs6259) genes were genotyped. We found no association between the 4 SNPs and breast cancer risk.",N,17beta-HSD1,HSD17B1,0.363636364
3652,bc_id3726,CANCER,CYP19A1,20432167,B,"Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.",2010,,"Four single nucleotide polymorphisms (SNPs) in CYP17 (rs743572), CYP19 (rs10046), 17beta-HSD1 (rs605059), and SHBG (rs6259) genes were genotyped. We found no association between the 4 SNPs and breast cancer risk.",N,CYP19,CYP19A1,0.181818182
3653,bc_id3727,CANCER,CYP17A1,20432167,B,"Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.",2010,,"Four single nucleotide polymorphisms (SNPs) in CYP17 (rs743572), CYP19 (rs10046), 17beta-HSD1 (rs605059), and SHBG (rs6259) genes were genotyped. We found no association between the 4 SNPs and breast cancer risk.",N,CYP17,CYP17A1,0.266666667
3654,bc_id3728,CANCER,SHBG,20432167,B,"Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.",2010,,"Four single nucleotide polymorphisms (SNPs) in CYP17 (rs743572), CYP19 (rs10046), 17beta-HSD1 (rs605059), and SHBG (rs6259) genes were genotyped. We found no association between the 4 SNPs and breast cancer risk.",N,SHBG,SHBG,0.333333333
3655,bc_id3729,CANCER,IL1B,20437198,B,Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis.,2010,,"Interleukin-1_ (IL-1_), which is involved in inflammatory and immunological responses, plays an important role in the development and progression of breast cancer.",Y,IL-1_,IL1B,0.2
3656,bc_id3730,CANCER,XRCC1,20450747,B,"[Relationship between polymorphisms of X-ray repair cross-complementing group 1 gene Arg194Trp, Arg399Gln and susceptibility of breast cancer.]",2010,The XRCC1 Arg194Trp and Arg399Gln may not play an important role in the susceptibility of breast cancer in Chinese women.,The XRCC1 Arg194Trp and Arg399Gln may not play an important role in the susceptibility of breast cancer in Chinese women.,A,XRCC1,XRCC1,0.543478261
3657,bc_id3731,CANCER,LSP1,20453838,B,Genome-wide association study identifies five new breast cancer susceptibility loci.,2010,,"We also identified SNPs in the 6q25.1 (rs3757318, P = 2.9 x 10(-6)), 8q24 (rs1562430, P = 5.8 x 10(-7)) and LSP1 (rs909116, P = 7.3 x 10(-7)) regions that showed more significant association with risk than those reported previously. Previously identified breast cancer susceptibility loci were also found to show larger effect sizes in this study of familial breast cancer cases than in previous population-based studies, consistent with polygenic susceptibility to the disease.",A,LSP1,LSP1,0.444444444
3658,bc_id3732,CANCER,RAD51,20454923,B,"RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects.",2011,,"In conclusion, this meta-analysis suggests that the RAD51 G135C polymorphism is a low-penetrant risk factor for developing breast cancer.",Y,RAD51,RAD51,0.230769231
3659,bc_id3733,CANCER,GSTT1,20459744,B,Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.,2010,These data support the hypothesis that genetic variability in cyclophosphamide metabolism independently impacts outcome from adjuvant chemotherapy for breast cancer.,X,X,X,X,0
3660,bc_id3734,CANCER,GSTP1,20459744,B,Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.,2010,These data support the hypothesis that genetic variability in cyclophosphamide metabolism independently impacts outcome from adjuvant chemotherapy for breast cancer.,X,X,X,X,0
3661,bc_id3735,CANCER,GSTM1,20459744,B,Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.,2010,These data support the hypothesis that genetic variability in cyclophosphamide metabolism independently impacts outcome from adjuvant chemotherapy for breast cancer.,X,X,X,X,0
3662,bc_id3736,CANCER,CYP3A5,20459744,B,Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.,2010,These data support the hypothesis that genetic variability in cyclophosphamide metabolism independently impacts outcome from adjuvant chemotherapy for breast cancer.,X,X,X,X,0
3663,bc_id3737,CANCER,CYP3A4,20459744,B,Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.,2010,These data support the hypothesis that genetic variability in cyclophosphamide metabolism independently impacts outcome from adjuvant chemotherapy for breast cancer.,X,X,X,X,0
3664,bc_id3738,CANCER,CYP2D6,20459744,B,Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.,2010,These data support the hypothesis that genetic variability in cyclophosphamide metabolism independently impacts outcome from adjuvant chemotherapy for breast cancer.,X,X,X,X,0
3665,bc_id3739,CANCER,CYP2C9,20459744,B,Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.,2010,These data support the hypothesis that genetic variability in cyclophosphamide metabolism independently impacts outcome from adjuvant chemotherapy for breast cancer.,X,X,X,X,0
3666,bc_id3740,CANCER,CYP2B6,20459744,B,Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.,2010,These data support the hypothesis that genetic variability in cyclophosphamide metabolism independently impacts outcome from adjuvant chemotherapy for breast cancer.,X,X,X,X,0
3667,bc_id3742,CANCER,AURKA,20464476,B,"Lack of an association between AURKA T91A polymorphisms and breast cancer: a meta-analysis involving 32,141 subjects.",2011,,"In conclusion, this meta-analysis indicates that the AURKA T91A polymorphism is not a risk factor for developing breast cancer.",N,AURKA,AURKA,0.25
3668,bc_id3743,CANCER,COMT,20464630,N,"Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls.",2010,,"In summary, the meta-analysis strongly suggests that COMT Val108/158Met polymorphism is not associated with increased breast cancer risk.",N,COMT,COMT,0.29787234
3669,bc_id3744,CANCER,PIK3CA,20479250,B,PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.,2010,,These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors.,A,PIK3CA,PIK3CA,0.466666667
3670,bc_id3745,CANCER,BRCA2,20482762,B,Incorporating tumour pathology information into breast cancer risk prediction algorithms.,2010,"This approach combines both full pedigree and tumour subtype data to predict BRCA1/2 carrier probabilities. Prediction of BRCA1/2 carrier status, and hence selection of women for mutation screening, may be substantially improved by combining tumour pathology with family history of cancer.","The cumulative risk of ER-negative breast cancer by age 70 for BRCA1 mutation carriers was estimated to be 55% and the risk of ER-positive disease was 18%. The corresponding risks for BRCA2 mutation carriers were 21% and 44% for ER-negative and ER-positive disease, respectively. The predicted BRCA1 carrier probabilities among ER-positive breast cancer cases were less than 1% at all ages.",A,BRCA2,BRCA2,0.576923077
3671,bc_id3746,CANCER,BRCA1,20482762,B,Incorporating tumour pathology information into breast cancer risk prediction algorithms.,2010,"This approach combines both full pedigree and tumour subtype data to predict BRCA1/2 carrier probabilities. Prediction of BRCA1/2 carrier status, and hence selection of women for mutation screening, may be substantially improved by combining tumour pathology with family history of cancer.","The cumulative risk of ER-negative breast cancer by age 70 for BRCA1 mutation carriers was estimated to be 55% and the risk of ER-positive disease was 18%. The corresponding risks for BRCA2 mutation carriers were 21% and 44% for ER-negative and ER-positive disease, respectively. The predicted BRCA1 carrier probabilities among ER-positive breast cancer cases were less than 1% at all ages.",A,BRCA1,BRCA1,0.60944206
3672,bc_id3747,CANCER,TP53,20482849,B,NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations.,2010,"This is the first study to show that the expression of NOTCH2 differs in subgroups of breast tumors and by genotypes of the breast cancer-associated SNP rs11249433. The NOTCH pathway has key functions in stem cell differentiation of ER+ luminal cells in the breast. Therefore, increased expression of NOTCH2 in carriers of rs11249433 may promote development of ER+ luminal tumors. Further studies are needed to investigate possible mechanisms of regulation of NOTCH2 expression by rs11249433 and the role of NOTCH2 splicing forms in breast cancer development.","Examined in 180 breast tumors, the expression of NOTCH2 was found to be lowest in tumors with TP53 mutations and highest in TP53 wild-type/ER+ tumors (p = 0.0059). In the latter group, the NOTCH2 expression was particularly increased in carriers of the risk genotypes (AG/GG) of rs11249433 when compared to the non-risk AA genotype (p = 0.0062).",A,TP53,TP53,0.482758621
3673,bc_id3748,CANCER,RAD54L,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3674,bc_id3749,CANCER,RAD52,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3675,bc_id3750,CANCER,RAD51L3,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3676,bc_id3751,CANCER,RAD51L1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3677,bc_id3752,CANCER,RAD51C,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3678,bc_id3753,CANCER,RAD51,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3679,bc_id3754,CANCER,RAD50,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3680,bc_id3755,CANCER,RAD23B,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3681,bc_id3756,CANCER,RAD23A,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3682,bc_id3757,CANCER,PRKDC,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3683,bc_id3758,CANCER,POLK,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3684,bc_id3759,CANCER,POLI,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3685,bc_id3760,CANCER,POLE,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3686,bc_id3761,CANCER,POLD1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3687,bc_id3762,CANCER,POLB,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3688,bc_id3763,CANCER,PMS2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3689,bc_id3764,CANCER,PMS1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3690,bc_id3765,CANCER,ATR,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3691,bc_id3766,CANCER,PCNA,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3692,bc_id3767,CANCER,OGG1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3693,bc_id3768,CANCER,ATM,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3694,bc_id3769,CANCER,NBN,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3695,bc_id3770,CANCER,MSH6,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3696,bc_id3771,CANCER,MSH3,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3697,bc_id3772,CANCER,MSH2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3698,bc_id3773,CANCER,MRE11A,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3699,bc_id3774,CANCER,MLH3,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3700,bc_id3775,CANCER,MLH1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3701,bc_id3776,CANCER,MGMT,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3702,bc_id3777,CANCER,LIG4,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3703,bc_id3778,CANCER,LIG3,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3704,bc_id3779,CANCER,LIG1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3705,bc_id3780,CANCER,CCNO,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3706,bc_id3781,CANCER,APEX1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3707,bc_id3782,CANCER,XRCC6,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3708,bc_id3783,CANCER,FEN1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3709,bc_id3784,CANCER,FANCF,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3710,bc_id3785,CANCER,FANCG,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3711,bc_id3786,CANCER,FANCE,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3712,bc_id3787,CANCER,FANCD2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3713,bc_id3788,CANCER,FANCC,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3714,bc_id3789,CANCER,FANCA,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3715,bc_id3790,CANCER,ERCC8,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3716,bc_id3791,CANCER,ERCC6,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3717,bc_id3792,CANCER,ERCC5,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3718,bc_id3793,CANCER,ERCC4,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3719,bc_id3794,CANCER,ERCC3,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3720,bc_id3795,CANCER,ERCC2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3721,bc_id3796,CANCER,ERCC1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3722,bc_id3797,CANCER,ADPRTL4,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3723,bc_id3798,CANCER,CHEK1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3724,bc_id3799,CANCER,NEIL2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3725,bc_id3800,CANCER,NEIL1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3726,bc_id3801,CANCER,DCLRE1C,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3727,bc_id3802,CANCER,CHEK2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3728,bc_id3803,CANCER,XRCC5,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3729,bc_id3804,CANCER,XRCC4,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,Eight linked loci within XRCC4 were associated with susceptibility to PR- breast cancer (main effect p-values corrected for multiple testing at the within-gene level < 0.04).,Y,XRCC4,XRCC4,0.4
3730,bc_id3805,CANCER,XRCC3,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3731,bc_id3806,CANCER,XRCC2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3732,bc_id3807,CANCER,XRCC1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3733,bc_id3808,CANCER,XPC,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3734,bc_id3809,CANCER,XPA,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3735,bc_id3810,CANCER,TP53,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3736,bc_id3811,CANCER,BRCA2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3737,bc_id3812,CANCER,BRCA1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3738,bc_id3813,CANCER,RPA3,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3739,bc_id3814,CANCER,RPA2,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3740,bc_id3815,CANCER,RPA1,20496165,B,Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.,2011,,X,X,X,X,0
3741,bc_id3816,CANCER,TP53,20496166,B,"No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects.",2011,,"In summary, this meta-analysis provides strong evidence that the TP53 codon 72 polymorphism is not associated with the risk of developing breast cancer.",N,TP53,TP53,0.149425287
3742,bc_id3817,CANCER,TP53,20501846,B,Population-Based Estimate of the Contribution of TP53 Mutations to Subgroups of Early-Onset Breast Cancer: Australian Breast Cancer Family Study.,2010,,"Germline TP53 mutations play a larger role in early-onset breast cancer than previously thought, and in this context, can be evident outside clinically defined Li-Fraumeni families.",Y,TP53,TP53,0.367816092
3743,bc_id3818,CANCER,TOX3,20502973,B,Breast cancer susceptibility variants alter risk in familial ovarian cancer.,2010,,"A total of 158 unrelated white British women (54 BRCA1/2 mutation positive and 104 BRCA1/2 mutation negative) with familial ovarian cancer were genotyped for FGFR2, TNRC9/TOX3 and CASP8 variants... The synonymous TNRC9/TOX3 (Ser51) variant was present at a significantly lower frequency than in patients with familial BRCA1/2 positive breast cancer (P = 0.0002).",A,TOX3,TOX3,0.5
3744,bc_id3819,CANCER,FGFR2,20502973,B,Breast cancer susceptibility variants alter risk in familial ovarian cancer.,2010,,X,X,X,X,0
3745,bc_id3820,CANCER,CASP8,20502973,B,Breast cancer susceptibility variants alter risk in familial ovarian cancer.,2010,,X,X,X,X,0
3746,bc_id3821,CANCER,SULT1A1,20505990,B,"The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects.",2011,,"When all the 21 studies were pooled into the meta-analysis, there was no evidence for significant association between SULT1A1 codon 213 polymorphism and breast cancer susceptibility.",N,SULT1A1,SULT1A1,0.290322581
3747,bc_id3822,CANCER,BRCA1,20507347,B,The contribution of founder mutations in BRCA1 to breast cancer in Belarus.,2010,,One of the three founder mutations in BRCA1 was present in 38 of 500 unselected cases of breast cancer (7.6%). A mutation was found in 12.6% of women diagnosed before age 50 and 5.6% of women diagnosed after age 50.,Y,BRCA1,BRCA1,0.326180258
3748,bc_id3823,CANCER,RANBP1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3749,bc_id3824,CANCER,BBS4,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3750,bc_id3825,CANCER,PLK1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3751,bc_id3826,CANCER,AXIN2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3752,bc_id3827,CANCER,PIK3CG,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3753,bc_id3828,CANCER,PIK3CB,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3754,bc_id3829,CANCER,PIK3CA,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3755,bc_id3830,CANCER,PAK1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3756,bc_id3831,CANCER,NUMA1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3757,bc_id3832,CANCER,NPM2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3758,bc_id3833,CANCER,NPM1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3759,bc_id3834,CANCER,NME1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3760,bc_id3835,CANCER,NEK2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3761,bc_id3836,CANCER,MCPH1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3762,bc_id3837,CANCER,MCM7,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3763,bc_id3838,CANCER,MCM5,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3764,bc_id3839,CANCER,MCM6,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3765,bc_id3840,CANCER,MCM4,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3766,bc_id3841,CANCER,MCM3,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3767,bc_id3842,CANCER,MCM2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3768,bc_id3843,CANCER,MAPRE1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3769,bc_id3844,CANCER,MAPK1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3770,bc_id3845,CANCER,TUBGCP4,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3771,bc_id3846,CANCER,CDK11B,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3772,bc_id3847,CANCER,CDK11A,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3773,bc_id3848,CANCER,NDC80,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3774,bc_id3849,CANCER,NUF2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3775,bc_id3850,CANCER,NCAPD2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3776,bc_id3851,CANCER,LATS1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3777,bc_id3852,CANCER,LATS2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3778,bc_id3853,CANCER,HSP90AA1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3779,bc_id3854,CANCER,KIF11,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3780,bc_id3855,CANCER,KIF23,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3781,bc_id3856,CANCER,KIF2C,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3782,bc_id3857,CANCER,KIF2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3783,bc_id3858,CANCER,KATNA1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3784,bc_id3859,CANCER,KATNB1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3785,bc_id3860,CANCER,GSK3B,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3786,bc_id3861,CANCER,DNM2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3787,bc_id3862,CANCER,CNTROB,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3788,bc_id3863,CANCER,GPSM2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3789,bc_id3864,CANCER,LZTS2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3790,bc_id3865,CANCER,CKAP5,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3791,bc_id3866,CANCER,DCTN1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3792,bc_id3867,CANCER,FZR1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3793,bc_id3868,CANCER,RABGAP1L,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3794,bc_id3869,CANCER,DCTN5,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3795,bc_id3870,CANCER,CSNK2A1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3796,bc_id3871,CANCER,CSNK1E,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3797,bc_id3872,CANCER,CSNK1D,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3798,bc_id3873,CANCER,PLK3,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3799,bc_id3874,CANCER,TUBE1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3800,bc_id3875,CANCER,JUB,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3801,bc_id3876,CANCER,CHUK,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3802,bc_id3877,CANCER,PLK2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3803,bc_id3878,CANCER,CHEK1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3804,bc_id3879,CANCER,ASPM,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3805,bc_id3880,CANCER,CETN3,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3806,bc_id3881,CANCER,CETN2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3807,bc_id3882,CANCER,CEP250,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3808,bc_id3883,CANCER,NEK9,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3809,bc_id3884,CANCER,CEP110,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3810,bc_id3885,CANCER,YPEL5,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3811,bc_id3886,CANCER,YPEL2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3812,bc_id3887,CANCER,YPEL3,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3813,bc_id3888,CANCER,YPEL4,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3814,bc_id3889,CANCER,CDK2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3815,bc_id3890,CANCER,RASSF5,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3816,bc_id3891,CANCER,CDC27,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3817,bc_id3892,CANCER,CDC25C,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3818,bc_id3893,CANCER,CDC25B,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3819,bc_id3894,CANCER,CDC2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3820,bc_id3895,CANCER,CDC16,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3821,bc_id3896,CANCER,CDC14A,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3822,bc_id3897,CANCER,CLASP1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3823,bc_id3898,CANCER,ESPL1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3824,bc_id3899,CANCER,TUBD1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3825,bc_id3900,CANCER,PCNT,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3826,bc_id3901,CANCER,CCNE1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3827,bc_id3902,CANCER,CCNB1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3828,bc_id3903,CANCER,NIN,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3829,bc_id3904,CANCER,LZTS1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3830,bc_id3905,CANCER,SPAG5,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3831,bc_id3906,CANCER,NEK7,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3832,bc_id3907,CANCER,YWHAE,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3833,bc_id3908,CANCER,YWHAG,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3834,bc_id3909,CANCER,YPEL1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3835,bc_id3910,CANCER,WRN,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3836,bc_id3911,CANCER,WEE1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3837,bc_id3912,CANCER,VCP,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3838,bc_id3913,CANCER,TPX2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3839,bc_id3914,CANCER,TUBG2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3840,bc_id3915,CANCER,TUBG1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3841,bc_id3916,CANCER,TTK,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3842,bc_id3917,CANCER,TNKS,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3843,bc_id3918,CANCER,TACC3,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3844,bc_id3919,CANCER,TACC1,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3845,bc_id3920,CANCER,TACC2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3846,bc_id3921,CANCER,PLK4,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3847,bc_id3922,CANCER,AURKB,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3848,bc_id3923,CANCER,AURKC,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3849,bc_id3924,CANCER,SKP2,20508983,B,"Centrosome-related genes, genetic variation, and risk of breast cancer.",2011,,X,X,X,X,0
3850,bc_id3925,CANCER,GEN1,20512659,B,Mutation and association analysis of GEN1 in breast cancer susceptibility.,2010,,"These data indicate that although it also plays a key role in double-strand DNA break repair, GEN1 does not make an appreciable contribution to breast cancer susceptibility by acting as a high- or intermediate-penetrance breast cancer predisposition gene like BRCA1, BRCA2, CHEK2, ATM, BRIP1 and PALB2 and that common GEN1 variants do not act as low-penetrance susceptibility alleles analogous to SNPs in FGFR2.",N,GEN1,GEN1,1
3851,bc_id3926,CANCER,ATR,20513533,B,Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population.,2010,,Both BRCA1/2 and ATM/ATR play a role in DNA repair pathways and breast cancer.,Y,ATR,ATR,0.333333333
3852,bc_id3927,CANCER,ATM,20513533,B,Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population.,2010,,Both BRCA1/2 and ATM/ATR play a role in DNA repair pathways and breast cancer.,Y,ATM,ATM,0.333333333
3853,bc_id3928,CANCER,BRCA2,20513533,B,Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population.,2010,,Both BRCA1/2 and ATM/ATR play a role in DNA repair pathways and breast cancer.,Y,BRCA1/2,BRCA2,0.324175824
3854,bc_id3929,CANCER,BRCA1,20513533,B,Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population.,2010,,Both BRCA1/2 and ATM/ATR play a role in DNA repair pathways and breast cancer.,Y,BRCA1/2,BRCA1,0.326180258
3855,bc_id3930,CANCER,ABO,20514537,B,Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes.,2010,", Lewis and Secretor genotyping could be useful to predict respectively breast cancer susceptibility and axillary lymph nodes metastasis.","No association was found between breast cancer and ABO antigen expression (P = 0.9323) or genotype (P = 0.9356). Lewis-negative genotype was associated with IDC (P = 0.0126) but not with anatomoclinical parameters. Nonsecretor genotype was associated with axillary lymph node metastasis (P = 0.0149). In conclusion, Lewis and Secretor genotyping could be useful to predict respectively breast cancer susceptibility and axillary lymph nodes metastasis.",N,ABO,ABO,1
3856,bc_id3931,CANCER,FUT3,20514537,B,Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes.,2010,", Lewis and Secretor genotyping could be useful to predict respectively breast cancer susceptibility and axillary lymph nodes metastasis.",X,X,X,X,0
3857,bc_id3932,CANCER,FUT2,20514537,B,Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes.,2010,", Lewis and Secretor genotyping could be useful to predict respectively breast cancer susceptibility and axillary lymph nodes metastasis.",X,X,X,X,0
3858,bc_id3933,CANCER,CYP2D6,20515869,B,CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.,2010,"MALDI-TOF MS/CNA is suitable for accurate CYP2D6 genotyping. For tamoxifen pharmacogenetics, broad CYP2D6 allele coverage is recommended to reduce phenotype misclassification. Classification based on refined EM and reduced-function metabolizers is advisable. AACR.",X,X,X,X,0
3859,bc_id3934,CANCER,ERBB2,20524057,N,"Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects.",2011,,"In summary, the meta-analysis suggests that HER2 codon 655 polymorphism is not associated with the increased breast cancer risk.",N,HER2,ERBB2,0.261904762
3860,bc_id3935,CANCER,GSTP1,20526737,B,"Glutathione S-transferase P1 Ile105Val polymorphism and breast cancer risk: a meta-analysis involving 34,658 subjects.",2011,,"In conclusion, our meta-analysis suggests that GSTP1 Ile105Val polymorphism may increase susceptibility to breast cancer in Asian population.",A,GSTP1,GSTP1,0.485714286
3861,bc_id3936,CANCER,CD44,20530438,B,Unique SNP in CD44 intron 1 and its role in breast cancer development.,2010,,"Our results suggest that CD44 polymorphism is associated with breast cancer development, and CD44 polymorphism analysis may be effectively used in the risk assessment, prediction, prevention, diagnosis and genetic epidemiological analysis of breast cancer.",Y,CD44,CD44,1
3862,bc_id3937,CANCER,IL8RB,20540789,B,Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.,2010,"Our results indicated that the polymorphisms in IL-8 and CXCR2 genes are associated with increased breast cancer risk, as well as disease progress, supporting our hypothesis for IL-8 and ELR+CXC chemokine receptor (CXCR2) involvement in breast cancer pathogenesis.","Our results indicated that the polymorphisms in IL-8 and CXCR2 genes are associated with increased breast cancer risk, as well as disease progress, supporting our hypothesis for IL-8 and ELR+CXC chemokine receptor (CXCR2) involvement in breast cancer pathogenesis.",Y,CXCR2,IL8RB,1
3863,bc_id3938,CANCER,IL8,20540789,B,Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.,2010,"Our results indicated that the polymorphisms in IL-8 and CXCR2 genes are associated with increased breast cancer risk, as well as disease progress, supporting our hypothesis for IL-8 and ELR+CXC chemokine receptor (CXCR2) involvement in breast cancer pathogenesis.","Our results indicated that the polymorphisms in IL-8 and CXCR2 genes are associated with increased breast cancer risk, as well as disease progress, supporting our hypothesis for IL-8 and ELR+CXC chemokine receptor (CXCR2) involvement in breast cancer pathogenesis.",Y,IL-8,IL8,0.4
3864,bc_id3939,CANCER,BRCA2,20541936,B,Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.,2010,,X,X,X,X,0
3865,bc_id3940,CANCER,BRCA1,20541936,B,Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.,2010,,"Compared to non-drinkers, exclusive consumption of wine was associated with a significant reduction in the risk of breast cancer among BRCA1 carriers (p-trend = 0.01). Alcohol consumption does not appear to increase breast cancer risk in women carrying a BRCA gene mutation.",A,BRCA1,BRCA1,0.60944206
3866,bc_id3941,CANCER,CDKN2A,20549370,B,Can a phenotype for recessive inheritance in breast cancer be defined?,2010,,"However, germline mutation carriers (BRCA1/2, TP53 or CDKN2A, present in 0.95% of the cases) had a significantly worse survival... Factors associated with a horizontal family history were found, defining a possible phenotype for a recessive inheritance: tubular breast cancer.",A,CDKN2A,CDKN2A,0.625
3867,bc_id3942,CANCER,TP53,20549370,B,Can a phenotype for recessive inheritance in breast cancer be defined?,2010,,"However, germline mutation carriers (BRCA1/2, TP53 or CDKN2A, present in 0.95% of the cases) had a significantly worse survival... Factors associated with a horizontal family history were found, defining a possible phenotype for a recessive inheritance: tubular breast cancer.",A,TP53,TP53,0.482758621
3868,bc_id3943,CANCER,BRCA2,20549370,B,Can a phenotype for recessive inheritance in breast cancer be defined?,2010,,"However, germline mutation carriers (BRCA1/2, TP53 or CDKN2A, present in 0.95% of the cases) had a significantly worse survival... Factors associated with a horizontal family history were found, defining a possible phenotype for a recessive inheritance: tubular breast cancer.",A,BRCA1/2,BRCA2,0.576923077
3869,bc_id3944,CANCER,BRCA1,20549370,B,Can a phenotype for recessive inheritance in breast cancer be defined?,2010,,"However, germline mutation carriers (BRCA1/2, TP53 or CDKN2A, present in 0.95% of the cases) had a significantly worse survival... Factors associated with a horizontal family history were found, defining a possible phenotype for a recessive inheritance: tubular breast cancer.",A,BRCA1/2,BRCA1,0.60944206
3870,bc_id3945,CANCER,IL10,20553628,B,Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population.,2010,Our findings suggest that IL-10 promoter polymorphisms participate in the progression of breast cancer rather than in its initial development in Chinese Han women.,Our findings suggest that IL-10 promoter polymorphisms participate in the progression of breast cancer rather than in its initial development in Chinese Han women.,Y,IL-10,IL10,0.125
3871,bc_id3946,CANCER,RELN,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,"Associations were observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6 and RELN for AA; FGFR2, TNRC9, H19 and MAP3K1 for Whites; FGFR2, TNRC9, Msc5A1 and chromosome 8q for women > or =50 years old and FGFR2 and TNRC9 for women <50 years old. FGFR2 haplotypes based upon rs11200014, rs2981579, rs1219648 and rs2420946 were associated with increased risk of breast cancer, including the GTGT haplotype in AAs [OR = 1.27, 95% confidence interval (CI) 1.04-1.56] and younger women of either race [OR = 1.35, 95% CI 1.02-1.78) and the ATGT haplotype in Whites (OR = 1.30, 95% CI 1.15-1.46).",Y,RELN,RELN,1
3872,bc_id3947,CANCER,MAP3K1,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,"Associations were observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6 and RELN for AA; FGFR2, TNRC9, H19 and MAP3K1 for Whites; FGFR2, TNRC9, Msc5A1 and chromosome 8q for women > or =50 years old and FGFR2 and TNRC9 for women <50 years old. FGFR2 haplotypes based upon rs11200014, rs2981579, rs1219648 and rs2420946 were associated with increased risk of breast cancer, including the GTGT haplotype in AAs [OR = 1.27, 95% confidence interval (CI) 1.04-1.56] and younger women of either race [OR = 1.35, 95% CI 1.02-1.78) and the ATGT haplotype in Whites (OR = 1.30, 95% CI 1.15-1.46).",Y,MAP3K1,MAP3K1,0.636363636
3873,bc_id3948,CANCER,LSP1,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,"Associations were observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6 and RELN for AA; FGFR2, TNRC9, H19 and MAP3K1 for Whites; FGFR2, TNRC9, Msc5A1 and chromosome 8q for women > or =50 years old and FGFR2 and TNRC9 for women <50 years old. FGFR2 haplotypes based upon rs11200014, rs2981579, rs1219648 and rs2420946 were associated with increased risk of breast cancer, including the GTGT haplotype in AAs [OR = 1.27, 95% confidence interval (CI) 1.04-1.56] and younger women of either race [OR = 1.35, 95% CI 1.02-1.78) and the ATGT haplotype in Whites (OR = 1.30, 95% CI 1.15-1.46).",Y,LSP1,LSP1,0.555555556
3874,bc_id3949,CANCER,H19,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,"Associations were observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6 and RELN for AA; FGFR2, TNRC9, H19 and MAP3K1 for Whites; FGFR2, TNRC9, Msc5A1 and chromosome 8q for women > or =50 years old and FGFR2 and TNRC9 for women <50 years old. FGFR2 haplotypes based upon rs11200014, rs2981579, rs1219648 and rs2420946 were associated with increased risk of breast cancer, including the GTGT haplotype in AAs [OR = 1.27, 95% confidence interval (CI) 1.04-1.56] and younger women of either race [OR = 1.35, 95% CI 1.02-1.78) and the ATGT haplotype in Whites (OR = 1.30, 95% CI 1.15-1.46).",Y,H19,H19,0.5
3875,bc_id3950,CANCER,FGFR2,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,"Associations were observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6 and RELN for AA; FGFR2, TNRC9, H19 and MAP3K1 for Whites; FGFR2, TNRC9, Msc5A1 and chromosome 8q for women > or =50 years old and FGFR2 and TNRC9 for women <50 years old. FGFR2 haplotypes based upon rs11200014, rs2981579, rs1219648 and rs2420946 were associated with increased risk of breast cancer, including the GTGT haplotype in AAs [OR = 1.27, 95% confidence interval (CI) 1.04-1.56] and younger women of either race [OR = 1.35, 95% CI 1.02-1.78) and the ATGT haplotype in Whites (OR = 1.30, 95% CI 1.15-1.46).",Y,FGFR2,FGFR2,0.708333333
3876,bc_id3951,CANCER,TLR6,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,"Associations were observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6 and RELN for AA; FGFR2, TNRC9, H19 and MAP3K1 for Whites; FGFR2, TNRC9, Msc5A1 and chromosome 8q for women > or =50 years old and FGFR2 and TNRC9 for women <50 years old. FGFR2 haplotypes based upon rs11200014, rs2981579, rs1219648 and rs2420946 were associated with increased risk of breast cancer, including the GTGT haplotype in AAs [OR = 1.27, 95% confidence interval (CI) 1.04-1.56] and younger women of either race [OR = 1.35, 95% CI 1.02-1.78) and the ATGT haplotype in Whites (OR = 1.30, 95% CI 1.15-1.46).",Y,TLR6,TLR6,1
3877,bc_id3952,CANCER,CASP8,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,X,X,X,X,0
3878,bc_id3953,CANCER,FBXO10,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,X,X,X,X,0
3879,bc_id3954,CANCER,TLR1,20554749,B,FGFR2 and Other Loci Identified in Genome-Wide Association Studies are Associated with Breast Cancer in African American and Younger Women.,2010,,"Associations were observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6 and RELN for AA; FGFR2, TNRC9, H19 and MAP3K1 for Whites; FGFR2, TNRC9, Msc5A1 and chromosome 8q for women > or =50 years old and FGFR2 and TNRC9 for women <50 years old. FGFR2 haplotypes based upon rs11200014, rs2981579, rs1219648 and rs2420946 were associated with increased risk of breast cancer, including the GTGT haplotype in AAs [OR = 1.27, 95% confidence interval (CI) 1.04-1.56] and younger women of either race [OR = 1.35, 95% CI 1.02-1.78) and the ATGT haplotype in Whites (OR = 1.30, 95% CI 1.15-1.46).",Y,TLR1,TLR1,1
3880,bc_id3955,CANCER,F5,20554945,B,Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer.,2010,"Among women taking adjuvant tamoxifen for early-stage breast cancer, those who had a TE were nearly five times more likely to carry a FVL mutation than those who did not have a TE. Postmenopausal women should be evaluated for the FVL mutation before prescription of adjuvant tamoxifen if a positive test would alter therapeutic decision making.",X,X,X,X,0
3881,bc_id3956,CANCER,GSTT1,20563767,B,The GSTT1 polymorphism of the glutathione S-transferase system in the intratumoral microvessel density of breast cancer patients.,2010,,"We investigated herein the influence of the GSTM1 and GSTT1 polymorphisms in the intratumoral angiogenesis of 87 patients with sporadic breast cancer... The high IMVD was more common in patients with the GSTT1 wild genotype than in those with the GSTT1 null genotype (P = 0.04). Our results suggest, for the first time, that the GSTT1 polymorphism constitutes an inherited determinant of intratumoral angiogenesis in sporadic breast cancer.",Y,GSTT1,GSTT1,0.578947368
3882,bc_id3957,CANCER,GSTM1,20563767,B,The GSTT1 polymorphism of the glutathione S-transferase system in the intratumoral microvessel density of breast cancer patients.,2010,,X,X,X,X,0
3883,bc_id3958,CANCER,CYP3A5,20565970,B,"Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.",2011,"We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and estrogen kinetics on treatment outcome are warranted.",X,X,X,X,0
3884,bc_id3959,CANCER,CYP2D6,20565970,B,"Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.",2011,"We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and estrogen kinetics on treatment outcome are warranted.",X,X,X,X,0
3885,bc_id3960,CANCER,CYP2C19,20565970,B,"Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.",2011,"We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and estrogen kinetics on treatment outcome are warranted.",X,X,X,X,0
3886,bc_id3961,CANCER,SULT1A1,20565970,B,"Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.",2011,"We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and estrogen kinetics on treatment outcome are warranted.",X,X,X,X,0
3887,bc_id3962,CANCER,BRIP1,20567916,B,Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.,2010,,Our results showed that exonic deletions or amplifications affecting the BRIP1 and CHK1 genes seem not to contribute to hereditary breast cancer susceptibility in the Finnish population.,N,BRIP1,BRIP1,0.3
3888,bc_id3963,CANCER,CHEK1,20567916,B,Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.,2010,,Our results showed that exonic deletions or amplifications affecting the BRIP1 and CHK1 genes seem not to contribute to hereditary breast cancer susceptibility in the Finnish population.,N,CHK1,CHEK1,0.5
3889,bc_id3964,CANCER,GSTT1,20568049,B,"GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.",2010,,"We examined whether GSTT1/GSTT1""null"", GSTM1/GSTM1""null"" and GSTP1Ile105Ile/GSTP1Ile105Val polymorphisms are associated with different response rates to neoadjuvant chemotherapy in the treatment of stage II and III breast cancer... These specific combinations were virtually absent in the combinations with few responding patients.",A,GSTT1,GSTT1,0.289473684
3890,bc_id3965,CANCER,GSTP1,20568049,B,"GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.",2010,,"We examined whether GSTT1/GSTT1""null"", GSTM1/GSTM1""null"" and GSTP1Ile105Ile/GSTP1Ile105Val polymorphisms are associated with different response rates to neoadjuvant chemotherapy in the treatment of stage II and III breast cancer... These specific combinations were virtually absent in the combinations with few responding patients.",A,GSTP1,GSTP1,0.485714286
3891,bc_id3966,CANCER,GSTM1,20568049,B,"GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.",2010,,"We examined whether GSTT1/GSTT1""null"", GSTM1/GSTM1""null"" and GSTP1Ile105Ile/GSTP1Ile105Val polymorphisms are associated with different response rates to neoadjuvant chemotherapy in the treatment of stage II and III breast cancer... These specific combinations were virtually absent in the combinations with few responding patients.",A,GSTM1,GSTM1,0.339622642
3892,bc_id3967,CANCER,BRCA1,20569256,B,High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.,2010,,"Taken together, these results identify three BRCA1 founder mutations as key components of inherited breast and ovarian cancer susceptibility in Belarus and might have implications for cancer prevention, treatment and genetic counselling in this population.",A,BRCA1,BRCA1,0.60944206
3893,bc_id3968,CANCER,ESR1,20570923,B,Diverse associations between ESR1 polymorphism and breast cancer development and progression.,2010,Our findings provide support for diverse roles of ESR1 polymorphism in determining susceptibility in different stages of breast cancer. The differences between the important ESR1 SNPs identified in Chinese women in this study and those identified in studies on Western women with breast cancer suggest different roles of ERalpha in these two populations.,Our findings provide support for diverse roles of ESR1 polymorphism in determining susceptibility in different stages of breast cancer. The differences between the important ESR1 SNPs identified in Chinese women in this study and those identified in studies on Western women with breast cancer suggest different roles of ERalpha in these two populations.,Y,ESR1,ESR1,0.282608696
3894,bc_id3969,CANCER,TYMS,20571234,B,Thymidylate synthase gene polymorphisms effecting 5-FU response in breast cancer patients.,2010,,Genetic screening of the drug metabolizing enzyme like TYMS for the presence of polymorphisms in breast cancer patients will become increasingly useful in individualizing drug therapy.,A,TYMS,TYMS,0.7
3895,bc_id3970,CANCER,RAD50,20571869,B,RAD50 gene mutations are not likely a risk factor for breast cancer in Poland.,2010,,ANF,ANF,ANF,ANF,0
3896,bc_id3971,CANCER,VEGF,20571871,B,Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival.,2010,"Our findings suggest inheritance of the VEGF(-2578)C allele could serve as an independent prognostic indicator of BrCA prognosis. The VEGF(-2578) marker may have clinical implications among a subset of ER(+)/PR(+) patients with an aggressive phenotype. Because the VEGF(-2578)C allele is linked to high VEGF expression, this cytokine is a potential prognostic and targeted clinical management tool.",Our findings suggest inheritance of the VEGF(-2578)C allele could serve as an independent prognostic indicator of BrCA prognosis.,A,VEGF,VEGF,0.5
3897,bc_id3973,CANCER,BRCA1,20587410,B,Risk of breast cancer in male BRCA2 carriers.,2010,,X,X,X,X,0
3898,bc_id3974,CANCER,ESR2,20604969,B,"Estrogen Receptor-Beta Gene Polymorphism in women with Breast Cancer at the Imam Khomeini Hospital Complex, Iran.",2010,,Our data suggest that ER-beta polymorphism in exon 7 codon 392 (C1176G) is correlated with various aspects of breast cancer and lymph node metastasis in our group of patients.,Y,ER-beta,ESR2,0.333333333
3899,bc_id3975,CANCER,ATM,20605201,B,Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.,2010,Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.,"We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption)... Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.",A,ATM,ATM,0.422222222
3900,bc_id3976,CANCER,MAP3K1,20605201,B,Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.,2010,Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.,"We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption)... Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.",A,MAP3K1,MAP3K1,0.272727273
3901,bc_id3977,CANCER,LSP1,20605201,B,Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.,2010,Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.,"We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption)... Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.",A,LSP1,LSP1,0.444444444
3902,bc_id3978,CANCER,TOX3,20605201,B,Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.,2010,Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.,"We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption)... Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.",A,TNRC9-rs3803662,TOX3,0.5
3903,bc_id3979,CANCER,FGFR2,20605201,B,Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.,2010,Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.,"We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption)... Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.",A,FGFR2,FGFR2,0.25
3904,bc_id3980,CANCER,CASP8,20605201,B,Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.,2010,Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.,"We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption)... Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.",A,CASP8,CASP8,0.285714286
3905,bc_id3981,CANCER,TGFB1,20605201,B,Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.,2010,Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.,"We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption)... Risks of breast cancer associated with low-penetrance susceptibility polymorphisms do not vary significantly with these ten established environmental risk factors.",A,TGFB1,TGFB1,0.518518519
3906,bc_id3982,CANCER,BRCA2,20609467,B,Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.,2010,The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favourable therapeutic index for a novel targeted treatment strategy in patients with tumours that have genetic loss of function of BRCA1-associated or BRCA2-associated DNA repair. Toxicity in women with BRCA1 and BRCA2 mutations was similar to that reported previously in those without such mutations.,The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favourable therapeutic index for a novel targeted treatment strategy in patients with tumours that have genetic loss of function of BRCA1-associated or BRCA2-associated DNA repair.,A,BRCA2,BRCA2,0.576923077
3907,bc_id3983,CANCER,BRCA1,20609467,B,Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.,2010,The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favourable therapeutic index for a novel targeted treatment strategy in patients with tumours that have genetic loss of function of BRCA1-associated or BRCA2-associated DNA repair. Toxicity in women with BRCA1 and BRCA2 mutations was similar to that reported previously in those without such mutations.,The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favourable therapeutic index for a novel targeted treatment strategy in patients with tumours that have genetic loss of function of BRCA1-associated or BRCA2-associated DNA repair.,A,BRCA1,BRCA1,0.60944206
3908,bc_id3984,CANCER,BRCA2,20625126,B,Is Mammographic Breast Density a Breast Cancer Risk Factor in Women With BRCA Mutations?,2010,"Increased mammographic breast density is not associated with higher breast cancer incidence in women with BRCA mutations. On the basis of these findings, density should not be considered a factor for these women in decision making regarding prophylactic surgery or chemoprevention.",Increased mammographic breast density is not associated with higher breast cancer incidence in women with BRCA mutations.,N,BRCA,BRCA2,0.098901099
3909,bc_id3985,CANCER,BRCA1,20625126,B,Is Mammographic Breast Density a Breast Cancer Risk Factor in Women With BRCA Mutations?,2010,"Increased mammographic breast density is not associated with higher breast cancer incidence in women with BRCA mutations. On the basis of these findings, density should not be considered a factor for these women in decision making regarding prophylactic surgery or chemoprevention.",Increased mammographic breast density is not associated with higher breast cancer incidence in women with BRCA mutations.,N,BRCA,BRCA1,0.064377682
3910,bc_id3986,CANCER,ABCB1,20628376,B,Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.,2010,These results suggest that C3435T polymorphism genotyping and menopausal status at the time of diagnosis might be useful when considering chemotherapy regimens including docetaxel in breast cancer patients.,X,X,X,X,0
3911,bc_id3987,CANCER,CYP1B1,20632082,B,Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients.,2010,,"We studied 95 patients affected by breast cancer and under treatment with taxanes as adjuvant, metastatic or neo-adjuvant therapy. We genotyped them for SNPs in the CYP2C8 (alleles *1, *2, *3 and *4),CYP1B1  (alleles *1 and *3) and ABCB1 (1236 C>T; 2677 G>T/A; 3435 C>T) genes by real-time PCR assay... We suggest that CYP1B1 might affect taxane hypersensitivity therefore representing, if confirmed in a large cohort of patients, an exploratory hypersensitivity predictive biomarker.",A,CYP1B1,CYP1B1,0.384615385
3912,bc_id3988,CANCER,PRLR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3913,bc_id3989,CANCER,PRL,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3914,bc_id3990,CANCER,POU1F1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3915,bc_id3991,CANCER,POMC,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3916,bc_id3992,CANCER,PGR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3917,bc_id3993,CANCER,MC2R,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3918,bc_id3994,CANCER,LHCGR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3919,bc_id3995,CANCER,AR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3920,bc_id3996,CANCER,IRS2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3921,bc_id3997,CANCER,IRS1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3922,bc_id3998,CANCER,INSR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3923,bc_id3999,CANCER,INHBB,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3924,bc_id4000,CANCER,INHBA,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3925,bc_id4001,CANCER,INHA,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3926,bc_id4002,CANCER,IGFBP6,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3927,bc_id4003,CANCER,IGFBP5,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3928,bc_id4004,CANCER,IGFBP4,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3929,bc_id4005,CANCER,IGFBP3,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3930,bc_id4006,CANCER,IGFBP2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3931,bc_id4007,CANCER,IGFBP1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3932,bc_id4008,CANCER,IGFALS,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3933,bc_id4009,CANCER,IGF2R,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3934,bc_id4010,CANCER,IGF2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3935,bc_id4011,CANCER,IGF1R,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3936,bc_id4012,CANCER,IGF1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,"We found no significant overall associations between breast cancer and common germline variation in 61 genes involved in steroid hormone and IGF-I metabolism in this large, comprehensive study.",N,IGF-I,IGF1,0.4
3937,bc_id4013,CANCER,HSD3B2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3938,bc_id4014,CANCER,HSD3B1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3939,bc_id4015,CANCER,HSD17B4,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3940,bc_id4016,CANCER,HSD17B3,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3941,bc_id4017,CANCER,HSD17B2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3942,bc_id4018,CANCER,HSD17B1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3943,bc_id4019,CANCER,GNRHR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3944,bc_id4020,CANCER,GNRH1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3945,bc_id4021,CANCER,GHRHR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3946,bc_id4022,CANCER,GHRH,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3947,bc_id4023,CANCER,GHR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3948,bc_id4024,CANCER,FSHR,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3949,bc_id4025,CANCER,FSHB,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3950,bc_id4026,CANCER,AKR1C3,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3951,bc_id4027,CANCER,ESR2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3952,bc_id4028,CANCER,ESR1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3953,bc_id4029,CANCER,CYP3A4,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3954,bc_id4030,CANCER,CYP1B1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3955,bc_id4031,CANCER,CYP1A2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3956,bc_id4032,CANCER,CYP1A1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3957,bc_id4033,CANCER,CYP19A1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3958,bc_id4034,CANCER,CYP17A1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3959,bc_id4035,CANCER,CYP11A1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3960,bc_id4036,CANCER,COMT,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3961,bc_id4037,CANCER,CGA,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3962,bc_id4038,CANCER,ACVR2A,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3963,bc_id4039,CANCER,ACVR1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3964,bc_id4040,CANCER,UGT2B7,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3965,bc_id4041,CANCER,SSTR5,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3966,bc_id4042,CANCER,SSTR4,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3967,bc_id4043,CANCER,SSTR3,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3968,bc_id4044,CANCER,SSTR2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3969,bc_id4045,CANCER,SSTR1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3970,bc_id4046,CANCER,SST,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3971,bc_id4047,CANCER,SRD5A2,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3972,bc_id4048,CANCER,SRD5A1,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3973,bc_id4049,CANCER,SHBG,20634197,B,Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.,2010,,X,X,X,X,0
3974,bc_id4050,CANCER,MTHFR,20638924,B,"Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.",2010,We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer.,X,X,X,X,0
3975,bc_id4051,CANCER,ABCB1,20638924,B,"Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.",2010,We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer.,X,X,X,X,0
3976,bc_id4052,CANCER,TYMS,20638924,B,"Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.",2010,We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer.,X,X,X,X,0
3977,bc_id4053,CANCER,MSX1,20638926,B,The c.469+46_56del mutation in the homeobox MSX1 gene-A novel risk factor in breast cancer?,2010,The del/del genotype of the c.469+46_56del mutation in the MSX1 gene may be associated with the increased risk of breast cancer in Polish population and may be considered as an early marker in this disease.,The del/del genotype of the c.469+46_56del mutation in the MSX1 gene may be associated with the increased risk of breast cancer in Polish population and may be considered as an early marker in this disease.,A,MSX1,MSX1,1
3978,bc_id4055,CANCER,SULT1A1,20663177,B,Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue.,2010,"We concluded that the polymorphism of SULT1A1 Arg213His might be one of the high risk factors for breast cancer in Asian women and in postmenopausal women for all races. We should point out that the publication bias among postmenopausal women may partly account for the result, but the conclusion might not affected deeply by the publication bias.","We concluded that the polymorphism of SULT1A1 Arg213His might be one of the high risk factors for breast cancer in Asian women and in postmenopausal women for all races. We should point out that the publication bias among postmenopausal women may partly account for the result, but the conclusion might not affected deeply by the publication bias.",A,SULT1A1,SULT1A1,0.387096774
3979,bc_id4056,CANCER,FGFR2,20677155,B,[Association of FGFR2 gene polymorphism with estrogen receptor positive breast cancer detected by fluorescent quantitative PCR.],2010,"Association was found in the single nucleotide polymorphism(SNP) of the rs2981582 locus of intron 2 in FGFR2 gene between the ER positive breast cancer patients and control patients with benign breast diseases. The fluorescent quantitative PCR is a specific, easy-to-operate, low-expense method and is suitable for SNP detection in large scale samples.",Association was found in the single nucleotide polymorphism(SNP) of the rs2981582 locus of intron 2 in FGFR2 gene between the ER positive breast cancer patients and control patients with benign breast diseases.,Y,FGFR2,FGFR2,0.708333333
3980,bc_id4057,CANCER,SLC2A1,20679470,B,The XbaI G&gt;T Polymorphism of the Glucose Transporter 1 Gene Modulates 18F-FDG Uptake and Tumor Aggressiveness in Breast Cancer.,2010,"This study found that the XbaI G&gt;T SNP of the GLUT1 gene is associated with an increased (18)F-FDG uptake and a more advanced tumor grade or growth in breast cancer. Thus, this genetic variant might favor aggressive phenotypes by modulating the efficiency of cancer cells to recruit glucose and escalate growth rate, suggesting the XbaI G&gt;T SNP as a proliferation-related prognostic factor.",This study found that the XbaI G>T SNP of the GLUT1 gene is associated with an increased (18)F-FDG uptake and a more advanced tumor grade or growth in breast cancer.,Y,GLUT1,SLC2A1,1
3981,bc_id4058,CANCER,TP53,20682393,B,"Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.",2010,,X,X,X,X,0
3982,bc_id4059,CANCER,NAT2,20683028,B,Combined effect of CYP1B1 codon 432 polymorphism and N-acetyltransferase 2 slow acetylator phenotypes in relation to breast cancer in the Turkish population.,2010,"The distribution of NAT2 activity in the healthy control group was found to be correlated with that of healthy caucasians. Patients had slow acetylator phenotypes of NAT2, 1.8 times higher than controls but no statistical differences were found (p=0.07). In addition, the NAT2*5 alelle was more statistically correlated with breast cancer patients rather than the controls (p=0.02). Moreover, NAT2*5B was the most frequent haplotype of the NAT2*5 family (p=0.000). Breast cancer patients were detected to posses more CYP1B1*3 mutant alleles than the controls (p=0.043). The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).",The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).,Y,NAT2,NAT2,0.37037037
3983,bc_id4060,CANCER,CYP1B1,20683028,B,Combined effect of CYP1B1 codon 432 polymorphism and N-acetyltransferase 2 slow acetylator phenotypes in relation to breast cancer in the Turkish population.,2010,"The distribution of NAT2 activity in the healthy control group was found to be correlated with that of healthy caucasians. Patients had slow acetylator phenotypes of NAT2, 1.8 times higher than controls but no statistical differences were found (p=0.07). In addition, the NAT2*5 alelle was more statistically correlated with breast cancer patients rather than the controls (p=0.02). Moreover, NAT2*5B was the most frequent haplotype of the NAT2*5 family (p=0.000). Breast cancer patients were detected to posses more CYP1B1*3 mutant alleles than the controls (p=0.043). The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).",The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).,Y,CYP1B1*3,CYP1B1,0.358974359
3984,bc_id4061,CANCER,CDKN1B,20683061,B,CCND1 and CDKN1B polymorphisms and risk of breast cancer.,2010,"Even though CDKN1B polymorphism appears to be an important predictive factor for breast cancer risk and CCND1 polymorphism may be a prognostic biomarker for breast cancer, further investigations with larger study groups are needed to fully elucidate the role of CCND1 and CDKN1B polymorphisms in the development and prognosis of breast cancer.","Even though CDKN1B polymorphism appears to be an important predictive factor for breast cancer risk and CCND1 polymorphism may be a prognostic biomarker for breast cancer, further investigations with larger study groups are needed to fully elucidate the role of CCND1 and CDKN1B polymorphisms in the development and prognosis of breast cancer.",A,CDKN1B,CDKN1B,0.714285714
3985,bc_id4062,CANCER,CCND1,20683061,B,CCND1 and CDKN1B polymorphisms and risk of breast cancer.,2010,"Even though CDKN1B polymorphism appears to be an important predictive factor for breast cancer risk and CCND1 polymorphism may be a prognostic biomarker for breast cancer, further investigations with larger study groups are needed to fully elucidate the role of CCND1 and CDKN1B polymorphisms in the development and prognosis of breast cancer.","Even though CDKN1B polymorphism appears to be an important predictive factor for breast cancer risk and CCND1 polymorphism may be a prognostic biomarker for breast cancer, further investigations with larger study groups are needed to fully elucidate the role of CCND1 and CDKN1B polymorphisms in the development and prognosis of breast cancer.",A,CCND1,CCND1,0.5
3986,bc_id4063,CANCER,UGT1A6,20686835,B,Combined UGT1A1 and UGT1A6 genotypes together with a stressful life event increase breast cancer risk.,2010,,ANF,ANF,ANF,ANF,0
3987,bc_id4064,CANCER,UGT1A1,20686835,B,Combined UGT1A1 and UGT1A6 genotypes together with a stressful life event increase breast cancer risk.,2010,,ANF,ANF,ANF,ANF,0
3988,bc_id4065,CANCER,NOS2A,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3989,bc_id4066,CANCER,NFKBIE,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3990,bc_id4067,CANCER,NFKB1,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3991,bc_id4068,CANCER,IL6,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3992,bc_id4069,CANCER,IL4,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3993,bc_id4070,CANCER,IL1B,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3994,bc_id4071,CANCER,IL12B,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3995,bc_id4072,CANCER,IL10,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3996,bc_id4073,CANCER,IFNG,20711808,B,"Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists.",2010,,X,X,X,X,0
3997,bc_id4074,CANCER,GLO1,20712647,B,Glyoxalase I Ala111Glu gene polymorphism: No association with breast cancer risk but correlated with absence of progesterone receptor.,2010,,"Thus, the polymorphic variant of the GLOI gene might not be a useful genetic marker to identify Malaysian Malay, Chinese or Indian women who could be at greater risk of developing breast cancer.",A,GLOI,GLO1,1
3998,bc_id4075,CANCER,ST14,20716618,B,ST14 Gene Variant and Decreased Matriptase Protein Expression Predict Poor Breast Cancer Survival.,2010,This is the first study showing that genetic variation in matriptase has clinical importance. The results encourage further study on the genetic variation affecting protein levels and function in type II transmembrane serine proteases.,Five single nucleotide polymorphisms in ST14 and three in SPINT1 were genotyped in 470 invasive breast cancer cases and 446 healthy controls... The ST14 variant rs704624 and protein expression of matriptase have prognostic significance in breast cancer.,Y,ST14,ST14,1
3999,bc_id4076,CANCER,SPINT1,20716618,B,ST14 Gene Variant and Decreased Matriptase Protein Expression Predict Poor Breast Cancer Survival.,2010,This is the first study showing that genetic variation in matriptase has clinical importance. The results encourage further study on the genetic variation affecting protein levels and function in type II transmembrane serine proteases.,Five single nucleotide polymorphisms in ST14 and three in SPINT1 were genotyped in 470 invasive breast cancer cases and 446 healthy controls... The ST14 variant rs704624 and protein expression of matriptase have prognostic significance in breast cancer.,A,SPINT1,SPINT1,1
4000,bc_id4077,CANCER,NBN,20720310,B,"Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population.",2011,,"Here we analysed polymorphisms in 5 genes involved in DNA repair (XPD Asp312Asn and Lys751Gln, XRCC1 Arg399Gln, APE1 Asp148Glu, NBS1 Glu185Gln, and XPA G-4A) and in a gene involved in regulation of the cell-cycle (CCND1 A870G)... Importantly, no differences in the distribution of these polymorphisms were found between healthy controls and breast cancer patients.",N,NBS1,NBN,0.238095238
4001,bc_id4078,CANCER,APEX1,20720310,B,"Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population.",2011,,"Here we analysed polymorphisms in 5 genes involved in DNA repair (XPD Asp312Asn and Lys751Gln, XRCC1 Arg399Gln, APE1 Asp148Glu, NBS1 Glu185Gln, and XPA G-4A) and in a gene involved in regulation of the cell-cycle (CCND1 A870G)... Importantly, no differences in the distribution of these polymorphisms were found between healthy controls and breast cancer patients.",N,APE1,APEX1,0.5
4002,bc_id4079,CANCER,ERCC2,20720310,B,"Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population.",2011,,"Here we analysed polymorphisms in 5 genes involved in DNA repair (XPD Asp312Asn and Lys751Gln, XRCC1 Arg399Gln, APE1 Asp148Glu, NBS1 Glu185Gln, and XPA G-4A) and in a gene involved in regulation of the cell-cycle (CCND1 A870G)... Importantly, no differences in the distribution of these polymorphisms were found between healthy controls and breast cancer patients.",N,XPD,ERCC2,0.1875
4003,bc_id4080,CANCER,CCND1,20720310,B,"Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population.",2011,,"We compared their frequencies in groups of colon, head and neck, and breast cancer patients, and 2 healthy control groups: (1) matched healthy Polish individuals and (2) a NCBI database control group. Highly significant differences in the distribution of genotypes of the APE1, XRCC1 and CCND1 genes were found between colon cancer patients and healthy individuals. The 148Asp APE1 allele and the 399Gln XRCC1 allele apparently increased the risk of colon cancer (OR = 1.9-2.3 and OR = 1.5-2.1, respectively). Additionally, frequencies of XPD genotypes differed between healthy controls and patients with colon or head and neck cancer. Importantly, no differences in the distribution of these polymorphisms were found between healthy controls and breast cancer patients.",N,CCND1,CCND1,0.3125
4004,bc_id4081,CANCER,XRCC1,20720310,B,"Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population.",2011,,"Here we analysed polymorphisms in 5 genes involved in DNA repair (XPD Asp312Asn and Lys751Gln, XRCC1 Arg399Gln, APE1 Asp148Glu, NBS1 Glu185Gln, and XPA G-4A) and in a gene involved in regulation of the cell-cycle (CCND1 A870G)... Importantly, no differences in the distribution of these polymorphisms were found between healthy controls and breast cancer patients.",N,XRCC1,XRCC1,0.217391304
4005,bc_id4082,CANCER,XPA,20720310,B,"Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population.",2011,,"Here we analysed polymorphisms in 5 genes involved in DNA repair (XPD Asp312Asn and Lys751Gln, XRCC1 Arg399Gln, APE1 Asp148Glu, NBS1 Glu185Gln, and XPA G-4A) and in a gene involved in regulation of the cell-cycle (CCND1 A870G)... Importantly, no differences in the distribution of these polymorphisms were found between healthy controls and breast cancer patients.",N,XPA,XPA,1
4006,bc_id4083,CANCER,NOS3,20720556,B,Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer: a genetic association study and meta-analysis.,2010,,"The available evidence from our study and the meta-analysis cannot support a major contributory role of these common NOS3 polymorphisms in BC, although future larger studies may help in drawing safer conclusions about the genetics of BC.",A,NOS3,NOS3,0.461538462
4007,bc_id4084,CANCER,PALB2,20722467,B,"Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.",2010,,"Our analysis led to the conclusion that CHEK2, STK11, and PALB2 mutations or large genomic rearrangements of either STK11 or PALB2 are rare, and do not contribute to a substantial fraction of breast cancer susceptibility in high-risk French Canadian breast cancer families.",N,PALB2,PALB2,0.166666667
4008,bc_id4085,CANCER,CHEK2,20722467,B,"Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.",2010,,"Our analysis led to the conclusion that CHEK2, STK11, and PALB2 mutations or large genomic rearrangements of either STK11 or PALB2 are rare, and do not contribute to a substantial fraction of breast cancer susceptibility in high-risk French Canadian breast cancer families.",N,CHEK2,CHEK2,0.233333333
4009,bc_id4086,CANCER,STK11,20722467,B,"Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.",2010,,"Our analysis led to the conclusion that CHEK2, STK11, and PALB2 mutations or large genomic rearrangements of either STK11 or PALB2 are rare, and do not contribute to a substantial fraction of breast cancer susceptibility in high-risk French Canadian breast cancer families.",N,STK11,STK11,1
4010,bc_id4087,CANCER,MTRR,20726305,B,MTRR polymorphism and the risk for colorectal and breast cancer in Romanian patients--a preliminary study.,2010,Study results do not demonstrate an association between A66G MTRR polymorphism and CRC or BC in Romanian patients.,Study results do not demonstrate an association between A66G MTRR polymorphism and CRC or BC in Romanian patients.,N,MTRR,MTRR,0.666666667
4011,bc_id4088,CANCER,GSTT1,20728566,B,Betel quid chewing as an environmental risk factor for breast cancer.,2010,this study suggests betel quid chewing as a significant risk factor for developing breast cancer.,"Polymorphisms in five gene variants (GSTT1, GSTM1, GSTP1, TP53 and CYP17) and four environmental exposure variables (tobacco smoking, tobacco chewing, betel quid chewing, alcohol) were analysed in 117 breast cancer cases and 174 cancer free controls... Moreover, the lack of detoxification enzymes GSTT1 and GSTM1 are associated with reduced breast cancer risk.",Y,GSTT1,GSTT1,0.578947368
4012,bc_id4089,CANCER,GSTP1,20728566,B,Betel quid chewing as an environmental risk factor for breast cancer.,2010,this study suggests betel quid chewing as a significant risk factor for developing breast cancer.,X,X,X,X,0
4013,bc_id4090,CANCER,GSTM1,20728566,B,Betel quid chewing as an environmental risk factor for breast cancer.,2010,this study suggests betel quid chewing as a significant risk factor for developing breast cancer.,"Polymorphisms in five gene variants (GSTT1, GSTM1, GSTP1, TP53 and CYP17) and four environmental exposure variables (tobacco smoking, tobacco chewing, betel quid chewing, alcohol) were analysed in 117 breast cancer cases and 174 cancer free controls... Moreover, the lack of detoxification enzymes GSTT1 and GSTM1 are associated with reduced breast cancer risk.",Y,GSTM1,GSTM1,0.452830189
4014,bc_id4091,CANCER,CYP17A1,20728566,B,Betel quid chewing as an environmental risk factor for breast cancer.,2010,this study suggests betel quid chewing as a significant risk factor for developing breast cancer.,X,X,X,X,0
4015,bc_id4092,CANCER,TP53,20728566,B,Betel quid chewing as an environmental risk factor for breast cancer.,2010,this study suggests betel quid chewing as a significant risk factor for developing breast cancer.,X,X,X,X,0
4016,bc_id4093,CANCER,CYP2D6,20731819,B,CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.,2011,"CYP2D6*6 may affect BCSS in tamoxifen-treated patients. However, the absence of an association with survival in more frequent variants, including CYP2D6*4, questions the validity of the reported association between CYP2D6 genotype and treatment response in breast cancer. Until larger, prospective studies confirming any associations are available, routine CYP2D6 genetic testing should not be used in the clinical setting.","However, the absence of an association with survival in more frequent variants, including CYP2D6*4, questions the validity of the reported association between CYP2D6 genotype and treatment response in breast cancer.",A,CYP2D6*4,CYP2D6,0.590909091
4017,bc_id4094,CANCER,CYP2D6,20799519,B,Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients.,2010,"Any conclusions should be interpreted with caution given the small population sample investigated. Nonetheless, our findings strongly suggest that Puerto Ricans exhibit distinct CYP2D6 allele frequencies and harbor a non-functional allele that is rare or absent in other populations and are highly valuable for the emerging practice of Personalized Medicine in admixed populations like Puerto Ricans.",X,X,X,X,0
4018,bc_id4095,CANCER,ATM,20799949,B,The association between ATM D1853N polymorphism and breast cancer susceptibility: a meta-analysis.,2010,Our results indicate that ATM D1853N polymorphism is not a risk factor for developing breast cancer.,Our results indicate that ATM D1853N polymorphism is not a risk factor for developing breast cancer.,N,ATM,ATM,0.244444444
4019,bc_id4096,CANCER,BRCA2,20807450,B,Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.,2011,"We observed differences in the frequency of common genetic variants of the BRCA1 and BRCA2 and their haplotypes between early-onset breast cancer cases who did and did not carry deleterious mutations in these genes. Although our data provide only weak evidence for a difference in frequencies at the population level, the number of deleterious mutation carriers was low and the results may yet be substantiated in a larger study using pooled data.","We observed differences in the frequency of common genetic variants of the BRCA1 and BRCA2 and their haplotypes between early-onset breast cancer cases who did and did not carry deleterious mutations in these genes. Although our data provide only weak evidence for a difference in frequencies at the population level, the number of deleterious mutation carriers was low and the results may yet be substantiated in a larger study using pooled data.",A,BRCA2,BRCA2,0.576923077
4020,bc_id4097,CANCER,BRCA1,20807450,B,Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.,2011,"We observed differences in the frequency of common genetic variants of the BRCA1 and BRCA2 and their haplotypes between early-onset breast cancer cases who did and did not carry deleterious mutations in these genes. Although our data provide only weak evidence for a difference in frequencies at the population level, the number of deleterious mutation carriers was low and the results may yet be substantiated in a larger study using pooled data.","We observed differences in the frequency of common genetic variants of the BRCA1 and BRCA2 and their haplotypes between early-onset breast cancer cases who did and did not carry deleterious mutations in these genes. Although our data provide only weak evidence for a difference in frequencies at the population level, the number of deleterious mutation carriers was low and the results may yet be substantiated in a larger study using pooled data.",A,BRCA1,BRCA1,0.60944206
4021,bc_id4098,CANCER,CYP2D6,20809362,B,Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.,2011,,Comprehensive genotyping of CYP2D6 and adherence to tamoxifen therapy may be useful to identify breast cancer patients most likely to benefit from adjuvant tamoxifen.,A,CYP2D6,CYP2D6,0.590909091
4022,bc_id4099,CANCER,POU1F1,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4023,bc_id4100,CANCER,IGFBP6,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4024,bc_id4101,CANCER,IGFBP5,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4025,bc_id4102,CANCER,IGFBP4,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4026,bc_id4103,CANCER,IGFBP3,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,"After adjusting for multiple testing, SNPs in the IGF1 and SSTR5 genes were significantly associated with circulating IGF-I (P < 2.1 _ 10(-4)); SNPs in the IGFBP3 and IGFALS genes were significantly associated with circulating IGFBP-3. Multi-SNP models explained R(2) = 0.62% of the variation in circulating IGF-I and 3.9% of the variation in circulating IGFBP-3. We saw no significant association between these multi-SNP predictors of circulating IGF-I or IGFBP-3 and risk of prostate or breast cancers.",N,IGFBP3,IGFBP3,0.214285714
4027,bc_id4104,CANCER,IGFBP2,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4028,bc_id4105,CANCER,IGFBP1,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4029,bc_id4106,CANCER,IGFALS,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,"After adjusting for multiple testing, SNPs in the IGF1 and SSTR5 genes were significantly associated with circulating IGF-I (P < 2.1 _ 10(-4)); SNPs in the IGFBP3 and IGFALS genes were significantly associated with circulating IGFBP-3. Multi-SNP models explained R(2) = 0.62% of the variation in circulating IGF-I and 3.9% of the variation in circulating IGFBP-3. We saw no significant association between these multi-SNP predictors of circulating IGF-I or IGFBP-3 and risk of prostate or breast cancers.",N,IGFALS,IGFALS,1
4030,bc_id4107,CANCER,IGF1,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,"After adjusting for multiple testing, SNPs in the IGF1 and SSTR5 genes were significantly associated with circulating IGF-I (P < 2.1 _ 10(-4)); SNPs in the IGFBP3 and IGFALS genes were significantly associated with circulating IGFBP-3. Multi-SNP models explained R(2) = 0.62% of the variation in circulating IGF-I and 3.9% of the variation in circulating IGFBP-3. We saw no significant association between these multi-SNP predictors of circulating IGF-I or IGFBP-3 and risk of prostate or breast cancers.",N,IGF1,IGF1,0.4
4031,bc_id4108,CANCER,GHRHR,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4032,bc_id4109,CANCER,GHRH,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4033,bc_id4110,CANCER,GHR,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4034,bc_id4111,CANCER,SSTR5,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,"After adjusting for multiple testing, SNPs in the IGF1 and SSTR5 genes were significantly associated with circulating IGF-I (P < 2.1 _ 10(-4)); SNPs in the IGFBP3 and IGFALS genes were significantly associated with circulating IGFBP-3. Multi-SNP models explained R(2) = 0.62% of the variation in circulating IGF-I and 3.9% of the variation in circulating IGFBP-3. We saw no significant association between these multi-SNP predictors of circulating IGF-I or IGFBP-3 and risk of prostate or breast cancers.",N,SSTR5,SSTR5,1
4035,bc_id4112,CANCER,SSTR4,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4036,bc_id4113,CANCER,SSTR3,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4037,bc_id4114,CANCER,SSTR2,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4038,bc_id4115,CANCER,SSTR1,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4039,bc_id4116,CANCER,SST,20810604,B,"Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer.",2010,Further studies are needed to explore contributions from other genetic factors such as rare variants in these genes and variation outside of these genes.,X,X,X,X,0
4040,bc_id4118,CANCER,PIK3CA,20813970,B,"PTEN, PIK3CA, p-AKT, and p-p70S6K Status. Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer.",2010,", PI3K pathway activation plays a pivotal role in trastuzumab resistance.","Primary tumor tissue was available from 137 patients with HER2-overexpressing metastatic breast cancer who had received trastuzumab-based chemotherapy. We observed that each of the four biomarkers alone did not significantly correlate with trastuzumab response, whereas PTEN loss alone significantly correlated with shorter survival times (P = 0.023). PI3K pathway activation, defined as PTEN loss and/or PIK3CA mutation, was associated with a poor response to trastuzumab (P = 0.047) and a shorter survival time (P = 0.015).",A,PIK3CA,PIK3CA,0.466666667
4041,bc_id4119,CANCER,ATM,20826828,B,"Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.",2010,Testing the combined effects of rare missense variants in known breast cancer genes in large collaborative studies should clarify their overall contribution to breast cancer susceptibility.,"In this large combined analysis, these five missense ATM SNPs were associated with a small increased risk of breast cancer, explaining an estimated 0.03% of the excess familial risk of breast cancer.",Y,ATM,ATM,0.333333333
4042,bc_id4120,CANCER,AR,20831839,B,"Androgen receptor status predicts response to chemotherapy, not risk of breast cancer in Indian women.",2011,"Although, expansion of the CAGn in the AR gene doesn\t show any major effect on breast cancer risk, patients with positive AR expression, pre neoadjuvant chemotherapy, were found to be good responders and a decrease in mRNA level of AR gene related to the chemotherapy-induced apoptosis could serve as an important independent predictor of response to NACT.","Although, expansion of the CAGn in the AR gene doesn't show any major effect on breast cancer risk, patients with positive AR expression, pre neoadjuvant chemotherapy, were found to be good responders and a decrease in mRNA level of AR gene related to the chemotherapy-induced apoptosis could serve as an important independent predictor of response to NACT.",N,AR,AR,0.25
4043,bc_id4121,CANCER,TGFB1,20845106,B,"TGF-?1 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25,996 subjects.",2010,,"However, larger scale primary studies are required to further evaluate the interaction of TGF-_1 29T/C polymorphism and breast cancer risk in specific populations.",A,TGF-_1,TGFB1,0.518518519
4044,bc_id4122,CANCER,CYP2D6,20849243,B,Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.,2010,"While earlier data on CYP2D6 and tamoxifen excluded women with prior chemotherapy, the present analysis suggests that CYP2D6*4 genotype might be particularly crucial in this group of high-risk patients. Key limitations are restriction to the CYP2D6*4 allele and missing data of comedication.",The cytochrome P450 2D6 (CYP2D6) polymorphism was reported to have a significant impact on outcome of tamoxifen treatment in estrogen receptor positive breast cancer patients.,Y,CYP2D6,CYP2D6,0.272727273
4045,bc_id4123,CANCER,ANKLE1,20852631,B,A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.,2010,,X,X,X,X,0
4046,bc_id4124,CANCER,BRCA1,20852631,B,A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.,2010,,X,X,X,X,0
4047,bc_id4125,CANCER,UBE2I,20863840,B,Efficacy of DNA double-strand breaks repair in breast cancer is decreased in carriers of the variant allele of the UBC9 gene c.73G&gt;A polymorphism.,2010,,"The variant allele of the UBC9 gene polymorphism was strongly inversely related to HER negative breast cancer patients (OR 0.03, 95% CI 0.00-0.23). Our results suggest that the c.73G>A polymorphism of the UBC9 gene may affect DNA DSBs repair efficacy in breast cancer patients.",Y,UBC9,UBE2I,1
4048,bc_id4126,CANCER,CHEK2,20875877,B,Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.,2010,,"No CHEK2*1100delC mutations were detected in any of the 102 individuals, including 51 women diagnosed with breast cancer at an early age (<45 years), 8 women with bilateral breast cancer, 3 men with breast cancer, and 8 women with ovarian cancer.",N,CHEK2*1100delC,CHEK2,0.233333333
4049,bc_id4127,CANCER,CYP1A1,20878621,B,Impact of CYP1A1 and COMT genotypes on breast cancer risk in Mexican women: a pilot study.,2011,This study suggests that the CYP1A1 (3801 T&gt;C) m2/m2 genotype may contribute to breast cancer susceptibility in Mexican women.,This study suggests that the CYP1A1 (3801 T>C) m2/m2 genotype may contribute to breast cancer susceptibility in Mexican women.,A,CYP1A1,CYP1A1,0.456521739
4050,bc_id4128,CANCER,COMT,20878621,B,Impact of CYP1A1 and COMT genotypes on breast cancer risk in Mexican women: a pilot study.,2011,This study suggests that the CYP1A1 (3801 T&gt;C) m2/m2 genotype may contribute to breast cancer susceptibility in Mexican women.,No association between COMT 1947 G>A (rs4680) or CYP1A1 4889 A>G (rs1048943) and breast cancer was found.,N,COMT,COMT,0.29787234
4051,bc_id4129,CANCER,LOX,20929399,B,Lysyl Oxidase 473 G&gt;A Polymorphism and Breast Cancer Susceptibility in Chinese Han Population.,2011,,These findings suggest that the LOX 473 GA genotype is independently associated with increased risk of breast cancer in Chinese female population.,Y,LOX,LOX,1
4052,bc_id4130,CANCER,ROCK2,20939434,B,Association between the Thr431Asn polymorphism of the ROCK2 gene and risk of developing metastases of breast cancer.,2010,,"Our results demonstrate that Thr431Asn polymorphism of the ROCK2 gene could be a risk factor for the metastases of the breast cancer, and may help in predicting the prognosis.",A,ROCK2,ROCK2,1
4053,bc_id4131,CANCER,AGTR1,20945417,B,Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in iranian population.,2010,,X,X,X,X,0
4054,bc_id4132,CANCER,ACE,20945417,B,Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in iranian population.,2010,,This is the first study indicating that ACE (I/D) polymorphism is associated with HER-2 expression and AT1R (A1166C) polymorphism is associated with tumor TNM stage in breast cancer patients.,A,ACE,ACE,0.571428571
4055,bc_id4133,CANCER,INSIG2,20955599,N,The INSIG2 rs7566605 polymorphism is not associated with body mass index and breast cancer risk.,2011,"In this study we were not able to find any statistically significant association between this SNP and BMI, nor did we find any significant association between the SNP and an increased risk of breast cancer overall and by subgroups of age, or menopausal status.","The single nucleotide polymorphism rs7566605, located in the promoter of the INSIG2 gene, has been the subject of a strong scientific effort aimed to elucidate its possible association with body mass index (BMI)... In this study we were not able to find any statistically significant association between this SNP and BMI, nor did we find any significant association between the SNP and an increased risk of breast cancer overall and by subgroups of age, or menopausal status.",N,INSIG2,INSIG2,1
4056,bc_id4134,CANCER,CTCFL,21034534,B,Susceptibility for breast cancer in young patients with short rare minisatellite alleles of BORIS.,2010,,Our data suggest that the short rare alleles of BORIS-MS2 could be used to identify the risk for breast cancer in young patients.,A,BORIS-MS2,CTCFL,1
4057,bc_id4135,CANCER,TYMS,21036767,B,Relationship between thymidylate synthase (TYMS) gene polymorphism and TYMS protein levels in patients with high-risk breast cancer.,2010,,These findings suggest that breast cancer patients with the TYMS 3'-UTR +6 bp/+6 bp polymorphism whose tumours show a 6 bp deletion within TYMS 3'-UTR represent a group that may derive the most benefit from 5-FU chemotherapy.,A,TYMS,TYMS,0.7
4058,bc_id4137,CANCER,SOD2,21056286,B,"Plasma antioxidant concentration, not superoxide dismutase polymorphism, is associated with breast cancer risk in Korean women.",2010,,"Our findings suggest that the SOD2 Val16Ala variant is not related to the risk of breast cancer in Korean women; however, it may affect the association between plasma _-tocopherol levels and the risk of breast cancer.",A,SOD2,SOD2,0.375
4059,bc_id4138,CANCER,ATM,21058196,B,"Antioxidant Vitamins Intake, Ataxia Telangiectasia Mutated (ATM) Genetic Polymorphisms, and Breast Cancer Risk.",2011,,This study suggested that some antioxidant vitamins intake may modify the effect of ATM diplotype on the breast cancer risk among Korean women.,A,ATM,ATM,0.422222222
4060,bc_id4139,CANCER,PTGS2,21059239,B,Polymorphisms in regulatory regions of Cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study.,2011,Our results indicate no strong association between the four most frequent PTGS2 SNPs and the risk of breast cancer.,Our results indicate no strong association between the four most frequent PTGS2 SNPs and the risk of breast cancer.,N,PTGS2,PTGS2,0.333333333
4061,bc_id4140,CANCER,FGFR2,21060860,B,Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.,2010,,"FGFR2 rs2981575 had the strongest association with breast cancer risk (per allele HR = 1.28, 95% CI 1.18-1.39, ).",Y,FGFR2,FGFR2,0.708333333
4062,bc_id4141,CANCER,BRCA2,21060860,B,Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.,2010,,"FGFR2 rs2981575 had the strongest association with breast cancer risk (per allele HR = 1.28, 95% CI 1.18-1.39, ). These results indicate that SNPs that modify BRCA2 penetrance identified by an agnostic approach thus far are limited to variants that also modify risk of sporadic BRCA2 wild-type breast cancer.",A,BRCA2,BRCA2,0.576923077
4063,bc_id4142,CANCER,TP53,21061796,B,TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study.,2010,,The study provides evidence of the association of the TP53 gene polymorphisms Arg72Pro and PIN3 (+16bp) with sporadic breast cancer in the Croatian population.,Y,TP53,TP53,0.367816092
4064,bc_id4143,CANCER,BRCA2,21079137,B,BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study.,2010,"Screening results were somewhat worse in BRCA1 mutation carriers, but 6-year survival was high in all risk groups.","Cumulative distant metastasis-free and overall survival at 6 years in all 42 BRCA1/2 mutation carriers with invasive breast cancer were 83.9% (95% CI, 64.1% to 93.3%) and 92.7% (95% CI, 79.0% to 97.6%), respectively, and 100% in the familial groups (n=43).",A,BRCA1/2,BRCA2,0.576923077
4065,bc_id4144,CANCER,BRCA1,21079137,B,BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study.,2010,"Screening results were somewhat worse in BRCA1 mutation carriers, but 6-year survival was high in all risk groups.","Cumulative distant metastasis-free and overall survival at 6 years in all 42 BRCA1/2 mutation carriers with invasive breast cancer were 83.9% (95% CI, 64.1% to 93.3%) and 92.7% (95% CI, 79.0% to 97.6%), respectively, and 100% in the familial groups (n=43).",A,BRCA1/2,BRCA1,0.60944206
4066,bc_id4145,CANCER,MTHFR,21090237,B,"[Polymorphic variants of folate metabolizing genes (C677T and A1298C MTHFR, C1420T SHMT1 and G1958A MTHFD) are not associated with the risk of breast cancer in West Siberian Region of Russia].",2010,,"We investigated the role of polymorphisms of folate metabolizing genes MTHFR (C677T and A1298C), SHMT1 (C1420T) and MTHFD (G1258A) in genetic susceptibility to this type of cancer... Meta-analysis also revealed no significant association of studied SNPs with breast cancer.",N,MTHFR,MTHFR,0.326923077
4067,bc_id4146,CANCER,MTHFD1,21090237,B,"[Polymorphic variants of folate metabolizing genes (C677T and A1298C MTHFR, C1420T SHMT1 and G1958A MTHFD) are not associated with the risk of breast cancer in West Siberian Region of Russia].",2010,,"We investigated the role of polymorphisms of folate metabolizing genes MTHFR (C677T and A1298C), SHMT1 (C1420T) and MTHFD (G1258A) in genetic susceptibility to this type of cancer... Meta-analysis also revealed no significant association of studied SNPs with breast cancer.",N,MTHFD,MTHFD1,0.666666667
4068,bc_id4147,CANCER,SHMT1,21090237,B,"[Polymorphic variants of folate metabolizing genes (C677T and A1298C MTHFR, C1420T SHMT1 and G1958A MTHFD) are not associated with the risk of breast cancer in West Siberian Region of Russia].",2010,,"We investigated the role of polymorphisms of folate metabolizing genes MTHFR (C677T and A1298C), SHMT1 (C1420T) and MTHFD (G1258A) in genetic susceptibility to this type of cancer... Meta-analysis also revealed no significant association of studied SNPs with breast cancer.",N,SHMT1,SHMT1,0.6
4069,bc_id4148,CANCER,TOPBP1,21108795,B,TOPBP1 missense variant Arg309Cys and breast cancer in a German hospital-based case-control study.,2011,,We conclude that there is no evidence for the TOPBP1*Arg309Cys variant to confer an increased risk for breast cancer in the German population.,N,TOPBP1*Arg309Cys,TOPBP1,0.5
4070,bc_id4149,CANCER,MAP3K1,21118973,B,Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.,2010,,"Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 _ 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively).",Y,MAP3K1,MAP3K1,0.636363636
4071,bc_id4150,CANCER,LSP1,21118973,B,Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.,2010,,"Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 _ 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively).",Y,LSP1,LSP1,0.555555556
4072,bc_id4151,CANCER,TOX3,21118973,B,Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.,2010,,"Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 _ 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively).",Y,TOX3,TOX3,0.5
4073,bc_id4152,CANCER,FGFR2,21118973,B,Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.,2010,,"Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 _ 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively).",Y,FGFR2,FGFR2,0.708333333
4074,bc_id4153,CANCER,STXBP4,21118973,B,Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.,2010,,X,X,X,X,0
4075,bc_id4154,CANCER,SLC4A7,21118973,B,Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.,2010,,"Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 _ 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively).",Y,SLC4A7,SLC4A7,1
4076,bc_id4155,CANCER,BRCA2,21118973,B,Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.,2010,,"Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 _ 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively).",A,BRCA2,BRCA2,0.576923077
4077,bc_id4156,CANCER,BRCA1,21118973,B,Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.,2010,,"Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 _ 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively).",A,BRCA1,BRCA1,0.60944206
4078,bc_id4157,CANCER,ABCC11,21187511,B,Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11.,2010,This study showed that Japanese women with wet earwax have a higher relative risk of developing breast cancer than those with dry earwax. The ABCC11 SNPs that determine these phenotypes should be further investigated in order to obtain insights into the mechanisms by which breast cancer develops and progresses.,The ABCC11 SNPs that determine these phenotypes should be further investigated in order to obtain insights into the mechanisms by which breast cancer develops and progresses.,A,ABCC11,ABCC11,1
4079,bc_id4158,CANCER,ATM,21187516,B,Association between ataxia telangiectasia mutated gene polymorphisms and breast cancer in Taiwanese females.,2010,"Our data indicate that ATM polymorphism is associated with breast cancer, and the A allele of ATM rs189037 is a minor risky biomarker of breast cancer in Taiwan. The gene-gene and gene-environment interactions of ATM with other factors is worthy of further investigation.","Our data indicate that ATM polymorphism is associated with breast cancer, and the A allele of ATM rs189037 is a minor risky biomarker of breast cancer in Taiwan. The gene-gene and gene-environment interactions of ATM with other factors is worthy of further investigation.",Y,ATM,ATM,0.333333333
